<SEC-DOCUMENT>0001493152-25-004528.txt : 20250203
<SEC-HEADER>0001493152-25-004528.hdr.sgml : 20250203
<ACCEPTANCE-DATETIME>20250203062435
ACCESSION NUMBER:		0001493152-25-004528
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		83
FILED AS OF DATE:		20250203
DATE AS OF CHANGE:		20250203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284277
		FILM NUMBER:		25580500

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>form424b4.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:ENVB="http://enveric.com/20240930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ENVB_enveric.com_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20240101_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityRegistrantName_Enveric Biosciences, Inc. -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DDocumentType_424B4 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_Z%2D%2D\2025 OPERATIONS\EDGAR\01 JANUARY\Enveric Biosciences, Inc\01%2D31%2D2025\Form 424B4\Draft\Production\forms%2D1.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_063_AUD_0_iso4217%2D%2DAUD -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000004" name="dei:EntityRegistrantName">Enveric Biosciences, Inc.</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000005" name="dei:DocumentType">424B4</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-09-30" id="Fact000006" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="xdx2ixbrl0035" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0074" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-12-31" id="xdx2ixbrl0075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0080" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="AsOf2023-12-31" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0177" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:InducementExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0253" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0262" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0271" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0398" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0400" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0413" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0415" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0428" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0430" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0580" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="xdx2ixbrl0595" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:InducementExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:NoncashIncomeTaxExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0718" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfEmbeddedDerivative" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0721" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockSubscriptionReceivable" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:OfferingCostsAccruedNotPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:WarrantsIssuedForOfferingCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0731" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0734" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="AsOf2022-12-31" id="xdx2ixbrl0787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember" id="xdx2ixbrl0864" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember" id="xdx2ixbrl0868" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-12-31" id="xdx2ixbrl0910" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PrepaidFranchiseTaxReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0913" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:GoodwillImpairmentLossGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0933" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:GoodwillCurrencyTranslationImpairmentLoss" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:GoodwillForeignCurrencyTranslationGainLossGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0941" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl0955" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2022-12-31" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccruedRestructuringCosts" contextRef="AsOf2022-12-31" id="xdx2ixbrl1021" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl1024" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1153" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1155" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1288" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1350" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1352" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl1386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember" id="xdx2ixbrl1524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl1527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember" id="xdx2ixbrl1533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember" id="xdx2ixbrl1536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1556" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1558" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember" id="xdx2ixbrl1597" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember" id="xdx2ixbrl1599" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember" id="xdx2ixbrl1601" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1685" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1687" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="xdx2ixbrl1689" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="xdx2ixbrl1721" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1786" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1792" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1793" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1802" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl1807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1833" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1834" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1870" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-09-30" id="xdx2ixbrl1959" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl1960" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2024-09-30" id="xdx2ixbrl1965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1966" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="AsOf2024-09-30" id="xdx2ixbrl1984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="AsOf2023-12-31" id="xdx2ixbrl1985" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" id="xdx2ixbrl1990" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl1991" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" id="xdx2ixbrl2017" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl2018" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2024-09-30" id="xdx2ixbrl2045" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl2105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl2106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl2125" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl2135" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl2136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl2140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl2141" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_MezzanineEquityMember" id="xdx2ixbrl2198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_MezzanineEquityMember" id="xdx2ixbrl2209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2212" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2213" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2214" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2246" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2254" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2268" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2278" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_MezzanineEquityMember" id="xdx2ixbrl2284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_MezzanineEquityMember" id="xdx2ixbrl2293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_custom_SubscriptionReceivableMember" id="xdx2ixbrl2296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl2319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl2343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl2405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_custom_SubscriptionReceivableMember" id="xdx2ixbrl2431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2450" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember" id="xdx2ixbrl2451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2470" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember" id="xdx2ixbrl2475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember" id="xdx2ixbrl2483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl2484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30" id="xdx2ixbrl2542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl2556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2570" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_MezzanineEquityMember" id="xdx2ixbrl2575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2582" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2591" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2595" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl2600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2604" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2608" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl2616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl2622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl2623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl2625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2636" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_custom_MezzanineEquityMember" id="xdx2ixbrl2641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember" id="xdx2ixbrl2648" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2667" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2719" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:DeferredOfferingCostsChargedToOfferingCosts" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2761" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2766" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl2769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2024-09-30" id="xdx2ixbrl2890" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:AccruedRestructuringCosts" contextRef="AsOf2024-09-30" id="xdx2ixbrl2962" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2024-09-30" id="xdx2ixbrl2965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl3064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl3066" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl3068" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-09-30" id="xdx2ixbrl3070" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-09-30" id="xdx2ixbrl3086" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2024-09-30" id="xdx2ixbrl3096" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="xdx2ixbrl3169" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2024-09-30_us-gaap_WarrantMember" id="xdx2ixbrl3185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" contextRef="AsOf2024-09-30_us-gaap_WarrantMember" id="xdx2ixbrl3193" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="xdx2ixbrl3203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember" id="xdx2ixbrl3211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember" id="xdx2ixbrl3218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2024-09-30" id="xdx2ixbrl3242" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="AsOf2024-09-30" id="xdx2ixbrl3256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20240930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SubscriptionReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_MezzanineEquityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-272025-01-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-27</xbrli:startDate>
        <xbrli:endDate>2025-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-01</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:MrKanubaddiEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-15</xbrli:startDate>
        <xbrli:endDate>2023-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:PrefundedCommonStockWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_country_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_country_AU">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_RestrictedStockUnitsUnvestedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_LabEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-03</xbrli:startDate>
        <xbrli:endDate>2023-11-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-03_custom_RegistrationRightsAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-132022-02-15_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-13</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-132022-02-15_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-13</xbrli:startDate>
        <xbrli:endDate>2022-02-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_UnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-21</xbrli:startDate>
        <xbrli:endDate>2022-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-21</xbrli:startDate>
        <xbrli:endDate>2022-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-022022-05-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-02</xbrli:startDate>
        <xbrli:endDate>2022-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-102022-02-11_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-10</xbrli:startDate>
        <xbrli:endDate>2022-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-11_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-14_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-28_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PreModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PostModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_DistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_custom_FebruaryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082024-03-08_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2024-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-032024-05-03_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-03</xbrli:startDate>
        <xbrli:endDate>2024-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-032024-05-03_custom_PurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-03</xbrli:startDate>
        <xbrli:endDate>2024-05-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_PurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_PurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_PurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_PurchaseAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:BoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:BoardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-28</xbrli:startDate>
        <xbrli:endDate>2023-12-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-28_custom_RothAndInducementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-04</xbrli:startDate>
        <xbrli:endDate>2022-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InitialMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ENVB:MeasurementInputMarketRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-25</xbrli:startDate>
        <xbrli:endDate>2022-07-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:OneTimeMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-25</xbrli:startDate>
        <xbrli:endDate>2017-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:AdditionalMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-25</xbrli:startDate>
        <xbrli:endDate>2017-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-25</xbrli:startDate>
        <xbrli:endDate>2017-12-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:OtherConsultingAndVendorAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_AvanceClinicalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_OtherConsultingAndVendorAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:OtherConsultingAndVendorAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-312023-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-31</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-27_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-29</xbrli:startDate>
        <xbrli:endDate>2024-02-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2024-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-02</xbrli:startDate>
        <xbrli:endDate>2024-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-11-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreeentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreeentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-092024-10-09_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-09</xbrli:startDate>
        <xbrli:endDate>2024-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-09_us-gaap_SubsequentEventMember_custom_IncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:IncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-072024-11-07_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-07</xbrli:startDate>
        <xbrli:endDate>2024-11-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_InvestmentOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="AUD">
      <xbrli:measure>iso4217:AUD</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed
Pursuant to Rule 424(b)(4)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-284277</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enveric
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,229,330
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,666,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Warrants to Purchase up to
1,666,666 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,666,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Warrants to Purchase up to
1,666,666 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>437,336
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded Warrants to Purchase 437,336
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,770,668
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock Underlying the Series
A Warrants, Series B Warrants and Pre-Funded Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>116,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement Agent Warrants to Purchase up
to 116,666 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>116,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock underlying the Placement
Agent Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 1,229,330 shares of common stock, together with Series A warrants to purchase up to 1,666,666 shares of common
stock, which we refer to as the &#8220;Series A warrants,&#8221; and Series B warrants to purchase up to 1,666,666 shares of common
stock, which we refer to as the &#8220;Series B warrants,&#8221; pursuant to this prospectus. The combined public offering price for
each share of common stock, together with each Series A warrant and Series B warrant to purchase one share of common stock, is $3.00.
The Series A warrants and the Series B warrants are hereinafter referred to as the &#8220;warrants.&#8221; Each share of our common
stock is being sold together with each Series A warrant and Series B warrant to purchase one share of common stock each. The Series A
warrants will have an exercise price of $3.00 per share and will be exercisable immediately upon issuance (the &#8220;Initial
Exercise Date&#8221;). The Series A warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B warrants
will have an exercise price of $3.00 per share and will be exercisable beginning on the Initial Exercise Date. The Series B warrants
will expire eighteen (18) months from the Initial Exercise Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also offering 437,336 pre-funded warrants (the &#8220;pre-funded warrants&#8221;) to those purchasers whose purchase of shares
of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this
offering in lieu of the shares of our common stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser,
9.99%). Each pre-funded warrant will be exercisable for one share of common stock at an exercise price of $0.0001 per share. Each pre-funded
warrant is being issued together with the same warrants described above being issued with each share of common stock. The combined public
offering price for each such pre-funded warrant, together with accompanying warrants is equal to the public offering price for
the common stock and accompanying warrants in this offering, minus $0.0001. Each pre-funded warrant will be exercisable upon issuance
and may be exercised at any time until all of the pre-funded warrants are exercised in full. This prospectus also relates to the offering
of the shares of common stock issuable upon exercise of the warrants, pre-funded warrants and Placement Agent Warrants (as defined herein).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the warrants or the pre-funded warrants, and we do not expect a market to develop. We do
not intend to apply for listing of the warrants or the pre-funded warrants on any securities exchange or other nationally recognized
trading system. Without an active trading market, the liquidity of the warrants and the pre-funded warrants will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering will terminate on February 13, 2025, unless we decide to terminate the offering (which we may do at any time in our discretion)
prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering price per
share of common stock (or pre-funded warrant) and accompanying warrants will be fixed for the duration of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;), to act as our exclusive placement agent in connection
with this offering. The Placement Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered
by this prospectus. The Placement Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is
not required to arrange the purchase or sale of any specific number of securities or dollar amount. We have agreed to pay to the Placement
Agent the Placement Agent fees set forth in the table below, which assumes that we sell all of the securities offered by this prospectus.
There is no minimum number of securities or amount of proceeds required as a condition to closing in this offering. <span style="background-color: white">In
addition, because there is no escrow trust or similar arrangement and no minimum offering amount, investors could be in a position where
they have invested in our company, but we are unable to fulfill all of our contemplated objectives due to a lack of interest in this
offering. Further, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty
about whether we would be able to use such funds to effectively implement our business plan</span>. We will bear all costs associated
with the offering. See &#8220;Plan of Distribution&#8221; on page 81 of this prospectus for more information regarding these arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025, pursuant to which every
15 shares of our issued and outstanding common stock were reclassified as one share of common stock. No fractional shares were
issued as a result of the reverse stock split. Any fractional shares that were to otherwise have resulted from the reverse stock
split were rounded up to the next whole number. The reverse stock split had no impact on the par value of our common stock or the
authorized number of shares of our common stock. Unless otherwise indicated, all share and per share information in this prospectus
is adjusted to reflect the reverse stock split prior to any rounding of fractional shares.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq, under the symbol &#8220;ENVB&#8221;. The last reported sale price of our common stock on Nasdaq on
January 30, 2025 was $3.90 per share. We do not intend to list the warrants or pre-funded warrants on the NASDAQ Capital
Market, any other national securities exchange or any other nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combined offering price per share of common stock and accompanying warrants and the combined offering price per pre-funded warrant and
accompanying warrants we are offering and the exercise price and other terms of the warrants was negotiated between us and the
purchasers, in consultation with the Placement Agent based on the trading of our common stock prior to this offering, among other factors.
Other factors considered in determining the offering price of the securities we are offering and the exercise price and other terms of
the warrants include the history and prospects of our company, the stage of development of our business, our business plans for the future
and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at
the time of the offering and such other factors as were deemed relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined under federal securities laws and, as such, have elected to comply with certain
reduced public company reporting requirements for this prospectus and may elect to
comply with reduced public company reporting requirements in future filings. See &#8220;Prospectus Summary&#8211;&#8211;Implications
of Being a Smaller Reporting Company.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our securities involves a high degree of risk. See the section entitled</b> &#8220;<b><span style="text-decoration: underline">Risk Factors</span></b>&#8221; <b>beginning
on page 6 of this prospectus for a discussion of risks that should
be considered in connection with an investment in our securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per
                                            Share and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accompanying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Per
                                            Pre-Funded</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrant
                                            and</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>accompanying</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    offering price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9999</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,999,954.27</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent fees (1)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.2100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">349,999.86</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us, before expenses
    (2)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.79</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7899</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,649,954.41</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to pay the Placement Agent a total cash fee equal to 7.0% of the gross proceeds raised in this offering. We have also
    agreed to pay the Placement Agent a management fee equal to 1.0% of the gross proceeds raised in this offering and to reimburse the
    Placement Agent for its non-accountable expenses in the amount of $25,000 and for its legal fees and expenses and other out-of-pocket
    expenses in an amount up to $100,000, and for its clearing expenses in the amount of $15,950. In addition, we have agreed to issue
    to the Placement Agent, or its designees, warrants to purchase a number of shares of our common stock equal to 7.0% of the aggregate
    number of shares of common stock and pre-funded warrants being offered at an exercise price equal to 125% of the combined public
    offering price per share of common stock and accompanying warrant. We refer you to &#8220;Plan of Distribution&#8221; on page 81
    of this prospectus for additional information regarding Placement Agent compensation. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual offering
    amount, Placement Agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total
    maximum offering amounts set forth above. We refer you to &#8220;Plan of Distribution&#8221; on page 81 of this prospectus
    for additional information regarding Placement Agent compensation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
delivery of the securities offered hereby is expected to be made on or about February 3, 2025, subject to satisfaction of certain
customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>H.C. Wainwright &amp; Co.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is January 30, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_001">ABOUT THIS PROSPECTUS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_002">PROSPECTUS SUMMARY</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_003">THE OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_004">RISK FACTORS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_005">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">34</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_006">MARKET PRICE AND DIVIDEND INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">35</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_007">BUSINESS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">36</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ar_008">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">49</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">SECURITY OWNERSHIP AND CERTAIN BENEFICIAL OWNERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">62</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">MANAGEMENT</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">EXECUTIVE AND DIRECTOR COMPENSATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">65</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">USE OF PROCEEDS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">72</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">DESCRIPTION OF CAPITAL STOCK</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">73</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">DESCRIPTION OF SECURITIES WE ARE OFFERING</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">77</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">PLAN OF DISTRIBUTION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">81</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">LEGAL MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">83</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010">EXPERTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">83</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011">WHERE YOU CAN FIND MORE INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">83</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-1</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_001"></span>ABOUT
THIS PROSPECTUS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully
read this prospectus before deciding to invest in our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations
other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have
referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others
may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions
where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only
as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations
and prospects may have changed since that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside the United States: We have not, and the Placement Agent has not, done anything that would permit this
offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in
the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe
any restrictions relating to, the offering of the securities and the distribution of this prospectus outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus may contain references to trademarks belonging to other
entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork, and other visual displays, may appear without the &#174; or TM symbols. We do not intend
our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of
us by, any other company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus.
You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered
hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is
current only as of its date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains estimates and other statistical data made by independent parties and by us relating to market size and growth and
other data about our industry. We obtained the industry and market data in this prospectus from our own research as well as from industry
and general publications, surveys and studies conducted by third parties. This data involves a number of assumptions and limitations
and contains projections and estimates of the future performance of the industries in which we operate that are subject to a high degree
of uncertainty. We caution you not to give undue weight to such projections, assumptions and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_002"></span>PROSPECTUS
SUMMARY</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you
should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the</i> &#8220;<i>Risk
Factors</i>&#8221; <i>section in this prospectus.
The terms the</i> &#8220;<i>Company</i>&#8221;<i>,</i> &#8220;<i>Enveric</i>&#8221;, &#8220;<i>our</i>&#8221;<i>, </i>&#8220;<i>us</i>&#8221;<i>,
or</i> &#8220;<i>we</i>&#8221; <i>refer to Enveric Biosciences, Inc. and its subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,
anxiety, addiction, and other psychiatric disorders. Leveraging our unique discovery and development platform, the Psybrary&#8482;, which
houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric
seeks to develop a robust intellectual property portfolio of novel drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric&#8217;s
lead program, the EVM301 Series, and its lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment
of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations
in the patient. Previously, Enveric was developing the EVM201 Series, and its lead drug candidate EB-002 (formerly EB-373), for the treatment
of neuropsychiatric disorders. The EVM201 Series comprised next generation synthetic prodrugs of the active metabolite, psilocin. Recently,
Enveric out-licensed the EVM201 Series program to MycoMedica Life Sciences, who will seek to develop, manufacture, and commercialize
EB-002, in exchange for certain development and milestone payments to Enveric (discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Neuroplastogens</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), we have continued to pursue the development
of MagicMed&#8217;s proprietary library, the Psybrary&#8482;, which we believe will help us to identify and develop the right drug candidates
needed to address mental health challenges, including depression, anxiety, and addiction disorders. We synthesize novel phenylalkylamines
and indolethylamines, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which currently
includes 20 patent families with claims covering a million potential molecular structures, over one thousand of which we have so far
synthesized in sufficient quantities to identify and hundreds of which we have screened for receptor binding and other relevant activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this stage, we have entered into several non-binding term sheets with strategic partners to out-license certain molecules from the Psybrary&#8482;.
Going forward, in order to build a pipeline of product candidates, we intend to both continue to internally develop new drug candidates
with associated intellectual property and to acquire, through in-licensing, additional intellectual property from pharmaceutical and
biotechnology companies and research institutions. The in-licensed assets could include both research stage and clinical stage drug candidates.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is to develop our lead asset EB-003 in the EVM301 Series. The development status of the product is shown in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    Candidates</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
    Indications</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
    Next Steps</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-003</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Psychedelic-inspired drug candidate</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mental
    health indication</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    Development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    Filing</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For more information, see
section entitled &#8220;Business&#8221; beginning on page 36 of this prospectus.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025, pursuant to which every
15 shares of our issued and outstanding common stock were reclassified as one share of common stock. No fractional shares were
issued as a result of the reverse stock split. Any fractional shares that were to otherwise have resulted from the reverse stock
split were rounded up to the next whole number. The reverse stock split had no impact on the par value of our common stock or the
authorized number of shares of our common stock. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NASDAQ
Bid Price Deficiency and Reverse Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2024, the Company received a letter from Nasdaq notifying the Company that for the prior 30 consecutive business days the bid
price for the Company&#8217;s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on Nasdaq
pursuant to Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule). The deficiency letter did not result in the immediate delisting of the Company&#8217;s
common stock from Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar
days, until November 12, 2024, to regain compliance with the Bid Price Rule. On November 20, 2024, Nasdaq issued a delisting notice,
indicating that the Company did not satisfy the Bid Price Rule by the compliance date and that unless the Company requested an appeal
of this determination before Nasdaq&#8217;s listing qualifications panel, our common stock would be scheduled for delisting from Nasdaq
and trading suspended. We appealed the determination before Nasdaq&#8217;s listing qualifications panel and on December 30, 2024, the
Company received an extension until May 19, 2025, to regain compliance with Bid Price Rule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, subject to stockholder approval, the Board approved an amendment to our certificate of incorporation to, at the
discretion of the Board, effect a reverse stock split of our outstanding common stock at a ratio between 1-for-10 and 1-for-100,
including shares held by the Company as treasury shares, with the exact ratio within such range to be determined by the Board at its
discretion. A meeting of the stockholders was held on January 17, 2025, whereby the stockholders approved the reverse
stock split. The Company effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. Nasdaq requires that the closing bid price of the Company remain
at $1.00 per share or greater for 10 consecutive business days before declaring that the Company has regained compliance with the
Bid Price Rule. As of the date of this prospectus, the Company has not completed 10 consecutive business days from the reverse stock
split effective date and therefore it is not in compliance with the Bid Price Rule. Even if we do regain compliance, we cannot
provide any assurance that our stock price will not drop below the minimum bid price requirement under the Bid Price
Rule following the completion of this offering and we will not be subject to another delisting notice from NASDAQ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreement with MycoMedica Life Sciences</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, Enveric executed a licensing agreement with MycoMedica Life Sciences, PBC (&#8220;MycoMedica&#8221;), out-licensing
the Company&#8217;s EVM201 program, including drug candidate EB-002. Pursuant to the terms of licensing agreement, MycoMedica will seek
to develop, manufacture, and commercialize EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, for the
treatment of neuropsychiatric disorders such as depression. MycoMedica received an exclusive, global license to the formulations,
drugs, method of use, and medical devices developed by Enveric to utilize the compound. MycoMedica assumed the responsibility for all
future preclinical, clinical, and commercial development on a royalty-bearing basis for all human and animal pharmaceutical applications.
As part of the license agreement, Enveric received a modest upfront payment, and if certain conditions are met, will receive
development and sales milestones potentially totaling up to $62 million, plus tiered single digit royalties on all future sales. <span style="background-color: white">MycoMedica
has the option during the license term to buyout its milestone and royalty payment obligations at a predetermined amount depending upon
the stage of product development and commercialization at the time of the buyout. Further, MycoMedica has the right to purchase the licensed
patents at a nominal amount upon a change of control of Enveric, although doing so does not relieve MycoMedica of any of its payment
obligations. No royalties have been received to date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>License
Agreement with Aries Science and Technology</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
July 10, 2024, Akos Biosciences, Inc., a Delaware corporation (&#8220;Akos&#8221;), wholly-owned subsidiary of Enveric, entered into
an exclusive license agreement with Aries Science and Technology, LLC (&#8220;Aries&#8221;) pursuant to which Akos granted Aries a license
of Akos&#8217;s patented radiation dermatitis topical product. The license allows Aries to use the patented formulation to develop pharmaceutical
or non-pharmaceutical products for treating radiation dermatitis suitable for administration to humans or animals. The license is exclusive
(subject to certain exceptions contained in the Agreement), worldwide, royalty-bearing, and includes the right to sublicense. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
will be eligible to receive aggregate milestone payments of up to $61 million, as well as tiered royalties on future sales, if all conditions
are met. <span style="background-color: white">Aries has the option during the license term, to purchase the rights to each licensed
product (on a licensed product-by-licensed product basis) in the form of an exclusive (as to the applicable licensed product), fully
paid, transferable right and license to the licensed product. No royalties have been received to date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Registered
Direct Offerings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
March and May 2024, Enveric entered into a series of common stock purchase agreements (the &#8220;Purchase Agreements&#8221;) for the
issuance in a registered direct offering of an aggregate of 45,780 shares of the Company&#8217;s common stock, par value $0.01
per share, to certain institutional investors. The issuance was made in exchange for the permanent and irrevocable waiver of the variable
rate transaction limitation contained in certain inducement offer letters, dated December 28, 2023, between the Company and the institutional
investors with respect to any existing or future agreement by the Company to effect any issuance of shares. The Company did not receive
any net proceeds in connection with the offering. The offering was made to obtain a waiver of the variable rate transaction limitation
as described above and further described in the Purchase Agreements so the Company could utilize its equity line of credit with Lincoln
Park Capital Fund, LLC, and enter into any future agreements that involve a variable rate transaction and issue such shares thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary executive offices are located at 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 and our telephone number is (239) 302-1707.
Our website address is <i>www.enveric.com</i>. The information contained on, or that can be accessed through, our website is not part
of this prospectus and should not be considered as part of this prospectus or in deciding whether to purchase our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psybrary
and our logo are some of our trademarks used in this prospectus. This prospectus also includes trademarks, tradenames and service
marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this
prospectus may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we
will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks
and tradenames.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being a Smaller Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a smaller reporting company as defined in the Exchange Act, and we will remain a smaller reporting company until the fiscal year
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    determination that our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business
    day of our second fiscal quarter; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    annual revenue is more than $100 million during the most recently completed fiscal year and our voting and non-voting common stock
    held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting companies are able to provide simplified executive compensation disclosure and have certain other reduced disclosure obligations,
including, among other things, being required to provide only two years of audited financial statements and not being required to provide
selected financial data, supplemental financial information or risk factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
as a non-accelerated filer, we will not be required to provide an auditor attestation of management&#8217;s assessment of internal control
over financial reporting, which is generally required for SEC reporting companies under Sarbanes-Oxley Act Section 404(b), and, in contrast
to other reporting companies, we&#8217;ll have more time to file our annual and periodic reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_003"></span>THE
OFFERING</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 28%; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
    we are offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,229,330
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock and pre-funded
    warrants to purchase 437,336 shares of common stock. Each share of common stock or pre-funded warrant is being offered
    together with one each Series A warrant and Series B warrant to purchase one share of common stock each. The Placement
    Agent has agreed to use its reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The Placement
    Agent is not purchasing or selling any of the securities we are offering and the Placement Agent is not required to arrange the purchase
    or sale of any specific number of securities or dollar amount. For more information about risks involved in a best-efforts offering,
    see &#8220;Risks Related to this Offering&#8221; under the section entitled &#8220;Risk Factors&#8221; beginning on page 6.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of warrants</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Series A warrants will have an exercise price of $3.00 per share and will be exercisable beginning on the Initial Exercise
    Date. The Series A warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B warrants will have
    an exercise price of $3.00 per share and will be exercisable beginning on the Initial Exercise Date. The Series B warrants
    will expire eighteen (18) months from the Initial Exercise Date. See &#8220;Description of Securities We Are Offering&#8221; for
    additional information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of the pre-funded warrants </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the issuance of shares of our common stock to a purchaser in this offering would result in such purchaser, together with its
    affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our
    outstanding common stock following the consummation of this offering, then such purchaser may purchase, if they so choose, in lieu
    of the shares of our common stock that would result in such excess ownership, a pre-funded warrant to purchase shares of our common
    stock for a purchase price per share of common stock subject to such pre-funded warrant equal to the per share public offering price
    for the common stock to be sold in this offering less $0.0001. Each pre-funded warrant will have an exercise price of $0.0001 per
    share, will be exercisable upon issuance and may be exercised at any time until all of the pre-funded warrants are exercised in
    full. Purchasers of pre-funded warrants will also receive accompanying Series A warrants and Series B warrants as if such
    purchasers were buying shares of our common stock in this offering. This prospectus also relates to the offering of the shares of
    common stock issuable upon exercise of these pre-funded warrants.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    of the offering </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    offering will terminate on February 13, 2025 unless we decide to terminate the offering (which we may do at any time in our
    discretion) prior to that date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    stock outstanding immediately before this offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">692,580
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
    stock outstanding immediately after this offering</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,359,246
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares assuming all of the pre-funded
    warrants offered hereby are exercised and none of the warrants or placement agent warrants issued in this offering are exercised.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lock-Up</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our directors and executive officers have agreed, subject to certain exceptions, not to sell, transfer or dispose of, directly
    or indirectly, any of our common stock or securities convertible into or exercisable or exchangeable for our common stock for a period
    of 60 days after the closing of this offering. See &#8220;Plan of Distribution&#8221; for more information.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of proceeds</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently intend to use the net proceeds from this offering for EB-003 development, working capital, and general corporate purposes.
    See &#8220;Use of Proceeds.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    Factors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    investment in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 6 of this prospectus
    for a discussion of the risk factors you should carefully consider before deciding to invest in our securities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
    listing symbol</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is listed on The Nasdaq Capital Market under the symbol &#8220;ENVB.&#8221; There is no established trading market for
    the warrants or pre-funded warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing
    of the warrants or pre-funded warrants on any national securities exchange or other trading market. Without an active trading market,
    the liquidity of the warrants and pre-funded warrants will be limited.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding after this offering is based on 692,580 shares outstanding as of January 24,
2025, and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,538
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon exercise
    of outstanding options granted under our equity incentive plans at a weighted average exercise price of $941.55 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,385
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon vesting
    of restricted stock units granted, inclusive of 1,369 shares previously vested and unissued, under our equity incentive plans;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56,308
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon exercise
    of outstanding warrants at a weighted average exercise price of $536.70 per share and 4,667 shares of our common stock
    issuable upon exercise of outstanding investment options at a weighted average exercise price of $150.00 per share.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9.9pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, all information contained in this prospectus assumes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9.9pt; text-align: justify; text-indent: 48.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the outstanding options, warrants, or pre-funded warrants, and no settlement of the restricted stock units described
    in the bullets above;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the warrants or the placement agent warrants issued in this offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_004"></span>RISK
FACTORS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our securities involves a high degree of risk. You should carefully consider the following risk factors in addition to the other
information included in this prospectus, including matters addressed in the section entitled &#8220;Cautionary Note Regarding Forward-Looking
Statement.&#8221; These risk factors are not exhaustive, and investors are encouraged to perform their own investigation with respect
to our business, financial condition and prospects. We may face additional risks and uncertainties that are not presently known to us,
or that we currently deem immaterial, which may also impair our business or financial condition. If any of these risks actually occur,
our business, financial condition and results of operations could be materially and adversely affected and we may not be able to achieve
our goals, the value of our securities could decline and you could lose some or all of your investment. Additional risks not presently
known to us or that we currently believe are immaterial may also significantly impair our business operations. If any of these risks
occur, our business, results of operations or financial condition and prospects could be harmed. In that event, the market price of our
common stock and the value of the warrants could decline, and you could lose all or part of your investment. The following discussion
should be read in conjunction with the financial statements and notes to the financial statements included herein.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to this Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>We will require substantial additional
funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce
or cease our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">We have used and we intend
to use the proceeds from this offering and any future offerings, product development, working capital and general corporate purposes.
We will require substantial additional future capital in order to complete clinical development and commercialize EB-003, including preclinical
studies, clinical trials, and filings with the FDA for approval of use and sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">We believe that our existing
cash and cash equivalents of $2.2 million as of December 31, 2024 will not be sufficient to fund our planned operations, without the
issuance of additional equity for cash. We believe that the net proceeds of approximately $4.28 million  from this offering will satisfy
our capital needs for less than a year from the completion of this offering, and we will require substantial additional funding thereafter
to support our product development plan. Our estimated uses of cash may deviate from our expectations based on the speed of our ability
to advance product development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our
results of operations and cause our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have considerable discretion in the application of the net proceeds of this offering. We intend to use the net proceeds from this
offering for product development, working capital and general corporate purposes. However, investors will be relying upon management&#8217;s
judgment with only limited information about our specific intentions for the use of the net proceeds of this offering. If we do not invest
or apply the net proceeds of this offering in ways that improve our operating results, we may fail to achieve expected financial results,
which could cause our stock price to decline. In addition, pending their use, we may invest the net proceeds from this offering in a
manner that does not produce income or that loses value. See &#8220;Use of Proceeds&#8221; for further information on the anticipated
use of proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock has often been thinly traded, so investors may be unable to sell at or near ask prices or at all if investors need to sell
shares to raise money or otherwise desire to liquidate their shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, there have been many days on which limited trading of our common stock took place. Furthermore, the stock markets, including our
stock, have experienced and will continue to experience price and volume fluctuations that have affected and continue to affect
the market prices of equity securities of many companies. We cannot predict the extent to which investors&#8217; interests will lead
to an active trading market for our common stock or whether the market price of our common stock will be volatile. If there are wide
fluctuations in trading volumes or the market prices are volatile, investors may have difficulty selling our common stock. We are likely
to be too small to attract the interest of many brokerage firms and analysts. We cannot give investors any assurance that an active public
trading market for our common stock will develop or be sustained. The market price of our common stock could be subject to wide fluctuations
in response to quarterly variations in our revenues and operating expenses, announcements of new products or services by us, significant
sales of our common stock, including &#8220;short&#8221; sales, the operating and stock price performance of other companies that investors
may deem comparable to us, and news reports relating to trends in our markets or general economic, political, and market conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require additional capital funding, the receipt of which may impair the value of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including our research, development, sales and marketing activities. We will need
to raise additional capital through public or private equity or debt offerings or through arrangements with strategic partners or other
sources in order to continue to develop our drug candidates. There can be no assurance that additional capital will be available when
needed or on terms satisfactory to us, if at all. To the extent we raise additional capital by issuing equity securities, our stockholders
may experience substantial dilution and the new equity securities may have greater rights, preferences or privileges than our existing
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock and currently do not plan to pay any cash dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Your
ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic
transactions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek to raise additional funds for our operations, to finance acquisitions or to develop strategic relationships by issuing
equity or convertible debt securities in addition to the securities issued in this offering, which would reduce the percentage ownership
of our existing stockholders. Our board of directors has the authority, without action or vote of the stockholders, to issue all or any
part of our authorized but unissued shares of common or preferred stock. Our amended and restated certificate of incorporation, as amended,
authorizes us to issue up to 100,000,000 shares of common stock and 20,000,000 shares of preferred stock. Future issuances of common
or preferred stock would reduce your influence over matters on which stockholders vote and would be dilutive to earnings per share. In
addition, any newly issued preferred stock could have rights, preferences and privileges senior to those of the common stock. Those rights,
preferences and privileges could include, among other things, the establishment of dividends that must be paid prior to declaring or
paying dividends or other distributions to holders of our common stock or providing for preferential liquidation rights. These rights,
preferences and privileges could negatively affect the rights of holders of our common stock, and the right to convert such preferred
stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is no public market for the warrants or pre-funded warrants being offered in this offering.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established public trading market for the warrants or pre-funded warrants being offered in this offering, and we do not expect
one to develop. In addition, we do not intend to apply to list the warrants or pre-funded warrants on any securities exchange or nationally
recognized trading system, including The Nasdaq Stock Market. Without an active market, the liquidity of the warrants and pre-funded
warrants will be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of our warrants and pre-funded warrants will have no rights as a common stockholder until they acquire our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
holders of our warrants and pre-funded warrants acquire shares of our common stock upon exercise of such warrants or pre-funded warrants,
the holders will have no rights with respect to shares of our common stock. Upon exercise of the warrants or pre-funded warrants, holders
will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not maintain a current and effective prospectus relating to the common stock issuable upon exercise of the warrants and pre-funded
warrants, public holders will only be able to exercise such warrants and pre-funded warrants on a</i></b><i> &#8220;<b>cashless basis.</b>&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not maintain a current and effective prospectus relating to the shares of common stock issuable upon exercise of the warrants and
pre-funded warrants at the time that holders wish to exercise such warrants, they will only be able to exercise them on a &#8220;cashless
basis,&#8221; and under no circumstances would we be required to make any cash payments or net cash  settle such warrants to the holders.
As a result, the number of shares of common stock that holders will receive upon exercise of the warrants and pre-funded warrants will
be fewer than it would have been had such holders exercised their warrants or pre-funded warrants for cash. We will do our best
efforts to maintain a current and effective prospectus relating to the shares of common stock issuable upon exercise of such warrants
until the expiration of such warrants. However, we cannot assure you that we will be able to do so. If we are unable to do so,
the potential &#8220;upside&#8221; of the holder&#8217;s investment in our company may be reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
warrants are speculative in nature.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants and the warrants offered hereby do not confer any rights of common stock ownership on their holders, such as voting
rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price. Specifically,
commencing on the date of issuance, holders of pre-funded warrants and the warrants may acquire the common stock issuable upon exercise
of such warrants at the stated exercise price per share. Moreover, following this offering, the market value of the warrants will be
uncertain and there can be no assurance that the market value of the warrants will equal or exceed their public offering price. There
can be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the warrants, and consequently,
whether it will ever be profitable for holders of the warrants to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>This
is a</i></b><i> &#8220;<b>best efforts</b>&#8221; <b>offering. No minimum amount of securities is required to be sold, and we may not
raise the amount of capital we believe is required for our business plans, including our near-term business plans.</b></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent has agreed to use their reasonable best efforts to solicit offers to purchase the securities in this offering. The placement
agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar
amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering.
Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement
agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above.
We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and
investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our
continued operations, including our near-term continued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be required to repurchase the warrants, which may prevent or deter a third party from acquiring us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants provide that in the event of a &#8220;Fundamental Transaction&#8221; (as defined in the related warrant agreement, which generally
includes any merger with another entity, the sale, transfer or other disposition of all or substantially all of our assets to another
entity, or the acquisition by a person of more than 50% of our common stock), each warrant holder will have the right at any time prior
to the consummation of the Fundamental Transaction to require us to repurchase the warrant for a purchase price in cash equal to the
Black-Scholes value (as calculated under the warrant agreement) of the then remaining unexercised portion of such warrant on the date
of such Fundamental Transaction, which may materially adversely affect our financial condition and/or results of operations and may prevent
or deter a third party from acquiring us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><i>FINRA sales practice requirements
may limit a stockholder&#8217;s ability to buy and sell our securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Effective June 30, 2020, the SEC implemented
Regulation Best Interest requiring that &#8220;[a] broker, dealer, or a natural person who is an associated person of a broker or dealer,
when making a recommendation of any securities transaction or investment strategy involving securities (including account recommendations)
to a retail customer, shall act in the best interest of the retail customer at the time the recommendation is made, without placing the
financial or other interest of the broker, dealer, or natural person who is an associated person of a broker or dealer making the recommendation
ahead of the interest of the retail customer.&#8221; This is a significantly higher standard for broker-dealers to recommend securities
to retail customers than before under FINRA &#8220;suitability rules.&#8221; FINRA suitability rules&#160;do still apply to institutional
investors and require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that
the investment is suitable for that customer. Prior to recommending securities to their customers, broker-dealers must make reasonable
efforts to obtain information about the customer&#8217;s financial status, tax status, investment objectives and other information, and
for retail customers determine the investment is in the customer&#8217;s &#8220;best interest&#8221; and meet other SEC requirements.
Both SEC Regulation Best Interest and FINRA&#8217;s suitability requirements may make it more difficult for broker-dealers to recommend
that their customers buy speculative, low-priced securities. They may affect investing in our common stock, which may have the effect
of reducing the level of trading activity in our securities. As a result, fewer broker-dealers may be willing to make a market in our
common stock, reducing a stockholder&#8217;s ability to resell our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business and Financial Condition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. We will
be unable to continue to operate for the foreseeable future without additional capital.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm issued a report dated March 25, 2024 in connection with the audits of our consolidated
financial statements for the years ended December 31, 2023 and December 31, 2022, which included an explanatory paragraph describing
the existence of conditions that raise substantial doubt about our ability to continue as a going concern including our recurring losses,
cash used in operations, and need to raise additional funds to meet our obligations and sustain our operations. In addition, the notes
to our financial statements for the year ended December 31, 2023, included in the registration statement of which this prospectus
forms a part, contain a disclosure describing the existence of conditions that raise substantial doubt about our ability to continue
as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain substantial additional funding
in connection with our continuing operations. Adequate additional financing may not be available to us in the necessary timeframe, in
the amounts we require, on terms that are acceptable to us, or at all. If we are unable to raise additional capital our business, prospectus,
financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern.
If we are not able to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those
assets are carried on our consolidated financial statements and/or seek protection under federal bankruptcy law, and it is likely that
holders of our common stock and holders of securities convertible into our common stock will lose all of their investment. If we seek
additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue
as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial
doubt about our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are dependent on the success of our prospective product candidates, which are in early stages of development, and there can be no assurances
that any such prospects will reach a particular stage in development, receive regulatory approval or be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend on our ability to successfully develop and commercialize our prospective product candidates through our development
programs. We intend to develop at least one product candidate, EB-003 by undergoing the long, costly clinical-trial process under an
IND application and, eventually, obtaining FDA approval under an NDA before proceeding to market. In order to proceed with development
of our pharmaceutical product candidates under the NDA pathway, we must obtain the FDA&#8217;s approval of our IND application and conduct
preclinical and clinical trials in compliance with the applicable IND regulations, clinical-study protocols, and other applicable regulations
and related requirements. We may never be able to develop products which are commercially viable or receive regulatory approval in the
U.S. or elsewhere. There can be no assurance that the FDA or any other regulatory authority will approve of our current or future product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or &#8220;FDCA,&#8221; and implementing regulations.
Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. The process required by the FDA before a new drug or biological product may be marketed in the United States
generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of preclinical laboratory tests, animal studies, and formulation studies according to Good Laboratory Practices and other applicable
    regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    to the FDA of an IND application, which must become effective before human clinical trials may begin in the United States;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance
    of adequate and well-controlled human clinical trials according to the FDA&#8217;s current good clinical practices, or GCPs, which
    sufficiently demonstrate the safety and efficacy of the proposed drug or biologic for its intended uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission
    to the FDA of a New Drug Application, or an NDA, for a new drug product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory
    completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess
    compliance with the FDA&#8217;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and
    controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
    FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or biologics license application;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and, potentially, approval of the NDA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require
the expenditure of substantial resources. There can be no certainty that approvals will be granted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter difficulties that may delay, suspend or scale back our efforts to advance additional early research programs through preclinical
development and IND application filings and into clinical development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to advance early research programs through preclinical development and to file an IND application for human clinical trials evaluating
the prospective product candidates in our pipeline. The preparation and submission of IND applications requires rigorous and time-consuming
preclinical testing, the results of which must be sufficiently documented to establish, among other things, the toxicity, safety, manufacturing,
chemistry and clinical protocol of the product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent
us from successfully executing our current development strategy. In addition, our ability to complete and file certain IND applications
may depend on the support of our partners and the timely performance of their obligations under relevant collaboration agreements. If
our relevant partners are not able to perform such obligations, or if they otherwise delay the progress, we may not be able to prepare
and file the intended IND applications on a timely basis or at all. Any delay, suspension or reduction of our efforts to pursue our preclinical
and IND strategy could have a material adverse effect on our business and cause our share price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Catastrophic
events could have a material adverse effect on our business, including current plans for product development, as well as any currently
ongoing preclinical studies and clinical trials and any future studies or other development or commercialization activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations and business could be disrupted by natural disasters; industrial accidents; public health issues and global pandemics such
as COVID 19; cybersecurity incidents; interruptions of service from utilities, transportation restrictions or disruptions, telecommunications,
or IT systems providers; manufacturing equipment failures; geopolitical conflict; terrorism; or other catastrophic events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catastrophic
events could severely impact our business, including, but not limited to, our current or future preclinical studies, clinical trials,
regulatory progress, or any other development or commercialization activities, including (among others):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in enrolling patients in clinical trials, specifically since many of the patients are considered immunocompromised;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial
    sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by
    federal or state governments, employers and others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees
    or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical
    trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in local regulations as part of a response to a catastrophic event which may require us to change the ways in which our clinical
    trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
    in employee resources or forced furlough of government employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention
    to approval of other therapeutics or other activities related; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a catastrophic event could disrupt our operations due to absenteeism by infected or ill members of management or other employees,
or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our
office or laboratory facilities, or due to quarantines. A catastrophic event could also impact members of our board of directors, resulting
in absenteeism from meetings of the directors or committees of directors, and making it more difficult to convene the quorums of the
full board of directors or our committees needed to conduct meetings for the management of our affairs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have significant and increasing liquidity needs and may require additional funding.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development, management and administrative expenses and cash used for operations will continue to be significant and may increase
substantially in the future in connection with new and continued research and development initiatives and our pursuit of IND authorization(s)
for some or all of our product candidates, as is required to initiate clinical trials in human subjects in the United States. We will
need to raise additional capital to fund our operations, continue to conduct clinical trials to support potential regulatory approval
of marketing applications, and to fund commercialization of our current and future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, number, initiation, progress, timing, costs, design, duration, delays (if any), and results of preclinical and clinical studies
    for our current or future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA,
    and comparable foreign regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and amount of revenue generated or received, including any revenue from grants or other sources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate of progress and cost of our clinical trials and other product development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights associated with our current
    and future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of competing technological and market developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">personnel,
    facilities and equipment requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    terms and timing of any additional collaborative, licensing, co-promotion or other arrangements that we may establish.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect to fund our future capital requirements from financing arrangements, we cannot assure you that any such financing arrangements
will be available to it on favorable terms, or at all. Even if we can raise funds from financing arrangements, the amounts raised may
not be sufficient to meet our future capital requirements. Additionally, the Company does not have sufficient unreserved, authorized
shares to secure an equity investment of a sufficient amount, based on the Company&#8217;s currently traded price per share, and the
Company will require stockholder approval to increase the amount of authorized shares. If we are not able to raise capital, we
could be required to postpone, scale back or eliminate some, or all, of our development objectives or commercialization efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on our current key personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have consolidated our employee base to save capital and focus on development of our lead candidate EB-303. As of the date hereof,
we employ five full-time employees and one part-time employee. We are highly dependent on our current management and scientific
personnel, including Joseph Tucker, Peter Facchini, and Kevin Coveney. The inability to hire or retain experienced management
personnel could adversely affect our ability to execute our business plan and harm our operating results. Due to the specialized
scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific,
technical and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense and we may be
unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable
replacement personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
has been limited study on the effects of psychedelic- inspired drug candidates, and future clinical research studies may lead
to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy,
dosing, and social acceptance of psychedelics.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
relating to the medical benefits, viability, safety, efficacy, and dosing of psychedelic-inspired drug candidates remains in relatively
early stages. There have been few clinical trials on the benefits of psychedelic-inspired drug candidates conducted by us or by
others. Future research and clinical trials may draw opposing conclusions to statements contained in the articles, reports and studies
we have relied on, or could reach different or negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing
or other facts and perceptions related to psychedelic-inspired drug candidates, which could adversely affect social acceptance
of such molecules and the demand for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
limited resources have lead us to focus on a particular candidate. As a result, we may fail to capitalize on product candidates that
may be more profitable or for which there is a greater likelihood of medical and commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our limited financial, managerial and scientific leadership resources we have focused on developing product candidates that
we have identified as most likely to succeed. As such, we have elected to forego or delay for the time being the development of other
candidates that may prove to have greater potential. Our resource allocation decisions may cause us to fail to capitalize on viable medical
solutions, therapeutic enhancements and commercial potentials for viable markets when our spending on our current and future defined
candidates with the indications specified therein may not yield any commercially viable products. Inaccurate evaluation of potential
may result in relinquishment of valuable product candidate opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to face intense competition, often from companies with greater resources and experience than us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry is highly competitive, with an emphasis on proprietary products and subject to rapid change. The industry continues
to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and
potential competitors have substantially greater financial, technological, managerial and research and development resources and experience
than us. Some of these competitors and potential competitors have more experience than us in the development of pharmaceutical products,
including validation procedures and regulatory matters. In addition, our future product candidates, if successfully developed, will compete
with product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than
us or our collaboration partners have. Other companies with greater resources than we may announce similar plans in the future. In addition,
small or early stage companies may prove to be competitors, particularly through collaborative arrangements with large and established
companies. If we are unable to compete successfully, our commercial opportunities will be reduced and our business, results of operations
and financial conditions may be materially harmed. In addition, we compete with these companies in recruiting and retaining scientific
personnel as well as establishing clinical trial sites and patient registration for clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and future preclinical and clinical studies may be conducted outside the United States, and the FDA may not accept data from
such studies to support any NDAs we may submit after completing the applicable developmental and regulatory prerequisites.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are conducting, or may conduct, preclinical and/or clinical studies outside the United States. To
the extent we do not conduct these clinical trials in accordance under an IND application, the FDA may not accept data from such trials.
Although the FDA may accept data from clinical trials conducted outside the United States that are not conducted under an IND application,
the FDA&#8217;s acceptance of the data is subject to certain conditions. For example, the clinical trial must be well designed and conducted
and performed by qualified investigators in accordance with ethical principles and all applicable FDA regulations. The trial population
must also adequately represent the intended U.S. population, and the data must be applicable to the U.S. population and U.S. medical
practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside
of the United States must be representative of the population for whom we intend to market the product candidate in the United States,
if approved. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent
upon our ability to verify the data and our determination that the trials also complied with all applicable U.S. laws and regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and foreign statutes and
regulations requires the expenditure of substantial time and financial resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data
from such clinical trials, we would likely result in the need for additional trials and the completion of additional regulatory steps,
which would be costly and time-consuming and could delay or permanently halt our development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, we may not have favorable
results in our planned and future clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of therapeutic products is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Drug
development involves long lead times and involves many variables of uncertainty. Product candidates that appear promising in the early
phases of development may fail to reach the market for several reasons including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical
    study results that may show the product to be less effective than desired (e.g., the study failed to meet our primary objectives)
    or to have harmful or problematic side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused
    by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis
    or an IND and later NDA, preparation, discussions with the FDA, an FDA request for additional preclinical or clinical data or unexpected
    safety or manufacturing issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    costs, pricing, or reimbursement issues or other factors that make the product not economical; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
positive results from our preclinical testing of our prospective product candidates may not necessarily be predictive of the results
from planned or future clinical trials for such product candidates. Many companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in clinical trials after achieving positive results in preclinical and early clinical development,
and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical
findings while clinical trials were underway or safety or efficacy observations in clinical trials, including adverse events. Moreover,
our interpretation of clinical data or our conclusions based on the preclinical in vitro and in vivo models may prove inaccurate, as
preclinical and clinical data can be susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory approvals.
Similarly, undesirable side effects caused by our product candidates could cause us or regulatory authorities to limit dosage in development
or interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval
by the FDA or other comparable foreign authorities. Restrictive label applications may include but are not limited to a Boxed Warning,
Risk Evaluation and Mitigation Strategies, or REMS, or other limitations of use. Drug-related side effects during one clinical trial
furthermore could affect patient recruitment or the ability of enrolled patients to complete the trial, result in potential product liability
claims or our ability to ensure enrollment for future trials. Any of these occurrences may harm our business, financial condition and
prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
approval is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated,
and we may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved
or &#8220;off-label&#8221; uses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
the FDA or comparable foreign regulatory authorities issue regulatory approval for a product candidate, the regulatory approval is limited
to those specific indications for which a product is approved. If we are not able to obtain FDA approval for any desired future indications
for our products and product candidates, our ability to effectively market and sell our products may be reduced and our business may
be adversely affected. While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling
and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, we are prohibited from marketing
and promoting the products for indications that are not specifically approved by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
&#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied
circumstances. Regulatory authorities in the United States generally do not restrict or regulate the behavior of physicians in their
choice of treatment within the practice of medicine. Regulatory authorities do, however, restrict communications by pharmaceutical companies
on off-label use. If the FDA determines that our promotional activities constitute promotion of an off-label use, it could request that
we modify our promotional materials or subject us to regulatory or enforcement actions by other agencies, including issuance of warning
letters, suspension or withdraw an approved product from the market, additional reporting requirements and/or oversight if we become
subject to a corporate integrity agreement or similar agreement, any of which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
interruptions could delay us in the process of developing our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
of our stored materials or facilities through fire, theft, or other causes could have an adverse effect on our ability to continue product
development activities and to conduct our business. Even if we obtain insurance coverage to compensate us for such business interruptions,
such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any significant property or
casualty loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and legal requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with
regulations promulgated by the FDA, SEC or Office of Inspector General of the Department of Health and Human Services, or regulations
of any other applicable regulatory authority, failure to provide accurate information to the FDA or the SEC, comply with applicable manufacturing
standards, other federal, state or foreign laws and regulations, report information or data accurately or disclose unauthorized activities.
Employee misconduct could also involve the improper use of confidential or protected information, including information obtained in the
course of clinical trials, or illegal pre-approval promotion of drug candidates, which could result in government investigations, enforcement
actions and serious harm to our reputation. We have adopted a Corporate Code of Conduct and Ethics and Whistleblower Policy, but employee
misconduct is not always possible to identify and deter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
precautions we take to detect and prevent these prohibited activities may not be effective in controlling unknown or unmanaged risks
or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending our Company or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to collect and store sensitive data, including valuable and commercially sensitive intellectual
property, clinical trial data, our proprietary business information and that of our future customers, suppliers and business partners,
and personally identifiable information of our customers, clinical trial subjects and employees, patients, in our data centers and on
our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security
measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance
or other disruptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any
such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the
privacy of personal information, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence
in our products and our ability to conduct clinical trials, which could adversely affect our business and reputation and lead to delays
in gaining regulatory approvals for our future product candidates. Although we may obtain business interruption insurance coverage in
the future, our insurance might not cover all losses from any future breaches of our systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
of our information technology systems, including cybersecurity attacks or other data security incidents, could significantly disrupt
the operation of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business depends on the use of information technologies. Our ability to execute our business plan and to comply with regulators&#8217;
requirements with respect to data control and data integrity, depends, in part, on the uninterrupted performance of our information technology
systems, or IT systems and the IT systems supplied by third-party service providers. Our IT systems are vulnerable to damage from a variety
of sources, including telecommunications or network failures, malicious human acts, natural disasters and more sophisticated and targeted
cyber-related attacks that pose a risk to the security of our information systems and networks and the confidentiality, availability
and integrity of data and information. A successful cybersecurity attack or other data security incident could result in the misappropriation
and/or loss of confidential or personal information, create system interruptions, or deploy malicious software that attacks our systems.
It is also possible that a cybersecurity attack might not be noticed for some period of time. In addition, sustained or repeated system
failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain data could
adversely affect our ability to operate our business. The occurrence of a cybersecurity attack or incident could result in business interruptions
from the disruption of our IT systems, or negative publicity resulting in reputational damage with our stockholders and other
stakeholders and/or increased costs to prevent, respond to or mitigate cybersecurity events. In addition, the unauthorized dissemination
of sensitive personal information or proprietary or confidential information could expose us or other third-parties to regulatory fines
or penalties, litigation and potential liability, or otherwise harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent it from accessing
critical information or expose it to liability, which could adversely affect our business and its reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we expect to collect and store sensitive data, including legally protected patient health information,
credit card information, personally identifiable information about our employees, intellectual property, and proprietary business information.
We expect to manage and maintain this data utilizing on-site systems. This data includes a wide variety of business-critical information
including research and development information, commercial information and business and financial information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy,
and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized
access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches or
interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any
such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties,
publicly disclosed, lost or stolen. In the future, any such access, disclosure or other loss of information could result in legal claims
or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability
Act (HIPPA) and European Union General Data Protection Regulation, government enforcement actions and regulatory penalties. Unauthorized
access, loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, share
and monitor safety data, bill payors or patients, provide customer support services, conduct research and development activities, process
and prepare company financial information, manage various general and administrative aspects of our business and may damage our reputation,
any of which could adversely affect our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
operating results may vary significantly in future periods.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the early stages of product development and expect to focus substantial efforts for, at least, the next several years on preclinical
and clinical trials and other research and development activities. We have not obtained regulatory approval for any product candidates.
Our revenues, expenses and operating results are likely to fluctuate significantly in the future. We expect to incur substantial additional
operating expenses over the next several years as our research, development, and preclinical and clinical study activities increase.
Our financial results are unpredictable and may fluctuate, for among other reasons, due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, number, progress, duration, endpoints, cost, results, and timing of our preclinical testing and clinical studies of current
    or potential future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funding to develop product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the commencement, enrollment and timing of clinical studies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus,
small declines in revenue could disproportionately affect financial results in a quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Significant
ongoing costs and obligations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a neuro-pharmaceutical drug discovery and development platform company, the Company expects to spend substantial funds on the research,
development and testing of psychedelic-inspired drug candidates. In addition, the Company expects to incur significant ongoing
costs and obligations related to its investment in infrastructure and growth and for regulatory compliance, which could have a material
adverse impact on the Company&#8217;s results of operations, financial condition and cash flows. The Company will also require significant
additional funds if it expands the scope of current plans for research and development or if it were to acquire any other assets and
advance their development. It is possible that future financing will not be available or, if available, may not be on favorable terms.
The availability of financing will be affected by the achievement of the Company&#8217;s corporate goals, the results of scientific and
clinical research, the need and ability to obtain regulatory approvals and the state of the capital markets generally. If adequate funding
is not available, the Company may be required to delay, reduce or eliminate one or more of its research and development programs, or
obtain funds through corporate partners or others who may require the Company to relinquish significant rights to its psychedelic-inspired drug candidates or obtain funds on less favorable terms than the Company would otherwise accept. To the extent that external
sources of capital become limited or unavailable or available on onerous terms, the Company&#8217;s intangible assets and its ability
to continue its business plans may become impaired, and the Company&#8217;s assets, liabilities, business, financial condition and results
of operations may be materially or adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, future changes in regulations, changes in legal status of psychedelic and/or psychedelic-inspired products, more vigorous
enforcement thereof or other unanticipated events could require extensive changes to the Company&#8217;s operations, increased compliance
costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial
condition of the Company. The Company&#8217;s efforts to grow its business may be costlier than expected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may rely on third parties to plan and conduct preclinical and clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may rely on third parties to conduct preclinical development activities and intend to partner with third parties who may conduct
clinical development activities with our psychedelic-inspired drug candidates and other product candidates. Preclinical activities
include &#8220;in vivo&#8221; studies providing access to specific disease models, pharmacology and toxicology studies, and assay development.
Clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring,
clinical data management and analysis, safety monitoring and project management. If there is any dispute or disruption in its relationship
with third parties, or if such third parties are unable to provide quality services in a timely manner and at a feasible cost, or if
such third parties fail to meet certain development milestones, our active development programs may face delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
if any of these third parties fails to perform as we expect or if their work fails to meet regulatory requirements, the testing and eventual
development of viable drug candidates could be delayed, cancelled or rendered ineffective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third-party contract manufacturers.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of the &#8220;in vitro&#8221; portion
of the preclinical testing we intend to conduct, when only lab-grade and lab-scale drug candidate molecules are required, we intend
to synthesize the required psychedelic molecules in our laboratories in Calgary or at other third-party contract research
organizations (&#8220;CROs&#8221;) that provide synthetic chemistry services. We have limited control over these third-party CROs. When
larger quantities and higher quality psychedelic molecules are required (e.g., for animal model testing), we intend to contract with
appropriate third-party contract manufacturing organizations (&#8220;CMOs&#8221;), over which we may have limited control
to, among other things, supply the active pharmaceutical ingredient (&#8220;API&#8221;) used in our drug candidates. We intend
to rely on CMOs to supply APIs and formulated drug products in compliance with GMP regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
applicable jurisdictions, including Health Canada, and the FDA, ensure the quality of drug candidates by carefully monitoring
drug manufacturers&#8217; compliance with GMP regulations. The GMP regulations for drug candidates contain minimum requirements
for the methods, facilities and controls used in manufacturing, processing and packing of APIs and formulated a drug products.
There can be no assurances that CMOs will be able to meet our timetable and requirements or carry out their contractual obligations
in accordance with the applicable regulations. In addition, the API and/or formulated drug product that they supply to us may
not meet our specifications and quality policies and procedures or they may not be able to supply the API and/or formulated drug product
in commercial quantities. If we are unable to arrange for alternative third-party supply sources on commercially reasonable terms
or in a timely manner, it may delay the development of our drug candidates and could have a material adverse effect on our business
operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the failure of CMOs to operate in compliance with GMP regulations could result in, among other things, certain product liability claims
in the event such failure to comply results in defective products (containing our drug candidates) that caused injury or harm.
In general, our dependence upon third parties for the supply of our APIs and formulated drug products may adversely affect profit
margins and our ability to develop and deliver viable drug candidates on a timely and competitive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination
or non-renewal of key licenses and agreements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is highly dependent on key licenses and agreements which expire in a short time period. Specifically, in conducting research
and preclinical studies in compliance with current legislation, we substantially rely on the Facchini Drug License, which expires on
December 31, 2025. Health Canada renews drug licenses annually and Dr. Facchini has held the Facchini Drug License since October 5, 1995
and it has been renewed each year without issue. Until Enveric obtains its own Dealer&#8217;s License or Section 56 Exemption necessary
for its business, the termination, non-renewal or hindrance of use of the Facchini Drug License would have a material adverse effect
on Enveric&#8217;s ability to develop psychedelic-inspired drug candidate, conduct research or operate its business as it currently
does. This could have a material adverse impact on Enveric&#8217;s financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negative
results from clinical trials or studies of others and adverse safety events involving our drug candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, studies or clinical trials on various aspects of biopharmaceutical or natural health products (&#8220;NHPs&#8221;) are
conducted by academic researchers, competitors or others. The results of these studies or trials, when published, may have a significant
effect on the market for the biopharmaceutical or NHP that is the subject of the study. The publication of negative results of studies
or clinical trials or adverse safety events related to the psychedelic compounds similar to those used by us in the development
of our psychedelic-inspired drug candidates, or the therapeutic areas in which our drug candidates compete, could adversely
affect our share price and our ability to finance future development of our drug candidates, and our business and financial results
could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials of our drug candidates may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or not
otherwise produce positive results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
we or third parties (who may license or acquire our drug candidates) are able to obtain marketing approval from regulatory
authorities for the sale of products containing our drug candidates, the completion of preclinical studies in animals and extensive
clinical trials in humans to demonstrate the safety and efficacy of the drug candidates will be required. Clinical testing is
expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical
studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not
necessarily predict final results. A number of companies in the pharmaceutical, NHP and biotechnology industries have suffered significant
setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier
trials. We do not know whether the clinical trials that we or third parties may conduct will demonstrate adequate efficacy and
safety to result in regulatory approval to market any products containing our drug candidates in any jurisdiction. A product/compound
candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk we face is the possibility that none
of the products containing our drug candidates will successfully gain market approval from Health Canada, the FDA or other regulatory
authorities, resulting in our inability to derive any royalty-based revenue from them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raw
materials requiring regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
raw materials used by us to create biosynthesized compounds may require regulatory approval by Health Canada, the FDA or
other regulatory authorities in foreign jurisdictions because the plant or fungi may contain a controlled substance. While we believe
that we can acquire, or indirectly make use of, the requisite licenses to conduct our intended research and development activities, there
is a risk that Health Canada, the FDA or other regulatory authorities can either reject or require further action to approve
the requisite licenses which would cause delays or result in losses for us and could result in the abandonment of a specific research
programs. Raw materials and supplies are generally available in quantities to meet the needs of our business. An inability to obtain
raw materials or product supply could have a material adverse impact on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Possible
increase in costs beyond what is currently expected as a result of regulatory review.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
Canada, the FDA or other regulatory authorities in foreign jurisdictions have not yet determined whether our psychedelic-inspired
drug candidates will be scheduled as controlled substances. Based on preclinical and/or clinical abuse liability studies,
Health Canada, the FDA or other regulatory authorities may determine that our products are controlled substances
and therefore, require additional regulatory controls. Such additional regulatory requirements may increase our costs and
cause a delay in our operations. Further, if Health Canada, the FDA or other regulatory authorities require that we perform
additional preclinical or clinical studies, or if we determine that additional preclinical or clinical studies are required
for our drug candidates, our expenses would further increase beyond what is currently expected and the anticipated timing of any
potential approval of our drug candidates or licensing out agreements would likely be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have never been profitable, have no products approved for commercial sale, and have generated no reported revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never been profitable and we do not expect to be profitable in the foreseeable future. Neither us, nor any third-party partner,
have submitted any applications containing our products for approval by regulatory authorities in Canada, the United States or
elsewhere. As of September 30, 2024, we had an accumulated deficit of $102,919,859 million and accumulated other comprehensive losses
of $534,998. To date, we have devoted most of our financial resources to research and development, including drug discovery research,
preclinical development activities, patent application filings and prosecution, and media relation efforts, as well as corporate
overhead.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generated no reportable revenues since inception through September 30, 2024, we expect to continue to incur losses for
the foreseeable future, and expect these losses to increase as we continue our product development activities. If our drug candidates
and other products developed do not achieve market acceptance, we may never become profitable. As a result of the foregoing, we expect
to continue to experience net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have
had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of
increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required
by the FDA, Health Canada or other regulatory authorities in foreign jurisdictions to perform preclinical studies or clinical
trials in addition to those currently expected, or if there are any delays in completing our preclinical studies or the development
of any of our drug candidates or other products. The amount of future net losses will depend, in part, on the rate of future growth
of our expenses and our ability to generate revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have no commercial licensing, marketing or distribution experience and will have to invest significant resources to develop those
capabilities or enter into acceptable third-party sales and marketing transactions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no commercial licensing, marketing or distribution experience. To develop commercial licensing, distribution and
marketing capabilities, we will have to invest significant amounts of financial and management resources, some of which will need to
be committed prior to any confirmation that our drug candidates will be approved by the FDA, Health Canada or other regulatory authorities in foreign jurisdictions.
Where we decide to perform commercial licensing, marketing and distribution functions itself or through third parties, we
could face a number of additional risks, including that we or our third-party collaborators may not be able to build and maintain an
effective marketing or sales force. If we use third parties to market and distribute any products arising from our drug
candidates, we may have limited or no control over our commercial licensing, marketing and distribution activities on
which our future revenues may depend.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time seek to enforce our intellectual property rights against infringers when we determine that a successful outcome
is probable and may lead to an increase in the value of the intellectual property. If we choose to enforce our patent rights against
a party, then that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced.
Additionally, the validity of our patents and the patents we have licensed may be challenged if a petition for post grant proceedings
such as inter-partes review and post grant review is filed within the statutorily applicable time with the United States Patent and Trademark
Office or other applicable patent authority. These lawsuits and proceedings are expensive and would consume time and resources
and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other
party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to
stop the other party on the ground that such other party&#8217;s activities do not infringe our intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law and its interpretation could diminish the value of patents in general, thereby impairing our ability to protect our drug
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other NHP, biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property rights,
particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity,
and obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. The Supreme Court of Canada
and the U.S. Supreme Court have ruled on several patent cases in recent years, either narrowing the scope of patent protection available
in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on decisions by the Canadian House of Representative, the Federal Court of Canada, the Canadian Intellectual
Property Office, U.S. Congress, the federal courts, and the U.S. Patent and Trademark Office and international treaties entered into
by these nations, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
patents or to enforce patents we may obtain in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to manage growth</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we advance our drug candidates through preclinical studies and early clinical development and seek business arrangements
and partnerships with third parties to advance our drug candidates through later stage clinical development, we will need
to increase our research and development personnel, scientific, management, and administrative headcount to manage these
programs and partnerships. In addition, to meet obligations as a public company, we may need to increase our general and administrative
capabilities and improve our operational and financial controls and reporting procedures. Our management, personnel and systems currently
in place may not be adequate to support this future growth. In managing our growing operations, we are also subject to the risks of over-hiring
and/or overcompensating our employees and over-expanding our operating infrastructure. As a result, we may be unable to manage our expenses
effectively in the future, which may negatively impact our gross profit or operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insurance
and uninsured risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks and hazards generally, including adverse preclinical trial results, accidents, labor disputes
and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental
damage, delays in operations, monetary losses and possible legal liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
insurance may not cover all the potential risks associated with our operations. We may also be unable to maintain insurance to cover
these risks at economically feasible premiums. Insurance coverage may not be available or may not be adequate to cover any resulting
liability. Moreover, insurance against risks such as environmental pollution or other hazards encountered in our operations is not generally
available on acceptable terms. We might also become subject to liability for pollution or other hazards which may not be insured against
or which we may elect not to insure against because of premium costs or other reasons. Losses from these events or any significant uninsured
liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become party to litigation from time to time in the ordinary course of business which could adversely affect our business. Should
any litigation in which we become involved be determined against us such a decision could adversely affect our ability to continue operating
and the market price for our shares and could use significant resources. Even if we are involved in litigation and win, litigation can
redirect significant company resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conflicts
of interest</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our directors and officers do not devote their full time to the affairs of the Company and certain of our directors and officers are
also directors, officers and stockholders of other biotechnology and research and development companies or other public companies
in general, and as a result they may find themselves in a position where their duty to another company conflicts with their duty to the
Company. There is no assurance that any such conflicts will be resolved in favor of the Company. If any such conflicts are not resolved
in our favor we may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic- inspired medicines industry and market are relatively new in this industry and the market may not continue
to exist or grow as anticipated.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate our business in a relatively new industry and market. In addition to being subject to general business risks, we must continue
to build brand awareness in this industry and market through significant investments in our strategy, our operational capacity, quality
assurance and compliance with regulations. In addition, there is no assurance that the industry and market will continue to exist and
grow as currently estimated or anticipated or function and evolve in the manner consistent with management&#8217;s expectations and assumptions.
Any event or circumstance that adversely affects the psychedelic-inspired medicines industry and market could have a material
adverse effect on our business, financial conditions and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic and psychedelic-inspired medicine market will face specific marketing challenges given the psychedelic products&#8217;
status as a controlled substance which resulted in past and current public perception that the products have negative health and lifestyle
effects and have the potential to cause physical and social harm due to psychoactive and potentially addictive effects. Any marketing
efforts by us would need to overcome this perception to build consumer confidence, brand recognition and goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelics-inspired medicines industry and market are relatively new, and the industry may not succeed in the long term.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate our business in a relatively new industry and market. The use of psychedelic-inspired medicines for medicinal purposes
has shown promise in various studies and we believe that both regulators and the public have an increasing awareness and acceptance of
this promising field. Nevertheless, psychedelics remain a controlled substance in the United States, Canada, and most other jurisdictions
and their use for research and therapeutic purposes remains highly regulated and narrow in scope. There is no assurance that the industry
and market will continue to grow as currently estimated or anticipated or function and evolve in the manner consistent with management&#8217;s
expectations and assumptions. Any event or circumstance that adversely affects the psychedelic manufacturing and medicines industry and
market could have a material adverse effect on our business, financial condition and results of operations. We have committed and expect
to continue committing significant resources and capital to the development of psychedelic-inspired products for therapeutic uses.
As a category of products, medical-grade psychedelics raw materials and psychedelic-derived APIs, and research into such substances,
represent relatively untested offerings in the marketplace, and we cannot provide assurance that psychedelics as a category, or that
our prospective psychedelic-inspired products, in particular, will achieve market acceptance. Moreover, as a relatively new industry,
there are not many established players in the psychedelic-inspired medicines industry whose business model we can emulate. Similarly,
there is little information about comparable companies available for potential investors to review in making a decision about whether
to invest in our common shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
psychedelic-inspired durg candidates may generate public controversy. Adverse publicity or public perception regarding the psychedelic-inspired
APIs we intend to utilize may negatively influence our success and that of our prospective investigational therapies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to establish and grow our business is substantially dependent on the success of the emerging market for psychedelic-inspired
medicines, which will depend upon, among other matters, pronounced and rapidly changing public preferences, factors which are difficult
to predict and over which we have little, if any, control. We and our clients will be highly dependent upon consumer perception of psychedelic-inspired
medicines and other products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapies
containing controlled substances may generate public controversy. Political and social pressures and adverse publicity could lead to
delays in approval of, and increased expenses for any future therapeutic candidates we may develop. Opponents of these therapies may
seek restrictions on marketing and withdrawal of any regulatory approvals. In addition, these opponents may seek to generate negative
publicity in an effort to persuade the medical community to reject these therapies. For example, we may face media-communicated criticism
directed at our clinical development program. Adverse publicity from psilocybin misuse may adversely affect the commercial success or
market penetration achievable by our product candidates. Anti-psychedelic protests have historically occurred and may occur in the future
and generate media coverage. Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit
or restrict the introduction and marketing of any future therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
expansion of the use of psychedelic-inspired medicines in the medical industry may require new clinical research into effective
medical therapies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
in United States and internationally regarding the medical benefits, viability, safety, efficacy, addictiveness, dosing and social acceptance
of psychedelic-inspired products remains in early stages. There have been relatively few clinical trials on the benefits of such
products. Although we believe that the articles, reports and studies support our beliefs regarding the medical benefits, viability, safety,
efficacy, dosing and social acceptance of psychedelic-inspired products, future research and clinical trials may prove such statements
to be incorrect, or could raise concerns regarding, and perceptions relating to, psychedelic-inspired products. Given these risks,
uncertainties and assumptions, readers should not place undue reliance on such articles and reports. Future research studies and clinical
trials may draw opposing conclusions to those stated in this prospectus or reach negative conclusions regarding the medical benefits,
viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to psychedelic-inspired products,
which could have a material adverse effect on the demand for our drug candidates with the potential to lead to a material adverse
effect on the Company&#8217;s business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic-inspired medicine industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy
of market data.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the psychedelic-inspired medicine industry is in a nascent stage with uncertain boundaries, there is a lack of information about
comparable companies available for potential investors to review in deciding about whether to invest in us and, few, if any, established
companies whose business model we can follow or upon whose success we can build. Accordingly, investors will have to rely on their own
estimates in deciding about whether to invest in us. There can be no assurance that our estimates are accurate or that the market size
is sufficiently large for our business to grow as projected, which may negatively impact our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic-inspired medicine and biotechnology industries are experiencing rapid growth and increased competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic-inspired medicine and biotechnology industries are undergoing rapid growth and substantial change, which has resulted
in an increase in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions
could harm us in a number of ways, including, without limitation, by losing strategic partners if they are acquired by or enter into
relationships with a competitor, losing customers, revenue and market share, or forcing us to expend greater resources to meet new or
additional competitive threats, all of which could harm our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
We have competitors in Canada, the United States, Europe and other jurisdictions, including, without limitation, major multinational
pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies and universities and
other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development
staff and more experienced marketing and manufacturing organizations than we do. Large pharmaceutical companies, in particular, have
extensive experience in, and substantial capital resources for, conducting research, molecular derivative development, obtaining regulatory
approvals, obtaining intellectual property protection and establishing key relationships. These companies also have significantly greater
sales and marketing capabilities and experience in completing collaborative transactions in our target markets with leading companies
and research institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may introduce new psychedelic-inspired medicines or develop technological advances that compete with us. We cannot predict
the timing or impact of competitors introducing new psychedelic-inspired medicines or technological advances. Such competing psychedelic-inspired
medicines may be safer, more effective, more effectively marketed, licensed or sold or have lower prices or superior performance features
than our psychedelic-inspired drug candidates, and this could negatively impact our business and results of operations. Established pharmaceutical
companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could
make the psychedelic-inspired drug candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed
in obtaining patent protection or discovering, developing and commercializing psychedelic-inspired medicines before we do or may develop
psychedelic-inspired medicines that are deemed to be more effective or gain greater market acceptance than those of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative transactions with large, established
companies. In addition, many universities and private and public research institutes may become active in the development of novel compounds.
Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and psychedelic-inspired medicines
that are more effective or less costly than any of the psychedelic-inspired drug candidates that we are currently developing or that
we may develop, which could render our psychedelic-inspired drug candidates obsolete or non-competitive. If our competitors market psychedelic-inspired
medicines that are more effective, safer or less expensive or that reach the market sooner than our psychedelic-inspired drug candidates,
if any, we may not achieve commercial success. In addition, because of our limited resources, it may be difficult for us to stay abreast
of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively.
Technological advances or products developed by our competitors may render our technologies or psychedelic-inspired drug candidates obsolete,
less competitive or not economical.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in legislation, regulations and guidelines</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to various laws, regulations and guidelines relating to, among other things, drug research, development, marketing
practices, health and safety, the conduct of operations and preclinical trials. In addition to FDA or Health Canada restrictions
on the marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing
practices in the pharmaceutical and medical industries in recent years, as well as consulting or other service agreements with physicians
or other potential referral sources. While to the knowledge of management, we are currently in compliance with all such laws, changes
to applicable laws, regulations and guidelines may cause adverse effects to its operations. The risks to the business of the Company
represented by this or similar risks are that they could significantly reduce the addressable market for our psychedelic-inspired
drug candidates and could materially and adversely affect the business, financial condition and results of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Regulatory Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
current and prospective product candidates, and the development thereof, are or will be subject to the various federal and state laws
and regulations relating to the safety and efficacy of health products, such as drugs and medical devices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of developing investigational new drugs for which we intend to pursue FDA approval via the NDA process. In these product
candidates synthetic molecules inspired by psychedelics, such as psilocybin, mescaline and MDMA, will be the active pharmaceutical
ingredients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our development and future commercialization (if applicable) of our prospective products, we, and each contemplated product
candidate, are subject to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer, in part, that drugs
and devices are safe and effective for their intended uses and that all labeling and packaging is truthful, informative, and not deceptive.
The FDCA and the U.S. Food and Drug Administration (FDA) regulations define the term &#8220;drug,&#8221; in part, by reference to its
intended use, as &#8220;articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease&#8221; and
&#8220;articles (other than food) intended to affect the structure or any function of the body of man or other animals.&#8221; The definition
also includes components of drugs, such as active pharmaceutical ingredients. To be lawfully marketed in the United States, drugs must
generally either receive premarket approval by FDA through the NDA process or conform to a &#8220;monograph&#8221; for a particular drug
category, as established by FDA&#8217;s Over-the-Counter (OTC) Drug Review. If the FDA does not award premarket approval for our product
candidates through the NDA process, this will have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the nature of the active ingredients we intend to utilize in our product candidates subjects us and our development and future commercialization
(as applicable) activities to additional regulatory scrutiny and oversight. In connection with our development and future commercialization
(if applicable) of psychedelic-inspired drug candidates, we and each contemplated drug candidate could be subject
to the federal Controlled Substances Act (CSA) and the Controlled Substances Import and Export Act in the United States and analogous
state and foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no guarantee that any of our investigational drugs will ever be approved as medicines in any jurisdiction in which the Company operates,
as there are currently no FDA-approved drugs containing the psychedelic-inspired ingredients we intend to utilize as active
ingredients. And, the laws and regulations generally applicable to the industry in which the Company is involved are subject to constant
evolution and may change in ways currently unforeseen. Any amendment to or replacement of existing laws or regulations, including the
re-classification of the substances the Company is developing or with which it is working, which are matters beyond the Company&#8217;s
control, may cause the Company&#8217;s business, financial condition, results of operations and prospects to be adversely affected or
may cause the Company to incur significant costs in complying with such changes or it may be unable to comply therewith. A violation
of any applicable laws and regulations of the jurisdictions in which the Company operates could result in significant fines, penalties,
administrative sanctions, convictions or settlements arising from civil proceedings initiated by either government entities in the jurisdictions
in which the Company operates, or private citizens or criminal charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
psychedelic-inspired drug candidates we are developing or may develop in the future may be subject to controlled substance
laws and regulations in the United States and other countries where the product will be marketed, and failure to comply with these laws
and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business operations
and our financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, psychedelics, such as psilocybin (and its active metabolite, psilocin), N,N-Dimethyltryptamine (&#8220;DMT&#8221;),
mescaline and MDMA, are classified by the DEA as a Schedule I substances under the CSA. The DEA regulates chemical compounds as Schedule
I, II, III, IV or V substances. Schedule I substances by-definition have a high potential for abuse, have no currently accepted medical
use in the United States, lack accepted safety for use under medical supervision, and may not be prescribed marketed or sold in the United
States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances
considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among
such substances. Schedule I and II substances are subject to the strictest controls under the CSA, including manufacturing and procurement
quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II substances is further restricted.
For example, they may not be refilled without a new prescription and may have a black box warning. For any product containing active
ingredients that are Schedule I controlled substances to be available for commercial marketing in the United States, the product must
be scheduled by the DEA to Schedule II, III, IV or V, which requires scheduling-related legislative or administrative action, which can
further delay the path to market. There can be no assurance that the DEA will make a favorable scheduling decision about our psychedelic-inspired
drug candidates. Even assuming categorization as a Schedule II or lower controlled substance (i.e., Schedule III, IV or V), at the
federal level, such substances would also require scheduling determinations under state laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is also a prerequisite to commercialization, and the controlled-substance status, currently undetermined, of our psychedelic-inspired
APIs may negatively impact the FDA&#8217;s decision regarding whether to approve the applicable product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the pre-market review process, the FDA may determine that additional data is needed for one or more of our psychedelic-inspired drug
candidates, either from non-clinical or clinical studies, including with respect to whether, or to what extent, the substance has
abuse potential. This may introduce a delay into the approval and any potential rescheduling process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, therapeutic candidates containing controlled substances are subject to DEA regulations relating to manufacturing, storage,
distribution and physician prescription procedures, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEA
    registration and inspection of facilities. Facilities conducting research, manufacturing, distributing, importing or exporting, or
    dispensing controlled substances must be registered (licensed) to perform these activities and have the security, control, recordkeeping,
    reporting and inventory mechanisms required by the DEA to prevent drug loss and diversion. All these facilities must renew their
    registrations annually, except dispensing facilities, which must renew every three years. The DEA conducts periodic inspections of
    certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations may result
    in delay of the importation, manufacturing or distribution of product candidates. Furthermore, failure to maintain compliance with
    the CSA, particularly non-compliance resulting in loss or diversion, can result in regulatory action that could have a material adverse
    effect on our business, financial condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary
    registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could
    lead to criminal proceedings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    controlled-substances laws. Individual U.S. states have also established controlled substance laws and regulations. Though state-controlled
    substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule product candidates.
    While some states automatically schedule a drug based on federal action, other states schedule drugs through rule making or a legislative
    action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling
    could have a material adverse effect on the commercial attractiveness of such product. We or any partners must also obtain separate
    state registrations, permits or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical
    trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the
    states in addition to those from the DEA or otherwise arising under federal law.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    trials. The abuse liability potential of our psychedelic-inspired drug candidates has not yet been studied. A Human Abuse Potential
    (HAP) study or an equivalent study may determine that, upon regulatory approval, our drug candidate will be a Schedule I controlled
    substance. Therefore, any future research or development activities with the approved drug may require submission of a preclinical
    or clinical protocols to the DEA and obtaining and maintaining a DEA license for each site that uses the approved drug. In that situation,
    if the DEA delays or denies the grant of a researcher registration to one or more research sites, future clinical trials could be
    significantly delayed, and we could lose clinical trial sites.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Importation.
    If any of our product candidates is approved and classified as a Schedule II, III or IV substance, an importer can only import it
    for commercial purposes if it obtains an importer registration and files an application for an import permit for each import. The
    DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled
    substances that the DEA authorizes to be imported. The failure to identify an importer or obtain the necessary import authority,
    including specific quantities, could affect the availability of our product candidates and have a material adverse effect on our
    business, results of operations and financial condition. In addition, an application for a Schedule II importer registration must
    be published in the Federal Register, and there is a waiting period for third-party comments to be submitted. It is always possible
    that adverse comments may delay the grant of an importer registration.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture.
    If, because of a Schedule II classification or voluntarily, we were to conduct manufacturing or repackaging/relabeling in the United
    States, our contract manufacturers would be subject to the DEA&#8217;s annual manufacturing and procurement quota requirements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution.
    If any of our product candidates is approved for marketing and scheduled under Schedule II, III or IV, we would also need to identify
    wholesale distributors with the appropriate DEA registrations and authority to possess and distribute or dispense such products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the psychedelic-inspired</i></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> APIs and
formulated drug products that we intend to utilize in the future are determined to be Schedule I controlled substances
under the CSA in the United States and under similar controlled-substance legislation in other countries, any significant violations
of these laws and regulations, or changes in the laws and regulations, may result in interruptions to our development activity or business
continuity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
psychedelic-inspired APIs we intend to utilize have not yet been studied in preclinical or clinical abuse liability studies
and may be categorized as Schedule I controlled substances under the CSA or the state or foreign equivalent and would likely be.
 illegal without the requisite regulatory authorizations (e.g., to allow for the use of such substances in clinical trials under
an IND and in compliance with all applicable FDA, DEA, and other regulatory requirements). Violations of any federal, state or foreign
laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from
civil proceedings conducted by either the federal government or private citizens, or criminal charges and penalties, including, but not
limited to, disgorgement of profits, cessation of business activities, divestiture or prison time. If such were to occur, this
could have a material adverse effect on us, including on our reputation and ability to conduct business, our financial position, operating
results, profitability or liquidity, the potential listing of our shares or the market price of our shares. In addition, it is difficult
for us to estimate the time or resources that would be needed for the investigation or defense of any such matters or our final resolution
because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the
applicable authorities involved, and such time or resources could be substantial. It is also illegal to aid or abet such activities or
to conspire or attempt to engage in such activities. An investor&#8217;s contribution to and involvement in such activities may result
in federal civil and/or criminal prosecution, including, but not limited to, forfeiture of his, her or its entire investment, fines and/or
imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
federal, state, provincial and local laws govern our business in any jurisdictions in which we may operate, and to which we may export
our products, including laws relating to health and safety, the conduct of our operations, and the production, storage, sale and distribution
of our products. Complying with these laws requires that we comply concurrently with complex federal, state, provincial and/or local
laws. These laws change frequently and may be difficult to interpret and apply. To ensure our compliance with these laws, we will need
to invest significant financial and managerial resources. It is impossible for us to predict the cost of such laws or the effect they
may have on our future operations. A failure to comply with these laws could negatively affect our business and harm our reputation.
Changes to these laws could negatively affect our competitive position and the markets in which we operate, and there is no assurance
that various levels of government in the jurisdictions in which we operate will not pass legislation or regulation that adversely impacts
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we or third parties were to conduct activities in compliance with U.S. state or local laws or the laws of other countries
and regions in which we conduct activities, potential enforcement proceedings could involve significant restrictions being imposed upon
us or third parties, while diverting the attention of key executives. Such proceedings could have a material adverse effect on our business,
revenue, operating results and financial condition as well as on our reputation and prospects, even if such proceedings conclude successfully
in our favor. In the extreme case, such proceedings could ultimately involve the criminal prosecution of our key executives, the seizure
of corporate assets, and consequently, our inability to continue business operations. Strict compliance with state and local laws with
respect to psilocybin and psilocin does not absolve us of potential liability under U.S. federal law, the Canadian law or EU law, nor
provide a defense to any proceeding which may be brought against us. Any such proceedings brought against us may adversely affect our
operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
prospective products will be subject to the various federal and state laws and regulations relating to health and safety.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of developing investigational new drugs for which we intend to pursue FDA approval via the NDA process. In connection
with our development and future commercialization (if applicable) of our products, we and each contemplated product candidate are subject
to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer, in part, that drugs and devices are safe
and effective for their intended uses and that all labeling and packaging is truthful, informative, and not deceptive. The FDCA and FDA
regulations define the term &#8220;drug,&#8221; in part, by reference to its intended use, as &#8220;articles intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease&#8221; and &#8220;articles (other than food) intended to affect the
structure or any function of the body of man or other animals.&#8221; Therefore, almost any ingested or topical or injectable product
that, through its label or labeling (including internet websites, promotional pamphlets, and other marketing material), that is claimed
to be beneficial for such uses will be regulated by FDA as a drug. The definition also includes components of drugs, such as active pharmaceutical
ingredients. Drugs must generally either receive premarket approval by FDA through the NDA process or conform to a &#8220;monograph&#8221;
for a particular drug category, as established by FDA&#8217;s Over-the-Counter (OTC) Drug Review. If the FDA does not award premarket
approval for our product candidates through the NDA process, this could have a material adverse effect on our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination. The results of clinical trials are open
to differing interpretations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have one drug candidate that is in preclinical development for indications such as depression and anxiety.
We intend to develop additional drug candidates targeting other indications, including, for example, addiction and PTSD. After
completing the requisite preclinical testing, submissions to the FDA (namely IND applications), internal review board (&#8220;IRB&#8221;)
review, and any other applicable obligations that must be completed before clinical testing may begin in the United States, we must conduct
extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, time consuming,
and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at
all. Failures in connection with one or more clinical trials can occur at any stage of testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and other applicable regulatory agencies may analyze or interpret the results of clinical trials differently than us. Even if the
results of our clinical trials are favorable, the clinical trials for a number of our product candidates are expected to continue for
several years and may take significantly longer to complete. Events that may prevent successful or timely completion of clinical development
include (without limitation):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory authorities on trial design;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organization (&#8220;CRO&#8221;) and clinical trial
    sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in sourcing materials and research animals for preclinical testing and correlated testing windows at the appropriate CRO facilities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or perceived lack of effectiveness of any product candidate during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discovery
    of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions,
    including those which cause confounding changes to the levels of other concomitant medications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">slower
    than expected rates of subject recruitment and enrollment rates in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in retaining subjects for the entire duration of applicable clinical studies (as study subjects may withdraw at any time due to adverse
    side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing
    constraints;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequacy
    of or changes in our manufacturing process or product candidate formulation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining regulatory authorizations, such as INDs and any others that must be obtained, maintained, and/or satisfied to commence
    a clinical trial, including &#8220;clinical holds&#8221; or delays requiring suspension or termination of a trial by a regulatory
    agency, such as the FDA, before or after a trial is commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature or timing of studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical trial sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">uncertainty
    regarding proper dosing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply product for use in clinical trials which conforms to regulatory specification;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    results from ongoing preclinical studies and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our CROs, or other third-party contractors to comply with all contractual requirements or to perform their services in a timely
    or acceptable manner;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us, our employees, our CROs or their employees to comply with all applicable FDA or other regulatory requirements relating to
    the conduct of clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scheduling
    conflicts with participating clinicians and clinical institutions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to design appropriate clinical trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    concerns with psychedelics or psychedelic-inspired drug candidates, generally, and the potential for abuse;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    data to support regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    or unwillingness of medical investigators to follow our clinical protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in maintaining contact with patients during or after treatment, which may result in incomplete data;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    clinical holds placed on company by regulatory agencies during review process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to supply psychedelic-inspired drug candidate for use in clinical trials due to cross-border or inter-continental
    shipment or customs handling and processing of controlled substances; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    finding clinical trials sites whose investigators possess the requisite credentials to oversee clinical trials involving a Schedule
    I substance, should such be required.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
third-parties we rely on to conduct our operations are subject to regulatory requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties to conduct our preclinical studies and expect to use clinical studies in the future. We rely on CROs and clinical
data management organizations to design, conduct, supervise and monitor our preclinical studies and clinical trials. We and our CROs
are required to comply with various regulations, including GCP, which are enforced by regulatory agencies, to ensure that the health,
safety and rights of patients are protected in clinical development and clinical trials, and that trial data integrity is assured. Regulatory
authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and trial
sites. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or
any of our CROs fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing
these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may
fail to perform at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third parties to supply the materials for, and manufacture, our research and development, and preclinical and clinical trial
supplies, APIs, and formulated drug products, and we expect to continue to rely on third-party manufacturers if we receive
regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements
with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual
and regulatory requirements, including those related to quality control and assurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Difficulty
or delays in enrolling patients in clinical trials may result in delay or prevention of necessary regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to locate and enroll a sufficient number of eligible patients to participate in our clinical trials for our product candidates
as required by the FDA or similar regulatory authorities outside the United States, we may not be able to initiate or conduct our trials.
Our inability to enroll a sufficient number of patients for our trials would result in significant delays could require us to postpone
or abandon clinical trials. Enrollment delays may result in increased development costs for our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure by us to comply with existing regulations could harm our reputation and operating results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by U.S. federal and state and foreign governments in each of the U.S., European and Canadian markets,
in which we plan to sell our product candidates. We must adhere to all regulatory requirements, including FDA&#8217;s Good Laboratory
Practice (&#8220;GLP&#8221;), GCP, and GMP requirements, pharmacovigilance requirements, advertising and promotion restrictions, reporting
and recordkeeping requirements, and their European equivalents. If we or our suppliers fail to comply with applicable regulations, including
FDA pre-or post-approval requirements, then the FDA or other foreign regulatory authorities could sanction our Company. Even if a drug
is approved by the FDA or other competent authorities, regulatory authorities may impose significant restrictions on a product&#8217;s
indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of our product candidates which may be approved in the U.S. will be subject to ongoing regulatory requirements for manufacturing, labeling,
packaging, storage, distribution, import, export, advertising, promotion, sampling, recordkeeping and submission of safety and other
post-market information, including both federal and state requirements. In addition, manufacturers and manufacturers&#8217; facilities
are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform
to GMP. As such, we and our contract manufacturers (in the event contract manufacturers are appointed in the future) are subject to continual
review and periodic inspections to assess compliance with GMP. Accordingly, we and others with whom we work will have to spend time,
money and effort in all areas of regulatory compliance, including manufacturing, production, quality control and quality assurance. We
will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements
concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a
variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. Similar
restrictions and requirements exist in the European Union and other markets where we operate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of the product,
it may impose restrictions on that product or on us, including requiring withdrawal of the product from the market. If we fail to comply
with applicable regulatory requirements, a regulatory agency or enforcement authority may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    warning letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    civil or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    regulatory approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any of our ongoing clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to approved applications submitted by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impose
    restrictions on our operations, including by requiring us to enter in to a Corporate Integrity Agreement or closing our contract
    manufacturers&#8217; facilities, if any; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain products or require a product recall.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to such healthcare laws
and regulations could adversely affect our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we successfully complete the requisite preclinical and clinical testing, make the required regulatory submissions and obtain any corresponding
authorizations or licenses (as applicable), fulfill all other applicable development-related regulatory obligations, and, eventually,
obtain FDA approval to market one or more of our current or future product candidates in the United States, we may be subject to certain
healthcare laws and regulations. In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory
proposals to change the healthcare system in ways that could impact our ability to sell our future product candidates. If we are found
to be in violation of any of these laws or any other federal, state or foreign regulations, we may be subject to administrative, civil
and/or criminal penalties, damages, fines, individual imprisonment, exclusion from federal health care programs and the restructuring
of our operations. Any of these could have a material adverse effect on our business and financial results. Since many of these laws
have not been fully interpreted by the courts, there is an increased risk that we may be found in violation of one or more of their provisions.
Any action against us for violation of these laws, even if we are ultimately successful in our defense, will cause us to incur significant
legal expenses and divert our management&#8217;s attention away from the operation of our business. In addition, in many foreign countries,
particularly the countries of the European Union, the pricing of prescription drugs is subject to government control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing vary widely from country to country. For example, some European Union jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate
to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company
profits. Such differences in national pricing regimes may create price differentials between European Union member states. There can
be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
products launched in the European Union do not follow price structures of the U.S.. In the European Union, the downward pressure on healthcare
costs in general, particularly prescription medicines, has become intense. As a result, barriers to entry of new products are becoming
increasingly high and patients are unlikely to use a drug product that is not reimbursed by their government.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition,
the importation of foreign products may compete with any future product that we may market, which could negatively impact our profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
expansion in the government&#8217;s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription
drug products, lower reimbursements or any other product for which we obtain regulatory approval, reduce product utilization and adversely
affect our business and results of operations. Any reduction in reimbursement from Medicare or other government programs may result in
a similar reduction in payments from private payors. The implementation of such cost containment measures and other healthcare reforms
may prevent us from being able to generate revenue, attain profitability, or commercialize any of our future product candidates for which
we may receive regulatory approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a high rate of failure for drug candidates proceeding through clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market. None of our prospective products or investigational drug candidates have ever been tested in a
human subject. Our ability to achieve and sustain profitability with respect to our product candidates depends on obtaining regulatory
approvals for and, if approved, successfully commercializing our product candidates, either alone or with third parties. Before obtaining
regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct
extensive preclinical tests and clinical trials to demonstrate the safety, purity and potency of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
there is a high rate of failure for drug candidates proceeding through clinical trials. We may suffer significant setbacks in our clinical
trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving
promising results in earlier trials. Further, even if we view the results of a clinical trial to be positive, the FDA or other regulatory
authorities may disagree with our interpretation of the data. In the event that we obtain negative results from clinical trials for product
candidates or other problems related to potential chemistry, manufacturing and control issues or other hurdles occur and our future product
candidates are not approved, we may not be able to generate sufficient revenue or obtain financing to continue our operations, our ability
to execute on our current business plan may be materially impaired, and our reputation in the industry and in the investment community
might be significantly damaged. In addition, our inability to properly design, commence and complete clinical trials may negatively impact
the timing and results of our clinical trials and ability to seek approvals for our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing, marketing and manufacturing of any new drug product for use in the United States will require approval from the FDA. We cannot
predict with any certainty the amount of time necessary to obtain such FDA approval and whether any such approval will ultimately be
granted. Preclinical and clinical trials may reveal that one or more products are ineffective or unsafe, in which event further development
of such products could be seriously delayed or terminated. Moreover, obtaining approval for certain products may require testing on human
subjects of substances whose effects on humans are not fully understood or documented. Delays in obtaining FDA or any other necessary
regulatory approvals of any proposed drug and failure to receive such approvals would have an adverse effect on the drug&#8217;s potential
commercial success and on our business, prospects, financial condition and results of operations. In addition, it is possible that a
proposed drug may be found to be ineffective or unsafe due to conditions or facts that arise after development has been completed and
regulatory approvals have been obtained. In this event, we may be required to withdraw such proposed drug from the market. To the extent
that our success will depend on any regulatory approvals from government authorities outside of the United States that perform roles
similar to that of the FDA, uncertainties similar to those stated above will also exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Serious
adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our prospective
products or current or future product candidates, limit the scope of any approved label or market acceptance, or cause the recall or
loss of marketing approval of products that are already marketed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our prospective products or current or future product candidates, prior to or after any approval for commercial sale, cause serious
or unexpected side effects, or are associated with other safety risks such as misuse, abuse or diversion, a number of potentially significant
negative consequences could result, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may interrupt, delay or halt clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may deny regulatory approval of our future product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for
    use, and/or impose restrictions on distribution in the form of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) in
    connection with approval or post-approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval, require more onerous labeling statements, impose a more restrictive REMS, or require it
    to recall any product that is approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    relationships with our collaboration partners may suffer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer. The reputational risk is heightened with respect to those of our future product candidates that are being
    developed for pediatric indications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may voluntarily suspend or terminate our clinical trials if at any time we believe that the product candidates present an unacceptable
risk to participants, or if preliminary data demonstrates that our future product candidates are unlikely to receive regulatory approval
or unlikely to be successfully commercialized.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completing preclinical testing and obtaining the requisite regulatory authorizations, as applicable, we may voluntarily suspend or terminate
our clinical trials for any number of reasons, including if we believe that a product&#8217;s use, or a person&#8217;s exposure to it,
may cause adverse health consequences or death. In addition, regulatory agencies, IRBs or data safety monitoring boards may at any time
recommend the temporary or permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical
trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that
they present an unacceptable safety risk to participants. Although we have never been asked by a regulatory agency, IRB or data safety
monitoring board to temporarily or permanently discontinue a clinical trial, if we elect or are forced to suspend or terminate a clinical
trial of any of our future product candidates, the commercial prospects for that product will be harmed and our ability to generate product
revenue from that product may be delayed or eliminated. Furthermore, any of these events may result in labeling statements such as warnings
or contraindications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, such events or labeling could prevent us or our partners from achieving or maintaining market acceptance of the affected product
and could substantially increase the costs of commercializing our future product candidates and impair our ability to generate revenue
from the commercialization of these products either by us or by our collaboration partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulatory
risks related to psychedelic-inspired drug candidates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
execution of our strategy is contingent, in part, upon compliance with regulatory requirements from time to time enacted by
governmental authorities and obtaining all regulatory approvals, where necessary, for the development of our psychedelic-inspired
drug candidates. The abuse liability potential of our psychedelic-inspired drug candidates has not yet been studied in preclinical
or clinical studies. Therefore, Health Canada or the FDA have not yet determined whether our psychedelic-inspired drug candidates
will be scheduled as controlled substances. Based on the studies Health Canada or the FDA or other regulatory authorities may
determine that our psychedelic-inspired drug candidates are controlled substances and therefore, would require classification as a
controlled substance with all the requisite controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we may not be able to predict the time required to secure all appropriate regulatory approvals for our psychedelic-inspired drug candidates,
or the extent of testing and documentation that may, from time to time, be required by governmental authorities. The impact of compliance
regimes, any delays in obtaining, or failure to obtain regulatory approvals may significantly delay or impact the development of markets,
our business and psychedelic-inspired drug candidates, and licensing initiatives and could have a material adverse effect on the business,
financial condition and operating results of the Company.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional
costs for corrective measures, penalties or result in restrictions on our operations. In addition, changes in regulations, more vigorous
enforcement thereof or other unanticipated events could require extensive changes to our operations, increased compliance costs or give
rise to material liabilities, which could have a material adverse effect on the business, financial condition and operating results of
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
management will be required to devote a substantial time to comply with public company regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley
Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as rules implemented
by the SEC and Nasdaq, impose various requirements on public companies, including those related to corporate governance practices. Our
management and other personnel must devote a substantial amount of time to these requirements. Moreover, these rules and regulations
increase our legal and financial compliance costs and make some activities more time consuming and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure
controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial
reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section
404 of the Sarbanes-Oxley Act. Our compliance with these requirements will require that we incur substantial accounting and related expenses
and expend significant management efforts. We have engaged third-party consultants to help satisfy the ongoing requirements of
Section 404 of the Sarbanes-Oxley Act. The costs of this outsourcing may be material and there can be no assurance that such staff will
be immediately available to us. Moreover, if we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act,
or if we identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, investors
could lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline and
we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities, which could require additional
financial and management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified a material weakness in our internal control over financial reporting. If we are unable to remediate the material weakness,
or if we experience additional material weaknesses in the future, our business may be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and
reporting on the effectiveness of our system of internal control. Internal control over financial reporting is a process used to provide
reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external
purposes in accordance with generally accepted accounting principles in the United States. As a public company, we are required to comply
with the Sarbanes-Oxley Act and other rules that govern public companies. In particular, we are required to certify our compliance with
Section 404 of the Sarbanes-Oxley Act, which requires us to furnish annually a report by management on the effectiveness of our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management performed an assessment of the Company&#8217;s significant processes and key controls. Based on this assessment, management
concluded that our internal control over financial reporting was not effective as of December 31, 2023 and September 30, 2024
due to the material weakness related to segregation of duties. As of December 31, 2023 and September 30, 2024, there were control
deficiencies which constituted a material weakness in our internal control over financial reporting. Management has taken, and is taking
steps to strengthen our internal control over financial reporting: we have conducted evaluation of the material weakness to determine
the appropriate remedy and have established procedures for documenting disclosures and disclosure controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the small size of our Company, we do not maintain sufficient segregation of duties to ensure the processing, review and authorization
of all transactions including non-routine transactions. While we have taken certain actions to address the material weaknesses identified,
additional measures including engaging third-party consultants may be necessary as we work to improve the overall effectiveness
of our internal controls over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remediation
efforts place a significant burden on management and add increased pressure to our financial resources and processes. If we are unable
to successfully remediate our existing material weakness or any additional material weaknesses in our internal control over financial
reporting that may be identified in the future in a timely manner, the accuracy and timing of our financial reporting may be adversely
affected; our liquidity, our access to capital markets, the perceptions of our creditworthiness may be adversely affected; we may be
unable to maintain or regain compliance with applicable securities laws, the listing requirements of the Nasdaq Stock Market; we may
be subject to regulatory investigations and penalties; investors may lose confidence in our financial reporting; our reputation may be
harmed; and our stock price may decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
risk</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to various taxes in either the United States, Canada and Australia, or all three, including, without limitation, the following:
income taxes, payroll taxes, workers compensation, goods and services tax, sales tax, and land transfer tax. Our tax filings will be
subject to audit by various taxation authorities. While we intend to base its tax filings and compliance on the advice of our tax advisors,
there can be no assurance that our tax filing positions will never be challenged by a relevant taxation authority resulting in a greater
than anticipated tax liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to adequately protect or enforce our intellectual property rights, which could harm our competitive position.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain and maintain additional patents, protect our trade secrets and operate without
infringing on the proprietary rights of others. We rely upon a combination of patents, trade secret protection (i.e., know-how), and
confidentiality agreements to protect the intellectual property of our future product candidates. The strengths of patents in the pharmaceutical
field involve complex legal and scientific questions and can be uncertain. Where appropriate, we seek patent protection for certain aspects
of our products and technology. Filing, prosecuting and defending patents globally can be prohibitively expensive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
policy is to look to patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However,
patent protection may not be available for some of the products or technology we are developing. If we must spend significant time and
money protecting, defending or enforcing our patents, designing around patents held by others or licensing, potentially for large fees,
patents or other proprietary rights held by others, our business, results of operations and financial condition may be harmed. We may
not develop additional proprietary products that are patentable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent positions of pharmaceutical products are complex and uncertain. The scope and extent of patent protection for our future product
candidates are particularly uncertain. Although we have sought, and will continue to seek, patent protection in the U.S., Europe and
other countries for our proprietary technologies, future product candidates, their methods of use, and methods of manufacture, any or
all of them may not be subject to effective patent protection. If any of our products is approved and marketed for an indication for
which we do not have an issued patent, our ability to use our patents to prevent a competitor from commercializing a non-branded version
of our commercial products for that non-patented indication could be significantly impaired or even eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
of information related to our future product candidates by us or others may prevent us from obtaining or enforcing patents relating to
these products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or
may design around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable.
If we fail to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product
to compete with our future product candidates. We may also face competition from companies who develop a substantially similar product
to our future product candidates that is not covered by any of our patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success depends on our ability to obtain additional intellectual property and operate without infringing the proprietary rights of others.
Infringement claims by third parties may result in liability for damages or prevent or delay our developmental and commercialization
efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success and ability to compete depend in part on our ability to obtain additional patents, protect our trade secrets, and operate without
infringing on the proprietary rights of others. If we fail to adequately protect our intellectual property, we may face competition from
companies who develop a substantially similar product to our future product candidates that is not covered by any of our intellectual
property. Many companies have encountered significant problems in protecting, defending, and enforcing intellectual property rights in
foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement
of patents and other intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for
us to stop the infringement of our intellectual property and other proprietary rights. There is also a substantial amount of litigation,
both within and outside the U.S., involving patient and other intellectual property rights in the pharmaceutical industry. We may, from
time to time, be notified of claims that we are infringing upon the proprietary rights of third parties, and we cannot provide assurances
that other companies will not, in the future, pursue such infringement claims against it, our commercial partners, or any third-party
proprietary technologies we have licensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unsuccessful in licensing additional intellectual property to develop new product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may in the future seek to in-license additional intellectual property that we believe could complement or expand our product candidates
or otherwise offer growth opportunities. The pursuit of such licenses may cause us to incur various expenses in identifying, investigating
and pursuing suitable intellectual property. If we acquire additional intellectual property to develop new therapeutic product candidates,
we may not be able to realize anticipated cost savings or synergies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties claim that intellectual property used by us infringes upon their intellectual property, our operating profits could be
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the
pharmaceutical industry. We may, from time to time, be notified of claims that we are infringing upon patents, trademarks, copyrights
or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the
future, pursue such infringement claims against us, our commercial partners or any third-party proprietary technologies we have licensed.
If we were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a
patent or other intellectual property right from a third party, or if a third party that we were licensing technologies from was found
to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages, including
damages of up to three times the damages found or assessed, if the infringement is found to be willful, suspend the manufacture of certain
products or reengineer or rebrand our products, if feasible, or we may be unable to enter certain new product markets. Any such claims
could also be expensive and time-consuming to defend and divert management&#8217;s attention and resources. Our competitive position
could suffer as a result. In addition, if we have declined or failed to enter into a valid non-disclosure or assignment agreement for
any reason, we may not own the invention or our intellectual property, and our products may not be adequately protected. Thus, we cannot
guarantee that any of our future product candidates, or our commercialization thereof, does not and will not infringe any third party&#8217;s
intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and
products could be significantly diminished.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secrets to protect our proprietary technologies, especially where it does not believe patent protection is appropriate
or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our current and former
employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors to
protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential
information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition,
we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets. Any
party with whom we or they have executed such an agreement may breach that agreement and disclose our proprietary information, including
our trade secrets, and we may not be able to obtain adequate remedies for such breaches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enforcing
a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome
is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
them, or those to whom they disclose such trade secrets, from using that technology or information to compete with us. If any of our
trade secrets were to be disclosed to or independently developed by a competitor or other third-party, our competitive position would
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights effectively outside of the United States.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. Therefore,
we choose to file applications and/or obtained patents only in key markets. Competitors may use our technologies in jurisdictions where
we have not obtained patent protection to develop their own products and, further, may be able to export otherwise infringing products
to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may
compete with our products in jurisdictions where we do not have any issued patents and/or our patent claims or other intellectual property
rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in certain foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our
business and could be unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
financial condition would be adversely impacted if our intangible assets become impaired</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangibles
are evaluated quarterly and are tested for impairment at least annually or when events or changes in circumstances indicate the carrying
value of each segment, and collectively the Company taken as a whole, might exceed its fair value. If we determine that the value of
our intangible assets is less than the amounts reflected on our balance sheet, we will be required to reflect an impairment of our intangible
assets in the period in which such determination is made. An impairment of our intangible assets would result in our recognizing an expense
in the amount of the impairment in the relevant period, which would also result in the reduction of our intangible assets and a corresponding
reduction in our stockholders&#8217; equity in the relevant period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
the event that we fail to regain compliance with the listing requirements of The Nasdaq Capital Market or satisfy any of the listing
requirements of Nasdaq, our common stock may be delisted, which could affect our market price and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on Nasdaq. For continued listing on Nasdaq, we will be required to comply with the continued listing
requirements, including the minimum market capitalization standard, the stockholders&#8217; equity requirement, the corporate
governance requirements and the minimum closing bid price requirement, among other requirements. As indicated earlier in this
prospectus, the Company is currently in default of Nasdaq&#8217;s Bid Price Rule. Also as noted earlier in this prospectus, the
Company effected a 1-for-15 reverse stock split of its outstanding shares of common stock on January 27, 2025, which began trading on a
split-adjusted basis on January 29, 2025. The principal purpose of the reverse stock split is to increase the trading price of
our common stock to meet the Bid Price Rule. In order to regain compliance, the bid price of the Company&#8217;s common stock needs
to remain at or above $1.00 per share for a minimum of 10 consecutive business days after the effective date of the reverse stock
split. As of the date of this prospectus, the Company has not completed 10 consecutive business days from the reverse stock split
effective date and therefore it is not in compliance with the Bid Price Rule. Even if we do regain compliance, we cannot provide
any assurance that our stock price will not drop below the minimum bid price requirement under the Bid Price Rule following
the completion of this offering and we will not be subject to another delisting notice from NASDAQ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we fail to regain compliance with the Bid Price Rule or satisfy any of the listing requirements of Nasdaq, our common
stock may be delisted. If our common stock is delisted from trading on Nasdaq, and we are not able to list our common stock on another
exchange or to have it quoted on Nasdaq, our securities could be quoted on the OTC Bulletin Board or on the &#8220;pink sheets.&#8221;
As a result, we could face significant adverse consequences including, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news and analyst coverage for our Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3 or obtain
    additional financing in the future).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our common stock may be subject to significant fluctuations and volatility, and our stockholders may be unable to resell
their shares at a profit and incur losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price our common stock could be subject to significant fluctuation. Market prices for securities of life sciences and biopharma
companies in particular have historically been particularly volatile and have shown extreme price and volume fluctuations that have often
been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general
economic, political and market conditions such as recessions or interest rate changes, may seriously affect the market price of our common
stock, regardless of our actual operating performance. Some of the factors that may cause the market price of our common stock to fluctuate
include, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors
    react negatively to the effect on our business and prospects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    announcement of new products, new developments, services or technological innovations by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated quarterly increases or decreases in revenue, gross margin or earnings, and changes in our business, operations or
    prospects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or
    other events by us or our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    or trends in the life sciences and biopharma industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the economic performance or market valuations of other life sciences and biopharma companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sale
    of our common stock by stockholders, including executives and directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    and limitations in trading volumes of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">volatility
    in the market prices and trading volumes of companies in the life sciences and biopharma industries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to finance our business;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ability
    to secure resources and the necessary personnel to pursue our plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failures
    to meet external expectations or management guidance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our capital structure or dividend policy, future issuances of securities, sales or distributions of large blocks of common stock
    by stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    and events surrounding financing efforts, including debt and equity securities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analyst
    research reports, recommendation and changes in recommendations, price targets, and withdrawals of coverage;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">departures
    and additions of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    and litigation related to intellectual properties, proprietary rights, and contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investigations
    by regulators into our operations or those of our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which may be out of our control.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, following periods of volatility in the overall market and the market prices of particular companies&#8217; securities, securities
class action litigations have often been instituted against these companies. Litigation of this type, if instituted against us, could
result in substantial costs and a diversion of our management&#8217;s attention and resources. Any adverse determination in any such
litigation or any amounts paid to settle any such actual or threatened litigation could require that we make significant payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
stockholders could attempt to influence changes within our Company which could adversely affect our operations, financial condition and
the value of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders may from time to time seek to acquire a controlling stake in our Company, engage in proxy solicitations, advance stockholder
proposals or otherwise attempt to effect changes. Campaigns by stockholders to effect changes at publicly-traded companies are sometimes
led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special
dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders
can be costly and time-consuming and could disrupt our operations and divert the attention of our board of directors and senior management
from the operation of our business. These actions could adversely affect our operations, financial condition and the value of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities analysts do not publish research or reports about our business, or if they publish negative evaluations, the price of our
common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will rely in part on the availability of research and reports that third-party industry or financial
analysts publish about our Company. There are many large, publicly traded companies active in the life sciences and biopharma industries,
which may mean it will be less likely that we receive widespread analyst coverage. Furthermore, if one or more of the analysts who do
cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our Company, we
could lose visibility in the market, which in turn could cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions under Delaware corporate law may make it difficult for our stockholders to replace or remove our board of directors and could
deter or delay third parties from acquiring our Company, which may be beneficial to our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our Amended and Restated Certificate of Incorporation, we are subject to the anti-takeover provisions of the Delaware General Corporation
Law (&#8220;DGCL&#8221;), including Section 203 of the DGCL. Under these provisions, if anyone becomes an &#8220;interested stockholder,&#8221;
we may not enter into a &#8220;business combination&#8221; with that person for three (3) years without special approval, which could
discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203 of
the DGCL, &#8220;interested stockholder&#8221; means, generally, someone owning fifteen percent (15%) or more of our outstanding voting
stock or an affiliate of ours that owned fifteen percent (15%) or more of our outstanding voting stock during the past three (3) years,
subject to certain exceptions as described in Section 203 of the DGCL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to maintain an active trading market for our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing of our common stock on Nasdaq does not assure that a meaningful, consistent and liquid trading market exists. If an active market
for our common stock does continue, it may be difficult for investors to sell their shares without depressing the market price for the
shares or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
maintain our cash at financial institutions, often in balances that exceed federally insured limits.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in non-interest-bearing
and interest-bearing operating accounts may exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If
such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations.
While the FDIC took control of one such banking institution, Silicon Valley Bank (&#8220;SVB&#8221;), on March 10, 2023, and the FDIC
also took control of Signature Bank (&#8220;Signature Bank&#8221;) on March 12, 2023, we did not have any accounts with SVB or Signature
Bank and therefore did not experience any specific risk of loss. The FDIC also announced that account holders would be made whole. Thus,
we do not view the risk as material to our financial condition. However, if such a situation arises again with a financial institution
we bank with, the risk of loss in excess of insurance limitations has generally increased. Any material loss that we may experience in
the future could have an adverse effect on our ability to pay our operational expenses or make other payments and may require us to move
our accounts to other banks, which could cause a temporary delay in making payments to our vendors and employees and cause other operational
inconveniences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a
strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. There is
no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction, which
could result in a material adverse effect on our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_005"></span>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the information in this prospectus contain forward-looking statements within the
meaning of the federal securities laws. You should not rely on forward-looking statements in this prospectus. Forward-looking statements typically are identified by use of terms such as &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221;
&#8220;continue,&#8221; and similar words, although some forward-looking statements are expressed differently. This prospectus may
also contain forward-looking statements attributed to third parties relating to their estimates regarding the markets we may enter
in the future. All forward-looking statements address matters that involve risk and uncertainties, and there are many important
risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements
contained in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should also carefully consider the statements under &#8220;<span style="text-decoration: underline">Risk Factors</span>&#8221; and other sections of this prospectus, which address
additional facts that could cause our actual results to differ from those set forth in the forward-looking statements. We caution investors
not to place significant reliance on the forward-looking statements contained in this prospectus. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information,
future developments or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_006"></span>MARKET
PRICE AND DIVIDEND INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock trades on Nasdaq under the symbol &#8220;ENVB.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
of Record</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of January 27, 2025, we had 183 holders of record of our common stock. The actual number of holders of our common stock
is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street
name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held
in trust by other entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has never declared or paid cash dividends on its common stock and has no intention to do so in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_007"></span>BUSINESS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell
company immediately prior to the completion of a &#8220;reverse merger&#8221; transaction on May 26, 2015, whereby Ameri100 Acquisition,
Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc., a Delaware
corporation (the &#8220;2015 Merger&#8221;). In connection with the 2015 Merger, we changed our name to AMERI Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.45in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ameri business ceased to be part of the Company on December 30, 2020, pursuant to a spin-off transaction. On December 30, 2020, we completed
a tender offer to purchase all of the outstanding common shares of Jay Pharma Inc., a Canada corporation, for shares of Company common
stock or certain preferred stock, and changed our name to &#8220;Enveric Biosciences, Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, the Company entered into an Amalgamation Agreement (the &#8220;Amalgamation Agreement&#8221;) with 1306432 B.C. Ltd., a
corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (&#8220;HoldCo&#8221;),
1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo
(&#8220;Purchaser&#8221;), and MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia (&#8220;MagicMed&#8221;),
pursuant to which, among other things, the Company, indirectly through Purchaser, acquired all of the outstanding securities of MagicMed
in exchange for securities of the Company by way of an amalgamation under the British Columbia Business Corporations Act, upon the terms
and conditions set forth in the Amalgamation Agreement, such that, upon completion of the Amalgamation, the amalgamated corporation (&#8220;Amalco&#8221;)
would be an indirect wholly-owned subsidiary of the Company. The Amalgamation was completed on September 16, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary (&#8220;Enveric Therapeutics&#8221;),
to support the Company&#8217;s plans to advance the EVM201 Series, comprised of next generation synthetic prodrugs of the active
metabolite, psilocin, towards the clinic. Enveric Therapeutics was established to oversee the Company&#8217;s intended
preclinical, clinical, and regulatory activities in Australia, including ongoing interactions with the local Human Research Ethics Committees
(&#8220;HREC&#8221;) and the Therapeutic Goods Administration, Australia&#8217;s regulatory authority. Enveric has since out-licensed
the EVM201 Series asset to MycoMedica Life Sciences, Inc. and is not currently performing activities in Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression,
anxiety, addiction, and psychiatric disorders. Leveraging our unique discovery and development platform, the Psybrary&#8482;, which houses
proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks
to develop a robust intellectual property portfolio of novel drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric&#8217;s
lead program, the EVM301 Series, and its lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment
of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations
in the patient. Previously, Enveric was developing the EVM201 Series, and its lead drug candidate EB-002 (formerly EB-373), for the treatment
of neuropsychiatric disorders. The EVM201 series comprised next generation synthetic prodrugs of the active metabolite, psilocin. Recently,
Enveric out-licensed the EVM201 Series program to MycoMedica Life Sciences, who will seek to develop, manufacture, and commercialize
EB-002, in exchange for certain development and milestone payments to Enveric (discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Neuroplastogens</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), we have continued to pursue the development
of MagicMed&#8217;s proprietary library, the Psybrary&#8482;, which we believe will help us to identify and develop the right drug candidates
needed to address mental health challenges, including depression, anxiety, and addiction disorders. We synthesize novel phenylalkylamines
and indolethylamines, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which currently
includes 20 patent families with claims covering over a million potential molecular structures, over one thousand of which we have so
far synthesized in sufficient quantities to identify and hundreds of which we have screened for receptor binding and other relevant activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this stage, we have entered into several non-binding term sheets with strategic partners to out-license certain molecules from the Psybrary&#8482;.
Going forward, in order to build a pipeline of product candidates, we intend to both continue to internally develop new drug candidates
with associated intellectual property and to acquire, through in-licensing, additional intellectual property from pharmaceutical and
biotechnology companies and research institutions. The in-licensed assets could include both research stage and clinical stage drug candidates.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is to develop our lead asset EB-003 in the EVM301 Series. The development status of the product is shown in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
pipeline of product candidates and key ongoing development programs are shown in the tables below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    Candidates</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
    Indications</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
    Next Steps</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>EB-003</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Psychedelic-inspired
    drug candidate</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mental
    health indication</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    Filing</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025, pursuant to which every
15 shares of our issued and outstanding common stock were reclassified as one share of common stock. No fractional shares were
issued as a result of the reverse stock split. Any fractional shares that were to otherwise have resulted from the reverse stock
split were rounded up to the next whole number. The reverse stock split had no impact on the par value of our common stock or the
authorized number of shares of our common stock. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NASDAQ
Bid Price Deficiency and Reverse Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2024, the Company received a letter from Nasdaq notifying the Company that for the prior 30 consecutive business days the bid
price for the Company&#8217;s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on Nasdaq
pursuant to Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule). The deficiency letter did not result in the immediate delisting of the Company&#8217;s
common stock from Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar
days, until November 12, 2024, to regain compliance with the Bid Price Rule. On November 20, 2024, Nasdaq issued a delisting notice,
indicating that the Company did not satisfy the Bid Price Rule by the compliance date and that unless the Company requested an appeal
of this determination before Nasdaq&#8217;s listing qualifications panel, our common stock would be scheduled for delisting from Nasdaq
and trading suspended. We appealed the determination before Nasdaq&#8217;s listing qualifications panel and on December 30, 2024, the
Company received an extension until May 19, 2025, to regain compliance with Bid Price Rule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, subject to stockholder approval, the Board approved an amendment to our certificate of incorporation to, at the
discretion of the Board, effect a reverse stock split of our outstanding common stock at a ratio between 1-for-10 and 1-for-100,
including shares held by the Company as treasury shares, with the exact ratio within such range to be determined by the Board at its
discretion. A meeting of the stockholders was held on January 17, 2025, whereby the stockholders approved the reverse stock split.
The Company effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. Nasdaq
requires that the closing bid price of the Company remain at $1.00 per share or greater for 10 consecutive business days before
declaring that the Company has regained compliance with the Bid Price Rule. As of the date of this prospectus, the Company has not
completed 10 consecutive business days from the reverse stock split effective date and therefore it is not in compliance with the
Bid Price Rule. Even if we do regain compliance, we cannot provide any assurance that our stock price will not drop below the
minimum bid price requirement under the Bid Price Rule following the completion of this offering and we will not be subject to
another delisting notice from NASDAQ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreement with MycoMedica Life Sciences</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, Enveric executed a licensing agreement with MycoMedica, out-licensing the Company&#8217;s EVM201 program, including
drug candidate EB-002. Pursuant to the terms of licensing agreement, MycoMedica will seek to develop, manufacture, and commercialize
EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, for the treatment of neuropsychiatric disorders
such as depression. MycoMedica received an exclusive, global license to the formulations, drugs, method of use, and medical devices developed
by Enveric to utilize the compound. MycoMedica assumed the responsibility for all future preclinical, clinical, and commercial development
on a royalty-bearing basis for all human and animal pharmaceutical applications. As part of the license agreement, Enveric received a
modest upfront payment, and if certain conditions are met, will receive development and sales milestones potentially totaling up
to $62 million, plus tiered single digit royalties on all future sales. <span style="background-color: white">MycoMedica has the option
during the license term to buyout its milestone and royalty payment obligations at a predetermined amount depending upon the stage of
product development and commercialization at the time of the buyout. Further, MycoMedica has the right to purchase the licensed patents
at a nominal amount upon a change of control of Enveric, although doing so does not relieve MycoMedica of any of its payment obligations.
No royalties have been received to date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>License
Agreement with Aries Science and Technology</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
July 10, 2024, Akos Biosciences, Inc., a Delaware corporation (&#8220;Akos&#8221;), wholly-owned subsidiary of Enveric, entered into
an exclusive license agreement with Aries Science and Technology, LLC (&#8220;Aries&#8221;) pursuant to which Akos granted Aries a license
to Akos&#8217;s patented radiation dermatitis topical product. The license allows Aries to use the patented formulation to develop
pharmaceutical or non-pharmaceutical products for treating radiation dermatitis suitable for administration to humans or animals. The
license is exclusive (subject to certain exceptions contained in the Agreement), worldwide, royalty-bearing, and includes the right to
sublicense. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric will be eligible to receive aggregate
milestone payments of up to $61 million, as well as tiered royalties on future sales, if all conditions are met. <span style="background-color: white">Aries
has the option during the license term, to purchase the rights to each licensed product (on a licensed product-by-licensed product basis)
in the form of an exclusive (as to the applicable licensed product), fully paid, transferable right and license to the licensed product.
No royalties have been received to date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Registered
Direct Offerings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
March and May 2024, Enveric entered into a series of common stock purchase agreements (the &#8220;Purchase Agreements&#8221;) for the
issuance in a registered direct offering of an aggregate of 45,780 shares of the Company&#8217;s common stock, par value $0.01
per share, to certain institutional investors. The issuance was made in exchange for the permanent and irrevocable waiver of the variable
rate transaction limitation contained in certain inducement offer letters, dated December 28, 2023, between the Company and the institutional
investors with respect to any existing or future agreement by the Company to effect any issuance of shares. The Company did not receive
any net proceeds in connection with the offering. The offering was made to obtain a waiver of the variable rate transaction limitation
as described above and further described in the Purchase Agreements so the Company could utilize its equity line of credit with Lincoln
Park Capital Fund, LLC, and enter into any future agreements that involve a variable rate transaction and issue such shares thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"></p>

<p style="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 4.75pt 0 0; text-align: justify; text-indent: 28.9pt"><span style="letter-spacing: -0.6pt">W</span>e
are a party <span style="letter-spacing: 0.05pt">t</span>o c<span style="letter-spacing: 0.05pt">e</span>rtain license agr<span style="letter-spacing: 0.05pt">e</span>emen<span style="letter-spacing: 0.05pt">t</span>s
as described belo<span style="letter-spacing: -0.45pt">w</span>, and going forward, to build a pipeline of product candidates, we intend
to both continue to internally dev<span style="letter-spacing: 0.05pt">e</span>lop new <span style="letter-spacing: 0.05pt">drug candidates
with associated i</span>ntellectual property and to acquire, through in-licensing, additional intellectual property from pharm<span style="letter-spacing: 0.05pt">a</span>ceuti<span style="letter-spacing: 0.05pt">c</span>al
<span style="letter-spacing: 0.05pt">a</span>nd b<span style="letter-spacing: 0.05pt">i</span>otechnology comp<span style="letter-spacing: 0.05pt">a</span>ni<span style="letter-spacing: 0.05pt">e</span>s
and res<span style="letter-spacing: 0.05pt">e</span>ar<span style="letter-spacing: 0.05pt">c</span>h institutions. The in-licensed assets
could include both research stage and clini<span style="letter-spacing: 0.05pt">c</span>al stage <span style="letter-spacing: 0.05pt">drug
candidates</span>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current focus of Enveric&#8217;s intellectual property is in neuroplastogens, including multiple portfolios of psychedelic-inspired
compounds and formulations and methods of making, using, and treating mental and neurological disorders. In addition, Enveric has intellectual
property related to computer assisted methods of discovering promising novel psychedelic-inspired compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Psychedelics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own rights to 20 active patent families related to compounds that are phenylalkylamine and indolethylamine derivatives. The 20
patent families are represented by a total of 17 issued United States patents and 47 pending United States and non-United States
patent applications for treatment of mental disorders, such as depression, anxiety, addiction, and other neuropsychiatric conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent portfolio includes the following published and unpublished applications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Glycosylated
    Psilocybin Derivatives and Methods of Using (WO 2022/040802)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Halogenated
    Psilocybin Derivatives and Methods of Using (WO2022/047579)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Hydroxylated
    Psilocybin Derivatives and Methods of Using (WO2022/047580)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nitrated
    Psilocybin Derivatives and Methods of Using (WO 2022/047583)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Aminated
    Psilocybin Derivatives and Methods of Using (WO2023/044556)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Nitrilated
    Psilocybin Derivatives and Methods of Using (WO2022/104475)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Carboxylated
    Psilocybin Derivatives and Methods of Using (WO2022/115944)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Aldehyde
    and Ketone Derivatives of Psilocybin and Methods of Using (WO2022/115960)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prenylated
    Psilocybin Derivatives and Methods of Using (WO2022/155751)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Multi-substituent
    Psilocybin Derivatives and Methods of Using (WO2022/170438)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>N-Heterocycle
    Substituted Tryptamine Derivatives and Methods of Using (Unpublished PCT/CA2024/050312)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tri-Halo-Alkoxy-Substituted
    Tryptamine Derivatives (Unpublished PCT/CA2024/050242)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C-4
    Substituted Tryptamine Derivatives and Methods of Using (WO2023/173227)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C-4
    Carboxylic Acid Substituted Tryptamine Derivatives and Methods of Using (WO2023/173196)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C-4
    Carbonothioate Substituted Tryptamine Derivatives and Methods of Using (WO 2023/173197)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Salts
    of C4-Carboxylic Acid and C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using (WO 2023/173229)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fused
    Heterocyclic Mescaline Derivatives (WO2024/026568A1)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C1-Substituted
    Isopropylamine Fused Heterocyclic Mescaline Derivatives (WO2024/086933)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Substituted
    N- Propylamine Fused Heterocyclic Mescaline Derivatives (WO2024/103185)</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Substituted
    Ethylamine Fused Heterocyclic Mescaline Derivatives (WO2024/124353)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cannabinoid
Conjugates and Formulations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own rights held by our wholly owned subsidiary Akos Biosciences, Inc. to 2 active patent families related to cannabinoids. One patent
family relates to cannabinoid cr&#232;me formulations for treatment of radiation dermatitis and is licensed to Aries Science &amp;
Technology, LLC, and comprises 1 United States patent and 2 pending non-United States patents applications. The other patent family relates
to cannabinoid conjugates in combination with COX-2 inhibitors for treatment of pain and joint disease and is the subject of a pending
license term sheet with a third party and comprises 3 United States patents, and 3 pending United States and non-United States patent
applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
                                            for topical treatment of radiation dermatitis (WO2023154264)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cannabinoid
                                            Conjugate Molecules (WO2023150057)</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Diverse
Biotech, Inc. In-License</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold limited rights to patent applications owned by Diverse Biotech, Inc. for the use of cannabinoids in conjugate form with five existing,
standard-of-care drugs (celecoxib and four selected steroids) via Diverse Biotech&#8217;s patent pending conjugate drug delivery platform.
Our rights extend to all fields of use. The intended target for development of such conjugates is alleviating pain, specifically the
pain of osteoarthritis, rheumatoid arthritis, and cancer, with the goal of achieving improved and novel therapeutic outcomes for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
in-licensed Diverse Biotech, Inc. portfolio includes two patent families comprising 2 issued United States patents and 13 pending
United States and non-United States applications. Those patents and applications disclose conjugate chemistry that combines cannabinoids
with existing drugs in conjugate form that we believe will provide differentiation in use and efficacy from combination therapy of drugs
and cannabinoids. The license extends for as long as Enveric intends to develop and commercialize the licensed Agents and Products. The
patent applications, should they issue, may expire as late as 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
&amp; Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
view of the urgent need for new and more effective mental health treatments, we intend to combine innovative scientific discoveries and
biosynthetic and chemical synthetic approaches, along with expedited clinical development plans to create, develop and
progress novel therapies using psychedelic-inspired drug candidates and similar compounds. Our current research and development
efforts are focused on developing novel molecules structurally related to certain naturally occurring psychedelics with improved pharmaceutical
characteristics. Some of the naturally occurring psychedelic molecules are currently being investigated by researchers around the world
as potential treatments for a broad range of psychiatric and neurologic disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Studies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing drug discovery and preclinical activities in order to advance a number of novel psychedelic-inspired molecules
towards the clinic. Enveric&#8217;s lead development candidate is EB-003. EB-003 is a novel derivative of DMT. It
is the lead drug candidate from the EVM301 Series currently advancing through preclinical studies with the aim of initiating first-in-human
studies to assess safety and tolerability including non-hallucinogenic properties, followed by clinical trials targeting the treatment
of depression or other neuropsychiatric disorders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to assemble a team of clinical experts and principal investigators with experience across multiple mental health
and central nervous system indications to be responsible for the management, monitoring, and integrity of the clinical research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to submit filings including Clinical Trial Applications (CTA), Investigational New Drug (&#8220;IND&#8221;) applications and, eventually,
new drug applications (&#8220;NDA&#8221;) to seek approval with the US FDA and with responsible regulatory agencies in other jurisdictions,
in connection with our product candidates. The selection, timing, duration, and design of any prospective studies are subject to regulatory
filings, approval and finalization of commercial plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
next step is to advance EB-003 into formal preclinical development studies in support of a future IND filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Scientific
Advisory Board</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established a scientific advisory board and plan to seek advice and input from these experienced clinical leaders on matters related
to our research and development programs. The members of our scientific advisory board consist of experts across a range of key disciplines
relevant to our programs. We intend to continue to leverage the broad expertise of our advisors by seeking their counsel on important
topics relating to our product development and clinical development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
scientific advisors are not our employees and do have commitments to, or consulting or advisory contracts with, other entities that may
limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies
in developing products or technologies that may compete with us. All of our scientific advisors are affiliated with other entities and
devote a limited portion of their time to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric&#8217;s
current scientific advisors are set forth in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Specialization</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maurizio
    Fava, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director of the Clinical Trials Network and Institute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen
    M. Stahl, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Psychopharmacology for the California Department of State Hospitals</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Krystal, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Yale Center for Clinical Investigation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Liebowitz, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Professor
    of Psychiatry; Director at Medical Research Network</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    Research</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Maurizio
Fava, M.D.</i> has served as a Scientific Advisor of Enveric since 2022. Dr. Maurizio Fava is Chair, Mass General Brigham Academic
Centers Psychiatry Department, Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH), executive director of the Clinical
Trials Network and Institute, (MGH), associate dean for clinical and translational research, and the Slater Family Professor of Psychiatry
at Harvard Medical School. Dr. Fava is a world leader in the field of depression. He has edited eight books and authored or co-authored
more than 900 original articles published in medical journals with international circulation, articles which have been cited more than
95,000 times in the literature and with an H index greater than 150. Dr. Fava founded and was director of MGH&#8217;s Depression Clinical
and Research Program from 1990 until 2014. Under Dr. Fava&#8217;s direction, the Depression Clinical and Research Program became one
of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion,
clinical and research work. In 2007, he also founded and is now the executive director of the MGH Psychiatry Clinical Trials Network
and Institute, the first academic CRO specialized in the coordination of multi-center clinical trials in psychiatry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stephen
M. Stahl, M.D., Ph.D.</i> has served as a Scientific Advisor of Enveric since 2022. Dr. Stephen Stahl has held faculty positions at Stanford
University, the University of California at Los Angeles, the Institute of Psychiatry London, the Institute of Neurology London, and,
currently, as Clinical Professor of Psychiatry and Neuroscience at the University of California Riverside, Adjunct Professor of Psychiatry
at the University of California San Diego and as Honorary Fellow in Psychiatry at the University of Cambridge. Dr. Stahl serves as editor-in-chief
of CNS Spectrums and is Senior Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals (DSH)
where he has a leadership role in addressing violence and decriminalization of the seriously mentally ill. Author of over 575 articles
and chapters with an H index of 69, and more than 2000 scientific presentations and abstracts, Dr. Stahl is an internationally renowned
clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written over 50 textbooks
and edited 15 others, including the best-selling and award-winning textbook, Stahl&#8217;s Essential Psychopharmacology, now in its fifth
edition, and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber&#8217;s Guide, now in its seventh
edition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>John
Krystal, M.D. </i>has served as a Scientific Advisor of Enveric since 2022. Dr. John Krystal is the Robert L. McNeil, Jr., Professor
of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University;
and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale School
of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of schizophrenia,
alcoholism, PTSD, and depression. Notably, his laboratory discovered the rapid antidepressant effects of ketamine in humans. Dr. Krystal
directs/co-directs the Yale Center for Clinical Investigation (CTSA), NIAAA Center for the Translational Neuroscience of Alcoholism,
and Clinical Neuroscience Division of the National Center for PTSD (VA). He is a member of the U.S. National Academy of Medicine; co-director
of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; Fellow of the American Association for
the Advancement of Science (AAAS); and editor of Biological Psychiatry (IF=13.382). Previously, Dr. Krystal chaired the NIMH Board of
Scientific Counselors and has served as a member of the NIMH National Mental Health Advisory Council and the NIAAA National Alcohol Advisory
Council. He also previously served as the president of the American College of Neuropsychopharmacology (ACNP) and the International College
of Neuropsychopharmacology (CINP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Michael
Liebowitz, M.D.</i> has served as a Scientific Advisor of Enveric since 2022. Dr. Michael Liebowitz is a Professor of Psychiatry at Columbia
University and New York State Psychiatric Institute (NYSPI) and is currently Director at Medical Research Network where he is engaged
in clinical trials for depression, anxiety, binge eating, ADHD, PTSD, and borderline personality disorders. Dr. Liebowitz completed his
fellowship in psychopharmacology at the Depression Evaluation Service at NYSPI, where he helped develop and validate the DSM criteria
for atypical depression. Dr. Liebowitz established the Anxiety Disorders Clinic at NYSPI, the first research clinic to specialize in
anxiety disorders in the United States. Over the next two decades, Dr. Liebowitz and colleagues helped refine treatments for panic disorder,
broadened the diagnostic criteria and established medication treatment for social anxiety disorder, and collaborated in clinical trials
comparing medications and behavioral treatments for several anxiety disorders. Dr. Liebowitz developed the Liebowitz Social Anxiety Scale
(LSAS) which has been the primary outcome measure for several registration programs in social anxiety disorder and is used worldwide
as a research and clinical measure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Academic
Partners</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also established relationships with certain academic partners, who we believe have the potential to accelerate our product development,
market entry, data collection, analysis and advancement of clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary academic partner is the University of Calgary, which brings excellence into advancing brain and mental health research
and education.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis
on proprietary products. While we believe that our scientific knowledge and technology and development experience provide us with competitive
advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology
companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we
successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to focus on the development of novel and viable psychedelic-inspired drug candidates for mental illnesses and unmet medical
needs, and partner with pharmaceutical and other drug development and biotechnology companies in developing and commercializing psychedelic-inspired
medicines for diverse psychological and neuropsychiatric indications, which will be fundamentally composed of the psychedelic-inspired
drug candidates contained in the Psybrary&#8482;. While we believe that our technology, knowledge and experience as well as the scientific
resources at our disposal provide us with significant competitive advantages, we face potential competition from many different sources.
Any product candidates we successfully identify will compete not only with existing therapies but also new therapies that may become
available in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial opportunities could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our
competitors also may obtain approval from the FDA or other regulatory agencies for their medicines more rapidly than us, which could
result in our competitors establishing a strong market position before we are able to enter the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
our Psybrary&#8482; and the intellectual property kept and developed therein, our success depends on our ability to protect our intellectual
property and our ability to achieve and maintain key partnerships aimed at the development, licensing and marketing of psychedelic-inspired
medicines without infringing on the proprietary rights of others. Patent positions within the pharmaceutical field can be highly
uncertain and involve complex legal, scientific and factual questions for which important legal principles remain unresolved. Patents
issued to us may be challenged, invalidated or circumvented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation and Product Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic
Act, or the FDCA, and, to a lesser extent, by state and local governments. Before our prescription products may be marketed in the U.S.,
they must be approved by the FDA for commercial distribution. Certain OTC products must comply with applicable FDA regulations, known
as OTC Monographs, in order to be marketed, but do not have the benefit of FDA review and approval before marketing. We are also subject
to regulation under federal, state and local laws, including requirements regarding occupational safety, laboratory practices, environmental
protection and hazardous substance control, and may be subject to other present and future local, state, federal and foreign regulations.
We cannot predict the extent to which we may be affected by legislative and other regulatory developments concerning our products and
the healthcare industry in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDCA and other federal and state statutes and regulations govern the testing, manufacture, quality control, export and import, labeling,
storage, record keeping, approval, pricing, advertising, promotion, sale and distribution of pharmaceutical products. Noncompliance with
applicable requirements both before and after approval, can subject us, our third-party manufacturers and other collaborative
partners to administrative and judicial sanctions, such as, among other things, warning letters, fines and other monetary payments, recall
or seizure of products, criminal proceedings, suspension or withdrawal of regulatory approvals, interruption or cessation of clinical
trials, total or partial suspension of production or distribution, injunctions, limitations on or the limitation of claims we can make
for our products, and refusal of the government to enter into supply contracts for distribution directly by governmental agencies, or
delay in approving or refusal to approve new drug applications. The FDA also has the authority to revoke or withhold approvals of new
drug applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
approval is required before any &#8220;new drug,&#8221; can be marketed. Our products are new drugs and require prior FDA approval. Such
approval must be based on extensive information and data submitted in a NDA, including, but not limited to, adequate and well controlled
laboratory and clinical investigations to demonstrate the safety and effectiveness of the drug product for its intended use(s) as well
as the manufacturing suitability of the product. In addition to providing required safety and effectiveness data for FDA approval, a
drug manufacturer&#8217;s practices and procedures must comply with current Good Manufacturing Practices (&#8220;cGMPs&#8221;), which
apply to manufacturing, receiving, holding and shipping, and include, among other things, demonstration of product purity, consistent
manufacturing and quality and at least six months of data supporting product expiration dating based on clinical registration batches.
Accordingly, manufacturers must continue to expend time, money and effort in all applicable areas relating to quality assurance and regulatory
compliance, including production and quality control to comply with cGMPs. Failure to so comply risks delays in approval of drug products
and possible FDA enforcement actions, such as an injunction against shipment of products, the seizure of non-complying products, criminal
prosecution and/or any of the other possible consequences described above. We are subject to periodic inspection by the FDA and the Drug
Enforcement Administration (&#8220;DEA&#8221;), which inspections may or may not be announced in advance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intellectual property kept and developed in our Psybrary&#8482; is focused on developing and commercializing non-hallucinogenic
synthetic derivatives of psychedelic substances. While we use psychedelic inspired compounds and classic psychedelics as our starting
point for our research and identification of compounds, we do not have any direct or indirect involvement in the illegal selling, production
or distribution of any substances in the jurisdictions in which we operate. Enveric is a neuro-pharmaceutical scientific company and
as such we do not advocate for the legalization of psychedelic substances nor do we deal with psychedelic substances except within laboratory settings conducted within approved regulatory frameworks. Our products will not be commercialized prior to applicable
regulatory approval and this approval will only be granted if clinical evidence of safety and efficacy for the specific intended use
is successfully developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
execution of our strategy is in part contingent upon compliance with regulatory requirements enacted by governmental authorities and
obtaining regulatory approvals for the development and license of our psychedelic-inspired drug candidates. The psychedelic-inspired
medicine industry is a new and emerging industry with ambiguous existing regulations and uncertainty as to future regulations; we
cannot predict the impact of the ever-evolving compliance regime in respect of this industry. The impact of compliance regimes, any delays
in obtaining, or failure to obtain regulatory approvals may significantly delay or impact our development of markets, our business, psychedelic-inspired
medicines, and licensing initiatives and could have a material adverse effect on our business, financial condition and operating
results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
New Drug Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDCA,
and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage,
recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import
and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as imposition of clinical holds, FDA refusal to approve pending NDAs, warning letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution,
disgorgement, civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
product development in the U.S. typically involves preclinical laboratory and animal tests and the submission to the FDA of an IND,
which must become effective before clinical testing may commence. For commercial approval, the sponsor must submit adequate tests by
all methods reasonably applicable to show that the drug is safe for use under the conditions prescribed, recommended or suggested in
the proposed labeling. The sponsor must also submit substantial evidence, generally consisting of adequate, well-controlled clinical
trials to establish that the drug will have the effect it purports or is represented to have under the conditions of use prescribed,
recommended or suggested in the proposed labeling. In certain cases, the FDA may determine that a drug is effective based on one clinical
study plus confirmatory evidence. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time
required may vary substantially based upon the type, complexity and novelty of the product or disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics
and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements,
including the FDA&#8217;s good laboratory practices regulations and the U.S. Department of Agriculture&#8217;s (USDA&#8217;s) regulations
implementing the Animal Welfare Act. The results of preclinical testing are submitted to the FDA as part of an IND application along
with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol.
Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND application
is submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
30-day waiting period after the submission of each IND application is required prior to the commencement of clinical testing in humans.
If the FDA has not imposed a clinical hold on the IND application or otherwise commented or questioned the IND application within this
30-day period, the clinical trial proposed in the IND application may begin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the IND to healthy volunteers or patients under the supervision of a qualified investigator. Clinical
trials must be conducted: (i) in compliance with federal regulations, (ii) in compliance with GCP (&#8220;Good Clinical Practice&#8221;),
an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators
and monitors, and (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the
effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted
to the FDA as part of the IND application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other sanctions if it believes that
the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical
trial patients. The trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional
review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements or may impose other conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In general,
in Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics,
pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually
involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance
and optimum dosage, and to identify common adverse effects and safety risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken
to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed
clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information
for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate
the efficacy of the drug. The FDA may, however, determine that a drug is effective based on one clinical study plus confirmatory evidence.
Only a small percentage of investigational drugs complete all three phases and obtain marketing approval. In some cases, the FDA may
require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information
on the drug&#8217;s effect in various populations and any side effects associated with long-term use. Depending on the risks posed by
the drugs, other post-market requirements may be imposed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the required clinical testing, an NDA is prepared and submitted to the FDA. The FDA approval of the NDA is required before
marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical, and other testing and
a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting
an NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the
FDA begins an in-depth review. Under the statute and implementing regulations, the FDA has 180 days (the initial review cycle) from the
date of filing to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement
between the FDA and the applicant or as a result of the applicant submitting a major amendment. In practice, the performance goals established
pursuant to the Prescription Drug User Fee Act have effectively extended the initial review cycle beyond 180 days. The FDA&#8217;s current
performance goals call for the FDA to complete review of 90 percent of standard (non-priority) NDAs within 10 months of receipt and within
six months for priority NDAs, but two additional months of review are added to standard and priority NDAs for a new molecular entity
(NME).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to
an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation
as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally
follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance
with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve
the product unless compliance with current GMP is satisfactory and the NDA contains data that provide substantial evidence that the drug
is safe and effective in the indication studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction
in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within
two to six months depending on the type of information included.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition
of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug
outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to
assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing,
dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially
affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and
surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory
standards is not maintained or problems are identified following initial marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disclosure
of Clinical Trial Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sponsors
of clinical trials of certain FDA-regulated products, including prescription drugs, are required to register and disclose certain clinical
trial information on a public website maintained by the U.S. National Institutes of Health. Information related to the product, patient
population, phase of investigation, study sites and investigator, and other aspects of the clinical trial is made public as part of the
registration. Sponsors are also obligated to disclose the results of these trials after completion. Disclosure of the results of these
trials can be delayed for up to two years if the sponsor certifies that it is seeking approval of an unapproved product or that it will
file an application for approval of a new indication for an approved product within one year. Competitors may use this publicly available
information to gain knowledge regarding the design and progress of our development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Special
Protocol Assessment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company may reach an agreement with the FDA under the Special Protocol Assessment, or &#8220;SPA&#8221;, process as to the required design
and size of clinical trials intended to form the primary basis of an efficacy claim. According to its performance goals, the FDA is supposed
to evaluate the protocol within 45 days of the request to assess whether the proposed trial is adequate, and that evaluation may result
in discussions and a request for additional information. A SPA request must be made before the proposed trial begins, and all open issues
must be resolved before the trial begins. If a written agreement is reached, it will be documented and made part of the administrative
record. Under the FDCA and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited
circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the study
begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and the FDA agree to
the change in writing, or if the study sponsor fails to follow the protocol that was agreed upon with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advertising
and Promotion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-approval
promotion of investigational drug candidates is prohibited by the FDA. Therefore, sponsors must ensure that any pre-approval communications
disseminated about its drug candidates do not state or imply that such candidates have been proven safe or effective for the applicable
use(s) or that they have been approved for commercialization in the United States. Further, once an NDA for a given candidate is approved,
if ever, the product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval
marketing and promotion of drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of
the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities,
require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new
indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions
in reviewing NDA supplements as it does in reviewing NDAs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
Event Reporting and GMP Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing
testing, known as Phase 4 testing, may require under a REMS special communication regarding the safety of the drug or heightened surveillance
to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or
use of the product. In addition, quality-control, drug manufacture, packaging, and labeling procedures must continue to conform to GMP,
after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and
certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the
agency inspects manufacturing facilities to assess compliance with GMP. Accordingly, manufacturers must continue to expend time, money
and effort in the areas of production and quality control to maintain compliance with GMP. Regulatory authorities may withdraw product
approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial
marketing or if previously unrecognized problems are subsequently discovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Exclusivity and Pediatric Use</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Best Pharmaceuticals for Children Act, or &#8220;BPCA&#8221;, provides NDA holders a six-month period of exclusivity attached to any
other exclusivity listed with the FDA&#8201;&#8212;&#8201;patent or non-patent&#8201;&#8212;&#8201;for a drug, if certain conditions
are met. Conditions for pediatric exclusivity include a determination by the FDA that information relating to the use of a new drug in
the pediatric population may produce health benefits in that population; a written request by the FDA for pediatric studies; and agreement
by the applicant to perform the requested studies and the submission to the FDA, completion of the studies in accordance with the written
request, and the acceptance by the FDA, of the reports of the requested studies within the statutory time frame. Applications under the
BPCA are treated as priority applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act, or &#8220;PREA&#8221;, NDAs or supplements to NDAs must contain data to assess the
safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration
for each pediatric subpopulation for which the drug is safe and effective, unless the sponsor has received a deferral or waiver from
the FDA. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has
been granted. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral
may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies
are complete or that additional safety or effectiveness data need to be collected before the pediatric studies begin. Under PREA, the
FDA must send a noncompliance letter requesting a response within 45 days to any sponsor that fails to submit the required assessment,
keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Controlled
Substances</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Controlled Substances Act of 1970, or &#8220;CSA&#8221;, and its implementing regulations establish a &#8220;closed system&#8221;
of regulations for controlled substances. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing,
distribution, importation and other requirements under the oversight of the Drug Enforcement Agency (&#8220;DEA&#8221;). The DEA is the
federal agency responsible for regulating controlled substances, and requires those individuals or entities that manufacture, import,
export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent the diversion
of controlled substances to illicit channels of commerce.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA categorizes controlled substances into one of five schedules&#8201;&#8212;&#8201;Schedule I, II, III, IV or V&#8201;&#8212;&#8201;with
varying qualifications for listing in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently
accepted medical use in treatment in the U.S., and lack accepted safety for use under medical supervision. Marijuana and psychedelics
such as psilocybin, DMT, mescaline and MDMA are currently Schedule I controlled substances, which means that no preclinical or clinical
studies of product candidates containing these substances may be conducted in the United States without the required DEA registration(s)
and related approvals, as applicable. Pharmaceutical products having a currently accepted medical use that are otherwise approved for
marketing may be listed as Schedule II, III, IV or V substances, with Schedule II substances presenting the highest potential for abuse
and physical or psychological dependence, and Schedule V substances presenting the lowest relative potential for abuse and dependence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facilities
that manufacture, distribute, import, or export any controlled substance must register annually with the DEA. The DEA registration is
specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are required
for importation and manufacturing activities, and each registration authorizes which schedules of controlled substances the registrant
may handle. However, certain coincidental activities are permitted without obtaining a separate DEA registration, such as distribution
of controlled substances by the manufacturer that produces them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
DEA inspects all manufacturing facilities to review security, recordkeeping, reporting, and handling prior to issuing a controlled substance
registration. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances
handled. The most stringent requirements apply to manufacturers of Schedules I and Schedule II substances. Required security measures
commonly include background checks on employees and physical control of controlled substances through storage in approved vaults, safes
and cages, and through use of alarm systems and surveillance cameras. An application for a manufacturing registration as a bulk manufacturer
(not a dosage form manufacturer or a repacker/relabeler) for a Schedule I or II substance must be published in the Federal Register,
and is open for 60 days to permit interested persons to submit comments, objections or requests for a hearing. A copy of the notice of
the Federal Register publication is simultaneously forwarded by DEA to all those registered, or applicants for registration, as bulk
manufacturers of that substance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances.
Manufacturers must submit periodic reports to the DEA of the distribution of Schedules I and II controlled substances, Schedule III narcotic
substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and
must obtain authorization to destroy or dispose of controlled substances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with applications for registration as a bulk manufacturer, an application for an importer registration for a Schedule I or II substance
must also be published in the Federal Register, which remains open for 30 days for comments. Imports of Schedules I and II controlled
substances for commercial purposes are generally restricted to substances not already available from a domestic supplier or where there
is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must
obtain a permit for every import or export of a Schedules I and II substance or Schedules III, IV and V narcotic, and submit import or
export declarations for Schedules III, IV and V non-narcotics. In some cases, Schedule III non-narcotic substances may be subject to
the import/export permit requirement, if necessary to ensure that the U.S. complies with its obligations under international drug control
treaties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
drugs manufactured in the U.S., the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II
that may be manufactured or produced in the U.S. based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical,
scientific, research and industrial needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
states also maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution,
and dispensing requirements. State Authorities, including Boards of Pharmacy, regulate use of controlled substances in each state. Failure
to maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can
result in enforcement action that could have a material adverse effect on our business, operations and financial condition. The DEA may
seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances,
violations could lead to criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Europe/Rest
of World Government Regulation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to regulations in the U.S., we are and will be subject, either directly or through our distribution partners, to a variety of
regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales (including pricing and reimbursement)
and distribution of our product candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in non-U.S. countries
prior to the commencement of clinical trials or marketing of the product in those countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, medicinal products are subject to extensive pre- and post-marketing regulation by regulatory authorities at both
the European Union and national levels. Additional rules also apply at the national level to the manufacture, import, export, storage,
distribution and sale of controlled substances. In many European Union member states the regulatory authority responsible for medicinal
products is also responsible for controlled substances. Responsibility is, however, split in some member states. Generally, any company
manufacturing or distributing a medicinal product containing a controlled substance in the European Union will need to hold a controlled
substances license from the competent national authority and will be subject to specific record-keeping and security obligations. Separate
import or export certificates are required for each shipment into or out of the member state.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials and Marketing Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities
of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies
from country to country and can involve additional product testing and additional administrative review periods. The time required to
obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in
one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may
negatively impact the regulatory process in others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
countries outside of the U.S. have a process that requires the submission of a clinical trial application much like an IND application
prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, or &#8220;CTA&#8221;, must
be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends
to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements and a company has received favorable
ethics committee approval, clinical trial development may proceed in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to
country, even though there is already some degree of legal harmonization in the European Union member states resulting from the national
implementation of underlying European Union legislation. In all cases, the clinical trials must be conducted in accordance with the International
Conference on Harmonization, or &#8220;ICH&#8221;, guidelines on GCP and other applicable regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain regulatory approval to place a drug on the market in European Union countries, Enveric must submit a marketing authorization application.
This application is similar to the NDA in the U.S., with the exception of, among other things, country-specific document requirements.
All application procedures require an application in the common technical document, or CTD, format, which includes the submission of
detailed information about the manufacturing and quality of the product, and nonclinical and clinical trial information. Drugs can be
authorized in the European Union by using (i) the centralized authorization procedure, (ii) the mutual recognition procedure, (iii) the
decentralized procedure, or (iv) national authorization procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Commission created the centralized procedure for the approval of human drugs to facilitate marketing authorizations that are
valid throughout the European Union and, by extension (after national implementing decisions) in Iceland, Liechtenstein and Norway, which,
together with the European Union Member States, comprise the European Economic Area, or &#8220;EEA&#8221;. Applicants file marketing
authorization applications with the EMA (European Medicines Agency), where they are reviewed by a relevant scientific committee, in most
cases the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;). The EMA forwards CHMP opinions to the European Commission,
which uses them as the basis for deciding whether to grant a marketing authorization. This procedure results in a single marketing authorization
granted by the European Commission that is valid across the European Union, as well as in Iceland, Liechtenstein and Norway. The centralized
procedure is compulsory for human drugs that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain
a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases,
autoimmune and other immune dysfunctions and viral diseases, (iii) officially designated &#8220;orphan drugs&#8221; (drugs used for rare
human diseases), and (iv) advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The
centralized procedure may at the voluntary request of the applicant also be used for human drugs that do not fall within the above-mentioned
categories if the CHMP agrees that the human drug (a) contains a new active substance not yet approved on November 20, 2005; (b) constitutes
a significant therapeutic, scientific or technical innovation, or (c) authorization under the centralized procedure is in the interests
of patients at the European Union level.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the centralized procedure in the European Union, the maximum time frame for the evaluation of a marketing authorization application by
the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response
to questions asked by the CHMP), with adoption of the actual marketing authorization by the European Commission thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest
from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated;
the absence of an appropriate alternative therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance,
EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
those medicinal products for which the centralized procedure is not available, the applicant must submit marketing authorization applications
to the national medicines regulators through one of three procedures: (i) the mutual recognition procedure (which must be used if the
product has already been authorized in at least one other European Union member state, and in which the European Union member states
are required to grant an authorization recognizing the existing authorization in the other European Union member state, unless they identify
a serious risk to public health), (ii) the decentralized procedure (in which applications are submitted simultaneously in two or more
European Union member states), or (iii) national authorization procedures (which results in a marketing authorization in a single European
Union member state).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Mutual
Recognition Procedure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
mutual recognition procedure, or &#8220;MRP&#8221;, for the approval of human drugs is an alternative approach to facilitate individual
national marketing authorizations within the European Union. Fundamentally, the MRP may be applied for all human drugs for which the
centralized procedure is not obligatory. The MRP is applicable to the majority of conventional medicinal products, and must be used if
the product has already been authorized in one or more European Union member states.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MRP functions by building on an already-existing marketing authorization in a member state of the European Union which is used as a reference
in order to obtain marketing authorizations in other European Union member states. Under the MRP, if a marketing authorization for a
drug already exists in one or more member states of the European Union and subsequently marketing authorization applications are made
in other European Union member states by referring to the initial marketing authorization. The member state in which the marketing authorization
was first granted will then act as the reference member state. The member states where the marketing authorization is subsequently applied
for act as concerned member states. The concerned member states are required to grant an authorization recognizing the existing authorization
in the reference member state, unless they identify a serious risk to public health.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MRP is based on the principle of the mutual recognition by European Union member states of their respective national marketing authorizations.
Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member
states. In such case, the reference member state shall update its existing assessment report about the drug in 90 days. After the assessment
is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling
and package leaflet. The concerned member states then have 90 days to recognize the decision of the reference member state and the summary
of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement
of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any European Union member state refuse to recognize the marketing authorization by the reference member state, on the grounds of potential
serious risk to public health, the issue will be referred to a coordination group. Within a time frame of 60 days, member states shall,
within the coordination group, make all efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific
committee for arbitration. The opinion of this EMA Committee is then forwarded to the European Commission, for the start of the decision-making
process. As in the centralized procedure, this process entails consulting various European Commission Directorates General and the Standing
Committee on Human Medicinal Products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Exclusivity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, marketing authorization applications for generic medicinal products do not need to include the results of preclinical
and clinical trials, but instead can refer to the data included in the marketing authorization of a reference product for which regulatory
data exclusivity has expired. If a marketing authorization is granted for a medicinal product containing a new active substance, that
product benefits from eight years of data exclusivity, during which generic marketing authorization applications referring to the data
of that product may not be accepted by the regulatory authorities, and a further two years of market exclusivity, during which such generic
products may not be placed on the market. The two-year period may be extended to three years if during the first eight years a new therapeutic
indication with significant clinical benefit over existing therapies is approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Orphan
Medicinal Products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA&#8217;s Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) may recommend orphan medicinal product designation to promote
the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating
conditions affecting not more than 5 in 10,000 persons in the European Union. Additionally, designation is granted for products intended
for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without
incentives, it is unlikely that sales of the product in the European Union would be sufficient to justify the necessary investment in
developing the medicinal product. The COMP may only recommend orphan medicinal product designation when the product in question offers
a significant clinical benefit over existing approved products for the relevant indication. Following a positive opinion by the COMP,
the European Commission adopts a decision granting orphan status. The COMP will reassess orphan status in parallel with EMA review of
a marketing authorization application and orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for
instance because in the meantime a new product was approved for the indication and no convincing data are available to demonstrate a
significant benefit over that product). Orphan medicinal product designation entitles a party to financial incentives such as reduction
of fees or fee waivers and ten years of market exclusivity is granted following marketing authorization. During this period, the competent
authorities may not accept or approve any similar medicinal product, unless it offers a significant clinical benefit. This period may
be reduced to six years if the orphan medicinal product designation criteria are no longer met, including where it is shown that the
product is sufficiently profitable not to justify maintenance of market exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pediatric
Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, companies developing a new medicinal product must agree to a Pediatric Investigation Plan, or &#8220;PIP&#8221;,
with the EMA and must conduct pediatric clinical trials in accordance with that PIP unless a waiver applies, for example, because the
relevant disease or condition occurs only in adults. The marketing authorization application for the product must include the results
of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which
case the pediatric clinical trials must be completed at a later date. Products that are granted a marketing authorization on the basis
of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under
a supplementary protection certificate (if the product covered by it qualifies for one at the time of approval). This pediatric reward
is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, most countries are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic
control of narcotic substances. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle
to us obtaining marketing approval for our product candidates in those countries. These countries may not be willing or able to amend
or otherwise modify their laws and regulations to permit our product candidates to be marketed, or achieving such amendments to the laws
and regulations may take a prolonged period of time. In that case, we would be unable to market our product candidates in those countries
in the near future or perhaps at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have consolidated our employee base to save capital and focus on development of our lead candidate EB-003. As of the date of hereof,
we employ five full-time employees and one part-time employee. We also work with scientific advisors, consultants and service providers,
mainly through academic institutions and contract research organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never had a work stoppage and none of our employees are covered by collective bargaining agreements or represented by a labor union.
We believe that we have good relationships with our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ar_008"></span>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>References
to the &#8220;Company,&#8221; &#8220;Enveric&#8221; &#8220;our,&#8221; &#8220;us,&#8221; or &#8220;we&#8221; in this section titled &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations of Enveric&#8221; refer to Enveric Biosciences, Inc. The following
discussion and analysis of our financial condition and results of operations should be read together with our financial statements and
related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth
elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes
forward-looking statements involving risks and uncertainties and should be read together with the &#8220;Risk Factors&#8221; and the
&#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; sections of this prospectus. Such risks and uncertainties could
cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the
following discussion and analysis.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment
of depression, anxiety, addiction, and other psychiatric disorders. Leveraging its unique discovery and development platform, the Psybrary&#8482;,
which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications,
Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric&#8217;s
lead program, the EVM301 Series, and its lead drug candidate, EB-003, are intended to offer a first-in-class, new approach to the treatment
of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations
in the patient. Previously, Enveric was developing the EVM201 Series, and its lead drug candidate EB-002 (formerly EB-373), for the treatment
of neuropsychiatric disorders. The EVM201 Series comprised next generation synthetic prodrugs of the active metabolite, psilocin. Recently,
Enveric out-licensed the EVM201 Series program to MycoMedica Life Sciences, who will seek to develop, manufacture, and commercialize
EB-002, in exchange for certain development and milestone payments to Enveric (discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Neuroplastogens</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
our amalgamation with MagicMed completed in September 2021, we have continued to pursue the development of MagicMed&#8217;s proprietary
library, the Psybrary&#8482;, which we believe will help us to identify and develop the right drug candidates needed to address mental
health challenges, including depression, anxiety, and addiction disorders. We synthesize novel phenylalkylamines and indolethylamines,
using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which currently includes 20 patent
families with claims covering over a million potential molecular structures, over one thousand of which we have so far synthesized in
sufficient quantities to identify and hundreds of which we have screened for receptor binding and other relevant activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
this stage, we have entered into several non-binding term sheets with strategic partners to out-license certain molecules from the Psybrary&#8482;.
Going forward, in order to build a pipeline of product candidates, we intend to both continue to internally develop new drug candidates
with associated intellectual property and to acquire, through in-licensing, additional intellectual property from pharmaceutical and
biotechnology companies and research institutions. The in-licensed assets could include both research stage and clinical stage drug candidates.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary focus is to develop our lead asset EB-003 in the EVM301 Series. The development status of the product is shown in the table below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 41%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
    Candidates</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Targeted
    Indications</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expected
    Next Steps</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EB-003</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Psychedelic-inspired drug candidates</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mental
    health indication</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preclinical
    Development</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IND
    Filing</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025, pursuant to which every
15 shares of our issued and outstanding common stock were reclassified as one share of common stock. No fractional shares were
issued as a result of the reverse stock split. Any fractional shares that were to otherwise have resulted from the reverse stock
split were rounded up to the next whole number. The reverse stock split had no impact on the par value of our common stock or the
authorized number of shares of our common stock. </span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>NASDAQ
Bid Price Deficiency and Reverse Split</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2024, the Company received a letter from Nasdaq notifying the Company that for the prior 30 consecutive business days the bid
price for the Company&#8217;s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on Nasdaq
pursuant to Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule). The deficiency letter did not result in the immediate delisting of the Company&#8217;s
common stock from Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar
days, until November 12, 2024, to regain compliance with the Bid Price Rule. On November 20, 2024, Nasdaq issued a delisting notice,
indicating that the Company did not satisfy the Bid Price Rule by the compliance date and that unless the Company requested an appeal
of this determination before Nasdaq&#8217;s listing qualifications panel, our common stock would be scheduled for delisting from Nasdaq
and trading suspended. We appealed the determination before Nasdaq&#8217;s listing qualifications panel and on December 30, 2024, the
Company received an extension until May 19, 2025, to regain compliance with Bid Price Rule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2024, subject to stockholder approval, the Board approved an amendment to our certificate of incorporation to, at the
discretion of the Board, effect a reverse stock split of our outstanding common stock at a ratio between 1-for-10 and 1-for-100,
including shares held by the Company as treasury shares, with the exact ratio within such range to be determined by the Board at its
discretion. A meeting of the stockholders was held on January 17, 2025, whereby the stockholders approved the reverse stock split.
The Company effected a 1-for-15 reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. Nasdaq
requires that the closing bid price of the Company remain at $1.00 per share or greater for 10 consecutive business days before
declaring that the Company has regained compliance with the Bid Price Rule. As of the date of this prospectus, the Company has not
completed 10 consecutive business days from the reverse stock split effective date and therefore it is not in compliance with the
Bid Price Rule. Even if we do regain compliance, we cannot provide any assurance that our stock price will not drop below the
minimum bid price requirement under the Bid Price Rule following the completion of this offering and we will not be subject to
another delisting notice from NASDAQ.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreement with MycoMedica Life Sciences</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, Enveric executed a licensing agreement with MycoMedica out-licensing the Company&#8217;s EVM201 program, including
drug candidate EB-002. Pursuant to the terms of licensing agreement, MycoMedica will seek to develop, manufacture, and commercialize
EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, for the treatment of neuropsychiatric disorders
such as depression. MycoMedica received an exclusive, global license to the formulations, drugs, method of use, and medical devices developed
by Enveric to utilize the compound. MycoMedica assumed the responsibility for all future preclinical, clinical, and commercial development
on a royalty-bearing basis for all human and animal pharmaceutical applications. As part of the license agreement, Enveric received a
modest upfront payment, and if certain conditions are met, will receive development and sales milestones potentially totaling up
to $62 million, plus tiered single digit royalties on all future sales. <span style="background-color: white">MycoMedica has the option
during the license term to buyout its milestone and royalty payment obligations at a predetermined amount depending upon the stage of
product development and commercialization at the time of the buyout. Further, MycoMedica has the right to purchase the licensed patents
at a nominal amount upon a change of control of Enveric, although doing so does not relieve MycoMedica of any of its payment obligations.
No royalties have been received to date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>License
Agreement with Aries Science and Technology</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
July 10, 2024, Akos Biosciences, Inc., a Delaware corporation (&#8220;Akos&#8221;), wholly-owned subsidiary of Enveric, entered into
an exclusive license agreement with Aries Science and Technology, LLC (&#8220;Aries&#8221;) pursuant to which Akos granted Aries a license
of Akos&#8217;s patented radiation dermatitis topical product. The license allows Aries to use the patented formulation to develop pharmaceutical
or non-pharmaceutical products for treating radiation dermatitis suitable for administration to humans or animals. The license is exclusive
(subject to certain exceptions contained in the Agreement), worldwide, royalty-bearing, and includes the right to sublicense. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
will be eligible to receive aggregate milestone payments of up to $61 million, as well as tiered royalties on future sales, if all conditions
are met. <span style="background-color: white">Aries has the option during the license term, to purchase the rights to each licensed
product (on a licensed product-by-licensed product basis) in the form of an exclusive (as to the applicable licensed product), fully
paid, transferable right and license to the licensed product. No royalties have been received to date.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Registered
Direct Offerings</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
March and May 2024, Enveric entered into a series of common stock purchase agreements (the &#8220;Purchase Agreements&#8221;) for the
issuance in a registered direct offering of an aggregate of 45,780 shares of the Company&#8217;s common stock, par value $0.01
per share, to certain institutional investors. The issuance was made in exchange for the permanent and irrevocable waiver of the variable
rate transaction limitation contained in certain inducement offer letters, dated December 28, 2023, between the Company and the institutional
investors with respect to any existing or future agreement by the Company to effect any issuance of shares. The Company did not receive
any net proceeds in connection with the offering. The offering was made to obtain a waiver of the variable rate transaction limitation
as described above and further described in the Purchase Agreements so the Company could utilize its equity line of credit with Lincoln
Park Capital Fund, LLC, and enter into any future agreements that involve a variable rate transaction and issue such shares thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Operating Results</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; color: #212529"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred for the research and development of our preclinical product candidates,
and include, without limitation:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, benefits and share-based compensation expense;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with contract research organizations, contract manufacturing organizations, and consultants and other entities
    engaged to support our product research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of acquiring, developing and manufacturing materials and lab supplies used in research and development activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facility,
    equipment, depreciation and other expenses, which include, without limitation direct and allocated expenses for rent, maintenance
    of our facilities and equipment, insurance and other supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with preclinical activities and regulatory operations, including, without limitation, patent related costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
    and professional fees associated with research and development activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -16.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expense research and development costs to operations as incurred. Research and development activities are central to our business model.
We utilize a combination of internal and external efforts to advance product development from early-stage work to future clinical trial
manufacturing and clinical trial support. External efforts include work with consultants and increasingly substantial work at CROs and
CMOs. We support an internal research and development team  in Calgary, Alberta, Canada. To move these programs forward
along our development timelines, a large portion (approximately 75%) of our staff are research and development employees. In January
2024, the Company reduced its discovery team in Calgary and was primarily focused on the development of EB-002 and EB-003
pipeline assets (until we out-licensed EB-002 to MycoMedica Lifesciences in November of 2024).  Because of the numerous risks and uncertainties associated
with product development, however, we cannot determine with certainty the duration and completion costs of these or other current or
future preclinical studies and clinical trials. The duration, costs and timing of clinical trials and development of our product candidates
will depend on a variety of factors, including the uncertainties of future clinical and preclinical studies, uncertainties in clinical
trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate
will depend on numerous factors, including competition, manufacturing capability and commercial viability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist principally of salaries, benefits and related costs such as stock-based compensation for personnel
and consultants in executive, finance, business development, corporate communications and human resource functions, facility costs not
otherwise included in research and development expenses, accounting and audit costs, tax compliance costs, SEC compliance costs, investor
relation costs, training and conference costs, insurance costs and legal fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Intangible Assets and Goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performs an annual impairment test of intangible assets and goodwill as of December 31 of each fiscal year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
significant portion of our operating expenses is related to stock-based compensation costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation consists of restricted stock units (&#8220;RSU&#8221;) and options to purchase shares of the Company&#8217;s common stock.
The Company follows Accounting Standards Codification (&#8220;ASC&#8221;) 718, Compensation - Stock Compensation, which addresses the
accounting for stock-based payment transactions, requiring such transactions to be accounted for using the fair value method. The fair
value of RSU or restricted stock awards (&#8220;RSAs&#8221;) is determined by the closing price per share of the Company&#8217;s common
stock on the date of the award. The Company uses the Black-Scholes option pricing model to determine the grant date fair value of options
issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RSU&#8217;s
may contain vesting conditions that include, without limitation, any or all of the following: immediate vesting, vesting over a defined
time period, vesting based on specific volume weighted average price levels being achieved by the Company&#8217;s common stock as publicly
traded within specified measurement periods, and vesting based on the achievement of specific performance milestones. Options contain
vesting conditions that provide for vesting over a defined time period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of RSU&#8217;s and options, is charged to expense, on a straight line basis over the vesting periods defined in the award
agreements, except for the fair value which is attributable to achievement of a specific performance milestones, which are charged to
expense upon achievement of such milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in fair value of warrant liabilities, investment options and derivative liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives
or contain features that qualify as embedded derivatives, pursuant to ASC 480. &#8220;Distinguishing Liabilities from Equity&#8221; (&#8220;ASC
480&#8221;) and ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;). The Company accounts for warrants for shares
of the Company&#8217;s common stock that are not indexed to its own stock as derivative liabilities at fair value on the consolidated
balance sheet. The Company adjusts this derivative liability at each reporting period, with the liability recorded on the balance sheet
being equal to fair value of such liability on the relevant balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value of derivative liabilities is determined in accordance with ASC 820-10 &#8220;Fair Value Measurement&#8221;. The fair value
of the embedded derivative liabilities was determined using weighted-average scenario analysis and the fair value of warrant liabilities
was determined using the Black-Scholes valuation model, both of which are level 3 methods, as defined in ASC 820-10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of
these derivative liabilities has a strong correlation to the price per share of the Company&#8217;s common stock as publicly traded.
Increases in the Company&#8217;s price per share will result in increased derivative liabilities, with a corresponding other expense
being recorded in the other income (expense) section of the statement of operations and comprehensive loss. Decreases in the Company&#8217;s
price per share will result in decreased derivative liabilities, with a corresponding other income being recorded in the other income
(expense) section of the statement of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
for the three months ended September 30, 2024 and 2023:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information comparing the components of net loss for the three months ended September 30, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended September 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,235,661</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,080,644</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">762,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,281,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">84,814</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">86,296</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,083,192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,448,395</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,083,192</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,448,395</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(122</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,822</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">562,715</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Interest income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(217</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,237</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">Total other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(840</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">632,774</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,084,032</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,815,621</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">Income tax expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,595</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,084,032</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,822,216</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses decreased to $1,235,661 for the three months ended September 30, 2024 from $2,080,644 for the
three months ended September 30, 2023, a decrease of $844,983, or 41%. This change was primarily driven by decreases in consulting
expenses of $138,778, salaries and wages of $263,764, and legal fees of $192,941, all a direct result of the second quarter 2023
reduction in force and no longer pursuing the transfer and spin-off its cannabinoid clinical development pipeline assets to Akos
Biosciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expense for the three months ended September 30, 2024 was $762,717 as compared to $1,281,455 for the three months
ended September 30, 2023 with a decrease of $518,738, or approximately 40%. This decrease was primarily driven by a decrease in CRO expense
of $4,206, salaries and wages of $212,377, and product development of $208,312.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Depreciation
and Amortization Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense for the three months ended September 30, 2024 was $84,814 as compared to $86,296 for the three months ended
September 30, 2023, with a decrease of $1,482, or approximately 2%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Warrant Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of warrant liabilities for the three months ended September 30, 2024 resulted in an expense of $122 as compared to income
of $67,822 for the three months ended September 30, 2023. The change in fair value of warrant liabilities is due to the exercise of 8,134
of warrants on December 28, 2023, resulting in less warrants outstanding and re-valued at September 30, 2024, as well as, the change
in the closing price of Common Stock at the end of each period, as compared to the closing price of Common Stock at the beginning of
each period with a strong inverse relationship between changes in fair value of warrant liabilities and the trading price of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Investment Option Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of investment option liability for the three months ended September 30, 2024 resulted in an expense of $501 as compared
to income of $562,715 during the three months ended September 30, 2023. The change in fair value is due to the exercise of 66,667
investment options on December 28, 2023, resulting in less investment options re-valued at September 30, 2024 and a significant decrease
in the Company&#8217;s stock price for the three months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
for the nine months ended September 30, 2024 and 2023:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information comparing the components of net loss for the nine months ended September 30, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,467,065</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,273,344</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,736,373</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,531,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">255,002</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">259,300</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 20pt; font-weight: bold; text-align: left">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,458,440</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,064,080</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,458,440</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,064,080</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,722</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(115,342</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(399,921</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Interest income, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">444</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,142</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; font-weight: bold; text-align: left">Total other income (expense)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,830</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">214,879</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,418,610</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(13,849,201</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Income tax expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,731</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,595</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,420,341</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,855,796</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 376.65pt; text-align: justify; text-indent: -10.7pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses decreased to $4,467,065 for the nine months ended September 30, 2024 from $8,273,344 for the nine
months ended September 30, 2023, a decrease of $3,806,279, or 46%. This change was primarily driven by decreases in consulting expenses
of $836,437, salaries and wages of $1,305,710, stock compensation expense of $623,259, investor relations of $313,509, legal fees of
$487,863, and accounting fees of $227,200, all a direct result of the second quarter 2023 reduction in force and no longer pursuing the
transfer and spin-off its cannabinoid clinical development pipeline assets to Akos Biosciences, Inc., and Delaware franchise taxes of
$246,144 partially offset by an increase in director fees of $107,186.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expense for the nine months ended September 30, 2024 was $1,736,373 as compared to $5,531,436 for the nine months
ended September 30, 2023 with a decrease of $3,795,063, or approximately 69%. This decrease was primarily driven by a decrease in
salaries and wages of $1,542,075, research costs of $1,056,511, product development costs of $532,063, CRO costs of $128,560 and
the gain realized related to the Australian R&amp;D tax incentive of $291,439.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Depreciation
and Amortization Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense for the nine months ended September 30, 2024 was $255,002 as compared to $259,300 for the nine months ended
September 30, 2023, with a decrease of $4,298, or approximately 2%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Warrant Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of warrant liabilities for the nine months ended September 30, 2024 resulted in income of $20,722 as compared to a loss
of $115,342 for the nine months ended September 30, 2023. The change in fair value of warrant liabilities is due to the exercise of 8,134
of warrants on December 28, 2023, resulting in less warrants outstanding and re-valued at September 30, 2024, as well as, the change
in the closing price of Common Stock at the end of each period, as compared to the closing price of Common Stock at the beginning of
each period with a strong inverse relationship between changes in fair value of warrant liabilities and the trading price of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Investment Option Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of investment option liability for the nine months ended September 30, 2024 resulted in income of $18,664 as compared
to a loss of $399,921 during the nine months ended September 30, 2023. The change in fair value is due to the exercise of 66,667
investment options on December 28, 2023, resulting in less investment options re-valued at September 30, 2024 and a significant decrease
in the Company&#8217;s stock price for the nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Derivative Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s change in fair value of derivative liability is due to the May 2023 redemption which ceased the probability of occurrence
of the Akos spin-off and Akos Series A Preferred Stock redemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
for the years ended December 31, 2023 and 2022:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information comparing the components of net loss for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,852,021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,605,761</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,252,437</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,027,773</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment of intangible assets and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,453,662</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">343,982</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">327,910</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">16,448,440</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">27,415,106</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(16,448,440</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(27,415,106</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inducement expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,848,235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,315,236</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,752</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,472,726</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(325,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,708</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,249</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total other (expense) income</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(814,379</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">7,457,713</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(17,262,819</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19,957,393</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (expense) benefit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,913</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,291,732</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,471,333</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Known
Trends or Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current inflationary trend existing in the North American economic environment is considered by Management to be reasonably likely to
have a material unfavorable impact on results of continuing operations. While inflation is experiencing a declining trend in recent
months, it remains at higher levels as compared to recent periods of price inflation, borrowing costs have not correspondingly
reduced, and the cost of labor and materials continue to remain high. Furthermore, due to a recent change in the administration,
there remains uncertainty in terms of domestic and international policies as they pertain to taxation, tariffs, energy, immigration,
artificial intelligence, all or some of which may affect inflationary trends, capital markets, and availability of resources and materials.
In addition, there is an increased risk of the Company experiencing labor shortages as a result of a potential inability to attract
and retain human resources due to increased labor costs resulting from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses decreased to $8,852,021 for the year ended December 31, 2023 from $11,605,761 for the year ended
December 31, 2022, a decrease of $2,753,740, or 24%. This change was primarily driven by decreases in insurance expenses of $1,112,059,
salaries and wages of $626,573, transaction expenses of $735,043, stock compensation expense of $351,898, marketing expense of $390,851,
and legal fees of $532,563. This is offset by an increase in consulting expenses of $381,786, Delaware Franchise Tax expenses of $247,389,
and accounting fees of $255,872. The decrease in insurance expense was due to a reduction in director and officer liability insurance
related to the Company&#8217;s reduction in force and restructuring during the year ended December 31, 2023. The decrease in salaries
and wages was due to the reduction in force during the year ended December 31, 2023. The decrease in transaction expenses was due to
the expenses related to non-recurring capital raises during the year ended December 31, 2022. The decrease in stock compensation expense
was due primarily to a reduction in expense related to restricted stock units as a result of forfeitures and decreased value of new grants
as a result of lower stock prices. The decrease in marketing and legal expenses was due to the termination of marketing efforts surrounding
the Akos cannabinoid spin-off. The increase in consulting expenses was due to increased outsourcing to contractors as a result of the
reduction in force during 2023. The increase in Delaware Franchise Tax expenses was due to taxes and penalty fees related to the 2022
franchise tax return. The increase in accounting fees was due to internal control deficiency remediation efforts related to deficiencies
identified in 2022 and technical accounting services related to 2023 transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expense for the year ended December 31, 2023 was $7,252,437 as compared to $8,027,773 for the year ended December
31, 2022 with a decrease of $775,336, or approximately 10%. This decrease was primarily driven by decreased salaries and wages of 1,608,437,
product development of $443,158, and lab expenses of $321,773, and increase in tax incentive of $141,185. This is slightly offset by
an increase in CRO costs of $1,674,958. The decrease in salaries and wages was primarily due to the reduction in force as a result of
the cost reduction plan that the Company entered into in May 2023 and the increase in CRO costs is due to contract in Australian Subsidiary
Research and Development that began in March 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of intangible assets and goodwill</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no impairment of intangible assets and goodwill for the year ended December 31, 2023 as compared to $7,453,662 for the year ended
December 31, 2022, as all recognized indefinite lived intangible assets and goodwill were fully impaired as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Depreciation
and Amortization Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense for the year ended December 31, 2023 was $343,982 as compared to $327,910 for the year ended December 31, 2022,
with a decrease of $16,072, or approximately 5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Warrant Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of warrant liabilities for the year ended December 31, 2023 resulted in income of $94,396 as compared to $4,315,236 for
the year ended December 31, 2022. The change in fair value of warrant liabilities is significantly influenced by the change in the closing
price of common stock at the end of each period, as compared to the closing price of common stock at the beginning of each period with
a strong inverse relationship between changes in fair value of warrant liabilities and the trading price of common stock. The significant
decrease in the Company&#8217;s stock price during the year ended December 31, 2023 compared to the year ended December 31, 2022, resulted
in the significant decrease to the change in fair value of warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Investment Option Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of investment option liability for the year ended December 31, 2023 resulted in income of $208,752 as compared to $3,472,726
for the year ended December 31, 2022. The change in fair value of investment option liability is significantly influenced by the change
in the closing price of common stock at the end of each period, as compared to the closing price of common stock at the beginning of
each period with a strong inverse relationship between changes in fair value of warrant liabilities and the trading price of common stock.
The significant decrease in the Company&#8217;s stock price during the year ended December 31, 2023 compared to the year ended December
31, 2022, resulted in the significant decrease to the change in fair value of warrant liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Fair Value of Derivative Liability</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s change in fair value of derivative liability increased by $1,052,000 for the year ended December 31, 2023, due primarily
to the termination of the planned spin-off of Akos and redemption of the underlying preferred stock in May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inducement
Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inducement
expense was $1,848,235 for the year ended December 31, 2023. The expenses recorded were related to inducement incurred related to the
conversion of warrants and investment options that occurred in December 2023. The Company did not incur such expenses in the prior period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax (Expense) Benefi</i></b>t</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax expense was $28,913 for the year ended December 31, 2023, which primarily related to state excise taxes, compared to an income tax
benefit of 1,486,060 for the year ended December 31, 2022 or a change of $1,514,973. For the year ended December 31, 2022, the Company
recognized a benefit for the reversal of the deferred tax liability for the indefinite lived intangible assets upon impairment, which
is the primary reason for the change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have primarily used our available cash to fund our product development and operations expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows for the Nine Months Ended September 30, 2024 and 2023:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of cash flows for the years presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(6,414,590</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(12,343,363</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by (used in) financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,210,386</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,157,057</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Effect of Foreign Exchange Rate on Changes on Cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,910</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">31,399</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Net increase (decrease) in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">823,706</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,457,316</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $6,414,590 during the nine months ended September 30, 2024, which consisted primarily of a net
loss adjusted for non-cash items of $5,114,009 and an increase in prepaid expenses and other current assets of $3,674 and a decrease
in accounts payable and accrued liabilities of $1,296,907.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $12,343,363 during the nine months ended September 30, 2023, which consisted primarily of a net
loss adjusted for non-cash items of $11,962,774, an increase in prepaid expenses and other current assets of $746,033, offset by an increase
in accounts payable and accrued liabilities of $429,688.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $0 during the nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities was $11,705 during the nine months ended September 30, 2023, which consisted of proceeds from disposal
of property and equipment of $16,900, offset by the purchase of property and equipment of $5,195.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $7,210,386 during the nine months ended September 30, 2024, which consisted of $1,804,819 from
the proceeds received from the stock subscription receivable, $2,676,980 for the exercise of the Inducement Warrants, $2,290,186 for
the common stock sold under the Distribution agreement, net of offering costs, and $599,862 for the common stock sold under the Purchase
Agreement, offset by $161,461 offering costs previously accrued for the Inducement Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was $1,157,057 during the nine months ended September 30, 2023, which consisted of the redemption of
redeemable non-controlling interest and payment of deferred offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows for the Years Ended December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth a summary of cash flows for the years presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Net cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(14,094,411</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(17,146,723</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(584,165</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash (used in) provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,343,141</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,180,137</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effect of Foreign Exchange Rate on Changes on Cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,022</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(81,364</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net (decrease) increase in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,435,907</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">367,885</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $14,094,411 during the year ended December 31, 2023, which consisted primarily of a net loss adjusted
for non-cash items of $13,919,661, an increase in prepaid expenses of $6,857, a decrease in accounts payable and accrued liabilities
of $103,848, and a decrease in right-of-use operating lease asset and obligation of $64,045.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $17,146,723 during the year ended December 31, 2022, which consisted primarily of a net loss adjusted
for non-cash items of $16,929,063, an increase in prepaid expenses and other current assets of $374,058, an increase in accounts payable
and accrued liabilities of $263,686, and a decrease in right-of-use operating lease asset and obligation of $107,288.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by investing activities was $11,667 during the year ended December 31, 2023, which consisted of the purchase of property
and equipment, offset by proceeds from sale of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $584,165 during the year ended December 31, 2022, which consisted of the purchase of property and
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was $1,343,141 during the year ended December 31, 2023, which consisted of $1,052,057 from the redemption
of Series A Preferred Stock and $291,084 for equity distribution offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $18,180,137 during the year ended December 31, 2022, which consisted of $17,222,099 in net
proceeds from the sale of common stock and warrants and warrant exercises, net of fees, and proceeds from the sale of redeemable non-controlling
interest, net of offering costs, of $958,038.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception through September 30, 2024, we have not generated reportable revenue and have incurred significant operating losses
and negative cash flow from our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">We are a pre-revenue biotech company
that has generated no reportable revenues through September 30, 2024. During the years ended December 31, 2023 and 2022,
we raised approximately $18.2 million from the sales of common stock, warrants, preferred investment options, and redeemable non-controlling
interest, and from proceeds realized from the exercise of cash warrants. These amounts were the primary source of funds upon which our
operations were financed during the year ended December 31, 2023. During the year ended December 31, 2024, we raised approximately $8.0
million from the sales of common stock and warrants. The maximum gross amount we expect to raise in this offering is $5.0 million,
excluding the exercise of any warrants. Following this offering, we will need to raise additional capital to fund our operations
and continue to support our planned development and commercialization activities.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $102,919,859 as of September 30, 2024 and further
losses are anticipated in the development of its business. Further, the Company had operating cash outflows of $6,414,590 for the nine
months ended September 30, 2024. For the nine months ended September 30, 2024, the Company had a loss from operations of $6,458,440.
Since inception, being a research and development company, the Company has generated no reportable revenue through September
30, 2024, and the Company has incurred continuing losses from its operations. The Company&#8217;s operations have been funded principally
through the issuance of debt and equity. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At September 30, 2024, the Company had
cash of $3,111,683 and working capital of $3,499,093. The Company&#8217;s current cash on hand is insufficient to satisfy its operating
cash needs for the 12 months following the date of this prospectus. These conditions raise substantial doubt regarding
the Company&#8217;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#8217;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, and may include additional collaborations with third parties as well as disciplined
cash spending. Adequate additional financing may not be available to us on acceptable terms, or at all. Should the Company be unable
to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing
certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of this prospectus. The Company&#8217;s consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation
of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect
the reported amount of assets, liabilities, costs and expenses and related disclosures. Our critical accounting estimates are those estimates
that involve a significant level of uncertainty at the time the estimate was made, and changes in them have had or are reasonably likely
to have a material effect on our financial condition or results of operations. Accordingly, actual results could differ materially from
our estimates. We base our estimates on past experience and other assumptions that we believe are reasonable under the circumstances,
and we evaluate these estimates on an ongoing basis. Our most critical accounting estimates include determining the accruals associated
with third-party providers supporting research and development efforts and the fair value of the inducement warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accrued
Research and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development
expenses. This process involves reviewing purchase orders, open contracts, reconciling payments and invoices and communicating with our
personnel and suppliers to identify services that have been performed on our behalf. It also includes the research and development vendors
providing us milestone and percentage completion reports on the statuses within each active purchase order and contract along with estimating
the level of service performed and the associated cost incurred for the services when we have not yet been invoiced or otherwise notified
of the actual cost. Our vendors invoice us in various ways via advance payments, as contractual milestones are met or monthly in arrears
for services performed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances
known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and adjust if necessary. The
significant estimates in our accrued research and development expenses include the costs incurred for services performed by clinical,
preclinical, and CMC vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
contract with these vendors to conduct clinical, preclinical, or CMC research and development services on our behalf. We base our expenses
on our estimates of the services received and efforts expended pursuant to quotes and contracts with the research and development vendors.
The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows.
There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of
the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and
the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Non-refundable advance payments for goods and services
that will be used in future research and development activities are expensed when the activity has been performed or when the goods have
been received rather than when the payment is made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing
of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts
that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such
expenses and the amounts actually incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value of Inducement Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inducement warrants are measured at estimated fair value using the Black Scholes valuation model. Inherent in this model are assumptions
related to expected stock price volatility, expected life, risk-free interest rate and dividend yield. We estimate the volatility of
our common stock at the date of issuance based on the historical implied volatility of our own stock price that matches the expected
remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the measurement
date for a maturity similar to the expected remaining life of the inducement warrants. The expected life of the inducement warrants is
assumed to be equivalent to their remaining contractual term. The dividend rate is based on our historical rate, which we anticipate
to remain at zero. The assumptions used in calculating the estimated fair value of the inducement warrants represent our best estimates.
However, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and
different assumptions are used, the inducement warrants estimated fair value could be materially different.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_001"></span>SECURITY
OWNERSHIP AND CERTAIN BENEFICIAL OWNERS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information with respect to the beneficial ownership of our Common Stock (including shares issuable upon the
exercise or conversion of securities that entitle the holders thereof to obtain Common Stock upon exercise or conversion in accordance
with the terms thereof) as of January 24, 2025, by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person known by us to be the beneficial owner of more than five percent of our outstanding shares of Common Stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    director;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    of our named executive officers; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    current directors and executive officers of the Company as a group.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, which generally attribute beneficial ownership of securities to persons
who possess sole or shared voting power or investment power with respect to those securities. We deem shares of our common stock which
the stockholder has the right to acquire within 60 days of January 24, 2025, whether through the vesting of restricted stock units,
or RSUs, or the exercise or conversion of any stock option, convertible security, warrant or other right, to be outstanding for the purpose
of computing the percentage ownership of such individual or group, but those shares are not deemed to be outstanding for the purpose
of computing the percentage ownership of any other person shown in the table. The indication herein that shares are beneficially owned
is not an admission on the part of the stockholder that he, she or it is a direct or indirect beneficial owner of those shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as indicated in the footnotes to this table, each beneficial owner named in the table below has sole voting and sole investment power
with respect to all shares beneficially owned and each person&#8217;s address is c/o Enveric Biosciences, Inc. 4851 Tamiami Trail N.,
Suite 200, Naples, FL 34103. As of January 24, 2025, we had 692,580 shares of Common Stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: center">Name of Beneficial Owner</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares of Common Stock Beneficially Owned</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Percentage of Class</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Tucker, Ph.D.<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">5,813</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter Facchini, Ph.D.<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin Coveney<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,995</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank Pasqualone<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George Kegler<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus Schabacker, M.D., Ph.D.<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Webb<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,183</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheila DeWitt, Ph.D.<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,857</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All directors and current executive officers as a group of eight (8) persons<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AdvisorShares Trust<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.8</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Represents less than 1%</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    2,075 shares of Common Stock and Vested and Unissued Restricted Stock Units, 2,586 Restricted Stock Units that will
    vest within 60 days of January 24, 2025, options to purchase 266 shares of Common Stock exercisable within 60 days
    of January 24, 2025, and warrants to purchase 886 shares of Common Stock exercisable within 60 days of January 24,
    2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    1,402 shares of Common Stock and Vested and Unissued Restricted Stock Units, 1,209 Restricted Stock Units that will
    vest within 60 days of January 24, 2025, options to purchase 133 shares of Common Stock exercisable within 60 days
    of January 24, 2025, and warrants to purchase 816 shares of Common Stock exercisable within 60 days of January 24,
    2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    442 shares of Common Stock and 1,553 Restricted Stock Units that will vest within 60 days of January 24, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share amounts consist of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share amounts consist of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share amounts consist of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share amounts consist of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share amounts consist of Common Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    18,616 shares of Common Stock and Vested and Unissued Restricted Stock Units, 5,348 Restricted Stock Units vesting
    within 60 days of January 24, 2025, options to purchase 399 shares of Common Stock exercisable within 60 days of January
    24, 2025, and warrants to purchase 1,702 shares of Common Stock exercisable within 60 days of January 24, 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
    to its most recent 13G filed with the SEC on January 6, 2025, AdvisorShares Trust (&#8220;AdvisorShares&#8221;) is an investment
    company organized under the laws of the State of Delaware with sole voting and dispositive power with respect to 39,991 shares.
    The principal address of AdvisorShares is 4800 Montgomery Lane, Suite 150, Bethesda, Maryland 20814.</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_002"></span>CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the director and executive officer compensation arrangements discussed in the &#8220;Executive Officer and Director Compensation&#8221;
section in this proxy statement, since January 1, 2022 we have engaged in the following transactions in which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amounts involved exceeded or will exceed the lesser of (i) $120,000, or (ii) 1% of the average
                                            of the Company&#8217;s total assets at December 31, 2023 and December 31, 2022; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            director, executive officer, holder of more than 5% of our voting securities, whom we refer
                                            to as our principal stockholders, or affiliates or immediate family members of our directors,
                                            executive officers and principal stockholders, had or will have a material interest.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that all of these transactions were on terms as favorable as could have been obtained from unrelated third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advisory
Services from Dr. Sheila DeWitt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
DeWitt has provided research and development services as an advisory consultant to the Company since May 2022. These services are provided
as needed on an hourly basis. As of January 24, 2025, the Company has incurred $189,125 in service fees for the fiscal year ending
December 31, 2024. Of these fees, $176,125 has been paid and $13,000 is included in accounts payable on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreement with David Johnson</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and David Johnson, the Company&#8217;s former Executive Chairman, entered into a consulting agreement on January 1, 2023 (the
&#8220;Agreement&#8221;). Mr. Johnson earned $23,833 per month ($286,000 per annum) in exchange for his services. The Company
also agreed to reimburse Mr. Johnson for such reasonable and necessary expenses incurred by him in carrying out his services under
the Agreement. In May of 2023, the Agreement was terminated without cause prior to the completion of the spin-off transaction
of Akos. The Company paid Mr. Johnson a termination fee of $286,000 over the 12 months following the termination of the
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policies
and Procedures for Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is responsible for reviewing and approving all transactions in which we are a participant and in which any parties related
to us, including our executive officers, directors, beneficial owners of more than 5% of our voting securities, immediate family members
of the foregoing persons, and any other persons whom our Board determines may be considered related parties, has or will have a direct
or indirect material interest and that involve consideration received or receivable by these persons in excess of the lesser of (i) $120,000,
and (ii) one percent of the average of the Company&#8217;s total assets at year end for the last two completed fiscal years. In reviewing
and approving these transactions, our Audit Committee obtains, or directs our management to obtain on its behalf, all information that
the Audit Committee believes to be material to a review of the transaction prior to its approval. It is contemplated that no related
person transaction will be entered into prior to the completion of these procedures; however, where permitted, a related person transaction
may be ratified upon completion of these procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_003"></span>MANAGEMENT</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding our executive officers and directors with their respective ages as of January 24,
2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Facchini, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Innovation Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Coveney</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    D. Webb</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Kegler</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Frank
    Pasqualone</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcus
    Schabacker, M.D., Ph.D.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sheila
    DeWitt, Ph.D.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Joseph
Tucker, Ph.D.</i> has served as our Chief Executive Officer and Director since September 16, 2021. Prior to joining the Company, Dr.
Tucker was the Chief Executive Officer, President and Director of MagicMed Industries Inc., from its founding in May 2020 until its acquisition
by the Company in September 2021. Dr. Tucker was the Executive Chairman of Willow Biosciences Inc., a TSX-listed public company, from
April 2019 to March 2020. From March 2014 until April 2019, Dr. Tucker was the Chief Executive Officer, President and Director of Epimeron
Inc., which amalgamated with BioCan Technologies Inc. in April 2019 to become Willow Biosciences, Inc. Between 2007 and 2014, Dr. Tucker
held President, Chief Executive Officer, and Chief Financial Officer roles in several other private biotechnology companies including
VirTech Bio, Inc., Taiga Bioactives Inc., SolAeroMed, Inc., and Pharmavation, Inc. From January 2001 until January 2007, Dr. Tucker was
Chief Executive Officer, President and Director of Stem Cell Therapeutics, a TSX-listed public biotechnology company. Prior to leading
biotechnology companies, Dr. Tucker was a healthcare analyst with two investment banks and also served in a technology commercialization
capacity for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University
of Calgary. Dr. Tucker&#8217;s relevant industry experience qualifies him to be a director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Peter
Facchini, Ph.D.,</i> has served as our Chief Innovation Officer since joining the Company in September 2021. Dr. Facchini has been a
Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary since 1995, during which he held
the Canada Research Chair in Plant Metabolic Processes Biotechnology, was a 2019 Parex Resources Innovation Fellow, received the 2021
Faculty of Science Innovation Excellence Award, and was a finalist for the 2022 Alberta Science, Technology and Leadership (ASTech) award.
Prior to joining the Company, Dr. Facchini co-founded and was the Chief Scientific Officer of Epimeron Inc., Willow Biosciences Inc.
and MagicMed Industries Inc. Dr. Facchini has published over 170 peer-reviewed scientific papers and co-invented innovations covered
by more than 50 patents. Dr. Facchini is an international leader in the fields of natural product metabolic biochemistry and biotechnology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Kevin
Coveney</i> has served as our Chief Financial Officer since March 13, 2023. Mr. Coveney brings to the Company over 30 years of experience
in biotechnology finance and accounting. Mr. Coveney is the founder of Coveney Capital Advisors and has provided fractional CFO and consulting
services to Progressive Therapeutics, Inc. from September 2022 to March 2023 and Power of Patients, LLC, from October 2022 to March 2023,
respectively. Mr. Coveney previously held the position of chief financial officer at Memgen, Inc. from November 2021 to June 2022 and
at Q-State Biosciences, Inc. from April 2020 to April 2021. Prior to his chief financial officer position, Mr. Coveney served as Senior
Vice President of Finance, HR &amp; IT of Vedanta Biosciences, Inc. from November 2018 to February 2020. He held various senior positions
at Berg Health LLC from September 2015 to November 2018. Mr. Coveney was an Audit Partner at Braver PC (now Marcum) from July 2007 through
October 2012. Mr. Coveney holds a Bachelor of Science degree in Management with a Concentration in Accounting from the University of
Massachusetts and served as a non-commissioned officer in the United States Coast Guard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Michael
D. Webb</i> has served as a non-employee director of the Company since June 13, 2022 and has served as Chairman of the Board since November
2022. Mr. Webb is the President and Chief Executive Officer of Epion Therapeutics, Inc. and a member of its board of directors, positions
he has held since 2017. He has served as a director at Videokawa since
2018, and at DeuteRx, LLC since 2012. He has been a founder and Chief Executive Officer of biotechnology companies, taking them from
seed round funding through venture financing and Nasdaq IPO. Mr. Webb began his career in Booz, Allen &amp; Hamilton&#8217;s Chicago
office, specializing in healthcare and life sciences and subsequently at CIBA-Geigy (now Novartis) where he was last a Senior Vice President.
Mr. Webb holds Bachelor&#8217;s degrees in Biochemistry and Economics from the University of Kansas, <i>summa cum laude</i> and an MA
in International Relations from Sussex University in the UK. In addition, he holds an MBA degree from Kellogg School of Management with
a concentration in healthcare management. He is a past Chairman of the Massachusetts Biotechnology Council. Mr. Webb&#8217;s relevant
industry experience qualifies him to be a director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>George
Kegler</i> has served as a non-employee director of the Company since December 30, 2020. Mr. Kegler was employed by Mallinckrodt Pharmaceuticals
from January 2013 to June 2019, serving as the Executive Vice President and Chief Financial Officer, Interim from December 2018 to May
2019, where he had responsibility for the global finance function and was a member of the executive committee, Vice President Finance
from November 2016 to November 2018, President Specialty Generics (Interim) and Vice President Finance from July 2016 to October 2016,
and Vice President, Finance from January 2013 to June 2016. He has served in various consulting roles since June 2019, which ended in
March 2020. Mr. Kegler has 40 years of experience in financial planning and analysis, corporate finance, controllership and business
development. Previously Mr. Kegler served as the Vice President of Commercial Finance for various businesses within Mallinckrodt and
was also interim President of the company&#8217;s specialty generics business. Prior to joining Mallinckrodt, he was the Chief Financial
Officer for Convatec, a private equity-owned company that was purchased from Bristol-Myers Squibb. He worked in various finance roles
within Bristol-Myers Squibb including commercial, international, technical operations, research &amp; development as well as the assistant
controller of internal controls. Mr. Kegler holds a bachelor&#8217;s degree in accounting from the University of Missouri, an MBA from
Saint Louis University and completed the Certified Public Accountant exam in Missouri. Mr. Kegler&#8217;s experience as an officer at
several companies and extensive knowledge of corporate finance qualify him to be a director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Frank
Pasqualone</i> has served as a non-employee director of the Company since July 13, 2022. Mr. Pasqualone has served as Senior Vice President,
Chief Business Officer of Theravance Biopharma, Inc. since November 2020 and joined Theravance Biopharma as Senior Vice President, Operations
in June 2014 in connection with its spin-off from Innoviva. Mr. Pasqualone held the position of Senior Vice President, Operations at
Innoviva since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa
and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone
held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led
the marketing group in the Diabetes business. After leaving Bristol-Myers Squibb and prior to joining Theravance, Mr. Pasqualone was
self-employed as a part-time consultant. Since October 2018, Mr. Pasqualone has served as a member of the board of trustees at Saint
Francis University. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University
in Ohio. Mr. Pasqualone&#8217;s relevant industry experience as an officer at several companies qualifies him to be a director of the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marcus
Schabacker</i>, <i>M.D., Ph.D.</i> has served as a non-employee director of the Company since December 30, 2020. Since January 2018,
Dr. Schabacker has served as President and Chief Executive Officer of the ECRI Institute, a non-profit organization with 500 employees
and an operating budget of $80 million focusing on advancing evidenced-based, effective healthcare globally. Prior to joining ECRI, Dr.
Schabacker worked at Baxter Healthcare Corporation, serving as Corporate Vice President and Chief Scientific Officer from July 2015 to
May 2017, chairman of the executive quality council from March 2014 to May 2017, Chief Scientific Officer, Medical Products from July
2014 to July 2015, and Vice President, R&amp;D, Medical Products from March 2011 to July 2014. During his clinical years, and his time
as an industry thought leader, Dr. Schabacker was focused on patient safety and enhancing patient care. For over a decade Dr. Schabacker
has served on numerous boards of small and midsize companies and organizations, providing management with guidance and expertise to strategically
accelerate growth and to build successful and sustainable high performing management teams. Dr. Schabacker&#8217;s medical background
and relevant research and development experience qualify him to be a director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 60pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sheila
DeWitt, Ph.D.</i> has served as a non-employee director of the Company by the Board since May of 2024. Dr. DeWitt has provided
research and development services as an advisory consultant to the Company since May 2022. These services are provided as needed on an
hourly basis. Since December of 2012, Dr. DeWitt has served as the President, Chief Executive Officer, and the Chair of the Board of
Directors of DeuteRx, LLC. She has also served as a Director at Neuromity Therapeutics, Inc. from November 2021 to December 2023, and
at RIFFIT, Inc. from March 2019 to November 2022. She also served as the President, Chief Executive Officer, and Chair of the Board of
Directors at Deuteria Pharmaceuticals, Inc. from December 2010 to December 2012. Dr. DeWitt is a life sciences executive and serial entrepreneur
with more than 35 years of experience in pharmaceutical and biotechnology companies including leading the start-up or turnaround of biotechnology
companies or business units, orchestrating M&amp;A transactions, and managing global R&amp;D organizations. She earned her B.A. in Chemistry
from Cornell University in 1982 and Ph.D. in Synthetic Organic Chemistry from Duke University in 1986 and has received numerous honors
including American Chemical Society (ACS) Hathryn C. Hach Award for Entrepreneurial Success (2025), ACS Gertrude Elion Medicinal Chemistry
Award (2025), and Famous Organic Chemists ACS Organic Division (2019),. Dr. DeWitt&#8217;s
relevant industry experience qualifies her to be a director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Composition
of the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation, as amended, and Bylaws provide that our Board will consist of such number of directors
as determined from time to time by resolution adopted by our Board. The size of our Board is currently fixed at six directors. Subject
to any rights applicable to any then-outstanding shares of preferred stock, any vacancies or newly created directorships resulting from
an increase in the authorized number of directors may be filled by a majority of the directors then in office. Stockholders vote to elect
directors with a term then expiring each year at our annual meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently listed on the Nasdaq Stock Market and therefore rely on the definition of independence set forth in the Nasdaq Listing
Rules (&#8220;Nasdaq Rules&#8221;). Under the Nasdaq Rules, a director will only qualify as an &#8220;independent director&#8221; if,
in the opinion of our Board, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. Based upon information requested from and provided by each director concerning his
background, employment, and affiliations, including family relationships, the Board has determined that Mr. Webb, Mr. Kegler, Mr. Pasqualone,
and Dr. Schabacker have no relationships with us that would interfere with the exercise of independent judgment and are &#8220;independent
directors&#8221; as that term is defined in the Nasdaq Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_004"></span>EXECUTIVE
AND DIRECTOR COMPENSATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 32.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth total compensation paid to the named executive officers for the years ended December 31, 2024 and 2023, comprised
of (i) the individual who served as our Chief Executive Officer during the 2024 fiscal year, (ii) the two most highly compensated executive
officers other than the Chief Executive Officer who were serving as an executive officer at the end of the 2024 fiscal year and whose
compensation, as determined by Regulation S-K, Item 402, exceeded $100,000 and (iii) any individual who would otherwise be included in
(ii) above but for the fact that such individual was not serving as an executive officer of ours at the end of the 2024 fiscal year. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 32.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards<sup>(1)</sup></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Equity Incentive Plan Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonqualified Deferred Compensation Earnings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joseph Tucker<sup>(2)</sup></b></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">458,640</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">152,724</td><td style="white-space: nowrap; width: 1%; text-align: left"><sup>(3)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">611,364</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">450,785</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,280</td><td style="white-space: nowrap; text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">577,065</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peter Facchini, Ph.D.<sup>(5)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,268</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,260</td><td style="white-space: nowrap; text-align: left"><sup>(6)(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">274,528</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Innovation Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,272</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48,790</td><td style="white-space: nowrap; text-align: left"><sup>(6)(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">282,062</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kevin Coveney<sup>(9)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">385,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,900</td><td style="white-space: nowrap; text-align: left">(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,989</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,688</td><td style="white-space: nowrap; text-align: left">(11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">358,677</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    compensation consists of Restricted Stock Unit Award (&#8220;RSUs&#8221;) and Restricted Stock Awards (&#8220;RSAs&#8221;). RSUs
    and RSAs may contain vesting conditions that include, without limitation, continued employment or engagement with the Company, achievement
    of defined stock price levels or achievement of defined performance milestones, termination of the employee without cause, resignation
    of the employee for good cause or change in control. Please also note there are no assurances that such vesting conditions will be
    met and accordingly there are no assurances that any unvested RSUs or RSAs will become vested prior to being forfeited on the expiration
    date defined in the relevant award agreements. Furthermore, RSUs require that the recipient&#8217;s employment with the Company be
    terminated, or that a change of control occur, as a prerequisite of conversion of vested restricted stock units into shares of Common
    Stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Tucker was appointed Chief Executive Officer on September 16, 2021. Effective February 1, 2023, Dr. Tucker&#8217;s annual base salary
    was increased from $364,000 to $458,640.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Tucker&#8217;s 2024 stock compensation consists of 6,667 RSUs, valued at $85,000, with such valuation being based on the Company&#8217;s
    closing price per share of $12.75 on the RSU grant date and 10,776 RSUs, valued at $67,724, with such valuation
    being based on the Company&#8217;s closing price per share of $6.285 on the RSU grant date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Tucker&#8217;s 2023 stock compensation consists of an aggregate of 2,934 RSUs, valued at $126,280, with such valuation being
    based on the Company&#8217;s closing price per share of $43.05 on the RSU grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Facchini has served as Chief Innovation Officer since September 16, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salaries,
    bonus and non-equity incentive plan compensation that were originally paid or recorded in Canadian dollars were converted to U.S.
    dollars using the Bloomberg exchange rate of C$1.00 to $0.694 for the 12-month period ended December 31, 2024 and C$1.00 to US$0.756
    for the 12-month period ended December 31, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Facchini&#8217;s 2024 stock compensation consists of 3,334 RSUs, valued at $42,500, with such valuation being based on the
    Company&#8217;s closing price per share of $12.75 on the RSU grant date and 2,667 RSUs, valued at $16,760, with such
    valuation being based on the Company&#8217;s closing price per share of $6.285 on the RSU grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Facchini&#8217;s 2023 stock compensation consists of an aggregate of 1,134 RSUs, valued at $48,790, with such valuation being
    based on the Company&#8217;s closing price per share of $43.05 on the RSU grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Coveney has served as Chief Financial Officer since March 13, 2023.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Coveney&#8217;s 2024 stock compensation consists of 4,000 RSUs, valued at $51,000, with such valuation being based on the
    Company&#8217;s closing price per share of $12.75 on the RSU grant date and 6,667 RSUs, valued at $41,900, with such
    valuation being based on the Company&#8217;s closing price per share of $6.285 on the RSU grant date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Coveney&#8217;s 2023 stock compensation consists of an aggregate of 1,767 RSUs, valued at $49,688, with such valuation being
    based on the Company&#8217;s closing price per share of $28.20 on the RSU grant date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tucker
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, Joseph Tucker, Ph.D. entered into an employment agreement (the &#8220;Tucker Employment Agreement&#8221;) with the Company
pursuant to which he became the Company&#8217;s Chief Executive Officer, effective as of the September 16, 2021 closing date of the Company&#8217;s
amalgamation (the &#8220;Tucker Effective Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tucker Employment Agreement, Dr. Tucker was initially entitled to an annual base salary of $350,000 (&#8220;Tucker Base Salary&#8221;).
Dr. Tucker also received, upon entering into the Tucker Employment Agreement, a one-time signing bonus of $100,000 and 92 RSUs,
of which half are subject to time-based vesting and the other half are subject to market-based vesting. Pursuant to the Tucker Employment
Agreement, upon entering into the agreement, Dr. Tucker also received an initial equity compensation grant of 1,000 RSUs, of which half
are subject to time-based vesting and the other half are subject to market-based vesting. The RSUs are subject to the terms and conditions
of the Company&#8217;s 2020 Long-Term Incentive Plan, as amended (the &#8220;Incentive Plan&#8221;) and will vest in quarters on each
of the first four anniversaries of the Tucker Effective Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of March 1, 2022, our Board approved an increase in annual base salary from $350,000 to $364,000 for Dr. Tucker. Beginning in calendar
year 2022, Dr. Tucker became eligible to receive annual performance bonuses of up to 75% of the Tucker Base Salary, as determined from
time to time by the Board. Effective as of February 1, 2023, our Board approved an increase in annual base salary from $364,000 to $458,640
for Dr. Tucker</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tucker Employment Agreement will remain in effect until terminated by either party. Either party may terminate the Tucker Employment
Agreement upon advance written notice of termination to the other party at least 30 days prior. In addition, the Tucker Employment Agreement
is subject to early termination by him or the Company in accordance with the terms of the Tucker Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Tucker Employment Agreement, if Dr. Tucker&#8217;s employment is terminated by the Company without Cause (as defined therein)
or by Dr. Tucker for Good Reason (as defined therein), then the Company must pay Dr. Tucker, in addition to any then-accrued and unpaid
obligations owed to him, 12 months of the then-current Tucker Base Salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tucker Employment Agreement also contains covenants restricting Dr. Tucker from soliciting the Company&#8217;s employees or customers
for a period of 12 months after the termination of Dr. Tucker&#8217;s employment with the Company and prohibiting him from disclosure
of confidential information regarding the Company at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, Dr. Tucker has been awarded an aggregate of 21,468 RSUs, of which 546 were forfeited to the Company
for failure to satisfy certain performance conditions, and 19,768 remain unvested. All unvested RSUs held by Dr. Tucker will become
fully vested upon the occurrence of a Change in Control or termination of service without cause or for good reason (as defined in the
Incentive Plan or in the award agreement). In addition, if we terminate Dr. Tucker&#8217;s employment without Cause or if Dr. Tucker
terminates his employment for Good Reason, all outstanding RSUs subject to time-based vesting and held by Dr. Tucker will become fully
vested, and all outstanding RSUs subject to market-based vesting that would have vested on the vesting date occurring on or next following
Dr. Tucker&#8217;s employment termination date will become fully vested, provided that the applicable performance goal has been achieved
by such date. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Coveney
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2023, Kevin Coveney entered into an employment agreement (the &#8220;Coveney Employment Agreement&#8221;) with the Company
pursuant to which he became the Company&#8217;s Chief Financial Officer, effective as of the March 13, 2023 (the &#8220;Coveney Effective
Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Coveney Employment Agreement, Mr. Coveney is entitled to an annual base salary of $385,000 (&#8220;Coveney Base Salary&#8221;).
Mr. Coveney also received, upon entering into the Coveney Employment Agreement 1,767 RSUs. The RSUs are subject to the terms and
conditions of the Company&#8217;s 2020 Long-Term Incentive Plan, as amended (the &#8220;Incentive Plan&#8221;) and will vest in quarters
on each of the first four anniversaries of the Coveney Effective Date. Mr. Coveney is also eligible to receive annual performance bonuses
of up to 40% of his Base Salary based on satisfaction of performance criteria/financial results, as determined by the Board in its sole
discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Coveney Employment Agreement will remain in effect until terminated by either party. Either party may terminate the Coveney Employment
Agreement upon advance written notice of termination to the other party at least 30 days prior.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Coveney Employment Agreement, if Mr. Coveney&#8217;s employment is terminated by the Company without Cause (as defined therein)
or by Mr. Coveney for Good Reason (as defined therein), then the Company must pay Mr. Coveney, in addition to any then-accrued and unpaid
obligations owed to him, 9 months of the then-current Coveney Base Salary, in exchange for release of claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Coveney Employment Agreement also contains covenants restricting Mr. Coveney from soliciting the Company&#8217;s employees or customers
for a period of 12 months after the termination of Mr. Coveney&#8217;s employment with the Company and prohibiting him from disclosure
of confidential information regarding the Company or from disparaging the Company at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, Mr. Coveney has been awarded an aggregate of 12,434 RSUs, of which 11,992 remain unvested. All outstanding
RSUs held by Mr. Coveney will become fully vested upon the occurrence of a Change in Control (as defined in the Incentive Plan). In addition,
if we terminate Mr. Coveney&#8217;s employment without Cause or if Mr. Coveney terminates his employment for Good Reason, all outstanding
RSUs shall immediately vest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Facchini
Employment Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 24, 2021, Peter Facchini, Ph.D. entered into an employment agreement (the &#8220;Facchini Employment Agreement&#8221;) with the Company
pursuant to which he serves as the Company&#8217;s Chief Innovation Officer, effective as of the September 16, 2021 closing date of the
Company&#8217;s amalgamation (the &#8220;Facchini Effective Date&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Facchini Employment Agreement, as of the Facchini Effective Date, Dr. Facchini is entitled to a base salary of C$295,000 annually
(&#8220;Facchini Base Salary&#8221;). Dr. Facchini also received a one-time signing bonus of C$50,000 and 769 RSUs, based on the
price of the Company&#8217;s shares at the Facchini Effective Date. Half of any such RSUs are subject to time-based vesting, and the
remaining half of any such RSUs are subject to market-based vesting. The RSUs are subject to the terms and conditions of the Incentive
Plan. The RSUs that are subject to time-based vesting and shall vest in quarters on each of the first four anniversaries of the Facchini
Effective Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Facchini Employment Agreement will remain in effect until terminated by either party upon written notice by either party, unless the
Company delivers advance written notice of termination to Dr. Facchini or Dr. Facchini delivers advance written notice of termination
to the Company at least 30 days prior. In addition, the Facchini Employment Agreement is subject to early termination by him or the Company
in accordance with the terms of the Facchini Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Facchini Employment Agreement, if Dr. Facchini&#8217;s employment is terminated by the Company without Cause (as defined in therein)
or by Dr. Facchini for Good Reason (as defined therein), then the Company must pay Dr. Facchini, in addition to any then-accrued and
unpaid obligations owed to him, 12 months of the then-current Facchini Base Salary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Facchini Employment Agreement also contains covenants restricting Dr. Facchini from soliciting the Company&#8217;s employees or customers
for a period of 12 months after the termination of Dr. Facchini&#8217;s employment with the Company and prohibiting him from disclosure
of confidential information regarding the Company at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, Dr. Facchini has been awarded an aggregate of 7,902 RSUs, of which 384 were forfeited to the Company
for failure to satisfy certain performance conditions, and 6,938 remain unvested. All outstanding RSUs held by Dr. Facchini will
become fully vested upon the occurrence of a Change in Control. In addition, all outstanding RSUs subject to time-based vesting and held
by Dr. Facchini will become fully vested if we terminate Dr. Facchini&#8217;s employment without Cause or if Dr. Facchini terminates
his employment for Good Reason, and all outstanding RSUs subject to market-based vesting that would have vested on the vesting date occurring
on or next following Dr. Facchini&#8217;s employment termination date will become fully vested, provided that the applicable performance
goal has been achieved by such date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows grants of stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding as of December 31, 2024, including
both awards subject to performance conditions and time-based awards, held by each of our named executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="17" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised
    Options Exercisable <br/>
    (#)<sup>(13)</sup></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised
    Options Unexercisable <br/>
    (#)<sup>(13)</sup></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number
    of Securities Underlying Unexercised Unearned Options <br/>
    (#)<sup>(13)</sup></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Exercise Price ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Expiration Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares or Units of Stock
    That Have Not Vested <br/>
    (#)<sup>(13)</sup></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
    Value of Shares or Units of Stock That Have Not Vested ($)<sup>(12)</sup></b></span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Joseph Tucker, Ph.D.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 8%; text-align: center">4/5/2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">125</td><td style="width: 1%; text-align: left"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">671.25</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,200</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,814.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,667</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,800.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,776</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,864.61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter Facchini, Ph.D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,110</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/5/2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">470.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,564.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,334</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,900.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,667</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,320.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Kevin Coveney</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">-</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325</td><td style="text-align: left"><sup>(9)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,115.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left"><sup>(10)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,480.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,667</td><td style="text-align: left"><sup>(11)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,800.00</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the unvested portion of 1,000 RSUs granted to Dr. Tucker on October 13, 2021, each of which represents the right to receive one
    share of common stock upon vesting. 50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche
    to vest on September 16, 2022. On December 31, 2024, 500 RSUs in connection with this grant were forfeited to the Company for failure
    to satisfy certain performance conditions. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the unvested portion of 2,934 RSUs granted to Dr. Tucker on January 25, 2023, each of which represents the right to receive
    one share of common stock upon vesting. The RSUs shall vest over 4 years in equal annual installments, with the first tranche to
    vest on January 25, 2024. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the unvested portion of 6,667 RSUs granted to Dr. Tucker on February 22, 2024, each of which represents the right to receive
    one share of common stock upon vesting. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An
    additional one-thirty-sixth of the RSUs will vest each month following the first vesting date. Any remaining RSUs will vest on the
    fourth anniversary of the date of issuance. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 10,776 RSUs granted to Dr. Tucker on October 9, 2024, each of which represents the right to receive one share of
    common stock upon vesting. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional
    one-thirty-sixth of the RSUs will vest each month following the first vesting date.Any remaining RSUs will vest on the fourth anniversary
    of the date of issuance.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 700 RSUs granted to Dr. Facchini on October 13, 2021, each of which represents the right to receive one share of
    common stock upon vesting. On December 31, 2024, 350 RSUs in connection with this grant were forfeited to the Company for
    failure to satisfy certain performance conditions.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 1,134 RSUs granted to Dr. Facchini on January 25, 2023, each of which represents the right to receive one share
    of common stock upon vesting. The RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January
    25, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 3,334 RSUs granted to Dr. Facchini on February 22, 2024, each of which represents the right to receive one share
    of common stock upon vesting. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional
    one-thirty-sixth of the RSUs will vest each month following the first vesting date.Any remaining RSUs will vest on the fourth anniversary
    of the date of issuance.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 2,667 RSUs granted to Dr. Facchini on October 9, 2024, each of which represents the right to receive one share
    of common stock upon vesting. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional
    one-thirty-sixth of the RSUs will vest each month following the first vesting date.Any remaining RSUs will vest on the fourth anniversary
    of the date of issuance.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 1,767 RSUs granted to Mr. Coveney on March 13, 2023, each of which represents the right to receive one share of
    common stock upon vesting. The RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on March
    13, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 4,000 RSUs granted to Mr. Coveney on February 22, 2024, each of which represents the right to receive one share
    of common stock upon vesting. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional
    one-thirty-sixth of the RSUs will vest each month following the first vesting date.Any remaining RSUs will vest on the fourth anniversary
    of the date of issuance.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents the unvested
    portion of 6,667 RSUs granted to Mr. Coveney on October 9, 2024, each of which represents the right to receive one share of
    common stock upon vesting. One-fourth of the RSUs will vest upon the one-year anniversary of the date of issuance. An additional
    one-thirty-sixth of the RSUs will vest each month following the first vesting date.Any remaining RSUs will vest on the fourth anniversary
    of the date of issuance.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market value of the
    restricted stock unit awards is based on the closing price of our common stock of $5.37 per share at December 31, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of shares of our
    common stock underlying stock options and option exercise price reflects the 1-for-15 reverse stock split of our issued and
    outstanding common stock on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025, prior to the rounding of any
    fractional shares.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Payments Upon Termination of Employment or Change in Control</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our named executive officers has a contract in place for change in control payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
employment agreements of Joseph Tucker, Ph.D., Peter Facchini, Ph.D. and Kevin Coveney include provisions for severance pay equal to
nine to twelve months of salary upon termination by the Company without cause, as defined in the employment agreements or termination
by the employee for good reason, as defined in the employment agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our named executive officers have also been granted RSUs under the Incentive Plan, which are currently either fully vested or contain
conditions providing for vesting upon change of control. Vested RSUs are eligible for conversion to an equivalent number of shares of
Common Stock upon the first occurrence of a termination of employment for any reason other than a termination by the Company for cause
or an event of change of control, and all unvested RSUs shall immediately vest upon the occurrence of a termination of employment by
either the Company without cause, a termination of employment by the employee for good reason or an event of change of control, and provided
the Company&#8217;s compliance with all terms and conditions of the Incentive Plan, including, without limitation, the availability of
shares approved by the Company&#8217;s stockholders for such issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 32.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the total compensation for each person who served as a non-employee director during the fiscal year ended December
31, 2024. Directors who are also employees are not compensated for their service on our Board.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees earned or paid in cash ($)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>(1)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock awards ($)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>(2)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option awards</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><sup>(3)</sup></b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nonqualifed deferred compensation earnings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All other compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Sheila DeWitt, Ph.D.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">30,473</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">11,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">&#160;&#160;&#160;-</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">42,140</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">George Kegler</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Frank Pasqualone</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marcus Schabacker, M.D., Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Michael Webb</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the fiscal year ended December 31, 2024, each individual that serves as a non-employee director was eligible to receive (paid pro-rata
    in quarterly installments) an annual cash retainer in the amount of $40,000, with additional cash fees as follows: (i) $15,000 for
    services as the chair of the Audit Committee and $7,500 for services as a member of the Audit Committee, (ii) $10,000 for services
    as the chair of the Compensation Committee and $5,000 for services as a member of the Compensation Committee; (iii) $8,000 for services
    as the chair of the Nominating and Governance Committee and $4,000 for services as a member of the Nominating and Governance Committee;
    and (iv) $8,000 for services as the chair of the Science and Technology Committee and $4,000 for services as a member of the Science
    and Technology Committee. The remainder represents additional cash fees paid in cash in lieu of stock awards to be granted to each
    non-employee director.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    non-employee director received an award of restricted stock with a value of $20,000 for their service to the Company, with such valuation
    being based on the closing price per share of $6.285 on the grant date. Dr. DeWitt&#8217;s award was pro-rated commensurate
    with the time of her service on the Board for the year 2024. The restricted stock fully vests on the first anniversary of the date
    of grant. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
    option awards were made to our non-employee directors during 2024, and no non-employee director held any unexercised
    options as of December 31, 2024. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_005"></span>USE
OF PROCEEDS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds from the offering will be approximately $4.28 million after deducting the placement agent fees and estimated
offering expenses payable by us, assuming no exercise of the warrants. However, because this is a &#8220;best efforts&#8221;
offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount,
the placement agent&#8217;s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum
amounts set forth on the cover page of this prospectus. The combined public offering price per share (or pre-funded warrant) and warrants
will be fixed for the duration of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
estimates exclude the proceeds, if any, from the exercise of warrants issued in this offering. If all of the warrants issued in this
offering were to be exercised in cash at an exercise price of $3.00 per share of common stock, we would receive additional proceeds
of approximately $10.0 million. We cannot predict when or if these warrants will be exercised. It is possible that these warrants
may expire and may never be exercised. Additionally, the warrants contain a cashless exercise provision that permit exercise of warrants
on a cashless basis at any time where there is no effective registration statement under the Securities Act covering the issuance of
the underlying share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds for product development, working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering.
Accordingly, our management will have broad discretion in the application of these proceeds. Net offering proceeds not immediately applied
to the uses summarized above will be invested in short-term investments such as money market funds, commercial paper, U.S. treasury bills
and similar securities investments pending their use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</p>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_006"></span>DESCRIPTION
OF CAPITAL STOCK</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following summary is a description of the material terms of our capital stock. This summary is not complete and is qualified by reference
to our amended and restated certificate of incorporation and our amended and restated bylaws, each as amended, which are filed as exhibits
to this prospectus. We encourage you to read our amended and restated certificate of incorporation,
our amended and restated bylaws, each as amended, and the applicable provisions of the Delaware General Corporation Law for additional
information.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
has authorized 120,000,000 shares of capital stock, par value $0.01 per share, of which 100,000,000 are shares of common stock and 20,000,000
are shares of &#8220;blank check&#8221; preferred stock. As of January 24, 2025, there were 692,580 shares of Enveric common
stock issued and outstanding, no shares of Series B or Series C preferred stock issued and outstanding, 1,538 shares of our common
stock issuable upon exercise of outstanding options granted under our equity incentive plans at a weighted average exercise price of
$941.55 per share, 56,308 shares of common stock issuable upon exercise of warrants at a weighted average exercise price
of $536.70 per share, and 4,667 shares of common stock issuable upon exercise of preferred investment options at a weighted
average exercise price of $150.00 per share, 49,385 shares of our common stock issuable upon vesting of restricted stock
units granted, inclusive of 1,369 shares previously vested and unissued. Each of the warrants and the preferred investment options
are exercisable for a period of five one and half expiry periods from 2024 to 2029. The authorized and unissued shares of common stock
and the authorized and undesignated shares of preferred stock are available for issuance without further action by our stockholders,
unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed. Unless approval
of our stockholders is so required, our board of directors does not intend to seek stockholder approval for the issuance and sale of
our common stock or preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and have no cumulative
voting rights. Holders of our common stock are entitled to receive ratably dividends as may be declared by our board of directors out
of funds legally available for that purpose, subject to any preferential dividend or other rights of any then outstanding preferred stock.
We have never paid cash dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future but intend
to retain our capital resources for reinvestment in our business. Any future disposition of dividends will be at the discretion of our
board of directors and will depend upon, among other things, our future earnings, operating and financial condition, capital requirements,
and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock do not have preemptive or conversion rights or other subscription rights. Upon liquidation, dissolution or winding-up,
holders of our common stock are entitled to share in all assets remaining after payment of all liabilities and the liquidation preferences
of any of our outstanding shares of preferred stock. The rights, preferences and privileges of holders of common stock are subject to
and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that is currently outstanding
or that we may designate and issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided by law, our amended and restated certificate of incorporation or amended and restated bylaws, each as amended,
in all matters other than the election of directors, the affirmative vote of a majority of the voting power of the shares present in
person or represented by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders. In addition,
except as otherwise provided by law, our certificate of incorporation or bylaws, directors are elected by a plurality of the votes of
the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
B Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our Series B preferred stock are not entitled to voting unless required by applicable law. Each share of Series B preferred stock
will be convertible into one share of common stock (subject to adjustment) at any time at the option of the holders, provided that each
holder would be prohibited from converting Series B preferred stock into shares of common stock if, as a result of such conversion, any
such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding.
This limitation may be waived with respect to a holder upon such holder&#8217;s provision of not less than 61 days&#8217; prior written
notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of Series B preferred stock are not entitled to receive any dividends, unless and until specifically declared by the board of directors.
However, holders of Series B preferred stock are entitled to receive dividends on shares of Series B preferred stock equal (on an as-if-converted-to-common-stock
basis) to and in the same form as dividends actually paid on shares of common stock when such dividends are specifically declared by
the board of directors. The Company will have no right to require a holder to surrender its Series B preferred stock for redemption.
Shares of Series B preferred stock will not otherwise be entitled to any redemption rights, or mandatory sinking fund or analogous fund
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
C Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
entitled to vote, holders of our Series C preferred stock are entitled to 1,000,000 votes per share. Thus, each one-thousandth of a share
of Series C preferred stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series C preferred stock will
vote together with the outstanding shares of common stock of the Company as a single class exclusively with respect to (1) any proposal
to adopt an amendment to the Company&#8217;s certificate of incorporation, to reclassify the outstanding shares of common stock into
a smaller number of shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the
&#8220;Reverse Stock Split&#8221;), (2) any proposal to adopt an amendment to the certificate of incorporation to increase the number
of authorized shares of the Corporation&#8217;s common stock (the &#8220;Share Increase Proposal&#8221;) and (3) any proposal to adjourn
any meeting of stockholders called for the purpose of voting on Reverse Stock Split or the Share Increase Proposal (the &#8220;Adjournment
Proposal&#8221;). The Series C preferred stock will not be entitled to vote on any other matter, except to the extent required by applicable
law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series C preferred stock, as such, will not be entitled to receive dividends of any kind. The Series C Preferred Stock will
rank senior to the common stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether
voluntarily or involuntarily (a &#8220;Dissolution&#8221;). Upon any Dissolution, each holder of outstanding shares of Series C Preferred
Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference
to any distribution to the holders of common stock, an amount in cash equal to $0.01 per outstanding share of Series C Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
certain circumstances, shares of the Series C preferred stock will be redeemed by the Company. The Series C preferred Stock is not convertible
into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series C preferred stock
has no stated maturity and is not subject to any sinking fund. The Series C preferred stock is not subject to any restriction on the
redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Liability and Indemnification of Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated certificate of incorporation, as amended limits the personal liability of our directors to the fullest extent
permitted by the Delaware General Corporation Law (&#8220;DGCL&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and officers are entitled to indemnification and advancement of expenses to the fullest extent permitted under Delaware
law, subject to the limitations set forth under the DGCL. We also maintain insurance which protects our officers and directors
against any liabilities incurred in connection with their service in such a capacity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act
and will be governed by the final adjudication of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Effects of Certain Provisions of Delaware Law, our Certificate of Incorporation and Bylaws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware
Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business
combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which
the person became an interested stockholder, unless:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by
employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to
the plan will be tendered in a tender or exchange offer; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which
is not owned by the interested stockholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines a business combination to include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any merger or consolidation involving the corporation and the interested stockholder;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to
the interested stockholder; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an &#8220;interested stockholder&#8221; as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The
term &#8220;owner&#8221; is broadly defined to include any person that, individually, with or through that person&#8217;s affiliates
or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately
exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the
stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose
of acquiring, holding, voting or disposing of the stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject
to Section 203 of the DGCL or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities
exchange or held of record by more than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section 203.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage
attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above
the prevailing market price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certificate
of Incorporation and Bylaws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
of our amended and restated certificate of incorporation and amended and restated bylaws, each as amended, may delay or discourage transactions
involving an actual or potential change in our control or change in our management, including transactions in which stockholders might
otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests.
Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation
and bylaws:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
permit our board of directors to issue up to 20,000,000 shares of preferred stock, without further action by the stockholders, with any
rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
provide that the authorized number of directors may be changed only by a resolution adopted by the entire board of directors;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote
in any election of directors to elect all of the directors standing for election, if they should so choose); and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
provide advance notice provisions with which a stockholder who wishes to nominate a director or propose other business to be considered
at a stockholder meeting must comply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Potential
Effects of Authorized but Unissued Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have shares of common stock and preferred stock available for future issuance without stockholder approval. We may utilize these additional
shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions
or payment as a dividend on the capital stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares to persons friendly
to current management or to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to
obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of the
Company&#8217;s management. In addition, our board of directors has the discretion to determine designations, rights, preferences, privileges
and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each
series of preferred stock, all to the fullest extent permissible under the DGCL and subject to any limitations set forth in our certificate
of incorporation. The purpose of authorizing our board of directors to issue preferred stock and to determine the rights and preferences
applicable to such preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred
stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could
have the effect of making it more difficult for a third-party to acquire, or could discourage a third party from acquiring, a majority
of our outstanding voting stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ENVB&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transfer Agent and Registrar for our common stock is Equiniti Trust Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_007"></span>DESCRIPTION
OF SECURITIES WE ARE OFFERING</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 1,229,330 shares of common stock and pre-funded warrants to purchase 437,336 shares of common stock, together with
each of 1,666,666 Series A warrants and 1,666,666 Series B warrants to collectively purchase up to 3,333,332 shares
of common stock (the &#8220;warrants&#8221;). We are offering the pre-funded warrants to those purchasers, whose purchase of shares
of common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially
owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock following the consummation of this
offering in lieu of the shares of our common stock that would result in ownership in excess of 4.99% (or, at the election of the purchaser,
9.99%). Each pre-funded warrant will be exercisable for one share of common stock. Each pre-funded warrant is being issued together with
the same warrants described above being issued with each share of common stock. The shares of common stock or pre-funded warrants, as
the case may be, and the accompanying warrants, can only be purchased together in this offering, but the shares of common stock and pre-funded
warrants and accompanying warrants are immediately separable and will be issued separately in this offering. We are also registering
the shares of common stock issuable from time to time upon exercise of the pre-funded warrants and warrants offered hereby.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of our common stock under the section &#8220;Description of Our Capital Stock&#8221; in this prospectus is incorporated herein
by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the Series A warrants and Series B warrants included with the shares of
common stock and the pre-funded warrants that are being issued hereby is not complete and is subject to, and qualified in its
entirety by, the provisions of the warrants, the form of which will be filed as an exhibit to the registration statement of which
this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant for a
complete description of the terms and conditions of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
and Exercise Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Series A warrant offered hereby will have an exercise price of $3.00 per share and will be exercisable beginning on the Initial
Exercise Date. The Series A warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B warrants will
have an exercise price of $3.00 per share and will be exercisable beginning on the Initial Exercise Date. The Series B warrants
will expire eighteen (18) months from the Initial Exercise Date. The exercise price and number of shares of common stock issuable upon
exercise of the warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar
events affecting our common stock and the exercise price. The warrants will be issued separately from the common stock and pre-funded
warrants and may be transferred separately immediately thereafter. The warrants will be issued in certificated form only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice
accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless
exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that
the holder would own more than 4.99% (or, at the election of the purchaser prior to the issuance of the warrants, 9.99%) of the outstanding
common stock immediately after exercise. Following the issuance of the warrants, upon notice from the holder to us, the holder may increase
or decrease the amount of beneficial ownership of outstanding stock after exercising the holder&#8217;s warrants up to 9.99% of the number
of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the warrants and in accordance with the rules and regulations of the SEC, provided that any increase
in the beneficial ownership limitation shall not be effective until 61 days following notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time a holder exercises its warrants, a registration statement registering the issuance of the shares of common stock underlying
the warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the
cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect
instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a
formula set forth in the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fractional
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of common stock will be issued upon the exercise of the warrants. Rather, the number of shares of common stock to be
issued will be rounded up to the next whole share or we will pay a cash adjustment equal to such fraction multiplied by the exercise
price to the holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, a warrant may be transferred at the option of the holder upon surrender of the warrant to us together with the appropriate
instruments of transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading
Market</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no trading market available for the warrants on any securities exchange or nationally recognized trading system, and we do not expect
a trading market to develop. We do not intend to list the warrants on any securities exchange or other trading market. Without a trading
market, the liquidity of the warrants will be extremely limited. The common stock issuable upon exercise of the warrants is currently
listed on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Right
as a Shareholder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the
warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a fundamental transaction, as described in the warrants and generally including any reorganization, recapitalization or
reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets,
our consolidation or merger with or into another person, the acquisition of greater than 50% of our outstanding common stock, or any
person or group becoming the beneficial owner of greater than 50% of the voting power represented by our outstanding common stock, the
holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property
that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction. In addition,
in the event of a fundamental transaction which is approved by our board of directors, the holders of the warrants have the right to
require us or a successor entity to redeem the warrant for cash in the amount of the Black-Scholes Value (as defined in the warrant)
of the unexercised portion of the warrant on the date of the consummation of the fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in the event of a fundamental transaction which is not in our control, including a fundamental transaction not approved by our Board,
the holders of the warrants will only be entitled to receive from us or our successor entity, as of the date of consummation of such
fundamental transaction the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised
portion of the warrant that is being offered and paid to the holders of our common stock in connection with the fundamental transaction,
whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of our common stock
are given the choice to receive alternative forms of consideration in connection with the fundamental transaction.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants may be modified or amended with the written consent of the holder of such warrant and us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the pre-funded warrants that are being issued hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which will be filed as an exhibit to the
registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions
of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
and Exercise Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.0001. The pre-funded warrants will be immediately
exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The exercise price and number
of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits,
reorganizations or similar events affecting our common stock and the exercise price. The pre-funded warrants will be issued separately
from the accompanying warrants, in certificated form only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of
a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant
to the extent that the holder would own more than 4.99% (or, at the election of the purchaser prior to the issuance of the pre-funded
warrant, 9.99%) of the outstanding common stock immediately after exercise. Following the issuance of the pre-funded warrants, upon notice
from the holder to us, the holder may increase or decrease the amount of beneficial ownership of outstanding stock after exercising the
holder&#8217;s pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants and in accordance
with the rules and regulations of the SEC. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of
the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock, provided that any increase
in the beneficial ownership limitation shall not be effective until 61 days following notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price,
the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined
according to a formula set forth in the pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable law, pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together
with the appropriate instruments of transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fractional
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of common stock will be issued upon the exercise of the pre-funded warrants. Rather, the number of shares of common
stock to be issued will be rounded up to the next whole share or we will pay a cash adjustment to such fraction multiplied by the exercise
price to the holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading
Market</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no trading market available for the pre-funded warrants on any securities exchange or nationally recognized trading system, and we
do not expect a trading market to develop. We do not intend to list the pre-funded warrants on any securities exchange or other trading
market. Without a trading market, the liquidity of the pre-funded warrants will be extremely limited. The common stock issuable upon
exercise of the pre-funded warrants is currently listed on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Right
as a Stockholder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the pre-funded warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders
of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they
exercise their pre-funded warrants. The pre-funded warrants will provide that holders have the right to participate in distributions
or dividends paid on our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transaction</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization
or reclassification of our shares of common stock, the sale, transfer or other disposition of all or substantially all of our properties
or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of the voting power represented
by our outstanding shares of capital stock, any person or group becoming the beneficial owner of more than 50% of the voting power represented
by our outstanding shares of capital stock, any merger with or into another entity or a tender offer or exchange offer approved by more
than 50% of the voting power represented by our outstanding shares of capital, then upon any subsequent exercise of a pre-funded warrant,
the holder will have the right to receive as alternative consideration, for each share of our common stock that would have been issuable
upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor
or acquiring corporation or of our company, if it is the surviving corporation, and any additional consideration receivable upon or as
a result of such transaction by a holder of the number of shares of our common stock for which the pre-funded warrant is exercisable
immediately prior to such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pre-funded warrants may be modified or amended with the written consent of the holder of such pre-funded warrant and us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement
Agent Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to issue to the placement agent (or its designees) placement agent warrants to purchase up to 116,666 shares
of common stock. The placement agent warrants will be exercisable upon issuance, and will have substantially the same terms as the warrants
described above, except that the placement agent warrants will have an exercise price of $3.75 per share (representing 125% of
the public offering price per share and accompanying warrants indicated on the cover page of this prospectus) and a termination date
that will be five years from the commencement of the sales pursuant to this offering. See &#8220;Plan of Distribution&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_008"></span>PLAN
OF DISTRIBUTION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to an engagement agreement, dated December 8, 2024,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
as amended, we have engaged H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) to act as our exclusive
placement agent to solicit offers to purchase the securities offered pursuant to this prospectus on a &#8220;reasonable best efforts&#8221;
basis. The engagement agreement does not give rise to any commitment by the Placement Agent to purchase any of our securities, and the
Placement Agent will have no authority to bind us by virtue of the engagement agreement. The Placement Agent is not purchasing or selling
any of the securities offered by us under this prospectus, nor is it required to arrange for the purchase or sale of any specific number
or dollar amount of securities. This is a best efforts offering and there is no minimum offering amount required as a condition to the
closing of this offering. The Placement Agent has agreed to use reasonable best efforts to arrange for the sale of the securities by
us. Therefore, we may not sell all of the shares of common stock, pre-funded warrants and warrants being offered. The terms of this offering
are subject to market conditions and negotiations between us, the Placement Agent and prospective investors. The Placement Agent does
not guarantee that it will be able to raise new capital in any prospective offering. The Placement Agent may engage sub-agents or selected
dealers to assist with the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchasing securities offered hereby will have the
option to execute a securities purchase agreement with us. In addition to rights and remedies available to all purchasers in this offering
under federal securities and state law, the purchasers which enter into a securities purchase agreement will also be able to bring claims
of breach of contract against us. The ability to pursue a claim for breach of contract is material to larger purchasers in this offering
as a means to enforce the following covenants uniquely available to them under the securities purchase agreement: (i) a covenant to not
enter into variable rate financings for a period of one year following the closing of the offering, subject to certain exceptions; and
(ii) a covenant to not enter into any equity financings for 60 days from closing of the offering, subject to certain exceptions. The
nature of the representations, warranties and covenants in the securities purchase agreements shall include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">standard
    issuer representations and warranties on matters such as organization, qualification, authorization, no conflict, no governmental
    filings required, current in SEC filings, no litigation, labor or other compliance issues, environmental, intellectual property and
    title matters and compliance with various laws such as the Foreign Corrupt Practices Act; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">covenants
    regarding matters such as registration of warrant shares, no integration with other offerings, no stockholder rights plans, no material
    nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing of shares of common stock, and no
    subsequent equity sales for 60 days, subject to certain exceptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering will terminate on February 13, 2025, unless we decide to terminate the offering (which we may do at any time in our
discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering
price per share (or pre-funded warrant) and warrants will be fixed for the duration of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent expects to deliver the shares and securities to the purchasers in the offering on or about February 3, 2025, subject
to satisfaction of certain conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
and Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the per share and accompanying warrants and per pre-funded warrant and accompanying warrants Placement Agent fees
and total Placement Agent fees we will pay in connection with the sale of the securities in this offering, assuming the purchase of all
of the securities we are offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left; padding-bottom: 1pt">Per share and accompanying warrant Placement Agent cash fees</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">0.21</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Per pre-funded warrant and accompanying warrant Placement Agent cash fees</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.21</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">349,999.86</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay the Placement Agent a total cash fee equal to 7.0% of the gross proceeds of this offering and a management fee equal
to 1.0% of the gross proceeds raised in this offering. We will also pay the Placement Agent a non-accountable expense allowance of $25,000,
$15,950 for the expenses of its clearing firm, and will reimburse the Placement Agent&#8217;s legal fees and expenses in an amount up
to $100,000. We estimate the total offering expenses of this offering that will be payable by us, excluding the Placement Agent&#8217;s
fees and expenses, will be approximately $174,429. After deducting the Placement Agent&#8217;s fees and our estimated offering
expenses, we expect the net proceeds from this offering to be approximately $4.28 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement
Agent Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to grant Placement Agent Warrants to the Placement Agent to purchase a number of shares of our common stock equal to 7.0%
of the aggregate number of shares of common stock and pre-funded warrants sold to the investors in this offering. The Placement Agent
Warrants will have an exercise price of $3.75 (125% of the combined public offering price per share of common stock and accompanying
warrants, indicated on the cover page of this prospectus) and will terminate on the five year anniversary of commencement of sales in
this offering. The Placement Agent Warrants are registered on the registration statement of which this prospectus is a part. The form
of the Placement Agent Warrants is included as an exhibit to the registration statement of which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right
of First Refusal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, with certain exceptions, for a period of twelve months following the closing of this offering,  if we decide to raise funds by means of a public offering (including at-the-market facility) the right to act as sole book-running manager, sole
underwriter or sole placement agent for such financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tail</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to pay the Placement Agent a tail fee equal to both the cash and warrant compensation in this offering, if any investor,
who was brought over-the-wall by the Placement Agent with respect to an offering other than a public offering or contacted by the
Placement Agent with respect to a public offering during the term of its engagement, provides us with capital in any public or private
offering or other financing or capital raising transaction during the twelve-month period following expiration or termination of our
engagement with the Placement Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Determination
of Offering Price</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price per share (or pre-funded warrant) and accompanying warrant we are offering and the exercise prices and other terms
of the warrants were negotiated between us and the investors, in consultation with the Placement Agent based on the trading of
our common stock prior to this offering, among other things. Other factors considered in determining the public offering prices of the
securities we are offering and the exercise prices and other terms of the warrants include the history and prospects of our Company,
the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment
of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.
The combined public offering price per share (or pre-funded warrant) and warrants will be fixed for the duration of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Placement Agent against certain liabilities, including certain liabilities arising under the Securities
Act, or to contribute to payments that the Placement Agent may be required to make for these liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulation
M</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent may be deemed to be underwriters within the meaning of Section 2(a)(11) of the Securities Act and any fees received by
them and any profit realized on the sale of the securities by them while acting as principal might be deemed to be underwriting discounts
or commissions under the Securities Act. The Placement Agent will be required to comply with the requirements of the Securities Act and
the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including, without limitation, Rule 10b-5 and Regulation M under
the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the Placement Agent.
Under these rules and regulations, the Placement Agent may not (i) engage in any stabilization activity in connection with our securities;
and (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted
under the Exchange Act, until they have completed their participation in the distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Electronic
Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on a website maintained by the Placement Agent and the Placement Agent may distribute
prospectuses electronically. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus
or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the Placement Agent
and should not be relied upon by investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lock-up
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and each of our officers and directors have agreed with the Placement Agent to be subject to a lock-up period of 60 days following the
date of closing of the offering pursuant to this prospectus. This means that, during the applicable lock-up period, we and such persons
may not offer for sale, contract to sell, sell, distribute, grant any option, right or warrant to purchase, pledge, hypothecate or otherwise
dispose of, directly or indirectly, any of our shares of common stock or any securities convertible into, or exercisable or exchangeable
for, shares of common stock, subject to customary exceptions. The Placement Agent may waive the terms of these lock-up agreements in
its sole discretion and without notice. In addition, we have agreed to not issue any securities that are subject to a price reset
based on the trading prices of our common stock or upon a specified or contingent event in the future or enter into any agreement to
issue securities at a future determined price for a period of one year following the closing date of this offering, subject to an exception.
The Placement Agent may waive this prohibition in its sole discretion and without notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Placement Agent may provide in the future, various advisory, investment and commercial banking and other services
to us in the ordinary course of business, for which it may receive customary fees and commissions. Except as disclosed in this prospectus,
we have no present arrangements with the Placement Agent for any services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the ordinary course of their business activities, the Placement Agent and its affiliates may make or hold a broad
array of investments and actively trade debt and equity securities (or related derivative securities) for their own account and for the
accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates.
The Placement Agent and its affiliates may also make investment recommendations and/or publish or express independent research
views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_009"></span>LEGAL
MATTERS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered hereby will be passed upon for us by Dickinson Wright, PLLC, Phoenix, Arizona. The Placement Agent
is being represented by Ellenoff Grossman &amp; Schole LLP, New York, New York in connection with this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_010"></span>EXPERTS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements as of and for the years ended December 31, 2023 and 2022 included in this prospectus have been
audited by Marcum LLP, an independent registered public accounting firm, as stated in their report (the report on the consolidated financial
statements contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern). Such financial statements
are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="a_011"></span>WHERE
YOU CAN FIND MORE INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act for the securities being offered by this prospectus.
This prospectus, which is part of the registration statement, does not contain all of the information included in the registration statement
and the exhibits. For further information about us and the securities offered by this prospectus, you should refer to the registration
statement and its exhibits. References in this prospectus to any of our contracts or other documents are not necessarily complete, and
you should refer to the exhibits attached to the registration statement for copies of the actual contract or document.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the reporting and information requirements of the Exchange Act and, as a result, we file periodic and current reports,
proxy statements and other information with the SEC. SEC filings are also available to the public at the SEC&#8217;s website at <i>www.sec.gov</i>.
We also make our periodic reports and other information filed with or furnished to the SEC, available, free of charge, through
our website, www.enveric.com, as soon as reasonably practicable after those reports and other information are filed with or furnished
to the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into,
this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_012"></span>ENVERIC
BIOSCIENCES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audited
Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_001">Reports of Independent Registered Accounting Firm</a> (PCAOB Firm ID: Marcum LLP #688)</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_002">Consolidated Balance Sheets</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_003">Consolidated Statements of Operations and Comprehensive Loss</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_004">Consolidated Statements of Changes in Mezzanine Equity and Shareholders&#8217; Equity</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#aj_006">Consolidated Statements of Cash Flows</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Na_001">Notes to Consolidated Financial Statements</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-9</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_001">Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023</a></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_002">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023</a> </span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_003">Unaudited Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&#8217; Equity for the three and nine months ended September 30, 2024 and 2023</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_004">Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-39</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#D_005">Notes to Consolidated Financial Statements</a></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-40</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Enveric Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31,
2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in mezzanine equity and shareholders&#8217;
equity and cash flows for the years ended December 31, 2023 and 2022, and the related notes (collectively referred to as the &#8220;financial
statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the two years in the period ended
December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Explanatory
Paragraph &#8211; Going Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described
in Note 1, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These
conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard
to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit<b>s</b>. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contracted
Research &amp; Development Cost Recognition:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Aptos; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Critical Audit Matter Description</i></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 2 to the financial statements, the Company records costs for contracted research and development costs based upon estimates of costs incurred through the balance sheet date for services performed by contract research organizations, clinical study sites and other research and development related vendors.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing the recognition of costs associated with contracted research and development organizations is challenging due to the significant judgment required to determine the nature and level of services that have been received, including determining the progress to completion of specific tasks and activities conducted in relation to what has been invoiced and recorded.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary procedures we performed to address this critical audit matter included:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 2in">&#160;</td>
    <td style="width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtained an understanding of the design and implementation of internal controls for contracted research and development cost.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tested the completeness and accuracy of the underlying data used in the estimates including, but not limited to, the estimated costs per project milestone and duration.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assessed the reasonableness of the significant assumptions, corroborated the progress of the contracted research and development costs with the Company&#8217;s operations personnel and to information obtained by the Company directly from third parties, and to information in contracts or statements of work including costs for those activities and project duration.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examined subsequent invoices received from contracted research and development cost third parties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum LLP<span style="font-variant: small-caps"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">East
Hanover, New Jersey</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2024 (except for the matter added and described in Notes 1 and 12, as to which the date is January 30, 2025)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_002"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_zBgckahe2511" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_494_20231231_z0aiWewdkgD2" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_494_20221231_zHVdYHfTPhj3" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsAbstract_iB_zuyasahyCNP8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsCurrentAbstract_i01B_zrClMKkAh7yl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Cash_i02I_maCzBWO_zyxYYxAAEQP4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 68%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" id="Fact000021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzBWO_zVz1e55wyfEa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">708,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrent_i02TI_mtCzBWO_maCzUBD_z229NEBugvEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,581,531</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,431,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsNoncurrentAbstract_i01B_zzoBKouyjvl4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Other assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCzcA6_zUHLIHlbqqr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,485</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maCzcA6_zjLX3afz62Rd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Right-of-use operating lease asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0035">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact000036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzcA6_z6KIKksKFCPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2022-12-31" id="Fact000039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsNoncurrent_i02TI_mtCzcA6_maCzUBD_zeSLDOrZTyW2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,309</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,120,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtCzUBD_zV1gC1DqOUrc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,552,925</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z6U1n2O7ocuh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_z0Bq1nUo3ktg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_i02I_maCzp0K_z8L6ewqh31bb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000053" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzp0K_zZa944R3psp" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,705,655</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzp0K_zUIRuAn8gjWi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of right-of-use operating lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0059">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,820</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzp0K_zdcg8en7w8zi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">851,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilitiesCurrent_i02I_maCzp0K_zv3bpoy8gag8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:WarrantLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:WarrantLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maCzp0K_zq8XbSHBrqu2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0068">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_i01TI_mtCzp0K_maLASEze7M_zarQUurgEM71" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,343,504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,995,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CommitmentsAndContingencies_i01I_maLASEze7M_zDBhSFmKHWci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies (Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0074">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0075">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--TemporaryEquityAbstract_i01B_zGeD7eqHwSee" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Mezzanine equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i02I_maCzcUj_zRiX4UyOKEph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series C redeemable preferred stock, $<span id="xdx_908_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zsd9onDW2XGi" title="Temporary equity, par value"><span id="xdx_903_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zEYUM3rnrqN3" title="Temporary equity, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000083" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000085" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zdbUrR6XRlvk" title="Temporary equity, shares authorized"><span id="xdx_904_eus-gaap--TemporaryEquitySharesAuthorized_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_pdd" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, and <span id="xdx_904_eus-gaap--TemporaryEquitySharesIssued_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zsLrMB9TFz74" title="Temporary equity, shares issued"><span id="xdx_901_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zf6ntM4K8Owf" title="Temporary equity, shares outstanding"><span id="xdx_90B_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zHvPNZlUbOV8" title="Temporary equity, shares issued"><span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_znQOCIrf3p7c" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000091" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000093" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0080">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_i02I_maCzcUj_zuQPiB8No3Ed" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redeemable non-controlling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0099">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2022-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_i02TI_mtCzcUj_maLASEze7M_zr0RNxWG5Csi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total mezzanine equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="AsOf2022-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockValue_i02I_maSEzCcC_zmjMd13jV02g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zA4AGtI9pdq1" title="Preferred stock, par value"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zxSA7020YjIa" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zw9nDXcTfuO" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zb7UdIJ03pXl" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; Series B preferred stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zV5YfohYgdu5" title="Preferred stock, par value"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znIQVh99GTP9" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000119" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000121" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDruAwhz4vXg" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbxwbBoNpEu3" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000125" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,600,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6kbYktmcB65" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzxTlHjt21I8" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_znava2C3DHWc" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDfHOSqiWmEh" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000127" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000129" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000131" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0108">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maSEzCcC_zK4DQjJMlTLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_zN0tYyDU5Mf"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zAHCyBE64uUj"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span>
    </span>par value, <span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zenR2Yp9gQDi"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_z9aE4nf3bpz"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20231231_zWzaQg9cmAjj" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zzlflLST2Qxj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,625</ix:nonFraction></ix:nonFraction></span>
    </span>and <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zDP20W8xUbhi" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_z3pqXnSAeUlg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,554</ix:nonFraction></ix:nonFraction></span></span> shares issued
    and outstanding as of December 31, 2023 and 2022, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdditionalPaidInCapital_i02I_maSEzCcC_zmT1MJGeXBEj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,841,416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,415,058</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_i02NI_di_msSEzCcC_zmQdB8isTLsb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2023-12-31" id="Fact000153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0154">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzCcC_z5SegL4empVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000157" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maSEzCcC_zwZJLUR6I2d6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">569,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2022-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzCcC_maLASEze7M_zpH6a87QNJJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,956,336</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000163" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEze7M_zxzjgGvkoOCh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities, mezzanine equity, and shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,552,925</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_003"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_zQznft75rFR8" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: center">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_490_20230101__20231231_zmrtvzbIFTI1" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_493_20220101__20221231_ziTmNqBHZihb" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zNXzBq3N8eb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzC9H_zRPCUH31POkg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 68%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,852,021</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,605,761</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzC9H_zHqcDFnG7eV9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,252,437</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,027,773</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GoodwillAndIntangibleAssetImpairment_i01_maCzC9H_zKahbQpfEEe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment of intangible assets and goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0177">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,453,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_i01_maCzC9H_zix1iK0Ytny8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">327,910</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingCostsAndExpenses_i01T_mtCzC9H_msCzzfK_zxDJBI3aERX9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-01-012023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,448,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-01-012022-12-31" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,415,106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_mtCzzfK_maILFCOzRDq_zYNq1quOqiS6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000186" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,448,440</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000187" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,415,106</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zIKg6Mapn9dk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--InducementExpense_i01N_di_msNIEzd72_zKXJbbL6iTFk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Inducement expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:InducementExpense" contextRef="From2023-01-012023-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,848,235</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0193">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEzd72_zavxJRG79X6l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,396</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,315,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainLossOnInvestments_i01_maNIEzd72_zTBX2nczkMR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-012023-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,472,726</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maNIEzd72_ztxXVjO6x3Md" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">325,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestIncomeExpenseNet_i01_maNIEzd72_zlWRyTwu9GG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Interest income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-12-31" id="Fact000204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,708</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2022-01-012022-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzd72_maILFCOzRDq_zhq82Hx34RA2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other (expense) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">814,379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,457,713</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzRDq_maNILzfq7_zHrrDmK0K62c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,262,819</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,957,393</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzfq7_zIAevkLUHAF6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax (expense) benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact000214" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_mtNILzfq7_maNILATzJ2K_z2qHnhQOMVoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--PreferredStockDividendsIncomeStatementImpact_msNILATzJ2K_za6LjvNffBJl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Less preferred dividends attributable to non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31" id="Fact000220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_msNILATzJ2K_zOQBk5x2GJR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less deemed dividends attributable to accretion of embedded derivative at redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2023-01-012023-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2022-01-012022-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_mtNILATzJ2K_maCINOTz2bP_z8tl8hk0Vu8g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss attributable to shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,458,761</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,800,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zk91A4M23sod" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_maCINOTz2bP_znfTkIUjvych" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_mtCINOTz2bP_zv9utR0rMgah" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,491,776</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,306,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_901_eus-gaap--EarningsPerShareBasic_c20230101__20231231_z9GWSrECUH91" title="Net loss per share - basic"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zMtiySpoTso3" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Net loss per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">121.29</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_906_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zfgbN6YZnuG5" title="Net loss per share - basic"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_z4jWAXc4g8Ea" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Net loss per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">195.02</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zyj4YORnt4v6" title="Weighted average shares outstanding, basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zDYepgwIObU7" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">143,938</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zFKvinjqI6ji" title="Weighted average shares outstanding, basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zlF7pom7UEnb" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,401</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_004"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_z0EhjKP0rRC7" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--SeriesCRedeemablePreferredStockMember_z8oapZNiJjzh" style="display: none; text-align: center">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_custom--RedeemableNoncontrollingInterestMember_zg3U8TPm9Y7h" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--MezzanineEquityMember_z7AF5sqiwnuk" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zq3M7CTsBF34" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKRWnQZY8Sw" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_znFiyoFadqLg" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zVoUE5hxVunc" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zrNmHeEF5OTl" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B6_zj7NWVEQSje6" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable Non-controlling Interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Mezzanine Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subscription Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43F_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zta1XTEyZpk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; font-weight: bold">Balance at January 1, 2023</td><td id="xdx_98A_ecustom--TemporaryEquityShares_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zzmZTTmCiIG4" style="text-align: center; width: 2%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0253"><span style="-sec-ix-hidden: xdx2ixbrl0262">-</span></span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TemporaryEquityShares_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zuwxrHNt0l55" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2x7NFWtlqG9" title="Beginning balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,415,058</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000259" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000260" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_iN_di_zmh64Dw85S73" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000269" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="Fact000270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0271">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_iN_di_zKH0Zggsq2sg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="Fact000280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zSXTBEtujUS3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series A preferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zAMxF1JFemKb" title="Redemption of Series A preferred, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000298" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000289" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember" id="Fact000290" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zYioNQaT0pyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zfDAiYSK2Vel" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares in exchange for RSU conversions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzUv3obJuiab" title="Issuance of common shares in exchange for RSU conversions, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z7doNkZPDHZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares for deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhn7iV3Nkfvj" title="Issuance of common shares for deferred offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,294</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact000330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zmipmDmJPhI5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of Inducement Warrants, net of offering costs of $<span id="xdx_90F_ecustom--NetOfferingCosts_c20230101__20231231_zJ4PcfOtpN03" title="Net offering costs"><ix:nonFraction name="ENVB:NetOfferingCosts" contextRef="From2023-01-012023-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,302</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967,424</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">280,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,686,924</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_zIe2Q3aXupq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Induced conversion of warrants and preferred investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,997</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueOther_z4yDJ6HnPU0f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Exercise of warrants and preferred investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdprlierDny6" title="Exercise of warrants and preferred investment options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,867</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,536,861</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,537,140</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zLceMYKxdzf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000375" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,015</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000376" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,015</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zCkukq0a3ml2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000384" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000386" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zEw6Y2EAHBh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td id="xdx_98F_ecustom--TemporaryEquityShares_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zb8A5oXTcvm3" title="Mezzanine equity ending balance, shares" style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0388"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></span></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_ecustom--TemporaryEquityShares_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zxz482BItqra" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAspnCvEcRui" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,625</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,841,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember" id="Fact000393" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,817,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">569,749</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000396" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,336</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_005"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-left: 10pt; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_custom--SeriesCRedeemablePreferredStockMember_z1VpA8Jszc3" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_custom--RedeemableNoncontrollingInterestMember_zkZF9hy2S6r2" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_custom--MezzanineEquityMember_z2ZzfyFDbZ61" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zzzkxTTZCIpi" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zXlIe0z8R6na" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zlzk67CHGmYg" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zUavTsFk6sFk" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_4B0_zcdBxuK4nQ1g" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series C Redeemable Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable Non-controlling Interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-left: Black 1pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Mezzanine Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="border-left: Black 1pt solid; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Other Comprehensive Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_43E_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z7g8z2zFffR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zIKW3Bbl1qka" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_z4mf2EoP8Zml" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBqqv2azeEOl" title="Beginning balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000407" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000408" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,072,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000409" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,736,453</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,802</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000411" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,305,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_43A_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zCxLol2au2qf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold">Balance</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zTeTMDkTaRzi" title="Mezzanine equity balance, shares" style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityShares_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_z6AbyWo1Y7ll" title="Mezzanine equity balance, shares" style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="display: none; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ1fVCJ5r20d" title="Beginning balance, shares" style="display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000432" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,462</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000422" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,072,741</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">60,736,453</ix:nonFraction></td><td style="display: none; text-align: left">)</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">30,802</ix:nonFraction></td><td style="display: none; text-align: left">)</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,305,920</ix:nonFraction></td><td style="display: none; text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_z8zrs1gtlKXb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">February 2022 registered direct offering, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjdHSCBWd0v7" title="February 2022 registered direct offering, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000443" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,802,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2022-01-012022-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,802,464</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z6X6iSnVDSL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,620,671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact000452" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,620,671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_z9VaIwgvjYpk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of RSUs into common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXo3Y7pagT33" title="Conversion of RSUs into common shares, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000463" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RedeemableNoncontrollingInterestValue_zMPwWZa4H14e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Redeemable non-controlling interest, net of $<span id="xdx_904_ecustom--RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_c20220101__20221231_zXkCMs1p2lTg" title="Issuance of embedded derivative"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" contextRef="From2022-01-012022-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,000</ix:nonFraction></span> embedded derivative and net of issuance costs of $<span id="xdx_900_ecustom--RedeemableNoncontrollingInterestIssuanceCosts_c20220101__20221231_zOBnKSEnYzEd" title="Redeemable noncontrolling interest issuance costs"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,962</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--RedeemableNoncontrollingInterestShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zcKLD4vPUwV" title="Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares" style="text-align: right"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestShares" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000478" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterestValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">556,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_zd75INF58Bb4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of redeemable Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zY9eiGpZV2A2" title="Issuance of redeemable Series C preferred stock, shares" style="text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000489" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000484" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact000487" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_iN_di_zriilB6nx1ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000493" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_iN_di_ztCGCr23pN7g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000501" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000502" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_zXZZ8qJHOyoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Conversion of RSAs into common shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBAFKHGetfMg" title="Conversion of RSAs into common shares, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000518" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000513" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0516">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_zxQAgDVgdvU6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzmDDCDNvCo3" title="July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares" style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000529" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000523" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,248,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" contextRef="From2022-01-012022-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,249,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfRoundedSharesAsResultOfReverseStockSplit_zNYDGfQf01ca" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of rounded shares as a result of the reverse stock split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhLD5wR6QJab" title="Issuance of rounded shares as a result of the reverse stock split, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000540" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,616</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000535" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zMIWVckDCAU3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series C preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zjJzJq4HF5Oj" title="Redemption of Series C preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">52,685</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember" id="Fact000544" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">)</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0548">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2022-01-012022-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zLHC6jkluDI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></td><td style="text-align: left">&#160;</td><td style="border-left: Black 1pt solid">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000559" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505,932</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2022-01-012022-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">505,932</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zM553y8V6Wuk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000567" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43D_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zFMQrM2EBs8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zSnsGirCEhzl" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zw0SZS0jPX7f" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000582" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact000573" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAbgqmUKXnP4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,415,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000577" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_434_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zyDG6p1w0kTg" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zwx8lrzErQn8" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0586">&#8212;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--TemporaryEquityShares_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zYmCLTl7ISkk" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000597" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact000587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="border-left: Black 1pt solid; display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSuz7bZsOHAl" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,554</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,415,058</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000591" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">)</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">)</td><td style="display: none; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="display: none; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="aj_006"></span>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zhNguabA34fa" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: center">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_497_20230101__20231231_zMJRHF5q3T45" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_492_20220101__20221231_zWzAOuQfZ1R" style="display: none; text-align: center">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zyxPCgN0FaCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_maNCPBUzuYE_zrmLL3Z3AAkh" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,291,732</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000605" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,471,333</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zFSGzYNhHRfe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzuYE_zKZVK9B5xsth" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000610" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">94,396</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000611" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,315,236</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--GainLossOnInvestments_i02N_di_msNCPBUzuYE_zoZKUocNnuof" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-012023-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,752</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2022-01-012022-12-31" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,472,726</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzuYE_zOjnFNHODJv5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-12-31" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000617" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">325,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_i02_maNCPBUzuYE_za3Q3P6VkpD2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,150,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,620,671</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--InducementExpense_i02_maNCPBUzuYE_zo9FmnyPrtVa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Inducement expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:InducementExpense" contextRef="From2023-01-012023-12-31" id="Fact000622" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,848,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GoodwillAndIntangibleAssetImpairment_i02_maNCPBUzuYE_zGlbjnR2BkMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt">Impairment of intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GoodwillAndIntangibleAssetImpairment" contextRef="From2022-01-012022-12-31" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,453,662</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NoncashIncomeTaxExpense_i02_maNCPBUzuYE_zQqg4kuFvVnj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash income tax benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:NoncashIncomeTaxExpense" contextRef="From2022-01-012022-12-31" id="Fact000629" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,504,302</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maNCPBUzuYE_z0ZkPiDw5bl7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Amortization of ROU asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-012023-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2022-01-012022-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,291</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_i02_maNCPBUzuYE_zgmM4OG4fe08" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt">Amortization of intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Depreciation_i02_maNCPBUzuYE_zNDck1Yj4CIf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,160</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_msNCPBUzuYE_zQf8O9eDR4wf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-12-31" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,206</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0641">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zTF64X1sapMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzuYE_zxxDlr437bDc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,857</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" id="Fact000647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">374,058</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maNCPBUzuYE_zesJZcLo5Y8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000649" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,848</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000650" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_i03N_di_msNCPBUzuYE_zRthgjOtPZY5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Right-of-use operating lease asset and obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" contextRef="From2023-01-012023-12-31" id="Fact000652" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,045</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" contextRef="From2022-01-012022-12-31" id="Fact000653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzuYE_maCCERCzwov_zhDo1IkUA5lg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000655" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,094,411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,146,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z9RlW89EOLh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzogo_zTlSHKq9ZdSf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,180</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,165</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUzogo_zS2BWBaDZ0U3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from disposal of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,847</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0665">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzogo_maCCERCzwov_zWzk8v0OIKsi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="Fact000668" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">584,165</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zo1qlouUT50j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz9AI_zmvdR1J0Msz" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sale of common stock, warrants, and investment options, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0673">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,222,099</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_i01_maNCPBUz9AI_zqkNGHjOAjOl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUz9AI_zitwgvrfhglj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from exercise of Inducement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts_i01_maNCPBUz9AI_zWVLbqBRRpO5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from common stock sold under the Purchase Agreement, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_msNCPBUz9AI_zXo241Mu7058" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payment for equity distribution offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="0" unitRef="USD">291,084</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_i01N_di_msNCPBUz9AI_zqJ4C6ZXn5yh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-012023-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromRepurchaseOfRedeemablePreferredStock_i01_maNCPBUz9AI_zjHt19hggLte" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from the sale of redeemable non-controlling interest, net of offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock" contextRef="From2022-01-012022-12-31" id="Fact000692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">958,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzwov_mtNCPBUz9AI_zbq7DzDgrqAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash (used in) provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,343,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,180,137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_maCCERCzwov_zcNWeBg0E2a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of Foreign Exchange Rate on Changes on Cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-12-31" id="Fact000697" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2022-01-012022-12-31" id="Fact000698" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">81,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzwov_zKZFAj35e885" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net (decrease) increase in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,435,907</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000701" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,885</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zMeS9FC6purf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash at beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,355,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zbbjgCJeCg1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash at end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zboEshf3wyl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash and non-cash transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestPaidNet_i01_z5mAqmQaCHm8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="Fact000713" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxesPaidNet_i01_zwGypZx5Ofa8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,507</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantsIssuedInConjunctionWithCommonStockIssuance_i01_zPv2Hp9tUea8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants issued in conjunction with common stock issuance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0718">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2022-01-012022-12-31" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,595,420</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr id="xdx_401_ecustom--IssuanceOfEmbeddedDerivative_i01_zoTCYW5e1gZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left; padding-bottom: 2.5pt">Issuance of embedded derivative</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="ENVB:IssuanceOfEmbeddedDerivative" contextRef="From2022-01-012022-12-31" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--StockSubscriptionReceivable_i01_zlvCprQ7Svcf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock subscription receivable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:StockSubscriptionReceivable" contextRef="From2023-01-012023-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OfferingCostsAccruedNotPaid_i01_zG4LzB9Tets2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Offering costs accrued not paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:OfferingCostsAccruedNotPaid" contextRef="From2023-01-012023-12-31" id="Fact000727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,724</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantsIssuedForOfferingCosts_i01_zZhecuyZpsi9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Warrants issued for offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:WarrantsIssuedForOfferingCosts" contextRef="From2023-01-012023-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,991</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0731">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonSharesForDeferredOfferingCosts_i01_ztTgXdib6AX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of common shares for deferred offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2023-01-012023-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,107</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0734">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InducedConversionOfWarrantsAndPreferredInvestmentOptions_i01_zOtXWsG0Bix6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Induced conversion of warrants and preferred investment options</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions" contextRef="From2023-01-012023-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,997</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_i01_zoyMIquVgGp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Preferred dividends attributable to redeemable non-controlling interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_i01_z7lj5X7ZsXP9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Investment options issued in conjunction with common stock issuance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" contextRef="From2022-01-012022-12-31" id="Fact000743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,323,734</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ModificationOfWarrantsAsPartOfShareCapitalRaise_i01_zBeiE4GNMBif" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Modification of warrants as part of share capital raise</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise" contextRef="From2022-01-012022-12-31" id="Fact000746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,357</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_i01_zy28eXaeLfFd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Accretion of embedded derivative to redemption value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2022-01-012022-12-31" id="Fact000749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="xdx_042_c20230101__20231231_znKS68TLLzS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Na_001"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000751" name="us-gaap:NatureOfOperations"><p id="xdx_808_eus-gaap--NatureOfOperations_zcYw7bouB0pi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_827_zeGb70wjgan">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&#8220;Enveric&#8221; or the &#8220;Company&#8221;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#8220;Jay Pharma&#8221;), 1306432 B.C. Ltd. (&#8220;HoldCo&#8221;),
MagicMed Industries, Inc. (&#8220;MagicMed&#8221;), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its unique discovery and development platform, the  Psybrary&#8482;, has created a robust intellectual property portfolio
of new chemical entities for specific mental health indications. Enveric&#8217;s lead program, the EVM201 Series, comprises next
generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#8211;
EB-373 &#8211; for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected
to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of
neuroplasticity without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Company&#8217;s amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), the Company has continued
to pursue the development of MagicMed&#8217;s proprietary Psychedelic Derivatives library, the Psybrary&#8482; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress.
The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry
and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million
potential variations and hundreds of synthesized molecules. Within the Psybrary&#8482; the Company has three different types of
molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities).
The Company is working to add novel molecular compounds and derivatives (&#8220;Psychedelic Derivatives&#8221;) on a regular basis
through its work at the Company&#8217;s labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with
expertise in synthetic biology and chemistry. To date the Company has created over 500 molecules that are housed
in the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
Company screens newly synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (&#8220;AI&#8221;)
tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company
believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological
effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable
can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New
compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal),
and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#8482; and the AI tool to categorize and characterize
the Psybrary&#8482; substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#8217;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#8220;EVM201
Series&#8221;), towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration
(TGA), Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zlYF6ZHetqpj" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-01-272025-01-27" id="Fact000753" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span>
reverse stock split (&#8220;Reverse Stock Split&#8221;) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025,
pursuant to which every 15 shares of the Company&#8217;s issued and outstanding common stock were reclassified as one share of
common stock. The Reverse Stock Split had no impact on the par value of the Company&#8217;s common stock or the authorized number of
shares of common stock. Unless otherwise indicated, all share and per share information in these consolidated financial statements
are adjusted to reflect the Reverse Stock Split, prior to the rounding of any fractional shares. Any fractional share resulting from
the Reverse Stock Split shall be rounded up to the next whole number of shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern, Liquidity and Other Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zeXL2JVUG7I7" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000755" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></span> as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company has operating cash outflows of $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zC9IEOtZAr8a" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000757" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,094,411</ix:nonFraction></span> for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $<span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20231231_zptySDPGyAxb" title="Loss from operations"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000759" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,448,440</ix:nonFraction></span>. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#8217;s operations have been funded principally through the issuance of equity. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $<span id="xdx_908_eus-gaap--Cash_iI_c20231231_zg6W1PD6T4He" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
working capital of $<span id="xdx_909_ecustom--WorkingCapital_iI_c20231231_zwCKXLM8F7e1" title="Working capital"><ix:nonFraction name="ENVB:WorkingCapital" contextRef="AsOf2023-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,238,027</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company&#8217;s current cash on hand is not sufficient enough to satisfy its operating cash needs for the 12 months from the filing
of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding the Company&#8217;s ability to continue as a going
concern for a period of one year after the date the financial statements are issued. Management&#8217;s plan to alleviate the conditions
that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other
sources, which has included the Equity Distribution Agreement with Canaccord for proceeds of up to $<span id="xdx_90E_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z0bSeaRLLC14" title="Additional working capital"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember" id="Fact000765" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (see Note 7), the Purchase Agreement
with Lincoln Park (see Note 7), subject to registration, the Inducement Letters and resulting sales of common stock under the Existing
Warrants for cash proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdbYkH7ofgh3" title="Warrants for cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember" id="Fact000767" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million received in January 2024 (see Note 7),
and the exercise of warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRrqgNwYrtA8" title="Exercise of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact000769" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,267</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock for cash proceeds
of approximately $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxBoa9iJSd54" title="Cash proceeds of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact000771" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in February 2024 (see Note 12), and may
include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available
to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required
to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the financial statements are issued. The Company&#8217;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#8220;RIF&#8221;) of approximately 35% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $<span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_z8D58hHBUYA" title="Severance costs"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2023-05-012023-05-31" id="Fact000773" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,059</ix:nonFraction></span> through
December 31, 2023. The plan included a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline while reducing the
rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded
in general and administrative accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating
Officer (the &#8220;Kanubaddi Separation Agreement&#8221;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi&#8217;s
outstanding restricted stock units (&#8220;RSUs&#8221;) will retain their vesting conditions. Mr. Kanubaddi&#8217;s 2023 salary and benefits
of $<span id="xdx_907_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_z2eyKHjPXPnh" title="Salaries and benefit"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember" id="Fact000775" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,974</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
inclusive of the 2023 performance bonus in the amount of $<span id="xdx_90D_eus-gaap--AccruedBonusesCurrent_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zrCCgVRmsV6k" title="Performance bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember" id="Fact000777" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,760</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were accrued and the salary and benefits, excluding
the 2023 performance bonus will be paid out in twelve equal monthly installments beginning in July 2023. As of December 31, 2023, the
performance metrics for the 2023 performance bonus were not achieved and the accrued amount of amount of $<span id="xdx_901_eus-gaap--RestructuringReserve_iI_c20231231_zsfpflMKZxWj" title="Reversed amount"><ix:nonFraction name="us-gaap:RestructuringReserve" contextRef="AsOf2023-12-31" id="Fact000779" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,760</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was reversed. Upon termination, any unvested
time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was $<span id="xdx_90A_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4HDlczxCn45" title="Expense related to acceleration of vesting"><ix:nonFraction name="ENVB:ExpenseRelatedToAccelerationOfVesting" contextRef="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000781" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,273</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All of the <span id="xdx_908_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CQB1lpNWGf" title="Market performance based shares"><ix:nonFraction name="ENVB:MarketPerformanceBasedShares" contextRef="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">752</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> market performance-based RSUs previously
granted that were subject to the original terms and conditions of Mr. Kanubaddi&#8217;s employment agreement were forfeited during the
year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000785" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" title="Restructuring cost payable, beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--RestructuringCostsIncurred_c20230101__20231231_zEYhLjXcC6Lc" title="Restructuring costs incurred" style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:RestructuringCostsIncurred" contextRef="From2023-01-012023-12-31" id="Fact000789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,004,033</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" title="Restructuring costs" style="text-align: right">(<ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="From2023-01-012023-12-31" id="Fact000791" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">572,628</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" title="Restructuring costs reversed" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherRestructuringCosts" contextRef="From2023-01-012023-12-31" id="Fact000793" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">129,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" title="Restructuring cost payable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="AsOf2023-12-31" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zbWxkJfj9qfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notice</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as
of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90A_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zRjXM8zUUidi" title="Minimum of stockholders equity required for continued listing pursuant to exchange"><ix:nonFraction name="ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" contextRef="AsOf2023-11-21" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> in stockholders&#8217; equity required for continued listing
pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension
to regain compliance with the minimum stockholders&#8217; equity requirement by May 20, 2024. If the Company fails to evidence compliance
upon filing its periodic report for June 30, 2024 with the SEC and Nasdaq, the Company may be subject to delisting. The Company plans
to regain and evidence compliance with the Stockholders&#8217; Equity Requirement by the required deadlines, but it is not assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000799" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z1Usp4Epnijl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_827_z29VOpGCLrQb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000801" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zbIKrsz2JJMb">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000803" name="us-gaap:UseOfEstimates"><p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMMySFR20SIc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods
reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of
changes in such estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and
assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred
investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting
research and development efforts. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000805" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zFKLsC1vhXHf">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000807" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zNjHpvv4Gia">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000809" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0Oa78Uy6iHe">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_US" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in the United States and Australia and $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_CA" id="Fact000813" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_US" id="Fact000815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at United States financial institutions, less than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_AU" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>
at Australian financial institutions, and greater than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31_country_CA" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000821" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztBjC43QkT38">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000823" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zPkCB4Owiyud">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#8217;s
expected future cash flows; a sustained, significant decline in the Company&#8217;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#8217;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000825" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdX7mG65WS1b">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#8217;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000827" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z622SrpvFB74">Property
&amp; Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#8217;s long-lived assets. The estimated
useful lives are typically <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000829" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000831" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years for office furniture and equipment and are depreciated on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000833" name="ENVB:DeferredOfferingCostsPolicyTextBlock"><p id="xdx_841_ecustom--DeferredOfferingCostsPolicyTextBlock_zC3UVlYm5iHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zmmelDy6vXh3">Deferred
Offering Costs</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (&#8220;ASC 340&#8221;) and SAB 5A <i>-
Expenses of Offering</i>. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction></span> in deferred offering costs in connection with the Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) and the Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000837" name="ENVB:WarrantLiabilityPolicyTextBlock"><p id="xdx_845_ecustom--WarrantLiabilityPolicyTextBlock_zLXVKuvvt2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zH6VWLIKl02j">Warrant
Liability and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#8220;Distinguishing
Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;) and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The Company accounts for warrants and investment options for shares of the Company&#8217;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000839" name="ENVB:ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock"><p id="xdx_845_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_z7oMqGQu7b2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zHBF6D1y83y9">Modification
and Inducement of Warrants and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000841" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zBwpH1gx3ZNb">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000843" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsORoSsW5NTg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000845" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVtfgEZ2LSf1">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s reasonable estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#8217;s common stock on the date of award grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#8217;s
board of directors (the &#8220;Board of Directors&#8221;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#8217;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSU&#8217;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#8217;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#8217;s that vest
immediately are charged to expense on the date awarded, value of RSU&#8217;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#8217;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#8217;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#8217;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#8217;s
engagement with the Company must either be terminated prior to such conversion of RSU&#8217;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#8220;specified
employee&#8221; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#8217;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSA&#8217;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#8217;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#8217;s that vest immediately are charged
to expense on the date awarded, value of RSA&#8217;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000847" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zX4N0aihbZJi">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zzehumrBJq1i" title="Stock and warrants issued"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember" id="Fact000849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,167</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> pre-funded common stock warrants, which were
exercised on various dates during the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26,
2022 based on the terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $<span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_z3Ex19wQ4NN7" title="Warrant exercise price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember" id="Fact000851" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0015</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these shares are considered outstanding common shares
and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is
virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000853" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,614</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,698</ix:nonFraction></p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,390</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,167</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember" id="Fact000861" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,366</ix:nonFraction></p>
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember" id="Fact000867" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000876" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,993</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">126,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000879" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztG9Z6EAI5m2">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000881" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zKPLQOyArmx4">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000883" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuz1Rz8vQhr9">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000885" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#8217;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a right-of-use asset, which represents the Company&#8217;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#8217;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000887" name="ENVB:RedeemableNoncontrollingInterestPolicyTextBlock"><p id="xdx_84B_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zkZiVDimAdil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_za6xEu8hPKl1">Redeemable
Non-controlling Interest</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#8220;RNCI&#8221;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000889" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zww0mCbaLZc1">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines its reporting units in accordance with FASB ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000891" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwwObdI2aaB5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</i> (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#8217;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000893" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zaAAsItDs3Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3.<span> <span id="xdx_82D_z7UD1gS7KARl">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000895" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zTydFvT6Kuv4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact000897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,320</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopment" contextRef="AsOf2022-12-31" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">268,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2023-12-31" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2022-12-31" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,782</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2022-12-31" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2022-12-31" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,179</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PrepaidFranchiseTaxReceivable" contextRef="AsOf2023-12-31" id="Fact000912" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2023-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">708,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zesRhFyyZGE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000921" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9SCaXsACTk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span>INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_828_zBJmKX4zYxVf" style="display: none">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performs an annual impairment test at the reporting unit level as of December 31 of each fiscal year. As of December 31, 2022,
the Company&#8217;s goodwill and intangible assets were fully impaired, and thus no annual impairment test was necessary as of December
31, 2023. The following table provides the Company&#8217;s goodwill, indefinite and definite lives intangible assets as of December 31,
2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000923" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s goodwill consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zywzBm3sR0Xd" style="display: none">SCHEDULE
OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Impairment Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Currency Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" title="Goodwill Gross, Beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:GoodwillGross" contextRef="AsOf2021-12-31" id="Fact000925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,834,855</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" title="Accumulated Impairment Losses, Beginning balance" style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="AsOf2021-12-31" id="Fact000927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225,862</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_z6Ico1CR2F3k" title="Currency Translation, Beginning balance" style="width: 11%; text-align: right">(<ix:nonFraction name="ENVB:GoodwillCurrencyTranslation" contextRef="AsOf2021-12-31" id="Fact000929" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,359</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" title="Goodwill, Beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" id="Fact000931" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,587,634</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zCD5RPP49Kt" title="Goodwill Gross, Impairment losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0933">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_z62rnT8rmnTk" title="Accumulated Impairment Losses, Impairment losses" style="text-align: right">(<ix:nonFraction name="ENVB:GoodwillAccumulatedImpairmentLoss" contextRef="From2022-01-012022-12-31" id="Fact000935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,486,060</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zSbfiyEI09me" title="Currency Translation, Impairment losses" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" title="Goodwill, Impairment losses" style="text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2022-01-012022-12-31" id="Fact000939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,486,060</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zg1fcBdDAJz1" title="Goodwill Gross, Loss on currency translation" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zUb2cKPLhd02" title="Accumulated Impairment Losses, Loss on currency translation" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_z8TE2v2Adkth" title="Currency Translation, Loss on currency translation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:GoodwillCurrencyTranslationLoss" contextRef="From2022-01-012022-12-31" id="Fact000945" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" title="Goodwill, Loss on currency translation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000947" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">101,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" title="Goodwill Gross, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GoodwillGross" contextRef="AsOf2022-12-31" id="Fact000949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,834,855</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" title="Accumulated Impairment Losses, Ending balance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" contextRef="AsOf2022-12-31" id="Fact000951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,711,922</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" title="Currency Translation, Ending balance" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:GoodwillCurrencyTranslation" contextRef="AsOf2022-12-31" id="Fact000953" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">122,933</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" title="Goodwill, Ending balance" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zxEPfyg8txe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000957" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s indefinite lived intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B7_zWEh1BmzLMM6" style="display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Indefinite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" title="Balance, Indefinite lived intangible assets" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2021-12-31" id="Fact000959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,375,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" title="Impairment losses" style="text-align: right">(<ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-12-31" id="Fact000961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,967,602</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" title="Loss on currency translation" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000963" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">407,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" title="Balance, Indefinite lived intangible assets" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 80%">Definite lived intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" title="Balance, Definite lived intangible assets" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-12-31" id="Fact000967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">548,436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact000969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" title="Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,754</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" title="Balance, Definite lived intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zXWcVfQneWi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
identified definite lived intangible assets, amortization expense amounted to $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zk2p8bhGkqR9" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000975" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,754</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zyBCbH7OAWC" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></span> during the years ended December 31,
2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000979" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company amortizes definite lived intangible assets on a&#8239;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zzVXkKpEcQPl" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact000981" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2023-12-31" id="Fact000983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite lived assets amortization
    expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zPK37hZCJdad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000987" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXXYZu4HU6c9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_825_zaytaYVEUUm6">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact000989" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#8220;EBCI&#8221;), with all amounts translated into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zxF5quYUvBz1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LabEquipmentMember" id="Fact000991" format="ixt:numdotdecimal" decimals="0" unitRef="USD">836,709</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_LabEquipmentMember" id="Fact000992" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,123</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact000994" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,379</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact000995" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,137</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact000998" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact001001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z2MshGQnoZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_zaY42joe7YG7" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact001003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,228</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--Depreciation_c20220101__20221231_z0vGnuRplH4c" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,160</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001007" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zBePLueQV7ve" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_828_zbdmk1JonaWe">ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001009" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B6_z2CYiR69qip9" style="display: none">SCHEDULE
OF ACCRUED LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:AccruedProductDevelopmentCost" contextRef="AsOf2023-12-31" id="Fact001011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,981</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:AccruedProductDevelopmentCost" contextRef="AsOf2022-12-31" id="Fact001012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,104</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2023-12-31" id="Fact001014" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,889</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2022-12-31" id="Fact001015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,175,963</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact001017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2022-12-31" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,255</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccruedRestructuringCosts" contextRef="AsOf2023-12-31" id="Fact001020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact001023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Patent costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2023-12-31" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2022-12-31" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001030" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,705,655</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zfLwpnfUgaDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001032" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDwGAQBPdjdj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_821_zPkNv6EA0ckj">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20230101__20231231_zyP7HBT2y9O4" title="Common stock voting rights"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact001034" name="us-gaap:CommonStockVotingRights">The
holders of the Company&#8217;s common stock are entitled to one vote per share</ix:nonNumeric></span>. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available
for distribution. As of December 31, 2023, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z3kEFDBFbKC" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of common stock and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zBU2P1eYPMuf" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></span> shares of Preferred Stock were authorized
under the Company&#8217;s articles of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into the Distribution Agreement, with Canaccord, pursuant to which the Company may offer and sell
from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zzPld5phABZh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share
having an aggregate offering price of up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zV61LRnnxsQj" title="Common stock, offering price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million. Due to the offering limitations applicable to the Company and in accordance
with the terms of the Distribution Agreement, the Company may offer common stock having an aggregate gross sales price of up to $<span id="xdx_900_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zFsQ1hTkiWgf" title="Aggregate gross sales price"><ix:nonFraction name="ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,514</ix:nonFraction></span>
pursuant to the prospectus supplement dated September 1, 2023 (the &#8220;Prospectus Supplement&#8221;). Subject to the terms and conditions
of the Distribution Agreement, Canaccord may sell the common stock by any method permitted by law deemed to be an &#8220;at-the-market
offering&#8221;. The Company will pay Canaccord a commission equal to <span id="xdx_909_ecustom--CommissionPercentage_pid_dp_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zXJHXmkSZzdf" title="Commission percentage"><ix:nonFraction name="ENVB:CommissionPercentage" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact001046" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross sales price of the common stock sold through
Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord for certain expenses. The Company may also sell
common stock to Canaccord as principal for Canaccord&#8217;s own account at a price agreed upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Letters (as defined below within this Note 7) prohibits the Company from entering into any variable rate transaction as defined
in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the
Company may issue securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The
variable rate transaction restriction expires after six-month from the closing date of December 28, 2023 for the Inducement Letters for
an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions. Subsequent to December 31, 2023, the limitation on the at-the-market offering was waived. See Note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lincoln
Park Equity Line</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into a Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $<span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zOOeNanEtQna" title="Purchase committment"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact001048" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million of the Company&#8217;s common stock,
par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zHrjprwA7De7" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-11-03_custom_RegistrationRightsAgreementMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share subject to certain limitations and satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $<span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zs6V54OtPzKd" title="Purchase committment"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact001052" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million of the Company&#8217;s common stock (the &#8220;Purchase Shares&#8221;).
However, such sales of common stock by the Company, if any, will be subject to important limitations set forth in the Purchase Agreement,
including limitations on number of shares that may be sold. Sales may occur from time to time, at the Company&#8217;s sole discretion,
over the 24-month period commencing on the date that the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase
Agreement are satisfied, including that a registration statement on Form S-1 covering the resale of the shares of our common stock that
have been and may be issued to Lincoln Park under the Purchase Agreement, which the Company has filed with the SEC pursuant to the Registration
Rights Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that
we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased
from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under
the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Equity Line or the Distribution Agreement.
The Company had capitalized deferred offering costs of $<span id="xdx_900_eus-gaap--DeferredOfferingCosts_iI_c20231231_zzLsnq1k5kij" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to establishing the Distribution Agreement
with Canaccord and the Purchase Agreement with Lincoln Park and no reductions to additional paid in capital. Of this amount, $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zr7r0FupoKy4" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,107</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">represents the fair value of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu4IDflEHz83" title="Fair value of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,294</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock issued to Lincoln
Park as consideration for its commitment under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Activity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023 a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zACfXzyGDWkb" title="Issuance of common shares in exchange for RSU conversions, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,910</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock were issued pursuant
to the conversion of restricted stock units. During the year ended December 31, 2022, a total of <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRxGHF4fDd91" title="Stock issued during period conversion of restricted stock award"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001062" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSeZCmLWDOGi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock were issued pursuant
to the conversion of restricted stock awards and restricted stock units, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company completed a public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziLd9Ejzode" title="Public offering"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-132022-02-15_us-gaap_IPOMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock and warrants to purchase
up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvMzmDEx4K17" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-15_us-gaap_IPOMember" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock for gross proceeds
of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z0hwt17EQEm2" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-02-132022-02-15_us-gaap_IPOMember" id="Fact001069" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting underwriting discounts
and commissions and other offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In
addition, Enveric granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcNqcSOye8fd" title="Additional shares of common stock purchase"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock and/or warrants to
purchase up to an additional <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zCXdezGPOPNl" title="Additional warrants purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-15_custom_UnderwritersMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock at the public offering
price, which the underwriter has partially exercised for warrants to purchase up to <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zF8kINnpLKRa" title="Exercised of warrants"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock. At closing, Enveric
received net proceeds from the offering of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zewrKhoDQgqb" title="Net proceeds from offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001077" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">9.1</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting underwriting discounts
and commissions and estimated offering expenses with $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z5M5uVBLR4rc" title="Offering expenses"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-02-15_custom_UnderwritersMember" id="Fact001079" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.8</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million allocated to equity, $<span id="xdx_907_ecustom--WarrantLiability_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z4AGZErBfTh6" title="Warrant liability"><ix:nonFraction name="ENVB:WarrantLiability" contextRef="AsOf2022-02-15_custom_UnderwritersMember" id="Fact001081" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to warrant liability and the remaining
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zjsSpSAPZmB1" title="Warrant expenses"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-02-132022-02-15_custom_UnderwritersMember" id="Fact001083" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company entered into a securities purchase agreement (the &#8220;Registered Direct Securities Purchase Agreement&#8221;)
with an institutional investor for the purchase and sale of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zO4AWf4MoaB9" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,766</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of the Company&#8217;s common stock,
pre-funded warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zBOqd5rgJ8h7" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,234</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock (the &#8220;RD Pre-Funded
Warrants&#8221;), and unregistered preferred investment options (the &#8220;RD Preferred Investment Options&#8221;) to purchase up to
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z8ztx6I6PEH" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock (the &#8220;RD Offering&#8221;).
The gross proceeds from the RD Offering were approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zeqlBU6CU5x8" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Subject to certain ownership limitations, the RD Pre-Funded Warrants became immediately exercisable at an exercise price equal to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zOtc0w6DyGY7" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0015</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> per share of common stock. On August 3, 2022,
all of the issued RD Pre-Funded Warrants were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#8220;PIPE Securities Purchase Agreement&#8221;)
with institutional investors for the purchase and sale of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_z0hXcaMlX7A4" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,734</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock, pre-funded warrants
to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zEjVcBB2ZAOl" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">33,933</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock (the &#8220;PIPE Pre-Funded
Warrants&#8221;), and preferred investment options (the &#8220;PIPE Preferred Investment Options&#8221;) to purchase up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zGhgi9jt7qq4" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of the common stock in a private placement
(the &#8220;PIPE Offering&#8221;). The gross proceeds from the PIPE Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_ztr23wWg2MJ3" title="Proceeds from issuance of warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Subject to certain ownership limitations, the PIPE Pre-Funded Warrants became immediately exercisable at an exercise price equal to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_z7Bx9J4w0Ahc" title="Share price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001103" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0015</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> per share of common stock. All of the issued
PIPE Pre-Funded Warrants were exercised on various dates prior to August 18, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RD Offering and PIPE Offering closed on July 26, 2022, with aggregate gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_pn6n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zFQmF58p6Dzl" title="Proceeds from RD offerings"><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001105" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million. The aggregate net proceeds
from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately $<span id="xdx_90B_ecustom--PaymentsOfStockIssuanceCost_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z5dRaFT5l3X6" title="Offerings costs"><ix:nonFraction name="ENVB:PaymentsOfStockIssuanceCost" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001107" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.1</ix:nonFraction></span> million,
with $<span id="xdx_90F_ecustom--PaymentsOfAllocatedEquity_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zZXV846aCuJc" title="Payments of allocated equity"><ix:nonFraction name="ENVB:PaymentsOfAllocatedEquity" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001109" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million allocated to equity, $<span id="xdx_904_ecustom--PaymentsOfInvestmentOptionLiability_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zNzhNf9F6Ud4" title="Payments of investment option liability"><ix:nonFraction name="ENVB:PaymentsOfInvestmentOptionLiability" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001111" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million to investment option liability, and the remaining $<span id="xdx_90E_ecustom--PaymentsOfStockIssuanceCostsRecordedExpense_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z4z8FpJlJbme" title="Payments of stock issuance costs recorded expense"><ix:nonFraction name="ENVB:PaymentsOfStockIssuanceCostsRecordedExpense" contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001113" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to 2020 Long-Term Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, our board of directors (&#8220;Board&#8221;) adopted the First Amendment (the &#8220;Plan Amendment&#8221;) to the Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan (the &#8220;Incentive Plan&#8221;) to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220502__20220503_zFYY00235oD8" title="Incentive plan description"><ix:nonNumeric contextRef="From2022-05-022022-05-03" id="Fact001115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">(i)
increase the aggregate number of shares available for the grant of awards by 9,739 shares to a total of 13,334 shares,
and (ii) add an &#8220;evergreen&#8221; provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive
Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of common
stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company&#8217;s common stock
authorized for issuance under the Incentive Plan will equal the greater of (x) 13,334 shares, and (y) 15% of the total number
of shares of the Company&#8217;s common stock outstanding as of such issuance date (the &#8220;Evergreen Provision&#8221;). The Plan
Amendment was approved by the Company&#8217;s shareholders at a special meeting of the Company&#8217;s shareholders held on July 14,
2022.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2023, the shareholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#8220;Amended Incentive Plan&#8221;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zKM0879PVxa5" title="Authorized shares reserved"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember" id="Fact001117" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,334</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to adjustment, and (ii) removed the Evergreen
Provision implemented in the Plan Amendment. As of December 31, 2023, the total number of shares available for grant under the Incentive
Plan was <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zfjoMgdI7OF" title="Shares available of grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,164</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001121" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zu3hZq6igFI4" style="display: none">SCHEDULE OF STOCK OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" title="Number of Shares, Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="Fact001123" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,589</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" title="Weighted Average Exercise Price, Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,185</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" title="Weighted Average Grant Date Fair Value, Outstanding at beginning" style="width: 9%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31" id="Fact001127" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,552.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" id="Fact001129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.3</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" title="Aggregate Intrinsic Value, Outstanding" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" id="Fact001131" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" title="Number of Shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31" id="Fact001133" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="Fact001135" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.05</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31" id="Fact001137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.70</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"><span></span></p>
                                                                          <p style="margin-top: 0; margin-bottom: 0"><span>&#160;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" title="Number of shares, forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31" id="Fact001139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" title="Weighted average exercise price, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" title="Weighted average grant date fair value, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,107.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" title="Number of Shares, Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" title="Weighted Average Exercise Price, Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact001147" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">555.75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" title="Weighted Average Grant Date Fair Value, Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31" id="Fact001149" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">672.30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" title="Number of Shares, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" title="Weighted Average Exercise Price, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1155">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" title="Number of shares, forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-012023-12-31" id="Fact001157" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" title="Weighted average exercise price, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31" id="Fact001159" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.05</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" title="Weighted average grant date fair value, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31" id="Fact001161" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" title="Number of Shares, Outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" title="Weighted Average Exercise Price, Outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001165" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">857.55</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" title="Weighted Average Grant Date Fair Value, Outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact001167" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,158.30</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001169" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.4</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" title="Exercisable shares at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-12-31" id="Fact001171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,712</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" title="Exercisable weighted average price at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">966.75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" title="Weighted average grant date fair value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact001175" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,330.80</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact001177" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zXYm0PO3CNlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001179" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zR9P2uQxAng7" style="display: none">SCHEDULE OF STOCK OPTION ASSUMPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001181" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_z0OXoTSTaL7h" title="Stock price"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" contextRef="AsOf2022-12-31" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.05</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-12-31" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.05</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" id="Fact001187" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2022-01-012022-12-31" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">112.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zSkXtPvxBb04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above assumptions are determined by the Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    price &#8211; Based on closing price of the Company&#8217;s common stock on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average risk-free interest rate &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which
    correspond to the expected term of the Company&#8217;s stock options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield &#8212; The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends
    on its common stock in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8212; Based on the historical volatility of comparable companies in a similar industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8212; The Company has had no stock options exercised since inception. The expected option term represents the period that
    stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#8220;SAB&#8221;)
    No. 107, Share-Based Payment, which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain
    vanilla&#8221; share options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock based compensation expense, recorded within general and administrative expense, related to stock options for the
years ended December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt08RojEH0Xh" title="General and administrative expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001193" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,075</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXVmi6fVuBdb" title="General and administrative expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001195" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">180,042</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za7OVdVnQO29" title="Unamortized stock option expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,774</ix:nonFraction></span> in unamortized stock option expense, which will be recognized over a weighted average period
of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN1HXhFc7nl6"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001198" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.00</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoynQV9JMUSl" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact001200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWmTrUjkTZp7" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember" id="Fact001202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,363</ix:nonFraction></span>, respectively, in stock-based compensation expense within
general and administrative expense, related to restricted stock awards. There were no RSA grants during the years ended December 31,
2023 and 2022. As of December 31, 2022, there were no unvested RSA shares. As of December 31, 2023, there were no unamortized stock-based
compensation costs related to restricted share awards. During the year ended December 31, 2023 the Company settled the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1bnkYOkliK7" title="Common stock , shares issued restricted stock awards"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48</ix:nonFraction></span> vested and
unissued shares (as of December 31, 2022) for cash of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLFTi9qtv6r6" title="Unissued shares for cash"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember" id="Fact001206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,250</ix:nonFraction></span>. There are <span id="xdx_904_ecustom--NumberOfVestedAndUnissuedShares_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfYgm2OkyJOl" title="Number of vested and unissued shares"><ix:nonFraction name="ENVB:NumberOfVestedAndUnissuedShares" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember" id="Fact001208" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> restricted stock awards as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Restricted Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001210" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zOnUfbNkVcx6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" title="Number of shares, Non-vested beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001212" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,135</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" title="Weighted average fair value, Non-vested beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" title="Weighted average fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001218" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">502.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" title="Number of shares, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,785</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" title="Weighted average fair value, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,194.60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" title="Number of shares, Vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">576</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" title="Weighted average fair value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001226" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,958.25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-vested at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" title="Number of shares, Non-vested beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" title="Weighted average fair value, Non-vested beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001230" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,388.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" title="Weighted average fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.95</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" title="Number of shares, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001236" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,896</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" title="Weighted average fair value, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">385.80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" title="Number of shares, vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" title="Weighted average fair value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">297.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" title="Number of shares, non-vested ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,366</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" title="Weighted average fair value, Non-vested ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">434.55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zBLyP5ujOgX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP10g2JH0QCe" title="Stock based compensation, expenses"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,994,085</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1WqVEZEw91j" title="Stock based compensation, expenses"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,266</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the consolidated statement of operations and comprehensive loss. As of December 31, 2023, the
Company had unamortized stock-based compensation costs related to restricted stock units of $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqhi2IvwBlqe" title="Stock-based compensation, unamortized"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,021,021</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will be recognized over a weighted average
period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2g7eZ22vSdd" title="Weighted average period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact001254" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.9</ix:nonNumeric></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and unamortized stock-based costs related
to restricted stock units which will be recognized upon achievement of specified milestones. As of December 31, 2023, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkUMlznJm2Kf" title="Common stock vested restricted stock units"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember" id="Fact001256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,390</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> restricted stock units are vested without
shares of common stock being issued, with all of these shares due as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001258" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zwVhDWsRp68h" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense for RSUs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,085,791</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,389,359</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">908,294</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact001264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,907</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact001266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,994,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" id="Fact001267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact001269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,994,085</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" id="Fact001270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,416,266</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zs23cTYn7Nd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
and Preferred Investment Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001272" name="ENVB:ScheduleOfWarrantsOutstandingTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" title="Warrant shares outstanding at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,031</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" title="Weighted average exercise Price, Outstanding at beginning" style="width: 11%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001276" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,965</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001278" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">3.4</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" title="Intrinsic Value, Outstanding beginning" style="width: 11%; text-align: right"><ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="Fact001280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">801,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFVujb1NhHh3" title="Warrant shares outstanding, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,834</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" title="Weighted average exercise price, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001284" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">154.65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" title="Warrant shares outstanding, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact001286" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,167</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged for common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBqLrW0x4Do" title="Exchanged for common stock" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" title="Warrant shares outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001290" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">43,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" title="Weighted average exercise Price, Outstanding at beginning" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001292" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">875.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001294" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">3.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" title="Intrinsic Value, Outstanding beginning" style="text-align: right"><ix:nonFraction name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact001296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,514</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI6yD0x3nmf" title="Warrant shares outstanding, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001298" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" title="Weighted average exercise price, Issued" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001300" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" title="Warrant shares outstanding, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" title="Weighted average exercise price, Exercised" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001304" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" title="Warrant shares outstanding, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001306" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,038</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPOuapURS518" title="Weighted average exercise price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact001308" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,672.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" title="Warrant shares outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" title="Weighted average exercise Price, Outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">176.85</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001314" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">4.6</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" title="Warrant shares outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,614</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" title="Weighted average exercise price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact001318" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">176.85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001320" name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">4.6</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" title="Intrinsic Value, Outstanding end" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zPsrElVeMZDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with A.G.P./Alliance
Global Partners (the &#8220;Underwriter&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell, in a firm commitment
offering, <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk3cRDFyl4Qk" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember" id="Fact001324" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,667</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
and accompanying warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd3bmfwqk333" title="Warrant exercises, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-02-11_us-gaap_WarrantMember" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,667</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock (&#8220;February
2022 Warrants&#8221;), as well as up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTzehTdxsXYj" title="Additional shares of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember" id="Fact001328" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional shares of common stock and/or
warrants to purchase an aggregate of up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z16mZQonqCC3" title="Warrant exercises, shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock that may be purchased
by the Underwriter pursuant to a 45-day option granted to the Underwriter by the Company (the &#8220;Offering&#8221;). Each share of
common stock was sold together with a common warrant to purchase one share of common stock, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIUneReLK98l" title="Warrant, exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-11_us-gaap_CommonStockMember" id="Fact001332" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">412.50</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Such common warrants were immediately
exercisable and will expire five years from the date of issuance. There is not expected to be any trading market for the common warrants
issued in the Offering. The combined public offering price of each share of common stock and accompanying common warrant sold in the
Offering was $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6xkgupOvnki" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-02-11_us-gaap_WarrantMember" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">375.00</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2022, the Underwriter exercised
its option to purchase an additional <span id="xdx_904_ecustom--ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_iI_c20220214__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJKKouHOOFm9" title="Purchase of additional warrants"><ix:nonFraction name="ENVB:ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-02-14_us-gaap_WarrantMember" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,000</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct (&#8220;RD&#8221;) Offering and the Private Investment in Public Entity (&#8220;PIPE&#8221;) Offering
entered into on July 22, 2022, the Company entered into Warrant Amendment (the &#8220;Warrant Amendments&#8221;) with the investors in
both offerings to amend certain existing warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zAjZ7cTA5rXl" title="Purchase of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,134</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that were previously
issued to the investors, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zvxqzNAYpZI" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember" id="Fact001340" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">412.50</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and expiration date of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zb4ECxOC8eU1" title="Warrant expiration"><ix:nonNumeric contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember" format="ixt:datemonthdayyearen" id="Fact001342" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">February
15, 2027</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Pursuant to the Warrant Amendments,
the previously issued warrants were amended, effective upon the closing of the offerings, so that the amended warrants have a reduced
exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBMhaY1KHxhg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember" id="Fact001344" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and expire five and one-half years
following the closing of the offerings. In connection with this transaction, the Company determined the fair value of the February 2022
Warrants immediately prior to the Warrant Amendment and the fair value of the amended warrants immediately after the Warrant Amendment.
For the year ended December 31, 2022, the incremental change in fair value was deemed to be $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zAcOFLnqEyCl" title="Offerings costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember" id="Fact001346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,357</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was included as equity issuance costs related to the RD and PIPE financing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February
2022 and July 2022 public offerings, that would require adjustment to the exercise price upon certain events when the offering price
is less than the stated exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001348" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zXmcUZK6ggX1" style="display: none">SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" title="Investment options Outstanding, beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zGMM0alY6k46" title="Weighted average exercise price, Outstanding beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" title="Intrinsic value, Outstanding beginning" style="text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; padding-bottom: 1.5pt">Issued</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" title="Investment options outstanding, Issued" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,334</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" title="Weighted average exercise price, Issued" style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember" id="Fact001358" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">118.95</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" title="Investment options outstanding, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember" id="Fact001360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" title="Weighted average exercise price, Outstanding beginning" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember" id="Fact001362" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">118.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001364" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">5.1</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" title="Intrinsic value, Outstanding beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1366">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" title="Investment options outstanding, Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" id="Fact001368" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">66,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zYmM8O9U70xg" title="Weighted average exercise price, Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" title="Investment options outstanding, end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001372" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" title="Weighted average exercise price, Outstanding end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001374" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001376" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" title="Intrinsic value, Outstanding end" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1378">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" title="Investment options outstanding, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001380" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" title="Weighted average exercise price, Outstanding end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact001382" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001384" name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">4.1</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zgN7qwVdAb5k" title="Intrinsic value, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zN7RQXnULVth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase
up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zSsrXPUEdiaa" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001388" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. Subject to certain
ownership limitations, the RD Preferred Investment Options became immediately exercisable at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z1uqcDaW7qh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember" id="Fact001390" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock. The RD Preferred
Investment Options are exercisable for five and one-half years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase up to
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zRwQ2nOsp9Nf" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001392" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the common stock. Subject to certain
ownership limitations, PIPE Preferred Investment Options became immediately exercisable at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zkaJQixeHNN1" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember" id="Fact001394" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock. The PIPE Preferred
Investment Options are exercisable for five and one-half years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2022, in connection with the RD Offering and PIPE Offering, the Company issued preferred investment options (the &#8220;Placement
Agent Preferred Investment Options&#8221;) to an entity to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220725__20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zd3qnd5iCLyd" title="Purchase of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the common stock for acting as
a placement agent. The Placement Agent Preferred Investment Options have substantially the same terms as the RD Preferred Investment
Options and the PIPE Preferred Investments Options, except the Placement Agent Preferred Investment Options have an exercise price of
$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z5L1L63tFikl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember" id="Fact001398" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Placement Agent Preferred
Investment Options are exercisable for five years from the date of the commencement of the RD Offering and PIPE Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with certain
holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment options to purchase
shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant to which the Holders
agreed to exercise for cash their Existing Warrants and Investment Options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zaKTUOZ2VM1f"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember" id="Fact001399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,800</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
in the aggregate, at a reduced exercised price of $<span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zmvD3OtwCWOc"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (from an original exercise price
of $<span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_z331mhMbpsH9"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share), in exchange for the Company&#8217;s
agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zBLXrJDQsa73"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,600</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
(the &#8220;Inducement Warrant Shares&#8221;), and the Holders to make a cash payment of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zczxnQc98rf6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember" id="Fact001403" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Inducement Warrant share for total proceeds
of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zcyzU36Ekmw8"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember" id="Fact001404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,500</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In January 2024, the Company received aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4oN8knfD0g8"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember" id="Fact001405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the exercise of the Existing Warrants and
Investment Options by the Holders and the sale of the Inducement Warrants. Because the Existing Warrants and Investment Options by the
Holders and the sale of the Inducement Warrants that exercised on December 28, 2023 and unsettled until January 2024, the proceeds are
included in the consolidated balance sheet as a subscription receivable as of December 31, 2023. As of December 31, 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU9SOH6jFOVg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,867</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were considered issued as the Company had the enforceable right to the obtain the cash proceeds, which were in-transit,
and the Holders were no longer able to rescind the exercise election. Due to the beneficial ownership limitation provisions, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zxGL0O0hxkrd"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_custom_FebruaryWarrantsMember" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder
that the shares may be issued in compliance with such limitation. <span id="xdx_904_ecustom--ClassOfWarrantOrRightReasonForIssuing_c20230101__20231231_zcAzUmhlaRN9"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact001408" name="ENVB:ClassOfWarrantOrRightReasonForIssuing">The
Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its financial advisor in connection with the transactions summarized
above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth was also issued
warrants to purchase up to 4,488 shares of common stock. The Roth Warrants have the same terms as the Inducement Warrants. The
grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to additional paid in
capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that were charged to additional
paid in capital as issuance costs.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares issued or issuable
upon the exercise of the Inducement Warrants (the &#8220;Resale Registration Statement&#8221;) by January 8, 2024 (filed January 11,
2024). In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any
other registration statement with the SEC (in each case, subject to certain exceptions) for a period ending on February 26, 2024. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until December
28, 2024. See the <i>Equity Distribution Agreement</i> section of this Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company determined the fair value of the Existing Warrants and Investment Options immediately prior
to the Inducement Letters and the fair value of the amended warrants and investment options immediately after the Inducement Letters.
The pre-modification measurement of fair value of the Existing Warrants and Investment Options were determined utilizing a Black-Scholes
model considering all relevant assumptions current at the date of modification (i.e. for the Existing Warrants share price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zCbGm8EEY1V3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001409" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.40</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price of $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z4tKTV7UOUG6"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">116.70</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zooxgXjsrNd2"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" format="ixt-sec:duryear" id="Fact001411" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.6</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, volatility of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zofY1yo9JWoe"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">94</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
risk-free rate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zcquYR7c56k4"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.96</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and expected dividend rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zokkfbNVJfv7"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember" id="Fact001414" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
resulting in a fair value per share of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zLgHJhiJMRBd"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and for the Investment Options share price
of $<span id="xdx_903_ecustom--InvestmentOptionSharePrice_iI_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zwBfp0BZQ80c"><ix:nonFraction name="ENVB:InvestmentOptionSharePrice" contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember" id="Fact001416" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23.40</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price of $<span id="xdx_900_ecustom--InvestmentOptionExercisePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zKcskuubDUpd"><ix:nonFraction name="ENVB:InvestmentOptionExercisePrice" contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember" id="Fact001417" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">term of <span id="xdx_903_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zU0nvYB2zE2k"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember" format="ixt-sec:duryear" id="Fact001418" name="ENVB:InvestmentOptionTerm">4.1</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, volatility of <span id="xdx_905_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zH70FMRqgzUb"><ix:nonFraction name="ENVB:InvestmentOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember" id="Fact001419" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">95</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
risk-free rate of <span id="xdx_90F_ecustom--InvestmentOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zTPQDN37G1rc"><ix:nonFraction name="ENVB:InvestmentOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.90</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and expected dividend rate of <span id="xdx_90A_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z8myANWwAgc6"><ix:nonFraction name="ENVB:InvestmentOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember" id="Fact001421" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
resulting in a fair value per share of $<span id="xdx_90F_ecustom--SharePriceOption_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zp1NydJ78A0g"><ix:nonFraction name="ENVB:SharePriceOption" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember" id="Fact001422" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.30</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total fair value of the <span id="xdx_90A_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zzX9YHTJMqi1"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember" id="Fact001423" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,134</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Warrants and <span id="xdx_909_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zQDt29TH03gd"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,667</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Options was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zq7HEdNl3oQb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember" id="Fact001425" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">65,349</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zUn4gcd9lAw1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">618,648</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. The post-modification fair value was determined using the intrinsic value of $<span id="xdx_909_ecustom--InvestmentIntrinsicValue_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zu7RNJpEOLU9"><ix:nonFraction name="ENVB:InvestmentIntrinsicValue" contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember" id="Fact001427" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due to the inducement and totaled $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zNlOcIN0WNE1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember" id="Fact001428" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">23,180</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zC7xL300AYW4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember" id="Fact001429" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">190,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the Existing Warrants and Investment Options,
respectively. The change in fair value from the date of the modification prior to modification and the fair value on the date of the
modification after the modification, but prior to exercise was $<span id="xdx_907_ecustom--InvestmentInducementGain_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zwUDTSOh5Wb"><ix:nonFraction name="ENVB:InvestmentInducementGain" contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember" id="Fact001430" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">470,817</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was reflected as an inducement gain, within other expenses on the Company&#8217;s consolidated statement of operations and comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant date fair value of these Inducement Warrants was estimated to be $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20231228__20231228_z2x1EoMCFBJl"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-12-282023-12-28" id="Fact001431" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,599,552</ix:nonFraction></span> on December 28, 2023 and the proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228_zJIFuTKtruIl"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-12-282023-12-28" id="Fact001432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,500</ix:nonFraction></span>,
which were received on January 2, 2024, for the issuance of the Inducement Warrants is reflected as inducement expense, within other
expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001434" name="ENVB:ScheduleOfValuationOfWarrantsTextBlock"><p id="xdx_899_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zKA67bcbOmMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zy2L3wh6IEsj" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Roth and Inducement Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 28, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)"><ix:nonNumeric contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" format="ixt-sec:duryear" id="Fact001436" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z3AuGTsHI5pl" title="Stock price"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001438" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.40</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z0UvQEgSl08f" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001442" format="ixt:zerodash" decimals="INF" scale="-2" unitRef="Pure">&#8212;</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.80</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zGfIo4VzY1I" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">17.40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zXHJwPy7aNrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
C Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, the Board of Directors (the &#8220;Board&#8221;) declared a dividend of one one-thousandth of a share of the Company&#8217;s
Series C Preferred Stock (&#8220;Series C Preferred Stock&#8221;) for each outstanding share of the Company&#8217;s common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022 (the &#8220;Record Date&#8221;). This dividend
was based on the number of outstanding shares of common stock prior to the Reverse Stock Split. The outstanding shares of Series C Preferred
Stock were entitled to vote together with the outstanding shares of the Company&#8217;s common stock, as a single class, exclusively
with respect to a proposal giving the Board the authority, as it determines appropriate, to implement a reverse stock split within twelve
months following the approval of such proposal by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split Proposal&#8221;),
as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split Proposal (the
&#8220;Adjournment Proposal&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders on July 14, 2022 (the &#8220;Special Meeting&#8221;) for the purpose of voting on, among
other proposals, a Reverse Stock Split Proposal and an Adjournment Proposal. All shares of Series C Preferred Stock that were not present
in person or by proxy at the Special Meeting were automatically redeemed by the Company immediately prior to the opening of the polls
at Special Meeting (the &#8220;Initial Redemption&#8221;). All shares that were not redeemed pursuant to the Initial Redemption were
redeemed automatically upon the approval by the Company&#8217;s stockholders of the Reverse Stock Split Proposal at the Special Meeting
(the &#8220;Subsequent Redemption&#8221; and, together with the Initial Redemption, the &#8220;Redemption&#8221;). <span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5dqYDZjASmi" title="Preferred stock voting rights"><ix:nonNumeric contextRef="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember" id="Fact001452" name="us-gaap:PreferredStockVotingRights">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were</ix:nonNumeric></span> <span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUuJvhOW6s9" title="Redeemable preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,684.548</ix:nonFraction></span> shares of Series C Preferred Stock issued and outstanding. As of December 31,
2022, both the Initial Redemption and the Subsequent Redemption had occurred. As a result, no shares of Series C Preferred Stock remain
outstanding. As of December 31, 2023 and 2022, there are <span id="xdx_90E_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjdiSzO1vp5b" title="Preferred Stock authorized for future issuances"><ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of Series C Preferred Stock authorized for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001458" name="ENVB:RedeemableNonControllingInterestTextBlock"><p id="xdx_80E_ecustom--RedeemableNonControllingInterestTextBlock_zcwkISFrpcJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_820_zpC01KA801s3">REDEEMABLE NON-CONTROLLING INTEREST</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Spin-Off
and Related Private Placement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Spin-Off, on May 5, 2022, Akos and the Company entered into into a Securities Purchase Agreement (the &#8220;Akos
Purchase Agreement&#8221;) with an accredited investor (the &#8220;Akos Investor&#8221;), pursuant to which Akos agreed to sell up to
an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcoQUJHN90ug" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact001460" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares of Akos Series A Preferred Stock, at price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWiC0QAHltf9" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per share, and warrants (the &#8220;Akos Warrants&#8221;)
to purchase shares of Akos&#8217; common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_ziqdyNm1proh" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001464" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (the &#8220;Akos Common Stock&#8221;), for an aggregate purchase
price of up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zewKu8BntBy9" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember" id="Fact001466" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> (the &#8220;Akos Private Placement&#8221;). The Akos Purchase Agreement was guaranteed by the Company. Pursuant
to the Akos Purchase Agreement, Akos issued <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG8bfr259E7" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember" id="Fact001468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></span> shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7nhFd17DNtk" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember" id="Fact001470" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000,000</ix:nonFraction></span>
on May 5, 2022. The additional $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zxgML5QugCI7" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001472" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></span> was to be received on or immediately prior to the Spin-Off. The issuance of the Akos Series
A Preferred Stock results in RNCI (see Note 2). Palladium Capital Advisors, LLC (&#8220;Palladium&#8221;) acted as placement agent for
the Akos Private Placement. <span id="xdx_901_ecustom--SpinoffAndRelatedPrivatePlacementDescription_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zux8vYKBzXke" title="Spin-off and related private placement, description"><ix:nonNumeric contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001474" name="ENVB:SpinoffAndRelatedPrivatePlacementDescription">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.</ix:nonNumeric></span> Palladium was also entitled to warrants to purchase Akos Common Stock in an amount
up to <span id="xdx_907_ecustom--WarrantsToPurchaseCommonStockPercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_z4zdKBKSkhG2" title="Warrants to purchase common stock, percentage"><ix:nonFraction name="ENVB:WarrantsToPurchaseCommonStockPercentage" contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember" id="Fact001476" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% of the number of shares of Akos Common Stock underlying the shares issuable upon conversion of the Akos Series A Preferred Stock.
As of December 31, 2023, no accruals are required to be recorded for the fees or warrants since the Akos Series A Preferred Stock has
been redeemed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Terms
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Certificate of the Designations, Preferences, and Rights of Series A Convertible Preferred Stock of Akos (the &#8220;Akos Series
A Preferred Certificate of Designations&#8221;), on or immediately prior to the completion of the spin-off of Akos into an independent,
separately traded public company listed on the Nasdaq Stock Market, the outstanding Akos Series A Preferred Stock automatically converted
into a number of shares of Akos Common Stock equal to <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zgm4sLjh8SB5" title="Percentage of stock issued and outstanding"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember" id="Fact001478" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% of the then issued and outstanding Akos Common Stock, subject to the Beneficial
Ownership Limitation (as defined in the Akos Purchase Agreement). Cumulative dividends on each share of Akos Series A Preferred Stock
accrue at the rate of <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zqfJDBLNLuU3" title="Dividend rate"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember" id="Fact001480" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations provided that upon the earlier of (i) the one-year anniversary of May 5, 2022, and
only in the event that the Spin-Off has not occurred; or (ii) such time that Akos and the Company have abandoned the Spin-Off or the
Company is no longer pursuing the Spin-Off in good faith, the holders of the Akos Series A Preferred Stock shall have the right (the
&#8220;Put Right&#8221;), but not the obligation, to cause Akos to purchase all or a portion of the Akos Series A Preferred Stock for
a purchase price equal to $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znidGcp5SmHb" title="Sale of stock, price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember" id="Fact001482" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per share, subject to certain adjustments as set forth in the Akos Series A Preferred Certificate of
Designations (the &#8220;Stated Value&#8221;), plus all the accrued but unpaid dividends per share. In addition, after the one-year anniversary
of May 5, 2022, and only in the event that the Spin-Off has not occurred and Akos is not in material default of any of the transaction
documents, Akos may, at its option, at any time and from time to time, redeem the outstanding shares of Akos Series A Preferred Stock,
in whole or in part, for a purchase price equal to the aggregate Stated Value of the shares of Akos Series A Preferred Stock being redeemed
and the accrued and unpaid dividends on such shares. Pursuant to the Akos Purchase Agreement, the Company has guaranteed the payment
of the purchase price for the shares purchased under the Put Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of Akos
Common Stock upon conversion of the Akos Series A Preferred Stock that would result in the number of shares of Akos Common Stock beneficially
owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Akos Common Stock outstanding immediately after
giving effect to the conversion (the &#8220;Beneficial Ownership Limitation&#8221;), except that upon notice from the holder to Akos,
the holder may increase or decrease the limit of the amount of ownership of outstanding shares of Akos Common Stock after converting
the holder&#8217;s shares of Akos Series A Preferred Stock, provided that any change in the Beneficial Ownership Limitation shall not
be effective until 61 days following notice to Akos.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $<span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztQh1TbMgLA2" title="Dividends, per share"><ix:nonFraction name="us-gaap:DividendsPayableAmountPerShare" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001484" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span>&#8239;per share, plus accrued
but unpaid dividends of approximately $<span id="xdx_90A_ecustom--UnpaidDividends_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGXioCLHfE1e" title="Unpaid dividends"><ix:nonFraction name="ENVB:UnpaidDividends" contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,000</ix:nonFraction></span>&#8239;for a total of approximately $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdtM4nK5oH7j" title="Dividends"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,000</ix:nonFraction></span>. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023. Upon redemption in May 2023, the Company revalued the
derivative liability and the Company recognized a change in fair value of the derivative liability on the Company&#8217;s consolidated
statement of operations during the second quarter of 2023 of $<span id="xdx_90D_ecustom--FairValueOfDerivativeLiability_c20230101__20230630_zkgTWFy1WwJj" title="Change in fair value of derivative liability"><ix:nonFraction name="ENVB:FairValueOfDerivativeLiability" contextRef="From2023-01-012023-06-30" id="Fact001490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">714,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, Akos, and the Akos Investor have terminated the Akos Purchase Agreement in connection with the planned Spin-Off and certain
registration rights agreement in connection with the Akos Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
for Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the shares of Akos Series A Preferred Stock were redeemable at the option of the holder and the redemption is not solely in the control
of the Company, the shares of Akos Series A Preferred Stock were accounted for as a redeemable non-controlling interest and classified
within mezzanine equity in the Company&#8217;s consolidated balance sheets. The redeemable non-controlling interest was initially measured
at fair value. Dividends on the shares of Akos Series A Preferred Stock were recognized as preferred dividends attributable to redeemable
non-controlling interest in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001492" name="us-gaap:TemporaryEquityTableTextBlock"><p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the reconciliation of changes in redeemable non-controlling interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zjoodKpMYtk6" style="display: none">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" title="Beginning balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="AsOf2022-12-31" id="Fact001494" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" title="Issuance of redeemable noncontrolling Series C preferred stock" style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31" id="Fact001496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" title="Accretion of embedded derivative to redemption value" style="text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValue" contextRef="From2023-01-012023-12-31" id="Fact001498" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redemption of Akos Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" title="Redemption of Akos Series A Preferred Stock" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-012023-12-31" id="Fact001500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_z5hvmzlTgjq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Akos Series A Preferred Stock was redeemed for a total of <span id="xdx_900_ecustom--RedeemableNoncontrollingInterest_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMwz0KsNsOXa" title="Redeemable noncontrolling interest"><ix:nonFraction name="ENVB:RedeemableNoncontrollingInterest" contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></span>, and the balance of the redeemable non-controlling
interest is $<span id="xdx_902_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iI_dxL_c20231231_zAeOWuDFnGDk" title="Redeemable non-controlling interest::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1506">0</span></span> as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001508" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zzc4DQdOVCk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82E_zsrUTbzuipf3">FAIR VALUE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001510" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none">SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeMO13hylIPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Warrant liabilities - January 2021 Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTOpwQ8OG55f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant liabilities - February 2021 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001515" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwTQbM3dQLe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrant liabilities - February 2022 Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9i5VrFNGzB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,215</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zMdkWlrsIj62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-bottom: 1.5pt">Derivative liability - May 2022</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 10%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1524">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember" id="Fact001525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEFcbOFbmgyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zSWqu8SwspQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Wainwright investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember" id="Fact001530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember" id="Fact001531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,904</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zWIcJvLDtsLe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RD investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1533">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember" id="Fact001534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z1YCCLCqkbX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PIPE investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember" id="Fact001537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">503,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziutXKvlcfW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of investment option liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">851,008</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zlaHAKR4Y6A2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities, derivative liability, and investment options are all classified as Level 3, for which there is no current market
for these securities such as the determination of fair value requires significant judgment or estimation. Changes in fair value measurement
categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded
within other income (expense) on the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InitialMeasurementMember" escape="true" id="Fact001542" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BA_zyGP5uMpiwf9" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Post-Modification Warrants (See Note 7)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 15, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zVPjfhQ1hMA5" title="Warrants term"><ix:nonNumeric contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001544" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_z7auqGCNbdGa" title="Warrants term"><ix:nonNumeric contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" format="ixt-sec:duryear" id="Fact001546" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" title="Warrants, stock price" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001548" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">236.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" title="Warrants, stock price" style="text-align: right"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001550" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">94.95</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" title="Warrants, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001552" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">412.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" title="Warrants, exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1556">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1558">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zIpLsb0r9873" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001560" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">74.1</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zEbPX8XFb5Ej" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001562" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zsu2orPGxhM7" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001564" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">1.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zYZ9cMkF2kc9" title="Warrants, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" title="Warrants, number of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" id="Fact001570" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,134</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001572" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">120.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" id="Fact001574" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.05</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">May 2022 Derivative Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">May 5, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zaAv4G5sSCic" title="Principal" style="width: 23%; text-align: right"><ix:nonFraction name="ENVB:ConvertiblePreferredStockPrincipalValue" contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember" id="Fact001576" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001578" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zfdU1bv2Iu1d" title="Market rate" style="text-align: right"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember" id="Fact001580" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Wainwright Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">RD Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">PIPE Options</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z65GnhDKxrH1"><ix:nonNumeric contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001581" name="ENVB:InvestmentOptionTerm">5.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ"><ix:nonNumeric contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001582" name="ENVB:InvestmentOptionTerm">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg"><ix:nonNumeric contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001583" name="ENVB:InvestmentOptionTerm">5.5</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" title="Investment, stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember" id="Fact001585" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">94.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" title="Investment, stock price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember" id="Fact001587" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">94.95</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" title="Investment, stock price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">94.95</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zjD6zOtXxyef" title="Investment, exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember" id="Fact001591" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" title="Investment, exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember" id="Fact001593" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" title="Investment, exercise price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember" id="Fact001595" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1599">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1601">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember" id="Fact001602" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember" id="Fact001603" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember" id="Fact001604" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">80.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember" id="Fact001605" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember" id="Fact001606" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember" id="Fact001607" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.9</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" title="Number of investment options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember" id="Fact001609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" title="Number of investment options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember" id="Fact001611" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" title="Number of investment options" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember" id="Fact001613" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">41,667</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" title="Value (per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember" id="Fact001615" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" title="Value (per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember" id="Fact001617" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.05</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" title="Value (per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember" id="Fact001619" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.05</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zqJvQKCnT5l7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subsequent
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember" escape="true" id="Fact001621" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zXzjxOoiQ9Qg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zf0YvucZm167" style="display: none">SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Fair value as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" title="Total beginning balance" style="width: 23%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001623" format="ixt:numdotdecimal" decimals="0" unitRef="USD">653,674</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of February 2022 warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" title="Issuance of equity" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001625" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,595,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value due to modification of February 2022 warrants as part of July 2022 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" title="Change in fair value, modification" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001627" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,357</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001629" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,315,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" title="Total beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,396</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRprDXlaTIXd" title="Exercise of warrants" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001635" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" title="Total beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" id="Fact001637" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" title="Total beginning balance" style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1639">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%; text-align: left; padding-bottom: 1.5pt">Issuance of May 2022 convertible preferred stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" title="Issuance of equity" style="padding-bottom: 1.5pt; width: 23%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001641" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001643" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">325,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" title="Total beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001645" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member" id="Fact001647" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" title="Total ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Investment Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" title="Total beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%">Issuance of July 2022 investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" title="Issuance of equity" style="width: 23%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001653" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,323,734</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001655" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,472,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" title="Total beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">851,008</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" title="Change in fair value" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001659" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">208,752</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVIt6yDO5kC9" title="Exercise of investment options" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001661" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">618,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of investment option liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" title="Total ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact001663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zTDiFxmrLd74" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember" escape="true" id="Fact001665" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zGwJ3NUryGMb" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 2022 Warrants Unmodified</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zFeN4U2oQbMg" title="Investment option term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember" format="ixt-sec:duryear" id="Fact001667" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.0</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z9qSoxj865ti" title="Investment option term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember" format="ixt-sec:duryear" id="Fact001669" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zHqUQQehlCYb" title="Investment option term"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001671" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.1</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za7OVDZZzYCl" title="Warrant measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001673" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" title="Warrant measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001675" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" title="Warrant measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ENVB:WarrantsAndRightsOutstandingStockPrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001677" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" title="Warrant measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001679" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,712.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" title="Warrant measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001681" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3,675.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" title="Warrant measurement input" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001683" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">412.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1685">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1687">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" title="Warrants, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1689">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001691" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">89.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001693" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">88.0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember" id="Fact001695" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">87.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001697" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.20</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001699" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.20</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" title="Warrants, measurement input" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001701" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" title="Warrants, number of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember" id="Fact001703" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,429</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" title="Warrants, number of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember" id="Fact001705" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,286</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" title="Warrants, number of warrants" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001707" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,534</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember" id="Fact001709" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember" id="Fact001711" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" title="Value (per share)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember" id="Fact001713" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.20</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">H.C. Wainwright &amp; Co., LLC Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2h5WTjUaE" title="Investment option term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" format="ixt-sec:duryear" id="Fact001715" name="ENVB:InvestmentOptionTerm">3.6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" title="Investment, stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001717" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zYJQsZKqOizg" title="Investment, exercise price" style="text-align: right"><ix:nonFraction name="ENVB:StockOptionExercisePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001719" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" title="Investment, measurement input" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1721">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001723" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">94.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input"><ix:nonFraction name="us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001725" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" title="Number of investment options" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001727" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" title="Value (per share)" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember" id="Fact001729" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zrbMv2JczZWj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of the redemption of the of Akos Series A Preferred Stock in May 2023, the derivative liability fair value was $<span id="xdx_905_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBe0f08cNDD6" title="Derivative liability fair value"><ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember" id="Fact001731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> due to the
probability of a spin-off occurring was zero. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001733" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJzHQhc2S99e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_824_zLAtIowfPq7c">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s
financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-373, the Company&#8217;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-373 in coordination with the Company&#8217;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-373. EB-373, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s
Therapeutic Goods Administration (TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total
cost of the Avance Clinical contract is approximately <span id="xdx_902_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zP5GfH9I9BH2" title="Contract cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001735" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,000,000</ix:nonFraction></span> AUD, which translates to approximately $<span id="xdx_905_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zh1rCXdtro0i" title="Contract cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> USD as of December
31, 2023. As of December 31, 2023, the Company has paid approximately $<span id="xdx_904_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zBWqr4Io24Ge" title="Payment of contract cost"><ix:nonFraction name="us-gaap:ConstructionContractCostProgressPaymentOffset" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,036,940</ix:nonFraction></span> of the Avance Clinical contract costs and has accrued
$<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z3EcyGn4t8s5" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001741" format="ixt:numdotdecimal" decimals="0" unitRef="USD">523,284</ix:nonFraction></span> recorded as accrued liabilities and $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zYKiKTtPTDXc" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_AvanceClinicalMember" id="Fact001743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,320</ix:nonFraction></span> as accounts payable on the accompanying consolidated balance sheet. For the year
ended December 31, 2023, the Company has expensed $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_ztSbfQPHmw17" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31_custom_AvanceClinicalMember" id="Fact001745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,751,444</ix:nonFraction></span> in research and development expenses within the accompanying consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Development
and Clinical Supply Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &#8220;PureForm Agreement&#8221;) with PureForm
Global, Inc. (&#8220;PureForm&#8221;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#8220;API&#8221;)
for the Company&#8217;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order of 1 kilogram during the first thirty (30) days from the effective date) and
has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be
owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts
by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the PureForm Agreement, subject to extension
by mutual agreement of the parties. The Company has met the minimum purchase requirement of 1 kilogram during the first thirty days of
the PureForm Agreement&#8217;s effectiveness. The Company did not pursue an extension of the PureForm Agreement beyond the initial term
and the agreement terminated in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#8220;Vogel-Nathan Purchase
Agreement&#8221;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The Vogel-Nathan Purchase Agreement includes a commitment to pay a one-time milestone
totaling $<span id="xdx_908_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--OneTimeMilestoneMember_zrCCC2obgoyi" title="Long-term purchase commitment, amount"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember" id="Fact001747" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> upon the issuance of a utility patent in the United States or by the European Patent Office, as defined in the agreement.
The Company has accrued such amount as of December 31, 2021, as a result of the milestone criteria being achieved. Payment was made during
January 2022. In addition, a milestone payment totaling $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--AdditionalMilestoneMember_zhdAQxZczHo1" title="Long-term purchase commitment, amount"><ix:nonFraction name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember" id="Fact001749" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> is due upon initiation of a Phase II(b) study. Research activities related
to the relevant patents are still in preclinical stage, and accordingly, this milestone has not been achieved. The Vogel-Nathan Purchase
Agreement contains a commitment for payment of royalties equaling <span id="xdx_90B_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zDQEojQYFYF1" title="Royalties percentage"><ix:nonFraction name="ENVB:RoyaltiesPercentage" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember" id="Fact001751" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2</ix:nonFraction></span>% of the first $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zoZY67IeTyk6" title="Payments for royalties"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember" id="Fact001753" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million in net sales derived from the commercialization
of products utilizing the relevant patent. As these products are still in the preclinical phase of development, no royalties have been
earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Consulting and Vendor Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between 1 and 18 months. These agreements, in aggregate, commit the Company to approximately $<span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_zXfWx4ycr8Rc" title="Future cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember" id="Fact001755" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million in future
cash payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Right-of-use
lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2021, MagicMed entered into a lease agreement (the &#8220;LSIH Lease&#8221;) with the University of Calgary for the use and
occupation of lab and office space at the University of Calgary&#8217;s Life Science Innovation Hub building located in Calgary, Alberta,
Canada (the &#8220;LSIH Facility&#8221;). The lease expired in July 2023, and was extended on a month-to-month basis through December
31, 2023. Accordingly, no operating lease liability or right-of-use asset is recorded as of December 31, 2023. The Company terminated
this lease effective in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense is recorded on the straight-line basis. Rent expense under the LSIH Lease for the years ended December 31, 2023 and 2022 was
$<span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20231231_zBINyAlGGitl" title="Rent expenses"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-012023-12-31" id="Fact001757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,241</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--PaymentsForRent_c20220101__20221231_zTe2yrPNRkw2" title="Rent expenses"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-01-012022-12-31" id="Fact001759" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,667</ix:nonFraction></span>, respectively. Rent expense is recorded in research and development costs on the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001761" name="ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zWHvKLl07Vnb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zQfu0TOu6lia" style="display: none">SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remaining lease term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" id="Fact001763" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">0.6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2022-12-31" id="Fact001765" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zFSM6H6fbVub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001767" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zYdOWhZhqi8i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_82E_zmpByKrEU5va">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001769" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zeA4xpukjyji" style="display: none">SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2023-01-012023-12-31" id="Fact001771" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,205,116</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2022-01-012022-12-31" id="Fact001772" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,251,228</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2023-01-012023-12-31" id="Fact001774" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,057,703</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2022-01-012022-12-31" id="Fact001775" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,706,165</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact001777" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,262,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact001778" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,957,393</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zhNKqIFZq044" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_z3Bd8okIz0A9" title="Income tax expenses and benefits"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></span> and an income tax benefit of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zTxFvfZupNSk" title="Income tax expenses and benefits"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001782" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></span>,
respectively. The income tax benefit (expense) is as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001784" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4LFMffO1bGa" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE BENEFITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Current:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001789" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1793">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total
    current income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1799">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1801">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001805" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001808" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact001810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,913</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="Fact001811" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,486,060</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zEMeV37Jgcl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001813" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets and deferred tax liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B9_zVn0082ZSHDi" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001815" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,889,863</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact001816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,927,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" id="Fact001819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,348,928</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_zeLuldfIHLJk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development capitalized expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:ResearchAndDevelopmentCapitalizedExpenses" contextRef="AsOf2023-12-31" id="Fact001821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">611,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:ResearchAndDevelopmentCapitalizedExpenses" contextRef="AsOf2022-12-31" id="Fact001822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_z3vKEWbpo3wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:DeferredTaxAssetsAndIntangibleAmortization" contextRef="AsOf2023-12-31" id="Fact001824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:DeferredTaxAssetsAndIntangibleAmortization" contextRef="AsOf2022-12-31" id="Fact001825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,141</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,730</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" id="Fact001828" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001830" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,837,755</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001831" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,977,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1833">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1834">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zv3ekvcOLIcc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001836" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially utilizable net operating loss tax carryforwards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt3NjQUFsfF" style="display: none">SCHEDULE
OF OPERATING LOSS CARRY FORWARDS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,268,692</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember" id="Fact001839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,349,753</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001841" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,220,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,892,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,672,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember" id="Fact001845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,377,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net operating loss tax carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,672,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember" id="Fact001848" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,377,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_z7S3r24z5eD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) limits the net operating loss deduction to 80% of taxable income for losses
arising in tax years beginning after December 31, 2017. As of December 31, 2023, the Company had federal net operating loss
carryforwards and state net operating loss carryforwards of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMyXJ1gm3FJ8"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember" id="Fact001849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,268,692</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zH57liFWfGbk" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001851" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,220,065</ix:nonFraction></span>,
respectively, both of which can be carried forward indefinitely and Canadian net operating loss carryforwards of $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zr2nJ9Kzy0j6" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember" id="Fact001853" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,672,420</ix:nonFraction></span>,
which will begin to expire in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001855" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s effective tax rate varied from the statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none">SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Federal income tax at the statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact001857" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 3%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001858" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax rate (net of federal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact001860" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.2</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact001861" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign tax rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-012023-12-31" id="Fact001863" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.0</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31" id="Fact001864" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.1</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" contextRef="From2023-01-012023-12-31" id="Fact001866" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" contextRef="From2022-01-012022-12-31" id="Fact001867" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.0</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zBQrMCzaAaZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup" contextRef="From2023-01-012023-12-31" id="Fact001869" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.2</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact001872" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001873" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23.3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact001875" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="Fact001876" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">7.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zsa35ks9ndR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased by
$<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znu1AgEoYdYj" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact001878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,859,862</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zQeSg7kdYWS3" title="Valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2022-01-012022-12-31" id="Fact001880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,429,869</ix:nonFraction></span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state and Canadian perspective the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. As of December 31, 2023, the Company has not filed tax returns for the fiscal year 2023 and Canadian corporate
tax returns for fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
382</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a substantial limitation in the event of any significant future
changes in its ownership structure under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result
in the expiration of the net operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
174</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures
in the current year and requires taxpayers to amortize US expenses over five years and foreign expense over fifteen years pursuant to
IRC Section 174. During the years ended December 31, 2023 and 2022, the Company has estimated and capitalized gross $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_z0NaECqIR2Wg" title="Research and development expense gross"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact001882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">463,696</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zOGeQR7Krns5" title="Research and development expense gross"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2022-01-012022-12-31" id="Fact001884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,684,319</ix:nonFraction></span>,
respectively, of research and development expenditures that will be amortized primarily over five years. This did not have a material
impact on the Company&#8217;s tax liability for the years ended December 31, 2023 and 2022. The Company will continue to evaluate the
impact of these tax law changes on the current and future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Reduction Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2022, President Joe Biden signed the Inflation Reduction Act of 2022 (the &#8220;Act&#8221;) into law. The Act includes a
new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December
31, 2022. These provisions did not have a material impact on the Company&#8217;s consolidated financial position as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-012023-12-31" escape="true" id="Fact001886" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z18CjkrOmpN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span id="xdx_820_zNqnVHMzgyjl">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed a <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zdVV237Bi36e" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-01-272025-01-27" id="Fact001888" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span>
reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. The Reverse Stock Split reduced the number
of shares of the Company&#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse
Stock Split. The number of shares of the Company&#8217;s authorized common stock was not affected by the Reverse Stock Split and the
par value of the Company&#8217;s common stock remained unchanged at $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHPoJR1PQ9U6" title="Share price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember" id="Fact001890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
per share. No fractional shares were issued in connection with the Reverse Stock Split. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
February 29, 2024, the Company issued all <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXqaJYv860yd" title="Number of common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001892" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock of the <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR2185JE00Nd" title="Existing Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Existing Warrants and Investment
Options exercised that were held in abeyance due to the beneficial ownership limitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, one investor exercised the Inducement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0AhH5MmtvB3" title="Warrants to purchase shares of common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001896" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,267</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for cash proceeds
of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMS2xAAK6T0e" title="Cash proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" id="Fact001898" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSeFskr2Lz9b"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001899" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,246</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaEtnlXUmCYi"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001900" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to the Holders of the Inducement Warrants.
The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction limitation solely with respect
to the entry into and/or issuance of shares of common stock in an at the market offering contained in the Inducement Letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company sold an aggregate of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zJmX0hu9ExH5" title="Number of shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember" id="Fact001902" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,200</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for aggregate gross
proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_z8Ub17d6Doq3" title="Gross proceeds from sale of shares"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember" id="Fact001904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,502</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zM52artKaMga" title="Net Proceeds from sale of shares"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember" id="Fact001906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,320,707</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Distribution Agreement with Canaccord.&#8221;</span></p>

</ix:nonNumeric><p id="xdx_81A_zTeRXMFLHAZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_001"></span>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_111_zNklc1rJ7q66" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240930_zPVND6Zr9Ca7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zAKim4Bc7seh" style="border-bottom: Black 1pt solid; font-weight: bold">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zz1eaANYFMd2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_i01B_zdxV3E3JKeY3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Cash_i02I_zZpnMR6shBYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; width: 60%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-09-30" id="Fact001914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact001915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zPHZK93nJUHg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact001917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,226,576</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,554</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrent_i02TI_zmjbsOxie0Qj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-09-30" id="Fact001920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,338,259</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,581,531</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsNoncurrentAbstract_i01B_zuE24OwFuvRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Other assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i02I_zf4gPWcogHfe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" id="Fact001926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,689</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,377</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_zjkbHVRt5fWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Intangible assets, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-09-30" id="Fact001929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,368</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact001930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsNoncurrent_i02TI_zvvamZZb0tbc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2024-09-30" id="Fact001932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,057</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact001933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,309</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_zqkrHxJzYp83" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 40pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-09-30" id="Fact001935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,790,316</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact001936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zulFZXbYUAA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrentAbstract_i01B_zeGBE41de782" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccountsPayableCurrent_i02I_zfocfihBdgKi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" id="Fact001944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,783</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_i02I_zqYAnlZc3d1b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact001947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,150</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001948" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_i02I_zLTQ35h8YK0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact001950" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001951" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,608</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilitiesCurrent_i02I_z3UXKWKcUg08" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:WarrantLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact001953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,748</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:WarrantLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,470</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrent_i01TI_zfUlBFffkwU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact001956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">839,166</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,343,504</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_i01I_zgzrYLG2CTs3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Commitments and contingencies (Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1959">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--TemporaryEquityAbstract_i01B_zk7Jio3G5EIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Mezzanine equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_i02I_z8WbruEhxN49" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1pt">Series C redeemable preferred stock, $<span id="xdx_904_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zw2teTVyBae2" title="Temporary equity, par value"><span id="xdx_903_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_ziqY9ql9a26h" title="Temporary equity, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember" id="Fact001968" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact001970" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_901_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zulR4FqvPzQa" title="Temporary equity, shares authorized"><span id="xdx_908_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zRQGNjo2OkH3" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember" id="Fact001972" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact001974" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, and <span id="xdx_90D_eus-gaap--TemporaryEquitySharesIssued_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zG8crtvQbdp4" title="Temporary equity, shares issued"><span id="xdx_902_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zLMMLwNvYJbl" title="Temporary equity, shares outstanding"><span id="xdx_90A_eus-gaap--TemporaryEquitySharesIssued_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_z1DLtwxIuH7d" title="Temporary equity, shares issued"><span id="xdx_903_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--SeriesCRedeemablePreferredStockMember_zl93WwUmlcRe" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember" id="Fact001976" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember" id="Fact001978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact001980" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember" id="Fact001982" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of September 30, 2024 and December 31, 2023</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1965">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1966">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_i02TI_zei8B0u0L3Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Total mezzanine equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1985">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B_zb8kY2Bobnni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Shareholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_zNZwDUS6Y1Lj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Preferred stock, $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930_z3J4NWh5qx7k" title="Preferred stock, par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_zAojZG3nlP8i" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact001993" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact001995" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930_zKlPxRT7Qjda" title="Preferred stock, shares authorized"><span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zGEmuZyqMdH8" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact001997" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001999" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; Series B preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zf3br25FE3u4" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z3PLfe8LvEad" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember" id="Fact002001" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact002003" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zPe796tlEZm9" title="Preferred stock, shares authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6qSXoAih7se" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember" id="Fact002005" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact002007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,600,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z6HriB5K0FZf" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zMQsl1qSwHEc" title="Preferred stock, shares outstanding"><span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zoNIYhnJhfXa" title="Preferred stock, shares issued"><span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNkA7mSFYXl8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember" id="Fact002009" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember" id="Fact002011" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact002013" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember" id="Fact002015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of September 30, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1991">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_zePVooDkiKEj" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Preferred stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2017">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2018">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--CommonStockValue_i02I_zdS4p5AXvoz6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Common stock, $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240930_zcV71kYgjgNb" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zdbRUYxBIES4" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" id="Fact002023" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact002025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span>
    </span>par value, <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20240930_zSVZLT7oKdQ4" title="Common stock, shares authorized"><span id="xdx_90D_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z6aRWpOuoPJ2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" id="Fact002027" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact002029" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized,
    <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20240930_z9pdmIxHEh63" title="Common stock, shares issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20240930_zEBIvYcQnpJj" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" id="Fact002031" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" id="Fact002033" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">599,669</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20231231_zkJzUsXBnI6f" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zmlW2KUcXRQg" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact002035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact002037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,625</ix:nonFraction></ix:nonFraction></span>
    </span>shares issued and outstanding as of September 30, 2024 and December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact002020" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,998</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact002021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommonStockValue_i02I_zl1p3Uq2tR5c" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Common stock, value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" id="Fact002039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,998</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact002040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--AdditionalPaidInCapital_i02I_zTxIAZX06kq8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-09-30" id="Fact002042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,400,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact002043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,841,416</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityNoteSubscriptionsReceivable_i02NI_di_z2f1aq6MAzgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="AsOf2023-12-31" id="Fact002046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zO2VT2TnQT3k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact002048" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">102,919,859</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact002049" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_zJxQ1yVkPxf7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-09-30" id="Fact002051" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">534,998</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="Fact002052" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">569,749</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquity_i02TI_zpblaDCbZ9Mc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact002054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,951,150</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact002055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,336</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zXtHZkmkszed" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities, mezzanine equity, and shareholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" id="Fact002057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,790,316</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact002058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,840</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the accompanying notes to the unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_002"></span>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_zFwiWCTf2Dnl" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20240701__20240930_zTK1Mp7NNtZ4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230701__20230930_zPl3jL0jMsoc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20240930_zlEoibNG8oU7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20230101__20230930_zM91HdaxjQph" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Three Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Nine Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zCtaNTZNGZyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_zUFj82kEyzdc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact002065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,661</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" id="Fact002066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,080,644</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-09-30" id="Fact002067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,467,065</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-09-30" id="Fact002068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,273,344</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i01_zNY5JRQXKMe8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact002070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">762,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" id="Fact002071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,281,455</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-09-30" id="Fact002072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,736,373</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30" id="Fact002073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,531,436</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_i01_zh9djQKbuZg2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-07-012024-09-30" id="Fact002075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,814</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-07-012023-09-30" id="Fact002076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,296</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-01-01to2024-09-30" id="Fact002077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,002</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-01-012023-09-30" id="Fact002078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">259,300</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingCostsAndExpenses_i01T_zytLl8HG8MU8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2024-07-012024-09-30" id="Fact002080" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,083,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-07-012023-09-30" id="Fact002081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,448,395</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2024-01-01to2024-09-30" id="Fact002082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,458,440</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2023-01-012023-09-30" id="Fact002083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,064,080</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingIncomeLoss_iT_zb43Tsu06u2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact002085" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,083,192</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact002086" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,448,395</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact002087" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,458,440</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact002088" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,064,080</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_ziNz8umtw35a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zrSF89VdC02d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-07-012024-09-30" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-012023-09-30" id="Fact002096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,822</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-09-30" id="Fact002097" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30" id="Fact002098" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,342</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GainLossOnInvestments_i01_zp0ZxI9KS487" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-07-012024-09-30" id="Fact002100" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">501</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-07-012023-09-30" id="Fact002101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">562,715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-01-01to2024-09-30" id="Fact002102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-012023-09-30" id="Fact002103" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">399,921</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_zsZJdLQ708D" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2106">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2107">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30" id="Fact002108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestIncomeExpenseNet_i01_zSNUTHK6wrtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Interest income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-07-012024-09-30" id="Fact002110" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">217</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-07-012023-09-30" id="Fact002111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,237</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2024-01-01to2024-09-30" id="Fact002112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-012023-09-30" id="Fact002113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,142</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NonoperatingIncomeExpense_i01T_z8OyyGmypmj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total other income (expense)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-07-012024-09-30" id="Fact002115" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">840</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" id="Fact002116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">632,774</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-09-30" id="Fact002117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,830</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-09-30" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,879</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_zSx9tuBHFXOf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-07-012024-09-30" id="Fact002120" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,084,032</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-07-012023-09-30" id="Fact002121" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,815,621</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-09-30" id="Fact002122" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,418,610</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-09-30" id="Fact002123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,849,201</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_iN_di_zdZHLorgQ5T7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2125">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-012023-09-30" id="Fact002126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,595</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-09-30" id="Fact002127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,731</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-09-30" id="Fact002128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,595</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_zmpEXW4X2Ym4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact002130" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,084,032</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact002131" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,822,216</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact002132" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,420,341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact002133" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,855,796</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockDividendsIncomeStatementImpact_zJcKiyzNwmJh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Less preferred dividends attributable to non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2135">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2136">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2137">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-012023-09-30" id="Fact002138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--TemporaryEquityAccretionToRedemptionValueAdjustment_z1fsteIJOzFh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less deemed dividends attributable to accretion of embedded derivative at redemption value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2142">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="From2023-01-012023-09-30" id="Fact002143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_zPjV7n4GWSE5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net loss attributable to shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-07-012024-09-30" id="Fact002145" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,084,032</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-07-012023-09-30" id="Fact002146" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,822,216</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-01-01to2024-09-30" id="Fact002147" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,420,341</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-012023-09-30" id="Fact002148" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,022,825</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_iB_zOY5vZ6nSgG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_i01_z6LX9q410nFa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact002155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,497</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact002156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,433</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-01to2024-09-30" id="Fact002157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,751</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-09-30" id="Fact002158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,115</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_zULnAg4sgdt6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact002160" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,052,535</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact002161" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,811,783</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-09-30" id="Fact002162" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,385,590</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-09-30" id="Fact002163" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,021,710</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20240701__20240930_zSTnPNpfMjk3" title="Net loss per share - basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20240701__20240930_zG1Y3Weveqfk" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Net loss per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-07-012024-09-30" id="Fact002165" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-012024-09-30" id="Fact002167" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">3.59</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230701__20230930_zxwYI0dVC67e" title="Net loss per share - basic"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20230701__20230930_zDDNwwBEMOkc" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Net loss per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" id="Fact002169" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" id="Fact002171" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">19.56</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_902_eus-gaap--EarningsPerShareBasic_c20240101__20240930_zLseGiGSD0kb" title="Net loss per share - basic"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20240101__20240930_zYl5BaE3VuF1" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Net loss per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-09-30" id="Fact002173" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-09-30" id="Fact002175" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">14.22</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_900_eus-gaap--EarningsPerShareBasic_c20230101__20230930_zAV6gDciugtg" title="Net loss per share - basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20230101__20230930_zR6pVY614p45" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Net loss per share - diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-09-30" id="Fact002177" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-09-30" id="Fact002179" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">99.35</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240701__20240930_z4KNqmV41cK2" title="Weighted average shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240701__20240930_zqzrLzIhvr33" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-07-012024-09-30" id="Fact002181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-012024-09-30" id="Fact002183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">580,197</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20230930_zJ6VPoH4HQI4" title="Weighted average shares outstanding, basic"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20230930_zCz6YS46ixo9" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" id="Fact002185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" id="Fact002187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,311</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240101__20240930_zPNbzjGKW2Fd" title="Weighted average shares outstanding, basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240101__20240930_zrAlinLfXBl3" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-09-30" id="Fact002189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-09-30" id="Fact002191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">451,411</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230930_zyBQ5T6vgYJg" title="Weighted average shares outstanding, basic"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230930_zy4yTIA33yV6" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBTdGF0ZW1lbnRzIG9mIE9wZXJhdGlvbnMgYW5kIENvbXByZWhlbnNpdmUgTG9zcwA_" title="Weighted average shares outstanding, diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-09-30" id="Fact002193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-09-30" id="Fact002195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">141,144</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the accompanying notes to the unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_003"></span>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_114_zqGn5UrTKied" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td>
    <td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--RedeemableNoncontrollingInterestMember_zUdBpBWX5Ng1" style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_custom--MezzanineEquityMember_z2V2l2WkEOyb" style="font-weight: bold; padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z75cW7wAXD9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zfX0Y6OAksb4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional<br/>
 Paid-In<br/>
 Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_custom--SubscriptionReceivableMember_z4dVSry1mShj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subscription<br/>
 Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z8AK7hA7rmV" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zZgfzAd1lccf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Other<br/>
 Comprehensive<br/>
 Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_zepGGjkoEadh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total <br/>
Shareholders&#8217;<br/>
 Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="display: none">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="display: none">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional<br/>
 Paid-In<br/>
 Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Subscription<br/>
 Receivable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Other<br/>
 Comprehensive<br/>
 Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total <br/>
Shareholders&#8217;<br/>
 Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_431_c20240101__20240331_eus-gaap--StockholdersEquity_iS_zqsXFd4q0hhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; font-weight: bold">Balance at January 1, 2024</td>
    <td style="display: none; width: 9%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2197">-</span></span></td><td style="width: 1%"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2198">-</span></span></td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoWNhpnPy293" title="Beginning balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact002206" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">182,625</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact002199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,827</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,841,416</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember" id="Fact002201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,817,640</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact002202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,499,518</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002203" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">569,749</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact002204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,956,336</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zY8iqWIBaXAb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2208">-</span></span></td><td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2209">-</span></span></td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2210">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2212">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2213">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2214">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-012024-03-31" id="Fact002215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,488</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_zhFi0aEe1Up6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock sold under the Equity Distribution Agreement, net of offering costs of $<span id="xdx_90D_ecustom--CommonStockEquityDistributionCosts_c20240101__20240331_zREVnS3GyCL4" title="Common stock equity distribution costs"><ix:nonFraction name="ENVB:CommonStockEquityDistributionCosts" contextRef="From2024-01-012024-03-31" id="Fact002226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,713</ix:nonFraction></span></td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEuyhQaernUi" title="Common stock sold under the Equity Distribution Agreement, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002220" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,807,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2222">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2223">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-01-012024-03-31" id="Fact002224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,808,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_zq1KxbIicjk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of direct offering shares (see Note 7)</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrYMhXPW4Uzl" title="Issuance of direct offering shares, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,246</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2234">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2235">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2236">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-01-012024-03-31" id="Fact002237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_z38cCNHCX2bj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Exercise of Inducement Warrants for common stock</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjJVMtxnKh7j" title="Exercise of Inducement Warrants for common stock, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002250" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">130,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,303</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,675,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2246">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" contextRef="From2024-01-012024-03-31" id="Fact002248" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,676,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zMowksdkJ3Le" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $<span id="xdx_908_ecustom--NetOfferingCosts_c20240101__20240331_zXx52ixkOwAl" title="Net offering costs"><ix:nonFraction name="ENVB:NetOfferingCosts" contextRef="From2024-01-012024-03-31" id="Fact002261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,821</ix:nonFraction></span></td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2254">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,821</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="Fact002256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2258">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2024-01-012024-03-31" id="Fact002259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueOther_zbwXWoCFAX25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjdugywHcw0l" title="Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember" id="Fact002265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">469</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember" id="Fact002267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,537,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2268">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2024-01-012024-03-31" id="Fact002270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,537,140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zk9rcym5r5p" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation gain</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2276">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2277">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2278">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2279">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,906</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-01-012024-03-31" id="Fact002281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,906</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zsMiKRlu4V3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2283">-</span></span></td><td style="padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2284">-</span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2286">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2287">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact002288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,456,915</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2289">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-03-31" id="Fact002290" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,456,915</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240401__20240630_eus-gaap--StockholdersEquity_iS_zdc8ZIsdRZ04" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2024</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2292">-</span></span></td><td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2293">-</span></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAZZwDO9imTe" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact002301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">486,272</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact002294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,863</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,985,269</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2296">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact002297" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,956,433</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">551,843</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact002299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,481,856</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zot9l0X6AAE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2305">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2307">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2308">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2309">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012024-06-30" id="Fact002310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_zeh9dVtoF29k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock sold under the Purchase Agreement, net of offering costs of $<span id="xdx_90F_ecustom--CommonStockEquityDistributionCosts_c20240401__20240630_zJZsGfFxI1Qa" title="Common stock equity distribution costs"><ix:nonFraction name="ENVB:CommonStockEquityDistributionCosts" contextRef="From2024-04-012024-06-30" id="Fact002321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,850</ix:nonFraction></span></td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7nP4iMSrCFe" title="Common stock sold under the Equity Distribution Agreement, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact002323" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact002314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 8pt/107% Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002315" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2316">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2318">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2319">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_zG57ZaNFWWBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of direct offering shares (see Note 7)</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2kgSaf4h6Mg" title="Issuance of direct offering shares, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact002334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact002327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2330">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2331">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" contextRef="From2024-04-012024-06-30" id="Fact002332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_zCBX983ObQob" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares for vested RSU</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_pid_c20240401__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziehXjjNeGDc" title="Issuance of common shares for vested RSU, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact002345" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember" id="Fact002338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002339" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2340">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2341">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2342">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2343">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zM7ncmsmPaUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation loss</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2351">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,652</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-04-012024-06-30" id="Fact002354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,652</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zRU838Uvpdma" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2356">-</span></span></td><td style="padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2357">-</span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2358">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2359">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2360">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact002361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,879,394</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2362">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012024-06-30" id="Fact002363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,879,394</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20240701__20240930_eus-gaap--StockholdersEquity_iS_zDoQ7tcAllji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2024</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2365">-</span></span></td><td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2366">-</span></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS3nQdGJxlR2" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact002374" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">525,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact002367" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,803,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2369">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact002370" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,835,827</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002371" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">566,495</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact002372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,406,264</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zY7kabeHlW7g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2378">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2380">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2381">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2382">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-07-012024-09-30" id="Fact002383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_zEvhzKrBP6wh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock sold under the Purchase Agreement, net of offering costs of $<span id="xdx_905_ecustom--CommonStockEquityDistributionCosts_c20240701__20240930_zLyrTWt6ungj" title="Common stock equity distribution costs"><ix:nonFraction name="ENVB:CommonStockEquityDistributionCosts" contextRef="From2024-07-012024-09-30" id="Fact002394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,029</ix:nonFraction></span></td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLKyFnIeIAT7" title="Common stock sold under the Equity Distribution Agreement, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact002396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,699</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact002387" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,080</ix:nonFraction></td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2389">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2390">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2391">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" contextRef="From2024-07-012024-09-30" id="Fact002392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_zfDiDv5OLLDf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares for vested RSU</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj1vUU6TUnE3" title="Issuance of common shares for vested RSU, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact002407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember" id="Fact002400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002401" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2402">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2404">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2405">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zBwEq6Euu1bb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation gain</td>
    <td style="display: none">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Beginning balance, shares" style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2411">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2412">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2413">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2414">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,497</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2024-07-012024-09-30" id="Fact002416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,497</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_z0gzsN1BLqrl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2418">-</span></span></td><td style="padding-bottom: 1pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2419">-</span></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Beginning balance, shares" style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2420">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2421">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2422">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember" id="Fact002423" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,084,032</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2424">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-07-012024-09-30" id="Fact002425" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,084,032</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20240701__20240930_eus-gaap--StockholdersEquity_iE_zFGx2Cue8eyc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2024</td>
    <td style="display: none"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2427">-</span></span></td><td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2428">-</span></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOUj1IPJKmI4" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0.65pt 0 0"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact002436" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">599,669</ix:nonFraction></p>
</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" id="Fact002429" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,998</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,400,009</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2431">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" id="Fact002432" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">102,919,859</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002433" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">534,998</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" id="Fact002434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,951,150</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the accompanying notes to the unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_custom--RedeemableNoncontrollingInterestMember_zbI3utHxLp2e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_custom--MezzanineEquityMember_zllFaicweVVj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/>
 Mezzanine<br/>
 Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zJserCG2kS8i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zCXAjjdk8M6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zwGcittyABqe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zoJVVYFcYsH9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Other<br/>
 Comprehensive<br/>
 Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_ztvM8Sav5xqf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total <br/>
Shareholders&#8217;<br/>
 Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Redeemable Non-controlling Interest</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/>
 Mezzanine<br/>
 Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Additional Paid-In Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Other<br/>
 Comprehensive<br/>
 Loss</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total <br/>
Shareholders&#8217;<br/>
 Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_439_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zQEDEKX4T057" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; font-weight: bold">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--TemporaryEquityShares_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_z2xqruRfpwCf" title="Mezzanine equity balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact002446" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember" id="Fact002438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_MezzanineEquityMember" id="Fact002439" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkE1pXiAQHx1" title="Beginning balance, shares" style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact002448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,554</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact002440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,415,058</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact002442" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,207,786</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002443" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">536,734</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 3%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact002444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,671,924</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zTQedZ90wpJj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2450">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2451">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2452">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,835</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2454">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2455">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-03-31" id="Fact002456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">532,835</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_iN_di_zrCgvQg6YROd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember" id="Fact002458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember" id="Fact002459" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,329</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2460">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,329</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2462">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2463">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-03-31" id="Fact002464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,329</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_iN_di_z915yNEDtgf9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember" id="Fact002466" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,991</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember" id="Fact002467" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">110,991</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2468">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,991</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2470">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2471">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-03-31" id="Fact002472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,991</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zqKmIkZ2iLWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2475">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2476">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2477">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2478">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-01-012023-03-31" id="Fact002480" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,968</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_zVrxm5msNhza" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2482">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2483">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2484">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2485">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="Fact002486" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,677,527</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2487">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" id="Fact002488" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,677,527</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_433_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zZVSJ71EJexl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--TemporaryEquityShares_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zs1ptYtTxnUl" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:TemporaryEquityShares" contextRef="AsOf2023-03-31_custom_RedeemableNoncontrollingInterestMember" id="Fact002498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_RedeemableNoncontrollingInterestMember" id="Fact002490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,008,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_custom_MezzanineEquityMember" id="Fact002491" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,008,348</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcirClzHPbRa" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact002500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact002492" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact002493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,824,573</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact002494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,885,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">534,766</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact002496" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,405,880</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z0IM0QMXaQv" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2502">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2503">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2504">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2506">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2507">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012023-06-30" id="Fact002508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">879,738</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_iN_di_zeott97W2wQ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Preferred dividends attributable to redeemable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="Fact002510" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="Fact002511" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,712</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2512">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002513" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,712</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2514">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2515">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-04-012023-06-30" id="Fact002516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,712</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_iN_di_zBPupgJkJgrd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="Fact002518" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,997</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="Fact002519" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">36,997</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2520">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,997</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2522">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2523">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-04-012023-06-30" id="Fact002524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,997</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_zMQJkjQGZt68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Redemption of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zbzumg1iDYPa" title="Redemption of Series A preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="Fact002534" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember" id="Fact002526" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember" id="Fact002527" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,052,057</ix:nonFraction></td><td style="text-align: left">)</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2528">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2529">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2530">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2531">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2532">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zckFBuRdnix5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares in exchange for RSU conversions from the reduction in force</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2536">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2537">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj9fsZmNRdf2" title="Issuance of common shares in exchange for RSU conversions from the reduction in force, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact002544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="Fact002538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002539" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2540">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2541">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2542">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zq8p8opsbUq7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2546">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2547">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2548">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2549">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2550">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002551" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,286</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-04-012023-06-30" id="Fact002552" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,286</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zJW22IZBrwt9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2554">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2555">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2556">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2557">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact002558" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,356,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2559">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" id="Fact002560" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,356,053</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zb9qZszEwsM5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at June 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--TemporaryEquityShares_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zMOqoCKSHVw3" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2570">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2562">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2563">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZt3aN6mc3Xc" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact002572" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact002564" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,428</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002565" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,660,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact002566" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,241,366</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002567" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">546,052</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact002568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,874,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zCcw681rSfA7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--TemporaryEquityShares_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zyRLDKU3tQv2" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2582">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2574">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2575">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIozSfwKZ2tf" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact002584" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact002576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,428</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,660,560</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact002578" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">90,241,366</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002579" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">546,052</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact002580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,874,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zFIQ0Ji2yM3i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2586">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2587">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2588">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,859</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2590">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2591">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-07-012023-09-30" id="Fact002592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_z6WeOqUlbSSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Issuance of common shares for vested RSU</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2594">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2595">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLgvnr01vAg9" title="Issuance of common shares for vested RSU, shares" style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact002602" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,676</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="Fact002596" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002597" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2598">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2599">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2600">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_z7hnBfsBwekb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation gain</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2604">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2605">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2606">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2607">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2608">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact002610" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_zVU4vzbEJrQ7" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Foreign exchange translation gain (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2612">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2613">&#8212;</span></td><td style="text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2614">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2615">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2616">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002617" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="From2023-07-012023-09-30" id="Fact002618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_zMhfsOzYeYyf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2620">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2621">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2622">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2623">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="Fact002624" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,822,216</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2625">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact002626" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,822,216</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zTDZN4JB6uTe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--TemporaryEquityShares_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_z5FhbOKKK7sb" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2636">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2628">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2629">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAod62GJq2qd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact002638" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact002630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,455</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002631" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,033,392</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact002632" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,063,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002633" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">535,619</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact002634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,435,646</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zeDW8u1pjFpb" style="display: none; vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--TemporaryEquityShares_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--RedeemableNoncontrollingInterestMember_zhkw2tBirWbh" title="Mezzanine equity balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2648">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2640">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2641">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-right: Black 1pt solid">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6k5oDPHGjxa" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact002650" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">145,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" id="Fact002642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,455</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact002643" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,033,392</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" id="Fact002644" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,063,582</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact002645" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">535,619</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact002646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,435,646</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the accompanying notes to the unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="D_004"></span><b>UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_zGKXp8VbISpc" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20240930_zjmcayJbe61e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_z6dqdAtEqzK6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Nine Months Ended September 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z5z5UwHS5VD6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_zbnBmH0cHNzl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact002655" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,420,341</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact002656" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,855,796</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zgKhaXeM0kml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FairValueAdjustmentOfWarrants_i02_zl0UKKad8pAb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-09-30" id="Fact002661" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,722</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30" id="Fact002662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,342</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainLossOnInvestments_i02N_di_zhFvAQwD8S11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of investment option liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2024-01-01to2024-09-30" id="Fact002664" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,664</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2023-01-012023-09-30" id="Fact002665" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">399,921</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_z9jPqwGIW8qi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2667">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30" id="Fact002668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">727,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ShareBasedCompensation_i02_zmPsc4CmrUol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-01to2024-09-30" id="Fact002670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,090,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30" id="Fact002671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785,432</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_zCgwGgtqldqd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2673">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-01-012023-09-30" id="Fact002674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,246</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_i02_zGvrWPsDp7Ga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Amortization of intangibles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-09-30" id="Fact002676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-09-30" id="Fact002677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,566</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Depreciation_i02_zsRpAFpJGthd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-09-30" id="Fact002679" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-09-30" id="Fact002680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_i02N_di_z1tA9K87TLhk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on disposal of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2682">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="From2023-01-012023-09-30" id="Fact002683" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,219</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zWZUzD9gnvQh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_zwYYPmGBBArl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-09-30" id="Fact002688" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,674</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-09-30" id="Fact002689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,033</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_zErMfutDbTEb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-09-30" id="Fact002691" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,296,907</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-09-30" id="Fact002692" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,688</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_i03N_di_zae7N0eNaqX3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Right-of-use operating lease asset and obligation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2694">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" contextRef="From2023-01-012023-09-30" id="Fact002695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,244</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_z6PHKDx2E023" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact002697" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,414,590</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-09-30" id="Fact002698" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,343,363</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: -10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zww4IBCPQbp7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Cash Flows From Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_zk1GSY19EGnd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2703">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30" id="Fact002704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,195</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_zftvvHnHF0e7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from disposal of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2706">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30" id="Fact002707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,900</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_zX0DWo2QXzj8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash provided by investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2709">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-09-30" id="Fact002710" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,705</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zv1mI7nDAaE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_i01_zzguerMyysFc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" contextRef="From2024-01-01to2024-09-30" id="Fact002715" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,804,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2716">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromWarrantExercises_i01_zfJ5Lk08p6hc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from exercise of Inducement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-01to2024-09-30" id="Fact002718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,676,980</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2719">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_zUqEwuZuTKSk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from common stock sold under the Equity Distribution Agreement, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-01to2024-09-30" id="Fact002721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,290,186</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2722">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts_i01_zy6PXRpr6oC5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from common stock sold under the Purchase Agreement, net of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" contextRef="From2024-01-01to2024-09-30" id="Fact002724" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,862</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2725">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di_z2bGqdZFBVx2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payment for offering costs previously accrued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-01to2024-09-30" id="Fact002727" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,461</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-01-012023-09-30" id="Fact002728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_i01N_di_z7zbPp4QREq7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Redemption of Series A Preferred Stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2730">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock" contextRef="From2023-01-012023-09-30" id="Fact002731" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,052,057</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_zi1hBTyt8c8g" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Net cash provided by (used in) financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact002733" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,210,386</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-09-30" id="Fact002734" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,157,057</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_zXEfkps2GXia" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Effect of Foreign Exchange Rate on Changes on Cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2024-01-01to2024-09-30" id="Fact002736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,910</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="From2023-01-012023-09-30" id="Fact002737" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,399</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zgZFDQ8gOC3g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-09-30" id="Fact002739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">823,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-09-30" id="Fact002740" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,457,316</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zzPxOnc6xi9i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact002742" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,287,977</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact002743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,723,884</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zWMRNtlbdg7k" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2024-09-30" id="Fact002745" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" id="Fact002746" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,266,568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zC66ROTwc3w6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash and non-cash transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestPaidNet_i01_zsyYwtC22xUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2751">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2752">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxesPaidNet_i01_zckQj7fyixx9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Income taxes paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2024-01-01to2024-09-30" id="Fact002754" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,001</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-012023-09-30" id="Fact002755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,595</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--OfferingCostsAccruedNotPaid_i01_zBySsH2L2QVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Offering costs accrued not paid</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:OfferingCostsAccruedNotPaid" contextRef="From2024-01-01to2024-09-30" id="Fact002757" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,455</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:OfferingCostsAccruedNotPaid" contextRef="From2023-01-012023-09-30" id="Fact002758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredOfferingCostsChargedToOfferingCosts_i01_zWu4pYHeH0L8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Deferred offering costs charged to offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:DeferredOfferingCostsChargedToOfferingCosts" contextRef="From2024-01-01to2024-09-30" id="Fact002760" format="ixt:numdotdecimal" decimals="0" unitRef="USD">495,544</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2761">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonSharesForDeferredOfferingCosts_i01_zP3n4Jv5olth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of common shares for offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts" contextRef="From2024-01-01to2024-09-30" id="Fact002763" format="ixt:numdotdecimal" decimals="0" unitRef="USD">771,293</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2764">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PreferredDividendsAttributableToRedeemableNoncontrollingInterest_i01_zpEzF6JDZ2hf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Preferred dividends attributable to redeemable non-controlling interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2766">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest" contextRef="From2023-01-012023-09-30" id="Fact002767" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AccretionOfEmbeddedDerivativeToRedemptionValue_i01_zeRGq4Yv2Kdl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Accretion of embedded derivative to redemption value</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2769">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue" contextRef="From2023-01-012023-09-30" id="Fact002770" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,988</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the accompanying notes to the unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p id="xdx_04C_c20240101__20240930_zfk9IQDUkKb" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="D_005"></span>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002772" name="us-gaap:NatureOfOperations"><p id="xdx_808_eus-gaap--NatureOfOperations_zh3tk2MuAILb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82F_z9UeT7gQdFnh">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&#8220;Enveric&#8221; or the &#8220;Company&#8221;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#8220;Jay Pharma&#8221;), 1306432 B.C. Ltd., MagicMed
Industries, Inc. (&#8220;MagicMed&#8221;), Enveric Biosciences Canada Inc., Akos Biosciences, Inc. (&#8220;Akos&#8221;), and Enveric
Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its unique discovery and development platform, The Psybrary&#8482;, Enveric has created a robust intellectual property portfolio of new
chemical entities for specific mental health indications. Enveric&#8217;s lead program, the EVM201 Series, comprises next generation
synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#8211; EB-002
(formerly EB-373) &#8211; for the treatment of psychiatric disorders. Enveric is also advancing its product EB-003, a non-hallucinogenic
neuroplastogen from the EVM301 Series, which is expected to offer a first-in-class, new approach to the treatment of difficult-to-address
mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has continued to pursue the development of MagicMed&#8217;s proprietary library, the Psybrary&#8482; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges. The Company synthesizes novel
analogues of serotonin, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which
includes 15 patent families with over a million potential variations and hundreds of synthesized molecules. The Company has created over
1,200 novel molecular compounds and derivatives that are housed in the Psybrary&#8482;. The Company&#8217;s current focus is to develop
its lead molecules, EB-002 and EB-003, and to out license other molecules from the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company screens newly
synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (&#8220;AI&#8221;) tool. Leveraging
AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company believes it streamlines
pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to
help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable can
then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds
of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and
ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#8482; and the AI tool to categorize and characterize
the Psybrary&#8482; substituents to focus on bringing more non-hallucinogenic neuroplastogen molecules from discovery to the clinical
phase.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zRUwE7LEfoM5" title="Reverse stock split"><ix:nonNumeric contextRef="From2025-01-272025-01-27" id="Fact002774" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span>
reverse stock split (&#8220;Reverse Stock Split&#8221;) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025,
pursuant to which every 15 shares of the Company&#8217;s issued and outstanding common stock were reclassified as one share of
common stock. The Reverse Stock Split had no impact on the par value of the Company&#8217;s common stock or the authorized number of
shares of common stock. Unless otherwise indicated, all share and per share information in these unaudited condensed consolidated
financial statements are adjusted to reflect the Reverse Stock Split, prior to any rounding of fractional shares. Any fractional
share resulting from the Reverse Stock Split shall be rounded up to the next whole number of shares.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern, Liquidity and Other Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_di_c20240930_z9jGJolLfKMf" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" id="Fact002776" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">102,919,859</ix:nonFraction></span> as of September 30, 2024, and further
losses are anticipated in the development of its business. For the nine months ended September 30, 2024, the Company has operating cash
outflows of $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_di_c20240101__20240930_z9GsNF9z32yb" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-09-30" id="Fact002778" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,414,590</ix:nonFraction></span> and had a loss from operations of $<span id="xdx_90D_eus-gaap--OperatingIncomeLoss_di_c20240101__20240930_znnSIVYeYnSk" title="Loss from operations"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-09-30" id="Fact002780" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,458,440</ix:nonFraction></span>. Being a research and development company, since inception, the Company
has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company&#8217;s operations have
been funded principally through the issuance of equity. These factors raise substantial doubt about the Company&#8217;s ability to continue
as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At September 30, 2024, the Company had
cash of $<span id="xdx_904_eus-gaap--Cash_iI_c20240930_zbypoEditXxg" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-09-30" id="Fact002782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,111,683</ix:nonFraction></span> and working capital of $<span id="xdx_908_ecustom--WorkingCapital_iI_c20240930_zT7OOFz3QUDh" title="Working capital"><ix:nonFraction name="ENVB:WorkingCapital" contextRef="AsOf2024-09-30" id="Fact002784" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,499,093</ix:nonFraction></span>. The Company&#8217;s current cash on hand is not sufficient to satisfy its operating
cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding
the Company&#8217;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#8217;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, the Purchase Agreement with Lincoln Park (see Note 7), subject to registration,
and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may
not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company
may be required to undertake further cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 126; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the unaudited condensed consolidated financial statements are issued. The
Company&#8217;s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notice</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;)
stating that as of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90C_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_z28sk83ryZt2" title="Minimum of stockholders equity required for continued listing pursuant to exchange"><ix:nonFraction name="ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" contextRef="AsOf2023-11-21" id="Fact002786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,500,000</ix:nonFraction></span> in stockholders&#8217; equity required for
continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting
the Company an extension to regain compliance with the minimum stockholders&#8217; equity requirement by May 20, 2024. On May 21, 2024,
the Company received a letter from Nasdaq notifying the Company that it regained compliance with the minimum stockholders&#8217; equity
requirement for continued listing on the Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2024, the Company received a letter from Nasdaq&#8217;s Listing Qualifications Department stating that because the closing bid
price for the Company&#8217;s common stock listed on Nasdaq was below $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240516_zLQ7bNdCX64f" title="Shares issued price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-05-16" id="Fact002788" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> for 30 consecutive business days, the Company no longer meets
the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the &#8220;Minimum Bid Price Requirement&#8221;).
The Company received an initial period of 180 calendar days from May 16, 2024, or until November 12, 2024, to regain compliance with
the Minimum Bid Price Requirement and was unable to regain compliance during that time. The Company has applied for a second 180-day
compliance period. As of the date hereof, the Company has not heard whether it will be granted the second compliance period. The Company
anticipates conducting a reverse split during the first or second quarter of 2025 in order to regain compliance with the Minimum Bid
Price Requirement if the bid price of the Company&#8217;s common stock fails to close at or above $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231112_zbsvJ8owuw56" title="Shares issued price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-11-12" id="Fact002790" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a minimum of 10
consecutive business days prior the end of the second compliance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002792" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zaoG89jTuAme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_82E_z9xYFaUkmv21">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002794" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zo1UCk4KVdqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6QO8pI0anKh">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and Article 8 of Regulation S-X. Accordingly,
they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Management&#8217;s opinion
is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results
for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year
ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated
financial statements for the year ended December 31, 2023, and related notes thereto included in the Company&#8217;s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 26, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s significant accounting policies and recent accounting standards are summarized in Note 2 of the Company&#8217;s consolidated
financial statements for the year ended December 31, 2023. There were no significant changes to these accounting policies during the
three and nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002796" name="us-gaap:UseOfEstimates"><p id="xdx_842_eus-gaap--UseOfEstimates_zgACgUEtt6Ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zlothHQNIky6">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during
the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements
of changes in such estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and assumptions
include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options,
and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development
efforts. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 127; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002798" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTxTblgKKu1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zClPDxHjeuxe">Reclassification</span>
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
reclassifications have been made to the prior period&#8217;s unaudited condensed consolidated financial statements in order to conform
to the current year presentation. In the prior year, the Company included certain investor related expenses within research and development
on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses
in the current year. This reclassification had no effect on the Company&#8217;s previously reported results of operations, changes in
equity, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002800" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z8ih6xEpJN52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z2bBJpwttRF8">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through September 30, 2024, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended September
30, 2024 and 2023, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the unaudited condensed consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002802" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zz9zwYQJZi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zufsvTMwOUZc">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zNxf3Y69sUla" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30_country_US" id="Fact002804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> in the United States and Australia and $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zTIEMpIcZPXf" title="Cash insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30_country_CA" id="Fact002806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of September 30, 2024, the Company had greater than $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zHuCBoZHjDqi" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30_country_US" id="Fact002808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at United States financial institutions, greater than
$<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--AU_zZeRB6GLgRU2" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30_country_AU" id="Fact002810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> at Australian financial institutions, and less than $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zRH1JuJVWiol" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30_country_CA" id="Fact002812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002814" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zouRUznD8kTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zzq57QAfXM98">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002816" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zr47DZI2OVxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zUgDD5X8Yzl3">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state, and Canadian perspective, the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. The Company receives no tax benefit from operating losses due to a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002818" name="ENVB:ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock"><p id="xdx_84A_ecustom--ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_zVUb3yNkNg7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zb8BN8cj268a">Research
and Development Tax Incentive Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program,
such that a percentage of the Company&#8217;s qualifying research and development expenditures are reimbursed by the Australian government,
and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive
is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and
the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the
Company based on available information at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 128; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002820" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zqZrJl4CcVT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z1Lg34EJJ6o5">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the three and nine months ended September 30, 2024
and 2023 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same for both
basic and fully diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included
in the calculation of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002822" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B7_z5CVvXWyeztg">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2023</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" title="Warrants to purchase shares of common stock" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact002824" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact002827" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,308</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" title="Warrants to purchase shares of common stock" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact002825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember" id="Fact002829" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,660</ix:nonFraction></ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" title="Restricted stock units - vested and unissued" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact002831" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact002834" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,369</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" title="Restricted stock units - vested and unissued" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact002832" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember" id="Fact002836" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,390</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" title="Restricted stock units - unvested" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_custom_RestrictedStockUnitsUnvestedMember" id="Fact002838" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_RestrictedStockUnitsUnvestedMember" id="Fact002841" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,441</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" title="Restricted stock units - unvested" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_custom_RestrictedStockUnitsUnvestedMember" id="Fact002839" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_RestrictedStockUnitsUnvestedMember" id="Fact002843" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,884</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" title="Investment options to purchase shares of common stock" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact002845" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact002848" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" title="Investment options to purchase shares of common stock" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact002846" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember" id="Fact002850" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,334</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" title="Options to purchase shares of common stock" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact002852" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact002855" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,538</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" title="Options to purchase shares of common stock" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact002853" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember" id="Fact002857" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,124</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" title="Total potentially dilutive securities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-012024-09-30" id="Fact002859" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-09-30" id="Fact002862" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,323</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" title="Total potentially dilutive securities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012023-09-30" id="Fact002860" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30" id="Fact002864" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,392</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zEtlBi6f4E33" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002866" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrJYXhzwvHwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zoAJUH5QYSWi">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently assessing the potential impacts of ASU 2023-07, however as the Company
currently has one reportable segment, does not expect this guidance will not have a material impact on its unaudited condensed consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its unaudited condensed consolidated
financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, Disaggregation of Income Statement Expenses</i>, that requires public companies to disclose, in interim and reporting periods,
additional information about certain expenses in the financial statements. The ASU is effective for annual periods beginning after December
15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective
basis or retrospective basis. The Company is currently assessing the potential impacts of ASU 2024-03.</span></p>

</ix:nonNumeric><p id="xdx_850_zAVno6KnfT8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 129; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002868" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zy8Edp5AHpw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_824_z7Mg8EsfDSL6">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002870" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ziQiCk2t3pPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024 and December 31, 2023, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zXzvuaP85kP6" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240930_zcoz1KJCoQJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zapJqSbDhavi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zKrZ6miixm9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopment" contextRef="AsOf2024-09-30" id="Fact002872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact002873" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,320</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_zFzvo0W6luq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2024-09-30" id="Fact002875" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2023-12-31" id="Fact002876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_zu4goeZGb4h8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-09-30" id="Fact002878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">249,048</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact002879" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,559</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zvVKHWyHRBF2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-09-30" id="Fact002881" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,061</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact002882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,036</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_ziA53GvK8xw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs (see Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-09-30" id="Fact002884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,599</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="Fact002885" format="ixt:numdotdecimal" decimals="0" unitRef="USD">567,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zlnv5bhFfkHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PrepaidFranchiseTaxReceivable" contextRef="AsOf2024-09-30" id="Fact002887" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,758</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:PrepaidFranchiseTaxReceivable" contextRef="AsOf2023-12-31" id="Fact002888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,258</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zpwpikb515y3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2890">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2023-12-31" id="Fact002891" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,349</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zodaOt1NZx24" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-09-30" id="Fact002893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,226,576</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact002894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,554</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zD37GGK6TrR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002896" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zAfpxE6QXUl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_827_z685ftKZZ6Og">INTANGIBLE ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002898" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zEFiR25itP9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, the Company&#8217;s intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zdH7GSYv7JN4" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Definite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20240101__20240930_zXzhU8vRzC1f" title="Balance, Definite lived intangible assets" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact002900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,932</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20240101__20240930_zV1sP78Womkd" title="Amortization" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-09-30" id="Fact002902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,564</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20240101__20240930_z44UqjI2pVDl" title="Balance, Definite lived intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" id="Fact002904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,368</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zCfuHWIedht1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
identified definite lived intangible assets, there was <span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20240701__20240930_znKeMJJlBwz9" title="Identified definite lived assets, impairment loss"><span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20240101__20240930_zF4knmIMfKF9" title="Identified definite lived assets, impairment loss"><span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230701__20230930_zpkuTOMQ2knb" title="Identified definite lived assets, impairment loss"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20230930_zUDOg1BlZA8" title="Identified definite lived assets, impairment loss"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2024-07-012024-09-30" id="Fact002906" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2024-01-01to2024-09-30" id="Fact002908" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2023-07-012023-09-30" id="Fact002910" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="From2023-01-012023-09-30" id="Fact002912" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> impairment expense during the three and nine months ended September 30, 2024
and 2023. For identified definite lived intangible assets, amortization expense amounted to $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20240701__20240930_zFV3U9HSup67" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-07-012024-09-30" id="Fact002914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,188</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20230930_zT56FTwyHc1c" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-012023-09-30" id="Fact002916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,191</ix:nonFraction></span> during the three months
ended September 30, 2024 and 2023, respectively and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20240930_zYo4XRsyJZDf" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-09-30" id="Fact002918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,564</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930_zoQh7EViEtUe" title="Intangible assets, amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-09-30" id="Fact002920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,566</ix:nonFraction></span> during each of the nine months ended September 30, 2024 and
2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 130; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002922" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmzzL4dR4bRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_822_znSH8hz3Mwm">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002924" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoCW0JWr2PTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada, with all amounts converted into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zyyD3AxBoyy6" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240930_zvOcwkWkXuS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zzAklmbnG9Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zZqbY38VQNO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-09-30_custom_LabEquipmentMember" id="Fact002926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">819,784</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LabEquipmentMember" id="Fact002927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">836,709</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zqQ9lVXpV0nh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-09-30_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact002929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact002930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,379</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zkzBYSlzRqa2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, gross </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-09-30_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact002932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,804</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember" id="Fact002933" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,379</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8mcxSLzQ0W8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-09-30" id="Fact002935" format="ixt:numdotdecimal" decimals="0" unitRef="USD">479,899</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact002936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">357,711</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zAksAuwNXz57" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" id="Fact002938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">367,689</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact002939" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,377</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z7AXiGSFvfN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_908_eus-gaap--Depreciation_c20240701__20240930_zaPojReubAp3" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-07-012024-09-30" id="Fact002941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,626</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--Depreciation_c20230701__20230930_zZJVuhP4S3s3" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-07-012023-09-30" id="Fact002943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,105</ix:nonFraction></span> for the three months ended September 30, 2024 and 2023, respectively and $<span id="xdx_90D_eus-gaap--Depreciation_c20240101__20240930_zBFwsYVXwDVd" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-09-30" id="Fact002945" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,438</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20230101__20230930_z42pMJ8m9Rf1" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-09-30" id="Fact002947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,734</ix:nonFraction></span> for the
nine months ended September 30, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002949" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFRpZpKPqIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_826_zgQfWA4c3m38">ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002951" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zd1I1uSsF2ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024 and December 31, 2023, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B6_zNKkwJIlhEh2" style="display: none">SCHEDULE OF ACCRUED LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240930_zvKzlW1DszQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zcTfVPR5LFYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_z77zAkrTjG7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:AccruedProductDevelopmentCost" contextRef="AsOf2024-09-30" id="Fact002953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,346</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ENVB:AccruedProductDevelopmentCost" contextRef="AsOf2023-12-31" id="Fact002954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,981</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zhKdxIdipW0j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2024-09-30" id="Fact002956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,736</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2023-12-31" id="Fact002957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,889</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zMeGRmc97SLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-09-30" id="Fact002959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact002960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">584,810</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zddf4tXqrQLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs (see Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2962">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ENVB:AccruedRestructuringCosts" contextRef="AsOf2023-12-31" id="Fact002963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_zwDevUv4HwWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2965">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact002966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zZWtGIQEPn21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Patent costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2024-09-30" id="Fact002968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2023-12-31" id="Fact002969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zqUxNkAHG3Th" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" id="Fact002971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,150</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact002972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,643</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zBQUxbyVXfxa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 131; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact002974" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zBW9WsdE8dR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_82D_zDM5roETPi27">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into the Equity Distribution Agreement (the &#8220;Distribution Agreement&#8221;), with Canaccord
Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales
agent and/or principal, shares of common stock of the Company, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zQJjjEt5ONJ2" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002976" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share having an aggregate offering price of up to
$<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zjMw7eP4KcRk" title="Common stock, offering price"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002978" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million. Due to the offering limitations applicable to the Company and in accordance with the terms of the Distribution Agreement,
the Company may offer Common Stock having an aggregate gross sales price of up to $<span id="xdx_90E_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zCKCnopvvOy7" title="Aggregate gross sales price"><ix:nonFraction name="ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,514</ix:nonFraction></span> pursuant to the prospectus supplement dated
September 1, 2023 (the &#8220;Prospectus Supplement&#8221;). Subject to the terms and conditions of the Distribution Agreement, Canaccord
may sell the Common Stock by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221;. The Company will pay Canaccord
a commission equal to <span id="xdx_90C_ecustom--CommissionPercentage_pid_dp_uPure_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zRmow85qe7q2" title="Commission percentage"><ix:nonFraction name="ENVB:CommissionPercentage" contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002982" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross sales price of the Common Stock sold through Canaccord under the Distribution Agreement and has
also agreed to reimburse Canaccord for certain expenses. The Company may also sell Common Stock to Canaccord as principal for Canaccord&#8217;s
own account at a price agreed upon at the time of sale. Any sale of Common Stock to Canaccord as principal would be pursuant to the terms
of a separate terms agreement between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zw6AOQYVAHNh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002983" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,200</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for gross proceeds
of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zbcrmnpiUsFd"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002984" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,392,502</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Distribution Agreement, and charged
offering costs of $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_z9buGjtR9bj3"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,713</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to additional paid in capital on the unaudited
condensed consolidated balance sheet. As of September 30, 2024 and December 31, 2023, there were deferred offering costs related to the
Distribution Agreement of $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_z6KdFHopkwa"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002986" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zdCiYoM7MaUk"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember" id="Fact002987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,944</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. As of September 30, 2024, there is $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_z34GOkjig08l"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-09-30_custom_DistributionAgreementMember" id="Fact002988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available under the Distribution Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with certain
holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment options to purchase
shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant to which the Holders
agreed to exercise for cash their Existing Warrants and Investment Options to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zgg3qk8xjax3" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember" id="Fact002990" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,800</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
in the aggregate, at a reduced exercised price of $<span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zYly7amKklKg" title="Share price"><ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember" id="Fact002992" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (from an original exercise price
of $<span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_zL7iumNRkoZj" title="Share price"><ix:nonFraction name="us-gaap:WarrantExercisePriceIncrease" contextRef="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember" id="Fact002994" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">116.70</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share), in exchange for the Company&#8217;s
agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zrltgSwz1F1k" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember" id="Fact002996" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,600</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
(the &#8220;Inducement Warrant Shares&#8221;), and the Holders to make a cash payment of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z687gHz4pNT8" title="Cash payment"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember" id="Fact002998" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.88</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Inducement Warrant share for total proceeds
of $280,500</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In January 2024, the Company received aggregate gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131_zHapCoYD7L6c" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-01-012024-01-31" id="Fact003000" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,817,640</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the exercise of the Existing Warrants and
Investment Options by the Holders and the sale of the Inducement Warrants. Because the Existing Warrants and Investment Options by the
Holders and the sale of the Inducement Warrants that exercised on December 28, 2023 and unsettled until January 2024, the proceeds are
included in the condensed consolidated balance sheet as a subscription receivable as of December 31, 2023. As of December 31, 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCBXDGsjb9y9" title="Shares other"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact003002" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,867</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were considered issued as the Company had the enforceable right to the obtain the cash proceeds, which were in-transit,
and the Holders were no longer able to rescind the exercise election. Due to the beneficial ownership limitation provisions, <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zVEWo3btbQQa" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2023-12-31_custom_FebruaryWarrantsMember" id="Fact003004" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder
that the shares may be issued in compliance with such limitation. During the nine months ended September 30, 2024, the Company issued
all <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z5TF2UUMp6xj" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-09-30_custom_FebruaryWarrantsMember" id="Fact003006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zg916ElDyDuj" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-09-30_custom_FebruaryWarrantsMember" id="Fact003008" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,934</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Existing Warrants and Investment
Options exercised that were held in abeyance due to the beneficial ownership limitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with certain
holders of warrants and preferred investment options. The Inducement Letters prohibit the Company from entering into any variable rate
transaction as defined in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2)
transactions whereby the Company may issue securities at a future determined price, such as through an at-the-market offering or an equity
line of credit. The variable rate transaction restriction would have expired after six-months from the closing date of December 28, 2023
for the Inducement Letters for an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions,
however the restriction was waived for the at-the-market offering on March 8, 2024 and the equity line on May 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240308__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zjYNro7XO5I9" title="Issued shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2024-03-08_custom_FebruaryWarrantsMember" id="Fact003010" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,246</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
to the Holders of the Inducement Warrants. The issuance was made in exchange for the permanent and irrevocable waiver of the variable
rate transaction limitation solely with respect to the entry into and/or issuance of shares of common stock in an at the market offering
contained in the Inducement Letters. The fair value of the shares issued for consideration of waiving the variable rate transaction limitation
was $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240308__20240308__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zi4HdS5ztZV4" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-03-082024-03-08_custom_PurchaseAgreementMember" id="Fact003012" format="ixt:numdotdecimal" decimals="0" unitRef="USD">322,453</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and was charged to additional paid in capital,
as it is direct and incremental to the Distribution Agreement, on the unaudited condensed consolidated balance sheet as an offering cost
related to the Distribution Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lincoln
Park Equity Line</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement
(the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which
Lincoln Park has committed to purchase up to $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zp8ZcmoueLP7" title="Repurchase of common stock"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact003014" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million of the Company&#8217;s common stock subject to certain limitations and satisfaction
of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $<span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zUYzst4x5SUf" title="Purchase committment"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact003016" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the Company&#8217;s Common Stock (the
&#8220;Purchase Shares&#8221;). However, such sales of Common Stock by the Company, if any, will be subject to important limitations
set forth in the Purchase Agreement, including limitations on number of shares that may be sold. Sales may occur from time to time, at
the Company&#8217;s sole discretion, over the 24-month period commencing on the date that the conditions to Lincoln Park&#8217;s purchase
obligation set forth in the Purchase Agreement are satisfied, including that a registration statement on Form S-1 covering the resale
of the shares of the Company&#8217;s Common Stock that have been and may be issued to Lincoln Park under the Purchase Agreement, which
the Company has filed with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus
relating thereto is filed with the SEC. As required under the Purchase Agreement, the Company registered a resale of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zshD4nkGDZ" title="Shares resale"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact003018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,032</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, plus the <span id="xdx_908_ecustom--StockIssuedDuringPeriodCommitmentShares_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zUdTF7KnqAw7" title="Shares commitment"><ix:nonFraction name="ENVB:StockIssuedDuringPeriodCommitmentShares" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact003020" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,294</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commitment shares, by Lincoln Park on a registration
statement on Form S-1 dated November 8, 2023, which was declared effective by the SEC on December 5, 2023. As of July 30, 2024, there
were no remaining shares available to be issued in connection with this registration statement. On September 4, 2024, the Company filed
an amended Form S-1, which was declared effective by the SEC on September 11, 2024. The amended Form S-1 registered an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zPkT5CXxYAD4" title="Shares Issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember" id="Fact003022" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">326,667</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that are available
to be issued to Lincoln Park in connection with this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of Common Stock that the Company may elect to sell to Lincoln
Park under the Purchase Agreement, if any, will fluctuate based on the market prices of the Company&#8217;s Common Stock at the time
the Company elects to sell shares to Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the
number of shares of Common Stock that the Company will sell to Lincoln Park under the Purchase Agreement, the purchase price per share
that Lincoln Park will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that the Company
will receive from those purchases by Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering of
an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z9RGlP2zcVE4" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-05-032024-05-03_custom_PurchaseAgreementMember" id="Fact003024" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,534</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
to certain institutional investors. The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction
limitation with respect to any existing or future agreement by the Company to effect any issuance of shares and issue such shares thereunder,
as contained in those certain Inducement Offer Letters, dated December 28, 2023, between the Company and those certain institutional
investors. The Company will not receive any net proceeds in connection with the offering. The fair value of the shares issued for consideration
of waiving the variable rate transaction limitation was $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zauMQSNDqcY1" title="Issued stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-05-032024-05-03_custom_PurchaseAgreementMember" id="Fact003026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">448,840</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and was recorded as deferred offering costs,
as direct and incremental to the Purchase Agreement, within prepaid expenses and other current assets on the unaudited condensed consolidated
balance sheet related to the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock purchase agreements contain customary representations and warranties and certain indemnification obligations of the Company.
The common stock purchase agreements also restrict the Company from issuing, entering into any agreement to issue, or announcing the
issuance of the Company&#8217;s common stock from the date of the common stock purchase agreements until the earlier of 30 days after
entering into the agreements or at such time as one million (<span id="xdx_900_ecustom--NumberOfCommonStockSharesTraded_pid_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zJkk6Fppt4he" title="Number of shares traded in market"><ix:nonFraction name="ENVB:NumberOfCommonStockSharesTraded" contextRef="From2024-05-032024-05-03_custom_PurchaseAgreementsMember" id="Fact003028" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock have
traded in the open market. The closing of the issuance of the Shares pursuant to the common stock purchase agreements closed on May 3,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2024, the Company had issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zAOUCLVuKtYj" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-07-012024-09-30_custom_PurchaseAgreementsMember" id="Fact003030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,699</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_z0t8SV8NVqSi" title="Issued shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementsMember" id="Fact003032" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">81,033</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, respectively, through
the Purchase Agreement for gross cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zXpw4CYe2v51" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-07-012024-09-30_custom_PurchaseAgreementsMember" id="Fact003034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">517,836</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zhpbJl87Coyd" title="Proceeds from common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementsMember" id="Fact003036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,686</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. During the three and nine months ended September 30, 2024, the Company charged offering costs of $<span id="xdx_90E_ecustom--CommonStockEquityDistributionCosts_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zIVdRvqS6kge" title="Deferred offering costs"><ix:nonFraction name="ENVB:CommonStockEquityDistributionCosts" contextRef="From2024-07-012024-09-30_custom_PurchaseAgreementsMember" id="Fact003038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">290,029</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_ecustom--CommonStockEquityDistributionCosts_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zOsq11v9Qzn3" title="Deferred offering costs"><ix:nonFraction name="ENVB:CommonStockEquityDistributionCosts" contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementsMember" id="Fact003040" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,879</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, to additional paid in capital on the unaudited condensed consolidated balance sheet. As of September 30, 2024 and December
31, 2023, the Company has capitalized deferred offering costs of $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zBNHG6DEuaXa" title="Offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2024-09-30_custom_PurchaseAgreementsMember" id="Fact003042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,599</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zxaEsNtxbjE4" title="Offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31_custom_PurchaseAgreementsMember" id="Fact003044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,660</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. As of September 30, 2024, there were <span id="xdx_904_eus-gaap--SharesIssued_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zpPIvOsSmdR7" title="Issued shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_custom_PurchaseAgreementsMember" id="Fact003046" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">321,667</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares available to be issued in connection
with the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to 2020 Long-Term Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2023, the stockholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#8220;Amended Incentive Plan&#8221;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zzGuhpjBd435" title="Authorized shares reserved"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember" id="Fact003048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,334</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to equitable adjustment, and (ii) removed
the Evergreen Provision implemented in the Plan Amendment. During the first quarter of 2024, the Board approved an equitable adjustment
to increase the number of shares available under the Plan by <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardMember_zaJLbhjnWrX5" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-03-31_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember" id="Fact003050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,986</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. As of September 30, 2024, the total
number of shares available for grant under the Incentive Plan was <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardMember_z8UIRa1rkCo1" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-09-30_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember" id="Fact003052" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">418</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003054" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z67kgDeUvC4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the nine months ended September 30, 2024 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z3alfNBYzdpj" style="display: none">SCHEDULE OF STOCK OPTION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; padding-bottom: 1pt">Outstanding at December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zZW4nPRH5Mh3" title="Number of shares, outstanding at beginning" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact003056" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,022</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zAPsEeKm3Wsi" title="Weighted average exercise price, outstanding at beginning" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact003058" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">857.55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930_zdSYfF4AjHx6" title="Weighted average grant date fair value, outstanding at beginning" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31" id="Fact003060" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,158.30</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zmJUkZMdSS5" title="Weighted average remaining contractual term, outstanding balance"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact003062" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.4</ix:nonNumeric></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_z6DDR6QXTCol" title="Aggregate intrinsic value, outstanding at beginning" style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930_zGyDNncyr5zd" title="Number of shares, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3066">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zdXm97VM8Oqj" title="Weighted average exercise price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3068">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zVr3xDBu5KQ7" title="Weighted average grant date fair value, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3070">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zCk41xdSAlQc" title="Number of shares, forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-01to2024-09-30" id="Fact003072" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">484</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zAtJuWhyGd0c" title="Weighted average exercise price, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-01to2024-09-30" id="Fact003074" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">590.25</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zOdybsNqZRfc" title="Weighted average grant date fair value, forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-09-30" id="Fact003076" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">810.30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_ztGb06PyFRPh" title="Number of shares, outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30" id="Fact003078" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,538</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zOJratgg199g" title="Weighted average exercise price, outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30" id="Fact003080" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">941.55</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zPgNtNP9oxsh" title="Weighted average grant date fair value, outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30" id="Fact003082" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,267.65</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwyipFQlqdic" title="Weighted average remaining contractual term, outstanding balance"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:duryear" id="Fact003084" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.6</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_zCRR4NZamkL9" title="Aggregate intrinsic value, outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3086">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_z6UC9WKyhkK9" title="Exercisable shares at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-09-30" id="Fact003088" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,477</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zvPkT2It5xdh" title="Exercisable weighted average price at end" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30" id="Fact003090" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">979.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zy4Bot6yFpwh" title="Weighted average grant date fair value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30" id="Fact003092" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,319.70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zdxHrNr9o8Xk" title="Weighted average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" format="ixt-sec:duryear" id="Fact003094" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">2.2</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zRjNsH3idAti" title="Aggregate intrinsic value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3096">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zsC91P5ApZF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock based compensation expense, recorded within general and administrative expense in the unaudited condensed consolidated
statement of operations and comprehensive loss, related to stock options for the three months ended September 30, 2024 and 2023 was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSCA63e3bYTb" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember" id="Fact003098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">414</ix:nonFraction></span>
and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqjzV3BM2Dj4" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember" id="Fact003100" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,606</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense, recorded within general and administrative expense, related to stock options for the
nine months ended September 30, 2024 and 2023 was $(<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYCgz05w29af" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember" id="Fact003102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,854</ix:nonFraction></span>) and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVrs83ruFYhb" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember" id="Fact003104" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">147,067</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, the Company had $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZGM38My6z95" title="Unamortized stock option expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-09-30_us-gaap_EmployeeStockOptionMember" id="Fact003106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,346</ix:nonFraction></span> in unamortized stock option expense, which will be recognized over a weighted average period
of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLCZ7PjsyzI2" title="Weighted average period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear" id="Fact003108" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.40</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Restricted Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003110" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zoide0sTJXC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQpY2rCnrVg8" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSDvnYRjVNsa" title="Number of shares, Non-vested beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,366</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1F1H1syKVd" title="Weighted average fair value, Non-vested beginning" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003114" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">434.55</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkidLJxfe9Q7" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,767</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3neHKhmj2c" title="Weighted average fair value, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003118" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3Vg6jd5reqj" title="Number of shares, Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">650</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAmEm1RiI2tg" title="Weighted average fair value, Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">43.05</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTolNPfIHg9j" title="Number of shares, vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003124" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,042</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zph55MgT0j7d" title="Weighted average fair value, Vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003126" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">333.30</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVQeX1FIO7Xc" title="Number of shares, non-vested ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003128" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,441</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTVyBNeKeyEf" title="Weighted average fair value, Non-vested ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003130" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">152.55</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z8HprySXCdfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2024 and 2023, the Company recorded $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA03ksBXys6h"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,200</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zupmoATWHKqa"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,253</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss. For the
nine months ended September 30, 2024 and 2023, the Company recorded $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUIxLYL4Eja"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003133" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,570</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGzAAvu3Pd9"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,638,365</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the condensed consolidated statement of operations and comprehensive loss. As of September 30,
2024, the Company had unamortized stock-based compensation costs related to restricted stock units of $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhRCjZ6b2pc7"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,109,526</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will be recognized over a weighted average
period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4M3FziNZl4k"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear" id="Fact003136" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.57</ix:nonNumeric>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. As of September 30, 2024, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUV73LUkgLz9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember" id="Fact003137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,369</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units are vested without
shares of common stock being issued, with all of these shares due as of September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003139" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zTOfSM9LLUo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zUqL5Ly2R5Wg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Stock-based compensation expense for RSUs:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240701__20240930_zmodFPmdDlIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20230930_zs4PFiYdjkd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_zmf0cVH1oD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_zZEsJ47Nk5Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Stock-based compensation expense for RSUs:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKUvRCyrlXe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact003141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact003142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,607</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact003143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">476,513</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact003144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">946,851</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy5GdtVHSVb2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact003146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">207,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact003147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,646</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact003148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">620,057</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact003149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">691,514</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zH3A95M0sis8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact003151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30" id="Fact003152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-09-30" id="Fact003153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30" id="Fact003154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,638,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_zIQQsMnjkR3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Stock-based compensation
    expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-07-012024-09-30" id="Fact003156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">369,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-07-012023-09-30" id="Fact003157" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-09-30" id="Fact003158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,570</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-09-30" id="Fact003159" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,638,365</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_z7vtTMy7sp51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
and Preferred Investment Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003161" name="ENVB:ScheduleOfWarrantsOutstandingTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zRDuE51nVwug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_z71NbaE89wo7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF WARRANTS OUTSTANDING</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk17tpUEWLX" title="Warrant shares outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact003163" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,614</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq56AKA0bj4h" title="Weighted average exercise price, outstanding at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact003165" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">176.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUDMMylc2Y6" title="Weighted average remaining life, outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact003167" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">4.6</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztviImRtgzRi" title="Intrinsic value, outstanding beginning" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3169">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLbx3ZUsJf3b" title="Warrant shares outstanding,expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact003171" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfKAFC3BlLMa" title="Weighted average exercise price, expired" style="text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact003173" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,400.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQCb5deT9I3g" title="Warrant shares outstanding, exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact003175" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">130,267</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAy3hDRC9Wj5" title="Weighted average exercise price, exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" id="Fact003177" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.55</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziYaK0NDJNMe" title="Warrant shares outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-09-30_us-gaap_WarrantMember" id="Fact003179" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA2daHh19Sa" title="Weighted average exercise price, outstanding at end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_WarrantMember" id="Fact003181" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">536.70</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrcQaXQIW2If" title="Weighted average remaining life, outstanding"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact003183" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">3.0</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z80MZv9WG0j2" title="Intrinsic value, outstanding ending" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3185">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEU0VfgR2f3" title="Warrant shares outstanding, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2024-09-30_us-gaap_WarrantMember" id="Fact003187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKD79Pj5ptJl" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_us-gaap_WarrantMember" id="Fact003189" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">536.70</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Gvlbmlniod" title="Weighted average remaining life, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact003191" name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">3.0</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wRhNTAjbr5" title="Intrinsic value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3193">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zG86r2zijGTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003195" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRHQg5nAtHC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zpBIF7iGXfLf" style="display: none">SCHEDULE OF   INVESTMENT OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 1pt">Outstanding at December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7C4CTJ0as81" title="Investment options outstanding, beginning" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember" id="Fact003197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zwpju5CZtKp8" title="Weighted average exercise price, issued" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsMember" id="Fact003199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_ziyuoHOnTHS7" title="Weighted average remaining life, outstanding"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact003201" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">4.1</ix:nonNumeric></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zpqBJPNNsSzc" title="Intrinsic value, outstanding beginning" style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3203">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zrCGOj1W0Is1" title="Investment options outstanding, end" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember" id="Fact003205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zZ4hyedUtGYe" title="Weighted average exercise price, issued" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember" id="Fact003207" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zU4T0rv80XJl" title="Weighted average remaining life, outstanding"><ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact003209" name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">2.9</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zAZK6Fg6sJZ3" title="Intrinsic value, outstanding end" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3211">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zRhtKwHprZp3" title="Investment options outstanding, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember" id="Fact003213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z3GskQ71Ikse"><ix:nonFraction name="ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember" id="Fact003214" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">150.00</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zmmJiJ55bMeg" title="Weighted average remaining life, exercisable"><ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsMember" format="ixt-sec:duryear" id="Fact003216" name="ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">2.9</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zcGeBdKJuGgj" title="Intrinsic value, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3218">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zZrTU04wDWBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003220" name="ENVB:LicensingAgreementsDisclosureTextBlock"><p id="xdx_806_ecustom--LicensingAgreementsDisclosureTextBlock_zG52ebE7ez33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_824_zObb3gdTRkdk">LICENSING AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2024, Akos entered into an Exclusive License Agreement (the &#8220;License Agreement&#8221;) with Aries Science and Technology,
LLC, an Ohio limited liability company (&#8220;Aries&#8221;), pursuant to which Akos granted Aries a license of Akos&#8217;s patented
radiation dermatitis topical product. The license allows Akos to use the patented formulation to develop pharmaceutical or non-pharmaceutical
products for treating radiation dermatitis suitable for administration to humans or animals. The license is exclusive (subject to certain
exceptions contained in the License Agreement), worldwide, royalty-bearing, and includes the right to sublicense. Akos is entitled to
potential license payments, milestone payments and royalties based on net revenues of the Licensed Product on a licensed product-by-licensed
product and country-by-country basis pursuant to the terms of the Agreement. Aries has the option during the license term, to purchase
the rights to each licensed product (on a licensed product-by-licensed product basis) in the form of an exclusive (as to the applicable
licensed product), fully paid, transferable right and license to the licensed product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not earned any revenue related to this agreement as of September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003222" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLh9T8RDzKTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82D_zwhFZNaJSV1b">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s
financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-002, the Company&#8217;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-002 in coordination with the Company&#8217;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-002. EB-002, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s
Therapeutic Goods Administration and is currently in preclinical development targeting the treatment of anxiety disorder. The total cost
of the Avance Clinical contract is approximately <span id="xdx_906_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zQ2Bv8HIf6i3" title="Contract cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2024-09-30_custom_AvanceClinicalMember" id="Fact003224" format="ixt:numdotdecimal" decimals="0" unitRef="AUD">3,400,000</ix:nonFraction></span> AUD, which translates to approximately $<span id="xdx_904_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zzF4cy903UQk" title="Contract cost"><ix:nonFraction name="us-gaap:CapitalizedContractCostNet" contextRef="AsOf2024-09-30_custom_AvanceClinicalMember" id="Fact003226" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,329,000</ix:nonFraction></span> USD as of September 30,
2024. As of September 30, 2024, the Company has paid 100% of the Avance Clinical contract costs and has $<span id="xdx_90B_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z8i7qjxAl014" title="Prepaid assets"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-09-30_custom_AvanceClinicalMember" id="Fact003228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> recorded as prepaid
assets within prepaid and other current assets, accrued $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z8l8kIySOmok" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30_custom_AvanceClinicalMember" id="Fact003230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> recorded as accrued liabilities and $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zMpSYaITZFrd" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30_custom_AvanceClinicalMember" id="Fact003232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as accounts payable on the accompanying
condensed consolidated balance sheet. For the three and nine months ended September 30, 2024 and 2023, the Company has expensed $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_iN_c20240701__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zZShdU2atqH5" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30_custom_AvanceClinicalMember" id="Fact003234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,385</ix:nonFraction></span>
and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zg1MdD5bmXg7" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-012024-09-30_custom_AvanceClinicalMember" id="Fact003236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">508,774</ix:nonFraction></span>, and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zqSzKt85YCNe" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_custom_AvanceClinicalMember" id="Fact003238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,117</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zkCFSJlnZzDl" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_custom_AvanceClinicalMember" id="Fact003240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,284</ix:nonFraction></span>, respectively, in research and development expenses within the accompanying unaudited condensed
consolidated statement of operations. As of September 30, 2024, all payments have been made and the project is substantially completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to Australian tax law, the Company is allowed an R&amp;D tax credit that reduces a company&#8217;s tax bill in Australia for expenses
incurred in R&amp;D subject to certain requirements. The Company&#8217;s Australian subsidiary submits R&amp;D tax credit requests annually
for research and development expenses incurred. At September 30, 2024 and December 31, 2023, the Company had a research and development
tax credit receivable of $<span id="xdx_902_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_dxL_c20240930_zRTgxwIWfh43" title="Research and development expense tax credit receivable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3242">0</span></span> and $<span id="xdx_90B_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_c20231231_zWQavAebeKKl" title="Research and development expense tax credit receivable"><ix:nonFraction name="ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable" contextRef="AsOf2023-12-31" id="Fact003244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,349</ix:nonFraction></span>, respectively, for R&amp;D expenses incurred in Australia, included in prepaid and other current
assets within the accompanying unaudited condensed consolidated statement of operations. The Company received the amount due in relation
to the research and development tax credit during the three months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#8220;Vogel-Nathan Purchase
Agreement&#8221;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The patent portfolio acquired and developed under the Vogel-Nathan Purchase Agreement
was sold to undisclosed buyers for an amount not material to these financials in the first quarter of 2024. No additional financial or
other obligations exist regarding the Vogel-Nathan Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Consulting and Vendor Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between one and 12 months. These agreements, in aggregate, commit the Company to approximately $<span id="xdx_905_eus-gaap--Cash_iI_pn5n6_c20240930__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_z4d5IeWyKFrl" title="Future cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2024-09-30_custom_OtherConsultingAndVendorAgreementsMember" id="Fact003246" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million in future
cash payments, inclusive of amounts in accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#8220;RIF&#8221;) of approximately <span id="xdx_90C_ecustom--ReductionInForceRestructuringPercentage_pid_dp_uPure_c20230531__20230531_zS8hAWRmTaBd" title="Reduction in force restructuring percentage"><ix:nonFraction name="ENVB:ReductionInForceRestructuringPercentage" contextRef="From2023-05-312023-05-31" id="Fact003248" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction></span>% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The plan included a focus on progressing the Company&#8217;s existing
non-cannabinoid pipeline while reducing the rate of spend and managing cash flow. In June 2023, the Company completed the reduction in
force, with such severance expenses recorded in general and administrative accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating Officer
(the &#8220;Kanubaddi Separation Agreement&#8221;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi received salary
and benefits that is paid out in twelve monthly installments beginning in July 2023, was eligible for his 2023 performance bonus, which
was not achieved, and any outstanding restricted stock units retained their vesting conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003250" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zpFIobmcUyYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Reduction in Force/Restructuring activity and ending balance at September 30, 2024 for the remaining severance
payments included in accrued expenses in the consolidated balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_zdmdhPytwCO" style="display: none">SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-right: 0.5in; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accrued
    Restructuring Costs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif">January 1, 2024 beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20240101__20240930_z2Ef8GLQ4vih" title="Restructuring cost payable, beginning" style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="AsOf2023-12-31" id="Fact003252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">301,645</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Restructuring costs paid</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--RestructuringCosts_c20240101__20240930_zqX3YtRiw8z1" title="Restructuring costs paid" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="From2024-01-01to2024-09-30" id="Fact003254" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">301,645</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024 ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20240101__20240930_zwQfLsOPTXb1" title="Restructuring cost payable, ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zC3lkyGUS4zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-09-30" escape="true" id="Fact003258" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zxCQVvJ8Awt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_82B_zgbEecB5evBj">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to September 30, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember_zMKqillto5Fi" title="Stock issued during period shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-10-012024-11-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember" id="Fact003260" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,334</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock through the Purchase
Agreement with Lincoln Park for gross cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241001__20241114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi8yIXYXJKA5" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-10-012024-11-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember" id="Fact003262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,820</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As of November 12, 2024, there are <span id="xdx_90F_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember_ztVrZ7zIer6d" title="Remaining shares"><ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember" id="Fact003264" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">258,334</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining registered shares available to
be issued in connection with this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company granted <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20241009__20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgektihs4axg" title="Restricted stock units, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-10-092024-10-09_us-gaap_SubsequentEventMember" id="Fact003266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,776</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units to its officers and
certain employees, which fully vest on October 9, 2028 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241009__20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxlNgw6lAww5" title="Restricted stock awards"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2024-10-092024-10-09_us-gaap_SubsequentEventMember" id="Fact003268" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,586</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock awards to its non-employee
directors, which fully vest on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 9, 2024, the Board approved an equitable adjustment to increase the number of shares available under the Incentive Plan by <span id="xdx_90D_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zAlFvAJFFIXi" title="Shares available for grant"><ix:nonFraction name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" contextRef="AsOf2024-10-09_us-gaap_SubsequentEventMember_custom_IncentivePlanMember" id="Fact003270" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,402</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares, which increased the total number
of authorized shares under the Incentive Plan to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zS5camNtv1pl" title="Authorized shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-10-09_us-gaap_SubsequentEventMember_custom_IncentivePlanMember" id="Fact003272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,721</ix:nonFraction></span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, the Company entered into an Out-Licensing Agreement (the &#8220;Agreement&#8221;) with MycoMedica Life Sciences, PBC,
a Delaware public benefit corporation (&#8220;MycoMedica&#8221;), pursuant to which the Company will out-license EB-002 and its EVM201
series to MycoMedica for further development and sales of the product in treatment of neuropsychiatric disorders. MycoMedica will receive
an exclusive, global license to the formulations, drugs, method of use, and medical devices developed by Enveric to utilize the compound.
As part of the Agreement, the Company will receive modest upfront payments, and if certain conditions are met, will receive development
and sales milestone payments of up to $<span id="xdx_908_ecustom--ProceedsFromAchievingDevelopmentAndSalesMilestones_pn6n6_c20241107__20241107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCjnaEc28OGl"><ix:nonFraction name="ENVB:ProceedsFromAchievingDevelopmentAndSalesMilestones" contextRef="From2024-11-072024-11-07_us-gaap_SubsequentEventMember" id="Fact003273" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">62</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and tiered single-digit royalties based
on future sales. MycoMedica has the option during the license term to buyout its milestone and royalty payment obligations at a predetermined
amount depending upon the stage of product development and commercialization at the time of the buyout. Further, MycoMedica has the right
to purchase the licensed patents at a nominal amount upon a change of control of the Company, although doing so does not relieve MycoMedica
of any of its payment obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">T<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
Company completed a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zQBsqKof122"><ix:nonNumeric contextRef="From2025-01-272025-01-27" id="Fact003274" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-15</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse
Stock Split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. The Reverse Stock Split reduced the number of
shares of the Company&#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse
Stock Split. The number of shares of the Company&#8217;s authorized common stock was not affected by the Reverse Stock Split and the
par value of the Company&#8217;s common stock remained unchanged at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV3e3b5rhSca"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember" id="Fact003275" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. No fractional shares were issued in connection with the Reverse Stock Split.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_81B_zqJSOJPNXFT9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Enveric
Biosciences, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,229,330
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,666,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Warrants to Purchase up to
1,666,666 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,666,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Warrants to Purchase up to
1,666,666 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>437,336
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Funded Warrants to Purchase 437,336
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3,770,668
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock Underlying the Series
A Warrants, Series B Warrants and Pre-Funded Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>116,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement Agent Warrants to Purchase up
to 116,666 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>116,666
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares of Common Stock underlying the Placement
Agent Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>H.C. Wainwright &amp; Co.</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
30,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>envb-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSDWbP9z5Z8SekhvWB4bclqryYnJQd9rCfBMEGWIToF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ENVB="http://enveric.com/20240930" elementFormDefault="qualified" targetNamespace="http://enveric.com/20240930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" id="StatementsOfChangesInMezzanineEquityAndShareholdersEquity">
          <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" id="StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical">
          <link:definition>00000006 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" id="BusinessAndLiquidityAndOtherUncertainties">
          <link:definition>999008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>999010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>999011 - Disclosure - INTANGIBLE ASSETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/AccruedLiabilities" id="AccruedLiabilities">
          <link:definition>999013 - Disclosure - ACCRUED LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" id="ShareCapitalAndOtherEquityInstruments">
          <link:definition>999014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" id="RedeemableNon-controllingInterest">
          <link:definition>999015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/FairValue" id="FairValue">
          <link:definition>999016 - Disclosure - FAIR VALUE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999017 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999018 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999019 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/LicensingAgreements" id="LicensingAgreements">
          <link:definition>999020 - Disclosure - LICENSING AGREEMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" id="BusinessAndLiquidityAndOtherUncertaintiesTables">
          <link:definition>999022 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>999024 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>999025 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/AccruedLiabilitiesTables" id="AccruedLiabilitiesTables">
          <link:definition>999027 - Disclosure - ACCRUED LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" id="ShareCapitalAndOtherEquityInstrumentsTables">
          <link:definition>999028 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" id="RedeemableNon-controllingInterestTables">
          <link:definition>999029 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/FairValueTables" id="FairValueTables">
          <link:definition>999030 - Disclosure - FAIR VALUE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>999031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999032 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" id="ScheduleOfRestructuringCostsPayableDetails">
          <link:definition>999033 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" id="BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative">
          <link:definition>999034 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" id="ScheduleOfPotentiallyDilutiveSecuritiesDetails">
          <link:definition>999035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>999037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" id="ScheduleOfGoodwillDetails">
          <link:definition>999038 - Disclosure - SCHEDULE OF GOODWILL (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>999039 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" id="ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails">
          <link:definition>999040 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>999041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" id="ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails">
          <link:definition>999042 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999043 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" id="ScheduleOfAccruedLiabilitiesDetails">
          <link:definition>999044 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" id="ScheduleOfStockOptionDetails">
          <link:definition>999045 - Disclosure - SCHEDULE OF STOCK OPTION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" id="ScheduleOfStockOptionAssumptionDetails">
          <link:definition>999046 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" id="ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails">
          <link:definition>999047 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" id="ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails">
          <link:definition>999048 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" id="ScheduleOfWarrantsOutstandingDetails">
          <link:definition>999049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" id="ScheduleOfWarrantsAndInvestmentOptionsDetails">
          <link:definition>999050 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" id="ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails">
          <link:definition>999051 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" id="ShareCapitalAndOtherEquityInstrumentsDetailsNarrative">
          <link:definition>999052 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" id="ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails">
          <link:definition>999053 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" id="RedeemableNon-controllingInterestDetailsNarrative">
          <link:definition>999054 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" id="ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails">
          <link:definition>999055 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" id="ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails">
          <link:definition>999056 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" id="ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails">
          <link:definition>999057 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/FairValueDetailsNarrative" id="FairValueDetailsNarrative">
          <link:definition>999058 - Disclosure - FAIR VALUE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" id="ScheduleOfWeightedAverageRemainingLeaseTermDetails">
          <link:definition>999059 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" id="ScheduleOfEarningLossBeforeIncomeTaxDetails">
          <link:definition>999061 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" id="ScheduleOfIncomeTaxExpenseBenefitsDetails">
          <link:definition>999062 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999063 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" id="ScheduleOfOperatingLossCarryForwardsDetails">
          <link:definition>999064 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" id="ScheduleOfEffectiveStatutoryIncomeTaxRateDetails">
          <link:definition>999065 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999066 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" id="ScheduleOfInvestmentOptionsDetails">
          <link:definition>999067 - Disclosure - SCHEDULE OF INVESTMENT OPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" id="ScheduleOfReductionInForcerestructuringActivityDetails">
          <link:definition>999069 - Disclosure - SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="ENVB_SeriesCRedeemablePreferredStockMember" name="SeriesCRedeemablePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestMember" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MezzanineEquityMember" name="MezzanineEquityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SubscriptionReceivableMember" name="SubscriptionReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_KanubaddiSeparationAgreementMember" name="KanubaddiSeparationAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MrKanubaddiEmploymentAgreementMember" name="MrKanubaddiEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrefundedCommonStockWarrantsMember" name="PrefundedCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" name="WarrantsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" name="RestrictedStockUnitsVestedAndUnIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestrictedStockUnitsUnvestedMember" name="RestrictedStockUnitsUnvestedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" name="RestrictedStockAwardsVestedAndUnIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CommonStockInAbeyanceMember" name="CommonStockInAbeyanceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" name="InvstmentOptionsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OptionsToPurchaseSharesOfCommonStockMember" name="OptionsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" name="InvestmentOptionsToPurchaseSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_LabEquipmentMember" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" name="ComputerEquipmentAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DistributionAgreementMember" name="DistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CanaccordGenuityLLCMember" name="CanaccordGenuityLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegistrationRightsAgreementMember" name="RegistrationRightsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_UnderwritersMember" name="UnderwritersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" name="RegisteredDirectSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PIPESecuritiesPurchaseAgreementMember" name="PIPESecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" name="RDOfferingAndPIPEInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" name="TwoThousandTwentyLongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantAmendmentAgreementsMember" name="WarrantAmendmentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PlacementAgentPreferredInvestmentOptionsMember" name="PlacementAgentPreferredInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryWarrantsMember" name="FebruaryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PreModificationWarrantsMember" name="PreModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ExistingWarrantsMember" name="ExistingWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionsMember" name="InvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PostModificationWarrantsMember" name="PostModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PurchaseAgreementsMember" name="PurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_BoardMember" name="BoardMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RothAndInducementWarrantsMember" name="RothAndInducementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AkosSecuritiesPurchaseAgreementMember" name="AkosSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AkosMember" name="AkosMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InitialMeasurementMember" name="InitialMeasurementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SubsequentMeasurementMember" name="SubsequentMeasurementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" name="WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" name="WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" name="WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" name="DerivativeLiabilityMayTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WainwrightInvestmentOptionsMember" name="WainwrightInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RDInvestmentOptionsMember" name="RDInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PIPEInvestmentOptionsMember" name="PIPEInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" name="FebruaryTwentyTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" name="FebruaryTwentyTwentyTwoPostModificationWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MeasurementInputMarketRateMember" name="MeasurementInputMarketRateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_JanuaryTwentyTwentyOneWarrantsMember" name="JanuaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FebruaryTwentyTwentyOneWarrantsMember" name="FebruaryTwentyTwentyOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" name="HCWainwrightAndCoLLCInvestmentOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AvanceClinicalMember" name="AvanceClinicalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_VogalNathanPurchaseAgreementMember" name="VogalNathanPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OneTimeMilestoneMember" name="OneTimeMilestoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AdditionalMilestoneMember" name="AdditionalMilestoneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OtherConsultingAndVendorAgreementsMember" name="OtherConsultingAndVendorAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PurchaseAgreeentMember" name="PurchaseAgreeentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IncentivePlanMember" name="IncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilitiesCurrent" name="WarrantLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InducementExpense" name="InducementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_TemporaryEquityShares" name="TemporaryEquityShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" name="PreferredDividendsAttributableToRedeemableNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" name="AccretionOfEmbeddedDerivativeToRedemptionValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" name="AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" name="StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" name="StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestValue" name="RedeemableNoncontrollingInterestValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestShares" name="RedeemableNoncontrollingInterestShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" name="IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" name="StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" name="StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" name="RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" name="RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" name="IssuanceOfRoundedSharesAsResultOfReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" name="StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" name="StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" name="StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" name="StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" name="StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" name="StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NetOfferingCosts" name="NetOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" name="RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" name="RedeemableNoncontrollingInterestIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CommonStockEquityDistributionCosts" name="CommonStockEquityDistributionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NoncashIncomeTaxExpense" name="NoncashIncomeTaxExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" name="IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" name="ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" name="WarrantsIssuedInConjunctionWithCommonStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfEmbeddedDerivative" name="IssuanceOfEmbeddedDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockSubscriptionReceivable" name="StockSubscriptionReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_OfferingCostsAccruedNotPaid" name="OfferingCostsAccruedNotPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsIssuedForOfferingCosts" name="WarrantsIssuedForOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" name="IssuanceOfCommonSharesForDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" name="InducedConversionOfWarrantsAndPreferredInvestmentOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" name="InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" name="ModificationOfWarrantsAsPartOfShareCapitalRaise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DeferredOfferingCostsChargedToOfferingCosts" name="DeferredOfferingCostsChargedToOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" name="DisclosureRedeemableNoncontrollingInterestAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNonControllingInterestTextBlock" name="RedeemableNonControllingInterestTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DisclosureLicensingAgreementsAbstract" name="DisclosureLicensingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_LicensingAgreementsDisclosureTextBlock" name="LicensingAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" name="ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" name="RedeemableNoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" name="ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ScheduleOfValuationOfWarrantsTextBlock" name="ScheduleOfValuationOfWarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RestructuringCostsIncurred" name="RestructuringCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ExpenseRelatedToAccelerationOfVesting" name="ExpenseRelatedToAccelerationOfVesting" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MarketPerformanceBasedShares" name="MarketPerformanceBasedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" name="MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrepaidResearchAndDevelopment" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrepaidFranchiseTaxReceivable" name="PrepaidFranchiseTaxReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" name="PrepaidResearchAndDevelopmentTaxIncentiveReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillCurrencyTranslation" name="GoodwillCurrencyTranslation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillImpairmentLossGross" name="GoodwillImpairmentLossGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillAccumulatedImpairmentLoss" name="GoodwillAccumulatedImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillCurrencyTranslationImpairmentLoss" name="GoodwillCurrencyTranslationImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" name="GoodwillForeignCurrencyTranslationGainLossGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" name="GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_GoodwillCurrencyTranslationLoss" name="GoodwillCurrencyTranslationLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AccruedProductDevelopmentCost" name="AccruedProductDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_AccruedRestructuringCosts" name="AccruedRestructuringCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" name="SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_CommissionPercentage" name="CommissionPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfStockIssuanceCost" name="PaymentsOfStockIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfAllocatedEquity" name="PaymentsOfAllocatedEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfInvestmentOptionLiability" name="PaymentsOfInvestmentOptionLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" name="PaymentsOfStockIssuanceCostsRecordedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NumberOfVestedAndUnissuedShares" name="NumberOfVestedAndUnissuedShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ClassOfWarrantOrRightReasonForIssuing" name="ClassOfWarrantOrRightReasonForIssuing" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionSharePrice" name="InvestmentOptionSharePrice" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionExercisePrice" name="InvestmentOptionExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOptionTerm" name="InvestmentOptionTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentOutstandingMeasurementInput" name="InvestmentOutstandingMeasurementInput" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SharePriceOption" name="SharePriceOption" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentIntrinsicValue" name="InvestmentIntrinsicValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_InvestmentInducementGain" name="InvestmentInducementGain" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockIssuedDuringPeriodCommitmentShares" name="StockIssuedDuringPeriodCommitmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_NumberOfCommonStockSharesTraded" name="NumberOfCommonStockSharesTraded" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_SpinoffAndRelatedPrivatePlacementDescription" name="SpinoffAndRelatedPrivatePlacementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsToPurchaseCommonStockPercentage" name="WarrantsToPurchaseCommonStockPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_UnpaidDividends" name="UnpaidDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FairValueOfDerivativeLiability" name="FairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RedeemableNoncontrollingInterest" name="RedeemableNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_WarrantsAndRightsOutstandingStockPrice" name="WarrantsAndRightsOutstandingStockPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ConvertiblePreferredStockPrincipalValue" name="ConvertiblePreferredStockPrincipalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_StockOptionExercisePrice" name="StockOptionExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_RoyaltiesPercentage" name="RoyaltiesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ReductionInForceRestructuringPercentage" name="ReductionInForceRestructuringPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ResearchAndDevelopmentCapitalizedExpenses" name="ResearchAndDevelopmentCapitalizedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_DeferredTaxAssetsAndIntangibleAmortization" name="DeferredTaxAssetsAndIntangibleAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" name="EffectiveIncomeTaxRateReconciliationDeferredTrueup" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" name="ProceedsFromAchievingDevelopmentAndSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ENVB_FairValueAdjustmentOfWarrantsOtherIncomeExpenses" name="FairValueAdjustmentOfWarrantsOtherIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>envb-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheets" xlink:href="envb-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheetsParenthetical" xlink:href="envb-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="envb-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:href="envb-20240930.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:href="envb-20240930.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfCashFlows" xlink:href="envb-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="envb-20240930.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssets" xlink:href="envb-20240930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipment" xlink:href="envb-20240930.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilities" xlink:href="envb-20240930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValue" xlink:href="envb-20240930.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingencies" xlink:href="envb-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxes" xlink:href="envb-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEvents" xlink:href="envb-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/LicensingAgreements" xlink:href="envb-20240930.xsd#LicensingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="envb-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsTables" xlink:href="envb-20240930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentTables" xlink:href="envb-20240930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilitiesTables" xlink:href="envb-20240930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueTables" xlink:href="envb-20240930.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:href="envb-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesTables" xlink:href="envb-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:href="envb-20240930.xsd#ScheduleOfRestructuringCostsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="envb-20240930.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:href="envb-20240930.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="envb-20240930.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:href="envb-20240930.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsDetailsNarrative" xlink:href="envb-20240930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:href="envb-20240930.xsd#ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="envb-20240930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:href="envb-20240930.xsd#ScheduleOfStockOptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:href="envb-20240930.xsd#ScheduleOfStockOptionAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="envb-20240930.xsd#ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:href="envb-20240930.xsd#ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="envb-20240930.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:href="envb-20240930.xsd#ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:href="envb-20240930.xsd#ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterestDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="envb-20240930.xsd#ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueDetailsNarrative" xlink:href="envb-20240930.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:href="envb-20240930.xsd#ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="envb-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:href="envb-20240930.xsd#ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:href="envb-20240930.xsd#ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:href="envb-20240930.xsd#ScheduleOfOperatingLossCarryForwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:href="envb-20240930.xsd#ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:href="envb-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:href="envb-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" xlink:href="envb-20240930.xsd#ScheduleOfReductionInForcerestructuringActivityDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesCurrent" xlink:label="loc_ENVBWarrantLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_ENVBWarrantLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NoncashIncomeTaxExpense" xlink:label="loc_ENVBNoncashIncomeTaxExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENVBNoncashIncomeTaxExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:label="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:label="loc_ENVBProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ENVBProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:title="999008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssets" xlink:title="999011 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipment" xlink:title="999012 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilities" xlink:title="999013 - Disclosure - ACCRUED LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="999014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:title="999015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValue" xlink:title="999016 - Disclosure - FAIR VALUE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxes" xlink:title="999018 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEvents" xlink:title="999019 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/LicensingAgreements" xlink:title="999020 - Disclosure - LICENSING AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:title="999022 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999024 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsTables" xlink:title="999025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentTables" xlink:title="999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilitiesTables" xlink:title="999027 - Disclosure - ACCRUED LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="999028 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:title="999029 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueTables" xlink:title="999030 - Disclosure - FAIR VALUE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:title="999031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesTables" xlink:title="999032 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:title="999033 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999034 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopment" xlink:label="loc_ENVBPrepaidResearchAndDevelopment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ENVBPrepaidResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidFranchiseTaxReceivable" xlink:label="loc_ENVBPrepaidFranchiseTaxReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ENVBPrepaidFranchiseTaxReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:title="999038 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999039 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:title="999040 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:title="999042 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999043 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="999044 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccruedProductDevelopmentCost" xlink:label="loc_ENVBAccruedProductDevelopmentCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_ENVBAccruedProductDevelopmentCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccruedRestructuringCosts" xlink:label="loc_ENVBAccruedRestructuringCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_ENVBAccruedRestructuringCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:title="999045 - Disclosure - SCHEDULE OF STOCK OPTION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:title="999046 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="999047 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:title="999048 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="999052 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:title="999053 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:title="999054 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="999055 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:title="999057 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueDetailsNarrative" xlink:title="999058 - Disclosure - FAIR VALUE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:title="999059 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:title="999061 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:title="999062 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:label="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:label="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:title="999064 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:title="999065 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:label="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" xlink:title="999067 - Disclosure - SCHEDULE OF INVESTMENT OPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:title="999068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" xlink:title="999069 - Disclosure - SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>envb-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheets" xlink:href="envb-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheetsParenthetical" xlink:href="envb-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="envb-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:href="envb-20240930.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:href="envb-20240930.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfCashFlows" xlink:href="envb-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="envb-20240930.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssets" xlink:href="envb-20240930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipment" xlink:href="envb-20240930.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilities" xlink:href="envb-20240930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValue" xlink:href="envb-20240930.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingencies" xlink:href="envb-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxes" xlink:href="envb-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEvents" xlink:href="envb-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/LicensingAgreements" xlink:href="envb-20240930.xsd#LicensingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="envb-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsTables" xlink:href="envb-20240930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentTables" xlink:href="envb-20240930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilitiesTables" xlink:href="envb-20240930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueTables" xlink:href="envb-20240930.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:href="envb-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesTables" xlink:href="envb-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:href="envb-20240930.xsd#ScheduleOfRestructuringCostsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="envb-20240930.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:href="envb-20240930.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="envb-20240930.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:href="envb-20240930.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsDetailsNarrative" xlink:href="envb-20240930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:href="envb-20240930.xsd#ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="envb-20240930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:href="envb-20240930.xsd#ScheduleOfStockOptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:href="envb-20240930.xsd#ScheduleOfStockOptionAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="envb-20240930.xsd#ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:href="envb-20240930.xsd#ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="envb-20240930.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:href="envb-20240930.xsd#ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:href="envb-20240930.xsd#ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterestDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="envb-20240930.xsd#ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueDetailsNarrative" xlink:href="envb-20240930.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:href="envb-20240930.xsd#ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="envb-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:href="envb-20240930.xsd#ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:href="envb-20240930.xsd#ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:href="envb-20240930.xsd#ScheduleOfOperatingLossCarryForwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:href="envb-20240930.xsd#ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:href="envb-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:href="envb-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" xlink:href="envb-20240930.xsd#ScheduleOfReductionInForcerestructuringActivityDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_100" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestMember" xlink:label="loc_ENVBRedeemableNoncontrollingInterestMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBRedeemableNoncontrollingInterestMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MezzanineEquityMember" xlink:label="loc_ENVBMezzanineEquityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBMezzanineEquityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubscriptionReceivableMember" xlink:label="loc_ENVBSubscriptionReceivableMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSubscriptionReceivableMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityShares" xlink:label="loc_ENVBTemporaryEquityShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityShares_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestValue" xlink:label="loc_ENVBRedeemableNoncontrollingInterestValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestValue_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestShares" xlink:label="loc_ENVBRedeemableNoncontrollingInterestShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestShares_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:label="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_100" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_100" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:label="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit_100" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_100" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" xlink:label="loc_ENVBStockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_100" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_100" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" xlink:label="loc_ENVBStockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_100" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_100" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:label="loc_ENVBStockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_100" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_100" xlink:type="arc" order="38" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:title="999008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssets" xlink:title="999011 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipment" xlink:title="999012 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilities" xlink:title="999013 - Disclosure - ACCRUED LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="999014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:title="999015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValue" xlink:title="999016 - Disclosure - FAIR VALUE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxes" xlink:title="999018 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEvents" xlink:title="999019 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/LicensingAgreements" xlink:title="999020 - Disclosure - LICENSING AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:title="999022 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999024 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsTables" xlink:title="999025 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentTables" xlink:title="999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilitiesTables" xlink:title="999027 - Disclosure - ACCRUED LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="999028 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:title="999029 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueTables" xlink:title="999030 - Disclosure - FAIR VALUE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:title="999031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesTables" xlink:title="999032 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:title="999033 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999034 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_EquityDistributionAgreementMember" xlink:label="loc_ENVBEquityDistributionAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBEquityDistributionAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_KanubaddiSeparationAgreementMember" xlink:label="loc_ENVBKanubaddiSeparationAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBKanubaddiSeparationAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MrKanubaddiEmploymentAgreementMember" xlink:label="loc_ENVBMrKanubaddiEmploymentAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBMrKanubaddiEmploymentAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WorkingCapital" xlink:label="loc_ENVBWorkingCapital_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBWorkingCapital_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromShortTermDebt_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSeveranceCosts1_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesAndWages_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaapRestructuringReserve_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRestructuringReserve_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:label="loc_ENVBExpenseRelatedToAccelerationOfVesting_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBExpenseRelatedToAccelerationOfVesting_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MarketPerformanceBasedShares" xlink:label="loc_ENVBMarketPerformanceBasedShares_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMarketPerformanceBasedShares_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:label="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_180" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_180" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockUnitsUnvestedMember" xlink:label="loc_ENVBRestrictedStockUnitsUnvestedMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsUnvestedMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockInAbeyanceMember" xlink:label="loc_ENVBCommonStockInAbeyanceMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBCommonStockInAbeyanceMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBInvestmentOptionsToPurchaseSharesOfCommonStockMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBInvestmentOptionsToPurchaseSharesOfCommonStockMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_410" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA" xlink:label="loc_countryCA_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_countryAU_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrefundedCommonStockWarrantsMember" xlink:label="loc_ENVBPrefundedCommonStockWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBPrefundedCommonStockWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockIssued1_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:title="999038 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999039 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:title="999040 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:title="999042 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_LabEquipmentMember" xlink:label="loc_ENVBLabEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBLabEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:label="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999043 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="999044 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:title="999045 - Disclosure - SCHEDULE OF STOCK OPTION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:title="999046 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="999047 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:title="999048 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_90" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBInvestmentOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RothAndInducementWarrantsMember" xlink:label="loc_ENVBRothAndInducementWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBRothAndInducementWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="999052 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegistrationRightsAgreementMember" xlink:label="loc_ENVBRegistrationRightsAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegistrationRightsAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBPIPESecuritiesPurchaseAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPIPESecuritiesPurchaseAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantAmendmentAgreementsMember" xlink:label="loc_ENVBWarrantAmendmentAgreementsMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBWarrantAmendmentAgreementsMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementMember" xlink:label="loc_ENVBPurchaseAgreementMember_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementMember_720" xlink:type="arc" order="721" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementsMember" xlink:label="loc_ENVBPurchaseAgreementsMember_740" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementsMember_740" xlink:type="arc" order="741" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CanaccordGenuityLLCMember" xlink:label="loc_ENVBCanaccordGenuityLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_ENVBCanaccordGenuityLLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:label="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_UnderwritersMember" xlink:label="loc_ENVBUnderwritersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENVBUnderwritersMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_BoardMember" xlink:label="loc_ENVBBoardMember_790" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENVBBoardMember_790" xlink:type="arc" order="792" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:label="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_620" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_620" xlink:type="arc" order="621" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ExistingWarrantsMember" xlink:label="loc_ENVBExistingWarrantsMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBExistingWarrantsMember_560" xlink:type="arc" order="562" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBInvestmentOptionsMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryWarrantsMember" xlink:label="loc_ENVBFebruaryWarrantsMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryWarrantsMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreModificationWarrantsMember" xlink:label="loc_ENVBPreModificationWarrantsMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPreModificationWarrantsMember_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PostModificationWarrantsMember" xlink:label="loc_ENVBPostModificationWarrantsMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPostModificationWarrantsMember_580" xlink:type="arc" order="581" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_520" xlink:type="arc" order="521" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_930" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_930" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_930" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_930" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_930" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:label="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation_930" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommissionPercentage" xlink:label="loc_ENVBCommissionPercentage_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBCommissionPercentage_930" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock_930" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_930" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_930" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_930" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_930" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_930" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_930" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_930" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_930" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised_930" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_930" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiability" xlink:label="loc_ENVBWarrantLiability_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBWarrantLiability_930" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_930" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_930" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_930" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity_930" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfStockIssuanceCost" xlink:label="loc_ENVBPaymentsOfStockIssuanceCost_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCost_930" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfAllocatedEquity" xlink:label="loc_ENVBPaymentsOfAllocatedEquity_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfAllocatedEquity_930" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfInvestmentOptionLiability" xlink:label="loc_ENVBPaymentsOfInvestmentOptionLiability_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfInvestmentOptionLiability_930" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:label="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense_930" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_930" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_930" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_930" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_930" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_930" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_930" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_930" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_930" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NumberOfVestedAndUnissuedShares" xlink:label="loc_ENVBNumberOfVestedAndUnissuedShares_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBNumberOfVestedAndUnissuedShares_930" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_930" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_930" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:label="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_930" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_930" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_930" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease_930" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease_930" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_930" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_930" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:label="loc_ENVBClassOfWarrantOrRightReasonForIssuing_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightReasonForIssuing_930" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_930" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_930" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice_930" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionSharePrice" xlink:label="loc_ENVBInvestmentOptionSharePrice_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionSharePrice_930" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionExercisePrice" xlink:label="loc_ENVBInvestmentOptionExercisePrice_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionExercisePrice_930" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionTerm_930" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOutstandingMeasurementInput" xlink:label="loc_ENVBInvestmentOutstandingMeasurementInput_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOutstandingMeasurementInput_930" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharePriceOption" xlink:label="loc_ENVBSharePriceOption_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharePriceOption_930" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding_930" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_930" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentIntrinsicValue" xlink:label="loc_ENVBInvestmentIntrinsicValue_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentIntrinsicValue_930" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentInducementGain" xlink:label="loc_ENVBInvestmentInducementGain_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentInducementGain_930" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_930" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights_930" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_930" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance_930" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodCommitmentShares" xlink:label="loc_ENVBStockIssuedDuringPeriodCommitmentShares_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodCommitmentShares_930" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NumberOfCommonStockSharesTraded" xlink:label="loc_ENVBNumberOfCommonStockSharesTraded_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBNumberOfCommonStockSharesTraded_930" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockEquityDistributionCosts" xlink:label="loc_ENVBCommonStockEquityDistributionCosts_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBCommonStockEquityDistributionCosts_930" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_930" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssued_930" xlink:type="arc" order="65" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:title="999053 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:title="999054 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBAkosSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBAkosSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBSecuritiesPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBSecuritiesPurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ENVBSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AkosMember" xlink:label="loc_ENVBAkosMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ENVBAkosMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:label="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:label="loc_ENVBWarrantsToPurchaseCommonStockPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBWarrantsToPurchaseCommonStockPercentage_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_UnpaidDividends" xlink:label="loc_ENVBUnpaidDividends_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBUnpaidDividends_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueOfDerivativeLiability" xlink:label="loc_ENVBFairValueOfDerivativeLiability_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBFairValueOfDerivativeLiability_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterest" xlink:label="loc_ENVBRedeemableNoncontrollingInterest_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterest_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_140" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="999055 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure_170" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MeasurementInputMarketRateMember" xlink:label="loc_ENVBMeasurementInputMarketRateMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_ENVBMeasurementInputMarketRateMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:label="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember_510" xlink:type="arc" order="512" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_580" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:label="loc_ENVBWarrantsAndRightsOutstandingStockPrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBWarrantsAndRightsOutstandingStockPrice_580" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_580" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_580" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_580" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_580" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ConvertiblePreferredStockPrincipalValue" xlink:label="loc_ENVBConvertiblePreferredStockPrincipalValue_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBConvertiblePreferredStockPrincipalValue_580" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput_580" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBInvestmentOptionTerm_580" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_580" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockOptionExercisePrice" xlink:label="loc_ENVBStockOptionExercisePrice_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBStockOptionExercisePrice_580" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:label="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_580" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_580" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:title="999057 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_160" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueDetailsNarrative" xlink:title="999058 - Disclosure - FAIR VALUE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:title="999059 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AvanceClinicalMember" xlink:label="loc_ENVBAvanceClinicalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBAvanceClinicalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_VogalNathanPurchaseAgreementMember" xlink:label="loc_ENVBVogalNathanPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBVogalNathanPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OtherConsultingAndVendorAgreementsMember" xlink:label="loc_ENVBOtherConsultingAndVendorAgreementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBOtherConsultingAndVendorAgreementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OneTimeMilestoneMember" xlink:label="loc_ENVBOneTimeMilestoneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBOneTimeMilestoneMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AdditionalMilestoneMember" xlink:label="loc_ENVBAdditionalMilestoneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBAdditionalMilestoneMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:label="loc_us-gaapConstructionContractCostProgressPaymentOffset_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapConstructionContractCostProgressPaymentOffset_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RoyaltiesPercentage" xlink:label="loc_ENVBRoyaltiesPercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBRoyaltiesPercentage_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCash_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRent_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ReductionInForceRestructuringPercentage" xlink:label="loc_ENVBReductionInForceRestructuringPercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBReductionInForceRestructuringPercentage_180" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:title="999061 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:title="999062 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:title="999064 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:title="999065 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" xlink:title="999067 - Disclosure - SCHEDULE OF INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBInvestmentOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_50" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:title="999068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementMember" xlink:label="loc_ENVBPurchaseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreeentMember" xlink:label="loc_ENVBPurchaseAgreeentMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreeentMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IncentivePlanMember" xlink:label="loc_ENVBIncentivePlanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENVBIncentivePlanMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" xlink:label="loc_ENVBProceedsFromAchievingDevelopmentAndSalesMilestones_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ENVBProceedsFromAchievingDevelopmentAndSalesMilestones_130" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" xlink:title="999069 - Disclosure - SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>envb-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="ENVB_SeriesCRedeemablePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesCRedeemablePreferredStockMember" xlink:to="ENVB_SeriesCRedeemablePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SeriesCRedeemablePreferredStockMember_lbl" xml:lang="en-US">Series C Redeemable Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestMember" xlink:label="ENVB_RedeemableNoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestMember" xlink:to="ENVB_RedeemableNoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestMember_lbl" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MezzanineEquityMember" xlink:label="ENVB_MezzanineEquityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MezzanineEquityMember" xlink:to="ENVB_MezzanineEquityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MezzanineEquityMember_lbl" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubscriptionReceivableMember" xlink:label="ENVB_SubscriptionReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubscriptionReceivableMember" xlink:to="ENVB_SubscriptionReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SubscriptionReceivableMember_lbl" xml:lang="en-US">Subscription Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_EquityDistributionAgreementMember" xlink:label="ENVB_EquityDistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EquityDistributionAgreementMember" xlink:to="ENVB_EquityDistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_EquityDistributionAgreementMember_lbl" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_KanubaddiSeparationAgreementMember" xlink:label="ENVB_KanubaddiSeparationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_KanubaddiSeparationAgreementMember" xlink:to="ENVB_KanubaddiSeparationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_KanubaddiSeparationAgreementMember_lbl" xml:lang="en-US">Kanubaddi Separation Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MrKanubaddiEmploymentAgreementMember" xlink:label="ENVB_MrKanubaddiEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MrKanubaddiEmploymentAgreementMember" xlink:to="ENVB_MrKanubaddiEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MrKanubaddiEmploymentAgreementMember_lbl" xml:lang="en-US">Mr Kanubaddi Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA" xlink:label="country_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl" xml:lang="en-US">CANADA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="country_AU" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US">AUSTRALIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrefundedCommonStockWarrantsMember" xlink:label="ENVB_PrefundedCommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrefundedCommonStockWarrantsMember" xlink:to="ENVB_PrefundedCommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrefundedCommonStockWarrantsMember_lbl" xml:lang="en-US">Prefunded Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Warrants to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:label="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_lbl" xml:lang="en-US">Restricted Stock Units Vested and Unissued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockUnitsUnvestedMember" xlink:label="ENVB_RestrictedStockUnitsUnvestedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsUnvestedMember" xlink:to="ENVB_RestrictedStockUnitsUnvestedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestrictedStockUnitsUnvestedMember_lbl" xml:lang="en-US">Restricted Stock Units Unvested [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:label="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_lbl" xml:lang="en-US">Restricted Stock Awards Vested and Unissued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockInAbeyanceMember" xlink:label="ENVB_CommonStockInAbeyanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockInAbeyanceMember" xlink:to="ENVB_CommonStockInAbeyanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CommonStockInAbeyanceMember_lbl" xml:lang="en-US">Common Stock in Abeyance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_OptionsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_OptionsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OptionsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember_lbl" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_LabEquipmentMember" xlink:label="ENVB_LabEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_LabEquipmentMember" xlink:to="ENVB_LabEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_LabEquipmentMember_lbl" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:label="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:to="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Computer Equipment and Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DistributionAgreementMember" xlink:label="ENVB_DistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DistributionAgreementMember" xlink:to="ENVB_DistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DistributionAgreementMember_lbl" xml:lang="en-US">Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CanaccordGenuityLLCMember" xlink:label="ENVB_CanaccordGenuityLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CanaccordGenuityLLCMember" xlink:to="ENVB_CanaccordGenuityLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CanaccordGenuityLLCMember_lbl" xml:lang="en-US">Canaccord Genuity LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegistrationRightsAgreementMember" xlink:label="ENVB_RegistrationRightsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegistrationRightsAgreementMember" xlink:to="ENVB_RegistrationRightsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegistrationRightsAgreementMember_lbl" xml:lang="en-US">Registration Rights Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_UnderwritersMember" xlink:label="ENVB_UnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnderwritersMember" xlink:to="ENVB_UnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_UnderwritersMember_lbl" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:label="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:to="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Registered Direct Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:label="ENVB_PIPESecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:to="ENVB_PIPESecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PIPESecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">PIPE Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:label="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:to="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_lbl" xml:lang="en-US">RD Offering and Pipe Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:to="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_lbl" xml:lang="en-US">2020 Long Term Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantAmendmentAgreementsMember" xlink:label="ENVB_WarrantAmendmentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantAmendmentAgreementsMember" xlink:to="ENVB_WarrantAmendmentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantAmendmentAgreementsMember_lbl" xml:lang="en-US">Wainwright Amendment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:label="ENVB_PlacementAgentPreferredInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:to="ENVB_PlacementAgentPreferredInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PlacementAgentPreferredInvestmentOptionsMember_lbl" xml:lang="en-US">Placement Agent Preferred Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryWarrantsMember" xlink:label="ENVB_FebruaryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryWarrantsMember" xlink:to="ENVB_FebruaryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryWarrantsMember_lbl" xml:lang="en-US">February Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreModificationWarrantsMember" xlink:label="ENVB_PreModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreModificationWarrantsMember" xlink:to="ENVB_PreModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PreModificationWarrantsMember_lbl" xml:lang="en-US">Pre Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ExistingWarrantsMember" xlink:label="ENVB_ExistingWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExistingWarrantsMember" xlink:to="ENVB_ExistingWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ExistingWarrantsMember_lbl" xml:lang="en-US">Existing Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="ENVB_InvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsMember" xlink:to="ENVB_InvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionsMember_lbl" xml:lang="en-US">Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PostModificationWarrantsMember" xlink:label="ENVB_PostModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PostModificationWarrantsMember" xlink:to="ENVB_PostModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PostModificationWarrantsMember_lbl" xml:lang="en-US">Post Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementMember" xlink:label="ENVB_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreementMember" xlink:to="ENVB_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementsMember" xlink:label="ENVB_PurchaseAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreementsMember" xlink:to="ENVB_PurchaseAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PurchaseAgreementsMember_lbl" xml:lang="en-US">Purchase Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_BoardMember" xlink:label="ENVB_BoardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_BoardMember" xlink:to="ENVB_BoardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_BoardMember_lbl" xml:lang="en-US">Board [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RothAndInducementWarrantsMember" xlink:label="ENVB_RothAndInducementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RothAndInducementWarrantsMember" xlink:to="ENVB_RothAndInducementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RothAndInducementWarrantsMember_lbl" xml:lang="en-US">Roth and Inducement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:label="ENVB_AkosSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:to="ENVB_AkosSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AkosSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Akos Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesAConvertiblePreferredStockMember" xlink:label="ENVB_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesAConvertiblePreferredStockMember" xlink:to="ENVB_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SecuritiesPurchaseAgreementMember" xlink:label="ENVB_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SecuritiesPurchaseAgreementMember" xlink:to="ENVB_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities purchase agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AkosMember" xlink:label="ENVB_AkosMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosMember" xlink:to="ENVB_AkosMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AkosMember_lbl" xml:lang="en-US">Akos [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InitialMeasurementMember" xlink:label="ENVB_InitialMeasurementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InitialMeasurementMember" xlink:to="ENVB_InitialMeasurementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InitialMeasurementMember_lbl" xml:lang="en-US">Initial Measurement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubsequentMeasurementMember" xlink:label="ENVB_SubsequentMeasurementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubsequentMeasurementMember" xlink:to="ENVB_SubsequentMeasurementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SubsequentMeasurementMember_lbl" xml:lang="en-US">Subsequent Measurement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">Warrant liabilities - January 2021 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">Warrant liabilities - February 2021 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_lbl" xml:lang="en-US">Warrant liabilities - February 2022 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:to="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">Derivative Liability May 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="ENVB_WainwrightInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WainwrightInvestmentOptionsMember" xlink:to="ENVB_WainwrightInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WainwrightInvestmentOptionsMember_lbl" xml:lang="en-US">Wainwright Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="ENVB_RDInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDInvestmentOptionsMember" xlink:to="ENVB_RDInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RDInvestmentOptionsMember_lbl" xml:lang="en-US">R D Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="ENVB_PIPEInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPEInvestmentOptionsMember" xlink:to="ENVB_PIPEInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PIPEInvestmentOptionsMember_lbl" xml:lang="en-US">Pipe Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:label="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryTwentyTwentyTwoWarrantsMember_lbl" xml:lang="en-US">February Twenty Twenty Two Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:label="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_lbl" xml:lang="en-US">February 2022 Post-Modification Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MeasurementInputMarketRateMember" xlink:label="ENVB_MeasurementInputMarketRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MeasurementInputMarketRateMember" xlink:to="ENVB_MeasurementInputMarketRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MeasurementInputMarketRateMember_lbl" xml:lang="en-US">Measurement Input Market Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_JanuaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_JanuaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_JanuaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">January Twenty Twenty One Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:label="ENVB_FebruaryTwentyTwentyOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FebruaryTwentyTwentyOneWarrantsMember_lbl" xml:lang="en-US">February Twenty Twenty One Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:label="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:to="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_lbl" xml:lang="en-US">HC Wainwright and Co LLC Investment Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeMember" xlink:to="us-gaap_DerivativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeMember_lbl" xml:lang="en-US">Derivative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AvanceClinicalMember" xlink:label="ENVB_AvanceClinicalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AvanceClinicalMember" xlink:to="ENVB_AvanceClinicalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AvanceClinicalMember_lbl" xml:lang="en-US">Avance Clinical [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_VogalNathanPurchaseAgreementMember" xlink:label="ENVB_VogalNathanPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_VogalNathanPurchaseAgreementMember" xlink:to="ENVB_VogalNathanPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_VogalNathanPurchaseAgreementMember_lbl" xml:lang="en-US">Vogal Nathan Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OneTimeMilestoneMember" xlink:label="ENVB_OneTimeMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OneTimeMilestoneMember" xlink:to="ENVB_OneTimeMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OneTimeMilestoneMember_lbl" xml:lang="en-US">One Time Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AdditionalMilestoneMember" xlink:label="ENVB_AdditionalMilestoneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdditionalMilestoneMember" xlink:to="ENVB_AdditionalMilestoneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AdditionalMilestoneMember_lbl" xml:lang="en-US">Additional Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OtherConsultingAndVendorAgreementsMember" xlink:label="ENVB_OtherConsultingAndVendorAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OtherConsultingAndVendorAgreementsMember" xlink:to="ENVB_OtherConsultingAndVendorAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OtherConsultingAndVendorAgreementsMember_lbl" xml:lang="en-US">Other Consulting and Vendor Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreeentMember" xlink:label="ENVB_PurchaseAgreeentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreeentMember" xlink:to="ENVB_PurchaseAgreeentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PurchaseAgreeentMember_lbl" xml:lang="en-US">Purchase Agreeent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IncentivePlanMember" xlink:label="ENVB_IncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncentivePlanMember" xlink:to="ENVB_IncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IncentivePlanMember_lbl" xml:lang="en-US">Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use operating lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of right-of-use operating lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesCurrent" xlink:label="ENVB_WarrantLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesCurrent" xlink:to="ENVB_WarrantLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Mezzanine equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xml:lang="en-US">Redeemable non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Total mezzanine equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Stock subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, mezzanine equity, and shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary equity, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary equity, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary equity, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Impairment of intangible assets and goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducementExpense" xlink:label="ENVB_InducementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducementExpense" xlink:to="ENVB_InducementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_InducementExpense_lbl" xml:lang="en-US">Inducement expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Change in fair value of investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Less preferred dividends attributable to non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US">Less deemed dividends attributable to accretion of embedded derivative at redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityShares" xlink:label="ENVB_TemporaryEquityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_TemporaryEquityShares_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:to="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_lbl" xml:lang="en-US">Preferred dividends attributable to redeemable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:to="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_lbl" xml:lang="en-US">Accretion of embedded derivative to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodValue_lbl" xml:lang="en-US">Redemption of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRedeemedOrCalledDuringPeriodShares_lbl" xml:lang="en-US">Redemption of Series A preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of common shares in exchange for RSU conversions from the reduction in force</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of common shares in exchange for RSU conversions from the reduction in force, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares for deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares for deferred offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xml:lang="en-US">Induced conversion of warrants and preferred investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_lbl" xml:lang="en-US">Foreign exchange translation gain (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_lbl" xml:lang="en-US">Issuance of direct offering shares (see Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_lbl" xml:lang="en-US">Issuance of direct offering shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Conversion of RSUs into common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Conversion of RSUs into common shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestValue" xlink:label="ENVB_RedeemableNoncontrollingInterestValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestValue" xlink:to="ENVB_RedeemableNoncontrollingInterestValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestValue_lbl" xml:lang="en-US">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestShares" xlink:label="ENVB_RedeemableNoncontrollingInterestShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestShares" xlink:to="ENVB_RedeemableNoncontrollingInterestShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestShares_lbl" xml:lang="en-US">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:label="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:to="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_lbl" xml:lang="en-US">Issuance of redeemable Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of redeemable Series C preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:label="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_lbl" xml:lang="en-US">Conversion of RSAs into common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_lbl" xml:lang="en-US">Conversion of RSAs into common shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_lbl" xml:lang="en-US">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_lbl" xml:lang="en-US">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:label="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:to="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Issuance of rounded shares as a result of the reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" xlink:label="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" xlink:to="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_lbl" xml:lang="en-US">Common stock sold under the Purchase Agreement, net of offering costs of $290,029</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" xlink:label="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" xlink:to="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_lbl" xml:lang="en-US">Common stock sold under the Equity Distribution Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" xlink:label="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" xlink:to="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_lbl" xml:lang="en-US">Exercise of Inducement Warrants for common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" xlink:label="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" xlink:to="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_lbl" xml:lang="en-US">Exercise of Inducement Warrants for common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:to="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common shares for vested RSU</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:to="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common shares for vested RSU, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_TemporaryEquityShares_2_lbl" xml:lang="en-US">Mezzanine equity balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NetOfferingCosts" xlink:label="ENVB_NetOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NetOfferingCosts" xlink:to="ENVB_NetOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NetOfferingCosts_lbl" xml:lang="en-US">Net offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_lbl" xml:lang="en-US">Issuance of embedded derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_lbl" xml:lang="en-US">Redeemable noncontrolling interest issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockEquityDistributionCosts" xlink:label="ENVB_CommonStockEquityDistributionCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockEquityDistributionCosts" xlink:to="ENVB_CommonStockEquityDistributionCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CommonStockEquityDistributionCosts_lbl" xml:lang="en-US">Common stock equity distribution costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnInvestments_2_lbl" xml:lang="en-US">Change in fair value of investment option liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducementExpense" xlink:to="ENVB_InducementExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InducementExpense_2_lbl" xml:lang="en-US">Inducement expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_2_lbl" xml:lang="en-US">Impairment of intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NoncashIncomeTaxExpense" xlink:label="ENVB_NoncashIncomeTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NoncashIncomeTaxExpense" xlink:to="ENVB_NoncashIncomeTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NoncashIncomeTaxExpense_lbl" xml:lang="en-US">Non-cash income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:to="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_lbl" xml:lang="en-US">Right-of-use operating lease asset and obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from disposal of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from common stock sold under the Equity Distribution Agreement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US">Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of Inducement Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:label="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:to="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts_lbl" xml:lang="en-US">Proceeds from common stock sold under the Purchase Agreement, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment for offering costs previously accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_lbl" xml:lang="en-US">Redemption of Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock_lbl" xml:lang="en-US">Proceeds from the sale of redeemable non-controlling interest, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Foreign Exchange Rate on Changes on Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash and non-cash transactions:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:label="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_lbl" xml:lang="en-US">Warrants issued in conjunction with common stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfEmbeddedDerivative" xlink:label="ENVB_IssuanceOfEmbeddedDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfEmbeddedDerivative" xlink:to="ENVB_IssuanceOfEmbeddedDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_IssuanceOfEmbeddedDerivative_lbl" xml:lang="en-US">Issuance of embedded derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockSubscriptionReceivable" xlink:label="ENVB_StockSubscriptionReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockSubscriptionReceivable" xlink:to="ENVB_StockSubscriptionReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockSubscriptionReceivable_lbl" xml:lang="en-US">Stock subscription receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OfferingCostsAccruedNotPaid" xlink:label="ENVB_OfferingCostsAccruedNotPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OfferingCostsAccruedNotPaid" xlink:to="ENVB_OfferingCostsAccruedNotPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_OfferingCostsAccruedNotPaid_lbl" xml:lang="en-US">Offering costs accrued not paid</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsIssuedForOfferingCosts" xlink:label="ENVB_WarrantsIssuedForOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedForOfferingCosts" xlink:to="ENVB_WarrantsIssuedForOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsIssuedForOfferingCosts_lbl" xml:lang="en-US">Warrants issued for offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_lbl" xml:lang="en-US">Issuance of common shares for offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_lbl" xml:lang="en-US">Induced conversion of warrants and preferred investment options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:to="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_2_lbl" xml:lang="en-US">Preferred dividends attributable to redeemable non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:label="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_lbl" xml:lang="en-US">Investment options issued in conjunction with common stock issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:label="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:to="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_lbl" xml:lang="en-US">Modification of warrants as part of share capital raise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:to="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_2_lbl" xml:lang="en-US">Accretion of embedded derivative to redemption value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredOfferingCostsChargedToOfferingCosts" xlink:label="ENVB_DeferredOfferingCostsChargedToOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredOfferingCostsChargedToOfferingCosts" xlink:to="ENVB_DeferredOfferingCostsChargedToOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DeferredOfferingCostsChargedToOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs charged to offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Redeemable Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNonControllingInterestTextBlock" xlink:label="ENVB_RedeemableNonControllingInterestTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNonControllingInterestTextBlock" xlink:to="ENVB_RedeemableNonControllingInterestTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNonControllingInterestTextBlock_lbl" xml:lang="en-US">REDEEMABLE NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureLicensingAgreementsAbstract" xlink:label="ENVB_DisclosureLicensingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DisclosureLicensingAgreementsAbstract" xlink:to="ENVB_DisclosureLicensingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DisclosureLicensingAgreementsAbstract_lbl" xml:lang="en-US">Licensing Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_LicensingAgreementsDisclosureTextBlock" xlink:label="ENVB_LicensingAgreementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_LicensingAgreementsDisclosureTextBlock" xlink:to="ENVB_LicensingAgreementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_LicensingAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">LICENSING AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Principal of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property &amp; Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:label="ENVB_DeferredOfferingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:to="ENVB_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilityPolicyTextBlock" xlink:label="ENVB_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilityPolicyTextBlock" xlink:to="ENVB_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liability and Investment Options</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:label="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:to="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_lbl" xml:lang="en-US">Modification and Inducement of Warrants and Investment Options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Redeemable Non-controlling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" xlink:label="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" xlink:to="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_lbl" xml:lang="en-US">Research and Development Tax Incentive Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRUCTURING COSTS PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ASSUMPTION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVESTMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:label="ENVB_ScheduleOfValuationOfWarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:to="ENVB_ScheduleOfValuationOfWarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ScheduleOfValuationOfWarrantsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:label="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:to="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_2_lbl" xml:lang="en-US">SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX EXPENSE BENEFITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LOSS CARRY FORWARDS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_lbl" xml:lang="en-US">Restructuring cost payable, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestructuringCostsIncurred" xlink:label="ENVB_RestructuringCostsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestructuringCostsIncurred" xlink:to="ENVB_RestructuringCostsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RestructuringCostsIncurred_lbl" xml:lang="en-US">Restructuring costs incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="us-gaap_RestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCosts_lbl" xml:lang="en-US">Restructuring costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts" xlink:label="us-gaap_OtherRestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestructuringCosts" xlink:to="us-gaap_OtherRestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestructuringCosts_lbl" xml:lang="en-US">Restructuring costs reversed</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_2_lbl" xml:lang="en-US">Restructuring cost payable, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WorkingCapital" xlink:label="ENVB_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WorkingCapital" xlink:to="ENVB_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Additional working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants for cash proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Exercise of warrants to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Cash proceeds of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salaries and benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Performance bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US">Reversed amount</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:label="ENVB_ExpenseRelatedToAccelerationOfVesting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:to="ENVB_ExpenseRelatedToAccelerationOfVesting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ExpenseRelatedToAccelerationOfVesting_lbl" xml:lang="en-US">Expense related to acceleration of vesting</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MarketPerformanceBasedShares" xlink:label="ENVB_MarketPerformanceBasedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MarketPerformanceBasedShares" xlink:to="ENVB_MarketPerformanceBasedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MarketPerformanceBasedShares_lbl" xml:lang="en-US">Market performance based shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:label="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:to="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_lbl" xml:lang="en-US">Minimum of stockholders equity required for continued listing pursuant to exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock and warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopment" xlink:label="ENVB_PrepaidResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopment" xlink:to="ENVB_PrepaidResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrepaidResearchAndDevelopment_lbl" xml:lang="en-US">Prepaid research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">Prepaid value-added taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred offering costs (see Note 7)</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidFranchiseTaxReceivable" xlink:label="ENVB_PrepaidFranchiseTaxReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidFranchiseTaxReceivable" xlink:to="ENVB_PrepaidFranchiseTaxReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrepaidFranchiseTaxReceivable_lbl" xml:lang="en-US">Franchise tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_lbl" xml:lang="en-US">R&amp;D tax incentive receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillGross" xlink:label="us-gaap_GoodwillGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_GoodwillGross_lbl" xml:lang="en-US">Goodwill Gross, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_lbl" xml:lang="en-US">Accumulated Impairment Losses, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslation" xlink:label="ENVB_GoodwillCurrencyTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_GoodwillCurrencyTranslation_lbl" xml:lang="en-US">Currency Translation, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillImpairmentLossGross" xlink:label="ENVB_GoodwillImpairmentLossGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillImpairmentLossGross" xlink:to="ENVB_GoodwillImpairmentLossGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_GoodwillImpairmentLossGross_lbl" xml:lang="en-US">Goodwill Gross, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillAccumulatedImpairmentLoss" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss_lbl" xml:lang="en-US">Accumulated Impairment Losses, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:to="ENVB_GoodwillCurrencyTranslationImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss_lbl" xml:lang="en-US">Currency Translation, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill, Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:label="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:to="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_lbl" xml:lang="en-US">Goodwill Gross, Loss on currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:label="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Accumulated Impairment Losses, Loss on currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslationLoss" xlink:label="ENVB_GoodwillCurrencyTranslationLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationLoss" xlink:to="ENVB_GoodwillCurrencyTranslationLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillCurrencyTranslationLoss_lbl" xml:lang="en-US">Currency Translation, Loss on currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Goodwill, Loss on currency translation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_GoodwillGross_2_lbl" xml:lang="en-US">Goodwill Gross, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_2_lbl" xml:lang="en-US">Accumulated Impairment Losses, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_GoodwillCurrencyTranslation_2_lbl" xml:lang="en-US">Currency Translation, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Goodwill, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Balance, Indefinite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US">Loss on currency translation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Balance, Indefinite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Balance, Definite lived intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Balance, Definite lived intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_3_lbl" xml:lang="en-US">Finite lived assets amortization expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xml:lang="en-US">Intangible assets, amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US">Identified definite lived assets, impairment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccruedProductDevelopmentCost" xlink:label="ENVB_AccruedProductDevelopmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedProductDevelopmentCost" xlink:to="ENVB_AccruedProductDevelopmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AccruedProductDevelopmentCost_lbl" xml:lang="en-US">Product development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued salaries, wages, and bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccruedRestructuringCosts" xlink:label="ENVB_AccruedRestructuringCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedRestructuringCosts" xlink:to="ENVB_AccruedRestructuringCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_AccruedRestructuringCosts_lbl" xml:lang="en-US">Accrued restructuring costs (see Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Accrued franchise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term, outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value, outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable shares at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable weighted average price at end</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, Non-vested beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Non-vested beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares, non-vested ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average fair value, Non-vested ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense for RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrant shares outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining life, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_lbl" xml:lang="en-US">Intrinsic value, outstanding beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_lbl" xml:lang="en-US">Warrant shares outstanding, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_lbl" xml:lang="en-US">Weighted average exercise price, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrant shares outstanding, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_lbl" xml:lang="en-US">Exchanged for common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrant shares outstanding, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Warrant shares outstanding at end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding at end</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_lbl" xml:lang="en-US">Warrant shares outstanding, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_lbl" xml:lang="en-US">Weighted average remaining life, exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2_lbl" xml:lang="en-US">Intrinsic value, outstanding ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrant shares outstanding,expired</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_lbl" xml:lang="en-US">Intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_2_lbl" xml:lang="en-US">Investment options outstanding, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_2_lbl" xml:lang="en-US">Weighted average remaining life, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Investment options outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding end</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_2_lbl" xml:lang="en-US">Weighted average remaining life, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants, number of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Common stock, offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:label="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:to="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_lbl" xml:lang="en-US">Aggregate gross sales price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommissionPercentage" xlink:label="ENVB_CommissionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommissionPercentage" xlink:to="ENVB_CommissionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_CommissionPercentage_lbl" xml:lang="en-US">Commission percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase committment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_3_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Issued stock value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_2_lbl" xml:lang="en-US">Issuance of common shares in exchange for RSU conversions, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_2_lbl" xml:lang="en-US">Stock issued during period conversion of restricted stock award</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Purchase of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercised of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds from offering</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiability" xlink:label="ENVB_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiability" xlink:to="ENVB_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_2_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Shares resale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from RD offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfStockIssuanceCost" xlink:label="ENVB_PaymentsOfStockIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCost" xlink:to="ENVB_PaymentsOfStockIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfStockIssuanceCost_lbl" xml:lang="en-US">Offerings costs</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfAllocatedEquity" xlink:label="ENVB_PaymentsOfAllocatedEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfAllocatedEquity" xlink:to="ENVB_PaymentsOfAllocatedEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfAllocatedEquity_lbl" xml:lang="en-US">Payments of allocated equity</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfInvestmentOptionLiability" xlink:label="ENVB_PaymentsOfInvestmentOptionLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfInvestmentOptionLiability" xlink:to="ENVB_PaymentsOfInvestmentOptionLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfInvestmentOptionLiability_lbl" xml:lang="en-US">Payments of investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:label="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:to="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_lbl" xml:lang="en-US">Payments of stock issuance costs recorded expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Incentive plan description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Authorized shares reserved</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unamortized stock option expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Common stock vested restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_lbl" xml:lang="en-US">Unissued shares for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NumberOfVestedAndUnissuedShares" xlink:label="ENVB_NumberOfVestedAndUnissuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NumberOfVestedAndUnissuedShares" xlink:to="ENVB_NumberOfVestedAndUnissuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NumberOfVestedAndUnissuedShares_lbl" xml:lang="en-US">Number of vested and unissued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:label="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:to="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of additional warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrant expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Offerings costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_3_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_2_lbl" xml:lang="en-US">Shares other</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:label="ENVB_ClassOfWarrantOrRightReasonForIssuing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:to="ENVB_ClassOfWarrantOrRightReasonForIssuing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ClassOfWarrantOrRightReasonForIssuing_lbl" xml:lang="en-US">[custom:ClassOfWarrantOrRightReasonForIssuing]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionSharePrice" xlink:label="ENVB_InvestmentOptionSharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionSharePrice" xlink:to="ENVB_InvestmentOptionSharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionSharePrice_lbl" xml:lang="en-US">[custom:InvestmentOptionSharePrice]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionExercisePrice" xlink:label="ENVB_InvestmentOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionExercisePrice" xlink:to="ENVB_InvestmentOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionExercisePrice_lbl" xml:lang="en-US">[custom:InvestmentOptionExercisePrice]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionTerm" xlink:label="ENVB_InvestmentOptionTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionTerm" xlink:to="ENVB_InvestmentOptionTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionTerm_lbl" xml:lang="en-US">[custom:InvestmentOptionTerm]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOutstandingMeasurementInput" xlink:label="ENVB_InvestmentOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOutstandingMeasurementInput" xlink:to="ENVB_InvestmentOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOutstandingMeasurementInput_lbl" xml:lang="en-US">[custom:InvestmentOutstandingMeasurementInput-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharePriceOption" xlink:label="ENVB_SharePriceOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharePriceOption" xlink:to="ENVB_SharePriceOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharePriceOption_lbl" xml:lang="en-US">[custom:SharePriceOption-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentIntrinsicValue" xlink:label="ENVB_InvestmentIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentIntrinsicValue" xlink:to="ENVB_InvestmentIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentIntrinsicValue_lbl" xml:lang="en-US">[custom:InvestmentIntrinsicValue]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentInducementGain" xlink:label="ENVB_InvestmentInducementGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentInducementGain" xlink:to="ENVB_InvestmentInducementGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentInducementGain_lbl" xml:lang="en-US">[custom:InvestmentInducementGain]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xml:lang="en-US">Preferred stock voting rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2_lbl" xml:lang="en-US">Redeemable preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Preferred Stock authorized for future issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodCommitmentShares" xlink:label="ENVB_StockIssuedDuringPeriodCommitmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodCommitmentShares" xlink:to="ENVB_StockIssuedDuringPeriodCommitmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockIssuedDuringPeriodCommitmentShares_lbl" xml:lang="en-US">Shares commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NumberOfCommonStockSharesTraded" xlink:label="ENVB_NumberOfCommonStockSharesTraded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NumberOfCommonStockSharesTraded" xlink:to="ENVB_NumberOfCommonStockSharesTraded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_NumberOfCommonStockSharesTraded_lbl" xml:lang="en-US">Number of shares traded in market</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockEquityDistributionCosts" xlink:to="ENVB_CommonStockEquityDistributionCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_CommonStockEquityDistributionCosts_2_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_DisclosureRedeemableNoncontrollingInterestAbstract_2_lbl" xml:lang="en-US">Schedule Of Reconciliation Change In Redeemable Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of redeemable noncontrolling Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US">Accretion of embedded derivative to redemption value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_2_lbl" xml:lang="en-US">Redemption of Akos Series A Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Sale of stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:label="ENVB_SpinoffAndRelatedPrivatePlacementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:to="ENVB_SpinoffAndRelatedPrivatePlacementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SpinoffAndRelatedPrivatePlacementDescription_lbl" xml:lang="en-US">Spin-off and related private placement, description</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:label="ENVB_WarrantsToPurchaseCommonStockPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:to="ENVB_WarrantsToPurchaseCommonStockPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsToPurchaseCommonStockPercentage_lbl" xml:lang="en-US">Warrants to purchase common stock, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Percentage of stock issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_UnpaidDividends" xlink:label="ENVB_UnpaidDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnpaidDividends" xlink:to="ENVB_UnpaidDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_UnpaidDividends_lbl" xml:lang="en-US">Unpaid dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueOfDerivativeLiability" xlink:label="ENVB_FairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueOfDerivativeLiability" xlink:to="ENVB_FairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_FairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterest" xlink:label="ENVB_RedeemableNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterest" xlink:to="ENVB_RedeemableNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterest_lbl" xml:lang="en-US">Redeemable noncontrolling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:label="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:to="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_lbl" xml:lang="en-US">Fair value of investment option liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Investment option term</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:label="ENVB_WarrantsAndRightsOutstandingStockPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:to="ENVB_WarrantsAndRightsOutstandingStockPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantsAndRightsOutstandingStockPrice_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xml:lang="en-US">Warrants, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ConvertiblePreferredStockPrincipalValue" xlink:label="ENVB_ConvertiblePreferredStockPrincipalValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ConvertiblePreferredStockPrincipalValue" xlink:to="ENVB_ConvertiblePreferredStockPrincipalValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ConvertiblePreferredStockPrincipalValue_lbl" xml:lang="en-US">Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AlternativeInvestmentMeasurementInput_lbl" xml:lang="en-US">Market rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionTerm" xlink:to="ENVB_InvestmentOptionTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_InvestmentOptionTerm_2_lbl" xml:lang="en-US">Investment option term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Investment, stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockOptionExercisePrice" xlink:label="ENVB_StockOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockOptionExercisePrice" xlink:to="ENVB_StockOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_StockOptionExercisePrice_lbl" xml:lang="en-US">Investment, exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:label="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:to="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_lbl" xml:lang="en-US">Investment, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Number of investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Total beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Issuance of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US">Change in fair value, modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Total ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_lbl" xml:lang="en-US">Exercise of investment options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xml:lang="en-US">Derivative liability fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Operating leases remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating lease discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US">Contract cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:to="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionContractCostProgressPaymentOffset_lbl" xml:lang="en-US">Payment of contract cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US">Long-term purchase commitment, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RoyaltiesPercentage" xlink:label="ENVB_RoyaltiesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RoyaltiesPercentage" xlink:to="ENVB_RoyaltiesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RoyaltiesPercentage_lbl" xml:lang="en-US">Royalties percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for royalties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Future cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_3_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_2_lbl" xml:lang="en-US">Research and development expense tax credit receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ReductionInForceRestructuringPercentage" xlink:label="ENVB_ReductionInForceRestructuringPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ReductionInForceRestructuringPercentage" xlink:to="ENVB_ReductionInForceRestructuringPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ReductionInForceRestructuringPercentage_lbl" xml:lang="en-US">Reduction in force restructuring percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred income tax (expense) benefit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:label="ENVB_ResearchAndDevelopmentCapitalizedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:to="ENVB_ResearchAndDevelopmentCapitalizedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ResearchAndDevelopmentCapitalizedExpenses_lbl" xml:lang="en-US">Research and development capitalized expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:label="ENVB_DeferredTaxAssetsAndIntangibleAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:to="ENVB_DeferredTaxAssetsAndIntangibleAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_DeferredTaxAssetsAndIntangibleAmortization_lbl" xml:lang="en-US">Intangible amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss tax carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal income tax at the statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax rate (net of federal)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign tax rate differential</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_lbl" xml:lang="en-US">Non-deductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:to="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_lbl" xml:lang="en-US">Deferred true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_3_lbl" xml:lang="en-US">Income tax expenses and benefits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_4_lbl" xml:lang="en-US">Income tax expenses and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expense gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_2_lbl" xml:lang="en-US">Weighted average exercise price, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_2_lbl" xml:lang="en-US">Intrinsic value, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_3_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Stock issued during period shares new issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Existing Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants to purchase shares of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_3_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3_lbl" xml:lang="en-US">Gross proceeds from sale of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted stock awards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Authorized shares</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" xlink:label="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" xlink:to="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones_lbl" xml:lang="en-US">[custom:ProceedsFromAchievingDevelopmentAndSalesMilestones]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DisclosureLicensingAgreementsAbstract" xlink:to="ENVB_DisclosureLicensingAgreementsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ENVB_DisclosureLicensingAgreementsAbstract_2_lbl" xml:lang="en-US">Schedule Of Reduction In Forcerestructuring Activity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCosts" xlink:to="us-gaap_RestructuringCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestructuringCosts_2_lbl" xml:lang="en-US">Restructuring costs paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WorkingCapital" xlink:to="ENVB_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesCurrent" xlink:to="ENVB_WarrantLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesCurrent_doc" xml:lang="en-US">Warrant liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:to="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_doc" xml:lang="en-US">Minimum of stockholders equity required for continued listing pursuant to exchange.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesCRedeemablePreferredStockMember" xlink:to="ENVB_SeriesCRedeemablePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SeriesCRedeemablePreferredStockMember_doc" xml:lang="en-US">Series C Redeemable Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" xlink:to="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_doc" xml:lang="en-US">Research and Development Tax Incentive Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Warrants to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestrictedStockUnitsVestedAndUnIssuedMember_doc" xml:lang="en-US">Restricted Stock Units Vested and Unissued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockUnitsUnvestedMember" xlink:to="ENVB_RestrictedStockUnitsUnvestedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestrictedStockUnitsUnvestedMember_doc" xml:lang="en-US">Restricted Stock Units Unvested [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_OptionsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OptionsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubscriptionReceivableMember" xlink:to="ENVB_SubscriptionReceivableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SubscriptionReceivableMember_doc" xml:lang="en-US">Subscription Receivable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestMember" xlink:to="ENVB_RedeemableNoncontrollingInterestMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestMember_doc" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" xlink:to="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution_doc" xml:lang="en-US">Stock issued during period value common stock sold under equity distribution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" xlink:to="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution_doc" xml:lang="en-US">Stock issued during period shares common stock sold under equity distribution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockEquityDistributionCosts" xlink:to="ENVB_CommonStockEquityDistributionCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CommonStockEquityDistributionCosts_doc" xml:lang="en-US">Common stock equity distribution costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost_doc" xml:lang="en-US">Stock issued during period value issued direct offering net of offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:to="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost_doc" xml:lang="en-US">Stock issued during period shares issued direct offering net of offering cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" xlink:to="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock_doc" xml:lang="en-US">Stock issued during period value exercise of inducement warrants for common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" xlink:to="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock_doc" xml:lang="en-US">Stock issued during period shares exercise of inducement warrants for common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NetOfferingCosts" xlink:to="ENVB_NetOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NetOfferingCosts_doc" xml:lang="en-US">Net offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:to="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits_doc" xml:lang="en-US">Stock issued during period value issuance of common shares for vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:to="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits_doc" xml:lang="en-US">Stock issued during period shares issuance of common shares for vested restricted stock units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MezzanineEquityMember" xlink:to="ENVB_MezzanineEquityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MezzanineEquityMember_doc" xml:lang="en-US">Mezzanine Equity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_TemporaryEquityShares_doc" xml:lang="en-US">Temporary Equity Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:to="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest_doc" xml:lang="en-US">Preferred dividends attributable to redeemable noncontrolling interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:to="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue_doc" xml:lang="en-US">Accretion of embedded derivative to redemption value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:to="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_doc" xml:lang="en-US">Right-of-use operating lease asset and obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:to="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts_doc" xml:lang="en-US">Proceeds from common stock sold under purchase agreement net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OfferingCostsAccruedNotPaid" xlink:to="ENVB_OfferingCostsAccruedNotPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OfferingCostsAccruedNotPaid_doc" xml:lang="en-US">Offering costs accrued not paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredOfferingCostsChargedToOfferingCosts" xlink:to="ENVB_DeferredOfferingCostsChargedToOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DeferredOfferingCostsChargedToOfferingCosts_doc" xml:lang="en-US">Deferred offering costs charged to offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:to="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts_doc" xml:lang="en-US">Issuance of common shares for deferred offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopment" xlink:to="ENVB_PrepaidResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrepaidResearchAndDevelopment_doc" xml:lang="en-US">Prepaid research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidFranchiseTaxReceivable" xlink:to="ENVB_PrepaidFranchiseTaxReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrepaidFranchiseTaxReceivable_doc" xml:lang="en-US">Prepaid franchise tax receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:to="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable_doc" xml:lang="en-US">Prepaid research and development tax incentive receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_LabEquipmentMember" xlink:to="ENVB_LabEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_LabEquipmentMember_doc" xml:lang="en-US">Lab Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:to="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ComputerEquipmentAndLeaseholdImprovementsMember_doc" xml:lang="en-US">Computer Equipment and Leasehold Improvements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedProductDevelopmentCost" xlink:to="ENVB_AccruedProductDevelopmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AccruedProductDevelopmentCost_doc" xml:lang="en-US">Accrued product and development cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AccruedRestructuringCosts" xlink:to="ENVB_AccruedRestructuringCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AccruedRestructuringCosts_doc" xml:lang="en-US">Accrued restructuring costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DistributionAgreementMember" xlink:to="ENVB_DistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DistributionAgreementMember_doc" xml:lang="en-US">Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CanaccordGenuityLLCMember" xlink:to="ENVB_CanaccordGenuityLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CanaccordGenuityLLCMember_doc" xml:lang="en-US">Canaccord Genuity LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:to="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_doc" xml:lang="en-US">Sale of stock consideration expected maximum price on limitation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommissionPercentage" xlink:to="ENVB_CommissionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CommissionPercentage_doc" xml:lang="en-US">Commission percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryWarrantsMember" xlink:to="ENVB_FebruaryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FebruaryWarrantsMember_doc" xml:lang="en-US">February Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreementMember" xlink:to="ENVB_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegistrationRightsAgreementMember" xlink:to="ENVB_RegistrationRightsAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegistrationRightsAgreementMember_doc" xml:lang="en-US">Registration Rights Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NumberOfCommonStockSharesTraded" xlink:to="ENVB_NumberOfCommonStockSharesTraded_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NumberOfCommonStockSharesTraded_doc" xml:lang="en-US">Number of common stock shares traded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreementsMember" xlink:to="ENVB_PurchaseAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PurchaseAgreementsMember_doc" xml:lang="en-US">Purchase Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:to="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_TwoThousandTwentyLongTermIncentivePlanMember_doc" xml:lang="en-US">2020 Long Term Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_BoardMember" xlink:to="ENVB_BoardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_BoardMember_doc" xml:lang="en-US">Board [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, outstanding at beginning of the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, expired, forfeited, or cancelled.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_doc" xml:lang="en-US">Weighted average grant date fair value, exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ScheduleOfWarrantsOutstandingTableTextBlock_doc" xml:lang="en-US">Schedule of warrants outstanding [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which option holders acquired shares when converting their warrants into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Warrants, weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_doc" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award equity instruments non options exercisable aggregate intrinsic value nonvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsMember" xlink:to="ENVB_InvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionsMember_doc" xml:lang="en-US">Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_doc" xml:lang="en-US">Weighted average exercise price, issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_LicensingAgreementsDisclosureTextBlock" xlink:to="ENVB_LicensingAgreementsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_LicensingAgreementsDisclosureTextBlock_doc" xml:lang="en-US">Licensing Agreements Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AvanceClinicalMember" xlink:to="ENVB_AvanceClinicalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AvanceClinicalMember_doc" xml:lang="en-US">Avance Clinical [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OtherConsultingAndVendorAgreementsMember" xlink:to="ENVB_OtherConsultingAndVendorAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OtherConsultingAndVendorAgreementsMember_doc" xml:lang="en-US">Other Consulting and Vendor Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ReductionInForceRestructuringPercentage" xlink:to="ENVB_ReductionInForceRestructuringPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ReductionInForceRestructuringPercentage_doc" xml:lang="en-US">Reduction in force restructuring percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PurchaseAgreeentMember" xlink:to="ENVB_PurchaseAgreeentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PurchaseAgreeentMember_doc" xml:lang="en-US">Purchase Agreeent [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncentivePlanMember" xlink:to="ENVB_IncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IncentivePlanMember_doc" xml:lang="en-US">Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodCommitmentShares" xlink:to="ENVB_StockIssuedDuringPeriodCommitmentShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodCommitmentShares_doc" xml:lang="en-US">Stock issued during period commitment shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options exercises in period weighted average expired price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" xlink:to="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones_doc" xml:lang="en-US">Proceeds from achieving development and sales milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EquityDistributionAgreementMember" xlink:to="ENVB_EquityDistributionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_EquityDistributionAgreementMember_doc" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_KanubaddiSeparationAgreementMember" xlink:to="ENVB_KanubaddiSeparationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_KanubaddiSeparationAgreementMember_doc" xml:lang="en-US">Kanubaddi Separation Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducementExpense" xlink:to="ENVB_InducementExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InducementExpense_doc" xml:lang="en-US">Inducement expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xml:lang="en-US">Induced conversion of warrants and preferred investment options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestValue" xlink:to="ENVB_RedeemableNoncontrollingInterestValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestValue_doc" xml:lang="en-US">Redeemable noncontrolling interest value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative_doc" xml:lang="en-US">Issuance of embedded derivative.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:to="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestIssuanceCosts_doc" xml:lang="en-US">Redeemable noncontrolling interest issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestShares" xlink:to="ENVB_RedeemableNoncontrollingInterestShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestShares_doc" xml:lang="en-US">Redeemable noncontrolling interest shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:to="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock_doc" xml:lang="en-US">Issuance of redeemable noncontrolling series preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_doc" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards_doc" xml:lang="en-US">Stock issued during period value conversion of restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:to="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_doc" xml:lang="en-US">Stock issued during period shares conversion of restricted stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts_doc" xml:lang="en-US">Registered direct offering pipe offering modification of warrants and exercise of prefunded warrants net of offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:to="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares_doc" xml:lang="en-US">Registered direct offering pipe offering modification of warrants and exercise of pre funded warrants net of offering costs shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:to="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit_doc" xml:lang="en-US">Issuance of rounded shares as result of reverse stock split.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NoncashIncomeTaxExpense" xlink:to="ENVB_NoncashIncomeTaxExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NoncashIncomeTaxExpense_doc" xml:lang="en-US">Noncash income tax expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance_doc" xml:lang="en-US">Warrants issued in conjunction with common stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfEmbeddedDerivative" xlink:to="ENVB_IssuanceOfEmbeddedDerivative_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_IssuanceOfEmbeddedDerivative_doc" xml:lang="en-US">Issuance of embedded derivative.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockSubscriptionReceivable" xlink:to="ENVB_StockSubscriptionReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockSubscriptionReceivable_doc" xml:lang="en-US">Stock subscription receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsIssuedForOfferingCosts" xlink:to="ENVB_WarrantsIssuedForOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsIssuedForOfferingCosts_doc" xml:lang="en-US">Warrants issued for offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_doc" xml:lang="en-US">Induced conversion of warrants and preferred investment options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:to="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance_doc" xml:lang="en-US">Investment options issued in conjunction with common stock issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:to="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise_doc" xml:lang="en-US">Modification of warrants as part of share capital raise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:to="ENVB_ExpenseRelatedToAccelerationOfVesting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ExpenseRelatedToAccelerationOfVesting_doc" xml:lang="en-US">Expense related to acceleration of vesting.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MarketPerformanceBasedShares" xlink:to="ENVB_MarketPerformanceBasedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MarketPerformanceBasedShares_doc" xml:lang="en-US">Market performance based shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestructuringCostsIncurred" xlink:to="ENVB_RestructuringCostsIncurred_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestructuringCostsIncurred_doc" xml:lang="en-US">Restructuring costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilityPolicyTextBlock" xlink:to="ENVB_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:to="ENVB_DeferredOfferingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DeferredOfferingCostsPolicyTextBlock_doc" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillCurrencyTranslation_doc" xml:lang="en-US">Goodwill currency translation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:to="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_doc" xml:lang="en-US">Modification and Inducement of Warrants and Investment Options [Policy text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_doc" xml:lang="en-US">Redeemable non controlling interest policy [Text block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillImpairmentLossGross" xlink:to="ENVB_GoodwillImpairmentLossGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillImpairmentLossGross_doc" xml:lang="en-US">Goodwill impairment loss gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss_doc" xml:lang="en-US">Goodwill accumulated impairment loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:to="ENVB_GoodwillCurrencyTranslationImpairmentLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss_doc" xml:lang="en-US">Goodwill currency translation impairment loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:to="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillForeignCurrencyTranslationGainLossGross_doc" xml:lang="en-US">Goodwill foreign currency translation gain loss gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_doc" xml:lang="en-US">Goodwill accumulated impairment loss foreign currency translation gain loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationLoss" xlink:to="ENVB_GoodwillCurrencyTranslationLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_GoodwillCurrencyTranslationLoss_doc" xml:lang="en-US">Goodwill currency translation loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Number of share warrants (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiability" xlink:to="ENVB_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiability_doc" xml:lang="en-US">Warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCost" xlink:to="ENVB_PaymentsOfStockIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfStockIssuanceCost_doc" xml:lang="en-US">Payments of stock issuance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfAllocatedEquity" xlink:to="ENVB_PaymentsOfAllocatedEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfAllocatedEquity_doc" xml:lang="en-US">Payments of allocated equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionTerm" xlink:to="ENVB_InvestmentOptionTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionTerm_doc" xml:lang="en-US">Investment option term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_StockOptionExercisePrice" xlink:to="ENVB_StockOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_StockOptionExercisePrice_doc" xml:lang="en-US">Stock option exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:to="ENVB_WarrantsAndRightsOutstandingStockPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsAndRightsOutstandingStockPrice_doc" xml:lang="en-US">Warrants, stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfInvestmentOptionLiability" xlink:to="ENVB_PaymentsOfInvestmentOptionLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfInvestmentOptionLiability_doc" xml:lang="en-US">Payments of investment option liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:to="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PaymentsOfStockIssuanceCostsRecordedExpense_doc" xml:lang="en-US">Payments of stock issuance costs recorded expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_NumberOfVestedAndUnissuedShares" xlink:to="ENVB_NumberOfVestedAndUnissuedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_NumberOfVestedAndUnissuedShares_doc" xml:lang="en-US">Number of vested and unissued shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_doc" xml:lang="en-US">Warrant shares outstanding, issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments exchanged.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award non options forfeited in eriod weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:to="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_doc" xml:lang="en-US">Class of warrant or right number of additional securities called by warrants or rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">Stock options, outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:to="ENVB_ClassOfWarrantOrRightReasonForIssuing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ClassOfWarrantOrRightReasonForIssuing_doc" xml:lang="en-US">Warrant issued description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionSharePrice" xlink:to="ENVB_InvestmentOptionSharePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionSharePrice_doc" xml:lang="en-US">Investment option share price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionExercisePrice" xlink:to="ENVB_InvestmentOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOptionExercisePrice_doc" xml:lang="en-US">Investment option exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOutstandingMeasurementInput" xlink:to="ENVB_InvestmentOutstandingMeasurementInput_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentOutstandingMeasurementInput_doc" xml:lang="en-US">Investment outstanding measurement input.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharePriceOption" xlink:to="ENVB_SharePriceOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SharePriceOption_doc" xml:lang="en-US">Share price option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentIntrinsicValue" xlink:to="ENVB_InvestmentIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentIntrinsicValue_doc" xml:lang="en-US">Investment intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentInducementGain" xlink:to="ENVB_InvestmentInducementGain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvestmentInducementGain_doc" xml:lang="en-US">Investment inducement gain.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:to="ENVB_ScheduleOfValuationOfWarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ScheduleOfValuationOfWarrantsTextBlock_doc" xml:lang="en-US">Schedule Of Valuation Of Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNonControllingInterestTextBlock" xlink:to="ENVB_RedeemableNonControllingInterestTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNonControllingInterestTextBlock_doc" xml:lang="en-US">Redeemable non controlling interest [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:to="ENVB_SpinoffAndRelatedPrivatePlacementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SpinoffAndRelatedPrivatePlacementDescription_doc" xml:lang="en-US">Spinoff and related private placement, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:to="ENVB_WarrantsToPurchaseCommonStockPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantsToPurchaseCommonStockPercentage_doc" xml:lang="en-US">Warrants to purchase common stock percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnpaidDividends" xlink:to="ENVB_UnpaidDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_UnpaidDividends_doc" xml:lang="en-US">Unpaid dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterest" xlink:to="ENVB_RedeemableNoncontrollingInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RedeemableNoncontrollingInterest_doc" xml:lang="en-US">Redeemable non controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ConvertiblePreferredStockPrincipalValue" xlink:to="ENVB_ConvertiblePreferredStockPrincipalValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ConvertiblePreferredStockPrincipalValue_doc" xml:lang="en-US">Convertible Preferred Stock Principal Value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of investment options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RoyaltiesPercentage" xlink:to="ENVB_RoyaltiesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RoyaltiesPercentage_doc" xml:lang="en-US">Royalties percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:to="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_doc" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:to="ENVB_ResearchAndDevelopmentCapitalizedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ResearchAndDevelopmentCapitalizedExpenses_doc" xml:lang="en-US">Research and development capitalized expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:to="ENVB_DeferredTaxAssetsAndIntangibleAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DeferredTaxAssetsAndIntangibleAmortization_doc" xml:lang="en-US">Deferred tax assets and intangible amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:to="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup_doc" xml:lang="en-US">Effective income tax rate reconciliation deferred trueup.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PrefundedCommonStockWarrantsMember" xlink:to="ENVB_PrefundedCommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PrefundedCommonStockWarrantsMember_doc" xml:lang="en-US">Prefunded Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:to="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RestrictedStockAwardsVestedAndUnIssuedMember_doc" xml:lang="en-US">Restricted Stock Awards Vested and Unissued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_CommonStockInAbeyanceMember" xlink:to="ENVB_CommonStockInAbeyanceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_CommonStockInAbeyanceMember_doc" xml:lang="en-US">Common stock in abeyance [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember_doc" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_UnderwritersMember" xlink:to="ENVB_UnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_UnderwritersMember_doc" xml:lang="en-US">Underwriters [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:to="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Registered Direct Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:to="ENVB_PIPESecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PIPESecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">PIPE Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:to="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RDOfferingAndPIPEInvestmentOptionsMember_doc" xml:lang="en-US">RD Offering and Pipe Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantAmendmentAgreementsMember" xlink:to="ENVB_WarrantAmendmentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantAmendmentAgreementsMember_doc" xml:lang="en-US">Wainwright Amendment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:to="ENVB_PlacementAgentPreferredInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PlacementAgentPreferredInvestmentOptionsMember_doc" xml:lang="en-US">Placement Agent Preferred Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PreModificationWarrantsMember" xlink:to="ENVB_PreModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PreModificationWarrantsMember_doc" xml:lang="en-US">Pre Modification Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ExistingWarrantsMember" xlink:to="ENVB_ExistingWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_ExistingWarrantsMember_doc" xml:lang="en-US">Existing Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PostModificationWarrantsMember" xlink:to="ENVB_PostModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PostModificationWarrantsMember_doc" xml:lang="en-US">Post Modification Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RothAndInducementWarrantsMember" xlink:to="ENVB_RothAndInducementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RothAndInducementWarrantsMember_doc" xml:lang="en-US">Roth And Inducement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:to="ENVB_AkosSecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AkosSecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Akos Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SeriesAConvertiblePreferredStockMember" xlink:to="ENVB_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SecuritiesPurchaseAgreementMember" xlink:to="ENVB_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities purchase agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AkosMember" xlink:to="ENVB_AkosMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AkosMember_doc" xml:lang="en-US">Akos [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InitialMeasurementMember" xlink:to="ENVB_InitialMeasurementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_InitialMeasurementMember_doc" xml:lang="en-US">Initial Measurement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WainwrightInvestmentOptionsMember" xlink:to="ENVB_WainwrightInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WainwrightInvestmentOptionsMember_doc" xml:lang="en-US">Wainwright Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SubsequentMeasurementMember" xlink:to="ENVB_SubsequentMeasurementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_SubsequentMeasurementMember_doc" xml:lang="en-US">Subsequent Measurement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_doc" xml:lang="en-US">Warrant liabilities - January 2021 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_doc" xml:lang="en-US">Warrant liabilities - February 2021 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:to="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_doc" xml:lang="en-US">Warrant liabilities - February 2022 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:to="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember_doc" xml:lang="en-US">Derivative Liability May 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RDInvestmentOptionsMember" xlink:to="ENVB_RDInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_RDInvestmentOptionsMember_doc" xml:lang="en-US">D Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_PIPEInvestmentOptionsMember" xlink:to="ENVB_PIPEInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_PIPEInvestmentOptionsMember_doc" xml:lang="en-US">Pipe Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:to="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_doc" xml:lang="en-US">February 2022 Post-Modification Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_MeasurementInputMarketRateMember" xlink:to="ENVB_MeasurementInputMarketRateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_MeasurementInputMarketRateMember_doc" xml:lang="en-US">Measurement Input Market Rate [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:to="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember_doc" xml:lang="en-US">HC Wainwright and Co LLC Investment Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_VogalNathanPurchaseAgreementMember" xlink:to="ENVB_VogalNathanPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_VogalNathanPurchaseAgreementMember_doc" xml:lang="en-US">Vogal Nathan Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_OneTimeMilestoneMember" xlink:to="ENVB_OneTimeMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_OneTimeMilestoneMember_doc" xml:lang="en-US">One Time Milestone [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_AdditionalMilestoneMember" xlink:to="ENVB_AdditionalMilestoneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_AdditionalMilestoneMember_doc" xml:lang="en-US">Additional Milestone [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueAdjustmentOfWarrantsOtherIncomeExpenses" xlink:label="ENVB_FairValueAdjustmentOfWarrantsOtherIncomeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueAdjustmentOfWarrantsOtherIncomeExpenses" xlink:to="ENVB_FairValueAdjustmentOfWarrantsOtherIncomeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FairValueAdjustmentOfWarrantsOtherIncomeExpenses_doc" xml:lang="en-US">Change in fair value of warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueOfDerivativeLiability" xlink:to="ENVB_FairValueOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ENVB_FairValueOfDerivativeLiability_doc" xml:lang="en-US">Fair value of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:to="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember_3_lbl" xml:lang="en-US">Investment Options to Purchase Shares of Common Stock [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_2_lbl" xml:lang="en-US">Stockholders' Equity Note, Subscriptions Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_2_lbl" xml:lang="en-US">Operating Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_TemporaryEquityShares" xlink:to="ENVB_TemporaryEquityShares_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_TemporaryEquityShares_4_lbl" xml:lang="en-US">TemporaryEquityShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:to="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation_3_lbl" xml:lang="en-US">IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_3_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock_3_lbl" xml:lang="en-US">Payments for Repurchase of Redeemable Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_IssuanceOfEmbeddedDerivative" xlink:to="ENVB_IssuanceOfEmbeddedDerivative_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_IssuanceOfEmbeddedDerivative_3_lbl" xml:lang="en-US">IssuanceOfEmbeddedDerivative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:to="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions_3_lbl" xml:lang="en-US">InducedConversionOfWarrantsAndPreferredInvestmentOptions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_2_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:to="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_RedeemableNoncontrollingInterestPolicyTextBlock_3_lbl" xml:lang="en-US">RedeemableNoncontrollingInterestPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_3_lbl" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillGross" xlink:to="us-gaap_GoodwillGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillGross_3_lbl" xml:lang="en-US">Goodwill, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3_lbl" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslation" xlink:to="ENVB_GoodwillCurrencyTranslation_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillCurrencyTranslation_4_lbl" xml:lang="en-US">GoodwillCurrencyTranslation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Goodwill [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillImpairmentLossGross" xlink:to="ENVB_GoodwillImpairmentLossGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillImpairmentLossGross_3_lbl" xml:lang="en-US">GoodwillImpairmentLossGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillAccumulatedImpairmentLoss" xlink:to="ENVB_GoodwillAccumulatedImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillAccumulatedImpairmentLoss_3_lbl" xml:lang="en-US">GoodwillAccumulatedImpairmentLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:to="ENVB_GoodwillCurrencyTranslationImpairmentLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_GoodwillCurrencyTranslationImpairmentLoss_3_lbl" xml:lang="en-US">GoodwillCurrencyTranslationImpairmentLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_2_lbl" xml:lang="en-US">Asset Impairment Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_4_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:to="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_4_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_WarrantLiability" xlink:to="ENVB_WarrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_WarrantLiability_3_lbl" xml:lang="en-US">WarrantLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_2_lbl" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueOfDerivativeLiability" xlink:to="ENVB_FairValueOfDerivativeLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FairValueOfDerivativeLiability_3_lbl" xml:lang="en-US">FairValueOfDerivativeLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_3_lbl" xml:lang="en-US">FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:to="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_3_lbl" xml:lang="en-US">FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_2_lbl" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Number of Shares</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>envb-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheets" xlink:href="envb-20240930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BalanceSheetsParenthetical" xlink:href="envb-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="envb-20240930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:href="envb-20240930.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:href="envb-20240930.xsd#StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/StatementsOfCashFlows" xlink:href="envb-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertainties" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="envb-20240930.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssets" xlink:href="envb-20240930.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipment" xlink:href="envb-20240930.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilities" xlink:href="envb-20240930.xsd#AccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValue" xlink:href="envb-20240930.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingencies" xlink:href="envb-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxes" xlink:href="envb-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEvents" xlink:href="envb-20240930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/LicensingAgreements" xlink:href="envb-20240930.xsd#LicensingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="envb-20240930.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsTables" xlink:href="envb-20240930.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentTables" xlink:href="envb-20240930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/AccruedLiabilitiesTables" xlink:href="envb-20240930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueTables" xlink:href="envb-20240930.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:href="envb-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesTables" xlink:href="envb-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:href="envb-20240930.xsd#ScheduleOfRestructuringCostsPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:href="envb-20240930.xsd#BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="envb-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="envb-20240930.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:href="envb-20240930.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="envb-20240930.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:href="envb-20240930.xsd#ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IntangibleAssetsDetailsNarrative" xlink:href="envb-20240930.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:href="envb-20240930.xsd#ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="envb-20240930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:href="envb-20240930.xsd#ScheduleOfStockOptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:href="envb-20240930.xsd#ScheduleOfStockOptionAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:href="envb-20240930.xsd#ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:href="envb-20240930.xsd#ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:href="envb-20240930.xsd#ScheduleOfWarrantsOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:href="envb-20240930.xsd#ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:href="envb-20240930.xsd#ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:href="envb-20240930.xsd#ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:href="envb-20240930.xsd#RedeemableNon-controllingInterestDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:href="envb-20240930.xsd#ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/FairValueDetailsNarrative" xlink:href="envb-20240930.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:href="envb-20240930.xsd#ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="envb-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:href="envb-20240930.xsd#ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:href="envb-20240930.xsd#ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="envb-20240930.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:href="envb-20240930.xsd#ScheduleOfOperatingLossCarryForwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:href="envb-20240930.xsd#ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:href="envb-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" xlink:href="envb-20240930.xsd#ScheduleOfInvestmentOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:href="envb-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" xlink:href="envb-20240930.xsd#ScheduleOfReductionInForcerestructuringActivityDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesCurrent" xlink:label="loc_ENVBWarrantLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_ENVBWarrantLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTemporaryEquityAbstract" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteSubscriptionsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesCRedeemablePreferredStockMember" xlink:label="loc_ENVBSeriesCRedeemablePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBSeriesCRedeemablePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestMember" xlink:label="loc_ENVBRedeemableNoncontrollingInterestMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBRedeemableNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MezzanineEquityMember" xlink:label="loc_ENVBMezzanineEquityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBMezzanineEquityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubscriptionReceivableMember" xlink:label="loc_ENVBSubscriptionReceivableMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_ENVBSubscriptionReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityShares" xlink:label="loc_ENVBTemporaryEquityShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:label="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBAdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestValue" xlink:label="loc_ENVBRedeemableNoncontrollingInterestValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestShares" xlink:label="loc_ENVBRedeemableNoncontrollingInterestShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterestShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:label="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRedeemableNoncontrollingSeriesPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueConversionOfRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:label="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:label="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBIssuanceOfRoundedSharesAsResultOfReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" xlink:label="loc_ENVBStockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" xlink:label="loc_ENVBStockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:label="loc_ENVBStockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TemporaryEquityShares" xlink:label="loc_ENVBTemporaryEquityShares_2" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBTemporaryEquityShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NetOfferingCosts" xlink:label="loc_ENVBNetOfferingCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBNetOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:label="loc_ENVBRedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBRedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestIssuanceCosts" xlink:label="loc_ENVBRedeemableNoncontrollingInterestIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBRedeemableNoncontrollingInterestIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockEquityDistributionCosts" xlink:label="loc_ENVBCommonStockEquityDistributionCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_ENVBCommonStockEquityDistributionCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Condensed Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducementExpense" xlink:label="loc_ENVBInducementExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENVBInducementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetImpairment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NoncashIncomeTaxExpense" xlink:label="loc_ENVBNoncashIncomeTaxExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ENVBNoncashIncomeTaxExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:label="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_ENVBIncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:label="loc_ENVBProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ENVBProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepurchaseOfRedeemablePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:label="loc_ENVBWarrantsIssuedInConjunctionWithCommonStockIssuance" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBWarrantsIssuedInConjunctionWithCommonStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfEmbeddedDerivative" xlink:label="loc_ENVBIssuanceOfEmbeddedDerivative" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBIssuanceOfEmbeddedDerivative" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockSubscriptionReceivable" xlink:label="loc_ENVBStockSubscriptionReceivable" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBStockSubscriptionReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OfferingCostsAccruedNotPaid" xlink:label="loc_ENVBOfferingCostsAccruedNotPaid" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBOfferingCostsAccruedNotPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsIssuedForOfferingCosts" xlink:label="loc_ENVBWarrantsIssuedForOfferingCosts" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBWarrantsIssuedForOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts" xlink:label="loc_ENVBIssuanceOfCommonSharesForDeferredOfferingCosts" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBIssuanceOfCommonSharesForDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:label="loc_ENVBInducedConversionOfWarrantsAndPreferredInvestmentOptions" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBInducedConversionOfWarrantsAndPreferredInvestmentOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBPreferredDividendsAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:label="loc_ENVBInvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBInvestmentOptionsIssuedInConjunctionWithCommonStockIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:label="loc_ENVBModificationOfWarrantsAsPartOfShareCapitalRaise" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBModificationOfWarrantsAsPartOfShareCapitalRaise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue" xlink:label="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBAccretionOfEmbeddedDerivativeToRedemptionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredOfferingCostsChargedToOfferingCosts" xlink:label="loc_ENVBDeferredOfferingCostsChargedToOfferingCosts" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_ENVBDeferredOfferingCostsChargedToOfferingCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties" xlink:title="999008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssets" xlink:title="999011 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipment" xlink:title="999012 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilities" xlink:title="999013 - Disclosure - ACCRUED LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstruments" xlink:title="999014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterest" xlink:title="999015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNonControllingInterestTextBlock" xlink:label="loc_ENVBRedeemableNonControllingInterestTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_ENVBRedeemableNonControllingInterestTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValue" xlink:title="999016 - Disclosure - FAIR VALUE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingencies" xlink:title="999017 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxes" xlink:title="999018 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEvents" xlink:title="999019 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/LicensingAgreements" xlink:title="999020 - Disclosure - LICENSING AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureLicensingAgreementsAbstract" xlink:label="loc_ENVBDisclosureLicensingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_LicensingAgreementsDisclosureTextBlock" xlink:label="loc_ENVBLicensingAgreementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureLicensingAgreementsAbstract" xlink:to="loc_ENVBLicensingAgreementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_ENVBDeferredOfferingCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBDeferredOfferingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilityPolicyTextBlock" xlink:label="loc_ENVBWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBWarrantLiabilityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:label="loc_ENVBModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterestPolicyTextBlock" xlink:label="loc_ENVBRedeemableNoncontrollingInterestPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBRedeemableNoncontrollingInterestPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" xlink:label="loc_ENVBResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_ENVBResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables" xlink:title="999022 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999024 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsTables" xlink:title="999025 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentTables" xlink:title="999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/AccruedLiabilitiesTables" xlink:title="999027 - Disclosure - ACCRUED LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables" xlink:title="999028 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_ENVBScheduleOfWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ScheduleOfValuationOfWarrantsTextBlock" xlink:label="loc_ENVBScheduleOfValuationOfWarrantsTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBScheduleOfValuationOfWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestTables" xlink:title="999029 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaapTemporaryEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapTemporaryEquityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueTables" xlink:title="999030 - Disclosure - FAIR VALUE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesTables" xlink:title="999031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:label="loc_ENVBScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_ENVBScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesTables" xlink:title="999032 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails" xlink:title="999033 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestructuringCostsIncurred" xlink:label="loc_ENVBRestructuringCostsIncurred" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_ENVBRestructuringCostsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaapRestructuringCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestructuringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringCosts" xlink:label="loc_us-gaapOtherRestructuringCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOtherRestructuringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999034 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_EquityDistributionAgreementMember" xlink:label="loc_ENVBEquityDistributionAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBEquityDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_KanubaddiSeparationAgreementMember" xlink:label="loc_ENVBKanubaddiSeparationAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBKanubaddiSeparationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MrKanubaddiEmploymentAgreementMember" xlink:label="loc_ENVBMrKanubaddiEmploymentAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBMrKanubaddiEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WorkingCapital" xlink:label="loc_ENVBWorkingCapital" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaapRestructuringReserve" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRestructuringReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ExpenseRelatedToAccelerationOfVesting" xlink:label="loc_ENVBExpenseRelatedToAccelerationOfVesting" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBExpenseRelatedToAccelerationOfVesting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MarketPerformanceBasedShares" xlink:label="loc_ENVBMarketPerformanceBasedShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMarketPerformanceBasedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:label="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_ENVBMinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBWarrantsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockUnitsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsVestedAndUnIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockUnitsUnvestedMember" xlink:label="loc_ENVBRestrictedStockUnitsUnvestedMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockUnitsUnvestedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RestrictedStockAwardsVestedAndUnIssuedMember" xlink:label="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBRestrictedStockAwardsVestedAndUnIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockInAbeyanceMember" xlink:label="loc_ENVBCommonStockInAbeyanceMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBCommonStockInAbeyanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBInvstmentOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:label="loc_ENVBInvestmentOptionsToPurchaseSharesOfCommonStockMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_ENVBInvestmentOptionsToPurchaseSharesOfCommonStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA" xlink:label="loc_countryCA" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_countryAU" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryAU" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrefundedCommonStockWarrantsMember" xlink:label="loc_ENVBPrefundedCommonStockWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBPrefundedCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopment" xlink:label="loc_ENVBPrepaidResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENVBPrepaidResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidFranchiseTaxReceivable" xlink:label="loc_ENVBPrepaidFranchiseTaxReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENVBPrepaidFranchiseTaxReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfGoodwillDetails" xlink:title="999038 - Disclosure - SCHEDULE OF GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaapGoodwillGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslation" xlink:label="loc_ENVBGoodwillCurrencyTranslation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillImpairmentLossGross" xlink:label="loc_ENVBGoodwillImpairmentLossGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillImpairmentLossGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillAccumulatedImpairmentLoss" xlink:label="loc_ENVBGoodwillAccumulatedImpairmentLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillAccumulatedImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslationImpairmentLoss" xlink:label="loc_ENVBGoodwillCurrencyTranslationImpairmentLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslationImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillForeignCurrencyTranslationGainLossGross" xlink:label="loc_ENVBGoodwillForeignCurrencyTranslationGainLossGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillForeignCurrencyTranslationGainLossGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:label="loc_ENVBGoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslationLoss" xlink:label="loc_ENVBGoodwillCurrencyTranslationLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslationLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaapGoodwillForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillGross" xlink:label="loc_us-gaapGoodwillGross_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillGross_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairedAccumulatedImpairmentLoss_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_GoodwillCurrencyTranslation" xlink:label="loc_ENVBGoodwillCurrencyTranslation_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_ENVBGoodwillCurrencyTranslation_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="999039 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:title="999040 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IntangibleAssetsDetailsNarrative" xlink:title="999041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails" xlink:title="999042 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_LabEquipmentMember" xlink:label="loc_ENVBLabEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBLabEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ComputerEquipmentAndLeaseholdImprovementsMember" xlink:label="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBComputerEquipmentAndLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999043 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails" xlink:title="999044 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccruedProductDevelopmentCost" xlink:label="loc_ENVBAccruedProductDevelopmentCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ENVBAccruedProductDevelopmentCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AccruedRestructuringCosts" xlink:label="loc_ENVBAccruedRestructuringCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_ENVBAccruedRestructuringCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionDetails" xlink:title="999045 - Disclosure - SCHEDULE OF STOCK OPTION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails" xlink:title="999046 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails" xlink:title="999047 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails" xlink:title="999048 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails" xlink:title="999049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails" xlink:title="999050 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails" xlink:title="999051 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RothAndInducementWarrantsMember" xlink:label="loc_ENVBRothAndInducementWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBRothAndInducementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative" xlink:title="999052 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegistrationRightsAgreementMember" xlink:label="loc_ENVBRegistrationRightsAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegistrationRightsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBRegisteredDirectSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPESecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBPIPESecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPIPESecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantAmendmentAgreementsMember" xlink:label="loc_ENVBWarrantAmendmentAgreementsMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBWarrantAmendmentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementMember" xlink:label="loc_ENVBPurchaseAgreementMember" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementsMember" xlink:label="loc_ENVBPurchaseAgreementsMember" />
      <link:presentationArc order="750" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CanaccordGenuityLLCMember" xlink:label="loc_ENVBCanaccordGenuityLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_ENVBCanaccordGenuityLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PlacementAgentPreferredInvestmentOptionsMember" xlink:label="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBPlacementAgentPreferredInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_UnderwritersMember" xlink:label="loc_ENVBUnderwritersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENVBUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_BoardMember" xlink:label="loc_ENVBBoardMember" />
      <link:presentationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_ENVBBoardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDOfferingAndPIPEInvestmentOptionsMember" xlink:label="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDOfferingAndPIPEInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_TwoThousandTwentyLongTermIncentivePlanMember" xlink:label="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENVBTwoThousandTwentyLongTermIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ExistingWarrantsMember" xlink:label="loc_ENVBExistingWarrantsMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBExistingWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ENVBInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryWarrantsMember" xlink:label="loc_ENVBFebruaryWarrantsMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PreModificationWarrantsMember" xlink:label="loc_ENVBPreModificationWarrantsMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPreModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PostModificationWarrantsMember" xlink:label="loc_ENVBPostModificationWarrantsMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBPostModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="110" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="120" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:label="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSaleOfStockConsiderationExpectedMaximumPriceOnLimitation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommissionPercentage" xlink:label="loc_ENVBCommissionPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBCommissionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiability" xlink:label="loc_ENVBWarrantLiability" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfStockIssuanceCost" xlink:label="loc_ENVBPaymentsOfStockIssuanceCost" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfAllocatedEquity" xlink:label="loc_ENVBPaymentsOfAllocatedEquity" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfAllocatedEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfInvestmentOptionLiability" xlink:label="loc_ENVBPaymentsOfInvestmentOptionLiability" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfInvestmentOptionLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PaymentsOfStockIssuanceCostsRecordedExpense" xlink:label="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBPaymentsOfStockIssuanceCostsRecordedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NumberOfVestedAndUnissuedShares" xlink:label="loc_ENVBNumberOfVestedAndUnissuedShares" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBNumberOfVestedAndUnissuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:label="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaapWarrantExercisePriceDecrease" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="loc_us-gaapWarrantExercisePriceIncrease" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantExercisePriceIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ClassOfWarrantOrRightReasonForIssuing" xlink:label="loc_ENVBClassOfWarrantOrRightReasonForIssuing" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBClassOfWarrantOrRightReasonForIssuing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionSharePrice" xlink:label="loc_ENVBInvestmentOptionSharePrice" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionExercisePrice" xlink:label="loc_ENVBInvestmentOptionExercisePrice" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOptionTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOutstandingMeasurementInput" xlink:label="loc_ENVBInvestmentOutstandingMeasurementInput" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharePriceOption" xlink:label="loc_ENVBSharePriceOption" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBSharePriceOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentIntrinsicValue" xlink:label="loc_ENVBInvestmentIntrinsicValue" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentInducementGain" xlink:label="loc_ENVBInvestmentInducementGain" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBInvestmentInducementGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaapPreferredStockVotingRights" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockIssuedDuringPeriodCommitmentShares" xlink:label="loc_ENVBStockIssuedDuringPeriodCommitmentShares" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBStockIssuedDuringPeriodCommitmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_NumberOfCommonStockSharesTraded" xlink:label="loc_ENVBNumberOfCommonStockSharesTraded" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBNumberOfCommonStockSharesTraded" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_CommonStockEquityDistributionCosts" xlink:label="loc_ENVBCommonStockEquityDistributionCosts" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_ENVBCommonStockEquityDistributionCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails" xlink:title="999053 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapTemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapTemporaryEquityAccretionToRedemptionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfRedeemablePreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative" xlink:title="999054 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureRedeemableNoncontrollingInterestAbstract" xlink:label="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureRedeemableNoncontrollingInterestAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AkosSecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBAkosSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBAkosSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SecuritiesPurchaseAgreementMember" xlink:label="loc_ENVBSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ENVBSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AkosMember" xlink:label="loc_ENVBAkosMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_ENVBAkosMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SpinoffAndRelatedPrivatePlacementDescription" xlink:label="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSpinoffAndRelatedPrivatePlacementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsToPurchaseCommonStockPercentage" xlink:label="loc_ENVBWarrantsToPurchaseCommonStockPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBWarrantsToPurchaseCommonStockPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="loc_us-gaapDividendsPayableAmountPerShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPayableAmountPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_UnpaidDividends" xlink:label="loc_ENVBUnpaidDividends" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBUnpaidDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueOfDerivativeLiability" xlink:label="loc_ENVBFairValueOfDerivativeLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RedeemableNoncontrollingInterest" xlink:label="loc_ENVBRedeemableNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBRedeemableNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails" xlink:title="999055 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBWarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesRelatedToInvestmentContractsFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails" xlink:title="999056 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InitialMeasurementMember" xlink:label="loc_ENVBInitialMeasurementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBInitialMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SubsequentMeasurementMember" xlink:label="loc_ENVBSubsequentMeasurementMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBSubsequentMeasurementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyTwoWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyTwoPostModificationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_JanuaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBJanuaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FebruaryTwentyTwentyOneWarrantsMember" xlink:label="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ENVBFebruaryTwentyTwentyOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaapMeasurementInputOptionVolatilityMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputOptionVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_MeasurementInputMarketRateMember" xlink:label="loc_ENVBMeasurementInputMarketRateMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_ENVBMeasurementInputMarketRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:label="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBDerivativeLiabilityMayTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WainwrightInvestmentOptionsMember" xlink:label="loc_ENVBWainwrightInvestmentOptionsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBWainwrightInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RDInvestmentOptionsMember" xlink:label="loc_ENVBRDInvestmentOptionsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBRDInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PIPEInvestmentOptionsMember" xlink:label="loc_ENVBPIPEInvestmentOptionsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBPIPEInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember" xlink:label="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ENVBHCWainwrightAndCoLLCInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_WarrantsAndRightsOutstandingStockPrice" xlink:label="loc_ENVBWarrantsAndRightsOutstandingStockPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBWarrantsAndRightsOutstandingStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ConvertiblePreferredStockPrincipalValue" xlink:label="loc_ENVBConvertiblePreferredStockPrincipalValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBConvertiblePreferredStockPrincipalValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaapAlternativeInvestmentMeasurementInput" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapAlternativeInvestmentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionTerm" xlink:label="loc_ENVBInvestmentOptionTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBInvestmentOptionTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_StockOptionExercisePrice" xlink:label="loc_ENVBStockOptionExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_ENVBStockOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:label="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapRetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails" xlink:title="999057 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeMember" xlink:label="loc_us-gaapDerivativeMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapDerivativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:label="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_ENVBFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/FairValueDetailsNarrative" xlink:title="999058 - Disclosure - FAIR VALUE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails" xlink:title="999059 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AvanceClinicalMember" xlink:label="loc_ENVBAvanceClinicalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_ENVBAvanceClinicalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_VogalNathanPurchaseAgreementMember" xlink:label="loc_ENVBVogalNathanPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBVogalNathanPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OtherConsultingAndVendorAgreementsMember" xlink:label="loc_ENVBOtherConsultingAndVendorAgreementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBOtherConsultingAndVendorAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_OneTimeMilestoneMember" xlink:label="loc_ENVBOneTimeMilestoneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBOneTimeMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_AdditionalMilestoneMember" xlink:label="loc_ENVBAdditionalMilestoneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_ENVBAdditionalMilestoneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="loc_us-gaapCapitalizedContractCostNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCapitalizedContractCostNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionContractCostProgressPaymentOffset" xlink:label="loc_us-gaapConstructionContractCostProgressPaymentOffset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapConstructionContractCostProgressPaymentOffset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaapLongTermPurchaseCommitmentAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLongTermPurchaseCommitmentAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_RoyaltiesPercentage" xlink:label="loc_ENVBRoyaltiesPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBRoyaltiesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:label="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBPrepaidResearchAndDevelopmentTaxIncentiveReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ReductionInForceRestructuringPercentage" xlink:label="loc_ENVBReductionInForceRestructuringPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_ENVBReductionInForceRestructuringPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails" xlink:title="999061 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails" xlink:title="999062 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentForeignTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentForeignTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999063 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ResearchAndDevelopmentCapitalizedExpenses" xlink:label="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENVBResearchAndDevelopmentCapitalizedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DeferredTaxAssetsAndIntangibleAmortization" xlink:label="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENVBDeferredTaxAssetsAndIntangibleAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails" xlink:title="999064 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails" xlink:title="999065 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:label="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_ENVBEffectiveIncomeTaxRateReconciliationDeferredTrueup" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/IncomeTaxesDetailsNarrative" xlink:title="999066 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfInvestmentOptionsDetails" xlink:title="999067 - Disclosure - SCHEDULE OF INVESTMENT OPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_InvestmentOptionsMember" xlink:label="loc_ENVBInvestmentOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ENVBInvestmentOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:label="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ENVBSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/SubsequentEventsDetailsNarrative" xlink:title="999068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreementMember" xlink:label="loc_ENVBPurchaseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DistributionAgreementMember" xlink:label="loc_ENVBDistributionAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_PurchaseAgreeentMember" xlink:label="loc_ENVBPurchaseAgreeentMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_ENVBPurchaseAgreeentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_IncentivePlanMember" xlink:label="loc_ENVBIncentivePlanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ENVBIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones" xlink:label="loc_ENVBProceedsFromAchievingDevelopmentAndSalesMilestones" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_ENVBProceedsFromAchievingDevelopmentAndSalesMilestones" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails" xlink:title="999069 - Disclosure - SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="envb-20240930.xsd#ENVB_DisclosureLicensingAgreementsAbstract" xlink:label="loc_ENVBDisclosureLicensingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureLicensingAgreementsAbstract" xlink:to="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaapRestructuringCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureLicensingAgreementsAbstract" xlink:to="loc_us-gaapRestructuringCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ENVBDisclosureLicensingAgreementsAbstract" xlink:to="loc_us-gaapRestructuringAndRelatedCostCostIncurredToDate1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889770352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">424B4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891891853584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,111,683<span></span>
</td>
<td class="nump">$ 2,287,977<span></span>
</td>
<td class="nump">$ 17,723,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,226,576<span></span>
</td>
<td class="nump">1,293,554<span></span>
</td>
<td class="nump">708,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,338,259<span></span>
</td>
<td class="nump">3,581,531<span></span>
</td>
<td class="nump">18,431,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">367,689<span></span>
</td>
<td class="nump">507,377<span></span>
</td>
<td class="nump">677,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">84,368<span></span>
</td>
<td class="nump">210,932<span></span>
</td>
<td class="nump">379,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">452,057<span></span>
</td>
<td class="nump">718,309<span></span>
</td>
<td class="nump">1,120,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,790,316<span></span>
</td>
<td class="nump">4,299,840<span></span>
</td>
<td class="nump">19,552,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">576,324<span></span>
</td>
<td class="nump">1,218,783<span></span>
</td>
<td class="nump">463,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">253,150<span></span>
</td>
<td class="nump">1,075,643<span></span>
</td>
<td class="nump">1,705,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of right-of-use operating lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">63,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Investment option liability</a></td>
<td class="nump">4,944<span></span>
</td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">851,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantLiabilitiesCurrent', window );">Warrant liability</a></td>
<td class="nump">4,748<span></span>
</td>
<td class="nump">25,470<span></span>
</td>
<td class="nump">185,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">839,166<span></span>
</td>
<td class="nump">2,343,504<span></span>
</td>
<td class="nump">3,995,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">885,028<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Total mezzanine equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">885,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">5,998<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
<td class="nump">1,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">107,400,009<span></span>
</td>
<td class="nump">100,841,416<span></span>
</td>
<td class="nump">94,415,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,817,640)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(102,919,859)<span></span>
</td>
<td class="num">(96,499,518)<span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(534,998)<span></span>
</td>
<td class="num">(569,749)<span></span>
</td>
<td class="num">(536,734)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">3,951,150<span></span>
</td>
<td class="nump">1,956,336<span></span>
</td>
<td class="nump">14,671,924<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and shareholders&#8217; equity</a></td>
<td class="nump">$ 4,790,316<span></span>
</td>
<td class="nump">$ 4,299,840<span></span>
</td>
<td class="nump">$ 19,552,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891894306640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">599,669<span></span>
</td>
<td class="nump">182,625<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">599,669<span></span>
</td>
<td class="nump">182,625<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENVB_SeriesCRedeemablePreferredStockMember', window );">Series C Redeemable Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_SeriesCRedeemablePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_SeriesCRedeemablePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891891672416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,235,661<span></span>
</td>
<td class="nump">$ 2,080,644<span></span>
</td>
<td class="nump">$ 4,467,065<span></span>
</td>
<td class="nump">$ 8,273,344<span></span>
</td>
<td class="nump">$ 8,852,021<span></span>
</td>
<td class="nump">$ 11,605,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">762,717<span></span>
</td>
<td class="nump">1,281,455<span></span>
</td>
<td class="nump">1,736,373<span></span>
</td>
<td class="nump">5,531,436<span></span>
</td>
<td class="nump">7,252,437<span></span>
</td>
<td class="nump">8,027,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangible assets and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,453,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">84,814<span></span>
</td>
<td class="nump">86,296<span></span>
</td>
<td class="nump">255,002<span></span>
</td>
<td class="nump">259,300<span></span>
</td>
<td class="nump">343,982<span></span>
</td>
<td class="nump">327,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,083,192<span></span>
</td>
<td class="nump">3,448,395<span></span>
</td>
<td class="nump">6,458,440<span></span>
</td>
<td class="nump">14,064,080<span></span>
</td>
<td class="nump">16,448,440<span></span>
</td>
<td class="nump">27,415,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,083,192)<span></span>
</td>
<td class="num">(3,448,395)<span></span>
</td>
<td class="num">(6,458,440)<span></span>
</td>
<td class="num">(14,064,080)<span></span>
</td>
<td class="num">(16,448,440)<span></span>
</td>
<td class="num">(27,415,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InducementExpense', window );">Inducement expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,848,235)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(122)<span></span>
</td>
<td class="nump">67,822<span></span>
</td>
<td class="nump">20,722<span></span>
</td>
<td class="num">(115,342)<span></span>
</td>
<td class="nump">94,396<span></span>
</td>
<td class="nump">4,315,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investment option liability</a></td>
<td class="num">(501)<span></span>
</td>
<td class="nump">562,715<span></span>
</td>
<td class="nump">18,664<span></span>
</td>
<td class="num">(399,921)<span></span>
</td>
<td class="nump">208,752<span></span>
</td>
<td class="nump">3,472,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
<td class="nump">727,000<span></span>
</td>
<td class="num">(325,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="num">(217)<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="nump">3,142<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
<td class="num">(5,249)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(840)<span></span>
</td>
<td class="nump">632,774<span></span>
</td>
<td class="nump">39,830<span></span>
</td>
<td class="nump">214,879<span></span>
</td>
<td class="num">(814,379)<span></span>
</td>
<td class="nump">7,457,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(2,084,032)<span></span>
</td>
<td class="num">(2,815,621)<span></span>
</td>
<td class="num">(6,418,610)<span></span>
</td>
<td class="num">(13,849,201)<span></span>
</td>
<td class="num">(17,262,819)<span></span>
</td>
<td class="num">(19,957,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,595)<span></span>
</td>
<td class="num">(1,731)<span></span>
</td>
<td class="num">(6,595)<span></span>
</td>
<td class="num">(28,913)<span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,084,032)<span></span>
</td>
<td class="num">(2,822,216)<span></span>
</td>
<td class="num">(6,420,341)<span></span>
</td>
<td class="num">(13,855,796)<span></span>
</td>
<td class="num">(17,291,732)<span></span>
</td>
<td class="num">(18,471,333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less preferred dividends attributable to non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="nump">33,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Less deemed dividends attributable to accretion of embedded derivative at redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="nump">295,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to shareholders</a></td>
<td class="num">(2,084,032)<span></span>
</td>
<td class="num">(2,822,216)<span></span>
</td>
<td class="num">(6,420,341)<span></span>
</td>
<td class="num">(14,022,825)<span></span>
</td>
<td class="num">(17,458,761)<span></span>
</td>
<td class="num">(18,800,323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">31,497<span></span>
</td>
<td class="nump">10,433<span></span>
</td>
<td class="nump">34,751<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
<td class="num">(505,932)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (2,052,535)<span></span>
</td>
<td class="num">$ (2,811,783)<span></span>
</td>
<td class="num">$ (6,385,590)<span></span>
</td>
<td class="num">$ (14,021,710)<span></span>
</td>
<td class="num">$ (17,491,776)<span></span>
</td>
<td class="num">$ (19,306,255)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (3.59)<span></span>
</td>
<td class="num">$ (19.56)<span></span>
</td>
<td class="num">$ (14.22)<span></span>
</td>
<td class="num">$ (99.35)<span></span>
</td>
<td class="num">$ (121.29)<span></span>
</td>
<td class="num">$ (195.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (3.59)<span></span>
</td>
<td class="num">$ (19.56)<span></span>
</td>
<td class="num">$ (14.22)<span></span>
</td>
<td class="num">$ (99.35)<span></span>
</td>
<td class="num">$ (121.29)<span></span>
</td>
<td class="num">$ (195.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">580,197<span></span>
</td>
<td class="nump">144,311<span></span>
</td>
<td class="nump">451,411<span></span>
</td>
<td class="nump">141,144<span></span>
</td>
<td class="nump">143,938<span></span>
</td>
<td class="nump">96,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">580,197<span></span>
</td>
<td class="nump">144,311<span></span>
</td>
<td class="nump">451,411<span></span>
</td>
<td class="nump">141,144<span></span>
</td>
<td class="nump">143,938<span></span>
</td>
<td class="nump">96,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891883981888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Series C Redeemable Preferred Stock [Member]</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Mezzanine Equity [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Subscription Receivable [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
<td class="nump">$ 83,072,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60,736,453)<span></span>
</td>
<td class="num">$ (30,802)<span></span>
</td>
<td class="nump">$ 22,305,920<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 33,014<span></span>
</td>
<td class="nump">33,014<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">295,976<span></span>
</td>
<td class="nump">295,976<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(295,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(295,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series A preferred stock</a></td>
<td class="num">$ (527)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of Series A preferred stock, shares</a></td>
<td class="num">(52,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,620,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,620,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(505,932)<span></span>
</td>
<td class="num">(505,932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,471,333)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,471,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost', window );">Issuance of direct offering shares (see Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">5,802,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,802,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost', window );">Issuance of direct offering shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Conversion of RSUs into common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Conversion of RSUs into common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestValue', window );">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 556,038<span></span>
</td>
<td class="nump">556,038<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestShares', window );">Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock', window );">Issuance of redeemable Series C preferred stock</a></td>
<td class="nump">$ 527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable Series C preferred stock, shares</a></td>
<td class="nump">52,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards', window );">Conversion of RSAs into common shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards', window );">Conversion of RSAs into common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts', window );">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">3,248,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,249,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares', window );">July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit', window );">Issuance of rounded shares as a result of the reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of rounded shares as a result of the reverse stock split, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="nump">885,028<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">94,415,058<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
<td class="num">(536,734)<span></span>
</td>
<td class="nump">14,671,924<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,329<span></span>
</td>
<td class="nump">12,329<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,991<span></span>
</td>
<td class="nump">110,991<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(110,991)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(110,991)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">532,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">532,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,677,527)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,677,527)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,008,348<span></span>
</td>
<td class="nump">1,008,348<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">94,824,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,885,313)<span></span>
</td>
<td class="num">(534,766)<span></span>
</td>
<td class="nump">10,405,880<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="nump">885,028<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">94,415,058<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
<td class="num">(536,734)<span></span>
</td>
<td class="nump">14,671,924<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(147,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,855,796)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,455<span></span>
</td>
<td class="nump">96,033,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,063,582)<span></span>
</td>
<td class="num">(535,619)<span></span>
</td>
<td class="nump">2,435,646<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="nump">885,028<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">94,415,058<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
<td class="num">(536,734)<span></span>
</td>
<td class="nump">14,671,924<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,041<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,041)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(147,988)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(147,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,052,057)<span></span>
</td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of Series A preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,150,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions from the reduction in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions from the reduction in force, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">255,014<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">255,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for deferred offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,967,424<span></span>
</td>
<td class="num">(280,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,686,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions', window );">Induced conversion of warrants and preferred investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">683,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">683,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">1,536,861<span></span>
</td>
<td class="num">(1,537,140)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,291,732)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,291,732)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="nump">100,841,416<span></span>
</td>
<td class="num">(1,817,640)<span></span>
</td>
<td class="num">(96,499,518)<span></span>
</td>
<td class="num">(569,749)<span></span>
</td>
<td class="nump">1,956,336<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,008,348<span></span>
</td>
<td class="nump">1,008,348<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">94,824,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,885,313)<span></span>
</td>
<td class="num">(534,766)<span></span>
</td>
<td class="nump">10,405,880<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,712<span></span>
</td>
<td class="nump">6,712<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,997<span></span>
</td>
<td class="nump">36,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,997)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(36,997)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Redemption of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,052,057)<span></span>
</td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Redemption of Series A preferred stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">879,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">879,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions from the reduction in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions from the reduction in force, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,356,053)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,356,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">95,660,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,241,366)<span></span>
</td>
<td class="num">(546,052)<span></span>
</td>
<td class="nump">4,874,570<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">372,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">372,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,433<span></span>
</td>
<td class="nump">10,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,822,216)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,822,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits', window );">Issuance of common shares for vested RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits', window );">Issuance of common shares for vested RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,455<span></span>
</td>
<td class="nump">96,033,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,063,582)<span></span>
</td>
<td class="num">(535,619)<span></span>
</td>
<td class="nump">2,435,646<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="nump">100,841,416<span></span>
</td>
<td class="num">(1,817,640)<span></span>
</td>
<td class="num">(96,499,518)<span></span>
</td>
<td class="num">(569,749)<span></span>
</td>
<td class="nump">1,956,336<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">351,488<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">351,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,821)<span></span>
</td>
<td class="nump">280,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">267,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="nump">1,537,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,537,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,906<span></span>
</td>
<td class="nump">17,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,456,915)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,456,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost', window );">Issuance of direct offering shares (see Note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">322,301<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">322,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost', window );">Issuance of direct offering shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution', window );">Common stock sold under the Purchase Agreement, net of offering costs of $290,029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
<td class="nump">1,807,677<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,808,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution', window );">Common stock sold under the Equity Distribution Agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock', window );">Exercise of Inducement Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,303<span></span>
</td>
<td class="nump">2,675,677<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,676,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock', window );">Exercise of Inducement Warrants for common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,863<span></span>
</td>
<td class="nump">105,985,269<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(98,956,433)<span></span>
</td>
<td class="num">(551,843)<span></span>
</td>
<td class="nump">6,481,856<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,827<span></span>
</td>
<td class="nump">100,841,416<span></span>
</td>
<td class="num">(1,817,640)<span></span>
</td>
<td class="num">(96,499,518)<span></span>
</td>
<td class="num">(569,749)<span></span>
</td>
<td class="nump">1,956,336<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_TemporaryEquityShares', window );">Mezzanine equity balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,420,341)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,998<span></span>
</td>
<td class="nump">107,400,009<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(102,919,859)<span></span>
</td>
<td class="num">(534,998)<span></span>
</td>
<td class="nump">3,951,150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,863<span></span>
</td>
<td class="nump">105,985,269<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(98,956,433)<span></span>
</td>
<td class="num">(551,843)<span></span>
</td>
<td class="nump">6,481,856<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,652)<span></span>
</td>
<td class="num">(14,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,879,394)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,879,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost', window );">Issuance of direct offering shares (see Note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">448,534<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">448,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost', window );">Issuance of direct offering shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution', window );">Common stock sold under the Purchase Agreement, net of offering costs of $290,029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution', window );">Common stock sold under the Equity Distribution Agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits', window );">Issuance of common shares for vested RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits', window );">Issuance of common shares for vested RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,253<span></span>
</td>
<td class="nump">106,803,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(100,835,827)<span></span>
</td>
<td class="num">(566,495)<span></span>
</td>
<td class="nump">5,406,264<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369,614<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">369,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">31,497<span></span>
</td>
<td class="nump">31,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,084,032)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,084,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution', window );">Common stock sold under the Purchase Agreement, net of offering costs of $290,029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 727<span></span>
</td>
<td class="nump">227,080<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">227,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution', window );">Common stock sold under the Equity Distribution Agreement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits', window );">Issuance of common shares for vested RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits', window );">Issuance of common shares for vested RSU, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,998<span></span>
</td>
<td class="nump">$ 107,400,009<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (102,919,859)<span></span>
</td>
<td class="num">$ (534,998)<span></span>
</td>
<td class="nump">$ 3,951,150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of embedded derivative to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Induced conversion of warrants and preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of redeemable noncontrolling series preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of rounded shares as result of reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred dividends attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct offering pipe offering modification of warrants and exercise of prefunded warrants net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct offering pipe offering modification of warrants and exercise of pre funded warrants net of offering costs shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock sold under equity distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of inducement warrants for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common shares for vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issued direct offering net of offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock sold under equity distribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value conversion of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of inducement warrants for common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issuance of common shares for vested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value issued direct offering net of offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_TemporaryEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_TemporaryEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period Shares New Issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891884107328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NetOfferingCosts', window );">Net offering costs</a></td>
<td class="nump">$ 12,821<span></span>
</td>
<td class="nump">$ 239,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative', window );">Issuance of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestIssuanceCosts', window );">Redeemable noncontrolling interest issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_CommonStockEquityDistributionCosts', window );">Common stock equity distribution costs</a></td>
<td class="nump">$ 583,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_CommonStockEquityDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock equity distribution costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_CommonStockEquityDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NetOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NetOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable noncontrolling interest issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of embedded derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891892753760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,420,341)<span></span>
</td>
<td class="num">$ (13,855,796)<span></span>
</td>
<td class="num">$ (17,291,732)<span></span>
</td>
<td class="num">$ (18,471,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(20,722)<span></span>
</td>
<td class="nump">115,342<span></span>
</td>
<td class="num">(94,396)<span></span>
</td>
<td class="num">(4,315,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investment option liability</a></td>
<td class="num">(18,664)<span></span>
</td>
<td class="nump">399,921<span></span>
</td>
<td class="num">(208,752)<span></span>
</td>
<td class="num">(3,472,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(727,000)<span></span>
</td>
<td class="num">(727,000)<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,090,716<span></span>
</td>
<td class="nump">1,785,432<span></span>
</td>
<td class="nump">2,150,160<span></span>
</td>
<td class="nump">2,620,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InducementExpense', window );">Inducement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848,235<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,453,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NoncashIncomeTaxExpense', window );">Non-cash income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,504,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,246<span></span>
</td>
<td class="nump">64,048<span></span>
</td>
<td class="nump">107,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="nump">126,564<span></span>
</td>
<td class="nump">126,566<span></span>
</td>
<td class="nump">168,754<span></span>
</td>
<td class="nump">168,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">128,438<span></span>
</td>
<td class="nump">132,734<span></span>
</td>
<td class="nump">175,228<span></span>
</td>
<td class="nump">159,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,219)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,674)<span></span>
</td>
<td class="num">(746,033)<span></span>
</td>
<td class="num">(6,857)<span></span>
</td>
<td class="num">(374,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,296,907)<span></span>
</td>
<td class="nump">429,688<span></span>
</td>
<td class="num">(103,848)<span></span>
</td>
<td class="nump">263,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation', window );">Right-of-use operating lease asset and obligation</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(64,244)<span></span>
</td>
<td class="num">(64,045)<span></span>
</td>
<td class="num">(107,288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,414,590)<span></span>
</td>
<td class="num">(12,343,363)<span></span>
</td>
<td class="num">(14,094,411)<span></span>
</td>
<td class="num">(17,146,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,195)<span></span>
</td>
<td class="num">(5,180)<span></span>
</td>
<td class="num">(584,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">16,847<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,705<span></span>
</td>
<td class="nump">11,667<span></span>
</td>
<td class="num">(584,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock sold under the Equity Distribution Agreement, net of offering costs</a></td>
<td class="nump">2,290,186<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,222,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options</a></td>
<td class="nump">1,804,819<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of Inducement Warrants</a></td>
<td class="nump">2,676,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts', window );">Proceeds from common stock sold under the Purchase Agreement, net of offering costs</a></td>
<td class="nump">599,862<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for offering costs previously accrued</a></td>
<td class="num">(161,461)<span></span>
</td>
<td class="num">(105,000)<span></span>
</td>
<td class="num">(291,084)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock', window );">Redemption of Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock', window );">Proceeds from the sale of redeemable non-controlling interest, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">958,038<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">7,210,386<span></span>
</td>
<td class="num">(1,157,057)<span></span>
</td>
<td class="num">(1,343,141)<span></span>
</td>
<td class="nump">18,180,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of Foreign Exchange Rate on Changes on Cash</a></td>
<td class="nump">27,910<span></span>
</td>
<td class="nump">31,399<span></span>
</td>
<td class="num">(10,022)<span></span>
</td>
<td class="num">(81,364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash</a></td>
<td class="nump">823,706<span></span>
</td>
<td class="num">(13,457,316)<span></span>
</td>
<td class="num">(15,435,907)<span></span>
</td>
<td class="nump">367,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at beginning of period</a></td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
<td class="nump">17,355,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash at end of period</a></td>
<td class="nump">3,111,683<span></span>
</td>
<td class="nump">4,266,568<span></span>
</td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash and non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">24,001<span></span>
</td>
<td class="nump">6,595<span></span>
</td>
<td class="nump">9,507<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance', window );">Warrants issued in conjunction with common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,595,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfEmbeddedDerivative', window );">Issuance of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockSubscriptionReceivable', window );">Stock subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,817,640<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_OfferingCostsAccruedNotPaid', window );">Offering costs accrued not paid</a></td>
<td class="nump">35,455<span></span>
</td>
<td class="nump">20,800<span></span>
</td>
<td class="nump">182,724<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsIssuedForOfferingCosts', window );">Warrants issued for offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,991<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts', window );">Issuance of common shares for offering costs</a></td>
<td class="nump">771,293<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">255,107<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions', window );">Induced conversion of warrants and preferred investment options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest', window );">Preferred dividends attributable to redeemable non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="nump">33,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance', window );">Investment options issued in conjunction with common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,323,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise', window );">Modification of warrants as part of share capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">251,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="nump">$ 147,988<span></span>
</td>
<td class="nump">$ 295,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DeferredOfferingCostsChargedToOfferingCosts', window );">Deferred offering costs charged to offering costs</a></td>
<td class="nump">$ 495,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of embedded derivative to redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DeferredOfferingCostsChargedToOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs charged to offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DeferredOfferingCostsChargedToOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use operating lease asset and obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Induced conversion of warrants and preferred investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InducementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inducement expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InducementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment options issued in conjunction with common stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_IssuanceOfEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of embedded derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_IssuanceOfEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of warrants as part of share capital raise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NoncashIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NoncashIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_OfferingCostsAccruedNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs accrued not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_OfferingCostsAccruedNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred dividends attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from common stock sold under purchase agreement net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsIssuedForOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsIssuedForOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in conjunction with common stock issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for reacquisition of callable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994913680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</a></td>
<td class="text"><p id="xdx_808_eus-gaap--NatureOfOperations_zh3tk2MuAILb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_82F_z9UeT7gQdFnh">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&#8220;Enveric&#8221; or the &#8220;Company&#8221;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#8220;Jay Pharma&#8221;), 1306432 B.C. Ltd., MagicMed
Industries, Inc. (&#8220;MagicMed&#8221;), Enveric Biosciences Canada Inc., Akos Biosciences, Inc. (&#8220;Akos&#8221;), and Enveric
Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its unique discovery and development platform, The Psybrary&#8482;, Enveric has created a robust intellectual property portfolio of new
chemical entities for specific mental health indications. Enveric&#8217;s lead program, the EVM201 Series, comprises next generation
synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#8211; EB-002
(formerly EB-373) &#8211; for the treatment of psychiatric disorders. Enveric is also advancing its product EB-003, a non-hallucinogenic
neuroplastogen from the EVM301 Series, which is expected to offer a first-in-class, new approach to the treatment of difficult-to-address
mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has continued to pursue the development of MagicMed&#8217;s proprietary library, the Psybrary&#8482; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges. The Company synthesizes novel
analogues of serotonin, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which
includes 15 patent families with over a million potential variations and hundreds of synthesized molecules. The Company has created over
1,200 novel molecular compounds and derivatives that are housed in the Psybrary&#8482;. The Company&#8217;s current focus is to develop
its lead molecules, EB-002 and EB-003, and to out license other molecules from the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company screens newly
synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (&#8220;AI&#8221;) tool. Leveraging
AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company believes it streamlines
pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to
help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable can
then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds
of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and
ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#8482; and the AI tool to categorize and characterize
the Psybrary&#8482; substituents to focus on bringing more non-hallucinogenic neuroplastogen molecules from discovery to the clinical
phase.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zRUwE7LEfoM5" title="Reverse stock split">1-for-15</span>
reverse stock split (&#8220;Reverse Stock Split&#8221;) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025,
pursuant to which every 15 shares of the Company&#8217;s issued and outstanding common stock were reclassified as one share of
common stock. The Reverse Stock Split had no impact on the par value of the Company&#8217;s common stock or the authorized number of
shares of common stock. Unless otherwise indicated, all share and per share information in these unaudited condensed consolidated
financial statements are adjusted to reflect the Reverse Stock Split, prior to any rounding of fractional shares. Any fractional
share resulting from the Reverse Stock Split shall be rounded up to the next whole number of shares.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern, Liquidity and Other Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_di_c20240930_z9jGJolLfKMf" title="Accumulated deficit">102,919,859</span> as of September 30, 2024, and further
losses are anticipated in the development of its business. For the nine months ended September 30, 2024, the Company has operating cash
outflows of $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_di_c20240101__20240930_z9GsNF9z32yb" title="Net cash used in operating activities">6,414,590</span> and had a loss from operations of $<span id="xdx_90D_eus-gaap--OperatingIncomeLoss_di_c20240101__20240930_znnSIVYeYnSk" title="Loss from operations">6,458,440</span>. Being a research and development company, since inception, the Company
has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company&#8217;s operations have
been funded principally through the issuance of equity. These factors raise substantial doubt about the Company&#8217;s ability to continue
as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At September 30, 2024, the Company had
cash of $<span id="xdx_904_eus-gaap--Cash_iI_c20240930_zbypoEditXxg" title="Cash">3,111,683</span> and working capital of $<span id="xdx_908_ecustom--WorkingCapital_iI_c20240930_zT7OOFz3QUDh" title="Working capital">3,499,093</span>. The Company&#8217;s current cash on hand is not sufficient to satisfy its operating
cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding
the Company&#8217;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#8217;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, the Purchase Agreement with Lincoln Park (see Note 7), subject to registration,
and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may
not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company
may be required to undertake further cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the unaudited condensed consolidated financial statements are issued. The
Company&#8217;s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notice</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (&#8220;Nasdaq&#8221;)
stating that as of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90C_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_z28sk83ryZt2" title="Minimum of stockholders equity required for continued listing pursuant to exchange">2,500,000</span> in stockholders&#8217; equity required for
continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting
the Company an extension to regain compliance with the minimum stockholders&#8217; equity requirement by May 20, 2024. On May 21, 2024,
the Company received a letter from Nasdaq notifying the Company that it regained compliance with the minimum stockholders&#8217; equity
requirement for continued listing on the Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2024, the Company received a letter from Nasdaq&#8217;s Listing Qualifications Department stating that because the closing bid
price for the Company&#8217;s common stock listed on Nasdaq was below $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240516_zLQ7bNdCX64f" title="Shares issued price">1.00</span> for 30 consecutive business days, the Company no longer meets
the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the &#8220;Minimum Bid Price Requirement&#8221;).
The Company received an initial period of 180 calendar days from May 16, 2024, or until November 12, 2024, to regain compliance with
the Minimum Bid Price Requirement and was unable to regain compliance during that time. The Company has applied for a second 180-day
compliance period. As of the date hereof, the Company has not heard whether it will be granted the second compliance period. The Company
anticipates conducting a reverse split during the first or second quarter of 2025 in order to regain compliance with the Minimum Bid
Price Requirement if the bid price of the Company&#8217;s common stock fails to close at or above $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231112_zbsvJ8owuw56" title="Shares issued price">1.00</span> per share for a minimum of 10
consecutive business days prior the end of the second compliance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--NatureOfOperations_zcYw7bouB0pi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1. <span id="xdx_827_zeGb70wjgan">BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (&#8220;Enveric&#8221; or the &#8220;Company&#8221;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#8220;Jay Pharma&#8221;), 1306432 B.C. Ltd. (&#8220;HoldCo&#8221;),
MagicMed Industries, Inc. (&#8220;MagicMed&#8221;), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (&#8220;Enveric Therapeutics&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging
its unique discovery and development platform, the  Psybrary&#8482;, has created a robust intellectual property portfolio
of new chemical entities for specific mental health indications. Enveric&#8217;s lead program, the EVM201 Series, comprises next
generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#8211;
EB-373 &#8211; for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected
to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of
neuroplasticity without also inducing hallucinations in the patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the Company&#8217;s amalgamation with MagicMed completed in September 2021 (the &#8220;Amalgamation&#8221;), the Company has continued
to pursue the development of MagicMed&#8217;s proprietary Psychedelic Derivatives library, the Psybrary&#8482; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress.
The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry
and synthetic biology, resulting in the expansion of the Psybrary&#8482;, which includes 15 patent families with over a million
potential variations and hundreds of synthesized molecules. Within the Psybrary&#8482; the Company has three different types of
molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities).
The Company is working to add novel molecular compounds and derivatives (&#8220;Psychedelic Derivatives&#8221;) on a regular basis
through its work at the Company&#8217;s labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with
expertise in synthetic biology and chemistry. To date the Company has created over 500 molecules that are housed
in the Psybrary&#8482;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The
Company screens newly synthesized molecules in the Psybrary&#8482; through PsyAI&#8482;, a proprietary artificial intelligence (&#8220;AI&#8221;)
tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company
believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological
effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable
can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New
compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal),
and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#8482; and the AI tool to categorize and characterize
the Psybrary&#8482; substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#8217;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#8220;EVM201
Series&#8221;), towards the clinic. Enveric Therapeutics will oversee the Company&#8217;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration
(TGA), Australia&#8217;s regulatory authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company effected a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zlYF6ZHetqpj" title="Reverse stock split">1-for-15</span>
reverse stock split (&#8220;Reverse Stock Split&#8221;) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025,
pursuant to which every 15 shares of the Company&#8217;s issued and outstanding common stock were reclassified as one share of
common stock. The Reverse Stock Split had no impact on the par value of the Company&#8217;s common stock or the authorized number of
shares of common stock. Unless otherwise indicated, all share and per share information in these consolidated financial statements
are adjusted to reflect the Reverse Stock Split, prior to the rounding of any fractional shares. Any fractional share resulting from
the Reverse Stock Split shall be rounded up to the next whole number of shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern, Liquidity and Other Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred a loss since inception resulting in an accumulated deficit of $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zeXL2JVUG7I7" title="Accumulated deficit">96,499,518</span> as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company has operating cash outflows of $<span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zC9IEOtZAr8a" title="Net cash used in operating activities">14,094,411</span> for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $<span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20231231_zptySDPGyAxb" title="Loss from operations">16,448,440</span>. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#8217;s operations have been funded principally through the issuance of equity. These factors raise substantial
doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the Company&#8217;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $<span id="xdx_908_eus-gaap--Cash_iI_c20231231_zg6W1PD6T4He" title="Cash">2,287,977</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
working capital of $<span id="xdx_909_ecustom--WorkingCapital_iI_c20231231_zwCKXLM8F7e1" title="Working capital">1,238,027</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company&#8217;s current cash on hand is not sufficient enough to satisfy its operating cash needs for the 12 months from the filing
of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding the Company&#8217;s ability to continue as a going
concern for a period of one year after the date the financial statements are issued. Management&#8217;s plan to alleviate the conditions
that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other
sources, which has included the Equity Distribution Agreement with Canaccord for proceeds of up to $<span id="xdx_90E_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z0bSeaRLLC14" title="Additional working capital">2.4
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (see Note 7), the Purchase Agreement
with Lincoln Park (see Note 7), subject to registration, the Inducement Letters and resulting sales of common stock under the Existing
Warrants for cash proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdbYkH7ofgh3" title="Warrants for cash proceeds">1.8
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million received in January 2024 (see Note 7),
and the exercise of warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRrqgNwYrtA8" title="Exercise of warrants to purchase">130,267</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock for cash proceeds
of approximately $<span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxBoa9iJSd54" title="Cash proceeds of warrants">2.7
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million in February 2024 (see Note 12), and may
include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available
to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required
to undertake cost-cutting measures including delaying or discontinuing certain operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as
a going concern for a period of one year after the date of the financial statements are issued. The Company&#8217;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#8220;RIF&#8221;) of approximately 35% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $<span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_z8D58hHBUYA" title="Severance costs">453,059</span> through
December 31, 2023. The plan included a focus on progressing the Company&#8217;s existing non-cannabinoid pipeline while reducing the
rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded
in general and administrative accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating
Officer (the &#8220;Kanubaddi Separation Agreement&#8221;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi&#8217;s
outstanding restricted stock units (&#8220;RSUs&#8221;) will retain their vesting conditions. Mr. Kanubaddi&#8217;s 2023 salary and benefits
of $<span id="xdx_907_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_z2eyKHjPXPnh" title="Salaries and benefit">550,974</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
inclusive of the 2023 performance bonus in the amount of $<span id="xdx_90D_eus-gaap--AccruedBonusesCurrent_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zrCCgVRmsV6k" title="Performance bonus">129,760
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were accrued and the salary and benefits, excluding
the 2023 performance bonus will be paid out in twelve equal monthly installments beginning in July 2023. As of December 31, 2023, the
performance metrics for the 2023 performance bonus were not achieved and the accrued amount of amount of $<span id="xdx_901_eus-gaap--RestructuringReserve_iI_c20231231_zsfpflMKZxWj" title="Reversed amount">129,760
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was reversed. Upon termination, any unvested
time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was $<span id="xdx_90A_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4HDlczxCn45" title="Expense related to acceleration of vesting">231,273</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All of the <span id="xdx_908_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CQB1lpNWGf" title="Market performance based shares">752</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> market performance-based RSUs previously
granted that were subject to the original terms and conditions of Mr. Kanubaddi&#8217;s employment agreement were forfeited during the
year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--RestructuringCostsIncurred_c20230101__20231231_zEYhLjXcC6Lc" style="width: 16%; text-align: right" title="Restructuring costs incurred">1,004,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs">(572,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs reversed">(129,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zbWxkJfj9qfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Notice</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as
of September 30, 2023, the Company did not meet the minimum of $<span id="xdx_90A_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zRjXM8zUUidi" title="Minimum of stockholders equity required for continued listing pursuant to exchange">2,500,000</span> in stockholders&#8217; equity required for continued listing
pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension
to regain compliance with the minimum stockholders&#8217; equity requirement by May 20, 2024. If the Company fails to evidence compliance
upon filing its periodic report for June 30, 2024 with the SEC and Nasdaq, the Company may be subject to delisting. The Company plans
to regain and evidence compliance with the Stockholders&#8217; Equity Requirement by the required deadlines, but it is not assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889322176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zaoG89jTuAme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_82E_z9xYFaUkmv21">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zo1UCk4KVdqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6QO8pI0anKh">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and Article 8 of Regulation S-X. Accordingly,
they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Management&#8217;s opinion
is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results
for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year
ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated
financial statements for the year ended December 31, 2023, and related notes thereto included in the Company&#8217;s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 26, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s significant accounting policies and recent accounting standards are summarized in Note 2 of the Company&#8217;s consolidated
financial statements for the year ended December 31, 2023. There were no significant changes to these accounting policies during the
three and nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--UseOfEstimates_zgACgUEtt6Ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zlothHQNIky6">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during
the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements
of changes in such estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and assumptions
include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options,
and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development
efforts. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTxTblgKKu1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zClPDxHjeuxe">Reclassification</span>
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
reclassifications have been made to the prior period&#8217;s unaudited condensed consolidated financial statements in order to conform
to the current year presentation. In the prior year, the Company included certain investor related expenses within research and development
on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses
in the current year. This reclassification had no effect on the Company&#8217;s previously reported results of operations, changes in
equity, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z8ih6xEpJN52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z2bBJpwttRF8">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through September 30, 2024, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended September
30, 2024 and 2023, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the unaudited condensed consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zz9zwYQJZi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zufsvTMwOUZc">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zNxf3Y69sUla" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zTIEMpIcZPXf" title="Cash insured amount">100,000</span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of September 30, 2024, the Company had greater than $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zHuCBoZHjDqi" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, greater than
$<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--AU_zZeRB6GLgRU2" title="Cash FDIC insured amount">250,000</span> at Australian financial institutions, and less than $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zRH1JuJVWiol" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zouRUznD8kTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zzq57QAfXM98">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zr47DZI2OVxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zUgDD5X8Yzl3">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state, and Canadian perspective, the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. The Company receives no tax benefit from operating losses due to a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_ecustom--ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_zVUb3yNkNg7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zb8BN8cj268a">Research
and Development Tax Incentive Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program,
such that a percentage of the Company&#8217;s qualifying research and development expenditures are reimbursed by the Australian government,
and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive
is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and
the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the
Company based on available information at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zqZrJl4CcVT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z1Lg34EJJ6o5">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the three and nine months ended September 30, 2024
and 2023 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same for both
basic and fully diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included
in the calculation of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B7_z5CVvXWyeztg">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2023</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock">56,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock">40,660</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" style="text-align: right" title="Restricted stock units - vested and unissued">1,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" style="text-align: right" title="Restricted stock units - vested and unissued">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" style="text-align: right" title="Restricted stock units - unvested">23,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" style="text-align: right" title="Restricted stock units - unvested">9,884</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" style="text-align: right" title="Investment options to purchase shares of common stock">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" style="text-align: right" title="Investment options to purchase shares of common stock">71,334</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock">1,538</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock">2,124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities">87,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities">125,392</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zEtlBi6f4E33" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrJYXhzwvHwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zoAJUH5QYSWi">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently assessing the potential impacts of ASU 2023-07, however as the Company
currently has one reportable segment, does not expect this guidance will not have a material impact on its unaudited condensed consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its unaudited condensed consolidated
financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, Disaggregation of Income Statement Expenses</i>, that requires public companies to disclose, in interim and reporting periods,
additional information about certain expenses in the financial statements. The ASU is effective for annual periods beginning after December
15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective
basis or retrospective basis. The Company is currently assessing the potential impacts of ASU 2024-03.</span></p>

<p id="xdx_850_zAVno6KnfT8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z1Usp4Epnijl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2. <span id="xdx_827_z29VOpGCLrQb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zbIKrsz2JJMb">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMMySFR20SIc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods
reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of
changes in such estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and
assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred
investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting
research and development efforts. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zFKLsC1vhXHf">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zNjHpvv4Gia">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0Oa78Uy6iHe">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount">100,000</span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, less than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount">250,000</span>
at Australian financial institutions, and greater than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztBjC43QkT38">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zPkCB4Owiyud">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#8217;s
expected future cash flows; a sustained, significant decline in the Company&#8217;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#8217;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdX7mG65WS1b">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#8217;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z622SrpvFB74">Property
&amp; Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#8217;s long-lived assets. The estimated
useful lives are typically <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives">3</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives">5</span> years for office furniture and equipment and are depreciated on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--DeferredOfferingCostsPolicyTextBlock_zC3UVlYm5iHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zmmelDy6vXh3">Deferred
Offering Costs</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (&#8220;ASC 340&#8221;) and SAB 5A <i>-
Expenses of Offering</i>. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs">567,603</span> in deferred offering costs in connection with the Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) and the Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--WarrantLiabilityPolicyTextBlock_zLXVKuvvt2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zH6VWLIKl02j">Warrant
Liability and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#8220;Distinguishing
Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;) and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The Company accounts for warrants and investment options for shares of the Company&#8217;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_z7oMqGQu7b2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zHBF6D1y83y9">Modification
and Inducement of Warrants and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zBwpH1gx3ZNb">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsORoSsW5NTg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVtfgEZ2LSf1">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s reasonable estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#8217;s common stock on the date of award grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#8217;s
board of directors (the &#8220;Board of Directors&#8221;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#8217;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSU&#8217;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#8217;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#8217;s that vest
immediately are charged to expense on the date awarded, value of RSU&#8217;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#8217;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#8217;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#8217;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#8217;s
engagement with the Company must either be terminated prior to such conversion of RSU&#8217;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#8220;specified
employee&#8221; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#8217;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSA&#8217;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#8217;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#8217;s that vest immediately are charged
to expense on the date awarded, value of RSA&#8217;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zX4N0aihbZJi">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zzehumrBJq1i" title="Stock and warrants issued">51,167</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> pre-funded common stock warrants, which were
exercised on various dates during the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26,
2022 based on the terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $<span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_z3Ex19wQ4NN7" title="Warrant exercise price">0.0015</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these shares are considered outstanding common shares
and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is
virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">186,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0">43,698</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right">9,366</p>
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,271</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,334</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,993</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztG9Z6EAI5m2">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zKPLQOyArmx4">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuz1Rz8vQhr9">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#8217;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a right-of-use asset, which represents the Company&#8217;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#8217;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zkZiVDimAdil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_za6xEu8hPKl1">Redeemable
Non-controlling Interest</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#8220;RNCI&#8221;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zww0mCbaLZc1">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines its reporting units in accordance with FASB ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwwObdI2aaB5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</i> (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#8217;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889320656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zy8Edp5AHpw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3. <span id="xdx_824_z7Mg8EsfDSL6">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ziQiCk2t3pPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024 and December 31, 2023, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zXzvuaP85kP6" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240930_zcoz1KJCoQJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zapJqSbDhavi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zKrZ6miixm9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">106,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,320</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_zFzvo0W6luq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245,972</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,429</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_zu4goeZGb4h8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,559</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zvVKHWyHRBF2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,036</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_ziA53GvK8xw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs (see Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">508,599</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,603</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zlnv5bhFfkHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,258</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zpwpikb515y3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2890">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zodaOt1NZx24" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,226,576</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,293,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zD37GGK6TrR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zaAAsItDs3Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3.<span> <span id="xdx_82D_z7UD1gS7KARl">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zTydFvT6Kuv4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">268,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,406</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,179</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,349</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,293,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">708,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zesRhFyyZGE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994980672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9SCaXsACTk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span>INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_828_zBJmKX4zYxVf" style="display: none">INTANGIBLE ASSETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company performs an annual impairment test at the reporting unit level as of December 31 of each fiscal year. As of December 31, 2022,
the Company&#8217;s goodwill and intangible assets were fully impaired, and thus no annual impairment test was necessary as of December
31, 2023. The following table provides the Company&#8217;s goodwill, indefinite and definite lives intangible assets as of December 31,
2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s goodwill consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zywzBm3sR0Xd" style="display: none">SCHEDULE
OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Impairment Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Currency Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance">9,834,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance">(8,225,862</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_z6Ico1CR2F3k" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance">(21,359</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance">1,587,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zCD5RPP49Kt" style="text-align: right" title="Goodwill Gross, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0933">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_z62rnT8rmnTk" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses">(1,486,060</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zSbfiyEI09me" style="text-align: right" title="Currency Translation, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses">(1,486,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zg1fcBdDAJz1" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zUb2cKPLhd02" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_z8TE2v2Adkth" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Ending balance">9,834,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance">(9,711,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Ending balance">(122,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zxEPfyg8txe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s indefinite lived intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B7_zWEh1BmzLMM6" style="display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Indefinite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets">6,375,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses">(5,967,602</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1pt solid; text-align: right" title="Loss on currency translation">(407,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 80%">Definite lived intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets">548,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1pt solid; text-align: right">(168,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right">379,686</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">(168,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zXWcVfQneWi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
identified definite lived intangible assets, amortization expense amounted to $<span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zk2p8bhGkqR9" title="Intangible assets, amortization expense">168,754</span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zyBCbH7OAWC" title="Intangible assets, amortization expense">168,750</span> during the years ended December 31,
2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company amortizes definite lived intangible assets on a&#8239;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zzVXkKpEcQPl" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">168,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">42,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite lived assets amortization
    expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zPK37hZCJdad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zAfpxE6QXUl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4. <span id="xdx_827_z685ftKZZ6Og">INTANGIBLE ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zEFiR25itP9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, the Company&#8217;s intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zdH7GSYv7JN4" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Definite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20240101__20240930_zXzhU8vRzC1f" style="width: 16%; text-align: right" title="Balance, Definite lived intangible assets">210,932</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20240101__20240930_zV1sP78Womkd" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">(126,564</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20240101__20240930_z44UqjI2pVDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets">84,368</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zCfuHWIedht1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
identified definite lived intangible assets, there was <span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20240701__20240930_znKeMJJlBwz9" title="Identified definite lived assets, impairment loss"><span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20240101__20240930_zF4knmIMfKF9" title="Identified definite lived assets, impairment loss"><span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230701__20230930_zpkuTOMQ2knb" title="Identified definite lived assets, impairment loss"><span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20230930_zUDOg1BlZA8" title="Identified definite lived assets, impairment loss">no</span></span></span></span> impairment expense during the three and nine months ended September 30, 2024
and 2023. For identified definite lived intangible assets, amortization expense amounted to $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20240701__20240930_zFV3U9HSup67" title="Intangible assets, amortization expense">42,188</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20230930_zT56FTwyHc1c" title="Intangible assets, amortization expense">42,191</span> during the three months
ended September 30, 2024 and 2023, respectively and $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20240930_zYo4XRsyJZDf" title="Intangible assets, amortization expense">126,564</span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930_zoQh7EViEtUe" title="Intangible assets, amortization expense">126,566</span> during each of the nine months ended September 30, 2024 and
2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889770352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmzzL4dR4bRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_822_znSH8hz3Mwm">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoCW0JWr2PTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada, with all amounts converted into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zyyD3AxBoyy6" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240930_zvOcwkWkXuS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zzAklmbnG9Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zZqbY38VQNO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">819,784</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">836,709</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zqQ9lVXpV0nh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zkzBYSlzRqa2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, gross </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8mcxSLzQ0W8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(479,899</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(357,711</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zAksAuwNXz57" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">367,689</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">507,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_z7AXiGSFvfN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_908_eus-gaap--Depreciation_c20240701__20240930_zaPojReubAp3" title="Depreciation">42,626</span> and $<span id="xdx_909_eus-gaap--Depreciation_c20230701__20230930_zZJVuhP4S3s3" title="Depreciation">44,105</span> for the three months ended September 30, 2024 and 2023, respectively and $<span id="xdx_90D_eus-gaap--Depreciation_c20240101__20240930_zBFwsYVXwDVd" title="Depreciation">128,438</span> and $<span id="xdx_90A_eus-gaap--Depreciation_c20230101__20230930_z42pMJ8m9Rf1" title="Depreciation">132,734</span> for the
nine months ended September 30, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXXYZu4HU6c9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5. <span id="xdx_825_zaytaYVEUUm6">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#8220;EBCI&#8221;), with all amounts translated into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zxF5quYUvBz1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">836,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">831,123</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(357,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(178,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">507,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">677,485</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z2MshGQnoZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_zaY42joe7YG7" title="Depreciation">175,228</span> and $<span id="xdx_905_eus-gaap--Depreciation_c20220101__20221231_z0vGnuRplH4c" title="Depreciation">159,160</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889737968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFRpZpKPqIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_826_zgQfWA4c3m38">ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zd1I1uSsF2ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024 and December 31, 2023, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B6_zNKkwJIlhEh2" style="display: none">SCHEDULE OF ACCRUED LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240930_zvKzlW1DszQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zcTfVPR5LFYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_z77zAkrTjG7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">112,346</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">139,981</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zhKdxIdipW0j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zMeGRmc97SLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,810</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zddf4tXqrQLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs (see Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2962">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,645</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_zwDevUv4HwWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2965">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,318</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zZWtGIQEPn21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Patent costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zqUxNkAHG3Th" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">253,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,075,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zBQUxbyVXfxa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zBePLueQV7ve" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6. <span id="xdx_828_zbdmk1JonaWe">ACCRUED LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B6_z2CYiR69qip9" style="display: none">SCHEDULE
OF ACCRUED LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">139,981</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">195,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175,963</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Patent costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">251,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,075,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,705,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zfLwpnfUgaDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889245472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zBW9WsdE8dR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_82D_zDM5roETPi27">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into the Equity Distribution Agreement (the &#8220;Distribution Agreement&#8221;), with Canaccord
Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales
agent and/or principal, shares of common stock of the Company, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zQJjjEt5ONJ2" title="Common stock, par value">0.01</span> per share having an aggregate offering price of up to
$<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zjMw7eP4KcRk" title="Common stock, offering price">10.0</span> million. Due to the offering limitations applicable to the Company and in accordance with the terms of the Distribution Agreement,
the Company may offer Common Stock having an aggregate gross sales price of up to $<span id="xdx_90E_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zCKCnopvvOy7" title="Aggregate gross sales price">2,392,514</span> pursuant to the prospectus supplement dated
September 1, 2023 (the &#8220;Prospectus Supplement&#8221;). Subject to the terms and conditions of the Distribution Agreement, Canaccord
may sell the Common Stock by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221;. The Company will pay Canaccord
a commission equal to <span id="xdx_90C_ecustom--CommissionPercentage_pid_dp_uPure_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zRmow85qe7q2" title="Commission percentage">3.0</span>% of the gross sales price of the Common Stock sold through Canaccord under the Distribution Agreement and has
also agreed to reimburse Canaccord for certain expenses. The Company may also sell Common Stock to Canaccord as principal for Canaccord&#8217;s
own account at a price agreed upon at the time of sale. Any sale of Common Stock to Canaccord as principal would be pursuant to the terms
of a separate terms agreement between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2024, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zw6AOQYVAHNh">111,200
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for gross proceeds
of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zbcrmnpiUsFd">2,392,502
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Distribution Agreement, and charged
offering costs of $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_z9buGjtR9bj3">583,713
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to additional paid in capital on the unaudited
condensed consolidated balance sheet. As of September 30, 2024 and December 31, 2023, there were deferred offering costs related to the
Distribution Agreement of $<span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_z6KdFHopkwa">0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zdCiYoM7MaUk">171,944</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. As of September 30, 2024, there is $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_z34GOkjig08l">0
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">available under the Distribution Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with certain
holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment options to purchase
shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant to which the Holders
agreed to exercise for cash their Existing Warrants and Investment Options to purchase <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zgg3qk8xjax3" title="Issued shares">74,800</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
in the aggregate, at a reduced exercised price of $<span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zYly7amKklKg" title="Share price">20.55</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (from an original exercise price
of $<span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_zL7iumNRkoZj" title="Share price">116.70</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share), in exchange for the Company&#8217;s
agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zrltgSwz1F1k" title="Issued shares">149,600</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
(the &#8220;Inducement Warrant Shares&#8221;), and the Holders to make a cash payment of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z687gHz4pNT8" title="Cash payment">1.88</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Inducement Warrant share for total proceeds
of $280,500</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In January 2024, the Company received aggregate gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131_zHapCoYD7L6c" title="Gross proceeds">1,817,640</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the exercise of the Existing Warrants and
Investment Options by the Holders and the sale of the Inducement Warrants. Because the Existing Warrants and Investment Options by the
Holders and the sale of the Inducement Warrants that exercised on December 28, 2023 and unsettled until January 2024, the proceeds are
included in the condensed consolidated balance sheet as a subscription receivable as of December 31, 2023. As of December 31, 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCBXDGsjb9y9" title="Shares other">27,867</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were considered issued as the Company had the enforceable right to the obtain the cash proceeds, which were in-transit,
and the Holders were no longer able to rescind the exercise election. Due to the beneficial ownership limitation provisions, <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zVEWo3btbQQa" title="Issued shares">46,934</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder
that the shares may be issued in compliance with such limitation. During the nine months ended September 30, 2024, the Company issued
all <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z5TF2UUMp6xj" title="Issued shares">46,934</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock of the <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zg916ElDyDuj" title="Issued shares">46,934</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Existing Warrants and Investment
Options exercised that were held in abeyance due to the beneficial ownership limitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with certain
holders of warrants and preferred investment options. The Inducement Letters prohibit the Company from entering into any variable rate
transaction as defined in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2)
transactions whereby the Company may issue securities at a future determined price, such as through an at-the-market offering or an equity
line of credit. The variable rate transaction restriction would have expired after six-months from the closing date of December 28, 2023
for the Inducement Letters for an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions,
however the restriction was waived for the at-the-market offering on March 8, 2024 and the equity line on May 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240308__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zjYNro7XO5I9" title="Issued shares">15,246</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
to the Holders of the Inducement Warrants. The issuance was made in exchange for the permanent and irrevocable waiver of the variable
rate transaction limitation solely with respect to the entry into and/or issuance of shares of common stock in an at the market offering
contained in the Inducement Letters. The fair value of the shares issued for consideration of waiving the variable rate transaction limitation
was $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240308__20240308__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zi4HdS5ztZV4" title="Shares issued value">322,453</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and was charged to additional paid in capital,
as it is direct and incremental to the Distribution Agreement, on the unaudited condensed consolidated balance sheet as an offering cost
related to the Distribution Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lincoln
Park Equity Line</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into a Purchase Agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement
(the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which
Lincoln Park has committed to purchase up to $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zp8ZcmoueLP7" title="Repurchase of common stock">10.0</span> million of the Company&#8217;s common stock subject to certain limitations and satisfaction
of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $<span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zUYzst4x5SUf" title="Purchase committment">10.0</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million of the Company&#8217;s Common Stock (the
&#8220;Purchase Shares&#8221;). However, such sales of Common Stock by the Company, if any, will be subject to important limitations
set forth in the Purchase Agreement, including limitations on number of shares that may be sold. Sales may occur from time to time, at
the Company&#8217;s sole discretion, over the 24-month period commencing on the date that the conditions to Lincoln Park&#8217;s purchase
obligation set forth in the Purchase Agreement are satisfied, including that a registration statement on Form S-1 covering the resale
of the shares of the Company&#8217;s Common Stock that have been and may be issued to Lincoln Park under the Purchase Agreement, which
the Company has filed with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus
relating thereto is filed with the SEC. As required under the Purchase Agreement, the Company registered a resale of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zshD4nkGDZ" title="Shares resale">76,032</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock, plus the <span id="xdx_908_ecustom--StockIssuedDuringPeriodCommitmentShares_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zUdTF7KnqAw7" title="Shares commitment">9,294</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commitment shares, by Lincoln Park on a registration
statement on Form S-1 dated November 8, 2023, which was declared effective by the SEC on December 5, 2023. As of July 30, 2024, there
were no remaining shares available to be issued in connection with this registration statement. On September 4, 2024, the Company filed
an amended Form S-1, which was declared effective by the SEC on September 11, 2024. The amended Form S-1 registered an additional <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zPkT5CXxYAD4" title="Shares Issues">326,667</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that are available
to be issued to Lincoln Park in connection with this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of Common Stock that the Company may elect to sell to Lincoln
Park under the Purchase Agreement, if any, will fluctuate based on the market prices of the Company&#8217;s Common Stock at the time
the Company elects to sell shares to Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the
number of shares of Common Stock that the Company will sell to Lincoln Park under the Purchase Agreement, the purchase price per share
that Lincoln Park will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that the Company
will receive from those purchases by Lincoln Park under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering of
an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z9RGlP2zcVE4" title="Shares issued">30,534</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
to certain institutional investors. The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction
limitation with respect to any existing or future agreement by the Company to effect any issuance of shares and issue such shares thereunder,
as contained in those certain Inducement Offer Letters, dated December 28, 2023, between the Company and those certain institutional
investors. The Company will not receive any net proceeds in connection with the offering. The fair value of the shares issued for consideration
of waiving the variable rate transaction limitation was $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zauMQSNDqcY1" title="Issued stock value">448,840</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and was recorded as deferred offering costs,
as direct and incremental to the Purchase Agreement, within prepaid expenses and other current assets on the unaudited condensed consolidated
balance sheet related to the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock purchase agreements contain customary representations and warranties and certain indemnification obligations of the Company.
The common stock purchase agreements also restrict the Company from issuing, entering into any agreement to issue, or announcing the
issuance of the Company&#8217;s common stock from the date of the common stock purchase agreements until the earlier of 30 days after
entering into the agreements or at such time as one million (<span id="xdx_900_ecustom--NumberOfCommonStockSharesTraded_pid_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zJkk6Fppt4he" title="Number of shares traded in market">1,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock have
traded in the open market. The closing of the issuance of the Shares pursuant to the common stock purchase agreements closed on May 3,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2024, the Company had issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zAOUCLVuKtYj" title="Issued shares">72,699</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_z0t8SV8NVqSi" title="Issued shares">81,033</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, respectively, through
the Purchase Agreement for gross cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zXpw4CYe2v51" title="Proceeds from common stock">517,836</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zhpbJl87Coyd" title="Proceeds from common stock">600,686</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. During the three and nine months ended September 30, 2024, the Company charged offering costs of $<span id="xdx_90E_ecustom--CommonStockEquityDistributionCosts_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zIVdRvqS6kge" title="Deferred offering costs">290,029</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90B_ecustom--CommonStockEquityDistributionCosts_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zOsq11v9Qzn3" title="Deferred offering costs">372,879</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, to additional paid in capital on the unaudited condensed consolidated balance sheet. As of September 30, 2024 and December
31, 2023, the Company has capitalized deferred offering costs of $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zBNHG6DEuaXa" title="Offering costs">508,599</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zxaEsNtxbjE4" title="Offering costs">395,660</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. As of September 30, 2024, there were <span id="xdx_904_eus-gaap--SharesIssued_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zpPIvOsSmdR7" title="Issued shares">321,667</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares available to be issued in connection
with the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to 2020 Long-Term Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2023, the stockholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#8220;Amended Incentive Plan&#8221;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zzGuhpjBd435" title="Authorized shares reserved">23,334</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to equitable adjustment, and (ii) removed
the Evergreen Provision implemented in the Plan Amendment. During the first quarter of 2024, the Board approved an equitable adjustment
to increase the number of shares available under the Plan by <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardMember_zaJLbhjnWrX5" title="Shares available for grant">8,986</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. As of September 30, 2024, the total
number of shares available for grant under the Incentive Plan was <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardMember_z8UIRa1rkCo1" title="Shares available for grant">418</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z67kgDeUvC4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the nine months ended September 30, 2024 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z3alfNBYzdpj" style="display: none">SCHEDULE OF STOCK OPTION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; padding-bottom: 1pt">Outstanding at December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zZW4nPRH5Mh3" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of shares, outstanding at beginning">2,022</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zAPsEeKm3Wsi" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, outstanding at beginning">857.55</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930_zdSYfF4AjHx6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, outstanding at beginning">1,158.30</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zmJUkZMdSS5" title="Weighted average remaining contractual term, outstanding balance">3.4</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_z6DDR6QXTCol" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl3064">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930_zGyDNncyr5zd" style="text-align: right" title="Number of shares, granted"><span style="-sec-ix-hidden: xdx2ixbrl3066">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zdXm97VM8Oqj" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl3068">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zVr3xDBu5KQ7" style="text-align: right" title="Weighted average grant date fair value, granted"><span style="-sec-ix-hidden: xdx2ixbrl3070">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zCk41xdSAlQc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(484</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zAtJuWhyGd0c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">590.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zOdybsNqZRfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">810.30</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_ztGb06PyFRPh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, outstanding at end">1,538</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zOJratgg199g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end">941.55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zPgNtNP9oxsh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, outstanding at end">1,267.65</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwyipFQlqdic" title="Weighted average remaining contractual term, outstanding balance">2.6</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_zCRR4NZamkL9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, outstanding at end"><span style="-sec-ix-hidden: xdx2ixbrl3086">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_z6UC9WKyhkK9" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end">1,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zvPkT2It5xdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end">979.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zy4Bot6yFpwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable">1,319.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zdxHrNr9o8Xk" title="Weighted average remaining contractual term, exercisable">2.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zRjNsH3idAti" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl3096">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A7_zsC91P5ApZF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock based compensation expense, recorded within general and administrative expense in the unaudited condensed consolidated
statement of operations and comprehensive loss, related to stock options for the three months ended September 30, 2024 and 2023 was $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSCA63e3bYTb" title="Stock based compensation expense">414</span>
and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqjzV3BM2Dj4" title="Stock based compensation expense">44,606</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock-based compensation expense, recorded within general and administrative expense, related to stock options for the
nine months ended September 30, 2024 and 2023 was $(<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYCgz05w29af" title="Stock based compensation expense">5,854</span>) and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVrs83ruFYhb" title="Stock based compensation expense">147,067</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, the Company had $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZGM38My6z95" title="Unamortized stock option expense">2,346</span> in unamortized stock option expense, which will be recognized over a weighted average period
of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLCZ7PjsyzI2" title="Weighted average period">1.40</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Restricted Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zoide0sTJXC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQpY2rCnrVg8" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSDvnYRjVNsa" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning">9,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1F1H1syKVd" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning">434.55</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkidLJxfe9Q7" style="text-align: right" title="Number of shares, Granted">16,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3neHKhmj2c" style="text-align: right" title="Weighted average fair value, Granted">12.75</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3Vg6jd5reqj" style="text-align: right" title="Number of shares, Forfeited">(650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAmEm1RiI2tg" style="text-align: right" title="Weighted average fair value, Forfeited">43.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTolNPfIHg9j" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested">(2,042</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zph55MgT0j7d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested">333.30</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVQeX1FIO7Xc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending">23,441</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTVyBNeKeyEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending">152.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z8HprySXCdfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three months ended September 30, 2024 and 2023, the Company recorded $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA03ksBXys6h">369,200
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zupmoATWHKqa">328,253</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss. For the
nine months ended September 30, 2024 and 2023, the Company recorded $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUIxLYL4Eja">1,096,570
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGzAAvu3Pd9">1,638,365</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the condensed consolidated statement of operations and comprehensive loss. As of September 30,
2024, the Company had unamortized stock-based compensation costs related to restricted stock units of $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhRCjZ6b2pc7">1,109,526
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will be recognized over a weighted average
period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4M3FziNZl4k">1.57
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. As of September 30, 2024, <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUV73LUkgLz9">1,369
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units are vested without
shares of common stock being issued, with all of these shares due as of September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zTOfSM9LLUo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zUqL5Ly2R5Wg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Stock-based compensation expense for RSUs:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240701__20240930_zmodFPmdDlIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20230930_zs4PFiYdjkd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_zmf0cVH1oD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_zZEsJ47Nk5Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Stock-based compensation expense for RSUs:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKUvRCyrlXe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">162,042</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">101,607</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">476,513</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">946,851</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy5GdtVHSVb2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">207,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226,646</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">620,057</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">691,514</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zH3A95M0sis8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">369,200</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">328,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,570</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,638,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_zIQQsMnjkR3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Stock-based compensation
    expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">369,200</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">328,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,570</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,638,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8AA_z7vtTMy7sp51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
and Preferred Investment Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zRDuE51nVwug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_z71NbaE89wo7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF WARRANTS OUTSTANDING</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk17tpUEWLX" style="width: 12%; text-align: right" title="Warrant shares outstanding at beginning">186,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq56AKA0bj4h" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding at beginning">176.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUDMMylc2Y6" title="Weighted average remaining life, outstanding">4.6</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztviImRtgzRi" style="width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl3169">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLbx3ZUsJf3b" style="text-align: right" title="Warrant shares outstanding,expired">(39</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfKAFC3BlLMa" style="text-align: right" title="Weighted average exercise price, expired">2,400.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQCb5deT9I3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, exercised">(130,267</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAy3hDRC9Wj5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">20.55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziYaK0NDJNMe" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end">56,308</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA2daHh19Sa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end">536.70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrcQaXQIW2If" title="Weighted average remaining life, outstanding">3.0</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z80MZv9WG0j2" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl3185">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEU0VfgR2f3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, exercisable">56,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKD79Pj5ptJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">536.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Gvlbmlniod" title="Weighted average remaining life, exercisable">3.0</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wRhNTAjbr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl3193">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zG86r2zijGTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRHQg5nAtHC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zpBIF7iGXfLf" style="display: none">SCHEDULE OF   INVESTMENT OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 1pt">Outstanding at December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7C4CTJ0as81" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment options outstanding, beginning">4,667</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zwpju5CZtKp8" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted average exercise price, issued">150.00</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_ziyuoHOnTHS7" title="Weighted average remaining life, outstanding">4.1</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zpqBJPNNsSzc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl3203">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zrCGOj1W0Is1" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end">4,667</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zZ4hyedUtGYe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, issued">150.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zU4T0rv80XJl" title="Weighted average remaining life, outstanding">2.9</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zAZK6Fg6sJZ3" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl3211">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zRhtKwHprZp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, exercisable">4,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z3GskQ71Ikse">150.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zmmJiJ55bMeg" title="Weighted average remaining life, exercisable">2.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zcGeBdKJuGgj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl3218">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zZrTU04wDWBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDwGAQBPdjdj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7. <span id="xdx_821_zPkNv6EA0ckj">SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Authorized
Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20230101__20231231_zyP7HBT2y9O4" title="Common stock voting rights">The
holders of the Company&#8217;s common stock are entitled to one vote per share</span>. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available
for distribution. As of December 31, 2023, <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z3kEFDBFbKC" title="Common stock, shares authorized">100,000,000</span> shares of common stock and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zBU2P1eYPMuf" title="Preferred stock, shares authorized">20,000,000</span> shares of Preferred Stock were authorized
under the Company&#8217;s articles of incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Distribution Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into the Distribution Agreement, with Canaccord, pursuant to which the Company may offer and sell
from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zzPld5phABZh" title="Common stock, par value">0.01</span> per share
having an aggregate offering price of up to $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zV61LRnnxsQj" title="Common stock, offering price">10.0</span> million. Due to the offering limitations applicable to the Company and in accordance
with the terms of the Distribution Agreement, the Company may offer common stock having an aggregate gross sales price of up to $<span id="xdx_900_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zFsQ1hTkiWgf" title="Aggregate gross sales price">2,392,514</span>
pursuant to the prospectus supplement dated September 1, 2023 (the &#8220;Prospectus Supplement&#8221;). Subject to the terms and conditions
of the Distribution Agreement, Canaccord may sell the common stock by any method permitted by law deemed to be an &#8220;at-the-market
offering&#8221;. The Company will pay Canaccord a commission equal to <span id="xdx_909_ecustom--CommissionPercentage_pid_dp_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zXJHXmkSZzdf" title="Commission percentage">3.0</span>% of the gross sales price of the common stock sold through
Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord for certain expenses. The Company may also sell
common stock to Canaccord as principal for Canaccord&#8217;s own account at a price agreed upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Inducement Letters (as defined below within this Note 7) prohibits the Company from entering into any variable rate transaction as defined
in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the
Company may issue securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The
variable rate transaction restriction expires after six-month from the closing date of December 28, 2023 for the Inducement Letters for
an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions. Subsequent to December 31, 2023, the limitation on the at-the-market offering was waived. See Note 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lincoln
Park Equity Line</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2023, the Company entered into a Purchase Agreement and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;),
with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $<span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zOOeNanEtQna" title="Purchase committment">10.0</span> million of the Company&#8217;s common stock,
par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zHrjprwA7De7" title="Common stock, par value">0.01</span> per share subject to certain limitations and satisfaction of the conditions set forth in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $<span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zs6V54OtPzKd" title="Purchase committment">10.0</span> million of the Company&#8217;s common stock (the &#8220;Purchase Shares&#8221;).
However, such sales of common stock by the Company, if any, will be subject to important limitations set forth in the Purchase Agreement,
including limitations on number of shares that may be sold. Sales may occur from time to time, at the Company&#8217;s sole discretion,
over the 24-month period commencing on the date that the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase
Agreement are satisfied, including that a registration statement on Form S-1 covering the resale of the shares of our common stock that
have been and may be issued to Lincoln Park under the Purchase Agreement, which the Company has filed with the SEC pursuant to the Registration
Rights Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that
we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased
from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under
the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Equity Line or the Distribution Agreement.
The Company had capitalized deferred offering costs of $<span id="xdx_900_eus-gaap--DeferredOfferingCosts_iI_c20231231_zzLsnq1k5kij" title="Deferred offering costs">567,603
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to establishing the Distribution Agreement
with Canaccord and the Purchase Agreement with Lincoln Park and no reductions to additional paid in capital. Of this amount, $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zr7r0FupoKy4" title="Number of shares issued">255,107
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">represents the fair value of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu4IDflEHz83" title="Fair value of shares">9,294</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock issued to Lincoln
Park as consideration for its commitment under the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Activity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023 a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zACfXzyGDWkb" title="Issuance of common shares in exchange for RSU conversions, shares">6,910</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock were issued pursuant
to the conversion of restricted stock units. During the year ended December 31, 2022, a total of <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRxGHF4fDd91" title="Stock issued during period conversion of restricted stock award">82</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> and <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSeZCmLWDOGi">60</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock were issued pursuant
to the conversion of restricted stock awards and restricted stock units, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, the Company completed a public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziLd9Ejzode" title="Public offering">26,667</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock and warrants to purchase
up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvMzmDEx4K17" title="Warrants to purchase">26,667</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock for gross proceeds
of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z0hwt17EQEm2" title="Proceeds from common stock">10.0</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, before deducting underwriting discounts
and commissions and other offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In
addition, Enveric granted the underwriter a 45-day option to purchase up to an additional <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcNqcSOye8fd" title="Additional shares of common stock purchase">4,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock and/or warrants to
purchase up to an additional <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zCXdezGPOPNl" title="Additional warrants purchase">4,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock at the public offering
price, which the underwriter has partially exercised for warrants to purchase up to <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zF8kINnpLKRa" title="Exercised of warrants">4,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock. At closing, Enveric
received net proceeds from the offering of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zewrKhoDQgqb" title="Net proceeds from offering">9.1</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, after deducting underwriting discounts
and commissions and estimated offering expenses with $<span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z5M5uVBLR4rc" title="Offering expenses">5.8</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million allocated to equity, $<span id="xdx_907_ecustom--WarrantLiability_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z4AGZErBfTh6" title="Warrant liability">3.6</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million to warrant liability and the remaining
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zjsSpSAPZmB1" title="Warrant expenses">0.3</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 22, 2022, the Company entered into a securities purchase agreement (the &#8220;Registered Direct Securities Purchase Agreement&#8221;)
with an institutional investor for the purchase and sale of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zO4AWf4MoaB9" title="Sale of stock">7,766</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of the Company&#8217;s common stock,
pre-funded warrants to purchase up to <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zBOqd5rgJ8h7" title="Purchase of common stock">17,234</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock (the &#8220;RD Pre-Funded
Warrants&#8221;), and unregistered preferred investment options (the &#8220;RD Preferred Investment Options&#8221;) to purchase up to
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z8ztx6I6PEH" title="Issued shares">25,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock (the &#8220;RD Offering&#8221;).
The gross proceeds from the RD Offering were approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zeqlBU6CU5x8" title="Proceeds from issuance of warrants">3,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Subject to certain ownership limitations, the RD Pre-Funded Warrants became immediately exercisable at an exercise price equal to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zOtc0w6DyGY7" title="Share price">0.0015</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> per share of common stock. On August 3, 2022,
all of the issued RD Pre-Funded Warrants were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#8220;PIPE Securities Purchase Agreement&#8221;)
with institutional investors for the purchase and sale of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_z0hXcaMlX7A4" title="Sale of stock">7,734</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock, pre-funded warrants
to purchase up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zEjVcBB2ZAOl" title="Purchase of common stock">33,933</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock (the &#8220;PIPE Pre-Funded
Warrants&#8221;), and preferred investment options (the &#8220;PIPE Preferred Investment Options&#8221;) to purchase up to <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zGhgi9jt7qq4" title="Issued shares">41,667</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of the common stock in a private placement
(the &#8220;PIPE Offering&#8221;). The gross proceeds from the PIPE Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_ztr23wWg2MJ3" title="Proceeds from issuance of warrants">5,000,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Subject to certain ownership limitations, the PIPE Pre-Funded Warrants became immediately exercisable at an exercise price equal to $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_z7Bx9J4w0Ahc" title="Share price">0.0015</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> per share of common stock. All of the issued
PIPE Pre-Funded Warrants were exercised on various dates prior to August 18, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RD Offering and PIPE Offering closed on July 26, 2022, with aggregate gross proceeds of approximately $<span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_pn6n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zFQmF58p6Dzl" title="Proceeds from RD offerings">8</span> million. The aggregate net proceeds
from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately $<span id="xdx_90B_ecustom--PaymentsOfStockIssuanceCost_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z5dRaFT5l3X6" title="Offerings costs">7.1</span> million,
with $<span id="xdx_90F_ecustom--PaymentsOfAllocatedEquity_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zZXV846aCuJc" title="Payments of allocated equity">3.2</span> million allocated to equity, $<span id="xdx_904_ecustom--PaymentsOfInvestmentOptionLiability_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zNzhNf9F6Ud4" title="Payments of investment option liability">4.3</span> million to investment option liability, and the remaining $<span id="xdx_90E_ecustom--PaymentsOfStockIssuanceCostsRecordedExpense_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z4z8FpJlJbme" title="Payments of stock issuance costs recorded expense">0.4</span> million recorded as an expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amendment
to 2020 Long-Term Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, our board of directors (&#8220;Board&#8221;) adopted the First Amendment (the &#8220;Plan Amendment&#8221;) to the Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan (the &#8220;Incentive Plan&#8221;) to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220502__20220503_zFYY00235oD8" title="Incentive plan description">(i)
increase the aggregate number of shares available for the grant of awards by 9,739 shares to a total of 13,334 shares,
and (ii) add an &#8220;evergreen&#8221; provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive
Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of common
stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company&#8217;s common stock
authorized for issuance under the Incentive Plan will equal the greater of (x) 13,334 shares, and (y) 15% of the total number
of shares of the Company&#8217;s common stock outstanding as of such issuance date (the &#8220;Evergreen Provision&#8221;). The Plan
Amendment was approved by the Company&#8217;s shareholders at a special meeting of the Company&#8217;s shareholders held on July 14,
2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 2, 2023, the shareholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#8220;Amended Incentive Plan&#8221;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zKM0879PVxa5" title="Authorized shares reserved">23,334</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to adjustment, and (ii) removed the Evergreen
Provision implemented in the Plan Amendment. As of December 31, 2023, the total number of shares available for grant under the Incentive
Plan was <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zfjoMgdI7OF" title="Shares available of grant">7,164</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zu3hZq6igFI4" style="display: none">SCHEDULE OF STOCK OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning">1,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">1,185</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">1,552.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)">5.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding">34,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted">1,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted">46.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted">38.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"><span></span></p>
                                                                          <p style="margin-top: 0; margin-bottom: 0"><span>&#160;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(67</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">2,625</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">2,107.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at beginning">3,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">555.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">672.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1155">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(1,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">46.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">38.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at end">2,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end">857.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end">1,158.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance">3.4</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end">1,712</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end">966.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable">1,330.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable">2.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zXYm0PO3CNlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zR9P2uQxAng7" style="display: none">SCHEDULE OF STOCK OPTION ASSUMPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_z0OXoTSTaL7h" title="Stock price">46.05</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price">46.05</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility">112.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A1_zSkXtPvxBb04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above assumptions are determined by the Company as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    price &#8211; Based on closing price of the Company&#8217;s common stock on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average risk-free interest rate &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which
    correspond to the expected term of the Company&#8217;s stock options.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    yield &#8212; The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends
    on its common stock in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility &#8212; Based on the historical volatility of comparable companies in a similar industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term &#8212; The Company has had no stock options exercised since inception. The expected option term represents the period that
    stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#8220;SAB&#8221;)
    No. 107, Share-Based Payment, which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain
    vanilla&#8221; share options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s stock based compensation expense, recorded within general and administrative expense, related to stock options for the
years ended December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt08RojEH0Xh" title="General and administrative expense">156,075</span> and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXVmi6fVuBdb" title="General and administrative expense">180,042</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had $<span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za7OVdVnQO29" title="Unamortized stock option expense">84,774</span> in unamortized stock option expense, which will be recognized over a weighted average period
of <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN1HXhFc7nl6">1.00</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoynQV9JMUSl" title="Stock-based compensation expense">0</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWmTrUjkTZp7" title="Stock-based compensation expense">24,363</span>, respectively, in stock-based compensation expense within
general and administrative expense, related to restricted stock awards. There were no RSA grants during the years ended December 31,
2023 and 2022. As of December 31, 2022, there were no unvested RSA shares. As of December 31, 2023, there were no unamortized stock-based
compensation costs related to restricted share awards. During the year ended December 31, 2023 the Company settled the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1bnkYOkliK7" title="Common stock , shares issued restricted stock awards">48</span> vested and
unissued shares (as of December 31, 2022) for cash of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLFTi9qtv6r6" title="Unissued shares for cash">14,250</span>. There are <span id="xdx_904_ecustom--NumberOfVestedAndUnissuedShares_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfYgm2OkyJOl" title="Number of vested and unissued shares">no</span> restricted stock awards as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Restricted Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zOnUfbNkVcx6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning">4,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning">1,890</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted">2,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted">502.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited">(1,785</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited">1,194.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Vested">(576</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested">1,958.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-vested at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning">4,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning">1,388.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted">12,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted">40.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited">(2,896</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited">385.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested">(4,176</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested">297.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending">9,366</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending">434.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zBLyP5ujOgX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP10g2JH0QCe" title="Stock based compensation, expenses">1,994,085</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1WqVEZEw91j" title="Stock based compensation, expenses">2,416,266</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the consolidated statement of operations and comprehensive loss. As of December 31, 2023, the
Company had unamortized stock-based compensation costs related to restricted stock units of $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqhi2IvwBlqe" title="Stock-based compensation, unamortized">2,021,021</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will be recognized over a weighted average
period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2g7eZ22vSdd" title="Weighted average period">1.9</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years and unamortized stock-based costs related
to restricted stock units which will be recognized upon achievement of specified milestones. As of December 31, 2023, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkUMlznJm2Kf" title="Common stock vested restricted stock units">1,390</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> restricted stock units are vested without
shares of common stock being issued, with all of these shares due as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zwVhDWsRp68h" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense for RSUs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,085,791</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,389,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">908,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,026,907</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A3_zs23cTYn7Nd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
and Preferred Investment Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning">13,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning">1,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding">3.4</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning">801,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFVujb1NhHh3" style="text-align: right" title="Warrant shares outstanding, Issued">81,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued">154.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised">(51,167</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged for common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBqLrW0x4Do" style="border-bottom: Black 1pt solid; text-align: right" title="Exchanged for common stock"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning">43,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning">875.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning">5,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI6yD0x3nmf" style="text-align: right" title="Warrant shares outstanding, Issued">154,088</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued">20.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised">(8,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised">20.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, Forfeited">(3,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPOuapURS518" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1,672.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end">186,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end">176.85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding">4.6</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable">186,614</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">176.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable">4.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A4_zPsrElVeMZDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with A.G.P./Alliance
Global Partners (the &#8220;Underwriter&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell, in a firm commitment
offering, <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk3cRDFyl4Qk" title="Sale of stock">26,667</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
and accompanying warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd3bmfwqk333" title="Warrant exercises, shares">26,667</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock (&#8220;February
2022 Warrants&#8221;), as well as up to <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTzehTdxsXYj" title="Additional shares of common stock">4,000</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional shares of common stock and/or
warrants to purchase an aggregate of up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z16mZQonqCC3" title="Warrant exercises, shares">4,000</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock that may be purchased
by the Underwriter pursuant to a 45-day option granted to the Underwriter by the Company (the &#8220;Offering&#8221;). Each share of
common stock was sold together with a common warrant to purchase one share of common stock, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIUneReLK98l" title="Warrant, exercise price">412.50</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. Such common warrants were immediately
exercisable and will expire five years from the date of issuance. There is not expected to be any trading market for the common warrants
issued in the Offering. The combined public offering price of each share of common stock and accompanying common warrant sold in the
Offering was $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6xkgupOvnki" title="Sale of stock, price per share">375.00</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 14, 2022, the Underwriter exercised
its option to purchase an additional <span id="xdx_904_ecustom--ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_iI_c20220214__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJKKouHOOFm9" title="Purchase of additional warrants">4,000</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct (&#8220;RD&#8221;) Offering and the Private Investment in Public Entity (&#8220;PIPE&#8221;) Offering
entered into on July 22, 2022, the Company entered into Warrant Amendment (the &#8220;Warrant Amendments&#8221;) with the investors in
both offerings to amend certain existing warrants to purchase up to an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zAjZ7cTA5rXl" title="Purchase of common stock">8,134</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock that were previously
issued to the investors, with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zvxqzNAYpZI" title="Exercise price">412.50</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and expiration date of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zb4ECxOC8eU1" title="Warrant expiration">February
15, 2027</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Pursuant to the Warrant Amendments,
the previously issued warrants were amended, effective upon the closing of the offerings, so that the amended warrants have a reduced
exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBMhaY1KHxhg" title="Exercise price">116.70</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and expire five and one-half years
following the closing of the offerings. In connection with this transaction, the Company determined the fair value of the February 2022
Warrants immediately prior to the Warrant Amendment and the fair value of the amended warrants immediately after the Warrant Amendment.
For the year ended December 31, 2022, the incremental change in fair value was deemed to be $<span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zAcOFLnqEyCl" title="Offerings costs">251,357</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was included as equity issuance costs related to the RD and PIPE financing transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February
2022 and July 2022 public offerings, that would require adjustment to the exercise price upon certain events when the offering price
is less than the stated exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zXmcUZK6ggX1" style="display: none">SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zGMM0alY6k46" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; padding-bottom: 1.5pt">Issued</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued">71,334</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued">118.95</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning">71,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning">118.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding">5.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1366">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, Exercised">(66,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zYmM8O9U70xg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised">20.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end">4,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding end">150.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1378">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable">4,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end">150.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable">4.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zgN7qwVdAb5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zN7RQXnULVth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Registered Direct Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase
up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zSsrXPUEdiaa" title="Issued shares">25,000</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. Subject to certain
ownership limitations, the RD Preferred Investment Options became immediately exercisable at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z1uqcDaW7qh" title="Exercise price">116.70</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock. The RD Preferred
Investment Options are exercisable for five and one-half years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the PIPE Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase up to
<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zRwQ2nOsp9Nf" title="Issued shares">41,667</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the common stock. Subject to certain
ownership limitations, PIPE Preferred Investment Options became immediately exercisable at an exercise price equal to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zkaJQixeHNN1" title="Exercise price">116.70</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share of common stock. The PIPE Preferred
Investment Options are exercisable for five and one-half years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 26, 2022, in connection with the RD Offering and PIPE Offering, the Company issued preferred investment options (the &#8220;Placement
Agent Preferred Investment Options&#8221;) to an entity to purchase up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220725__20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zd3qnd5iCLyd" title="Purchase of common stock">4,667</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the common stock for acting as
a placement agent. The Placement Agent Preferred Investment Options have substantially the same terms as the RD Preferred Investment
Options and the PIPE Preferred Investments Options, except the Placement Agent Preferred Investment Options have an exercise price of
$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z5L1L63tFikl" title="Exercise price">150.00</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. The Placement Agent Preferred
Investment Options are exercisable for five years from the date of the commencement of the RD Offering and PIPE Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#8220;Inducement Letters&#8221;) with certain
holders (the &#8220;Holders&#8221;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment options to purchase
shares of the Company&#8217;s common stock (the &#8220;Existing Warrants and Investment Options&#8221;) pursuant to which the Holders
agreed to exercise for cash their Existing Warrants and Investment Options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zaKTUOZ2VM1f">74,800
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
in the aggregate, at a reduced exercised price of $<span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zmvD3OtwCWOc">20.55
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (from an original exercise price
of $<span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_z331mhMbpsH9">116.70
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share), in exchange for the Company&#8217;s
agreement to issue new warrants (the &#8220;Inducement Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zBLXrJDQsa73">149,600
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock
(the &#8220;Inducement Warrant Shares&#8221;), and the Holders to make a cash payment of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zczxnQc98rf6">1.88
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Inducement Warrant share for total proceeds
of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zcyzU36Ekmw8">280,500</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
In January 2024, the Company received aggregate gross proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4oN8knfD0g8">1,817,640
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the exercise of the Existing Warrants and
Investment Options by the Holders and the sale of the Inducement Warrants. Because the Existing Warrants and Investment Options by the
Holders and the sale of the Inducement Warrants that exercised on December 28, 2023 and unsettled until January 2024, the proceeds are
included in the consolidated balance sheet as a subscription receivable as of December 31, 2023. As of December 31, 2023, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU9SOH6jFOVg">27,867
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were considered issued as the Company had the enforceable right to the obtain the cash proceeds, which were in-transit,
and the Holders were no longer able to rescind the exercise election. Due to the beneficial ownership limitation provisions, <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zxGL0O0hxkrd">46,934
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Existing Warrants and Investment
Options exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder
that the shares may be issued in compliance with such limitation. <span id="xdx_904_ecustom--ClassOfWarrantOrRightReasonForIssuing_c20230101__20231231_zcAzUmhlaRN9">The
Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its financial advisor in connection with the transactions summarized
above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth was also issued
warrants to purchase up to 4,488 shares of common stock. The Roth Warrants have the same terms as the Inducement Warrants. The
grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to additional paid in
capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that were charged to additional
paid in capital as issuance costs.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company also agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares issued or issuable
upon the exercise of the Inducement Warrants (the &#8220;Resale Registration Statement&#8221;) by January 8, 2024 (filed January 11,
2024). In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any
other registration statement with the SEC (in each case, subject to certain exceptions) for a period ending on February 26, 2024. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until December
28, 2024. See the <i>Equity Distribution Agreement</i> section of this Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this transaction, the Company determined the fair value of the Existing Warrants and Investment Options immediately prior
to the Inducement Letters and the fair value of the amended warrants and investment options immediately after the Inducement Letters.
The pre-modification measurement of fair value of the Existing Warrants and Investment Options were determined utilizing a Black-Scholes
model considering all relevant assumptions current at the date of modification (i.e. for the Existing Warrants share price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zCbGm8EEY1V3">23.40</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price of $<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z4tKTV7UOUG6">116.70</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zooxgXjsrNd2">3.6
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, volatility of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zofY1yo9JWoe">94</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
risk-free rate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zcquYR7c56k4">3.96</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and expected dividend rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zokkfbNVJfv7">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
resulting in a fair value per share of $<span id="xdx_904_eus-gaap--SharePrice_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zLgHJhiJMRBd">8.10
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and for the Investment Options share price
of $<span id="xdx_903_ecustom--InvestmentOptionSharePrice_iI_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zwBfp0BZQ80c">23.40</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise price of $<span id="xdx_900_ecustom--InvestmentOptionExercisePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zKcskuubDUpd">116.70</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">term of <span id="xdx_903_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zU0nvYB2zE2k">4.1
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, volatility of <span id="xdx_905_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zH70FMRqgzUb">95</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
risk-free rate of <span id="xdx_90F_ecustom--InvestmentOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zTPQDN37G1rc">3.90</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
and expected dividend rate of <span id="xdx_90A_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z8myANWwAgc6">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%,
resulting in a fair value per share of $<span id="xdx_90F_ecustom--SharePriceOption_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zp1NydJ78A0g">9.30</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">).
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total fair value of the <span id="xdx_90A_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zzX9YHTJMqi1">8,134
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing Warrants and <span id="xdx_909_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zQDt29TH03gd">66,667
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Options was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zq7HEdNl3oQb">65,349
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zUn4gcd9lAw1">618,648</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. The post-modification fair value was determined using the intrinsic value of $<span id="xdx_909_ecustom--InvestmentIntrinsicValue_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zu7RNJpEOLU9">2.85
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">due to the inducement and totaled $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zNlOcIN0WNE1">23,180
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zC7xL300AYW4">190,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the Existing Warrants and Investment Options,
respectively. The change in fair value from the date of the modification prior to modification and the fair value on the date of the
modification after the modification, but prior to exercise was $<span id="xdx_907_ecustom--InvestmentInducementGain_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zwUDTSOh5Wb">470,817</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which was reflected as an inducement gain, within other expenses on the Company&#8217;s consolidated statement of operations and comprehensive
loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant date fair value of these Inducement Warrants was estimated to be $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20231228__20231228_z2x1EoMCFBJl">2,599,552</span> on December 28, 2023 and the proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228_zJIFuTKtruIl">280,500</span>,
which were received on January 2, 2024, for the issuance of the Inducement Warrants is reflected as inducement expense, within other
expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zKA67bcbOmMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zy2L3wh6IEsj" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Roth and Inducement Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 28, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z3AuGTsHI5pl" title="Stock price">23.40</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z0UvQEgSl08f" title="Exercise price">20.55</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility">92.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate">3.80</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants">154,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zGfIo4VzY1I" style="text-align: right" title="Value (per share)">17.40</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zXHJwPy7aNrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Series
C Preferred Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2022, the Board of Directors (the &#8220;Board&#8221;) declared a dividend of one one-thousandth of a share of the Company&#8217;s
Series C Preferred Stock (&#8220;Series C Preferred Stock&#8221;) for each outstanding share of the Company&#8217;s common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022 (the &#8220;Record Date&#8221;). This dividend
was based on the number of outstanding shares of common stock prior to the Reverse Stock Split. The outstanding shares of Series C Preferred
Stock were entitled to vote together with the outstanding shares of the Company&#8217;s common stock, as a single class, exclusively
with respect to a proposal giving the Board the authority, as it determines appropriate, to implement a reverse stock split within twelve
months following the approval of such proposal by the Company&#8217;s stockholders (the &#8220;Reverse Stock Split Proposal&#8221;),
as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split Proposal (the
&#8220;Adjournment Proposal&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company held a special meeting of stockholders on July 14, 2022 (the &#8220;Special Meeting&#8221;) for the purpose of voting on, among
other proposals, a Reverse Stock Split Proposal and an Adjournment Proposal. All shares of Series C Preferred Stock that were not present
in person or by proxy at the Special Meeting were automatically redeemed by the Company immediately prior to the opening of the polls
at Special Meeting (the &#8220;Initial Redemption&#8221;). All shares that were not redeemed pursuant to the Initial Redemption were
redeemed automatically upon the approval by the Company&#8217;s stockholders of the Reverse Stock Split Proposal at the Special Meeting
(the &#8220;Subsequent Redemption&#8221; and, together with the Initial Redemption, the &#8220;Redemption&#8221;). <span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5dqYDZjASmi" title="Preferred stock voting rights">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were</span> <span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUuJvhOW6s9" title="Redeemable preferred stock, shares outstanding">52,684.548</span> shares of Series C Preferred Stock issued and outstanding. As of December 31,
2022, both the Initial Redemption and the Subsequent Redemption had occurred. As a result, no shares of Series C Preferred Stock remain
outstanding. As of December 31, 2023 and 2022, there are <span id="xdx_90E_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjdiSzO1vp5b" title="Preferred Stock authorized for future issuances">100,000</span> shares of Series C Preferred Stock authorized for future issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891995037168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract', window );"><strong>Redeemable Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNonControllingInterestTextBlock', window );">REDEEMABLE NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_80E_ecustom--RedeemableNonControllingInterestTextBlock_zcwkISFrpcJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_820_zpC01KA801s3">REDEEMABLE NON-CONTROLLING INTEREST</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Spin-Off
and Related Private Placement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Spin-Off, on May 5, 2022, Akos and the Company entered into into a Securities Purchase Agreement (the &#8220;Akos
Purchase Agreement&#8221;) with an accredited investor (the &#8220;Akos Investor&#8221;), pursuant to which Akos agreed to sell up to
an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcoQUJHN90ug" title="Sale of stock">5,000</span> shares of Akos Series A Preferred Stock, at price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWiC0QAHltf9" title="Sale of stock price per share">1,000</span> per share, and warrants (the &#8220;Akos Warrants&#8221;)
to purchase shares of Akos&#8217; common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_ziqdyNm1proh" title="Common stock par value">0.01</span> per share (the &#8220;Akos Common Stock&#8221;), for an aggregate purchase
price of up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zewKu8BntBy9" title="Sale of stock, value">5,000,000</span> (the &#8220;Akos Private Placement&#8221;). The Akos Purchase Agreement was guaranteed by the Company. Pursuant
to the Akos Purchase Agreement, Akos issued <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG8bfr259E7" title="Sale of stock">1,000</span> shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7nhFd17DNtk" title="Sale of stock, value">1,000,000</span>
on May 5, 2022. The additional $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zxgML5QugCI7" title="Sale of stock, value">4,000,000</span> was to be received on or immediately prior to the Spin-Off. The issuance of the Akos Series
A Preferred Stock results in RNCI (see Note 2). Palladium Capital Advisors, LLC (&#8220;Palladium&#8221;) acted as placement agent for
the Akos Private Placement. <span id="xdx_901_ecustom--SpinoffAndRelatedPrivatePlacementDescription_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zux8vYKBzXke" title="Spin-off and related private placement, description">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.</span> Palladium was also entitled to warrants to purchase Akos Common Stock in an amount
up to <span id="xdx_907_ecustom--WarrantsToPurchaseCommonStockPercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_z4zdKBKSkhG2" title="Warrants to purchase common stock, percentage">8</span>% of the number of shares of Akos Common Stock underlying the shares issuable upon conversion of the Akos Series A Preferred Stock.
As of December 31, 2023, no accruals are required to be recorded for the fees or warrants since the Akos Series A Preferred Stock has
been redeemed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Terms
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Certificate of the Designations, Preferences, and Rights of Series A Convertible Preferred Stock of Akos (the &#8220;Akos Series
A Preferred Certificate of Designations&#8221;), on or immediately prior to the completion of the spin-off of Akos into an independent,
separately traded public company listed on the Nasdaq Stock Market, the outstanding Akos Series A Preferred Stock automatically converted
into a number of shares of Akos Common Stock equal to <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zgm4sLjh8SB5" title="Percentage of stock issued and outstanding">25</span>% of the then issued and outstanding Akos Common Stock, subject to the Beneficial
Ownership Limitation (as defined in the Akos Purchase Agreement). Cumulative dividends on each share of Akos Series A Preferred Stock
accrue at the rate of <span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zqfJDBLNLuU3" title="Dividend rate">5</span>% annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations provided that upon the earlier of (i) the one-year anniversary of May 5, 2022, and
only in the event that the Spin-Off has not occurred; or (ii) such time that Akos and the Company have abandoned the Spin-Off or the
Company is no longer pursuing the Spin-Off in good faith, the holders of the Akos Series A Preferred Stock shall have the right (the
&#8220;Put Right&#8221;), but not the obligation, to cause Akos to purchase all or a portion of the Akos Series A Preferred Stock for
a purchase price equal to $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znidGcp5SmHb" title="Sale of stock, price per share">1,000</span> per share, subject to certain adjustments as set forth in the Akos Series A Preferred Certificate of
Designations (the &#8220;Stated Value&#8221;), plus all the accrued but unpaid dividends per share. In addition, after the one-year anniversary
of May 5, 2022, and only in the event that the Spin-Off has not occurred and Akos is not in material default of any of the transaction
documents, Akos may, at its option, at any time and from time to time, redeem the outstanding shares of Akos Series A Preferred Stock,
in whole or in part, for a purchase price equal to the aggregate Stated Value of the shares of Akos Series A Preferred Stock being redeemed
and the accrued and unpaid dividends on such shares. Pursuant to the Akos Purchase Agreement, the Company has guaranteed the payment
of the purchase price for the shares purchased under the Put Right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Akos Series A Preferred Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of Akos
Common Stock upon conversion of the Akos Series A Preferred Stock that would result in the number of shares of Akos Common Stock beneficially
owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Akos Common Stock outstanding immediately after
giving effect to the conversion (the &#8220;Beneficial Ownership Limitation&#8221;), except that upon notice from the holder to Akos,
the holder may increase or decrease the limit of the amount of ownership of outstanding shares of Akos Common Stock after converting
the holder&#8217;s shares of Akos Series A Preferred Stock, provided that any change in the Beneficial Ownership Limitation shall not
be effective until 61 days following notice to Akos.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Redemption
of Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $<span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztQh1TbMgLA2" title="Dividends, per share">1,000</span>&#8239;per share, plus accrued
but unpaid dividends of approximately $<span id="xdx_90A_ecustom--UnpaidDividends_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGXioCLHfE1e" title="Unpaid dividends">52,000</span>&#8239;for a total of approximately $<span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdtM4nK5oH7j" title="Dividends">1,052,000</span>. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023. Upon redemption in May 2023, the Company revalued the
derivative liability and the Company recognized a change in fair value of the derivative liability on the Company&#8217;s consolidated
statement of operations during the second quarter of 2023 of $<span id="xdx_90D_ecustom--FairValueOfDerivativeLiability_c20230101__20230630_zkgTWFy1WwJj" title="Change in fair value of derivative liability">714,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, Akos, and the Akos Investor have terminated the Akos Purchase Agreement in connection with the planned Spin-Off and certain
registration rights agreement in connection with the Akos Private Placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting
for Akos Series A Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the shares of Akos Series A Preferred Stock were redeemable at the option of the holder and the redemption is not solely in the control
of the Company, the shares of Akos Series A Preferred Stock were accounted for as a redeemable non-controlling interest and classified
within mezzanine equity in the Company&#8217;s consolidated balance sheets. The redeemable non-controlling interest was initially measured
at fair value. Dividends on the shares of Akos Series A Preferred Stock were recognized as preferred dividends attributable to redeemable
non-controlling interest in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the reconciliation of changes in redeemable non-controlling interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zjoodKpMYtk6" style="display: none">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance">885,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock">19,041</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value">147,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redemption of Akos Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock">(1,052,057</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_z5hvmzlTgjq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Akos Series A Preferred Stock was redeemed for a total of <span id="xdx_900_ecustom--RedeemableNoncontrollingInterest_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMwz0KsNsOXa" title="Redeemable noncontrolling interest">1,052,057</span>, and the balance of the redeemable non-controlling
interest is $<span id="xdx_902_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iI_dxL_c20231231_zAeOWuDFnGDk" title="Redeemable non-controlling interest::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1506">0</span></span> as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureRedeemableNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNonControllingInterestTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNonControllingInterestTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889316752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zzc4DQdOVCk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82E_zsrUTbzuipf3">FAIR VALUE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none">SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeMO13hylIPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Warrant liabilities - January 2021 Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTOpwQ8OG55f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant liabilities - February 2021 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwTQbM3dQLe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrant liabilities - February 2022 Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">185,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9i5VrFNGzB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zMdkWlrsIj62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-bottom: 1.5pt">Derivative liability - May 2022</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 10%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1524">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">727,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEFcbOFbmgyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">727,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zSWqu8SwspQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Wainwright investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">23,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">44,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zWIcJvLDtsLe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RD investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1533">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,289</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z1YCCLCqkbX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PIPE investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziutXKvlcfW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of investment option liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">851,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zlaHAKR4Y6A2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrant liabilities, derivative liability, and investment options are all classified as Level 3, for which there is no current market
for these securities such as the determination of fair value requires significant judgment or estimation. Changes in fair value measurement
categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded
within other income (expense) on the consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BA_zyGP5uMpiwf9" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Post-Modification Warrants (See Note 7)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 15, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zVPjfhQ1hMA5" title="Warrants term">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_z7auqGCNbdGa" title="Warrants term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price">236.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price">94.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price">412.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price">116.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1556">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1558">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zIpLsb0r9873" title="Warrants, measurement input">74.1</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zEbPX8XFb5Ej" title="Warrants, measurement input">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zsu2orPGxhM7" title="Warrants, measurement input">1.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zYZ9cMkF2kc9" title="Warrants, measurement input">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants">30,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants">8,134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)">120.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)">61.05</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">May 2022 Derivative Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">May 5, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zaAv4G5sSCic" style="width: 23%; text-align: right" title="Principal">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate">5.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zfdU1bv2Iu1d" style="text-align: right" title="Market rate">4.4</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Wainwright Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">RD Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">PIPE Options</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z65GnhDKxrH1">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price">94.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94.95</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94.95</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zjD6zOtXxyef" style="text-align: right" title="Investment, exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116.70</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1599">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1601">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,667</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,667</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.05</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.05</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zqJvQKCnT5l7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subsequent
measurement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zXzjxOoiQ9Qg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zf0YvucZm167" style="display: none">SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Fair value as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance">653,674</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of February 2022 warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity">3,595,420</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value due to modification of February 2022 warrants as part of July 2022 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification">251,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(4,315,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance">185,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value">(94,396</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRprDXlaTIXd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of warrants">(65,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1639">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%; text-align: left; padding-bottom: 1.5pt">Issuance of May 2022 convertible preferred stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity">402,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">325,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance">727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(727,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Investment Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%">Issuance of July 2022 investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity">4,323,734</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(3,472,726</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance">851,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value">(208,752</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVIt6yDO5kC9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of investment options">(618,648</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of investment option liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zTDiFxmrLd74" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zGwJ3NUryGMb" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 2022 Warrants Unmodified</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zFeN4U2oQbMg" title="Investment option term">2.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z9qSoxj865ti" title="Investment option term">2.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zHqUQQehlCYb" title="Investment option term">3.1</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za7OVDZZzYCl" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,712.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,675.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">412.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1685">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1687">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1689">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input">89.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input">88.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input">87.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input">4.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,429</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,286</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,534</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">H.C. Wainwright &amp; Co., LLC Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2h5WTjUaE" title="Investment option term">3.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price">19.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zYJQsZKqOizg" style="text-align: right" title="Investment, exercise price">150.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1721">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input">94.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input">4.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options">4,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)">5.10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zrbMv2JczZWj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date of the redemption of the of Akos Series A Preferred Stock in May 2023, the derivative liability fair value was $<span id="xdx_905_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBe0f08cNDD6" title="Derivative liability fair value">0</span> due to the
probability of a spin-off occurring was zero. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889771664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLh9T8RDzKTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9. <span id="xdx_82D_zwhFZNaJSV1b">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s
financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-002, the Company&#8217;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-002 in coordination with the Company&#8217;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-002. EB-002, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s
Therapeutic Goods Administration and is currently in preclinical development targeting the treatment of anxiety disorder. The total cost
of the Avance Clinical contract is approximately <span id="xdx_906_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zQ2Bv8HIf6i3" title="Contract cost">3,400,000</span> AUD, which translates to approximately $<span id="xdx_904_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zzF4cy903UQk" title="Contract cost">2,329,000</span> USD as of September 30,
2024. As of September 30, 2024, the Company has paid 100% of the Avance Clinical contract costs and has $<span id="xdx_90B_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z8i7qjxAl014" title="Prepaid assets">0</span> recorded as prepaid
assets within prepaid and other current assets, accrued $<span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z8l8kIySOmok" title="Accrued liabilities">0</span> recorded as accrued liabilities and $<span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zMpSYaITZFrd" title="Accounts payable">0</span> as accounts payable on the accompanying
condensed consolidated balance sheet. For the three and nine months ended September 30, 2024 and 2023, the Company has expensed $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_iN_c20240701__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zZShdU2atqH5" title="Research and development expenses">264,385</span>
and $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zg1MdD5bmXg7" title="Research and development expenses">508,774</span>, and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zqSzKt85YCNe" title="Research and development expenses">157,117</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zkCFSJlnZzDl" title="Research and development expenses">401,284</span>, respectively, in research and development expenses within the accompanying unaudited condensed
consolidated statement of operations. As of September 30, 2024, all payments have been made and the project is substantially completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to Australian tax law, the Company is allowed an R&amp;D tax credit that reduces a company&#8217;s tax bill in Australia for expenses
incurred in R&amp;D subject to certain requirements. The Company&#8217;s Australian subsidiary submits R&amp;D tax credit requests annually
for research and development expenses incurred. At September 30, 2024 and December 31, 2023, the Company had a research and development
tax credit receivable of $<span id="xdx_902_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_dxL_c20240930_zRTgxwIWfh43" title="Research and development expense tax credit receivable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl3242">0</span></span> and $<span id="xdx_90B_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_c20231231_zWQavAebeKKl" title="Research and development expense tax credit receivable">145,349</span>, respectively, for R&amp;D expenses incurred in Australia, included in prepaid and other current
assets within the accompanying unaudited condensed consolidated statement of operations. The Company received the amount due in relation
to the research and development tax credit during the three months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#8220;Vogel-Nathan Purchase
Agreement&#8221;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The patent portfolio acquired and developed under the Vogel-Nathan Purchase Agreement
was sold to undisclosed buyers for an amount not material to these financials in the first quarter of 2024. No additional financial or
other obligations exist regarding the Vogel-Nathan Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Consulting and Vendor Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between one and 12 months. These agreements, in aggregate, commit the Company to approximately $<span id="xdx_905_eus-gaap--Cash_iI_pn5n6_c20240930__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_z4d5IeWyKFrl" title="Future cash">0.1</span> million in future
cash payments, inclusive of amounts in accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reduction
in Force/Restructuring</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#8220;RIF&#8221;) of approximately <span id="xdx_90C_ecustom--ReductionInForceRestructuringPercentage_pid_dp_uPure_c20230531__20230531_zS8hAWRmTaBd" title="Reduction in force restructuring percentage">35</span>% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The plan included a focus on progressing the Company&#8217;s existing
non-cannabinoid pipeline while reducing the rate of spend and managing cash flow. In June 2023, the Company completed the reduction in
force, with such severance expenses recorded in general and administrative accounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#8217;s President and Chief Operating Officer
(the &#8220;Kanubaddi Separation Agreement&#8221;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi received salary
and benefits that is paid out in twelve monthly installments beginning in July 2023, was eligible for his 2023 performance bonus, which
was not achieved, and any outstanding restricted stock units retained their vesting conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zpFIobmcUyYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Reduction in Force/Restructuring activity and ending balance at September 30, 2024 for the remaining severance
payments included in accrued expenses in the consolidated balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_zdmdhPytwCO" style="display: none">SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-right: 0.5in; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accrued
    Restructuring Costs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif">January 1, 2024 beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20240101__20240930_z2Ef8GLQ4vih" style="width: 14%; text-align: right" title="Restructuring cost payable, beginning"><span style="font-family: Times New Roman, Times, Serif">301,645</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Restructuring costs paid</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--RestructuringCosts_c20240101__20240930_zqX3YtRiw8z1" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs paid"><span style="font-family: Times New Roman, Times, Serif">(301,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024 ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20240101__20240930_zwQfLsOPTXb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p id="xdx_8AF_zC3lkyGUS4zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJzHQhc2S99e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_824_zLAtIowfPq7c">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#8217;s
financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Australian
Subsidiary Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-373, the Company&#8217;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-373 in coordination with the Company&#8217;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-373. EB-373, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#8217;s
Therapeutic Goods Administration (TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total
cost of the Avance Clinical contract is approximately <span id="xdx_902_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zP5GfH9I9BH2" title="Contract cost">3,000,000</span> AUD, which translates to approximately $<span id="xdx_905_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zh1rCXdtro0i" title="Contract cost">2,000,000</span> USD as of December
31, 2023. As of December 31, 2023, the Company has paid approximately $<span id="xdx_904_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zBWqr4Io24Ge" title="Payment of contract cost">1,036,940</span> of the Avance Clinical contract costs and has accrued
$<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z3EcyGn4t8s5" title="Accrued liabilities">523,284</span> recorded as accrued liabilities and $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zYKiKTtPTDXc" title="Accounts payable">239,320</span> as accounts payable on the accompanying consolidated balance sheet. For the year
ended December 31, 2023, the Company has expensed $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_ztSbfQPHmw17" title="Research and development expenses">1,751,444</span> in research and development expenses within the accompanying consolidated
statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Development
and Clinical Supply Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &#8220;PureForm Agreement&#8221;) with PureForm
Global, Inc. (&#8220;PureForm&#8221;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#8220;API&#8221;)
for the Company&#8217;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order of 1 kilogram during the first thirty (30) days from the effective date) and
has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be
owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts
by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the PureForm Agreement, subject to extension
by mutual agreement of the parties. The Company has met the minimum purchase requirement of 1 kilogram during the first thirty days of
the PureForm Agreement&#8217;s effectiveness. The Company did not pursue an extension of the PureForm Agreement beyond the initial term
and the agreement terminated in 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#8220;Vogel-Nathan Purchase
Agreement&#8221;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The Vogel-Nathan Purchase Agreement includes a commitment to pay a one-time milestone
totaling $<span id="xdx_908_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--OneTimeMilestoneMember_zrCCC2obgoyi" title="Long-term purchase commitment, amount">200,000</span> upon the issuance of a utility patent in the United States or by the European Patent Office, as defined in the agreement.
The Company has accrued such amount as of December 31, 2021, as a result of the milestone criteria being achieved. Payment was made during
January 2022. In addition, a milestone payment totaling $<span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--AdditionalMilestoneMember_zhdAQxZczHo1" title="Long-term purchase commitment, amount">300,000</span> is due upon initiation of a Phase II(b) study. Research activities related
to the relevant patents are still in preclinical stage, and accordingly, this milestone has not been achieved. The Vogel-Nathan Purchase
Agreement contains a commitment for payment of royalties equaling <span id="xdx_90B_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zDQEojQYFYF1" title="Royalties percentage">2</span>% of the first $<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zoZY67IeTyk6" title="Payments for royalties">20</span> million in net sales derived from the commercialization
of products utilizing the relevant patent. As these products are still in the preclinical phase of development, no royalties have been
earned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Consulting and Vendor Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between 1 and 18 months. These agreements, in aggregate, commit the Company to approximately $<span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_zXfWx4ycr8Rc" title="Future cash">1.3</span> million in future
cash payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Right-of-use
lease</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2021, MagicMed entered into a lease agreement (the &#8220;LSIH Lease&#8221;) with the University of Calgary for the use and
occupation of lab and office space at the University of Calgary&#8217;s Life Science Innovation Hub building located in Calgary, Alberta,
Canada (the &#8220;LSIH Facility&#8221;). The lease expired in July 2023, and was extended on a month-to-month basis through December
31, 2023. Accordingly, no operating lease liability or right-of-use asset is recorded as of December 31, 2023. The Company terminated
this lease effective in March 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expense is recorded on the straight-line basis. Rent expense under the LSIH Lease for the years ended December 31, 2023 and 2022 was
$<span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20231231_zBINyAlGGitl" title="Rent expenses">114,241</span> and $<span id="xdx_900_eus-gaap--PaymentsForRent_c20220101__20221231_zTe2yrPNRkw2" title="Rent expenses">120,667</span>, respectively. Rent expense is recorded in research and development costs on the consolidated statements of operations
and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zWHvKLl07Vnb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zQfu0TOu6lia" style="display: none">SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remaining lease term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term">0.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate">12.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_zFSM6H6fbVub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891890214752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zYdOWhZhqi8i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11. <span id="xdx_82E_zmpByKrEU5va">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zeA4xpukjyji" style="display: none">SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,205,116</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,251,228</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,057,703</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,706,165</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,262,819</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,957,393</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_zhNKqIFZq044" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recorded income tax expense of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_z3Bd8okIz0A9" title="Income tax expenses and benefits">28,913</span> and an income tax benefit of $<span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zTxFvfZupNSk" title="Income tax expenses and benefits">1,486,060</span>,
respectively. The income tax benefit (expense) is as follows:</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4LFMffO1bGa" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE BENEFITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Current:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(28,913</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1793">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total
    current income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1799">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1801">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,913</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zEMeV37Jgcl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets and deferred tax liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B9_zVn0082ZSHDi" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,889,863</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,927,330</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,185,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,348,928</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_zeLuldfIHLJk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development capitalized expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">614,041</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_z3vKEWbpo3wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,837,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,977,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1833">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1834">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zv3ekvcOLIcc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially utilizable net operating loss tax carryforwards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt3NjQUFsfF" style="display: none">SCHEDULE
OF OPERATING LOSS CARRY FORWARDS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,268,692</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18,349,753</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,220,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,892,754</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net operating loss tax carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A8_z7S3r24z5eD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) limits the net operating loss deduction to 80% of taxable income for losses
arising in tax years beginning after December 31, 2017. As of December 31, 2023, the Company had federal net operating loss
carryforwards and state net operating loss carryforwards of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMyXJ1gm3FJ8">24,268,692</span>
and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zH57liFWfGbk" title="Net operating loss carryforwards">11,220,065</span>,
respectively, both of which can be carried forward indefinitely and Canadian net operating loss carryforwards of $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zr2nJ9Kzy0j6" title="Net operating loss carryforwards">17,672,420</span>,
which will begin to expire in 2040.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s effective tax rate varied from the statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none">SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Federal income tax at the statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax rate (net of federal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.6</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign tax rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.1</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zBQrMCzaAaZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

<p id="xdx_8A9_zsa35ks9ndR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased by
$<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znu1AgEoYdYj" title="Valuation allowance">1,859,862</span> and $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zQeSg7kdYWS3" title="Valuation allowance">4,429,869</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state and Canadian perspective the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. As of December 31, 2023, the Company has not filed tax returns for the fiscal year 2023 and Canadian corporate
tax returns for fiscal year 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
382</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
utilization of the Company&#8217;s net operating losses may be subject to a substantial limitation in the event of any significant future
changes in its ownership structure under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result
in the expiration of the net operating loss carryforwards before their utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Section
174</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures
in the current year and requires taxpayers to amortize US expenses over five years and foreign expense over fifteen years pursuant to
IRC Section 174. During the years ended December 31, 2023 and 2022, the Company has estimated and capitalized gross $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_z0NaECqIR2Wg" title="Research and development expense gross">463,696</span> and $<span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zOGeQR7Krns5" title="Research and development expense gross">2,684,319</span>,
respectively, of research and development expenditures that will be amortized primarily over five years. This did not have a material
impact on the Company&#8217;s tax liability for the years ended December 31, 2023 and 2022. The Company will continue to evaluate the
impact of these tax law changes on the current and future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Inflation
Reduction Act</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2022, President Joe Biden signed the Inflation Reduction Act of 2022 (the &#8220;Act&#8221;) into law. The Act includes a
new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December
31, 2022. These provisions did not have a material impact on the Company&#8217;s consolidated financial position as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891890218128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zxCQVvJ8Awt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10. <span id="xdx_82B_zgbEecB5evBj">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to September 30, 2024, the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember_zMKqillto5Fi" title="Stock issued during period shares new issues">63,334</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock through the Purchase
Agreement with Lincoln Park for gross cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241001__20241114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi8yIXYXJKA5" title="Gross proceeds">405,820</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
As of November 12, 2024, there are <span id="xdx_90F_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember_ztVrZ7zIer6d" title="Remaining shares">258,334</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining registered shares available to
be issued in connection with this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 9, 2024, the Company granted <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20241009__20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgektihs4axg" title="Restricted stock units, shares">25,776</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock units to its officers and
certain employees, which fully vest on October 9, 2028 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241009__20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxlNgw6lAww5" title="Restricted stock awards">14,586</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restricted stock awards to its non-employee
directors, which fully vest on December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
October 9, 2024, the Board approved an equitable adjustment to increase the number of shares available under the Incentive Plan by <span id="xdx_90D_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zAlFvAJFFIXi" title="Shares available for grant">64,402</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares, which increased the total number
of authorized shares under the Incentive Plan to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zS5camNtv1pl" title="Authorized shares">96,721</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, the Company entered into an Out-Licensing Agreement (the &#8220;Agreement&#8221;) with MycoMedica Life Sciences, PBC,
a Delaware public benefit corporation (&#8220;MycoMedica&#8221;), pursuant to which the Company will out-license EB-002 and its EVM201
series to MycoMedica for further development and sales of the product in treatment of neuropsychiatric disorders. MycoMedica will receive
an exclusive, global license to the formulations, drugs, method of use, and medical devices developed by Enveric to utilize the compound.
As part of the Agreement, the Company will receive modest upfront payments, and if certain conditions are met, will receive development
and sales milestone payments of up to $<span id="xdx_908_ecustom--ProceedsFromAchievingDevelopmentAndSalesMilestones_pn6n6_c20241107__20241107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCjnaEc28OGl">62
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and tiered single-digit royalties based
on future sales. MycoMedica has the option during the license term to buyout its milestone and royalty payment obligations at a predetermined
amount depending upon the stage of product development and commercialization at the time of the buyout. Further, MycoMedica has the right
to purchase the licensed patents at a nominal amount upon a change of control of the Company, although doing so does not relieve MycoMedica
of any of its payment obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">T<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he
Company completed a <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zQBsqKof122">1-for-15</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse
Stock Split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. The Reverse Stock Split reduced the number of
shares of the Company&#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse
Stock Split. The number of shares of the Company&#8217;s authorized common stock was not affected by the Reverse Stock Split and the
par value of the Company&#8217;s common stock remained unchanged at $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV3e3b5rhSca">0.01 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. No fractional shares were issued in connection with the Reverse Stock Split.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z18CjkrOmpN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
12. <span id="xdx_820_zNqnVHMzgyjl">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company completed a <span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zdVV237Bi36e" title="Reverse stock split">1-for-15</span>
reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. The Reverse Stock Split reduced the number
of shares of the Company&#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse
Stock Split. The number of shares of the Company&#8217;s authorized common stock was not affected by the Reverse Stock Split and the
par value of the Company&#8217;s common stock remained unchanged at $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHPoJR1PQ9U6" title="Share price">0.01</span>
per share. No fractional shares were issued in connection with the Reverse Stock Split. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
February 29, 2024, the Company issued all <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXqaJYv860yd" title="Number of common stock issued">46,934</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of common stock of the <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR2185JE00Nd" title="Existing Warrants">46,934</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Existing Warrants and Investment
Options exercised that were held in abeyance due to the beneficial ownership limitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 29, 2024, one investor exercised the Inducement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0AhH5MmtvB3" title="Warrants to purchase shares of common stock">130,267</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for cash proceeds
of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMS2xAAK6T0e" title="Cash proceeds">2.7</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSeFskr2Lz9b">15,246</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s common stock,
par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaEtnlXUmCYi">0.01</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share to the Holders of the Inducement Warrants.
The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction limitation solely with respect
to the entry into and/or issuance of shares of common stock in an at the market offering contained in the Inducement Letters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to December 31, 2023, the Company sold an aggregate of <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zJmX0hu9ExH5" title="Number of shares sold">111,200</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock for aggregate gross
proceeds of $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_z8Ub17d6Doq3" title="Gross proceeds from sale of shares">2,392,502</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and net proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zM52artKaMga" title="Net Proceeds from sale of shares">2,320,707</span>
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the Distribution Agreement with Canaccord.&#8221;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994895376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureLicensingAgreementsAbstract', window );"><strong>Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_LicensingAgreementsDisclosureTextBlock', window );">LICENSING AGREEMENTS</a></td>
<td class="text"><p id="xdx_806_ecustom--LicensingAgreementsDisclosureTextBlock_zG52ebE7ez33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8. <span id="xdx_824_zObb3gdTRkdk">LICENSING AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2024, Akos entered into an Exclusive License Agreement (the &#8220;License Agreement&#8221;) with Aries Science and Technology,
LLC, an Ohio limited liability company (&#8220;Aries&#8221;), pursuant to which Akos granted Aries a license of Akos&#8217;s patented
radiation dermatitis topical product. The license allows Akos to use the patented formulation to develop pharmaceutical or non-pharmaceutical
products for treating radiation dermatitis suitable for administration to humans or animals. The license is exclusive (subject to certain
exceptions contained in the License Agreement), worldwide, royalty-bearing, and includes the right to sublicense. Akos is entitled to
potential license payments, milestone payments and royalties based on net revenues of the Licensed Product on a licensed product-by-licensed
product and country-by-country basis pursuant to the terms of the Agreement. Aries has the option during the license term, to purchase
the rights to each licensed product (on a licensed product-by-licensed product basis) in the form of an exclusive (as to the applicable
licensed product), fully paid, transferable right and license to the licensed product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not earned any revenue related to this agreement as of September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_LicensingAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreements Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_LicensingAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891892391760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principal of Consolidation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zo1UCk4KVdqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_z6QO8pI0anKh">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and Article 8 of Regulation S-X. Accordingly,
they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Management&#8217;s opinion
is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results
for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year
ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated
financial statements for the year ended December 31, 2023, and related notes thereto included in the Company&#8217;s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 26, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s significant accounting policies and recent accounting standards are summarized in Note 2 of the Company&#8217;s consolidated
financial statements for the year ended December 31, 2023. There were no significant changes to these accounting policies during the
three and nine months ended September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zbIKrsz2JJMb">Basis
of Presentation and Principal of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_842_eus-gaap--UseOfEstimates_zgACgUEtt6Ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zlothHQNIky6">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during
the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements
of changes in such estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and assumptions
include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options,
and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development
efforts. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zMMySFR20SIc">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods
reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of
changes in such estimates in future periods could be significant. Significant areas requiring management&#8217;s estimates and
assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred
investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting
research and development efforts. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z8ih6xEpJN52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z2bBJpwttRF8">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through September 30, 2024, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended September
30, 2024 and 2023, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the unaudited condensed consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zFKLsC1vhXHf">Foreign
Currency Translation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#8217;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#8217; equity as a component of accumulated other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zNjHpvv4Gia">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zz9zwYQJZi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zufsvTMwOUZc">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zNxf3Y69sUla" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zTIEMpIcZPXf" title="Cash insured amount">100,000</span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of September 30, 2024, the Company had greater than $<span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zHuCBoZHjDqi" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, greater than
$<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--AU_zZeRB6GLgRU2" title="Cash FDIC insured amount">250,000</span> at Australian financial institutions, and less than $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zRH1JuJVWiol" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z0Oa78Uy6iHe">Concentration
of Credit Risk</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount">250,000</span> in the United States and Australia and $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount">100,000</span> in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount">250,000</span> at United States financial institutions, less than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount">250,000</span>
at Australian financial institutions, and greater than $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount">100,000</span> at Canadian financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztBjC43QkT38">Comprehensive
Loss</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#8217; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zPkCB4Owiyud">Intangible
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of the Psybrary&#8482; and Patent Applications, In Process Research and Development (&#8220;IPR&amp;D&#8221;) and license
agreements. Psybrary&#8482; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IPR&amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#8217;s
expected future cash flows; a sustained, significant decline in the Company&#8217;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#8217;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zdX7mG65WS1b">Goodwill</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#8217;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property &amp; Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z622SrpvFB74">Property
&amp; Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#8217;s long-lived assets. The estimated
useful lives are typically <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives">3</span> to <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives">5</span> years for office furniture and equipment and are depreciated on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_841_ecustom--DeferredOfferingCostsPolicyTextBlock_zC3UVlYm5iHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zmmelDy6vXh3">Deferred
Offering Costs</span> </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#8217;s consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (&#8220;ASC 340&#8221;) and SAB 5A <i>-
Expenses of Offering</i>. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs">567,603</span> in deferred offering costs in connection with the Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) and the Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability and Investment Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--WarrantLiabilityPolicyTextBlock_zLXVKuvvt2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zH6VWLIKl02j">Warrant
Liability and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#8220;Distinguishing
Liabilities from Equity&#8221; (&#8220;ASC 480&#8221;) and FASB ASC Topic 815, &#8220;Derivatives and Hedging&#8221; (&#8220;ASC 815&#8221;).
The Company accounts for warrants and investment options for shares of the Company&#8217;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock', window );">Modification and Inducement of Warrants and Investment Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_845_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_z7oMqGQu7b2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zHBF6D1y83y9">Modification
and Inducement of Warrants and Investment Options</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#8220;Debt with Conversion and Other
Options&#8221; (&#8220;ASC 470-20-40&#8221;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zBwpH1gx3ZNb">Derivative
Liability</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zr47DZI2OVxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zUgDD5X8Yzl3">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files U.S. federal and state returns. The Company&#8217;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state, and Canadian perspective, the years that remain open to examination are consistent with each jurisdiction&#8217;s
statute of limitations. The Company receives no tax benefit from operating losses due to a full valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zsORoSsW5NTg">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#8217;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#8217;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#8220;unrecognized tax benefits&#8221; is recorded for any tax benefits claimed in the Company&#8217;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#8220;major&#8221; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zVtfgEZ2LSf1">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#8217;s reasonable estimates and involve inherent uncertainties and the application
of management&#8217;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#8217;s common stock on the date of award grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#8217;s
board of directors (the &#8220;Board of Directors&#8221;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#8217;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSU&#8217;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#8217;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#8217;s that vest
immediately are charged to expense on the date awarded, value of RSU&#8217;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#8217;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#8217;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#8217;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#8217;s
engagement with the Company must either be terminated prior to such conversion of RSU&#8217;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#8220;specified
employee&#8221; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#8217;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of RSA&#8217;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#8217;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#8217;s that vest immediately are charged
to expense on the date awarded, value of RSA&#8217;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zqZrJl4CcVT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z1Lg34EJJ6o5">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the three and nine months ended September 30, 2024
and 2023 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same for both
basic and fully diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included
in the calculation of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B7_z5CVvXWyeztg">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2023</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock">56,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock">40,660</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" style="text-align: right" title="Restricted stock units - vested and unissued">1,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" style="text-align: right" title="Restricted stock units - vested and unissued">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" style="text-align: right" title="Restricted stock units - unvested">23,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" style="text-align: right" title="Restricted stock units - unvested">9,884</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" style="text-align: right" title="Investment options to purchase shares of common stock">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" style="text-align: right" title="Investment options to purchase shares of common stock">71,334</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock">1,538</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock">2,124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities">87,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities">125,392</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zEtlBi6f4E33" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zX4N0aihbZJi">Net
Loss per Share</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022 the Company issued <span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zzehumrBJq1i" title="Stock and warrants issued">51,167</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> pre-funded common stock warrants, which were
exercised on various dates during the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26,
2022 based on the terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $<span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_z3Ex19wQ4NN7" title="Warrant exercise price">0.0015</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">these shares are considered outstanding common shares
and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is
virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">186,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0">43,698</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right">9,366</p>
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,271</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,334</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,993</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_ztG9Z6EAI5m2">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value
Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zKPLQOyArmx4">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zouRUznD8kTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zzq57QAfXM98">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zuz1Rz8vQhr9">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#8217;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes a right-of-use asset, which represents the Company&#8217;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#8217;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate<b><i>.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterestPolicyTextBlock', window );">Redeemable Non-controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zkZiVDimAdil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_za6xEu8hPKl1">Redeemable
Non-controlling Interest</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#8220;RNCI&#8221;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zww0mCbaLZc1">Segment
Reporting</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines its reporting units in accordance with FASB ASC 280, &#8220;Segment Reporting&#8221; (&#8220;ASC 280&#8221;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrJYXhzwvHwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zoAJUH5QYSWi">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently assessing the potential impacts of ASU 2023-07, however as the Company
currently has one reportable segment, does not expect this guidance will not have a material impact on its unaudited condensed consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its unaudited condensed consolidated
financial statements and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2024, the FASB issued ASU 2024-03, <i>Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, Disaggregation of Income Statement Expenses</i>, that requires public companies to disclose, in interim and reporting periods,
additional information about certain expenses in the financial statements. The ASU is effective for annual periods beginning after December
15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective
basis or retrospective basis. The Company is currently assessing the potential impacts of ASU 2024-03.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zwwObdI2aaB5">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>Debt&#8212;Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</i> (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#8217;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2023, the FASB issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTxTblgKKu1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zClPDxHjeuxe">Reclassification</span>
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
reclassifications have been made to the prior period&#8217;s unaudited condensed consolidated financial statements in order to conform
to the current year presentation. In the prior year, the Company included certain investor related expenses within research and development
on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses
in the current year. This reclassification had no effect on the Company&#8217;s previously reported results of operations, changes in
equity, or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock', window );">Research and Development Tax Incentive Receivable</a></td>
<td class="text"><p id="xdx_84A_ecustom--ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_zVUb3yNkNg7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zb8BN8cj268a">Research
and Development Tax Incentive Receivable</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program,
such that a percentage of the Company&#8217;s qualifying research and development expenditures are reimbursed by the Australian government,
and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive
is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and
the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the
Company based on available information at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification and Inducement of Warrants and Investment Options [Policy text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest policy [Text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Incentive Receivable [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994895376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">SCHEDULE OF RESTRUCTURING COSTS PAYABLE</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zpFIobmcUyYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Reduction in Force/Restructuring activity and ending balance at September 30, 2024 for the remaining severance
payments included in accrued expenses in the consolidated balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_zdmdhPytwCO" style="display: none">SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-right: 0.5in; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accrued
    Restructuring Costs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif">January 1, 2024 beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20240101__20240930_z2Ef8GLQ4vih" style="width: 14%; text-align: right" title="Restructuring cost payable, beginning"><span style="font-family: Times New Roman, Times, Serif">301,645</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Restructuring costs paid</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--RestructuringCosts_c20240101__20240930_zqX3YtRiw8z1" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs paid"><span style="font-family: Times New Roman, Times, Serif">(301,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024 ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20240101__20240930_zwQfLsOPTXb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--RestructuringCostsIncurred_c20230101__20231231_zEYhLjXcC6Lc" style="width: 16%; text-align: right" title="Restructuring costs incurred">1,004,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs">(572,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs reversed">(129,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889748672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span style="display: none"><span id="xdx_8B7_z5CVvXWyeztg">SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES</span></span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2024</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three and nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30, 2023</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock">56,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock">40,660</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" style="text-align: right" title="Restricted stock units - vested and unissued">1,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" style="text-align: right" title="Restricted stock units - vested and unissued">1,390</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" style="text-align: right" title="Restricted stock units - unvested">23,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" style="text-align: right" title="Restricted stock units - unvested">9,884</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" style="text-align: right" title="Investment options to purchase shares of common stock">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" style="text-align: right" title="Investment options to purchase shares of common stock">71,334</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock">1,538</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock">2,124</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities">87,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities">125,392</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3HM0uaIm6yl" style="display: none">SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Warrants to purchase shares of common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">186,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><p style="margin: 0">43,698</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock units - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,390</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,167</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock units - unvested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right">9,366</p>
</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,271</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted stock awards - vested and unissued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock in abeyance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,934</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment options to purchase shares of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,334</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options to purchase shares of common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,993</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">126,740</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891995030912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ziQiCk2t3pPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024 and December 31, 2023, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zXzvuaP85kP6" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20240930_zcoz1KJCoQJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zapJqSbDhavi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zKrZ6miixm9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">106,138</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,320</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_zFzvo0W6luq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245,972</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,429</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_zu4goeZGb4h8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">249,048</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,559</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zvVKHWyHRBF2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,061</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,036</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_ziA53GvK8xw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs (see Note 7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">508,599</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,603</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zlnv5bhFfkHf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,258</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zpwpikb515y3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2890">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,349</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zodaOt1NZx24" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,226,576</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,293,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zTydFvT6Kuv4" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Prepaid research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">46,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">268,686</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid value-added taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,782</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,406</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,036</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,179</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">567,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0910">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Franchise tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,258</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0913">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">R&amp;D tax incentive receivable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">145,349</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,293,554</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">708,053</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889669104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">SCHEDULE OF GOODWILL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s goodwill consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zywzBm3sR0Xd" style="display: none">SCHEDULE
OF GOODWILL</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Goodwill</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accumulated Impairment Losses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Currency Translation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance">9,834,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance">(8,225,862</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_z6Ico1CR2F3k" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance">(21,359</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance">1,587,634</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zCD5RPP49Kt" style="text-align: right" title="Goodwill Gross, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0933">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_z62rnT8rmnTk" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses">(1,486,060</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zSbfiyEI09me" style="text-align: right" title="Currency Translation, Impairment losses"><span style="-sec-ix-hidden: xdx2ixbrl0937">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses">(1,486,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zg1fcBdDAJz1" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0941">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zUb2cKPLhd02" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_z8TE2v2Adkth" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Loss on currency translation">(101,574</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Ending balance">9,834,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance">(9,711,922</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Ending balance">(122,933</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zEFiR25itP9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024, the Company&#8217;s intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zdH7GSYv7JN4" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Definite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%">Balance at January 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20240101__20240930_zXzhU8vRzC1f" style="width: 16%; text-align: right" title="Balance, Definite lived intangible assets">210,932</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20240101__20240930_zV1sP78Womkd" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">(126,564</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20240101__20240930_z44UqjI2pVDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets">84,368</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the Company&#8217;s indefinite lived intangible assets consisted of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B7_zWEh1BmzLMM6" style="display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Indefinite lived intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; font-weight: bold">Balance at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets">6,375,492</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Impairment losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses">(5,967,602</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Loss on currency translation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1pt solid; text-align: right" title="Loss on currency translation">(407,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Balance at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;</p>



<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; width: 80%">Definite lived intangible assets</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets">548,436</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1pt solid; text-align: right">(168,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold">Balance at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right">379,686</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization">(168,754</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company amortizes definite lived intangible assets on a&#8239;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zzVXkKpEcQPl" style="display: none">SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ending December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">168,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">42,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Finite lived assets amortization
    expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,932</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891995021168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoCW0JWr2PTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada, with all amounts converted into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zyyD3AxBoyy6" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240930_zvOcwkWkXuS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20231231_zzAklmbnG9Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zZqbY38VQNO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">819,784</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">836,709</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zqQ9lVXpV0nh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zkzBYSlzRqa2" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, gross </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,804</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8mcxSLzQ0W8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(479,899</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(357,711</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zAksAuwNXz57" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">367,689</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">507,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#8220;EBCI&#8221;), with all amounts translated into U.S. dollars:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zxF5quYUvBz1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">836,709</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">831,123</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computer equipment and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,379</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,137</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(357,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(178,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net of accumulated depreciation</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">507,377</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">677,485</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889670656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zd1I1uSsF2ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2024 and December 31, 2023, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8B6_zNKkwJIlhEh2" style="display: none">SCHEDULE OF ACCRUED LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240930_zvKzlW1DszQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zcTfVPR5LFYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_z77zAkrTjG7l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">112,346</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">139,981</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zhKdxIdipW0j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,736</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zMeGRmc97SLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,810</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zddf4tXqrQLj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs (see Note 9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2962">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,645</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_zwDevUv4HwWb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2965">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,318</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zZWtGIQEPn21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Patent costs</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zqUxNkAHG3Th" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">253,150</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,075,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B6_z2CYiR69qip9" style="display: none">SCHEDULE
OF ACCRUED LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Product development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">139,981</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">195,104</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued salaries, wages, and bonuses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,175,963</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">584,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,255</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued restructuring costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,645</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1021">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued franchise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,318</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1024">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Patent costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">18,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">251,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,075,643</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,705,655</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891894098768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z67kgDeUvC4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the nine months ended September 30, 2024 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z3alfNBYzdpj" style="display: none">SCHEDULE OF STOCK OPTION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; padding-bottom: 1pt">Outstanding at December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zZW4nPRH5Mh3" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of shares, outstanding at beginning">2,022</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zAPsEeKm3Wsi" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, outstanding at beginning">857.55</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930_zdSYfF4AjHx6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, outstanding at beginning">1,158.30</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zmJUkZMdSS5" title="Weighted average remaining contractual term, outstanding balance">3.4</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_z6DDR6QXTCol" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning"><span style="-sec-ix-hidden: xdx2ixbrl3064">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930_zGyDNncyr5zd" style="text-align: right" title="Number of shares, granted"><span style="-sec-ix-hidden: xdx2ixbrl3066">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zdXm97VM8Oqj" style="text-align: right" title="Weighted average exercise price, granted"><span style="-sec-ix-hidden: xdx2ixbrl3068">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zVr3xDBu5KQ7" style="text-align: right" title="Weighted average grant date fair value, granted"><span style="-sec-ix-hidden: xdx2ixbrl3070">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zCk41xdSAlQc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(484</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zAtJuWhyGd0c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">590.25</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zOdybsNqZRfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">810.30</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_ztGb06PyFRPh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, outstanding at end">1,538</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zOJratgg199g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end">941.55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zPgNtNP9oxsh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, outstanding at end">1,267.65</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwyipFQlqdic" title="Weighted average remaining contractual term, outstanding balance">2.6</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_zCRR4NZamkL9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, outstanding at end"><span style="-sec-ix-hidden: xdx2ixbrl3086">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_z6UC9WKyhkK9" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end">1,477</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zvPkT2It5xdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end">979.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zy4Bot6yFpwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable">1,319.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zdxHrNr9o8Xk" title="Weighted average remaining contractual term, exercisable">2.2</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zRjNsH3idAti" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl3096">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the stock option activity under the Company&#8217;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zu3hZq6igFI4" style="display: none">SCHEDULE OF STOCK OPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning">1,589</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">1,185</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">1,552.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)">5.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding">34,333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted">1,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted">46.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted">38.70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin-top: 0; margin-bottom: 0"><span></span></p>
                                                                          <p style="margin-top: 0; margin-bottom: 0"><span>&#160;</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(67</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">2,625</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">2,107.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at beginning">3,222</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning">555.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning">672.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1155">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited">(1,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited">46.05</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited">38.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at end">2,022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end">857.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end">1,158.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance">3.4</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end">1,712</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end">966.75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable">1,330.80</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable">2.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF STOCK OPTION ASSUMPTION</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zR9P2uQxAng7" style="display: none">SCHEDULE OF STOCK OPTION ASSUMPTION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_z0OXoTSTaL7h" title="Stock price">46.05</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price">46.05</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility">112.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate">3.9</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zoide0sTJXC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the nine months ended September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQpY2rCnrVg8" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average fair value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSDvnYRjVNsa" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning">9,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1F1H1syKVd" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning">434.55</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkidLJxfe9Q7" style="text-align: right" title="Number of shares, Granted">16,767</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3neHKhmj2c" style="text-align: right" title="Weighted average fair value, Granted">12.75</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3Vg6jd5reqj" style="text-align: right" title="Number of shares, Forfeited">(650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAmEm1RiI2tg" style="text-align: right" title="Weighted average fair value, Forfeited">43.05</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTolNPfIHg9j" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested">(2,042</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zph55MgT0j7d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested">333.30</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVQeX1FIO7Xc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending">23,441</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTVyBNeKeyEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending">152.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s activity in restricted stock units was as follows for the year ended December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zOnUfbNkVcx6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average<br/>
 fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Non-vested at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning">4,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning">1,890</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted">2,497</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted">502.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited">(1,785</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited">1,194.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Vested">(576</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested">1,958.25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Non-vested at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning">4,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning">1,388.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted">12,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted">40.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited">(2,896</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited">385.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested">(4,176</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested">297.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Non-vested at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending">9,366</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending">434.55</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zTOfSM9LLUo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B0_zUqL5Ly2R5Wg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Stock-based compensation expense for RSUs:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20240701__20240930_zmodFPmdDlIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20230930_zs4PFiYdjkd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20240930_zmf0cVH1oD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20230930_zZEsJ47Nk5Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">Stock-based compensation expense for RSUs:</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKUvRCyrlXe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">162,042</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">101,607</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">476,513</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">946,851</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy5GdtVHSVb2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">207,158</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">226,646</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">620,057</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">691,514</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zH3A95M0sis8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">369,200</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">328,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,570</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,638,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_zIQQsMnjkR3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Stock-based compensation
    expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">369,200</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">328,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,096,570</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,638,365</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s recognition of stock-based compensation for restricted stock units for the following periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zwVhDWsRp68h" style="display: none">SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense for RSUs:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,085,791</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,389,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">908,294</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,026,907</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Stock-based compensation expense for RSUs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,994,085</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,416,266</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ScheduleOfWarrantsOutstandingTableTextBlock', window );">SCHEDULE OF WARRANTS OUTSTANDING</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zRDuE51nVwug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_z71NbaE89wo7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF WARRANTS OUTSTANDING</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Outstanding at December 31, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk17tpUEWLX" style="width: 12%; text-align: right" title="Warrant shares outstanding at beginning">186,614</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq56AKA0bj4h" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding at beginning">176.85</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUDMMylc2Y6" title="Weighted average remaining life, outstanding">4.6</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztviImRtgzRi" style="width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl3169">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLbx3ZUsJf3b" style="text-align: right" title="Warrant shares outstanding,expired">(39</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfKAFC3BlLMa" style="text-align: right" title="Weighted average exercise price, expired">2,400.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQCb5deT9I3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, exercised">(130,267</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAy3hDRC9Wj5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised">20.55</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziYaK0NDJNMe" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end">56,308</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA2daHh19Sa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end">536.70</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrcQaXQIW2If" title="Weighted average remaining life, outstanding">3.0</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z80MZv9WG0j2" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding ending"><span style="-sec-ix-hidden: xdx2ixbrl3185">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEU0VfgR2f3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, exercisable">56,308</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKD79Pj5ptJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">536.70</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Gvlbmlniod" title="Weighted average remaining life, exercisable">3.0</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wRhNTAjbr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl3193">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none">SCHEDULE
OF WARRANTS OUTSTANDING</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant shares outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Outstanding at January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning">13,031</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning">1,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding">3.4</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning">801,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFVujb1NhHh3" style="text-align: right" title="Warrant shares outstanding, Issued">81,834</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued">154.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised">(51,167</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchanged for common stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBqLrW0x4Do" style="border-bottom: Black 1pt solid; text-align: right" title="Exchanged for common stock"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning">43,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning">875.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding">3.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning">5,514</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI6yD0x3nmf" style="text-align: right" title="Warrant shares outstanding, Issued">154,088</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued">20.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised">(8,134</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised">20.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, Forfeited">(3,038</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPOuapURS518" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1,672.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end">186,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end">176.85</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding">4.6</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable">186,614</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">176.85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable">4.6</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRHQg5nAtHC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zpBIF7iGXfLf" style="display: none">SCHEDULE OF   INVESTMENT OPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 1pt">Outstanding at December 31, 2023</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7C4CTJ0as81" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment options outstanding, beginning">4,667</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zwpju5CZtKp8" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted average exercise price, issued">150.00</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_ziyuoHOnTHS7" title="Weighted average remaining life, outstanding">4.1</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zpqBJPNNsSzc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl3203">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zrCGOj1W0Is1" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end">4,667</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zZ4hyedUtGYe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, issued">150.00</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zU4T0rv80XJl" title="Weighted average remaining life, outstanding">2.9</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zAZK6Fg6sJZ3" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl3211">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zRhtKwHprZp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, exercisable">4,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z3GskQ71Ikse">150.00</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zmmJiJ55bMeg" title="Weighted average remaining life, exercisable">2.9</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zcGeBdKJuGgj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl3218">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zXmcUZK6ggX1" style="display: none">SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Investment options outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted average remaining life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1350">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zGMM0alY6k46" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; padding-bottom: 1.5pt">Issued</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued">71,334</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued">118.95</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right">&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning">71,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning">118.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding">5.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"><span style="-sec-ix-hidden: xdx2ixbrl1366">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, Exercised">(66,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zYmM8O9U70xg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised">20.55</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end">4,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding end">150.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, Outstanding end"><span style="-sec-ix-hidden: xdx2ixbrl1378">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable">4,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end">150.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable">4.1</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zgN7qwVdAb5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1386">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ScheduleOfValuationOfWarrantsTextBlock', window );">SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zKA67bcbOmMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zy2L3wh6IEsj" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Roth and Inducement Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 28, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z3AuGTsHI5pl" title="Stock price">23.40</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z0UvQEgSl08f" title="Exercise price">20.55</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility">92.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate">3.80</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants">154,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zGfIo4VzY1I" style="text-align: right" title="Value (per share)">17.40</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ScheduleOfValuationOfWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Valuation Of Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ScheduleOfValuationOfWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrants outstanding [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994990592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract', window );"><strong>Redeemable Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the reconciliation of changes in redeemable non-controlling interest:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zjoodKpMYtk6" style="display: none">SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Balance at December 31, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance">885,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Preferred dividends attributable to redeemable non-controlling interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock">19,041</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value">147,988</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Redemption of Akos Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock">(1,052,057</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureRedeemableNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45892000994064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none">SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeMO13hylIPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Warrant liabilities - January 2021 Warrants</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">81</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTOpwQ8OG55f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant liabilities - February 2021 Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwTQbM3dQLe9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Warrant liabilities - February 2022 Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">25,462</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">185,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9i5VrFNGzB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of warrant liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zMdkWlrsIj62" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; padding-bottom: 1.5pt">Derivative liability - May 2022</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 10%; text-align: center">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1524">&#8212;</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">727,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEFcbOFbmgyj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">727,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zSWqu8SwspQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Wainwright investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">23,608</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">44,904</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zWIcJvLDtsLe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">RD investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1533">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">302,289</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z1YCCLCqkbX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">PIPE investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">503,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziutXKvlcfW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Fair value of investment option liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">851,008</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BA_zyGP5uMpiwf9" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">February 2022 Post-Modification Warrants (See Note 7)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 15, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zVPjfhQ1hMA5" title="Warrants term">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_z7auqGCNbdGa" title="Warrants term">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price">236.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price">94.95</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price">412.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price">116.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1556">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1558">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zIpLsb0r9873" title="Warrants, measurement input">74.1</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zEbPX8XFb5Ej" title="Warrants, measurement input">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zsu2orPGxhM7" title="Warrants, measurement input">1.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zYZ9cMkF2kc9" title="Warrants, measurement input">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants">30,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants">8,134</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)">120.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)">61.05</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">May 2022 Derivative Liability</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">May 5, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Principal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zaAv4G5sSCic" style="width: 23%; text-align: right" title="Principal">1,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate">5.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zfdU1bv2Iu1d" style="text-align: right" title="Market rate">4.4</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Wainwright Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">RD Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">PIPE Options</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">July 26, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z65GnhDKxrH1">5.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg">5.5</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price">94.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94.95</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94.95</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zjD6zOtXxyef" style="text-align: right" title="Investment, exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">150.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116.70</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116.70</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1597">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1599">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1601">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb">80.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9">80.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi">2.9</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh">2.9</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,667</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,667</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.05</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61.05</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zGwJ3NUryGMb" style="display: none">SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 2021 Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">February 2022 Warrants Unmodified</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zFeN4U2oQbMg" title="Investment option term">2.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z9qSoxj865ti" title="Investment option term">2.1</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zHqUQQehlCYb" title="Investment option term">3.1</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za7OVDZZzYCl" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,712.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,675.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">412.50</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1685">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1687">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1689">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input">89.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input">88.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input">87.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input">4.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input">4.00</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Number of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,429</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,286</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,534</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">H.C. Wainwright &amp; Co., LLC Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Term (years)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2h5WTjUaE" title="Investment option term">3.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price">19.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zYJQsZKqOizg" style="text-align: right" title="Investment, exercise price">150.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"><span style="-sec-ix-hidden: xdx2ixbrl1721">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input">94.0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input">4.00</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Number of investment options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options">4,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Value (per share)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)">5.10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zXzjxOoiQ9Qg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zf0YvucZm167" style="display: none">SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Warrant Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 73%">Fair value as of December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance">653,674</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of February 2022 warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity">3,595,420</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value due to modification of February 2022 warrants as part of July 2022 raise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification">251,357</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(4,315,236</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance">185,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value">(94,396</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRprDXlaTIXd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of warrants">(65,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance">25,470</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Derivative Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1639">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%; text-align: left; padding-bottom: 1.5pt">Issuance of May 2022 convertible preferred stock</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity">402,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">325,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance">727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(727,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Fair value of derivative liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1649">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Investment Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Fair value as of December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1651">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 73%">Issuance of July 2022 investment options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity">4,323,734</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(3,472,726</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance">851,008</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value">(208,752</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercise of investment options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVIt6yDO5kC9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of investment options">(618,648</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Fair value of investment option liability as of December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance">23,608</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_InitialMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889183648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock', window );">SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zWHvKLl07Vnb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_zQfu0TOu6lia" style="display: none">SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Remaining lease term (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">Operating leases</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term">0.6</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate">12.0</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zpFIobmcUyYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Reduction in Force/Restructuring activity and ending balance at September 30, 2024 for the remaining severance
payments included in accrued expenses in the consolidated balance sheet:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_zdmdhPytwCO" style="display: none">SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-right: 0.5in; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accrued
    Restructuring Costs</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%"><span style="font-family: Times New Roman, Times, Serif">January 1, 2024 beginning balance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20240101__20240930_z2Ef8GLQ4vih" style="width: 14%; text-align: right" title="Restructuring cost payable, beginning"><span style="font-family: Times New Roman, Times, Serif">301,645</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Restructuring costs paid</span></td><td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--RestructuringCosts_c20240101__20240930_zqX3YtRiw8z1" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs paid"><span style="font-family: Times New Roman, Times, Serif">(301,645</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">September 30, 2024 ending balance</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20240101__20240930_zwQfLsOPTXb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl3256">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_ztulwBwkUNX1" style="display: none">SCHEDULE
OF RESTRUCTURING COSTS PAYABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Accrued<br/>
Restructuring Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>January 1, 2023 Beginning balance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: left">Restructuring costs incurred</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--RestructuringCostsIncurred_c20230101__20231231_zEYhLjXcC6Lc" style="width: 16%; text-align: right" title="Restructuring costs incurred">1,004,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restructuring costs paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs">(572,628</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Restructuring costs reversed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs reversed">(129,760</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">December 31, 2023 ending balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending">301,645</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Weighted Average Remaining Lease Term [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994939744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zeA4xpukjyji" style="display: none">SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(10,205,116</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(7,251,228</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7,057,703</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,706,165</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(17,262,819</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,957,393</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF INCOME TAX EXPENSE BENEFITS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4LFMffO1bGa" style="display: none">SCHEDULE
OF INCOME TAX EXPENSE BENEFITS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">Current:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1787">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(28,913</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1793">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"> Total
    current income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(28,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1799">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1801">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1804">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred income tax (expense) benefit</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1807">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,486,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,913</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,486,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s deferred tax assets and deferred tax liabilities consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B9_zVn0082ZSHDi" style="display: none">SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,889,863</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,927,330</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,185,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,348,928</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_zeLuldfIHLJk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development capitalized expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">614,041</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_z3vKEWbpo3wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,730</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,453</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowances</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,837,755</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,977,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1833">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1834">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">SCHEDULE OF OPERATING LOSS CARRY FORWARDS</a></td>
<td class="text"><p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially utilizable net operating loss tax carryforwards:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt3NjQUFsfF" style="display: none">SCHEDULE
OF OPERATING LOSS CARRY FORWARDS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Federal</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">24,268,692</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">18,349,753</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White">
    <td>State</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,220,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,892,754</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Foreign</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net operating loss tax carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,672,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,377,435</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s effective tax rate varied from the statutory rate as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none">SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Federal income tax at the statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 3%; text-align: left">)%</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax rate (net of federal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.2</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.6</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign tax rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.0</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.1</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-deductible expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zBQrMCzaAaZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1870">&#8212;</span></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(7.4</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45892010395200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost payable, beginning</a></td>
<td class="nump">$ 301,645<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RestructuringCostsIncurred', window );">Restructuring costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs</a></td>
<td class="num">(301,645)<span></span>
</td>
<td class="num">(572,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Restructuring costs reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost payable, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 301,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RestructuringCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RestructuringCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891893399888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2025</div></th>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Jun. 16, 2023</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 16, 2024</div></th>
<th class="th"><div>Nov. 21, 2023</div></th>
<th class="th"><div>Nov. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,919,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,919,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,499,518<span></span>
</td>
<td class="nump">$ 79,207,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,414,590<span></span>
</td>
<td class="nump">$ 12,343,363<span></span>
</td>
<td class="nump">14,094,411<span></span>
</td>
<td class="nump">17,146,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,083,192<span></span>
</td>
<td class="nump">$ 3,448,395<span></span>
</td>
<td class="nump">6,458,440<span></span>
</td>
<td class="nump">14,064,080<span></span>
</td>
<td class="nump">16,448,440<span></span>
</td>
<td class="nump">27,415,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,499,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,499,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants for cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,676,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reversed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange', window );">Minimum of stockholders equity required for continued listing pursuant to exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,919,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,919,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,499,518)<span></span>
</td>
<td class="num">(79,207,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,414,590)<span></span>
</td>
<td class="num">(12,343,363)<span></span>
</td>
<td class="num">(14,094,411)<span></span>
</td>
<td class="num">(17,146,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,083,192)<span></span>
</td>
<td class="num">$ (3,448,395)<span></span>
</td>
<td class="num">$ (6,458,440)<span></span>
</td>
<td class="num">$ (14,064,080)<span></span>
</td>
<td class="num">(16,448,440)<span></span>
</td>
<td class="num">$ (27,415,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_MarketPerformanceBasedShares', window );">Market performance based shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants for cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercise of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Additional working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_KanubaddiSeparationAgreementMember', window );">Kanubaddi Separation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Performance bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_MrKanubaddiEmploymentAgreementMember', window );">Mr Kanubaddi Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ExpenseRelatedToAccelerationOfVesting', window );">Expense related to acceleration of vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ExpenseRelatedToAccelerationOfVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense related to acceleration of vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ExpenseRelatedToAccelerationOfVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_MarketPerformanceBasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Market performance based shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_MarketPerformanceBasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum of stockholders equity required for continued listing pursuant to exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_KanubaddiSeparationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_KanubaddiSeparationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_MrKanubaddiEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_MrKanubaddiEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891995040528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">87,323<span></span>
</td>
<td class="nump">125,392<span></span>
</td>
<td class="nump">87,323<span></span>
</td>
<td class="nump">125,392<span></span>
</td>
<td class="nump">250,993<span></span>
</td>
<td class="nump">126,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_WarrantsToPurchaseSharesOfCommonStockMember', window );">Warrants to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">56,308<span></span>
</td>
<td class="nump">40,660<span></span>
</td>
<td class="nump">56,308<span></span>
</td>
<td class="nump">40,660<span></span>
</td>
<td class="nump">186,614<span></span>
</td>
<td class="nump">43,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsVestedAndUnIssuedMember', window );">Restricted Stock Units Vested and Unissued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsUnvestedMember', window );">Restricted Stock Units Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">23,441<span></span>
</td>
<td class="nump">9,884<span></span>
</td>
<td class="nump">23,441<span></span>
</td>
<td class="nump">9,884<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
<td class="nump">4,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockAwardsVestedAndUnIssuedMember', window );">Restricted Stock Awards Vested and Unissued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_CommonStockInAbeyanceMember', window );">Common Stock in Abeyance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember', window );">Investment Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_OptionsToPurchaseSharesOfCommonStockMember', window );">Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">2,124<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember', window );">Investment Options to Purchase Shares of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive securities</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_WarrantsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_WarrantsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsVestedAndUnIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsVestedAndUnIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockUnitsUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockAwardsVestedAndUnIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_RestrictedStockAwardsVestedAndUnIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_CommonStockInAbeyanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_CommonStockInAbeyanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_OptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_OptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891894133504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 508,599<span></span>
</td>
<td class="nump">$ 567,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_PrefundedCommonStockWarrantsMember', window );">Prefunded Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock and warrants issued</a></td>
<td class="nump">$ 51,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.0015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">AUSTRALIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENVB_PrefundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENVB_PrefundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994890288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">$ 106,138<span></span>
</td>
<td class="nump">$ 46,320<span></span>
</td>
<td class="nump">$ 268,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid value-added taxes</a></td>
<td class="nump">245,972<span></span>
</td>
<td class="nump">243,429<span></span>
</td>
<td class="nump">159,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">249,048<span></span>
</td>
<td class="nump">149,559<span></span>
</td>
<td class="nump">174,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">99,061<span></span>
</td>
<td class="nump">62,036<span></span>
</td>
<td class="nump">105,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs (see Note 7)</a></td>
<td class="nump">508,599<span></span>
</td>
<td class="nump">567,603<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidFranchiseTaxReceivable', window );">Franchise tax receivable</a></td>
<td class="nump">17,758<span></span>
</td>
<td class="nump">79,258<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable', window );">R&amp;D tax incentive receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">145,349<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,226,576<span></span>
</td>
<td class="nump">$ 1,293,554<span></span>
</td>
<td class="nump">$ 708,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidFranchiseTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid franchise tax receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidFranchiseTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development tax incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889841328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GOODWILL (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill Gross, Beginning balance</a></td>
<td class="nump">$ 9,834,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated Impairment Losses, Beginning balance</a></td>
<td class="num">(8,225,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslation', window );">Currency Translation, Beginning balance</a></td>
<td class="num">(21,359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning balance</a></td>
<td class="nump">1,587,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillImpairmentLossGross', window );">Goodwill Gross, Impairment losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillAccumulatedImpairmentLoss', window );">Accumulated Impairment Losses, Impairment losses</a></td>
<td class="num">(1,486,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslationImpairmentLoss', window );">Currency Translation, Impairment losses</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment losses</a></td>
<td class="num">(1,486,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillForeignCurrencyTranslationGainLossGross', window );">Goodwill Gross, Loss on currency translation</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss', window );">Accumulated Impairment Losses, Loss on currency translation</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslationLoss', window );">Currency Translation, Loss on currency translation</a></td>
<td class="num">(101,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Goodwill, Loss on currency translation</a></td>
<td class="num">(101,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill Gross, Ending balance</a></td>
<td class="nump">9,834,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated Impairment Losses, Ending balance</a></td>
<td class="num">(9,711,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_GoodwillCurrencyTranslation', window );">Currency Translation, Ending balance</a></td>
<td class="num">(122,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill accumulated impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill accumulated impairment loss foreign currency translation gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillCurrencyTranslationImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill currency translation impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillCurrencyTranslationImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillCurrencyTranslationLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill currency translation loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillCurrencyTranslationLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillForeignCurrencyTranslationGainLossGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill foreign currency translation gain loss gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillForeignCurrencyTranslationGainLossGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_GoodwillImpairmentLossGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill impairment loss gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_GoodwillImpairmentLossGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891892004544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Balance, Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,375,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,967,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Loss on currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Balance, Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Balance, Definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,932<span></span>
</td>
<td class="nump">379,686<span></span>
</td>
<td class="nump">379,686<span></span>
</td>
<td class="nump">548,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">$ (42,188)<span></span>
</td>
<td class="num">$ (42,191)<span></span>
</td>
<td class="num">(126,564)<span></span>
</td>
<td class="num">$ (126,566)<span></span>
</td>
<td class="num">(168,754)<span></span>
</td>
<td class="num">(168,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Balance, Definite lived intangible assets</a></td>
<td class="nump">$ 84,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,932<span></span>
</td>
<td class="nump">$ 379,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994931632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived assets amortization expense</a></td>
<td class="nump">$ 84,368<span></span>
</td>
<td class="nump">$ 210,932<span></span>
</td>
<td class="nump">$ 379,686<span></span>
</td>
<td class="nump">$ 548,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891893624304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets, amortization expense</a></td>
<td class="nump">$ 42,188<span></span>
</td>
<td class="nump">$ 42,191<span></span>
</td>
<td class="nump">$ 126,564<span></span>
</td>
<td class="nump">$ 126,566<span></span>
</td>
<td class="nump">$ 168,754<span></span>
</td>
<td class="nump">$ 168,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Identified definite lived assets, impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891890317136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">$ (479,899)<span></span>
</td>
<td class="num">$ (357,711)<span></span>
</td>
<td class="num">$ (178,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation</a></td>
<td class="nump">367,689<span></span>
</td>
<td class="nump">507,377<span></span>
</td>
<td class="nump">677,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">819,784<span></span>
</td>
<td class="nump">836,709<span></span>
</td>
<td class="nump">831,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_ComputerEquipmentAndLeaseholdImprovementsMember', window );">Computer Equipment and Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 27,804<span></span>
</td>
<td class="nump">$ 28,379<span></span>
</td>
<td class="nump">$ 25,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_ComputerEquipmentAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_ComputerEquipmentAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889910688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 42,626<span></span>
</td>
<td class="nump">$ 44,105<span></span>
</td>
<td class="nump">$ 128,438<span></span>
</td>
<td class="nump">$ 132,734<span></span>
</td>
<td class="nump">$ 175,228<span></span>
</td>
<td class="nump">$ 159,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891894371376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccruedProductDevelopmentCost', window );">Product development</a></td>
<td class="nump">$ 112,346<span></span>
</td>
<td class="nump">$ 139,981<span></span>
</td>
<td class="nump">$ 195,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries, wages, and bonuses</a></td>
<td class="nump">8,736<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
<td class="nump">1,175,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">114,068<span></span>
</td>
<td class="nump">584,810<span></span>
</td>
<td class="nump">83,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_AccruedRestructuringCosts', window );">Accrued restructuring costs (see Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">301,645<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued franchise taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,318<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Patent costs</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">251,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 253,150<span></span>
</td>
<td class="nump">$ 1,075,643<span></span>
</td>
<td class="nump">$ 1,705,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccruedProductDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued product and development cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccruedProductDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_AccruedRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_AccruedRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891890428512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding at beginning</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at beginning</a></td>
<td class="nump">$ 857.55<span></span>
</td>
<td class="nump">$ 555.75<span></span>
</td>
<td class="nump">$ 1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, outstanding at beginning</a></td>
<td class="nump">$ 1,158.30<span></span>
</td>
<td class="nump">$ 672.30<span></span>
</td>
<td class="nump">$ 1,552.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding balance</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 46.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, forfeited</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 590.25<span></span>
</td>
<td class="nump">$ 46.05<span></span>
</td>
<td class="nump">$ 2,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited</a></td>
<td class="nump">$ 810.30<span></span>
</td>
<td class="nump">$ 38.70<span></span>
</td>
<td class="nump">$ 2,107.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, outstanding at end</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at end</a></td>
<td class="nump">$ 941.55<span></span>
</td>
<td class="nump">$ 857.55<span></span>
</td>
<td class="nump">$ 555.75<span></span>
</td>
<td class="nump">$ 1,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, outstanding at end</a></td>
<td class="nump">$ 1,267.65<span></span>
</td>
<td class="nump">$ 1,158.30<span></span>
</td>
<td class="nump">$ 672.30<span></span>
</td>
<td class="nump">$ 1,552.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable shares at end</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">1,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable weighted average price at end</a></td>
<td class="nump">$ 979.50<span></span>
</td>
<td class="nump">$ 966.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, exercisable</a></td>
<td class="nump">$ 1,319.70<span></span>
</td>
<td class="nump">$ 1,330.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding at end</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, expired, forfeited, or cancelled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value, outstanding at beginning of the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891898228656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ASSUMPTION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 46.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 46.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889845424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Non-vested beginning</a></td>
<td class="nump">9,366<span></span>
</td>
<td class="nump">4,271<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Non-vested beginning</a></td>
<td class="nump">$ 434.55<span></span>
</td>
<td class="nump">$ 1,388.55<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Granted</a></td>
<td class="nump">16,767<span></span>
</td>
<td class="nump">12,167<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Granted</a></td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="nump">$ 40.95<span></span>
</td>
<td class="nump">$ 502.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited</a></td>
<td class="num">(650)<span></span>
</td>
<td class="num">(2,896)<span></span>
</td>
<td class="num">(1,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Forfeited</a></td>
<td class="nump">$ 43.05<span></span>
</td>
<td class="nump">$ 385.80<span></span>
</td>
<td class="nump">$ 1,194.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="num">(2,042)<span></span>
</td>
<td class="num">(4,176)<span></span>
</td>
<td class="num">(576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Vested</a></td>
<td class="nump">$ 333.30<span></span>
</td>
<td class="nump">$ 297.00<span></span>
</td>
<td class="nump">$ 1,958.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, non-vested ending</a></td>
<td class="nump">23,441<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
<td class="nump">4,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value, Non-vested ending</a></td>
<td class="nump">$ 152.55<span></span>
</td>
<td class="nump">$ 434.55<span></span>
</td>
<td class="nump">$ 1,388.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45892000952208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for RSUs</a></td>
<td class="nump">$ 369,200<span></span>
</td>
<td class="nump">$ 328,253<span></span>
</td>
<td class="nump">$ 1,096,570<span></span>
</td>
<td class="nump">$ 1,638,365<span></span>
</td>
<td class="nump">$ 1,994,085<span></span>
</td>
<td class="nump">$ 2,416,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for RSUs</a></td>
<td class="nump">162,042<span></span>
</td>
<td class="nump">101,607<span></span>
</td>
<td class="nump">476,513<span></span>
</td>
<td class="nump">946,851<span></span>
</td>
<td class="nump">1,085,791<span></span>
</td>
<td class="nump">1,389,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense for RSUs</a></td>
<td class="nump">$ 207,158<span></span>
</td>
<td class="nump">$ 226,646<span></span>
</td>
<td class="nump">$ 620,057<span></span>
</td>
<td class="nump">$ 691,514<span></span>
</td>
<td class="nump">$ 908,294<span></span>
</td>
<td class="nump">$ 1,026,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891892972240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS OUTSTANDING (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">186,614<span></span>
</td>
<td class="nump">43,698<span></span>
</td>
<td class="nump">13,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at beginning</a></td>
<td class="nump">$ 176.85<span></span>
</td>
<td class="nump">$ 875.40<span></span>
</td>
<td class="nump">$ 1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life, outstanding</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,514<span></span>
</td>
<td class="nump">$ 801,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued', window );">Warrant shares outstanding, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,088<span></span>
</td>
<td class="nump">81,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice', window );">Weighted average exercise price, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="nump">$ 154.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrant shares outstanding, exercised</a></td>
<td class="num">(130,267)<span></span>
</td>
<td class="num">(8,134)<span></span>
</td>
<td class="num">(51,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged', window );">Exchanged for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Warrant shares outstanding, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,672.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">56,308<span></span>
</td>
<td class="nump">186,614<span></span>
</td>
<td class="nump">43,698<span></span>
</td>
<td class="nump">13,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at end</a></td>
<td class="nump">$ 536.70<span></span>
</td>
<td class="nump">$ 176.85<span></span>
</td>
<td class="nump">$ 875.40<span></span>
</td>
<td class="nump">$ 1,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Warrant shares outstanding, exercisable</a></td>
<td class="nump">56,308<span></span>
</td>
<td class="nump">186,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 536.70<span></span>
</td>
<td class="nump">$ 176.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption', window );">Weighted average remaining life, exercisable</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,514<span></span>
</td>
<td class="nump">$ 801,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Warrant shares outstanding,expired</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice', window );">Weighted average exercise price, expired</a></td>
<td class="nump">$ 2,400.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested', window );">Intrinsic value, exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant shares outstanding, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their warrants into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options exercises in period weighted average expired price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options forfeited in eriod weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award equity instruments non options exercisable aggregate intrinsic value nonvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891892415856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details) - Investment Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted average exercise price, Outstanding beginning</a></td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="nump">$ 118.95<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued', window );">Investment options outstanding, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice', window );">Weighted average exercise price, Issued</a></td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life, Outstanding</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Investment options outstanding, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised', window );">Weighted average exercise price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted average exercise price, Outstanding end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="nump">$ 118.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Warrant shares outstanding, exercisable</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption', window );">Weighted average remaining life, Exercisable</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1', window );">Intrinsic value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant shares outstanding, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options, outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_InvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_InvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891890216832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_RothAndInducementWarrantsMember', window );">Roth and Inducement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice', window );">Stock price</a></td>
<td class="nump">$ 23.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants</a></td>
<td class="nump">154,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 17.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_RothAndInducementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_RothAndInducementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891797263360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 09, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 03, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 26, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 22, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 14, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 03, 2022</div></th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 27, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 02, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 14, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
holders of the Company&#8217;s common stock are entitled to one vote per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 567,603<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued stock value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290,186<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,222,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Incentive plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
increase the aggregate number of shares available for the grant of awards by 9,739 shares to a total of 13,334 shares,
and (ii) add an &#8220;evergreen&#8221; provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive
Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of common
stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company&#8217;s common stock
authorized for issuance under the Incentive Plan will equal the greater of (x) 13,334 shares, and (y) 15% of the total number
of shares of the Company&#8217;s common stock outstanding as of such issuance date (the &#8220;Evergreen Provision&#8221;). The Plan
Amendment was approved by the Company&#8217;s shareholders at a special meeting of the Company&#8217;s shareholders held on July 14,
2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,096,570<span></span>
</td>
<td class="nump">1,638,365<span></span>
</td>
<td class="nump">1,994,085<span></span>
</td>
<td class="nump">2,416,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offerings costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,461<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">$ 291,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,676,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ClassOfWarrantOrRightReasonForIssuing', window );">[custom:ClassOfWarrantOrRightReasonForIssuing]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to act as its financial advisor in connection with the transactions summarized
above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth was also issued
warrants to purchase up to 4,488 shares of common stock. The Roth Warrants have the same terms as the Inducement Warrants. The
grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to additional paid in
capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that were charged to additional
paid in capital as issuance costs.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,599,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,722)<span></span>
</td>
<td class="nump">115,342<span></span>
</td>
<td class="num">$ (94,396)<span></span>
</td>
<td class="num">(4,315,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_CommonStockEquityDistributionCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,029<span></span>
</td>
<td class="nump">$ 82,850<span></span>
</td>
<td class="nump">$ 583,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares</a></td>
<td class="nump">25,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,817,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryWarrantsMember', window );">February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionSharePrice', window );">[custom:InvestmentOptionSharePrice] | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionExercisePrice', window );">[custom:InvestmentOptionExercisePrice] | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">[custom:InvestmentOptionTerm]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharePriceOption', window );">[custom:SharePriceOption-0] | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre Modification Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOutstandingMeasurementInput', window );">[custom:InvestmentOutstandingMeasurementInput-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre Modification Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOutstandingMeasurementInput', window );">[custom:InvestmentOutstandingMeasurementInput-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember', window );">Pre Modification Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOutstandingMeasurementInput', window );">[custom:InvestmentOutstandingMeasurementInput-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PostModificationWarrantsMember', window );">Post Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentIntrinsicValue', window );">[custom:InvestmentIntrinsicValue] | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentInducementGain', window );">[custom:InvestmentInducementGain] | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | February Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,854<span></span>
</td>
<td class="nump">147,067<span></span>
</td>
<td class="nump">$ 156,075<span></span>
</td>
<td class="nump">180,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized stock option expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Common stock vested restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid', window );">Unissued shares for cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NumberOfVestedAndUnissuedShares', window );">Number of vested and unissued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,096,570<span></span>
</td>
<td class="nump">$ 1,638,365<span></span>
</td>
<td class="nump">$ 1,994,085<span></span>
</td>
<td class="nump">$ 2,416,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized stock option expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,021,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Common stock vested restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,176<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember', window );">Existing Warrants [Member] | Pre Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember', window );">Existing Warrants [Member] | Post Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember', window );">Investment Options [Member] | Pre Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember', window );">Investment Options [Member] | Post Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ENVB_TwoThousandTwentyLongTermIncentivePlanMember', window );">2020 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized shares reserved | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ENVB_RDOfferingAndPIPEInvestmentOptionsMember', window );">RD Offering and Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from RD offerings | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfStockIssuanceCost', window );">Offerings costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfAllocatedEquity', window );">Payments of allocated equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfInvestmentOptionLiability', window );">Payments of investment option liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PaymentsOfStockIssuanceCostsRecordedExpense', window );">Payments of stock issuance costs recorded expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offerings costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,684.548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred Stock authorized for future issuances | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ENVB_UnderwritersMember', window );">Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercised of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantLiability', window );">Warrant liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ENVB_BoardMember', window );">Board [Member] | 2020 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued stock value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common shares in exchange for RSU conversions, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards', window );">Stock issued during period conversion of restricted stock award | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares resale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares other | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,669<span></span>
</td>
<td class="nump">525,245<span></span>
</td>
<td class="nump">486,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,465<span></span>
</td>
<td class="nump">142,789<span></span>
</td>
<td class="nump">599,669<span></span>
</td>
<td class="nump">145,465<span></span>
</td>
<td class="nump">182,625<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Common stock vested restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights', window );">Purchase of additional warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ENVB_PlacementAgentPreferredInvestmentOptionsMember', window );">Placement Agent Preferred Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember', window );">Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember', window );">Distribution Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Common stock, offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,320,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares resale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember', window );">Distribution Agreement [Member] | Canaccord Genuity LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Common stock, offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation', window );">Aggregate gross sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_CommissionPercentage', window );">Commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offerings costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_RegistrationRightsAgreementMember', window );">Registration Rights Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase committment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares resale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockIssuedDuringPeriodCommitmentShares', window );">Shares commitment | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember', window );">Registered Direct Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares resale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_PIPESecuritiesPurchaseAgreementMember', window );">PIPE Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares resale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_WarrantAmendmentAgreementsMember', window );">Wainwright Amendment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Cash payment | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="nump">$ 412.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issued stock value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 448,840<span></span>
</td>
<td class="nump">$ 322,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementsMember', window );">Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 517,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_NumberOfCommonStockSharesTraded', window );">Number of shares traded in market | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_CommonStockEquityDistributionCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Issued shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of additional securities called by warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ClassOfWarrantOrRightReasonForIssuing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant issued description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ClassOfWarrantOrRightReasonForIssuing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_CommonStockEquityDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock equity distribution costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_CommonStockEquityDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentInducementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment inducement gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentInducementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment outstanding measurement input.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NumberOfCommonStockSharesTraded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares traded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NumberOfCommonStockSharesTraded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_NumberOfVestedAndUnissuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vested and unissued shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_NumberOfVestedAndUnissuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfAllocatedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of allocated equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfAllocatedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfInvestmentOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of investment option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfInvestmentOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PaymentsOfStockIssuanceCostsRecordedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance costs recorded expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PaymentsOfStockIssuanceCostsRecordedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration expected maximum price on limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharePriceOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharePriceOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share warrants (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to settle liability for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_PreModificationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_PostModificationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_PostModificationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENVB_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ENVB_InvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ENVB_TwoThousandTwentyLongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ENVB_TwoThousandTwentyLongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_RDOfferingAndPIPEInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_RDOfferingAndPIPEInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ENVB_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ENVB_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ENVB_BoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ENVB_BoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_PlacementAgentPreferredInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_PlacementAgentPreferredInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ENVB_CanaccordGenuityLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ENVB_CanaccordGenuityLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_RegistrationRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_RegistrationRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PIPESecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PIPESecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_WarrantAmendmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_WarrantAmendmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994984368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract', window );"><strong>Redeemable Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable noncontrolling Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of embedded derivative to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock', window );">Redemption of Akos Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,052,057)<span></span>
</td>
<td class="num">(1,052,057)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureRedeemableNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureRedeemableNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for reacquisition of callable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891893266160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_FairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 885,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_UnpaidDividends', window );">Unpaid dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RedeemableNoncontrollingInterest', window );">Redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,052,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SpinoffAndRelatedPrivatePlacementDescription', window );">Spin-off and related private placement, description</a></td>
<td class="text">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsToPurchaseCommonStockPercentage', window );">Warrants to purchase common stock, percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember', window );">Akos Securities Purchase Agreement [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember', window );">Securities purchase agreement [Member] | Series A Preferred Stock [Member] | Akos [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stock issued and outstanding</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_FairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_FairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable non controlling interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SpinoffAndRelatedPrivatePlacementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Spinoff and related private placement, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SpinoffAndRelatedPrivatePlacementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_UnpaidDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_UnpaidDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsToPurchaseCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase common stock percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsToPurchaseCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_AkosSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENVB_AkosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ENVB_AkosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891889841392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 25,470<span></span>
</td>
<td class="nump">$ 185,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">851,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">44,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">R D Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">302,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure', window );">Fair value of investment option liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">503,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember', window );">Warrant liabilities - January 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember', window );">Warrant liabilities - February 2021 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember', window );">Warrant liabilities - February 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of warrant liability</a></td>
<td class="nump">$ 25,462<span></span>
</td>
<td class="nump">$ 185,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability related to investment contracts for example, but not limited to, guaranteed investment contract or annuities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478850/944-825-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891897661888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ConvertiblePreferredStockPrincipalValue', window );">Principal | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 54.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | R D Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 61.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 61.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="nump">41,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Share Price [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="nump">$ 94.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="nump">150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Share Price [Member] | R D Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="nump">94.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="nump">116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Share Price [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="nump">94.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | R D Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Option Volatility [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Option Volatility [Member] | R D Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Option Volatility [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Wainwright Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | R D Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | Pipe Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | Measurement Input Market Rate [Member] | Derivative Liability May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February Twenty Twenty Two Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Investment option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Investment option term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="nump">8,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="nump">$ 61.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="nump">94.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="nump">$ 116.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember', window );">Initial Measurement [Member] | February 2022 Post-Modification Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_InvestmentOptionTerm', window );">Investment option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of investment options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Share Price [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Investment, stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_StockOptionExercisePrice', window );">Investment, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Expected Dividend Rate [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Option Volatility [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | Measurement Input, Risk Free Interest Rate [Member] | HC Wainwright and Co LLC Investment Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput', window );">Investment, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty Two Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Investment option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty Two Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Twenty Twenty One Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Investment option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Twenty Twenty One Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Twenty Twenty One Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,712.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Twenty Twenty One Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Twenty Twenty One Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | January Twenty Twenty One Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty One Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Investment option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty One Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_WarrantsAndRightsOutstandingStockPrice', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty One Warrants [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,675.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty One Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty One Warrants [Member] | Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember', window );">Subsequent Measurement [Member] | February Twenty Twenty One Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ConvertiblePreferredStockPrincipalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Principal Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ConvertiblePreferredStockPrincipalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_InvestmentOptionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment option term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_InvestmentOptionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_WarrantsAndRightsOutstandingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, stock price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_WarrantsAndRightsOutstandingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure direct or indirect retained investment in deconsolidated subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_InitialMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_InitialMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_WainwrightInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_RDInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_PIPEInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ENVB_MeasurementInputMarketRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ENVB_MeasurementInputMarketRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_SubsequentMeasurementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_JanuaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_JanuaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ENVB_FebruaryTwentyTwentyOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891891112416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total beginning balance</a></td>
<td class="nump">$ 185,215<span></span>
</td>
<td class="nump">$ 653,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,595,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Change in fair value, modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(94,396)<span></span>
</td>
<td class="num">(4,315,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="num">(65,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total ending balance</a></td>
<td class="nump">25,470<span></span>
</td>
<td class="nump">185,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total beginning balance</a></td>
<td class="nump">727,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(727,000)<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">727,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total beginning balance</a></td>
<td class="nump">851,008<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,323,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(208,752)<span></span>
</td>
<td class="num">(3,472,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Total ending balance</a></td>
<td class="nump">23,608<span></span>
</td>
<td class="nump">$ 851,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions', window );">Exercise of investment options</a></td>
<td class="num">$ (618,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of investment options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994996400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE (Details Narrative)<br></strong></div></th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Derivative liability fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480463/815-10-45-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994895632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating leases remaining lease term</a></td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891891817184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>Dec. 26, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 762,717<span></span>
</td>
<td class="nump">$ 1,281,455<span></span>
</td>
<td class="nump">$ 1,736,373<span></span>
</td>
<td class="nump">$ 5,531,436<span></span>
</td>
<td class="nump">$ 7,252,437<span></span>
</td>
<td class="nump">$ 8,027,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Future cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,977<span></span>
</td>
<td class="nump">17,723,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,241<span></span>
</td>
<td class="nump">120,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,075,643<span></span>
</td>
<td class="nump">1,705,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,218,783<span></span>
</td>
<td class="nump">463,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(762,717)<span></span>
</td>
<td class="num">(1,281,455)<span></span>
</td>
<td class="num">(1,736,373)<span></span>
</td>
<td class="num">(5,531,436)<span></span>
</td>
<td class="num">(7,252,437)<span></span>
</td>
<td class="num">(8,027,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable', window );">Research and development expense tax credit receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,349<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ReductionInForceRestructuringPercentage', window );">Reduction in force restructuring percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember', window );">Vogal Nathan Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_RoyaltiesPercentage', window );">Royalties percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember', window );">Vogal Nathan Purchase Agreement [Member] | One Time Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember', window );">Vogal Nathan Purchase Agreement [Member] | Additional Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_OtherConsultingAndVendorAgreementsMember', window );">Other Consulting and Vendor Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Future cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_AvanceClinicalMember', window );">Avance Clinical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionContractCostProgressPaymentOffset', window );">Payment of contract cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,036,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,385<span></span>
</td>
<td class="nump">157,117<span></span>
</td>
<td class="nump">508,774<span></span>
</td>
<td class="nump">401,284<span></span>
</td>
<td class="nump">1,751,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (264,385)<span></span>
</td>
<td class="num">$ (157,117)<span></span>
</td>
<td class="num">$ (508,774)<span></span>
</td>
<td class="num">$ (401,284)<span></span>
</td>
<td class="num">$ (1,751,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development tax incentive receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ReductionInForceRestructuringPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in force restructuring percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ReductionInForceRestructuringPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionContractCostProgressPaymentOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of progress payment netted against construction contract cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 910<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482332/910-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionContractCostProgressPaymentOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_VogalNathanPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_OneTimeMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_OneTimeMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ENVB_AdditionalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ENVB_AdditionalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_OtherConsultingAndVendorAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_OtherConsultingAndVendorAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_AvanceClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ENVB_AvanceClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891994936288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,205,116)<span></span>
</td>
<td class="num">$ (7,251,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,057,703)<span></span>
</td>
<td class="num">(12,706,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (2,084,032)<span></span>
</td>
<td class="num">$ (2,815,621)<span></span>
</td>
<td class="num">$ (6,418,610)<span></span>
</td>
<td class="num">$ (13,849,201)<span></span>
</td>
<td class="num">$ (17,262,819)<span></span>
</td>
<td class="num">$ (19,957,393)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891888296048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,913)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (expense) benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,913)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax (expense) benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (expense) benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (6,595)<span></span>
</td>
<td class="num">$ (1,731)<span></span>
</td>
<td class="num">$ (6,595)<span></span>
</td>
<td class="num">$ (28,913)<span></span>
</td>
<td class="nump">$ 1,486,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891891974320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,889,863<span></span>
</td>
<td class="nump">$ 8,927,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,185,399<span></span>
</td>
<td class="nump">1,348,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ResearchAndDevelopmentCapitalizedExpenses', window );">Research and development capitalized expenses</a></td>
<td class="nump">611,245<span></span>
</td>
<td class="nump">614,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DeferredTaxAssetsAndIntangibleAmortization', window );">Intangible amortization</a></td>
<td class="nump">80,518<span></span>
</td>
<td class="nump">54,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">70,730<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowances</a></td>
<td class="num">(12,837,755)<span></span>
</td>
<td class="num">(10,977,893)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DeferredTaxAssetsAndIntangibleAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and intangible amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DeferredTaxAssetsAndIntangibleAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ResearchAndDevelopmentCapitalizedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development capitalized expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ResearchAndDevelopmentCapitalizedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45892002105968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">$ 24,268,692<span></span>
</td>
<td class="nump">$ 18,349,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">11,220,065<span></span>
</td>
<td class="nump">16,892,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss tax carryforwards</a></td>
<td class="nump">$ 17,672,420<span></span>
</td>
<td class="nump">$ 16,377,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45892090306896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at the statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax rate (net of federal)</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(2.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="num">(3.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation', window );">Non-deductible expenses</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup', window );">Deferred true-up</a></td>
<td class="nump">13.20%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">23.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(7.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation deferred trueup.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891894087648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses and benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,595<span></span>
</td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">$ 6,595<span></span>
</td>
<td class="nump">$ 28,913<span></span>
</td>
<td class="num">$ (1,486,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses and benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (6,595)<span></span>
</td>
<td class="num">$ (1,731)<span></span>
</td>
<td class="num">$ (6,595)<span></span>
</td>
<td class="num">(28,913)<span></span>
</td>
<td class="nump">1,486,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,889,863<span></span>
</td>
<td class="nump">8,927,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,859,862<span></span>
</td>
<td class="nump">4,429,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development expense gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,696<span></span>
</td>
<td class="nump">$ 2,684,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,268,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,220,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,672,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891891809280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INVESTMENT OPTIONS (Details) - Investment Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at beginning</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice', window );">Weighted average exercise price, issued</a></td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life, outstanding</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrant shares outstanding at end</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">71,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, outstanding at end</a></td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber', window );">Warrant shares outstanding, exercisable</a></td>
<td class="nump">4,667<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="nump">$ 150.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption', window );">Weighted average remaining life, exercisable</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested', window );">Intrinsic value, exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award equity instruments non options exercisable aggregate intrinsic value nonvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ENVB_InvestmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ENVB_InvestmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891892240944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2025</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>May 03, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,290,186<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,222,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones', window );">[custom:ProceedsFromAchievingDevelopmentAndSalesMilestones]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,320,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,392,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member] | Purchase Agreeent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from achieving development and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ENVB_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ENVB_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_DistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreeentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ENVB_PurchaseAgreeentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45891995054880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ENVB_DisclosureLicensingAgreementsAbstract', window );"><strong>Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost payable, beginning</a></td>
<td class="nump">$ 301,645<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring costs paid</a></td>
<td class="num">(301,645)<span></span>
</td>
<td class="num">(572,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost payable, ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 301,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ENVB_DisclosureLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ENVB_DisclosureLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ENVB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MG:I+Q[>X+&.(C2R-7],LU2F^T+7LE[=(S=R,H (9FK ) J.^-&%3M$\B&#>
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M +Y?%H4^?J@[./T7@<?_ U!+ P04    "  ',T-:P&=3&W0>  "JBP$ &
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M/V:EWR^55^NOZW9YOSJ*7E\-[9X6P93\6;[#UT)L??>%H><;7_1%;*F0:"5
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M=@+5L1(%JN: F*1 F7@HD * ]"SH?3Y_VNC[W;* _4Y!6F?7ONU5^6W/S81
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MF2]0<W0.C<X7U'ZF9]!PO1^DYO.>A/!JX["=XTP;GVAXU;9,_<B<QE$?0*)
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M2_HFCYKE4<Z21QE[*)#(B)) ^P#PC"@)I \ AXY73<0=.P"<:DH> $XT9 \
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MJTM0U@#GYU*:3<<N4->KX1]02P,$%     @ !S-#6O"+DJ]Y#   P$@  !@
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M>]W)^E=>OFV[>KT;+.]@+:KA_^S[#HBC 5(// #O!F!] )T90'8#B#X@F!E
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M>,'7FWU/X$&B)CG2G7=_"/!]9QJ$RU%G:$F@SI#/L*^7QY*3)5,'-S<%].B
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M]Q^?>2;7B1*0?U_5=;?_HBYP>&G1[?\!4$L#!!0    (  <S0UK\UN+)[A,
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M%-6T6&9E D_/ZJJ%T\OY\<VM-1F<ZV*956L\V565K?*BLWDRK0&-JY;_)9_
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MA*033+B:&O:X"XRJ:&"ZK(%S63;U'<HL8"RK)1ZZ2!]+K B'R>T=V'%+A,;
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MQ$Q*21F234Y;:VCKW58^9I>2; Z[WW;J!$UT@I$RQTLN,]%!MTES *" GST
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ME,;2B.,<R2UET-\6<R2ELH"W=6ICZ^U?$:<99LT5\Z(B-,&092<"";T(XCP
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MT''HTLZ1P$%%QWV@$E>V/AW/ B 6RBVX 08'.F AJPK1EK-IQ*O4%0($)J/
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MP3B,/C5UF29]SS)JG")^/ &RD["/W@W5YV[_TF *,W_+&,"HZPM]2.T(9S_
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MI9+=(S="YE'9>)*0<%*<.][RK3:V7,>;Z7-\Q8"+BXLY'%AP%U-E(KCT4\U
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M:&5E=#$P+GAM;+U6;6_;-A#^[E]Q4(M@ [1(HMZLQ#;@V Y28$T,.]D&#/M
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MK8YRM0#GMPP_WJ:C-FCOB9-_ 5!+ P04    "  ',T-:_+H:>:@J   %K@
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M,.?H)"H5*;-;U :,#:)^A2]/R4>:)DF/P=2'J4I/U+F''D@SN<Q 7H!)AC/
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M1=8F;K]U=)7L9W,Z>H+>&84S 5Y87%^^R]+[XQLP@\ ZF,,/J)@_P#8YT=?
MW@+B!7WZ&*WQ@#3FXYA(CUYH)M\ZA>UOFG&43?0FBW+B_9/-/>@8H?,N["CL
MB7(UW5&KR![*IO9GY%'RBC5S5"C8*Q<DVH!QDQ-5J5U6Z;$+.E,SXJTRNCLF
M(8MZ%7U*5IL5#@P(' PPU\\*%]()%B=S+/YSPZ>U'!L]2@!&,!T0*R1BSL$>
M1;H!FU^?26.T<4F$5(EGFMKLLR-#[I*\*.6_-U%>\E(K4<'X-KN@SS-KD"'5
M:+35L-9@",LG08A@7R?>=*(/P7:P&R<U-?W":GB6KJA/JHEJ^$>Z"OV)A+F$
M*KDP)B,G&ZRKN@@\=:A&JNO$Q(R\QI&U^["/*$876)E&:(YA$<@/<G;ZV_G9
MQW?G\NHM,.O5Z7_(JP\W%U>7XM*L6*G-/ZBJ D8^@>V/[C'A1&43?"#OM?'[
MKX24,S0^WJ*I_#N9RHW'KDW\Z13@QU3Z#4ARXM(C/.0M7H&4TJ[:!3P!-GXR
MY]'$U:8L2B!2?!W,CD:B$0@,3-9\*2?#,>8%8@Z9/YSTP* 9]$+XDQ ;_"@(
M6(!*_5W]8GW2S[[-\KN8U,M1. GE*Q3LTWXOP.$G?A\'UX_6X&O9%!\<SPF\
M. U]#6 P&O=&0QGT1A: "MO,!QTCA>,QCC2>]H9]&FG@3S&M,>@%UC+0KF[$
MWOET(6)-N4*;GTUB9?][E<>A'(3[.(7]6W+\=K&"'>0@("<-X#M:#NST#*QX
MZ!T:=;EEN2,P>?R I4<P,AABA6?[#C;[5)$ -E%VL0,.3S2B7"P_!#?+&_5'
MW1@Z_KH8VKT4L1=CNRLYDD-O,@1Z",=>'RR$$TK%W,<,I:SY<"3]'KB:%TJ]
MX,O7RJ7!Z0G,CVD"NK4-3T:&)552"2HP>FU#KY&:Q24N0005!\DP5V!=G\]N
MP&1!DX-EU\?+"[ TT%XY^>/D^@P^GMY<_'YQ\R]+G!4U<18I.52Y\V!NI,<8
M.<!?VX3*U!N,D#?#00@\:V2'/_+&(^1 /^B-A[:8& $_OJ(7>OVA^)V'/@+9
M% ;T_6 P *E1F[=EHT%QAZ&/,PP#E!8PA3B<X!NYMTRV ,9H2J46RCP-)EXP
M'#1,\"3=R0PV7;<3@3:Y,"Y.0V2I$@"W&1BIW;Q#P*$6HY0:_&,1 US9F@2(
M"5?L*7OD8;*GAQ@_G"\[$0Y.WG3D#<>F"L,;#29 7,/_UDC_2JANL<M$N]R"
M75YE><F6<A>6&J4Q'=))99K[_:DW#$9">0;J?!WW[CZEB>AT.@)GS)4C0IU1
M8[)5;S@69,)L,S)!2X^FH@,8/ =2$@&U2K8IN^J@;F.*R)#;IQ(^,,F5S<S"
MQ"8QX33J@.7;^X"H,%CLDR= Q@P;Q(#2HM7@51C7&5*=VXM:I .)6L%4,_,>
M%94V$=K\/7YSPDMY_P$6=8*FL'Q[==VA:L1L%T_BW->SCS 5"W"R2?4G<4-R
MVRZ4M;;E$D5,^V]?.N^OW:8)T/Z(%1/FN8! ZJ-&"\<@IOP!V:DCL"Y\<=TE
M#8+^&$UL&>"I*A@3HZ#O]8=C.9KZ6!<H;JA*Q"@;2]%8\M"6A9V+%?7%'C*J
MR5LDV?;!Y"JW5&_LH-HDY8)\\N!N@47M<P#+ S7)T=DNI\"U<L"2N3Y![KGZ
M> .\='EV<?FK<*IOW"$;EHU;\-3\O<H 6"9WMH_UN)^/Y4]@I_V0J@A'O<E0
MAC7/A7.(CP93,'8"+^SW>_U^T[_2+@X^Z@,JP W"YZF>J_GP;L]J./(&?72M
MA@,J[L*"U$/\J:WO'TX4+;5_!Q+"!4CGV0U*4N6DS^S"IK9!OSLIA!231/N4
M]CCL^0=M6>WUH#<]:,>VO2[;2NJ_3V'ZB8GC"9UVB=3SX*94;SW]0#L XSY4
MY 6V"QZI/&:EG2[B\ZD*G:P$U<>O7A7?E0[LUK@?7KTN#JI>E]^A>OU0:TBR
M-;2'#=12"G%DU:Q0;$Z'$2AWZ!+W>OS*E,>XY6W[U,?(]OH8T9G&_BWJ8V17
M?8RPZ>*[U,?(EOH8L5]]#!?%%/6BF -J8HQ)VEX3([Y730R(L<UM 0A1!\_M
M[0;L= 1UPM:!X*J2!D8&RY;(U@]ZWS2U?H^<>7EXSKQHY,RWB;3/28(G<?-_
M4R;\U\]F;.9?/L5;DQBM[+..4_#/3&+$#."NI$4$R@7(I"J*;YZJV#SQ:DM5
M%$_Q-\E0E =F*(JOF*&HEW1X8F(':3BI'"1#.:+7(0UM;E/'[&G63;PLO>G<
MU))[V=8>*>+FP8UP[9]A,!J#RSZP2ZI <X'T3XH'K<G;)Q6N 6=*&ULD;K.<
MB-)!,N[,80HONA,U>O+JC@V;:)5M<.=?RF X]/S^6)C\+99E;I8=9]UW%>[5
M\[%9W7 JHE5H1X?GI9;5M*+M>:O,5AR'D"?Z@&-/H@'=Q(TQ -R1-_7[7>!S
M-3ZO04L,4>D"\- *%01KCW,Y)^Q;( H\&Z1)0)LW^A9@14]1OF#=UA60=C-?
MP!HP77;\H8;6R2#"[@ QN:P #9#UW,[KE=LS^:U40+?Q#JNS[2^W-YJB1(5/
M"7CZ6(/JEH9ATBJ\A38KL06 2'3VA&8MFH=),4?JYQ 446-1F) X)UN:Q>D@
M.S@?O5]['WJO3Y:J2\*OR^P6]A)HO4PI$X:P'*F"*NS">)QO4K($5\#=V)Y"
M:]PJH?4B%9I=/7F.NPJ8O5<'6WR2HB"GJ'<X/%Z@!\=Y"TW+P"VP",D3[=X4
M=.&L?1%?,%BIU)9#&4)Y"I4;:J\&Y3BX@ZH)1M6VX<Z%JK[$;7# )I7:"S#H
M%*8GAI-K;+P&FX[K9#7M^155L=_Q640%7$B#+IJ$Q5(=-$AO8K(U 2/9W.@1
M4E\HJ@>]D7G$:B\!]'B;+%$T:MUA?!"!7O; O&2G+T<F:'WX^<-^'C=(%:J
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MR<<"<4-@8Q%=8(G)J8"+/(4$7O 0*+>3"_Q0,E:RUY*.96EJ(#\!6^-(JQA
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MJASIM(K,;K1RMR+6UN0QK-X2GX%P.8^4BUSQV=\3,>#C2]DY>"B+)SHX73\
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MT?5CAR3G)3BE?A-Q*N\M^\[L\P5]_>2SE"D6R_I=4U"]:VIM7O(ED#(S52>
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MRZ62.'<:@.=S8USU@S:H/Z!\^V]02P,$%     @ !S-#6O(]!'?!"0  91<
M !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULM5C;;MM($GWG5S0TDX$-
M,#(ONMEQ#,@2O:/ D0Q)SLQBL0\MLF7UA!=--VG9^?H]U:0HR9:3[ +[8I.M
MKNJJ4U6GJGFYR=17O1(B9T])G.J/C56>KR_.SG2X$@G7S6PM4ORRS%3"<[RJ
MAS.]5H)'1BB)SSS'Z9PE7*:-JTNS=J>N+K,BCV4J[A3319)P]7PMXFSSL>$V
MM@M3^;#*:>'LZG+-'\1,Y/?K.X6WLUI+)!.1:IFE3(GEQT;?O;ANT7ZSX8L4
M&[WWS,B3199]I9=1]+'AD$$B%F%.&CC^/8J!B&-2!#/^KG0VZB-)</]YJ_W&
M^ Y?%ER+01;_(:-\];'1:[!(+'D1Y]-L\[NH_&F3OC"+M?G+-N5>WV^PL-!Y
MEE3"L""1:?F?/U4X[ GTG#<$O$K ,W:7!QDKASSG5Y<JVS!%NZ&-'HRK1AK&
MR92",LL5?I60RZ]&X\'D<\#F_3^#V>59#HVT?A96TM>EM/>&M.NQSUF:KS0+
MTDA$APK.8$IMC[>UY]K[KL:A")O,=VWF.9[_'7U^[9]O]/EO^9>&62+8G#^Q
MH=1AG.E""?:O_D+G"AGQ[V,^EQI;QS52E5SH-0_%QP;*0 OU*!I7O_WB=IP/
MW[&W5=O;^I[V'\;CN]+';1M/YH'ENDVVKYO-5\(:9,F:I\^__=+SW.X'S>Z;
MLR;C:<10[$CGE $NS1:"7IDLD<SYD]",8T&#,O!+OL(.U/8%FPU^#X;WMP&;
MW+"@/QV/QO]@)[>3V>R470<WDVE066#! HOB2T'V+(1<) NA*.Q[R_>IS$7$
M9CG/<>"O[,1U;,]IVZ[;8:?TWK6]MFM[7H^=6C>5P5ATVEV[Z_C8<^)Z>.K8
M;J>-+?,LY['1 \&.9_?<\U*/>VZ?0\8_)QDHLO*58,^"*\T$937;-]#DI<&(
MC+09[:U@!$>%F2*!'51,/($^M6#9$D=Y/?O<]9EKMWH=V^DX-6(6$-M%AP5_
MW@7C60#4QL'-:#X[A&A0*"72_(+ML+H1D5#&.Q-+[\/NR3( LI/J[--Z?0O9
M:PF#E!66Q^P[<U)Y<XJ(IV(I<X*O5KQ3,!1+ >'HXB<,VZZ_958-5F565.G^
MD5V[\UYH^&\<VD4J&'\)IJ.!=3V:S :C8#P(9C:%K,GZXR&;W5_/1L-1?SI"
M95&]H;XF;# 9SR:WHV%_'@S9S6C<'P]&_5LVFV/A<S">'R_"VD$RD&M4F3;Y
M=K >2[Z0L<PE2B/,T")U3BE&V;C,8E2C3!\N#M)K&-P$TRD,H03KSV8!CB?3
M;T?]Z]'M: [+?UR3P]>V75AC\ "&!,5S'%I21LB5>@8W;+B*J'91NKW>N=WK
M^'@!O![*S7>0 5GX]3TUU0A>)!0*;GJU:[N]-BKR'$]^BP1ZUA1\QE6XJL!X
M!.>L$TK0D*\EXBJ_04L53\TZ+JBAU<;_ENVT7&N4YCQ]D(M8,)Z M.2W\J2>
M8[?='FNW;!>[)@!0L:YC=WV'^;[=:OO6K8!#CSPN2@%.Z/(TQ!G$+ST?;--N
M&[9Q[/-NU^X1CQA0CD7R2"'L9P%;\>@PBFR=Y?!2XMQG5N0(^C=.7J2O4:=C
M#I _S(#)73#MSXF4B9/9H#^=_I.!EO_H3X<_$?M=*7LM$&C/[IQ[%-H>(G0.
M#/RJH+%$K.R@;-KTT@$BX.%VJRYM+';M3M>S6YY3[O"!6\MO'TNE5TZ]+6Z
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M>%9I#<_ER-:F59W!TP880;N@SX(7*P:I ,R8F]+4:5&L$1"S:OG==F'TEY(
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M5_M%OY\5U6TCLD;2$=M*@?;/,\%GEG#79H[J$!.69/F$5(/[VMR+.!!S"L
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MZ_4J=:I9N"1>)>T ,9WH-87F/_)B,=!&EF@/]?&0B^Z%$CT"'=@&9G\U*D7
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MQM6HM (M8E/.+9HBL6 U*)MQ:=>8L%47C'J35UW8@X(1+CQ5RA 8Z%LAG?:
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MAIX LV>3TLWBCBGT'>@I\2R Q#U(=<*S.L4%^)@_1GWKJDATWYF.&J>('T>
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M(-=XD71X!US4GK#=1"4+PGV02=WONDV+3->&_0%$#J[RJ*7D3]IFLCIN*0O
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MBW^/VQ'V?NDWS@Y58]O;R..<&IVENB[RN6_$&;9'"M#VOD.,]+M5OAW3:)N
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M5Q<.J/*=+2=&9L53M9&&'KYBN*=/$U36@/:W4IKCQ#JH/W:&?P-02P,$%
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M>',#;2:25?H2MV(2KX1ZF.*EG7)E@/MKA@&U$W7 _F_ Z$]02P,$%     @
M!S-#6FC8 USZ P  Z0H  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
MO59M;]LV$/[N7W%0BZ %M.A=LA+;@&,[2($U,>QD&S#L RV=;:&2J)%TG.[7
M[R@I:M8X7AH,^V(=R7ON]2%]@ST77^064<%#D9=R:&R5JLXL2R9;+)@\Y166
M=++FHF"*EF)CR4H@2VM0D5NN;8=6P;+2& WJO;D8#?A.Y5F)<P%R5Q1,?+W
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M=_2D0FD,:#T5] .U [-!]TB;?@-02P,$%     @ !S-#6M,ORQGI"0  228
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M=7OM@2K[;#DQ<NUZVT(:ZI1NF-'3A,H:T/Y22G.8V #58]?] U!+ P04
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MGQ/3%Q'%ZA/>721$%*CFFA+P/TD XZL(7#5[D0L4WW0O_@M02P,$%     @
M!S-#6N7<+; A!   U0H  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
MK59M;^(X$/Z>7V%E]U:MQ)$07MKM E(:TI;3 E6@7:U.]\$D T2;Q*SME/9^
M_8V=P-(VC7JG^P*./<]XGF?L\?1WC/\0&P!)'M,D$P-S(^7VPK)$N(&4BB;;
M0H8K*\93*O&3KRVQY4 C#4H3R['MGI72.#.'?3UWRX=]ELLDSN"6$Y&G*>5/
MEY"PW<!LF?N)(%YOI)JPAOTM7<,<Y-WVEN.7=? 2Q2ED(F89X; :F&[KPNLJ
M>VUP'\-.'(V)8K)D[(?Z&$<#TU8!00*A5!XH_CV !TFB'&$8/TN?YF%+!3P>
M[[U?:>[(94D%>"SY%D=R,S#/31+!BN:)#-CN!DH^.L"0)4+_DEUAV^V8),R%
M9&D)Q@C2."O^Z6.IPQ'@W'X#X)0 Y[V =@EH:Z)%9)K6B$HZ['.V(UQ9HS<U
MT-IH-+*),Y7%N>2X&B-.#KW99#)>3/SI8D[<Z8AXL^EB/+WVI][8GY.3!5TF
M($[[EL2]%,(*2[^7A5_G#;^?R81E<B.(GT405>"]>GS+J7%@(<D#4V?/]-*I
M]3B';9.T[09Q;*=3%5 ]? 0APEL:WJX)IWT0OJW]M=\2GJ5I+/$^2$%H%A$/
MV<;9&K(P!D%&L0@3)G(.Y$]W*23'X_Y751:*33K5FZ@2<"&V-(2!B7=< '\
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M(5_>Z;/C@XBR*!JZUE*A>54,<@B<*69R*5C7L,X,R^W=TC.]EBW5CL@H-/P
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M)QFI::BFHYJQT6K7%X?RH+][V<!$RUJH9J.:L]%JIT3]07^T>\G%_2-EI<:
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M[Z$1Y"F^F&:\^D;'.C8(#!3ON:!Y Y8[R-.B_B6OC1$G ,M] V W /M2@-,
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MY+BL+R!U08M-=>A?"&VN$-7CVES:0)85S/>E$'I?*#MHKH&3GU!+ P04
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MP%<.BJ0I[T5<FG*5L% E+%()BU7"D@;F[27_R@V\@6><R+[79=_KS?Y[GG+
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MT" ,0+]?<:Z>-\9!.Y*G_P)02P,$%     @ !S-#6E>_GX=\ P  "@X  !D
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M*P]KP%2!?+^F5)P::G=?'__\[U!+ P04    "  (,T-:MO7:1^<"  #F"0
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M+.0Z0,VO&)/GCA8HG\#@)U!+ P04    "  (,T-:H:1E;S($  #W#@  &0
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MK>Q,"<L!\OF:4O%\D[^@[G5'_P-02P,$%     @ "#-#6@WZZP7# P  % \
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M,21W8I):3%Y7/A7OC0K2^FYRU"@4\I:[&BVE;*XJMKKJE=M";W9;A[5'K51
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MN;:!]M]?.PDAT&!"FY<2)W..9XX]XZG;&T+_L@4 1Z]A$+&.MN!\>:/KS%U
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M%63H]SV$4Z!_Q-?GB8,N_OW:UKEP44ZDNZD[MXD[UA%WKM$]B?B"H4'D@5>
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MX@[Z^IQSM3V);Y!O'?7^!5!+ P04    "  (,T-:0FSK*D9C  #Q3P@ &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6S,W6ES&]FYINOO]2LRJGTZRA&R
M"A-!TMM6Q+*0\SQG8D=_@,B4B#8)T  HE1S]XP\&0D@DP4PF?!^=KMBNS9*
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M6HIJ&:KEJ#9&-;$?_I>E'V<Z[SN5O10$.\4%.\8%.\<%-LB/ ]=ACX$>L<=
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MB^5LEG-8SF4YC^5\E@M8+F2YB.5BEDM8+F6YC.5REANSG&@* ^WC&NO!04#
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M[ 5O=L!Z\(07W(BO9*_29@?=^LT.O*?%S=UDN2TXN)D_/,QGSQT@]3&,W?H
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M8+F0Y2*6BUDNV7-'^;_7OSB.,"F[:L9R^:E/8GC=[;S(87!?/^O!<UO @UO
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M8>RV 2@GLYS"<BK+:7ON:,_,SNZ?%TF,W1( Y4R6LUC.9CF'Y5R6\UC.9[F
MY4*6BU@N9KF$Y5*6RU@N9[DQRXFF.7]&$H.W!& ]>,H+;LQ7DEAI2X#+^BT!
MQ)<OB^++9%5(7Q;SY5+:W"ZP; IB[/X *#=B.9GE%)9364[;<R]NP>\.7N0P
MMOH?Y4R6LUC.9CF'Y5R6\UC.9[F Y4*6BU@N9KF$Y5*6RU@N9[DQRXFF*7]&
M#H,W%& ]>,@+;LI7<EAI0X'+^@T%-D?$ILOEYGZ!QV)Q4\Q6DR_%Z?3%;A6
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MM_MOGA?XOMY\>?GG7_X/4$L#!!0    (  @S0UJRP7L(G ,  /,-   9
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MD1E>QO*>K?XDQ07U-2]DL<C_HE5QKM5!X5)(EA3!J@<)3=?_\4LQ$(<$.$6
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M[*,^V&=][,,9*;0S4G1R\4V!&ATH3:$TH6BV?MKH*-I>?--T9TL_*%@2U+M
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MOET@H\_CV6Q\L_SR6S6XJB:+/YC__LMX/%M_LQC@?CSYOIS>R?\#4$L#!!0
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M[7<:?=MIGZB4>!N]$DW]0*A"-<%\;N36%IN>$6I4YJI)OCU8Y+>_"W>K'//
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M"Q"S32ZK[U^SVEP9QF6G?+ ^@8,IU*P'<!#JUB-U]:AN"C_"5O>6:\*722Y
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MG*'5XQ)P!%0.$._GA/!M0TY0W;0,_P=02P,$%     @ "#-#6B3F)24@#0
M7,T  !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULK=U;<^)&&L;QKZ)B
MM[:R5<F Q,G,>EPU,SH?O>.=Y"*U%S)NV]0 (I*PDZU\^!4@6PA$&V7^N7
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MC%ZOC33(ZE2R.G\I2Z*NI.Z7'Q1,_IZ2TUHI-7Z=<]=W+RJ_=ZGZ5:K^/Y\
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MOQKF#1A8'LCT=W.-KS9>(8?K %O30Q6"C12O1&RD^%P#XI\W8"2)?[6Q/,#
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M'$F5F9P&P159\""5? LQ,=G8AF6#%Q=P@<G&9&,;ELT@FL\+#8B)^<8V[1N
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M4$L! A0#%     @ !S-#6A'H<3&[ P  (A(  !@              ("!)Q(
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  <S0UHH+X96
M# D  "XP   8              " @1@6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  ',T-:P&=3&W0>  "JBP$ &
M@(%:'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ !S-#
M6M/>>74[ P  NPH  !@              ("!!#X  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    (  <S0UKPBY*O>0P  ,!(   8
M      " @75!  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M"  ',T-:_-;BR>X3   .0@  &               @($D3@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ !S-#6GS8!PP?+0  MZ<  !@
M             ("!2&(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    (  <S0UI3M.#0_ ,  #@+   9              " @9V/  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ !S-#6HA\L42:!0
MA1   !D              ("!T),  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    "  ',T-:R>I@5 ,$  #+"@  &0              @(&A
MF0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (  <S0UHJ
M*L AY@,  #,*   9              " @=N=  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ !S-#6ORZ&GFH*@  !:X  !D
M     ("!^*$  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  <S0UJJ@LJ&<0@  /$4   9              "
M@2WW  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ !S-#
M6KHZDW.5!   &@H  !D              ("!U?\  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    "  ',T-:B\^,S- O  "3O0  &0
M        @(&A! $ >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   (  <S0UHA./J1I ,  /@(   9              " @:@T 0!X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ !S-#6MO]:&HK!   $@P
M !D              ("!@S@! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    "  ',T-::-@#7/H#  #I"@  &0              @('E/ $
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  <S0UJGFQ18
MM@0  )H.   9              " @19! 0!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ !S-#6OI\LTO6 P  9 H  !D
M ("! T8! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  '
M,T-:GK<(D)P#  "P"0  &0              @($02@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  <S0UK3+\L9Z0D  $DF   9
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M970S,BYX;6Q02P$"% ,4    "  ',T-:S^VF>@P#  !:"0  &0
M    @(%!;@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M  <S0UK[]BV]E T  )2[   9              " @81Q 0!X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ !S-#6B:<XFM\!@  PCP  !D
M             ("!3W\! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    "  ',T-:%UN&*\H$  #]'0  &0              @($"A@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  <S0UH'[-9"V ,
M (4,   9              " @0.+ 0!X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ !S-#6JPEM^Z3 P  $@X  !D              ("!
M$H\! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  ',T-:
M8! 7Y!4$  "*%0  &0              @('<D@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    (  <S0UJ?[^EUYP(  +H)   9
M      " @2B7 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ !S-#6AOF'#$Q P  G@L  !D              ("!1IH! 'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  ',T-:5[^?AWP#   *#@
M&0              @(&NG0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    (  @S0UJV]=I'YP(  .8)   9              " @6&A 0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ "#-#6J,CM:QH
M P  2@L  !D              ("!?Z0! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    "  (,T-:5200?<,%  !2(0  &0
M@($>J $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (  @S
M0UI)MG\RM (   X'   9              " @1BN 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ "#-#6J&D96\R!   ]PX  !D
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M=#4Q+GAM;%!+ 0(4 Q0    (  @S0UI";.LJ1F,  /%/"  9
M  " @63( 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
M"#-#6K+!>PB< P  \PT  !D              ("!X2L" 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    "  (,T-:GG7[>:D'   "/P  &0
M            @(&T+P( >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    (  @S0UIY_*U5KP0  (P<   9              " @90W @!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ "#-#6AC:3\&Y%
MV3<! !D              ("!>CP" 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    "  (,T-:O?3JGM0$  #U%0  &0              @(%J
M40( >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (  @S0UI+
M3/89! (  !<$   9              " @756 @!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ "#-#6HTP8$]0 @  Z00  !D
M     ("!L%@" 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  @S0UKP4%UW$P,  ,\+   9              "
M@<9P @!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ "#-#
M6J&^ABU@ P  ?PH  !D              ("!$'0" 'AL+W=O<FMS:&5E=',O
M<VAE970V-2YX;6Q02P$"% ,4    "  (,T-:,?+C Q@%   *)0  &0
M        @(&G=P( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0
M   (  @S0UJ ?T!IT ,  '41   9              " @?9\ @!X;"]W;W)K
M<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ "#-#6B3F)24@#0  7,T
M !D              ("!_8 " 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q0
M2P$"% ,4    "  (,T-:]BHI3;4"  "*!P  &0              @(%4C@(
M>&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (  @S0UI^&[NE
M20,  + 4   -              "  4"1 @!X;"]S='EL97,N>&UL4$L! A0#
M%     @ "#-#6I>*NQS     $P(   L              ( !M)0" %]R96QS
M+RYR96QS4$L! A0#%     @ "#-#6D<\GRC+!0  Z"T   \
M ( !G94" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  @S0UJ7=W+D+ (
M /8H   :              "  96; @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    (  @S0UK62",N]P$  "LH   3              "
M ?F= @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !- $T $A4  "&@ @
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>451</ContextCount>
  <ElementCount>425</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>99</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties</Role>
      <ShortName>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999011 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999013 - Disclosure - ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/AccruedLiabilities</Role>
      <ShortName>ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ShareCapitalAndOtherEquityInstruments</Role>
      <ShortName>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/RedeemableNon-controllingInterest</Role>
      <ShortName>REDEEMABLE NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999016 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/FairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999017 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999018 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999019 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999020 - Disclosure - LICENSING AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/LicensingAgreements</Role>
      <ShortName>LICENSING AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999022 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables</Role>
      <ShortName>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999024 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/PropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/AccruedLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables</Role>
      <ShortName>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/ShareCapitalAndOtherEquityInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/RedeemableNon-controllingInterestTables</Role>
      <ShortName>REDEEMABLE NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/RedeemableNon-controllingInterest</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/FairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/FairValue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://enveric.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails</Role>
      <ShortName>SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative</Role>
      <ShortName>BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - SCHEDULE OF GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfGoodwillDetails</Role>
      <ShortName>SCHEDULE OF GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/IntangibleAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - SCHEDULE OF STOCK OPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfStockOptionDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ASSUMPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails</Role>
      <ShortName>SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS OUTSTANDING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails</Role>
      <ShortName>SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative</Role>
      <ShortName>SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails</Role>
      <ShortName>SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative</Role>
      <ShortName>REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/RedeemableNon-controllingInterestTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - FAIR VALUE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/FairValueDetailsNarrative</Role>
      <ShortName>FAIR VALUE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/FairValueTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails</Role>
      <ShortName>SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999065 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails</Role>
      <ShortName>SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999066 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/IncomeTaxesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999067 - Disclosure - SCHEDULE OF INVESTMENT OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfInvestmentOptionsDetails</Role>
      <ShortName>SCHEDULE OF INVESTMENT OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://enveric.com/role/SubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="form424b4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999069 - Disclosure - SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails</Role>
      <ShortName>SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>envb-20240930.xsd</File>
    <File>envb-20240930_cal.xml</File>
    <File>envb-20240930_def.xml</File>
    <File>envb-20240930_lab.xml</File>
    <File>envb-20240930_pre.xml</File>
    <File doctype="424B4" isDefinitelyFs="true" isUsgaap="true" original="form424b4.htm">form424b4.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1555">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form424b4.htm": {
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "envb-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "envb-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "envb-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form424b4.htm"
     ]
    }
   },
   "keyStandard": 301,
   "keyCustom": 124,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 63,
   "hidden": {
    "total": 477,
    "http://fasb.org/us-gaap/2024": 319,
    "http://enveric.com/20240930": 154,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 451,
   "entityCount": 1,
   "segmentCount": 99,
   "elementCount": 678,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1555,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://enveric.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://enveric.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://enveric.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity",
     "shortName": "Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Changes in Mezzanine Equity and Shareholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "ENVB:NetOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-03-31",
      "name": "ENVB:NetOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://enveric.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties",
     "longName": "999008 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES",
     "shortName": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "999010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://enveric.com/role/IntangibleAssets",
     "longName": "999011 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://enveric.com/role/PropertyAndEquipment",
     "longName": "999012 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://enveric.com/role/AccruedLiabilities",
     "longName": "999013 - Disclosure - ACCRUED LIABILITIES",
     "shortName": "ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://enveric.com/role/ShareCapitalAndOtherEquityInstruments",
     "longName": "999014 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS",
     "shortName": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://enveric.com/role/RedeemableNon-controllingInterest",
     "longName": "999015 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST",
     "shortName": "REDEEMABLE NON-CONTROLLING INTEREST",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "ENVB:RedeemableNonControllingInterestTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "ENVB:RedeemableNonControllingInterestTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://enveric.com/role/FairValue",
     "longName": "999016 - Disclosure - FAIR VALUE",
     "shortName": "FAIR VALUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://enveric.com/role/CommitmentsAndContingencies",
     "longName": "999017 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://enveric.com/role/IncomeTaxes",
     "longName": "999018 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://enveric.com/role/SubsequentEvents",
     "longName": "999019 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://enveric.com/role/LicensingAgreements",
     "longName": "999020 - Disclosure - LICENSING AGREEMENTS",
     "shortName": "LICENSING AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "ENVB:LicensingAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "ENVB:LicensingAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables",
     "longName": "999022 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)",
     "shortName": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "999024 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://enveric.com/role/IntangibleAssetsTables",
     "longName": "999025 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://enveric.com/role/PropertyAndEquipmentTables",
     "longName": "999026 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://enveric.com/role/AccruedLiabilitiesTables",
     "longName": "999027 - Disclosure - ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables",
     "longName": "999028 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)",
     "shortName": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://enveric.com/role/RedeemableNon-controllingInterestTables",
     "longName": "999029 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Tables)",
     "shortName": "REDEEMABLE NON-CONTROLLING INTEREST (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://enveric.com/role/FairValueTables",
     "longName": "999030 - Disclosure - FAIR VALUE (Tables)",
     "shortName": "FAIR VALUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://enveric.com/role/CommitmentsAndContingenciesTables",
     "longName": "999031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://enveric.com/role/IncomeTaxesTables",
     "longName": "999032 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails",
     "longName": "999033 - Disclosure - SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)",
     "shortName": "SCHEDULE OF RESTRUCTURING COSTS PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "ENVB:RestructuringCostsIncurred",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
     "longName": "999034 - Disclosure - BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "shortName": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-01-272025-01-27",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "ENVB:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
     "longName": "999035 - Disclosure - SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)",
     "shortName": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember",
      "name": "us-gaap:StockIssued1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "999037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ENVB:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ENVB:PrepaidResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://enveric.com/role/ScheduleOfGoodwillDetails",
     "longName": "999038 - Disclosure - SCHEDULE OF GOODWILL (Details)",
     "shortName": "SCHEDULE OF GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:GoodwillGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "999039 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
     "longName": "999040 - Disclosure - SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)",
     "shortName": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://enveric.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "999041 - Disclosure - INTANGIBLE ASSETS (Details Narrative)",
     "shortName": "INTANGIBLE ASSETS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
     "longName": "999042 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://enveric.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999043 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails",
     "longName": "999044 - Disclosure - SCHEDULE OF ACCRUED LIABILITIES (Details)",
     "shortName": "SCHEDULE OF ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ENVB:AccruedProductDevelopmentCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ENVB:AccruedProductDevelopmentCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://enveric.com/role/ScheduleOfStockOptionDetails",
     "longName": "999045 - Disclosure - SCHEDULE OF STOCK OPTION (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-09-30",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails",
     "longName": "999046 - Disclosure - SCHEDULE OF STOCK OPTION ASSUMPTION (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ASSUMPTION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
     "longName": "999047 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)",
     "shortName": "SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
     "longName": "999048 - Disclosure - SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)",
     "shortName": "SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
     "longName": "999049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)",
     "shortName": "SCHEDULE OF WARRANTS OUTSTANDING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-09-30_us-gaap_WarrantMember",
      "name": "ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWarrantsOutstandingTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
     "longName": "999050 - Disclosure - SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF WARRANTS AND INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_InvestmentOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_InvestmentOptionsMember",
      "name": "ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
     "longName": "999051 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)",
     "shortName": "SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfValuationOfWarrantsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
     "longName": "999052 - Disclosure - SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)",
     "shortName": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails",
     "longName": "999053 - Disclosure - SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)",
     "shortName": "SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
     "longName": "999054 - Disclosure - REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)",
     "shortName": "REDEEMABLE NON-CONTROLLING INTEREST (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-06-30",
      "name": "ENVB:FairValueOfDerivativeLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ENVB:RedeemableNonControllingInterestTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
     "longName": "999055 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
     "longName": "999056 - Disclosure - SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember",
      "name": "ENVB:ConvertiblePreferredStockPrincipalValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember",
      "name": "ENVB:ConvertiblePreferredStockPrincipalValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails",
     "longName": "999057 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://enveric.com/role/FairValueDetailsNarrative",
     "longName": "999058 - Disclosure - FAIR VALUE (Details Narrative)",
     "shortName": "FAIR VALUE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember",
      "name": "us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails",
     "longName": "999059 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)",
     "shortName": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999060 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails",
     "longName": "999061 - Disclosure - SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)",
     "shortName": "SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails",
     "longName": "999062 - Disclosure - SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)",
     "shortName": "SCHEDULE OF INCOME TAX EXPENSE BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999063 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails",
     "longName": "999064 - Disclosure - SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)",
     "shortName": "SCHEDULE OF OPERATING LOSS CARRY FORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails",
     "longName": "999065 - Disclosure - SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)",
     "shortName": "SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://enveric.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999066 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
     "longName": "999067 - Disclosure - SCHEDULE OF INVESTMENT OPTIONS (Details)",
     "shortName": "SCHEDULE OF INVESTMENT OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_InvestmentOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_custom_InvestmentOptionsMember",
      "name": "ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://enveric.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999068 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "From2025-01-272025-01-27",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-092024-10-09_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails",
     "longName": "999069 - Disclosure - SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)",
     "shortName": "SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form424b4.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "AU",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/AccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r60",
      "r886"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r742"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r925"
     ]
    },
    "ENVB_AccretionOfEmbeddedDerivativeToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AccretionOfEmbeddedDerivativeToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of embedded derivative to redemption value",
        "label": "Accretion of embedded derivative to redemption value",
        "documentation": "Accretion of embedded derivative to redemption value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued franchise taxes",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r107"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ENVB_AccruedProductDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AccruedProductDevelopmentCost",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product development",
        "documentation": "Accrued product and development cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ENVB_AccruedRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AccruedRestructuringCosts",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued restructuring costs (see Note 9)",
        "documentation": "Accrued restructuring costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r704"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued salaries, wages, and bonuses",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r704"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r136",
      "r559"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r70",
      "r142",
      "r555",
      "r577",
      "r578"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r20",
      "r423",
      "r426",
      "r471",
      "r573",
      "r574",
      "r806",
      "r807",
      "r808",
      "r816",
      "r817",
      "r818",
      "r820"
     ]
    },
    "ENVB_AdditionalMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AdditionalMilestoneMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Milestone [Member]",
        "documentation": "Additional Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r742",
      "r956"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r816",
      "r817",
      "r818",
      "r820",
      "r900",
      "r957"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r332"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r39",
      "r94"
     ]
    },
    "ENVB_AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Induced conversion of warrants and preferred investment options",
        "documentation": "Induced conversion of warrants and preferred investment options."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_AkosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AkosMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akos [Member]",
        "documentation": "Akos [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_AkosSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AkosSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Akos Securities Purchase Agreement [Member]",
        "documentation": "Akos Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense for RSUs",
        "verboseLabel": "Stock based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r370"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market rate",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r904",
      "r905",
      "r906"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsDetailsNarrative",
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangibles",
        "negatedLabel": "Amortization",
        "verboseLabel": "Intangible assets, amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r271",
      "r272",
      "r718"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total potentially dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment losses",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r114",
      "r138",
      "r164",
      "r196",
      "r200",
      "r209",
      "r210",
      "r248",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r417",
      "r420",
      "r455",
      "r549",
      "r628",
      "r710",
      "r711",
      "r742",
      "r764",
      "r855",
      "r856",
      "r916"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r143",
      "r164",
      "r248",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r417",
      "r420",
      "r455",
      "r742",
      "r855",
      "r856",
      "r916"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r248",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r417",
      "r420",
      "r455",
      "r855",
      "r856",
      "r916"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ENVB_AvanceClinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "AvanceClinicalMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Avance Clinical [Member]",
        "documentation": "Avance Clinical [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Principal of Consolidation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_BoardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "BoardMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board [Member]",
        "documentation": "Board [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CA",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_CanaccordGenuityLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "CanaccordGenuityLLCMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canaccord Genuity LLC [Member]",
        "documentation": "Canaccord Genuity LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract cost",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "verboseLabel": "Future cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r551",
      "r599",
      "r623",
      "r742",
      "r764",
      "r801"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r80",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r80"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r139",
      "r140",
      "r141",
      "r164",
      "r186",
      "r187",
      "r190",
      "r192",
      "r198",
      "r199",
      "r248",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r305",
      "r306",
      "r308",
      "r311",
      "r318",
      "r455",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r615",
      "r637",
      "r655",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r786",
      "r812",
      "r821"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash payment",
        "verboseLabel": "Warrant measurement input",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of additional warrants",
        "documentation": "Class of warrant or right number of additional securities called by warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued shares",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of warrants to purchase",
        "verboseLabel": "Purchase of common stock",
        "terseLabel": "Warrants to purchase shares of common stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, number of warrants",
        "verboseLabel": "Existing Warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ClassOfWarrantOrRightReasonForIssuing": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ClassOfWarrantOrRightReasonForIssuing",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ClassOfWarrantOrRightReasonForIssuing]",
        "documentation": "Warrant issued description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "ENVB_CommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "CommissionPercentage",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commission percentage",
        "documentation": "Commission percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r109",
      "r550",
      "r614"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r287",
      "r288",
      "r687",
      "r852",
      "r854"
     ]
    },
    "ENVB_CommonStockEquityDistributionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "CommonStockEquityDistributionCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock equity distribution costs",
        "verboseLabel": "Deferred offering costs",
        "documentation": "Common stock equity distribution costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_CommonStockInAbeyanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "CommonStockInAbeyanceMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock in Abeyance [Member]",
        "documentation": "Common stock in abeyance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r816",
      "r817",
      "r820",
      "r900",
      "r955",
      "r957"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Authorized shares",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r615"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r615",
      "r634",
      "r957",
      "r958"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r553",
      "r742"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r146",
      "r148",
      "r153",
      "r545",
      "r565",
      "r566"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ComputerEquipmentAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ComputerEquipmentAndLeaseholdImprovementsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment and Leasehold Improvements [Member]",
        "documentation": "Computer Equipment and Leasehold Improvements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r121"
     ]
    },
    "us-gaap_ConstructionContractCostProgressPaymentOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionContractCostProgressPaymentOffset",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of contract cost",
        "documentation": "Amount of progress payment netted against construction contract cost."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ENVB_ConvertiblePreferredStockPrincipalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ConvertiblePreferredStockPrincipalValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal",
        "documentation": "Convertible Preferred Stock Principal Value."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r814",
      "r894"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r814"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total current income tax (expense) benefit",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r814"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r814",
      "r894"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r893",
      "r894"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r893"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income tax (expense) benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r127",
      "r814"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "verboseLabel": "Deferred offering costs (see Note 7)",
        "terseLabel": "Offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ENVB_DeferredOfferingCostsChargedToOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DeferredOfferingCostsChargedToOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs charged to offering costs",
        "documentation": "Deferred offering costs charged to offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Deferred Offering Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r893",
      "r894"
     ]
    },
    "ENVB_DeferredTaxAssetsAndIntangibleAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DeferredTaxAssetsAndIntangibleAmortization",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible amortization",
        "documentation": "Deferred tax assets and intangible amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowances",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://enveric.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r36"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r36"
     ]
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/FairValueDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability fair value",
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ENVB_DerivativeLiabilityMayTwoThousandTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DerivativeLiabilityMayTwoThousandTwentyTwoMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability May 2022 [Member]",
        "documentation": "Derivative Liability May 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r732"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r50",
      "r51",
      "r52",
      "r53",
      "r167",
      "r181"
     ]
    },
    "ENVB_DisclosureLicensingAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DisclosureLicensingAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements",
        "verboseLabel": "Schedule Of Reduction In Forcerestructuring Activity"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_DisclosureRedeemableNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DisclosureRedeemableNoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Non-controlling Interest",
        "verboseLabel": "Schedule Of Reconciliation Change In Redeemable Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_DistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "DistributionAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distribution Agreement [Member]",
        "documentation": "Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableAmountPerShare",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, per share",
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r94"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r779"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r183",
      "r186",
      "r190",
      "r191",
      "r192",
      "r195",
      "r412",
      "r415",
      "r431",
      "r432",
      "r546",
      "r567",
      "r706"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r186",
      "r190",
      "r191",
      "r192",
      "r195",
      "r412",
      "r415",
      "r431",
      "r432",
      "r546",
      "r567",
      "r706"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r194"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Foreign Exchange Rate on Changes on Cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r728"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal income tax at the statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r379",
      "r402",
      "r728"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r728",
      "r815",
      "r887"
     ]
    },
    "ENVB_EffectiveIncomeTaxRateReconciliationDeferredTrueup": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTrueup",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred true-up",
        "documentation": "Effective income tax rate reconciliation deferred trueup."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign tax rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r383",
      "r728",
      "r815",
      "r887"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r728"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r887",
      "r888"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEffectiveStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax rate (net of federal)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r728",
      "r815",
      "r887"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r728"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized stock option expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r131",
      "r150",
      "r151",
      "r152",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r197",
      "r249",
      "r250",
      "r277",
      "r320",
      "r400",
      "r401",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r471",
      "r563",
      "r573",
      "r574",
      "r575",
      "r588",
      "r655"
     ]
    },
    "ENVB_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r408",
      "r788",
      "r789",
      "r790",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of stock issued and outstanding",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ENVB_ExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ExistingWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrants [Member]",
        "documentation": "Existing Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ExpenseRelatedToAccelerationOfVesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ExpenseRelatedToAccelerationOfVesting",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense related to acceleration of vesting",
        "documentation": "Expense related to acceleration of vesting."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liabilities",
        "label": "Change in fair value of warrant liability",
        "verboseLabel": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r447",
      "r729"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r447",
      "r729"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r734"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r734"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r734"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r446",
      "r447",
      "r449",
      "r478",
      "r479",
      "r480",
      "r719",
      "r720",
      "r723",
      "r724",
      "r725",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r729",
      "r905",
      "r911"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r444",
      "r445",
      "r446",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r542",
      "r729",
      "r735"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r435",
      "r436",
      "r437",
      "r438",
      "r447",
      "r480",
      "r719",
      "r720",
      "r723",
      "r724",
      "r725",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r443",
      "r448"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r729",
      "r905",
      "r911"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of equity",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r448"
     ]
    },
    "ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of investment options",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of investment options.",
        "label": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercise of warrants",
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period exercise of warrants.",
        "label": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r910"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value, modification",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r910"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liability",
        "periodStartLabel": "Total beginning balance",
        "periodEndLabel": "Total ending balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r448"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r446",
      "r447",
      "r449",
      "r478",
      "r479",
      "r480",
      "r719",
      "r720",
      "r723",
      "r724",
      "r725",
      "r729",
      "r734"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r911"
     ]
    },
    "ENVB_FairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FairValueOfDerivativeLiability",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of derivative liability",
        "documentation": "Fair value of derivative liability.",
        "label": "FairValueOfDerivativeLiability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FebruaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Twenty Twenty One Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryTwentyTwentyTwoPostModificationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FebruaryTwentyTwentyTwoPostModificationWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2022 Post-Modification Warrants [Member]",
        "documentation": "February 2022 Post-Modification Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryTwentyTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FebruaryTwentyTwentyTwoWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Twenty Twenty Two Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_FebruaryWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "FebruaryWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Warrants [Member]",
        "documentation": "February Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r303",
      "r316",
      "r428",
      "r454",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r564",
      "r714",
      "r729",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r743",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r829",
      "r830",
      "r831",
      "r832",
      "r901",
      "r904",
      "r905",
      "r906",
      "r909",
      "r911"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liability",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r902",
      "r903",
      "r909"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r700",
      "r718"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r700",
      "r718"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Definite lived intangible assets",
        "periodEndLabel": "Balance, Definite lived intangible assets",
        "totalLabel": "Finite lived assets amortization expense",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r849"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of investment option liability",
        "negatedLabel": "Change in fair value of investment option liability",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r785"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r639"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Goodwill, Beginning balance",
        "periodEndLabel": "Goodwill, Ending balance",
        "label": "Goodwill [Default Label]",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r262",
      "r543",
      "r711",
      "r717",
      "r730",
      "r742",
      "r838",
      "r845"
     ]
    },
    "ENVB_GoodwillAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillAccumulatedImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Impairment Losses, Impairment losses",
        "documentation": "Goodwill accumulated impairment loss.",
        "label": "GoodwillAccumulatedImpairmentLoss"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Impairment Losses, Loss on currency translation",
        "documentation": "Goodwill accumulated impairment loss foreign currency translation gain loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets and goodwill",
        "verboseLabel": "Impairment of intangibles",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r848"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r268",
      "r717"
     ]
    },
    "ENVB_GoodwillCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Currency Translation, Beginning balance",
        "periodEndLabel": "Currency Translation, Ending balance",
        "documentation": "Goodwill currency translation.",
        "label": "GoodwillCurrencyTranslation"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_GoodwillCurrencyTranslationImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillCurrencyTranslationImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Currency Translation, Impairment losses",
        "documentation": "Goodwill currency translation impairment loss.",
        "label": "GoodwillCurrencyTranslationImpairmentLoss"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_GoodwillCurrencyTranslationLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillCurrencyTranslationLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency Translation, Loss on currency translation",
        "documentation": "Goodwill currency translation loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Loss on currency translation",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "ENVB_GoodwillForeignCurrencyTranslationGainLossGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillForeignCurrencyTranslationGainLossGross",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill Gross, Loss on currency translation",
        "documentation": "Goodwill foreign currency translation gain loss gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillGross",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Goodwill Gross, Beginning balance",
        "periodEndLabel": "Goodwill Gross, Ending balance",
        "label": "Goodwill, Gross",
        "documentation": "Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r267",
      "r717"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Accumulated Impairment Losses, Beginning balance",
        "negatedPeriodEndLabel": "Accumulated Impairment Losses, Ending balance",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r267",
      "r717"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Goodwill, Impairment losses",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r263",
      "r265",
      "r268",
      "r717",
      "r730"
     ]
    },
    "ENVB_GoodwillImpairmentLossGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "GoodwillImpairmentLossGross",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Goodwill Gross, Impairment losses",
        "documentation": "Goodwill impairment loss gross.",
        "label": "GoodwillImpairmentLossGross"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_HCWainwrightAndCoLLCInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "HCWainwrightAndCoLLCInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "HC Wainwright and Co LLC Investment Options [Member]",
        "documentation": "HC Wainwright and Co LLC Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Identified definite lived assets, impairment loss",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r86",
      "r731"
     ]
    },
    "ENVB_IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "IncentivePlanMember",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Plan [Member]",
        "documentation": "Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r378"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r111",
      "r113",
      "r547",
      "r561",
      "r707",
      "r710",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfEarningLossBeforeIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r378"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r279",
      "r282",
      "r440",
      "r443",
      "r448",
      "r570",
      "r572",
      "r640",
      "r700",
      "r733",
      "r927"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r282",
      "r440",
      "r443",
      "r448",
      "r570",
      "r572",
      "r640",
      "r700",
      "r733",
      "r927"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r379",
      "r380",
      "r388",
      "r396",
      "r728",
      "r890"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r379",
      "r380",
      "r388",
      "r396",
      "r728",
      "r890"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r374",
      "r379",
      "r385",
      "r386",
      "r387",
      "r389",
      "r394",
      "r403",
      "r405",
      "r406",
      "r407",
      "r587",
      "r728"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfIncomeTaxExpenseBenefitsDetails",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "negatedTotalLabel": "Total income tax (expense) benefit",
        "label": "Income tax expenses and benefits",
        "negatedTerseLabel": "Income tax expenses and benefits",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r128",
      "r180",
      "r181",
      "r196",
      "r201",
      "r210",
      "r377",
      "r379",
      "r404",
      "r568",
      "r728"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r375",
      "r376",
      "r389",
      "r390",
      "r393",
      "r398",
      "r581"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense gross",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r887",
      "r888"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r160",
      "r395",
      "r396"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ENVB_IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use operating lease asset and obligation",
        "documentation": "Right-of-use operating lease asset and obligation.",
        "label": "IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, Indefinite lived intangible assets",
        "periodEndLabel": "Balance, Indefinite lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r274",
      "r718"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on currency translation",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ENVB_InducedConversionOfWarrantsAndPreferredInvestmentOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InducedConversionOfWarrantsAndPreferredInvestmentOptions",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Induced conversion of warrants and preferred investment options",
        "documentation": "Induced conversion of warrants and preferred investment options.",
        "label": "InducedConversionOfWarrantsAndPreferredInvestmentOptions"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InducementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InducementExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inducement expense, net",
        "label": "Inducement expense",
        "documentation": "Inducement expense."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InitialMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InitialMeasurementMember",
     "presentation": [
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Measurement [Member]",
        "documentation": "Initial Measurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INTANGIBLE ASSETS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r275",
      "r276",
      "r699",
      "r700"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r511",
      "r705",
      "r848"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r849",
      "r851"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income (expense), net",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r824"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r158",
      "r159"
     ]
    },
    "ENVB_InvestmentInducementGain": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentInducementGain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InvestmentInducementGain]",
        "documentation": "Investment inducement gain."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentIntrinsicValue",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InvestmentIntrinsicValue]",
        "documentation": "Investment intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOptionExercisePrice",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InvestmentOptionExercisePrice]",
        "documentation": "Investment option exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionSharePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOptionSharePrice",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InvestmentOptionSharePrice]",
        "documentation": "Investment option share price."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOptionTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InvestmentOptionTerm]",
        "verboseLabel": "Investment option term",
        "documentation": "Investment option term."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment options issued in conjunction with common stock issuance",
        "documentation": "Investment options issued in conjunction with common stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Options [Member]",
        "documentation": "Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOptionsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOptionsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investment Options to Purchase Shares of Common Stock [Member]",
        "documentation": "Investment Options to Purchase Shares of Common Stock [Member]",
        "label": "Investment Options to Purchase Shares of Common Stock [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_InvestmentOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvestmentOutstandingMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:InvestmentOutstandingMeasurementInput-0]",
        "documentation": "Investment outstanding measurement input."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of investment options",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r605",
      "r663",
      "r671",
      "r678",
      "r756"
     ]
    },
    "ENVB_InvstmentOptionsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "InvstmentOptionsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Options to Purchase Shares of Common Stock [Member]",
        "documentation": "Investment Options to Purchase Shares of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfCommonSharesForDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "IssuanceOfCommonSharesForDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for offering costs",
        "documentation": "Issuance of common shares for deferred offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "IssuanceOfEmbeddedDerivative",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of embedded derivative",
        "documentation": "Issuance of embedded derivative.",
        "label": "IssuanceOfEmbeddedDerivative"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfRedeemableNoncontrollingSeriesPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "IssuanceOfRedeemableNoncontrollingSeriesPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of redeemable Series C preferred stock",
        "documentation": "Issuance of redeemable noncontrolling series preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_IssuanceOfRoundedSharesAsResultOfReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "IssuanceOfRoundedSharesAsResultOfReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of rounded shares as a result of the reverse stock split",
        "documentation": "Issuance of rounded shares as result of reverse stock split."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_JanuaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "JanuaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Twenty Twenty One Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_KanubaddiSeparationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "KanubaddiSeparationAgreementMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kanubaddi Separation Agreement [Member]",
        "documentation": "Kanubaddi Separation Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "documentation": "Lab Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWeightedAverageRemainingLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r914"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, mezzanine equity, and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r110",
      "r557",
      "r742",
      "r813",
      "r833",
      "r912"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r134",
      "r164",
      "r248",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r418",
      "r420",
      "r421",
      "r455",
      "r742",
      "r855",
      "r916",
      "r917"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesRelatedToInvestmentContractsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesRelatedToInvestmentContractsFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of investment option liability",
        "documentation": "Fair value portion of liability related to investment contracts for example, but not limited to, guaranteed investment contract or annuities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r902",
      "r903",
      "r909"
     ]
    },
    "ENVB_LicensingAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "LicensingAgreementsDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/LicensingAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LICENSING AGREEMENTS",
        "documentation": "Licensing Agreements Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term purchase commitment, amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_MarketPerformanceBasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "MarketPerformanceBasedShares",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market performance based shares",
        "documentation": "Market performance based shares."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r328",
      "r371",
      "r438",
      "r506",
      "r569",
      "r571",
      "r579",
      "r606",
      "r607",
      "r661",
      "r665",
      "r669",
      "r670",
      "r676",
      "r697",
      "r698",
      "r713",
      "r721",
      "r726",
      "r734",
      "r735",
      "r739",
      "r740",
      "r752",
      "r857",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "ENVB_MeasurementInputMarketRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "MeasurementInputMarketRateMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Market Rate [Member]",
        "documentation": "Measurement Input Market Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r734"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r734"
     ]
    },
    "ENVB_MezzanineEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "MezzanineEquityMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity [Member]",
        "documentation": "Mezzanine Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r328",
      "r371",
      "r438",
      "r506",
      "r569",
      "r571",
      "r579",
      "r606",
      "r607",
      "r661",
      "r665",
      "r669",
      "r670",
      "r676",
      "r697",
      "r698",
      "r713",
      "r721",
      "r726",
      "r734",
      "r735",
      "r739",
      "r752",
      "r857",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "ENVB_MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum of stockholders equity required for continued listing pursuant to exchange",
        "documentation": "Minimum of stockholders equity required for continued listing pursuant to exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification and Inducement of Warrants and Investment Options",
        "documentation": "Modification and Inducement of Warrants and Investment Options [Policy text block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ModificationOfWarrantsAsPartOfShareCapitalRaise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ModificationOfWarrantsAsPartOfShareCapitalRaise",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants as part of share capital raise",
        "documentation": "Modification of warrants as part of share capital raise."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_MrKanubaddiEmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "MrKanubaddiEmploymentAgreementMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Kanubaddi Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r129"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows From Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r82",
      "r112",
      "r132",
      "r145",
      "r147",
      "r152",
      "r164",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r180",
      "r181",
      "r188",
      "r248",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r412",
      "r415",
      "r432",
      "r455",
      "r562",
      "r636",
      "r653",
      "r654",
      "r762",
      "r855"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to shareholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r184",
      "r189",
      "r192",
      "r415"
     ]
    },
    "ENVB_NetOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "NetOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net offering costs",
        "documentation": "Net offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_NoncashIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "NoncashIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash income tax benefit",
        "documentation": "Noncash income tax expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_NumberOfCommonStockSharesTraded": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "NumberOfCommonStockSharesTraded",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares traded in market",
        "documentation": "Number of common stock shares traded."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_NumberOfVestedAndUnissuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "NumberOfVestedAndUnissuedShares",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of vested and unissued shares",
        "documentation": "Number of vested and unissued shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_OfferingCostsAccruedNotPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "OfferingCostsAccruedNotPaid",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs accrued not paid",
        "documentation": "Offering costs accrued not paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_OneTimeMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "OneTimeMilestoneMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Time Milestone [Member]",
        "documentation": "One Time Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "negatedLabel": "Loss from operations",
        "label": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r707",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of right-of-use operating lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use operating lease asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of right of use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss tax carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r624",
      "r629",
      "r643",
      "r649",
      "r673",
      "r674",
      "r675",
      "r754",
      "r755"
     ]
    },
    "ENVB_OptionsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "OptionsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options to Purchase Shares of Common Stock [Member]",
        "documentation": "Options to Purchase Shares of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation",
        "verboseLabel": "Foreign exchange translation gain (loss)",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r563"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_OtherConsultingAndVendorAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "OtherConsultingAndVendorAgreementsMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Consulting and Vendor Agreements [Member]",
        "documentation": "Other Consulting and Vendor Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://enveric.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment option liability",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r742"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r834"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs reversed",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ENVB_PIPEInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PIPEInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipe Investment Options [Member]",
        "documentation": "Pipe Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PIPESecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PIPESecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Securities Purchase Agreement [Member]",
        "documentation": "PIPE Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expenses",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase committment",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfRedeemablePreferredStock",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of Series A Preferred Stock",
        "negatedTerseLabel": "Redemption of Akos Series A Preferred Stock",
        "label": "Payments for Repurchase of Redeemable Preferred Stock",
        "documentation": "The cash outflow for reacquisition of callable preferred stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ENVB_PaymentsOfAllocatedEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PaymentsOfAllocatedEquity",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of allocated equity",
        "documentation": "Payments of allocated equity."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PaymentsOfInvestmentOptionLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PaymentsOfInvestmentOptionLiability",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of investment option liability",
        "documentation": "Payments of investment option liability."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PaymentsOfStockIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PaymentsOfStockIssuanceCost",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offerings costs",
        "documentation": "Payments of stock issuance cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for offering costs previously accrued",
        "verboseLabel": "Offerings costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ENVB_PaymentsOfStockIssuanceCostsRecordedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PaymentsOfStockIssuanceCostsRecordedExpense",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of stock issuance costs recorded expense",
        "documentation": "Payments of stock issuance costs recorded expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ENVB_PlacementAgentPreferredInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PlacementAgentPreferredInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Preferred Investment Options [Member]",
        "documentation": "Placement Agent Preferred Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885"
     ]
    },
    "ENVB_PostModificationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PostModificationWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Modification Warrants [Member]",
        "documentation": "Post Modification Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ENVB_PreModificationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PreModificationWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Modification Warrants [Member]",
        "documentation": "Pre Modification Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PreferredDividendsAttributableToRedeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PreferredDividendsAttributableToRedeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred dividends attributable to redeemable",
        "label": "Preferred dividends attributable to redeemable non-controlling interest",
        "documentation": "Preferred dividends attributable to redeemable noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock authorized for future issuances",
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r662",
      "r666",
      "r668",
      "r677"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less preferred dividends attributable to non-controlling interest",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r615"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r615",
      "r634",
      "r957",
      "r958"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r552",
      "r742"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r63"
     ]
    },
    "ENVB_PrefundedCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PrefundedCommonStockWarrantsMember",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Common Stock Warrants [Member]",
        "documentation": "Prefunded Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ENVB_PrepaidFranchiseTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PrepaidFranchiseTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Franchise tax receivable",
        "documentation": "Prepaid franchise tax receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r715",
      "r834"
     ]
    },
    "ENVB_PrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PrepaidResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid research and development",
        "documentation": "Prepaid research and development."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PrepaidResearchAndDevelopmentTaxIncentiveReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PrepaidResearchAndDevelopmentTaxIncentiveReceivable",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D tax incentive receivable",
        "verboseLabel": "Research and development expense tax credit receivable",
        "documentation": "Prepaid research and development tax incentive receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid value-added taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r716",
      "r834"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ENVB_ProceedsFromAchievingDevelopmentAndSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ProceedsFromAchievingDevelopmentAndSalesMilestones",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ProceedsFromAchievingDevelopmentAndSalesMilestones]",
        "documentation": "Proceeds from achieving development and sales milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from common stock sold under the Purchase Agreement, net of offering costs",
        "documentation": "Proceeds from common stock sold under purchase agreement net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from common stock sold under the Equity Distribution Agreement, net of offering costs",
        "verboseLabel": "Proceeds from common stock",
        "terseLabel": "Gross proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants for cash proceeds",
        "verboseLabel": "Proceeds from issuance of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from RD offerings",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromRepurchaseOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepurchaseOfRedeemablePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of redeemable non-controlling interest, net of offering costs",
        "documentation": "Cash inflows (outflows) from issuing and redeeming redeemable preferred stock; includes convertible and nonconvertible redeemable preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from disposal of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional working capital",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of Inducement Warrants",
        "verboseLabel": "Cash proceeds of warrants",
        "terseLabel": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r469"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r122",
      "r125",
      "r126"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r135",
      "r560"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Property and equipment, net of accumulated depreciation",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r469",
      "r548",
      "r560",
      "r742"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property &amp; Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r122",
      "r125",
      "r558"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://enveric.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r469"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PurchaseAgreeentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PurchaseAgreeentMember",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreeent [Member]",
        "documentation": "Purchase Agreeent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_PurchaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "PurchaseAgreementsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreements [Member]",
        "documentation": "Purchase Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RDInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RDInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R D Investment Options [Member]",
        "documentation": "D Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RDOfferingAndPIPEInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RDOfferingAndPIPEInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RD Offering and Pipe Investment Options [Member]",
        "documentation": "RD Offering and Pipe Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r321",
      "r328",
      "r359",
      "r360",
      "r361",
      "r371",
      "r438",
      "r481",
      "r490",
      "r506",
      "r569",
      "r571",
      "r579",
      "r606",
      "r607",
      "r661",
      "r665",
      "r669",
      "r670",
      "r676",
      "r697",
      "r698",
      "r713",
      "r721",
      "r726",
      "r734",
      "r735",
      "r739",
      "r740",
      "r752",
      "r756",
      "r853",
      "r857",
      "r905",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r321",
      "r328",
      "r359",
      "r360",
      "r361",
      "r371",
      "r438",
      "r481",
      "r490",
      "r506",
      "r569",
      "r571",
      "r579",
      "r606",
      "r607",
      "r661",
      "r665",
      "r669",
      "r670",
      "r676",
      "r697",
      "r698",
      "r713",
      "r721",
      "r726",
      "r734",
      "r735",
      "r739",
      "r740",
      "r752",
      "r756",
      "r853",
      "r857",
      "r905",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ]
    },
    "ENVB_RedeemableNonControllingInterestTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNonControllingInterestTextBlock",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REDEEMABLE NON-CONTROLLING INTEREST",
        "documentation": "Redeemable non controlling interest [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable noncontrolling interest",
        "documentation": "Redeemable non controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable non-controlling interest",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r91",
      "r92"
     ]
    },
    "ENVB_RedeemableNoncontrollingInterestIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterestIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable noncontrolling interest issuance costs",
        "documentation": "Redeemable noncontrolling interest issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of embedded derivative",
        "documentation": "Issuance of embedded derivative."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterestMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Noncontrolling Interest [Member]",
        "documentation": "Redeemable Noncontrolling Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterestPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Redeemable Non-controlling Interest",
        "documentation": "Redeemable non controlling interest policy [Text block].",
        "label": "RedeemableNoncontrollingInterestPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterestShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962, shares",
        "documentation": "Redeemable noncontrolling interest shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RedeemableNoncontrollingInterestValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RedeemableNoncontrollingInterestValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable non-controlling interest, net of $402,000 embedded derivative and net of issuance costs of $41,962",
        "documentation": "Redeemable noncontrolling interest value."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ReductionInForceRestructuringPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ReductionInForceRestructuringPercentage",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction in force restructuring percentage",
        "documentation": "Reduction in force restructuring percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs",
        "documentation": "Registered direct offering pipe offering modification of warrants and exercise of prefunded warrants net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2022 registered direct offering, PIPE offering, modification of warrants and exercise of pre-funded warrants, net of offering costs, shares",
        "documentation": "Registered direct offering pipe offering modification of warrants and exercise of pre funded warrants net of offering costs shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegisteredDirectSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RegisteredDirectSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Securities Purchase Agreement [Member]",
        "documentation": "Registered Direct Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RegistrationRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RegistrationRightsAgreementMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Rights Agreement [Member]",
        "documentation": "Registration Rights Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ResearchAndDevelopmentCapitalizedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ResearchAndDevelopmentCapitalizedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development capitalized expenses",
        "documentation": "Research and development capitalized expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expenses",
        "negatedLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r700",
      "r710",
      "r924"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ENVB_ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Tax Incentive Receivable",
        "documentation": "Research and Development Tax Incentive Receivable [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RestrictedStockAwardsVestedAndUnIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RestrictedStockAwardsVestedAndUnIssuedMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards Vested and Unissued [Member]",
        "documentation": "Restricted Stock Awards Vested and Unissued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RestrictedStockUnitsUnvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RestrictedStockUnitsUnvestedMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Unvested [Member]",
        "documentation": "Restricted Stock Units Unvested [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RestrictedStockUnitsVestedAndUnIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RestrictedStockUnitsVestedAndUnIssuedMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units Vested and Unissued [Member]",
        "documentation": "Restricted Stock Units Vested and Unissued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails",
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring cost payable, beginning",
        "periodEndLabel": "Restructuring cost payable, ending",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "documentation": "Amount of costs incurred to date for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r283",
      "r284",
      "r286"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfReductionInForcerestructuringActivityDetails",
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs",
        "verboseLabel": "Restructuring costs paid",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ENVB_RestructuringCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RestructuringCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestructuringCostsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring costs incurred",
        "documentation": "Restructuring costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reversed amount",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r285"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r94",
      "r556",
      "r576",
      "r578",
      "r586",
      "r616",
      "r742"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r249",
      "r250",
      "r277",
      "r400",
      "r401",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r422",
      "r424",
      "r425",
      "r427",
      "r430",
      "r464",
      "r465",
      "r573",
      "r575",
      "r588",
      "r957"
     ]
    },
    "us-gaap_RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, measurement input",
        "documentation": "Value of input used to measure direct or indirect retained investment in deconsolidated subsidiary."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r904",
      "r905",
      "r906"
     ]
    },
    "ENVB_RothAndInducementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RothAndInducementWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Roth and Inducement Warrants [Member]",
        "documentation": "Roth And Inducement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalties percentage",
        "documentation": "Royalties percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and benefit",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ENVB_SaleOfStockConsiderationExpectedMaximumPriceOnLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SaleOfStockConsiderationExpectedMaximumPriceOnLimitation",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross sales price",
        "documentation": "Sale of stock consideration expected maximum price on limitation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, offering price",
        "verboseLabel": "Sale of stock, value",
        "terseLabel": "Gross proceeds from sale of shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares resale",
        "verboseLabel": "Sale of stock",
        "terseLabel": "Number of shares sold",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, price per share",
        "verboseLabel": "Investment, stock price",
        "terseLabel": "Share price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "auth_ref": [
      "r182",
      "r329",
      "r787",
      "r819"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://enveric.com/role/AccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF ACCRUED LIABILITIES",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INCOME TAX EXPENSE BENEFITS",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://enveric.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EFFECTIVE STATUTORY INCOME TAX RATE",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r728",
      "r887"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r408",
      "r788",
      "r789",
      "r790",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risk [Table]",
        "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF GOODWILL",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF EARNING (LOSS) BEFORE INCOME TAX",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INTANGIBLE ASSETS",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r848"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfPropertyPlantAndEquipmentNetOfAccumulatedDepreciationDetails",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r469"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesTables",
      "http://enveric.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RESTRUCTURING COSTS PAYABLE",
        "verboseLabel": "SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r88",
      "r89"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r101"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r96"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ASSUMPTION",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF INVESTMENT OPTIONS",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ENVB_ScheduleOfValuationOfWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ScheduleOfValuationOfWarrantsTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS",
        "documentation": "Schedule Of Valuation Of Warrants [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ScheduleOfWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ScheduleOfWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS OUTSTANDING",
        "documentation": "Schedule of warrants outstanding [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERM",
        "documentation": "Schedule of Weighted Average Remaining Lease Term [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://enveric.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r850"
     ]
    },
    "ENVB_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities purchase agreement [Member]",
        "documentation": "Securities purchase agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r212",
      "r213",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r602",
      "r603",
      "r604",
      "r664",
      "r667",
      "r672",
      "r679",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r701",
      "r722",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r753",
      "r756",
      "r859",
      "r926",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r211",
      "r212",
      "r708",
      "r709",
      "r712"
     ]
    },
    "ENVB_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r858"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r858"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r858"
     ]
    },
    "ENVB_SeriesCRedeemablePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SeriesCRedeemablePreferredStockMember",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Redeemable Preferred Stock [Member]",
        "documentation": "Series C Redeemable Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive plan description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Non-vested beginning",
        "periodEndLabel": "Number of shares, non-vested ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average fair value, Non-vested beginning",
        "periodEndLabel": "Weighted average fair value, Non-vested ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unissued shares for cash",
        "documentation": "Amount of cash paid to settle liability for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested",
        "label": "Common stock vested restricted stock units",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions stock price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchanged for common stock",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exchanged."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrant shares outstanding, exercised",
        "label": "Investment options outstanding, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrant shares outstanding,expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrant shares outstanding, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant shares outstanding, Issued",
        "verboseLabel": "Investment options outstanding, Issued",
        "documentation": "Warrant shares outstanding, issued."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Issued",
        "verboseLabel": "Weighted average exercise price, issued",
        "documentation": "Weighted average exercise price, issued"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Exercised",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments issued in period weighted average exercise price exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrant shares outstanding at beginning",
        "periodEndLabel": "Warrant shares outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding at beginning",
        "periodEndLabel": "Weighted average exercise price, outstanding at end",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, Outstanding beginning",
        "periodEndLabel": "Weighted average exercise price, Outstanding end",
        "documentation": "Stock options, outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life, outstanding",
        "verboseLabel": "Weighted average remaining life, Outstanding",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Warrant shares outstanding, exercisable",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, exercisable",
        "documentation": "Warrants, weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized shares reserved",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable shares at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable weighted average price at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, exercisable",
        "documentation": "Weighted average grant date fair value, exercisable.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, forfeited",
        "documentation": "Weighted average grant date fair value, expired, forfeited, or cancelled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value, granted",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock awards",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, outstanding at beginning",
        "periodEndLabel": "Aggregate intrinsic value, outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, outstanding at beginning",
        "periodEndLabel": "Number of shares, outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, outstanding at beginning",
        "periodEndLabel": "Weighted average exercise price, outstanding at end",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, outstanding at beginning",
        "periodEndLabel": "Weighted average grant date fair value, outstanding at end",
        "documentation": "Weighted average grant date fair value, outstanding at beginning of the year.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfRestrictedStockUnitsAndAwardsActivityDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362"
     ]
    },
    "ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their warrants into shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Share based compensation arrangements by share based payment award non options exercises in period weighted average expired price."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, Forfeited",
        "documentation": "Share based compensation arrangements by share based payment award non options forfeited in eriod weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r337",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r365",
      "r366",
      "r367",
      "r368"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value (per share)",
        "verboseLabel": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_SharePriceOption": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SharePriceOption",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:SharePriceOption-0]",
        "documentation": "Share price option."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Intrinsic value, outstanding beginning",
        "periodEndLabel": "Intrinsic value, outstanding ending",
        "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments non options, aggregate intrinsic value.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Intrinsic value, exercisable",
        "label": "Intrinsic value, exercisable",
        "documentation": "Sharebased compensation arrangement by sharebased payment award equity instruments non options exercisable aggregate intrinsic value nonvested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelForValuationOfWarrantsDetails",
      "http://enveric.com/role/ScheduleOfStockOptionAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrinsic value, Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ENVB_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption",
     "presentation": [
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life, exercisable",
        "verboseLabel": "Weighted average remaining life, Exercisable",
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Non Option."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://enveric.com/role/ScheduleOfStockOptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, outstanding balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued shares",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r162"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ENVB_SpinoffAndRelatedPrivatePlacementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SpinoffAndRelatedPrivatePlacementDescription",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Spin-off and related private placement, description",
        "documentation": "Spinoff and related private placement, description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfOperatingLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r139",
      "r140",
      "r141",
      "r164",
      "r186",
      "r187",
      "r190",
      "r192",
      "r198",
      "r199",
      "r248",
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r305",
      "r306",
      "r308",
      "r311",
      "r318",
      "r455",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r600",
      "r615",
      "r637",
      "r655",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r786",
      "r812",
      "r821"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r67",
      "r68",
      "r131",
      "r150",
      "r151",
      "r152",
      "r168",
      "r169",
      "r170",
      "r172",
      "r177",
      "r179",
      "r181",
      "r197",
      "r249",
      "r250",
      "r277",
      "r320",
      "r400",
      "r401",
      "r409",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r430",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r471",
      "r563",
      "r573",
      "r574",
      "r575",
      "r588",
      "r655"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r602",
      "r603",
      "r604",
      "r664",
      "r667",
      "r672",
      "r679",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r701",
      "r722",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r753",
      "r756",
      "r859",
      "r926",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r197",
      "r465",
      "r510",
      "r580",
      "r600",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r638",
      "r639",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r757"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r329",
      "r787",
      "r791",
      "r819"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/FairValueDetailsNarrative",
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ScheduleOfInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfStock-basedCompensationForRestrictedStockUnitsDetails",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r197",
      "r214",
      "r465",
      "r510",
      "r580",
      "r600",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r635",
      "r638",
      "r639",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r655",
      "r757"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock and warrants issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "ENVB_StockIssuedDuringPeriodCommitmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodCommitmentShares",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares commitment",
        "documentation": "Stock issued during period commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock sold under the Equity Distribution Agreement, shares",
        "documentation": "Stock issued during period shares common stock sold under equity distribution."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSAs into common shares, shares",
        "verboseLabel": "Stock issued during period conversion of restricted stock award",
        "documentation": "Stock issued during period shares conversion of restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for RSU conversions from the reduction in force, shares",
        "verboseLabel": "Issuance of common shares in exchange for RSU conversions, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r63",
      "r64",
      "r94"
     ]
    },
    "ENVB_StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Inducement Warrants for common stock, shares",
        "documentation": "Stock issued during period shares exercise of inducement warrants for common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for vested RSU, shares",
        "documentation": "Stock issued during period shares issuance of common shares for vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of direct offering shares, shares",
        "documentation": "Stock issued during period shares issued direct offering net of offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for deferred offering costs, shares",
        "verboseLabel": "Issued shares",
        "terseLabel": "Stock issued during period shares new issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r64",
      "r94",
      "r582",
      "r655",
      "r681"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance, shares",
        "verboseLabel": "Shares other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSUs into common shares, shares",
        "verboseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock units, shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of rounded shares as a result of the reverse stock split, shares",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ENVB_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised of warrants",
        "documentation": "Number of share warrants (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock sold under the Purchase Agreement, net of offering costs of $290,029",
        "documentation": "Stock issued during period value common stock sold under equity distribution."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSAs into common shares",
        "documentation": "Stock issued during period value conversion of restricted stock awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares in exchange for RSU conversions from the reduction in force",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r64",
      "r67",
      "r68",
      "r94"
     ]
    },
    "ENVB_StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Inducement Warrants for common stock",
        "documentation": "Stock issued during period value exercise of inducement warrants for common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for vested RSU",
        "documentation": "Stock issued during period value issuance of common shares for vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of direct offering shares (see Note 7)",
        "documentation": "Stock issued during period value issued direct offering net of offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares for deferred offering costs",
        "verboseLabel": "Issued stock value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r64",
      "r94",
      "r588",
      "r655",
      "r681",
      "r763"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of common stock in abeyance",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of RSUs into common shares",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r64",
      "r94"
     ]
    },
    "ENVB_StockOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockOptionExercisePrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, exercise price",
        "documentation": "Stock option exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Series A preferred stock, shares",
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption of Series A preferred stock",
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for grant",
        "label": "Share Repurchase Program, Remaining Authorized, Number of Shares",
        "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_StockSubscriptionReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "StockSubscriptionReceivable",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock subscription receivable",
        "documentation": "Stock subscription receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets",
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67",
      "r68",
      "r84",
      "r617",
      "r634",
      "r656",
      "r657",
      "r742",
      "r764",
      "r813",
      "r833",
      "r912",
      "r957"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r163",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r320",
      "r429",
      "r658",
      "r659",
      "r685"
     ]
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock subscription receivable",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r63",
      "r64",
      "r67",
      "r660"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ENVB_SubscriptionReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SubscriptionReceivableMember",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Receivable [Member]",
        "documentation": "Subscription Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r473"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://enveric.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r474"
     ]
    },
    "ENVB_SubsequentMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "SubsequentMeasurementMember",
     "presentation": [
      "http://enveric.com/role/FairValueTables",
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Measurement [Member]",
        "documentation": "Subsequent Measurement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF OPERATING LOSS CARRY FORWARDS",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash and non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accretion of embedded derivative to redemption value",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less deemed dividends attributable to accretion of embedded derivative at redemption value",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r295",
      "r296",
      "r297",
      "r300",
      "r301",
      "r369",
      "r554"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total mezzanine equity",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r164",
      "r248",
      "r455"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r40"
     ]
    },
    "ENVB_TemporaryEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "TemporaryEquityShares",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Mezzanine equity balance, shares",
        "periodEndLabel": "Mezzanine equity balance, shares",
        "documentation": "Temporary Equity Shares.",
        "label": "TemporaryEquityShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://enveric.com/role/BalanceSheetsParenthetical",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares outstanding",
        "verboseLabel": "Redeemable preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ENVB_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://enveric.com/role/StatementsOfChangesInMezzanineEquityAndShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of redeemable Series C preferred stock, shares",
        "documentation": "Temporary Equity Stock Issued During Period Shares New Issues."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ScheduleOfReconciliationChangeInRedeemableNoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of redeemable noncontrolling Series C preferred stock",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityTableTextBlock",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST",
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r40"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r915"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r303",
      "r316",
      "r428",
      "r454",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r564",
      "r729",
      "r732",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r743",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r829",
      "r830",
      "r831",
      "r832",
      "r901",
      "r904",
      "r905",
      "r906",
      "r909",
      "r911"
     ]
    },
    "ENVB_TwoThousandTwentyLongTermIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "TwoThousandTwentyLongTermIncentivePlanMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2020 Long Term Incentive Plan [Member]",
        "documentation": "2020 Long Term Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_UnderwritersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "UnderwritersMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriters [Member]",
        "documentation": "Underwriters [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_UnpaidDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "UnpaidDividends",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid dividends",
        "documentation": "Unpaid dividends."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r118",
      "r120",
      "r123",
      "r124"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "ENVB_VogalNathanPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "VogalNathanPurchaseAgreementMember",
     "presentation": [
      "http://enveric.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vogal Nathan Purchase Agreement [Member]",
        "documentation": "Vogal Nathan Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WainwrightInvestmentOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WainwrightInvestmentOptionsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wainwright Investment Options [Member]",
        "documentation": "Wainwright Investment Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantAmendmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantAmendmentAgreementsMember",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wainwright Amendment Agreements [Member]",
        "documentation": "Wainwright Amendment Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative",
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price",
        "verboseLabel": "Share price",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "ENVB_WarrantLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://enveric.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://enveric.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability",
        "documentation": "Warrant liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - February 2021 Warrants [Member]",
        "documentation": "Warrant liabilities - February 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - February 2022 Warrants [Member]",
        "documentation": "Warrant liabilities - February 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueHierarchyOfValuationInputsOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities - January 2021 Warrants [Member]",
        "documentation": "Warrant liabilities - January 2021 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability",
        "documentation": "Warrant liability.",
        "label": "WarrantLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://enveric.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability and Investment Options",
        "documentation": "Warrant Liability [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfFairValueOfWarrantLiabilitiesAndDerivativeLiabilityAndInvestmentOptionsDetails",
      "http://enveric.com/role/ScheduleOfWarrantsOutstandingDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "verboseLabel": "Warrants, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "ENVB_WarrantsAndRightsOutstandingStockPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantsAndRightsOutstandingStockPrice",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant measurement input",
        "documentation": "Warrants, stock price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://enveric.com/role/ScheduleOfBlackScholesValuationModelsOfWarrantLiabilitiesAndInvestmentOptionsDetails",
      "http://enveric.com/role/ShareCapitalAndOtherEquityInstrumentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Investment option term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r904",
      "r905",
      "r906"
     ]
    },
    "ENVB_WarrantsIssuedForOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantsIssuedForOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for offering costs",
        "documentation": "Warrants issued for offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantsIssuedInConjunctionWithCommonStockIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantsIssuedInConjunctionWithCommonStockIssuance",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued in conjunction with common stock issuance",
        "documentation": "Warrants issued in conjunction with common stock issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantsToPurchaseCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantsToPurchaseCommonStockPercentage",
     "presentation": [
      "http://enveric.com/role/RedeemableNon-controllingInterestDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock, percentage",
        "documentation": "Warrants to purchase common stock percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ENVB_WarrantsToPurchaseSharesOfCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WarrantsToPurchaseSharesOfCommonStockMember",
     "presentation": [
      "http://enveric.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Shares of Common Stock [Member]",
        "documentation": "Warrants to Purchase Shares of Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r192"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://enveric.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r192"
     ]
    },
    "ENVB_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://enveric.com/20240930",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/BusinessAndLiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Working capital."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "825",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478850/944-825-25-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480647/815-10-15-83"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "910",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482332/910-20-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001493152-25-004528-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-004528-xbrl.zip
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M_-75F]>OKZ]^'PZFG.XB(OSXZ!#W6QGY]8</'ZYX:DQ:H'Q<^$Y<]-LKEKQ
M%"<E0RJIH2<N#9!K9>CM(,F0)GYW%25F2$DIZ?N(E,2D-L[146R]6GGW5Y
M]&]^C@E#>KE":)L0+Q%=\$)W"1EBZ@=%0OB8)[H,GK:8EI)&29D,=N#G,F1Z
M#9*O6#++\^;R]=O+M]=Q3GUT=Y-DPBXH([&8,//B7W]XRU32P1OL!GW/W_3P
M$H4.</!'B!RR)-B^4 +DKW# I)-ND87K"XLE'+FN!XH VKC[PKYMMP0D/?D
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MO\:SS[JIS$>:;LY48S0S]&F':+GVA9L-\I_&RRE9N; \MI ;J);EA8"+NYJ
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MJ@XM".82 +G66:?W^[H6G?F<J;/Y;&Q^30_>( #=J83F4PG)I0E5!Q*J"00
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MMH]Z@WD\\G[R8RU#O%E@_X*W&<Q)06+B."SUTP68F&PLA=:2CS#&$L^>\:G
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MT2.+*>62,78'9$."3+3:$?EEC0MBQY8)9<>]05E8;"':A]A6I!VG)ZR<4]U
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MK /O_G!?\M9ZZE+!8(W]"-F\KA^0[_Q=\-L5M=:P1H&?_P=02P,$%     @
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M#8ICY)/OYIZIZ*"3?+7Q%#.31Q=G6M GNOM$[%EV/JS,A_10JF?$S0WRV T
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M=E^+3-ZB=6F:H1?+]OU#B)\08B>F['@K.BF"719OVO;EM[$RX"K,PZN)/F^
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MJ%X+J\$RP4EZB7VR<7ML:3\$)OY8#<RU%G&3X V^45:+Y &IR%+)N:V;D?6
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M7DR&0P.4_7]K:EG^^9."UI$7:.DK+M'<!$>K^+5-WA<0^-?2UX]! UL7%Z2
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MHULB;H>P%1#;U,O>$L3,B-FX><K4LV52.J"-.B2BVC]LPF*YVAA:WLTE">J
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M\;1OOYK:L_F4_/)JZHP^]RSZ3*(S_V/W.<1<%/0_- N8_.;_ U!+ P04
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M2N]0,E*/#XU+8E13PT'0;+L]/!]B>O2P*IYP1O=+,_R$DSQZP4L2QC^+'=4
M?J?SGJU9G3G0E!D,&FTUYN;&U7R)9D6110^'@KFX(B6S9(:3\19M)T-U0V2O
M=K,L(YJS'37%7J:$UB4$E>JVX28D! ,ME79\"!\3[C0+"@([U.)!01)V_INA
M%!5/ 0G".DR3'M*4"]#+*"^!3F;UV6.&F4;R:,R R5E(9FQ $Y=I.;P#S4I-
MR2E?FQ$UG'!<%PTD\=\.] 3SA?P/'5.J@Q@9M=-M<[7*G2US,:EW9)GI)PKZ
M2VK$R!&E!W,.TS5%?0(CIO4((L6IBX@0*H"T:\8.?";>7/C7(#D\!&$8W>%]
MD 6&DYH)E[-9S=R$9EK3LW@'CYV>?1@UC.C(.<',)CM)R9KG+Y[W<?K* C\]
MK,SXW)VS6)AQ/'8Q8((!+@M-N4.9#!T1=F2&&#O-O@19J(F8>C1.=QI$ZG5V
M$]H$WH&CTHK;%: TH,*?-:9Q_K:H4A[NDZC(UW?WFFU/)8_;W4\#];N;H H&
M,%@RT9+?$JUYJA,_QH6^)7SY'R9V/GE6M,!&_NL(-/(?QXRMCSA]S(+]4[0-
M8H'ST="Z ):1NA102D+O0#+1K@^@-MD4[BG'VS\^IB_D[1^2(GLM 5/]QQ$O
MU1_^2C3JFM3^P042>$7H9S_^U?LWYE3I?]#[F^5F<8GN-K/-XL[CIYS/))K3
M'UQ^RJ,B[4\YGX'YE(TJW#[P[&9V.?/X#6?W$I7I#RZ_X5&1]C><W8/YAHTJ
M7/!W?[=9SZZ7XWY&TSEX34\*)'-NZS=7<RRG3CVG-C]X_Z B;;B]*3+'1GG!
MILQ/.,@/6;76FS"ZUWSH3U$2/1^>A1&\X'=7'URH5OW1.S^"^/ BC;@E?TD#
M9V%_FZ5[G!6OMT3-8I:$]"QG3_'XX56SW#?B=+FPLS"EO;PS8/,.+WM=^\"[
M3I/'=]?1"UGJ;<C?(YI>,,MS/*W?L0#B:K>+MK@Q2+F;(*%U"3:ENFUX"0G!
M $JE71]")2UJB/UN$'P*OJKGK.[OSN8LD5K-G-7^T3L&9!IQ<U9),_5Q![T4
M=:"7U%NYZK\$-%VE$*=4&G,Y.^HP-Z$YZ-"S>,>)G9Y]]#2,J'.WH.:%$PG-
MDB(*H_A ,Z#N\/:0146$\\77;7P@VE^1KTP3^@X%.P5<[>HLTEN<W3T%&?[P
M*A:@.C"9\HE.CU^F?W6=PYSI'N=]L+FSD=MK:#&@(\>TR8"U&]BDM^3M/04Y
M9NKGJYWN7I@]N[-I8(!1S7Q@P>L=JP,5[@.OF0IHNG,E Y5"Z!7\2:ZD26]*
M\X=HG\G?<$@66_?),L\/.%1=E[9@=WAGVMJHUL5I8UX8<+17V/!0M!3"<JC)
M'Y@8'VB\3UZ8(G8@['-YQ9[8!"7DNBQPD2;4TQ!@-:]C5+'\DA.<G(;?%]*,
MS))A3LD,$GTF&FMQ6 KQX>E:H<(RF3W@5UHV5 Y!);DSQ!DHW0!,00L#3WH%
ME:4"H@353%-C99F\Y 7=?URQ*\%#EPZ#Q#C#U@E&-I@;( ,&%H<KWL?HDLVI
MY66W4A: 1<9IN 4)UQ-0>F[@/!F3<(!X'!TGN](!<ESZTL%FMIVIM1"G@'W!
MV4/:5"T>YR.=DU<EAJL/CZ54SH H5[&!&4\"P^M)]>+R#(*'"4Z(Y<N&_:'
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M2\9%:\;RN9E'D\9I-;=T^^O=4T!>X.I0Y'0&)8K)=\&53(Z/%PP,Z!TR*#@
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M34KM%'MJE3N@$Y/"09M2/WZ?Z07G19F]MF= JWW:R5=<</+RP,#Q_J<?WS.
M+&X^?_CK+T&6!4FAQ8>.V 4\S!2FZ%!3>@>'D7I<:Y&2?CQ$G.Q9+G$6O02T
M=(FQ>U&SN/0Q)LJW'8V*WCN@+)3DLKD;%D#(,L:3;Q298<<S8K3[G,9@Z::E
M0(JWZ<V8B,V<=/MLGK(;Z#C9$MTD1BLYG&90ZE7O)%;*R<'X(;V.?,?+AH.E
M%FS;/.C;F[3 Z*<_>(?9!C_3^R[9J]&VNI3:);PT*K>A)2$% RNU?GU(?<*_
M_18D48)9G@J 6:VG_IP$=*\$X[-GN@DV*XHL>C@4=!]LD]X&BDEO@!R/@#,W
M4P%%O1"H(#76G*^\GE'7-T<9#C%^IAQHG]$;=N0/*"^O@/[=^S^^_Q[M@PR]
M!/$!7Z#OW[^_>/_^/<K+NZ'!H7A*L^@W'%XPM]K\$-$:N&&9?WR\/XJ"G&YM
MW)$OC&EU#?3C^PM$<<P(+_&V^NOW[*\_>A]1Z^;5T--Y,F60KT/D/[*JBF0E
M+?H$DL\V3)3+<76*L>VA-40.F-%U@O)<DMEQ7"5I\JXE#$65-.\ 5SJ395)E
M+]V6NY)=YR)^/[)H>(H'@9ET3GI1QK/2H*? 6@A.9I]X(?D,+4*S3IR!DBIC
MEQQS!NDPU@DPK!A&Q5!GMP!!U6T=M3&C/M- 36*UD-+Q[3V9JKW;>GTR,,B1
MZR:XC=>-IED,[1TNK?(P*JSP9*XWK41*]G>JVC1@(")13+0GE2:PP#$+0U;'
M(HAO@RA<)O-@'Q5<@W<MM=/L%+7*G=P4,2D8X*CUX_)2&FI$;_V^BQ*T+1F\
MPXB?7ND.Z]WA(=]F$3MYSM=DM1^]T.#.>(I6RO ;#AF8IXZ0% +<P/.G$IX)
M?J3EEE11_!#E^3(Z1 ;*6SPH:WB\PW>-BX L&\)%D"6TYMYLNST\'V+Z8B[Q
M+MI&\ET>/:/;/1U30[H[.#HN,![36%5!4E]-B,*2TCOL6CJQO!Y:?98L.G"2
M1R^8%D-[QM=I3B^6K7:;X*ML$K&5XCB5=(B)O013&Q%@H#I,;Q5NJ\H>;3DH
M3D=NXC'.]&\\E?B>R,UF:UC;:E+]Q-MB.=RM#-TM)7V"B80-TKTR30J/D <6
MX RU%<.OE=9SP6W1EL>(@!':U'_<*)<N72(O!3PW\L5'FP+,_"A42UY^\R^,
MS'^5S4:C:X)BVCE"=@0F(O0"#$Y1(3@:*G@ Z:NF  DE9?T\<O](Z9U^W0;9
M*F.JAFR7\!9G[)#![.Q,SNWQ6%1GDN*L4\8*!GUV^G)37\W=S'--4@TT7)9E
MWV=-9H_9^^"Y/.)09H("?WT6J+B3Z*G'&Y>Q!1-WK'FZ%>9J#N]XZZJNQ5I)
M#AMG'1V-,58F_\'$E[Q+B3F;=Z1).I68\L#&G+Y;B11XZ42M2D[/RK ,]DR9
M_>5NV(1Z9IQ@4&FEKC;I TZ<U[7+,,S3,?E#H$F0I^8 BCC#$(]#&KP(3V27
M,L!3,?A&FCR\DU.#1I@RN).A"TAL)[)'']IIN7QC3!/8:5A HTT?ULD@!RFJ
M:Z7V689T1IR>4BQM@CD#-C X--=5G9L))X;C>CMJ S@EAR>\F81N"G*(^#(,
MVKJX@A>Q<18IPS4IM5=<R0,U"2E</"E#-"&6@,1G%MV!S5B\(DH3EH'N"VRA
MI!' ($5C9=9<<]RKN4PGI7;;"D&I<K?[@9 4#*+4^O&UYR@U:IW-P^F4VM1L
MG*<Y*RE3]5[3-4\UX/-24U-GAK"LIHP)#-Y,->7:5#7%,^N^>-X!]Q$G1*>8
MV# +GZ,DHOK3&FF519(7H.5R"39#$]I0T["  9J9GGV855PL@3'H\'F'VQKG
MF+S+)V+1)7[!<<JZ:JG!IN%Q>XO%0/WN!18% QB8F6C)%Q4I>1C*PB.7=XC5
M'8Z(,;U&2,OG?1!ES_)Z4V:L3GV;A3$=!V? !P9^%LIRL5Q#0,LY1?WN50R<
MCY5X[\B\Q/L,;R-6+9NZ]&=:7N0W]I^2-Z/D<%M$5JMZMX:LE!P,ZO0Z\A5D
MCQSEY-KB\8XN:5!J&\0"62I8+1%@W4K1J2EIJ 9O== 8<KP5J#.Y3>D%1[RJ
M0@0=R8!BAU.0ZX1%?D+T)=3(21/_B+E)D[1K0=T]7KV!8<#G$DW&9K2QI64"
M,_>9:BKNLQV5&VC?5F[JY&+%DHX-RR0\;+%\?2@C<M:A0:I@TYF!HX!204.I
M';]A6M/5,Q.,KK!7)/1G1^BS\+\.93>1U:[J'B&;IS0\+GV,D?IM_Z)D@((L
M&V6Y8YXG\E^8^!>T(]QEH@-=UWWI=02!4(?_8Q E= 9>)<=>-C+026B=;B2H
MU.WL'(@(P4Q<*NU,T11-UWMHQ$XS1TN/?[O!^G8S4CX_/6<T9H@;STB8P*#0
M5%-31(806]/4E6T[\:$<@7)RMX?::J6[I]IB6C PTRC(AVDE.1>?PXC6I&L.
MVS4*D)6@U0H0UAZ#3DW)_M0DB[^14F^H$[XB'ZYLP7,@AJV:39$/>)=F56&K
M3? 5YXNO9)&;9F&4!-DKJ\D@+NJM3#>9Z(GN4X F?75\&M$DCX,UOJ8WM#]"
MR:S "JZA!R:X'J4%%0UDA!(S*R_S 2=X)ZU<*:5V/S*D*O.HYDBAK<?5:DIR
MY A^ZBT?[R@B$->>0O1HG,8)(O4ZL4&; ):_$JDF\S#><="]TG49O40A3L*\
MEP-*$P.DAPUV(OQ=Q3,S3GXO3\T/9ITS0&GN+ R3N>_8-"RL9:"@U;L%%>G9
M-$":;;<9IJ'")J7MFY[91E5O/U7R.@=)\MFHT<)451-' S%@(#]<=R'R:7\O
M)>R#^@%TNXGVM@M#5FZZV7<*"M9^KWPRD"N&G6EI]A)$<=F!J76!I"K-^2'(
MHZW)Y&8BQ5O48&ZB-*[0BP <>1@K+UW]]&'?+M_J'<XFM;9OR8A,0_+W# <Y
MOL3E/W67/T80[#159[07T<GL.5DJF-EA-%/$^1O=.NWE5@'HT7&59CAZ3,J6
M[=O7318D.3&R3-QD_Q67:9S-9*GI3##5PZ",HM-?F.G(&OZDLQAM)YO7'X&5
M0+2M)*+B*,3[&!2\!,U 4G(XOBFM4[UW45I&#BM TBLJN"L-K0M'W1.G+G6B
M"M<EM"ZQI%2WC2(A(1B_IM).&D'O27S HF;T#CU0!G#@N8SB0R$M!"*E]@F@
MGLHJ"%6D8$'4U<\(1F')XAU(OY")]XDH,GO!6?"(;P[/#SA;[;@:%"KO9"G#
M)>@&F=>&HI4 ,  =HG4?MK4,%)1"!!5&+H!X0XFYU; TK7!C+04 D'4F&D!9
M)@(ZF#5Z#X*S@5>>\!L/;G?V@]-OM6>;+'=%D!6J(%VA9__;? C(?VY/WFZ1
M7)D1EC'O*:TB='9U1JEH<WU&2 4) %HM^Y__4Z_+&)E5&![JHE;>YQ?3&<3S
M'&$T"_CU\Z:^P]"I?\"/44)#\;$A(W$ES:%\<QX_:QVNE.>4^)G^NU'NY$@R
MG3FHL<QO?-FI J'DDXUIC+SNLOPD.VM$3P3\YBQ^M5M4!^7'NQW<^;SH[=A*
M< ;J8:8U$+9C!P780:H+.AZKDR@J>()*HF"Q:3D><;C*YD$<$]L/&1F-Y1&B
M",:VS,X[)1L;Q"TGM)Q@%H-6ZO+EN1H<$K#>$7JR )RU4N18+57XZ!0N8:RY
M0>&37^Q8LIX/0I5K(3.(@ED9'8]X\TTZ"\.(:A[$MT$4+I-YL(^*(&;V/@0Y
M#NDI'$YR=JZ[IFN]/"HPL?$EVN+RW:SQ-GU,(EDDX>ZQ+@>'JY?8'E53/Q/,
M<'1D*-_DF S3=TPF2RVJA7H?L4RQLG ]-VW.T^0%9SF+".^)C<HIQER&\XG&
MUCQNNC$5  ;E0[3FKC<1=KJ'0B>>;55;ONI:D"#\=5O>T]^E&5K?W1.*6FI5
M;ZMXPC30/[!$(':=/\U.W].="N_E)'PBX*5" "!>8Z !Y"42H&->K;83T(,)
MSU1NX09_8;\,<?(M7@!0%YMCZM0;1NC %FIKCF>*X;!>1:0[\B]TWWQ+BW%"
MQ6DYE <"E6,&@%2)0<;.^&RP*E9W%+""<:XF*XNJMINR3=< .=!6IT(S;9>;
M'2%@ #Y4<_X8)]UB'+;BAOSPD&^SJ-SLR? 61R_L/"?#,=VVIQOGE"QJ#9)6
MT<FZ:B"K8T1_ZXX2^I>_^_Z'B__YP_=3'0FI7DRI:-B.PFJ%9TG8'&D=Z]6M
MV&L0IF5,]"!W!TQ3OJCC.=043_$^"B<W35S6-6Q%^JU:FV7KA.->+%<TT?^D
MI(H=V9V> 3%GQ0<@?N+-,(WR&9-W.-MJ.MHD@K_B;!OEV K,C" 2Q&A4>[K8
M)4:]CI&X-^WZ80#L.XP <"\PQ'C-<!;(YU4]$^B;K$8FQ,O9WW=UF[I,IO2'
M-,>JU,.)[91=?6VV&EM77]%C0)#V+;T[I*PH.2&^+ MXN?V:*C\CUFNJ^EV2
M)9)JFJ_^'!''12!2+MT86NK_H&UR1-'P"$*=+7U&>P'-,N=DB=X1.JH9JAVU
MD$DX[@M46VO?YABCF[3 Z!^G:E*BG.3'!KZ55-_('_ *=-"W$ D:^_9VV(,?
MS-ZQ:ORO22R:1=NB*OTW(T%K^#&3U_<<* O LL;,7-,EOE20=]B/H3U?T:*]
M0;6^NZ<GUF3)TSE'@8KS<JR/!'2M, !(-S38>%%_ME@W4W\0V">^^Z6[OB.]
M^6+(Z"PTL3*DB3Z,N+RCSUI54?YUR2NMBMN<N/W=W[__X>+]^_?BVJ%)6-,U
M^TC'D[F___[BI__Q@R>DRF] FW*"P:KDCK09VWF@57M=P!E<)W:P=?B^VLE>
M27D=HEL96_1*ATIRUR3S)%./G30'B8$!^Y-T5ZW\CG=AZ^LS\[%O>!D6FAB2
MU':*(&^%*JR3W89+@0'>4U0_$;L3.V'3BP2B"%Z(Y1,%^MZPLS/<:)M:*PT&
MQL<P0;>.FTVQ:3%D4WI,:!M+](UM2]/--J+/&]UV-@R"]^3;%(]13B/_WB;Z
M;;3'];]_2L-H%VV#HI\NMZAR)58[&G8=$K)(J'_E-N$E"TAW3W>X"'7]2EL+
M65>/AC$LG=O;'\+_YQ"_(C*J?B"Q6*U*_S#I MTN;Q>M_WQN:<2E&;7SCT@L
M]ZY4K*&1Y&^?O7=0;3*YUN$->@KIQI=;!7YO7D.Y&0?%=[C;ITN9/N5+F=%3
MG4-<T)")1D&8Q4MW^YAK:CI8BH_].4L317MSAB)@C*7!>BOW-4I1=0I20/X_
M&2-4'OVUO$3-I%8)MCF5"_WPNO<:!IY:\U( '5?+3+0XI^Z+\([RT_0>'>5>
M]_.:?G)W:1S>$^6S<D/S,LK+ I-D4K+?&S*3ZGOW8\ K,-S>,Q'I?1B,:X>@
MW\[QND1.V!$=&AD;!+=$_:> C(+98X;995;5'=8??GI_\?Z'G_QL"HX\/NS$
M^AX@0UZ"Z1[AV0^1 8;8C)%2"&I+:0\7;U/&<;%TO(I>KY:NTJSU/FS=C8UD
MWR-CX*LPFC[,Q8(>'\-LZ0^116O]*ZA]P,J$M&_F^9@E)AD2]J)]CXFA+\-L
MQG@CHV*@,:<."X\3QG$[H3*+*4*L_(SS H>]TS51#;YI'N%[N)SZ<HPOQ%G*
M!SU\3C3*KOS4"Q-'D\U]W9*;;MR<\ S? ^?DUV-^G^XM#9U3K1HZ=CS71V!V
M#&FI]J.'MDB+1-BKPT#+ 0W57.6&VC0Q\]''3O+2#;0<LXW9E$-@6%<P0-]"
MKR07(+.?X?61*X*"A>JK'3^89P_$^0;;_F&I):_;PR,+<[K^UH#1^W0Z1%N^
M#4#%R[IYM+C_WWJ+[R^UA/^<*,QD20R:M#V>QEF8)U.OF2KZ!-YQH=)*5&#&
M46*7^A;9,?+C6WV)4VI.D0?F?J")V<:W!E7"8*!R! M4@;[@XJ!G."L2D:T$
M@ .L+!W8@ON\(*GRHMU;KJ)+KKU+JQ.ALK4SRY_R2:%HPN4,?^8F-*#3L\!
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MKK<T"MY7(M##:Y5[?!Z1\%64!,EVA$A8*0@ D@T,-4"T0@H8MSQ8=5TDW$B
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M,NKZ?;^-';.E#*?=DH>8UVF:;", #&*':,WU3JYD,)]YE +;<1H9KO.EMD+
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M6X@!<G@LG?DIC4.<Y:5V-VF!S5V<!;_3@TU;LSIGFZ;,8,!GJS%WPOGS;+U
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M249CEAVGI/E3D,E[PLB(G=:U4BK<*50EI(2VBZS4LH\L>*<0FB$S>&$Y@EQ
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M]HY+8Q7[N&(,M+-@G9Y#FU=1)C"M?X0F76L:_>B8O(.,,T +M&MP+7N,U+0
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MXY(YW,%F$US0.>4;(\,:$MTRJA<8$G2UC0C15!EP^!$:WJ9?/FVK\EGD8G%
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M.]YYSHYWEMEQ9IL3W8RISTBB)(.7_$*TB.^\9Y>J>G:MTIG*=+GD_9I;^Y8
MH?)'&/[L,5#$;B4->7G,TT>UXJMZ<4DJ"\7)&]^71PK)<]GLJOCS]>:1LJ.C
M/G P52]E4YQJ[OV1>;:/UEXNX0"=G)BR+A_A_GW,K$_M9^[U2D2W;T -CWRJ
M]>WZ+:OLDH55KH%G>,^42VROV6_C.I?\K#_L_DSA/0B#4&OC?HFI@^/\@GP_
M<>G77XR-BS\M'^D)R&-@?NZMZ*<U5R;.*;UO@>+D&"#/&YDQ>_T8UDGC>9RT
M^5JF#Y/].QGWN1(HA)"1,HF-*NGYU@S$&$8V+:1'Y;^3C"]SNR5%WMF98Z=H
M=+3+EE"9<&D8G@\RZR$8FJ]G,CEPE,0-K'^VX!4/7=CS15ZGF[)NJXEK83\R
M7/H1)+.1]$$1]^/#.W+R+?(M\.H9@F#.V8_S--DX-@I;(UP834AHO#3G38EJ
M&[?L:_-(*W@CVF[ A[<JLM]HD975[%,*7T)<* 5*;23R W+2T?/L#8(#EM<7
MMQ322K#A7Q8?2_;Y!OD/)E[">M+A@C-,:$M%44'-K&<(S$OI*/E#Y%>T@W=
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MTSQ/OQ,^* 3HBNZ:K@L:F"WH ![J-9U1)\2-WP.]CG]=N&1,0$>)2U@-Z]&
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M"04PRY1:U<1QX]"SD90',D, A,)<P%"91#WY&&D:)K4HX]!]VB?LVH1$GBP
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MIS_D4Q^747*M#^AZ>UBSM#2TK'<PBK?W-6_O:VIZ7[,-*&_/W"A3JN=%SC;
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M&[47!I]^4Q!:!&^6%RML+^4.V%D5M='AT6X*-CG;&(I.51?LI(?:^/#IO^0
MQ=,1*'F&<[:3Q+'\*#K[+%>SP3][L[D)<2GL5!N_R<\YQ79($2>R-\!Y3X"G
M@$6S?1S%EL]2,*=[SAW1X4ZY_4\AG[>JH59][KXNAR\^O[%%SOQ,W,US3)P^
MU3+6AIP]&-N)1(HG@'WV[%I0(7!@BR_G.*6/"Y_84\9#*R;WEAM^MKP][Q&O
M;J> ?=P6RV;W_#!#.MM1KD]RICTI,VU!6(!$<M;V$\RH*;LBX?:#1-%V/1EL
M;P9<Z>+ A'Z^:W%=CRF)KA^Y-D^OMK_'%3^)[9WI>H^O9OEUZ,T&'$JVE&CL
MI\5")1%66CZ&[8CJ1! %;#9?KT5*Q&DZV[0Y"6S?6CLBUSXLFJY\6ED\I$A!
M9^<3^.>QGW31?S91A<)\Y28A^#X(U\2-]Q3)PTK2MS]6?@S[[9A.]D<!FR\Z
M1+6Q$J]@#-(&JSP3[&=PNMEE:P)DZ%8[>MVQUPDRHH@S"P>6;Q//P]M^FTT)
M_44?_7MR&YA=_#Z->;&G\M;!U=R9G$AOQ9."7;_V:[G<,^)M)9/N]TR1X-O]
M'IN"$>\]F77%9XJ HJO8;-FRJ#3=6WS%I] ?J.I$:7)Y?).] U]PMG?P!- ?
MW>I:3CL(WC%S:^?SH,.SN<H4H**)=._2/4-,$$[TR!T^RW@A(>_U1>[4F@Q4
MKI'N?3!9<WW>)?30'94CTF5?"@E9<-.=YVORG$/=J,C2-Z%R:<"=CU:N7\\K
M+KELIWX4[;>RO*<_@_.>^LOEX\,M!:H[G7$T/$] LKLC8M.=7)=9!?CFQ21%
M:>6Y:??!51-/= '/S]'H]"3[FMD)25I)OW0+NGH%Z/69 ;YI=AI1!PRX3KE*
M->O0?7$=:NXLK+@[\:KZ].7D]'0!P74)6\$)\CE@CSI[E-T=2IUD#M>=XU,;
ME.N2PX4;_78?$G84)13?N$/QJ_[T=2?TJ$)@TF,]2>DIEZGGQ,)\]-TXJ>_"
MZ(KZ=DQU=OPF.-S_172X7XR6J\5XP-[=2<_YC],Q>X%U.NSU?^XOAO2?@]7X
M\WCUR^V\7^^1G?JQRN!7>!I_PHPG)& JH#VJ\1_MJ:W/)O)'?=H8VPRY:'TM
MM;6K3$QZ-2@E4_H^4*'9UX%P@6CT1X'J4WFBQ'=8B>NIM96^(J3G:V9(3J74
MMY8M)**_X8M$C66HRBQ<+!^YC^AD_23=L'VV.E=&02Q #+S<4V=J38U]5K<V
M8=PL?B;AZMGRLPO1:4#/'!$E7UM<KOH4D*^5VK/'VC(QZJ+X]99(@7.L3OQE
M=WBVF29Y6R[UP;^M)"XSSVN58*R6X@RP+P@O<$54@WC%=H^PPHX9FX#R%+&O
M+"]>[K^"G'LI1XZU"# U>L4DL"]$+U"XN5!>=UV>IOQB]6",W!#4YH=]EWNY
M"T9) *YX*_B<G)$P]X'B#+"K/UZ@3%>#>-L! ,PR<A-0GB)V9<N+7S.WK<#$
M:P*%7$IMJ907*-H57&S%PVE$.J8ASF(S;PH4%HRV',]+7C"8U9YP<TC?/149
M2P]*51?G@OC3OTJ32]_=]9>C86\P>YB/ILM^DEUZ/UOP@E-O@:@JVI&*1;(,
M9-&DA79FA/? 0D(+4S<@KO,PHY+R$C!^8ES<9:7H\)@_,2D8,GT,^#0W]A'&
M.V%HI+#3!4$BI ,]]I$S.UD0HZ2;&?  Q Z&E2E!AI^(3TT>CZ6;.%O7=YD>
MCMT7PA(&_8C(@@V!W;'C6$ B60!.B3/H[@%JLA'Z^6<ZW2%Y(5ZP8X0"401U
MQKZ!KH.A E?0$>Q[R;C4YJX\[V23%L3] _MC1V!R+:=B2+\2/TS*Y_O9"I/0
M@URA+,'IZ:/H]/1S?['H3^F1:/:X6J[ZT^%X^NEV/%):5K:]W^X])DC)\9_)
M4$B>J>Q079[JE$D019+#D]HH9M@JH*.5&F'X!R_@? '',O61S("UCD#7 ]VH
M ]]QWTC%FDTY\)E33WSDDW2[&D@E=*(?"@O3DAT&.<W-@ LDB@5\. 1A'_\R
M4T5V0"@TPS[."86IP/A*"M&-_=IW&M,@N[PH7VYT\-22TM>1#QIU+86V;I]J
M((6=B=)VM4(0"Q0?;FA4U:^%"6'KOJ9BC<V_FZ3+ZK.;(/3\N6$G8%V<_,M@
MUEEBMG2Y#ZB-6R+M2'34WVS")$;TO+[V,8Q")+F=3P7;7]V:H"*!^/6HZ'$4
M[<7"J^=[V&E/AJK2<SA,J\ MF[?DM>FT4<?&K?K,L!.,C!9-=8BOT=]P(%='
M\A#HJ]@)0^8Z&$K08*8$=:> 1Z_V,^O=X5:>^R1V+HZA*K,$"M:&SJTK=C*-
M#^N&5S2@%=]4^_/ 3I7I1/)TP7>-6W,NU[G3S?GLN]CY*.9NSQ7P7.(&#5B1
MI2H52 I5<1Y@'[^ILHO$M^O5J(9=KJH\-FKL353'_&K%JVG8D^/7=\&J(MFW
M.R8N"Z]:V/,OO7*U<3L85'T**I[FWRQI0N$K$#L4G0J? %1$K_QJ214Q<P6W
MSAVPE >\R(3W1P:V?:'?RI2@PFW^Y10RJK?($QU34;%@C;V;PF2>";K81!_$
MZ'7GALDPW7IUS[X+E6QCK[DZXM-5NW7E%RV4$PVC7%J?!E1R;]=D%>A=D*F0
MLXP,LAJ49@4556/OSHS@HB8[ KVL0-]WQ@F1C#D98_CU!7[\#E1?@+T'/)Y^
M'BU7#Z/IJC>;LQIMMTILMU(#MU(#MU(#MU(#MU(#MU(#7W>I 8X%7[)$N*4$
M6'-N:^RL6E!% 2$%M]B76V$!; _4K;  -$;BO7&!+^_QE: 9E[:-(359V+_>
M:[$KJAQP2\C^NA.RKSRP"YZ0K2:&5&<_!1&Y)!'\JI*YKSP8S)AD;A.,X:NN
M/61^X!<^*_%UN8FNCEM- V-]&Z*:!H:K8=!&DVPQ(OG#W 6+D[O5.F@;Z)OC
MV*2D26-CP&XYDS??<<6,3'C_TU"=K,)"T\7]Z_4>JR15F%^5X2M-JOC:$X*O
M_.+N$A.";WF5ZGF5UWE!IR>OTJ@;DCILJ5S=Y_N,T![6]\WK*<.@&Q>3WD:\
M\RS[-_HC_6W$9IF,_A XQ+L/PN,O3LD.@L2&]Z+$AKM)?_!/]IO99+3L?>Y/
M'M-7YQ]FP]$D>7O^]+M\'L0MX4%AM@//BJ(C5K-PP12F)+U!U,>,F%M0,H.(
M#/S4A<K9E101$)R):6D)<K&#@#4Q*>6@<H;B= -!EVN"R9"D@LJYR5(+A)T,
M!DF07" D24^*P2*(GY.<1V=O)S;1P380IAI(>V%'VP(D*F\I KE@QCU2'8OV
MWG(3 Y#THVB_/=BV.V)3^SHY9TENCS1]$SG9 +:35UT/:<7 M,OWJHDOX\#^
M34MPGNQK1JH6/=X_&./-T$IMT2>K]M?TDA;P3>Q8^OIJ22L(UR9GJ>8=NB^N
M0WQG8<7=B5O5I['CXTV0.CXDUR5\!>_WY\"CHWEN_-:A%$KF@!W7CB^.()"N
M2RX7;O3;?4B8KYM0O.,.Q;'ZT]A!Z?A2*(($7?@JV9,+"E+TWISUQ([6K@4]
ME"'HR"4""+&QU6QB;4')]1>BS(;M^K:.S6E@[=S8\OI^>KE9"C_*[LFFC-K8
M?3E-/W=#]Z%T0_=3?S'J#?KS\:H_26J.S58_C1:]T;\>QZM?>N/I<K5X9 7(
M3A=QO>,7;E=RMQIDMQIDMQID7T4-LA4=>[;.&63BRT!.\ZN!D$,?^K5@OO(N
MW2JG@6^=?K.B_XJH+G)%9;$./%(=R QHA6):7(:J).JY3J0&21RZ3_N$41MZ
M;&&?%UXE"GM@^\1J2F#>^0_@B*;[G@79L&\GS$K,Y0B&"* ?]K&\!5S W-&*
M#CW2.T,W)':\)/8^=&.71/-]:#];$5%!2VD<_.#.MN"KP3Y-<,['\U%="(%]
M\9_F:0Z;$ILT097Y$/KT@TZRJQZ^+HYYD7>#[E;Z,K>; P1ECJYEI+9P&BZ5
MOYBLX9#T6/&KXD7!;PZ%P&AM)6%&JU[<B-A_V@0OWSK$30]']!^G,Q']X=<)
MV5C>R(^9)Z;ZP$I;E1J9<99I<DRMHBH7@]$%Z]-/<T-2:9/S%LA,K^)8B:?G
M,]9S'AQ8OF7;=.Q/Q&<>Q,ED(-0G@O9H9\$2J\J*0DHF_GW/K>Q^\[+[W]_*
M[E]5V?WF]]_!=AOX24BFS =9T13[3A54EY\_?4,T6W9BD?&_T RZFV@[(:@P
MOY)$70< STI3(/H;^C_S0XJUVE,4JH- @\VT19N!GZBHQQ[T1;+</T6NXUKA
MV])BF<+)0I9L_?PN9NPC;6S[?!IS\8U(D)UF-+6V])^Y,ZML_X?T-0-$J6 6
M$0-0AFT5C.<SV6Z4:X)=6@PN9P4H2F3JT7)1&.>83G\Z,9S^\.N*A43-UF/?
M85'C>\OC:#7:EM/4C(701)OQ:<M=Q"%"\K,;/R^(EW T>G9WJT#B3ZDB2#8(
M,HQ\#.18R4C3XYMY].FH7T(W)J'8FJMJB%>6JPX#RW8<GWA-=O5=8(6.D,UG
M+<"U5 WE;P6Y^$;PP?&0!1-#C&!^E\O?-N0TYF+L41,,DBD!"T*<M34#)*G@
M56<1G%&BJ?S#<+:F)UC7W_1]AUW.JYWSX=VA^X7N!((*23H+*U'D![Y.HY,E
MT>#HB #Y(H6=H'DWNA-1!4A!R# $G[EG^>Q8)=YFSEN9H;1:V%G.R<JYLW&Q
MD&TDQ79FX%$E21Q^Z]TS5E^"U7.PCRS?67VA\WZ;!/Z&%3"A0D%_I-+!YB'<
M-]2&@.X=VEPDU8*3WS?J\ 1=-R4YIRS(7*R<"LW,6 UM9*Z<TY5[G<+03.Z(
MES=\HH0:+4 EI^=KA@A'E6"K)FG7HA_;]3S:[KS@C9#$%$HM5IDQ*.@"+82C
MK=:2SB51C#"0<0Y=72M@V@!+;5>L'6)I+H8+PK*!6)$;T$&-TQR*I;;8V@ZQ
M%'+,-#P??3>.%LM'15R+W:#X:GM)"P_?:@YJ\LF/J'D0L[>+(#5/>8VAN7#:
M/%M=@"5B@%:(U/R13=V//U[TBA)R0*?"E-P'+QB-_&OYW)\-.3XTNXK/T9.+
MW>B8W=QE<IB@(:GNY_RJYF5+*>NUF/E@O;K;_5;$SD(3:&1I^X9VD5\E;E82
M@Z(2'EQ?RM;S)M 0T?:W63E;JXA!-TVO\=6#%KQ^D'<0L*^[;P\A=/\0PCUY
M"O=6^ 8Z"_ :0Y54MT4+^=:BF&A=&08A>0@<=^W:"5] #)?T@9KWW9;L%F01
M0%B@B_U!%*OS7]()"H"V*SI5 $!,0-_#670\^<^>Y<J]T/^1W]5Q.YBQ#[24
MLE%)83[BU!BTI+=P_"YF(":10#DXIMR,%:8FO4&I;@XN?*7-CR23,3$BANFW
M!V*QXK7,737V=WN @N/W,&.]M*#A^"3F'PDV!S"9CA/U,0,TF1@" #)%S17G
MEGJ!3V\7R/0>M#]4$6J+$I5+H@0U,6>,4XU5[P"H@BD: PJHMOB QH#*.60<
MJ%4OWJB"*AH#"JJV0('&H,HYA YJKC3&YX!=D*;E1 4..UX'(%RFOKDN(\\\
MO)(;UZB_CY^#T/W]](2#$+-R)VB \N4 QV,,.GCGR1YP_&3]H"$WAD,(8P\Z
MBCE)FUOA+$P2Y)SDZ:,Y"9-I@Y8BOS-ZY?#6EZ2,4>B@Y@I)# )*)V5P6EV;
MV(02[<S\7&4)@>=%;1CHE8OA0-=BGJ8; MY<#K98%D:0/*PT\R?NUDW9S;D[
MJ#\<>IGYAM@VHUXKQDRQN%%$/T3U"$M1LC:\EYRKFT+31$W&1L0$='6:Q0!&
M]T&X(+NL$O%LG=L1!-8.H"]V]<&V+!XPF] 1'6:VV2'%?!!$HF,BISFX,HC9
MN F9D8-J=[!H)RF#N$0D%+!R+B1IB9JE,XZB/7&&>T8852UND)IL4_(E^8NP
MX BH.W;1L+:L'A5FU1:*%Q(^!6:*17I"JR\7I?Y@5\1E2@:'7]<K&M1FI'-D
M)LILG>3&U!21BG'P2GAU*"I<_F&*#._<!26DD#.59(A4"49R_F@X*%1*C/6,
MM<$$?)'1JV6JR/X44J[6U#:"\:#R9+IGKAD_+UJ4*F,MIWMV*3=;GU[W&EB>
M1YR[8W!QUE U_T!E8*APF>X-;(G#%RUE\S"P"7&B>\ICMLXLWP:[/^1=H9)B
MK&\13BJ^+-2Q=PXR/7HEH>U&E7=[TJV]8A H\$8[+NMQ#MT!5B6L8VJ4NY8W
MWS]YKGUP!JDM;<X0Z"4G-2YQ(=<T71ED<C5QK:<D8(ZS(,O-H$ 8Z[*L)@M?
MKVK:8P\*1'6#/?5#K]BG=7<M\N>B12#__,/!P$RVD71[&2M?V@-& 0?;&"X>
M=7B'O@E7GBT.MD)Z#;TN'BC>*Y[9Y,.AEY;3>5*#<A-=%O+Z+>%"^@X63/&?
M=8#B::R;4$:@5M/J<(F=*9/#5L/N1#E6EK '% QC?6Q2"CM"H^\E_8C#71?G
M,RVU1Z^ZV"X2''YHQZ%8U4IV!@'U1*^BV"XV4AYUK[NB!6&/(E-Q>64ESW@!
M9DHC0%$SVG]3@V?HMH*T@AVO@-V01';H[B0'B%9&APJ'Z2Z?-GE]N8)S?J:"
M9'EH^!1Z+59LD9*A<#7R]6*Y'DO+OP_"3^R\IE_,RE^$2IOICC/=F* +W=$2
MKJ:4;_ <^ SL#\YC,EP@U/AUT1[5XTL")'QQ;5)-\#1(S'62EO>-5D%L>?F_
M,U-P&L2_D)C9@QM?O.]I_"14 $UWU&E'!5TE::,PO5Q.$BR27[%V H]PU_.
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M/%F51D%__ZV+TQ6'=T8#OB+AMA[(:4^\UT>[ S;/(W0PDYTC,0<E]V!9&RA
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M5<)7"K*1E <R U:AB!;K!*J2J$?5?0XVEC>UXF?+G^]#^YF>1ON;D)"T:J%
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M%J7/4: $**_T5/H<N[2-TN>HUS:NRKCT-=&C=>?9HV?5(0_/JDU@\W<JW60
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M&MG$G?PH 10RRQ6\PV[PJ1],#;ZZNZW_GC]X0T?7=-6>/:@&[#YKT1T;W1O
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M'J(V9M2'0DII'\"N'K3[L*5X[D2XE^),#=U%ROB[:E+'K7/L.VY,V@Z! LS
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MOC..KT/EU@R?T6GYS^  ^!HV@AZDMQ%I-OQ I]\.+0J/CVP'?G?&LY3W^A4
MD1723'O6\PL>YYFT$V"<#\ %I*8*H(@V6#(:?@A%(YC1Q4L"_.I2!D1 O3X$
M?WK W&/_F!'TK$F,YKR&9?W=AI@G^$PTS^")@B$F(D30\!M+X?>.Y]"6'QK-
M]&0+Y7GWFRZ3=WL$N3YB.]9M121&8UYB8,Z]2UBN)R,8*F<"RVXQK23H9(>$
M[2YJCX @0C$0:5M""1HL44Q!I.4\8%<R"?354FV-?\<9"V2T1N4TS7]D=1J,
M#JDE"O+:LJ<6+U'!-GZ,^1M8F&$3-Y)53!_>5)CW0FWT%)>%&:D+O065WH@O
M W9Q7PDQ?1>H19G!_Z/5;(3IV-P ?B9&4&KDLP8V<+6)ZGC@X+#+FJ%L)&]H
M?[.WX9<TR1B\'9L6K6 >9LC"8143QZ&+Y4,1+(##H4P(B>J4R#XX5.C3%49<
MKG;$:Z/MJ^9O"_8JXHXT8G[.8P3<[7J.A[X>X>K?"54%6@[X/# Z%&9TQ/4N
MW#(!L=2 RY.V! CA)RRW0D,(/K>7V35AGP%#M5-U%;;X9"+0KWJ(*\Q&4F$.
M@IPXC;/$7-O Y/-9IP2_H&+I@I=ZFFPW\::(L@0ZH3"R?F6LDV FS7_Q LRD
MCS'36$M1 S0%>:2:\,1&M/ESV R9-3?&9@V4DM@VTOH+7(5F6],4RS#<\*A-
MR'JSQ5;9H';"V"]8"<V%B(S1G;"!**T7C+Q_&._<9/(N6@E#AFMQZCA50,G5
M__BG[C[T-<LY;PRPQ1>E3588M: P4GK1U2$]L(,"5^;8-X/\PE'RA@*7>=%^
M48.B9MODIG+W]4QYS\]VPZO"@K>P4 1KZ])\9UYR&Y1N1XK'THJ-#Y6[B!/L
M!LUG0.RE++\977I0I=O(7J6K^%6ZB1+G)FK[9!GRPBKDH @Y*(QNQ/HX+"Z,
M9G86+=+V*^D.HS#%/1H:,7@!.)X,:PA^LE^BPS&%,'B\YVVS00NGL?;<?6:^
MM.=P#$SHLPW$D8[-0#FNF&7GTPT\$_0TQ9&O@3#4&UL=[=T7F&3)D0+8'*GA
MMR$,TUV:2O@IOA_Q7A$F[>8P4PUW=C DS(IA%A=_MO+L3=!PQW)#T+$8-T@4
MX;#F_*RVIC%P:(F3OXD^[B*TY(,>"3Q-+ V;,WE34)>TE>6,74J+%,=!;530
M:=^A+08 YTU&COQ1C62Q-^U3&Y9\.V&U(#9VM5P5DUIX4/TO1QV_J+"I3 TL
M[]1IE1?R@H'M/)[ !F*HHHU@65LJCGGZID,E)FT69C"&>]M ^XTV*I^R,D[/
M]HV1@.JPEHQ6=LVP5P$V$0AKV&F1$]L]'VN*-02QR-UZZM\ 543<"G4"*W(5
MUCB4@6^QKNZLH"E2,)9$9Y2GF8/&K5U7GP06-EOGH7+IV6@2Q62'#ZWM-ZJ<
M>O8(OB11B+4&*P'EJS<MC&@8_KIQM? MK_2GQSFF:UNT/QBG+* ; ZL]L94F
MK91SK+"EF,T+>2.KPH:@YLQOG<O1V(B@D9X2A3M/#V^&Z"L&)(RB,-9R=V>T
M7HT-KB4YQ(LML0'M6<%5,Z7ZQZ"Z4#8NJS) 2[8;3+>_>R#RVT$\<_#3<N;[
MU:$]<DX,]1752S00Y1MG>%ND#\$SN(^S ^L5Y6K0XFX6$T716N%&U+R85XVK
M";"I7%^'EB*]TE]-RBDZA1',01/M4O98WSJEW85]8%A/!"ISX4*,Q#"@P7+"
M9$27%OU-J:[GFH%%@0( T(=V^!O0H.'R/'ADQ&**E@_&[8@&F!M80YVP+O@;
M>>LN-/=0HJ<NTO%TELU&+1<-0P*T[IJ_EMHQ#IOR@W:,$X<"FS[Z>]-X'_'M
M?>L#?B6\@W*B*SM1 B&"5&'9AO:J:SAT*&Y8<8/&;W80TX0.[7>-*PE/T46W
M>6I08VE(%-"!3SIBB@;HJ0X#,GS"((U+TEKDH%W+K:1V:"5%&GES6REF'D5-
MHR;:<6@OA39<@]MP6:TF1E_9#*;FG'%AL]ZD\#7!;E.AK<%MG??4K A*POG7
M!\/90?([9AY_\+>>SJFA)D2$M]^'D[PBLZN23\(.3W0LWE35-3I)Q'3&Q*;7
M,L)@S<EC[D?R(54V3K:9+7LDLV7%9<MV9;;L#D3(RC*M[\D3:%XZ)N5<MU&-
MWO(PN@QH5L9<?O?E*SOQ;'QC4SE U>#I?2*N&6UUHRH.[>:0S*(,-6U@RSJQ
M-EYW_N^!G13:K7XH#Y-!Z+F/3D-2 0DI&B.AZ"@WC$<%Y@K\W>LWCT]:D<S$
M5>E%S4C^XU]:AZUV(S@ ;$9MODC?&-J8AD_^XRUD_!7C62L=R9)L0DBM8#10
M33^$HMLV>;&8.?"JZB\LI1*O>P$3$;]NL/$@: OPZ7SA=)*XX1DN$NP /FJ+
M=MID24FP\QIMRQ.<WG=.J/O3;0:'W;&S:],?\!*!.3+MD'HG&'\,SKQF89]9
M ):;>Z$[DS@;1].+G]7C,"@?>4%&:?QH.<RH8J$]_,XD+EH](X(-MU@\T.05
M4L$QI$\F[&D!T01;A&D'0]94?L$&*$LVH$%CR,[(UH<82AM:+\Q%&[-@5^0W
M;AVF4#Z&HZ)X86V'_"@PAJ#PY-+%UG2L?],(N$#GWN$U)D@89N-.M7\J9^I4
MQ^9QER"%J6O(' S*LYQC,2DYL2_\F)P/Q@$T+ :<4BPF:;$ >I#3#'Q)CU3+
M/-*LM2@77)-RQD,3I'$5E@S*JI3JJ-9HYR1V-(A>H84=!0D[O# LUMH<.+%W
MTF\KC_ F^)_R:*N8=PF/]O#(J]-J@3$^I1[TY;72[;5;75X  >J%&&3ZC(XZ
MS\[70>UVNJ<?E&ZK<] ^;AT?-G!J\2L9.O@PO^<D7(;S'%Y?#PE3\X>@&]$R
M6S9_#AU^?TPL#K >X@D=0,.:_M*6;BS-T7\;3Q?!TZ#&?!H+.Y]A8S=X/H4_
MOH,5782G2&E3H8/1'J_/A$K>J+\_-S-^9^AJYQC%[VW8\&D:)Z&RN6C6)*A-
MB4P>]9STL9!S QUY4V\_UA8\@4]L95--*1'B2(H1:?#)IOY<-MZ6C#4?#&:D
M6O:3:O+3KR5#81.+#@;#+IP+&YT%N'S"*SZ+=X+TY[RR*91PI4.BPVT1BG#T
MJ_\Z-E.AZ0^%?E5I[UM:I=0(LINPH9OM-H,C;\_ D"#+]O73J:*!+?65P<RC
M;-ST93$L_S@_&0=C(T"QY2J)X*H1QY5DWHJH:+ ZKB;A03]*]*^$M>)]P($;
M0!#W!"<_X'?!Q*)R+!(YKBM+F2<;M>+PS;*#S1J%N<M8V!(YU;CP?=G!B"=C
M^!F0+'UVZ>-8/0"5'KJ#)SDS$&B-(.%2MG/<>CO'E-AR_NY:P7);AYUBY>9&
M7>$*7.3IT?&IH%463,-@Y-.UQ>N%@GSK%RLR.L@\X'_&J_-X[0/^KH)78^AT
M*"Y88+21#3S*5/[2Z;>"-NT36A1!W0AVBJ6".>'GIK/%\%'TS':W,*C"Y,:?
M'G@">(J!$^F*ZSBW26,YGT(W:MHDX"$+*"?RY"IAK8H28E]% @8L<&VJ:6+7
M=2P/P5[P<88&310P=.3@?6(Y+$Z+LQPBE2@1O1^$+%;+%M[N+H-\.6YEE"\K
M9<MAJF"1C<TJ"1!W-QI)DU/G+J_*$UO\JB)'1[^%M@()0W%X"_B@JC\\!0O&
M:)0<9WK0V3+\<,4?TH%'+%KTRDA^:*0XL(EYJG@>PH)2SWCFB<<M-&F)521I
MT<59)F8BOUJ42^C1E0K/8=QCJB;-U\96Z3QRS_C&7?S AD,,5I(7WJ^IKHH%
MF^" $SYN)OPQ-E,0'7CGIS)FXVME=+\B%.^G4C=H+QHJ$T?@7> @-[K1!J99
M)XK3TH@-CTV1NC %S@5YR@\5@>A@%>H3)8[@N!1#0([CUU;X$T'\=.L&G:L3
MDE' C'Y=)XAJ-FL.4^V#Q6"@[.'B;,Y=1-YE4:4'U1ZJ(+0/;M\,,D//$]#"
M3J-ZK=[[X0?JB#;Y\9]K@YQO^*UUTAZ+B.$P82T#LC93(8!RQ UBCRH&KOF0
MPUAC!%JB@,_;]2#4TC2J8YE&)2Z-JB?3J"IC] PM0ZMN )(]2==^?:?:/UJM
M;M#X]/%O%XW;R\N+^ZN;WVH,W\Z$T3:)F"4%4#B?X.2O"[QML2,7@C-2"@-8
M$*Q%'LN9$3>*84M3%S8*;"P06QR4XY906-K-3N>TV>VV& BBT__#O+AX\Q,T
M=6QR,*:]!1D)J#;6BSBQX_1>]QC6=J2D/^90N5#]W*"Y5X"Y%[[!?SK:ALR!
MH:3&7XU#7:D11_.<,*F!)NH_L(S#07 SKII_^37X,G;ZOZC9(WT@2W&X S.%
MFKOTU8,GM'*QLH F26E^$0OF8F$W%\OD8Z@<VB0#34*: &?;L4P_+'0(>K$$
MK.4#R=+AY@ZMT]?BYTXPF'B"';AV!@N>S%)>D^#>()TO>'S\T5'_P >$'GES
M--+%X$LY4/C28&A\I!ED!$Y;T5"8VKQ4\U!):VR.27.>2_U,Q\]!TUC.)^+W
MP,>O#T>3+L0A02[I/;WSGAC4^:$GR "2GV#L=T0/.WXLZJ&.SU$NF:>[N(_Z
M47IH:-MZHF#=4-5X:OD2O]CU[PL]@:UQ3C-C:=$6$RWC0-F(,C0DK<T?\275
MI\,G6*LT<1D#HO8(&Q('3;+^THVWPZ*G_G[9(+N:*\.(J$0Y>\6[2E[P1[)Y
M*UAW1K7<@H60-QP3Y#]CK+^0 WY>8&)NML/+:=->,/_PKRE0\E.-(B%=MA!F
M544@)9@3A:GW[]LG'T [FNYSI"W7@D<_A.HOPD<(1&C"8S?( ;P@J0E!G3(<
M1 ?L!NI8JC<I<J1Z*T2]L032I//C*%+=B:>]JS'S(:-564M;U5.W)W!V[""C
M."P8HIGI83]G6@ 37-],N*LZE_21LVK:,(<?(MK<6\&<=GHF,20F[2%-3T>L
M5ZI=PI/MWN'IZ5^5]Y;M=S]5Z*%>I/=I9"&G>/$'#B.CO47=3I/=#DW'F_A'
M?XE^A[3+9!)JFIGL_T4K^N&B&=8SC9XMRV%)Q89.O"@++-L#FG:<AFCLM> X
MB!FP 9[U:9.U,4H&$J)N?]I[F._(8;<C&\ZM@$C7ST2H(-K>EN)@_N4$6RC[
M&=+ADZ:TD4-(2/1-="%^G"!)A]A*TC*T>1JD/:JQ/+'5:O,P2\HZ5AET['Y<
M(4,'*W),LW1H;Z6 ?V@/,]CP\")6KD)K^?#TC&5X8E.')=(.41+>KK,MP7SR
MPZ VCIU[I]U,%TD3^8,N%2.>7XKXF;<ITX)#>)2)M(K[2-\^#=]+AVL,O5FD
MK6\:H29W9D&U 6/SH/-#M&(UQ@ET%?$7(-*#+0@VD=WHI&)66FY2>TK+;7/+
M[9'8DZB^"KA6VFE%A"5TAR/;M[-0Q/MIR#00<$F&MD?;E7=9GV]_6L,K865_
MK!5.<$MLT]ZS[!.X%%679L44%J9S<1LI;*3^@0\PH4(;KHZWRMDC7I"R5<I6
MX77J"2L\ZIH$TW&,F=](/V9D2?DKGAJ/3CO-_DFAQ\S[2.I2=$K1N2W1J8Y=
MEFDN)6>1Q-AI=ONGS4[OJ- 4'=KJG69OI$55XBDZ?EX)'^43#[3P IL@'R6\
MRU:F04:(2C-"@M_X/+:Y.%3LT=(VECPE!?SF OX:A/K!]ZF4U>+I:F 8?D0'
M0[FL@2"VL*/=T1+MF&S>,Y>E_L4&V\UW?F[2W#D\%""&$7;LI;EONC.U:,RV
MR=]HS/PD.NRZPKYI^ME[:2.7(\ETM)L,8 YCPK23&_P<#=73/UEWAJ#E]=PC
M^9D'P6H6'R%'+38)S#<;PEEIR2.@6-K!G:'20Z)S;*FM#VEWP$B&P5R:G]02
MDINEEMA<2WSW,W''0>=+J3'$T]@?#,L@?FU6Q<YZ9D6G&<2:C_*$K:B1C%*0
MCKGJ1N?FT'$ /^E)/&O6R?KH\-+(8,8$/=%']>$<\K2]0/)^9^> =_S5AUSJ
M[B,_2/DJY:M@^8I5 '3%O!) "M<"S'$6QF*=I&G<@1W$1>U=7@F"]>W/.@[N
M(FB.H^##2I&8*9JQ<".E=VB0A:/2\S^/#@+T(R31S@?*S/+\YJ0CU29T2D?0
MGS0R]I?U(*5]%1&X><"D'2S92,KIS>7T#9WT3=?L3UAFS4^EP"ZN&50B18UB
MGK58PEH'MB5!$_IOJOV31$=ML_WQI?;%S>]??=L5;[=Y@V@%VY ,X<G/1 O&
MP$_8L_S2A;D =EJ>(>M.J5DT0D/>Z)0"U7]2.'7L4+DR@UJ(9N26T.+'3K6S
M(%N3DULT16C56BS66M=4>;U%1,\%XR$P7L-Z!,5@/E3^X"U_L5D+FX ;OZ(9
MH,30__1  ;FSN77%*WL3^91#P@8:+ KEE]/V2JA\D'V**M%U XO.(J7!Z57G
M+.$Y>IJ9<H))2\15APD;GK00/#!Z*WW^WU63)HQU>LT&)HSQ,1AOK/=W09UF
M93>,[/IJX;"HC7M*%-TY1C:;W72M[6:_>U)T7XOYC/W4A/KP5"@4(1:?Z>D/
M2F4&##Z0C^'136Q_@XIX:JC^3.U75L>I*2H0//J;*847I[WV8;\?EH:(LMW+
M8K)][FM;"#JK**7V52SU3IO=D_Z6Y1+&C"*^!=SD@O1 L<*N]DQL0<,E4Y--
M,W'8T;72;G:/3GV;"(S]%]WR'/!;\)D\ 0ANIQD]S95"[1=>)J])$25%E!11
MU1!1_:-FMU5ETRF,-V0UB?K=H\/C9-.-7O/HZ'A)^24[/5A8(1E+C W/&'R[
M+O/:VOU6K"%(.=&1T\-3'*=;S1Z9]0H_?*=E8@T:5GO%O?6'78$"Q'S:]+EV
M\[/$6!9N48&#S!O>.SD\"EN!RC##*GTH*IJPA8,<02&&$E9>'^UI6G1IB5KZ
M-->_&2BRYH*(?I/GTRL.<5W#'[7,CHW3;?9@$# _^J;7#G&,'JI+G!M<:#1
MU/%>FAU;QR=7'K_5E"Y2G*P2)]&C0%JLLV9M34E'<(?'B]1#PN@X*'Q\V\J)
M R=RXH"XB0/]/9PX4#%BKU=C_L3@@5YPNGY_]?"/QN7@[/'V_J'&\-5["*_^
MY<KT@\;K)U'^<VE6(VW &G2(BZ5#ZF'*3-#<"KWL1M2EYK.VTSQJ'KKF62RN
MBT57?!A].&UV4:/N,Y56&^$!_XWE$N6>/*DV?=2E98-^U0ZN+0M3[!L/_J"L
M:**1DTCM]*=BD[=G%7?HA3#KGH6._"M 2@)R03:Q 4K$1CAQF;J-7>GXU7P
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MR]677_]AM3FNL06(+@((_GA1X@;$8-AJ(ZW2W<+NL>##$.MCQ%N*0X\7'E@
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MANE!*XDD)G$KTDP"MX;"ITM[,7Z: CIWB7A0AO!__X_??_7E?_RA3R)A(/4
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M<\:OP;R-_<2%T-:8V4VL+>4%VZ+;ZKK%MG 6(49 /JPO!=2%?146_:8ZD*_
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M'8UG,HA@34/LO=I770<:[,3TD&B5N-87A1)Z#W6*80)',B4S_0)$X[24,7.
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M207]H6-))+"PL.9[SC'*WC213W8X<LK.S$,<<B'3;399;7F6DQ MBY<1%CN
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M/D80$ST"EW3'*=?&J[<_2OCHATM,LP::&+H'@ H5,F,UVADPO/XD,)/ '(/
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M[;KB/A$T+;XVW68U2Y<'T+@RS1;HT=D:)1>'79$QL2W]2,XUR!9I*[/MH![
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MRCTTC.K/D"]IGY+IQ+%(X>IVL9[&1M&O;0CEQ^'*=7OAML ^G)TEYI21%YN
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M-]=[<5'_Q;$GH"\'1SM\/?DN>$%F,.0YTY-K<B-,Y8+07"TDV!@U,$GOO03
MS=>J]EE_GMS-A^BP><"9SA, <\/!C\9%/=!I-R9I1RWMC*0.2@07TUQK,"VD
M-HKG<'0^%E6961> 6AO;.WA"8[6=0:4[&JMTW_,IAFM1=1Z?3:@Z=XBJ\VQ"
MU;FGTSI? "S:>PJLMOSTCM-LDI,*T,ITMMDEG5G%"DZ*HGML,-BE3MI@;,;.
M@0DBG(=PC&1F&S?3N4J=-K!X\@[NF(=KQB!0KHDCA"LER:J]ED,M1N1&Z\([
M) %,01V,?2C "M/WX<GI'_O3\_=<YQ]/\"0A]%O?Y"$C,2$:1+T#*B])P(+V
ML-YR5;8WS?\Y(LC/_^B?>['W[N!][@=ZYY(4D2!R!&%3;9L0LUIA/58\,)R)
M4IG%[;;4(>3,!S%[(A?UA9'R08B _QH*683-(_)#OYCR#QJ>NC$W^H_&)H<!
M8PM('C>B/G.84>%@IQVA&Q&OJ ^6P3E0&4M# 40TMH=IN>92(_!? @F],TIH
M4C<4J4L(&.09V%.W$9%\Q*+$+SD@^+L$WL^3(DF36)\/8_J.+@5W2(V$1\8#
M+MQVI9$-=6I\M,T1[=06= 8_><B!T_C'I&;" IE>E>7N7^((4$^_L2UR*_>Y
MN5OM;U*9\45:BAN[@5>= >!%GM0U#Q)*!RY]/!J[C,;F>=Y+^5@<YSLUK).R
MNN:!+'Q4-(Y69'%+%$NGV]%4DW+C:>=<U,:VRI)F-)7K 71N<_IFD9YR 3]@
M+RW(%UJ4#3EC?*YIY;.A-IQU6K#(D]NG$ATB,.-S+P/]&RD]A:0.TB&FQTP
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M._(7U:+>='SR<L].SVG+OW0(3O;F>%;^_;?/OK^CI7_FM2:\,I9D!(9"-B%
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M+@3/&_^M!"?.1;JA!?,((BLCMS#WG.$SM,V:\3S\#B*?7HNY:9N3/%M@PE[
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MT/?&P+9DBS7 8\<C!(:V>Q><)?OH?M.C39E23!RW6[)S:!P7+ 3%J5BZZ;P
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M@,PAJZ5!BW&<1Q[8%?/O%C+X !$'KYF^?G(V35_?X?3ULVGZ^AYH_+O&KNE
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M.9]E5M5XUR?KEEY39+^!':QK&*,Z61HM>#>T2?"\\PRL[HZ^'5'WFE1Q2^L
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MZW=?42LH>),E - V"?U*6X9K@ZVH..OHASCX> =MQGG>%J;36[(A/!I8AI0
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MA,!"P^@#>^O1X,). *O0TDU)9#S)!<I$1SO)[\XC!G/DN7K&B<0,,](Y33R
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MA/[!_M'=AK,VW-,K;/\.P6TP?!X[U>U!=K)[^F<-BVZ1 CF\E1GTVW&=?<^
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M(HDET/6=Z_E&\3SL0IA&$XDCI->X8;T-;-3!DFQ:'2\VH:"G8$'%7Q00ML0
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M],5X)K#<[UD^! _7Y4/[*Q\:U.5#IQ5H?/Y8L??K!^6?6E>&0>O5<=\CN8L
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M%&Z,;=KDNN&OIL)WJ8TUKCNLAE;9U@1'V) @66N?(Y[0%;CZT@C/C QI^3A
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M]B/^GPHDRI9[4]EY7/:-+K4B!]%!6%\7WDO[1:O==)J(50>/7GCPF]9/RC.
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M"?.KPH+:7 %7?Q3' _F.8^J5#^_DW7"KS;L2F^%<V>59O<S$9,*BEN='(N-
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MR")@W#3+O!0UN M'[U8&:?!KF>>^\MT@T%@@="'EP1&9A-$JC A+0WGFB%L
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MD:YKWD/FZ#'R- I.^%K5FYM)L#]H88/.AU)\74+3"X- *%2<9$$^L@:V(U%
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M8T7_/ RG_#S2,EFXP5S(EF?8([%A?_0)@I&PX0/"1:0NK!+VUHWC%)M B=B
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M4G3J7(K]Y5(,FG4N15&9G-;Y^67\Z\<PP39K8"M^=*D'>&S_@9;G9Z,3.$C
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MW\HO'*_J?J[J=RHYC]<T6]?4-@.Q_:>38@QJII)<--'U3GAMTQ[%YO$(5OT
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M3&@PQ I"^6^K]G@QG"HCNV[9V[^&[32_3B=D^TNTQ8GF8T9H"SH.Z!!AZVK
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M,+D;>;PP(+QS5 ?[,"HZ:HXUD/ DF[):FL2O]!68C_+T 4!N5//..5)MI;G
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MP:[WS8D+)(?(M;]$-L5B1JXW\(O+XK!:>VFQ+37#'" O!EDU?1\89DBL(.N
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MKI3S5;X8P0_>$_.F3#Q?H5Q,["Q4JE6^5"MO2#S?RU9U7#8ZETV=7,BB(=\
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M%#*;19&-ABKU3&UT3^> D>GAKLJZRFU!%:ZJVFAQEYX!%VE/%YW&:>>BT^]
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M3N.FT^[]]\_PXX'MNGG5[5U==%J-?KN5Z_71_URVN_T>=W7&75VW;QK]#OH
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M>\=4 +ER()TOD\JE.%?K4I+J_DUF9>"N#.XMU>+OD"L.:\Q@OB%3B_$]]N9
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MSNXKZ#\OFHCYP7(DG3XMOI34KX5=\PN.IZV)VQ"_Q'8_ MX9H<9N334G\G3
M;_O?F\KZ?+]#B_J\T(]"Q.KFFIQM;W&6X<UA]1"Q%'+EA4'DSRHI'!1 )N>)
MP^;DF-&9-BF2[%OPQ:-:S_'A[XELG67U](@]LQV.S>0Q'1=U@(MRE(5G0I\(
MJ>L37*:54961^FX;,VVAIJX5LKK;X]F^W-WV->3/<G:Y.W%2TM[]3DR+(]\?
M^3[Z;JW(#@>AG9..RM'@SJNA@!UPX%KR6!DIK^?P'5O'P1;.%6WA+J*BJ;P
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M;<L;?;EHE1ZN;Q^_!5RK$'%-Y4@">4&8>L/2J&@DC6AHTA'*T4CGN=M1#<Z
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M,+6XD3R=4IKC<X2?T;I&[&?W&T;:="K.#;00]J\/W*,BF7>PM?S?/GN%+%)
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M:^!&&GX6HP*>^0Y%CWD!0I[N^0@L+M@CYI2[<<S0"'EW<=3\2\D6[2CFVR"
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MYB%FBV 35"2B1C]D=%:>F8)IY]TNF!D$TE$8=)DH$N 1GX7.W7/Q.#I>+@>
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MN2TE]=#0G"0]5"Z1;()_0VJ$HD374)GON=B@W>^?[4C?$-XG)\!'COW3. U
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M"!R3_Q=^XF8;D1(5]6.?5VRI/=]",Q=9:,8B"RU1W4C[G*?U4L4-'(9;C)Q
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M%WB8AZ"29RP^F 4<_^XL0+/26WZCPR:8%RDIOO9CPDJUR5'QN/9,ZE)33QO
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M))V)SVB04XUAV?B6,=\ >/R A48VZD3NB+?9$8.($S2D=D*[8#/P5G>V:"-
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M99VF2[BM"R\= 5<-A=T<7+,NES<7^:??]TMZ3\I&6Q<AJ0O#TS<."@A76NW
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M_0%!1K+/N\,[-KFP@9-VIV4RE/$+@:V<S<+PB4<(!1>'JQMSG*O(.DA;LMS
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M4K>N,S-FC9I' L-Q"I8\!1O'@(6_!7@;PW]" ]5M4J Y'S!@X%T01,,ZO+,
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MFRA^@D--;>N\ 3U46Z+5DB'P$[UKGP"X>[QY8^_:UIV=</+5ATG^1F)J%:-
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M7C0@3QWJ7HUC7A^< @M]A#5L9K<0&#R5)./ IB-40/B%"BQ?"14LV*',91]
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M)-/K2*'CG$!Z=S+MZ$NB/;,;Z=%FU)2),719A5RV^R@-!T/FNF0THS'M/IT
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MLOD#QE/3#J<?,'Z9Y-:&,R[#C*0U9P[5$@#O &2PM((7@>88;5!8%S(((V[
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M[U"1'WMW399G3,6QF!+A!LO%F'?HJ4!WWH=-@\;KS4\7#C55SMR<'P['&KU
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MH#,6%#^P,5(I7KZZ2%9<QDD<.2/Q8!LX 0TVI'(2^.*,$Y#T9T;<!DE[+?Z
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M3@K<$1VC/EE(F!EN/FTN$5XML1A>P1)>.ILC#B%JWI^U#T[I3,?\7N,Z9J\
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M#KE \8S$*FG@:^V=BKB27Y*([E,BJ.-LIFKA?RDW_R.10M0\D>JVJTWJNP(
MU489V0P4_[>L(+ </Y]26A2+JG#OO"*AJ<JM5M7(F#>N,UQ+K-ZG=:8K%5!_
M17]" *9,=<"I>;B3*VA++R6X3VDTJHB<YD'5;C?NK@%E*/.S72D J_E'Z?WI
MU\7J]RLPT1P=!EPEM@AES=,[T_9I ",-L<58:\A$C/CPV-%R=0.P?OMYZ\@/
M6J_6H=BTZ0^<039GHA1+C2"N@;<Y23<O_Z5CK&'HI,:RI"AF#V:9Y5$I@S$0
M0-%8"OZ\@=#'"6*H&^89.QQ*<Y'D.VL-@RD6Y>/K%$3_E7*NBO)>E7-!ZY?
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M63([(<O21NDO_F2YABI949PC^712]X]TNZ@^TX^%K=''D-<*40E'RO^,:CW
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M81X(GV_Q0*8A.[)P#9SLCYA3"K)&J%B<7 Q'8$(3%T,'N8U3*!%+\P4C6?4
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M9=1+\JCTRLK#FUP$EA$05G$P<&T!H;CJ6DP,8O%A79Z;/"<QO-6@$HFGY&)
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M1R@;K_-XTBGJ,)D! VUFM,"-YY0<@XC#X;,?*MZBMX"5&9*GUB]]3IR$H;T
M*UPWTB<=*SR499J\XAG%M"^4JYZRL%?X>@N*Q X6I4N%4:.9053(4*1([3!@
MY,QZ@.K>?S]B=D''&(4S:-IMP^Q\=PO#-]<"^^IQT<($]?;AZN3RK/"TSUK;
M\.*'HXW]]PR5]]\GVG_/'4K__5' $]:5S?@^@!Y]L!W?7[+-?:Y^R\] E,]*
MMTKU6KE2:U3*1PO][\7"90$ AFB<52JKG>]8< ABM@BP2=L7CB:F/*G/ KL%
MN 3/T]K+H$V;Y^(K7.!BC8?@X!/T$2 FO"03<0P\32B487:XY&^[*2H#%.!H
M]%45IB%C Q-O-W6*NV[C;5PN.E:<S%+/T^O[6EEX,N62(B:](+:ACFS7_Z><
M3$/H0./$%^/& TS%U[]>N-"&7+$M6FH?'S"+2Y2)2.N!][I'.?(2X8@T\/=8
M5\8=#7#=/_'>O6Z'BN\H&SX>/+'?'TMR=A<46L V!:;PLU9\GDYI52G4'D^N
M.DPJX_<#+EQH-)" 3W5I3/@'@QZ8H<,$(E-:06;)Z3B?XY2B 58['_=LA3V_
M4!\3W++J,:WC%]!4(,\&F;\EKRL>G?C?# ([4X<)Q#SO3] I5A\@FJD^3Y]&
M^M6M8/6+CR^IL.\BSAF$<U?;"U#9PZ.DL/CY?V/N? Y)^(%#KLOHR<<LM1AQ
MH+'C7BP)0[>"%+Z+!7_K]0% -6B4C$Q'W042$,=A))&4Q: X#B940Q7EM:F.
M%*WCSFLIZ)TZ7 "P('%=!KP^>[J06?W\[JR7EJ1E5MRU-7MLH-WGGGP^O0DU
M[*'U!>T%,1S!),OJ$I2P.&8H[F((@ZAK&P.F]#.,0/)B^*[F0&,X*OB^/-J"
MI<T6RQ48F25Y'F,Q33C:XMET4,(T@8@9_FE9]0]-I6[^[$#'LU'MNC4"J&G8
MRB!$UFSCQ";CKF]#VB&/CD3MF.*(V6*-!8L((&C>%XYO'AV<.;(QA1A#XQNB
MO$23/!N^%CP99$<-S40P@;+KEF7J,*$^HD-S-4-O!P8(QA6&J[^?C-]NNSO0
M*3%B!4CKYY&"+:B@LECE, )8G5P/%$ ">@?VH*"1C375<V"Z7._Z=]OHG775
MW3HPT%=Q3H=\%-4[&AI5MI>5W;Y*B+50BZ&KL2L76$$D!2E<4^^)4A,&7K#N
MP_:[>$HDV0C! @S.*BW,I[45O0>'NKJ25K4K:*@\(/M3P^C <:(NA_UY:9W=
MW]I\]W=K9S&ZB,;Z_!:S#8@^YOMT/F84I,5@\*B=(BLT"B?O"AAKNK]D8  ;
M:8&"A<7VH!B:(F468Q,Q9ER VV#->:&!MS=E^/34HNQ6.RWEG4P\P/"9=;F#
M&.P@SM$;70:Q^!/:>8:D^' ]F8<#]H+M8.'%XF);I"62I785_ F49_2*/(.^
M*)1BKR_FV<?Y]'$DX62KXQI('+Y 8YS5\(Y(PQ9F#-Z">?0UHF.,@2:,B).5
MA-_V#XY!X3&D&'9RD"-%F2)9.GZ6A7'VR*<KR;XTJH-%&+97##A<EDF)"VJ,
M2@?5>5@S$P$MUJ<X+MU='YIJ%?3.ZIS>A=JV\>#DZ:'U>%<H[*:T+8B>+JN%
M8O6RVJS"BN^KRM-3H5:M58C*S5VU^4@ZY=]GA=O*6?VR7+EMN)W[[M\SB*%,
M'2:07 K!Y!)<**>>%BL<W5%%":?\,:U"N<'\V'D,'(<&%FS-=AO@S+:NE0FL
MNU\LW^D:[:[6+W9Z%]K>8G/??GE'!/8#.B,>F%=,@/C*/!!4T>TX#KMTCA<%
MDF7"BRZ2)<R=0BS0'.*P+5^:9(!/)T8H-MPRAP2N:([5SJHH=5GH];&@#Y[:
M;(?&"6]OE4!RC^:7EWO-?:P%50P6PDY\,#Q+TGRX=9S)K%$\R 6STA8U7Y3(
MDP*7"BOYK5>4W%[+2)?-&Y;O2X\7U"[JO-;QU'QBK;=R=+9?;Z\4L@9VT3F+
MWZ)V"FBVP^2K.% +Y"H>NPB)84F!"D]R8;!4^5GUIB2X4Z;6\A1[]W#Q^Z)]
MUZ.D3)1GN^==Y:E/D[:KU.Z+_ZY%2PQVQ8YU<Z3(Y<G5Q+$4+![PA\3P)"?&
MC^7A9E.9C5$!+Q/1O1L43[K=E_<[[N!*K0.,X#SGYNG!K201=LA:8F62%C [
M0/(<:_KX#I9I^"X8R7(LR5.8S2-Y@N(PHXW<TO!<#;E/,$%1,N ^\9ZJMP$A
M0B4#=$QO:CY>GC*EII5.MCM:I'E^3%1]V_8?E/B[9M@J(?^3,@(6IJQT-&LT
M4";_$H!MO-PD]O 9_X./+;5]K'T<][5.1P4O!SACM(^6.0"<+G_[=;RT@"@;
MM+EWT C4EJ#)95,F9)-_@W-3'<+]X.9D.5>*4F$OXKEFL*=\I3K8GURZ4J=3
M1==T%?4#I!YR^IPXE];CO 1<O@D0](4A3%L4;&=((4Q=-(UKQ1<XD7ZWS'&E
M_U'CY'03HX&&:<-9P%"""VQ5=8CF98U,M:N:<*6",\Y^=;XGM_[>X8/LX6"H
MR%M;O/"3<\[2[>R4U]XA%Q:YO#.VVKR?%!65F8WKG!W0I722F(WG__9K^68L
M_LV<R4YIW4Q[?91?![+""/V(-]MHMD>\VR;?S9LP&ND"BX:_$#6#L'X<?WK7
M<UV5+:XGIK9M8.-*QSGVR95!Y_1ZNG9>69CM>]X-IXX'M]S)Z]OU]$;90,_N
MP.SY,NI5CMT@@]?=+%U.O;TYK?TQF/K+&1OS9G%(>OEN*7&JN-V$]>2OE !W
M;K?XDJ8HD@H<&K^9.5<03B)_<)F<-YB1_MG[NV'24ZEMVF\WK<Z("R?EV;;=
MI1LQ83<*7/B:YK4NKZXNWVMOC^>M0?BU#-]2UI6[%>)A*UW!0Y<O[?>/ZOA,
M[.!C:X,!M!9;Z5YK(+._W^^&@_:M&A=;\:6/@Z^TA.EV"R,QKA-AH_"V=\(S
MY;:XTP84;:\<)#S3+444)7"G[71X)%473QD&JT9OA3V<HS8'"J&@'1.KXW[1
M!W$&X&8V@1PU8LC#ETH,S?Q<$S#\,BGWJ! 34H!8Z&28C1&AJNYV5E\;)MK-
ML1 A@CV+0!28QF  /E)%2S,MU,>'NI%532I28^J2O4NG@&W;3/EP37#Q$Y.8
MQ.5,&1-B:8BQ/!F2B<"XW^?;U#N&\B$MZ>61*1HM74^G-212/@19.^XIO=ZP
M/#."30!+,WY]%BH*P+JYC]K3>_FN(3S2ESAZ+'+N PWK#4EIR&L/'"VC,67/
MN=KO/O_Z(;[,W-25UV[(//#8!_!62AA_GDY9?7 M:=$.$#8E-L(1HM=VR5&K
M3'%#_EL<.+ X28[:,+2[('YQ+8ELCN%/+P;7'[=-\>9/1UE/&A%B[878!W!I
M\[0R'#]-7J\Z9U*\ \1 >9R(^!*JH]:AX3C]&(<,IL?MUJ4S*&J=3.3Z)^&F
MC8L1<L7K:08[55P:*);E[O1<W@6)#E8,CB1VV9;)\"<5=LQAB6AF2Q&=X%78
MZ\NN*EV^591.)H3]?!GE^E/[Z9F!>\JRKA P+K6]EDM:::PW;&(G?G&)]5H5
M9<$>5)Z&\E;JYP13_21X%>&U\6 4M+YHJ9E09!@DBF?7I*WL,"ZRG=:&37.)
M97(W%4@%P21B$A>;2L],K<A?4"=/W5 J79<(7.^/Q,_:XM[CZL8:T*^-][-*
M._0>&_.T899SQ#0M[CV,6O6QKY_WNP_A]O<Z?$CQ\9'X/6HO!7'8.'E\&(2;
M\3$RL>LQDK#HV\Z$CG^)J.G7V#>A\8PG_)M$2+K&OP2>L90>.O!OLIU./<P,
MZRX:,C:D#V0J+'V0A8Z231>@M[M 8-QUO;7OC[NJU_>&47[1+BKSN.M2[\MN
MPK#(9\D$/@ 3BP=-4. "4@($M4A.Q:6&.T-?H:5.@QOQA8<W8RKL:,&)TU1G
MZ)%B^;Y31PSDM^]%^N6Q]Z=7:\V,G,47;@@1G>"]V@V3=EJW=X\?Q6JEP45X
M]>:ED>$OCQH@A>=+.5:#>]J 2"GX[8XC]P[%.C]O",24@DDC)'3?N'^Z;(K&
M1>=F'4E$")R4X[W:I49!N?T]JH^-ZW,FQJNCXADW7 ]^FV:X/NX)@REP.T?#
M+3%/*#CAD.<2150V4410=&(JCSK#ZL=9I2^PFZDAB@.[\LJUT81II5A]>VS?
MZ*/S/YO?&\/A7'/CZ"3(INE_;0).C"-NYUWQLDP*0M <^\WT%]33$(/87-'S
M<CZ]LQZ*>E7HXA';QE>N#95,AX/?S,5=^^'VIK<78@N4)I&'MN^$V(*/N)U(
MIB6&%!@>2^,>DFL[\OXX5,R>!OY Q4 /LH9B:$GL*7P\*<M!8[U&F7&(M@=9
ML-K&'L%'DQ*3RB:TY8DG 0[8@!ZQ=Z^,?<NWMW?FD_#'=N+4[Y*56.S]8U^6
ME3ALZ9,8*VT8M PH&#Y5&5PK6J>JEY219BO>%L'F1[7P]$ )+Z^I3;*DUXU9
MGAV,@"O:CS6=:#MGVRL9K(%7= ;BL)=GT91(<L@5.M MG7%@%\Q)V.,YH1LI
M<33)15C:@Z&:Z(TUWG"P56/<LMJFAH8;6[? V-+>8'L+Y+-:];FC/4^9+JV\
M"E>%:6\7DYC7L1TZ/6'Y3DN8L]-F)+C+A79+[(G\_]Y,_[$H(P978(^*!/J%
M%DDAPG:C5:#\LX$=_(W3MZJM:+K:J2BF#LC/*K3;X^%X &.:9;6KM35O^$^=
MN6\R3?VFR;[L7-?,SP3 A0ZU7TH)!UH,A1-C1+T%S@A8;U5Z,J1,RZ3$XVB>
MM"?ZI0/+8%:+8?VN@:4LD)PLDSR-,Z5\$]/Y8^J^.Z)A['#L@*GV5=W2WM2J
MWC:&ZJ5AP:VV]6Y3^7 Y\/SCAI[<OUQ_=,6]:: UO91^#G76NK;]5R(&X#8'
MW"<80L(QT1E=-L09M+^&GGF66^/8834P_I-C<1,6 Z42'\.E6(=%029%#G-5
M*[YQL&H1>6W=H]9 *9=:3_)5:DNFF40FH5NAS9(;>B^_V(#L573'$%780_]9
M4N;I2%N*\I'H>\)XL%C;8DV9S LDR^YJ"'[H^(NP#:+>*H@'^^SI9?ABH0Q[
MZA;8%@)P82FU;PD$N3+OPAGMEJB4_/P+CL/H)8;8Q-XKD&^Y/D0B"):DV%OJ
M]K?_^@<:__/KZ&B>WH+/<OS&L GTLT08^.CLO\4WMU4X26@IZ+C5E'OO%FY$
M<G1(9V^HZA'P20BE#?UJ18?#F0C=L,%#;(. ?QGKRKBC0?\;4%T'."W.3\A6
M0&YY5],5O:U!D]CKK;&^'R8T C!Y]-__'!\3)YHZZ/Q+7"L]%39^OXY5O0V_
MQ= _"905!#\3Q\>N*.IH;U%M+>>:L[\+:&L"X@!PO<' 92[$H/#?X&!M[]^+
M;P"FP$ 96> @WD\_B7>M8_?AW:B_@I8SK)\/9!NC('9=$Z)R\+#PNF^_3H[]
M@/- ]I-H3D;@! 43B+CV3Z(&!)\#UIH!X<?R_F_]\+X&_S27$IZ(^.\' '0
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M*.YSF+\V)MJ\<$/@RU:R9]ZGF;\P<F(A8%Y,B9V8QM#)BXK'%+TN0RIL46;
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MNH[<U,L/D\'#A ZIFG&IZWL555WM:L!,<XJ7.T]GEX;9N^&;..5J:RRUR'E
MSS;S9E,<LBL<,<7.A!8Y?)7@020UM$*X6.85?IB.Y),;"''(0=4$D15N?F&'
MY^ 0Q7 =GZ,K)F]M-,^PXW)I\%9NI>6'R>!A JTTQI\"5NVEV0_#4>7A-_?
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M+RG&+>K"DZ'G0.N:\1EFZX9#P(EX)X:I@N>6QL"DT=N3)C!T+.<4!;V#_C5
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M12>2PFZP^DWG]/QC<,L<RGBL.&E/<;LJ29[A28:+/\KO4X^.26H411P\XB\
M @CD\_%8Z2,P1LY;P*]%H 12HEB237+RSZ= :505%]O1_M1@2VQJ4FRW,<X&
MJ'5&-461$LN3$B/F8Y)212AFADC</C3 "P+)R0D:( >.WR31NX0L[(IDGN2
M6F*$^,XM_ABL\D['8#V*+TI+/1O\%G$J5;8J7LYG7^VII""[F\(R.0='G 70
M9$RK6,2>P_=)9E])AUY&)!UZ&9&4U3*B0^#Y16Z68@3-=S;[2DYV]E7EK3^]
M,(O7PGM_CP6LZ8W!XC'&8"V&:*>7$[/YVQ;&>N]/-L9@;:)9_!GTC$R1%!,T
MG7R_<[ J:<S!2B$*?WDQ.=&K:K70%#_S'*PU1E)([%>..A0T.(8O,J0@!Y%F
MAC5;RE.4\/ @8<?@Q0@1JAS^<9R%.*O8ED0U(Y*4A-$__2,+!NJAMTK(A^[C
MR)GU<?;/R$MJ"SN@"%E4HK85F3L?<= M:^4WOGYY6>[F(PZ6#-'PR69)C#A(
MP3+]0[_=W0G-.[W"?M81!UC6$ #V=B,.2)')AQPDC1/L@>.TE%E<!.TRR\#H
M@ZUM6"[RZL(-*? @M!W0)%:.RFS$->H%MNR^W_\%N$._P)9+:@+MQ,(.YA\4
MWRNO0F4\IELX([%V,O^@IVAYICEM J8SZU)&O<"A"W'ZT(4XG5DAGJ$^^G46
M&U9Q&Q=GCOY2@I,F.?G  L)9P-@2_/%7I24!_[A3#ZC>U*K1Q<M7<Y!//8C9
MF,3!;0&'./6 @UL"\JD'A]U>&A773-Z1'A=BH89O#K$EB.5-WPDV?:\Q"".T
MKW"1=Y.MC]TQ)"5Q),6&CU[*IQ[,&2#4T<D9 )<!EBA\^SUA:5%XX-2#(L;4
M@\KS].3T@RF-54F=I+,D"6OJ04,=V4CH'-3H XY9,^-K Z(S,OJ 8]9X&.F.
M/J WCSZHI)O:KM_]H:O7YQ?#*C=+;5?0JY.>>["Z;3'RHL7O GPX!9-^"8U/
MB)-09;<KO>1EF12$H-K+T:^C2*SQ61N/D^ICC(-,!KO!B"=E.3Q!GB-P6P3&
M2)ZS^*4.E$AR%$525'A1]-=":41=&;[DZ4N!+;&6^]A.:)PE4FMG*#"D3,ND
MQ"?(# ?>8Y\.0C'33.SV@0:>Y9+57P>.WR31NX0L[ 8REI1YFJ3Y\+Z$K68H
M_+ 5 )5?1T?+)CGTEJ+9Y,>V,0)V.7RG^POO)"OIIS;P0P ]+RJ6K=PY[TZN
MUAEM=1-TXOE_:9^]H:I'L'=-:<,Y#HH^@8Z6;MC@(;:!NMK&NC(&!A":]* #
MK>O,?-!1# C*#:*KZ< MTY0!.)#K]EG?#Q,: 9@\^N]_CH^)$TT==/XEKI4>
MX-Z&^CI6@2,*OL6P/PE4PPE^)HZ/78G2T=ZBQM"6J%5 X0'$#^!Z@X'+5X@W
MX;_!P=K>OQ??T#8& V5D@8-X/_TDWK6.W8=WH_X*BD+8YKK8$N"F(.9=DX=V
M\+#PNF^_3H[]@/- ]I-H3D;@! 53:6GMGT0-2#D'K#4#PH\5_=_ZX7T-_FDN
M,SR!\=\/ .@ D)NJ\G+<4H', \\>(93YI80#X]4"7C\!C!8>[C\2/"O"-!95
M!X$M@@3+I95+LJU?E=I]Y;9:.BI6ZXU2M5(K51HD4:V5OA.%6IEHW!4;U7*U
M<%NM-/[[T?IUL->\JQ7NRM5FI7Q4JM?*E5JC4B; 3XWZ9;5< +\F&DWP/U>5
M6K-!U$^(TEFA=EII $ 05Y6GIT*M6JL0E9N[:O/1@<M9X;9R5K\L5VX;R$L2
M?[I_/F@HG=1OCYIG%:)Y=ENIH(NBBU_5:\VS!E$!@ -7KUP#0!4KM[.P-?H@
M^(%-Y.X99>E8.B3Z;:-IFV]>)B0X>!Z<RIBG*=9XX!&R%FM38^"8$#K_]XV)
M7'02\+H@@G;"JI%R1RM/7!=K2.JFLT14D8\:G/<:XF[5CJH.(1'5#!VZ&B9
M-#A %=Y:M6PO7M^JLF/[[.-RQ*A)0[8P-,:ZG77(EN)"]DJ=3A5=TU7G4QX@
M!X,316N_J_?W?Y(&9-.PE<%_+?,'N,OL[>Z_G4,D .0USK3I?'SIZ&FCYRNR
M>"$J(6Y*OYU;JEDZ95X:DO8UV9F*#<6-^8'G:>FA\.=/YT6Z$A('Z.S%!'SS
M<54GW'=G'<A<;" '1YZ?I^^G;<VV)X7B:_+J9QX;)<IJ5P,ORCI<A?C$&S4
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M(9*^ <M&93)4*+MJ1\7KQMB]$MD6#SOR(Y@$AGR2%,^ _[*HRO> A0@>!)/
M=,^M@9[[#XF949F=IA3U O*!7X#-J@<7^0)9G9$9^0);^D*!EN^**5>UK'&
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M(!F_?413(#F&(EF.#HV6;83-2ASS$.'-.O!>%Y+DM^];HUE2XGE2E,.#DU'
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MLP/;RY^(H1VOY(4^;3S2<N54QTEO)A8[')OMO@*#AAG/P(A45BMI0C1?=-K
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M'Q9KT'/42> [M:NUQO-T>OU1U]O"AR;C3-2/'O!=L&Y0A:-B$RVUI^DZ#-7
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M#N+]])-XUSIV']Z-^BO@LAM*;@ W!3'O&@WIX&'A==]^G1S[ >>!["?1G(S
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MA&81"M'2@$_0[NO&P.A-"-=7 )[CFSHP1H[/ 'XD='5L&J.!8ME&3]6!R+6
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M9TRA+,@7Q;2A%0.IW3&'M!Z*\<\\E>K,];0-8P"\D;F!5J@"-K!L=6@MZUC
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M_#B,=/0,$T$*DC:X(2 I%?[B*.@1,*@!_(LQS-C"[SN2&^BC%J1">/\A()D
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M#=DQ.>AVPH,6 480FRIN:6T:+IJZU'H2',8F%FOHJ80:8.JY;4 25!Q'K5B
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M%%BK-!1,R_<1,E/G9\C\A"2YLS#,CJ.Q9,JA"6A)+5I'F"UTGC1(3MFB$F2
M/^O"F"7!;5)0 !(?_DZ33$&EHG\PNNY\67>N<QZM6>PEC_LSW2">C&>]SY#6
MPO,52',Q7H^U3O,!0X5X"P*IY,0@GL3I6+X,@\*6KGU *;>+\3Z25'NTA37H
M Y< TOR<.0+)<<@F:*GI<YG5OHKT)K@/"B<W3%PDZA>J(J[XL[OM35@@\,V(
M3H-1)/CY4'Z(O"S:]B[BV;]8Z5+ 6?0>U_0FN\^<K(A>$ &'=<Z[G#HL&,O/
MLC_A@J@BVX?4YB=7L6OT61=/?=:)]EGS?U&?== 91IC#>)S*]]2)?>K$/ER?
MA_?UOM4$'3!8#!/6>J5K8P6J5GRSM_CS6[]1LI7!8S=WS/Y+H;?@[IXSV=K-
M35[+??G>D*:I.ZCG!-QMO//M."A_R9#:'9D_ , [2*G2E-3BVICI,IDW-YL2
MLQYI0QF7O5L?I;;^NP2S+<&@I?5K=H3>(+#R>.B= ^5>FTTQ/" >6V[#\M,^
MDU155O!+EZQG9IA?6O)V\YUD$0)8R/(0[4.9D9"7/7G._4G'\E+^Y3&MD*\Y
M"@:IET#PJ7P?!)1];.#-)IK9>P9I*)*"H4<TL2NF3?2FU%=[VY!-09[ G'Y\
M+$U'FO@/\87(*0FF ]6'"V8"+C@>"FO*;.]CJ/%CN&HMS>,%O'R*&>I;%::(
MD 4YG1K:;0^)'9I#0Q(:?PHQ_"A%-H:!<V?6J\$WJOOA@LN="L/GTR9"J2FB
M;5%% 4LM9&#Z!1/'%%&+I.(^38JDA1OHO6U*R((>F%#  +OEI4T_@5F7,)GI
M4*1&F,5\#,RLL39)MX=.R+%V_,1/[HTEK^S](P<&(TF<*8 >Z5'>6#Q"E)*<
M?A<8-\0(*#GK0V,^L;?@I5SN5?RHEB?/6X5ZW_9%MFRAD H0"L $"AX/9B9M
ML4@DXY5LO \J8T1[?J!'NIE<$46^I:*A3)ORS3E"RNS"'-+$"^9\#'S\CC'I
M[!7#.)HS<\.?B3,/\4E46CB?)\K&1!'0LY#(D+YXC=8+9+3F*H]O/Y_FTF+Z
M_.5[IW)=JS[<U6!*1@NY68TN<J/N?C'5^MU#M_Y88SJURD.[WG5.R5CV#[[G
MM>(WT6DA6J3G"P0MEL1VB+'\A88VIJ(E<B&\8@=X\%D3#0;?4<1O#-V,96YS
M3H&-OFT^$=8%Q_'_OM"!/W#TV1+?PU6<A337ZUGUG(O93;JP*#^\/ADE;T@K
M-&@6L+9 J]\3XZ&.@]]MP!@<JVPA?+=,PO]OC27Z114)4[FO+>". L[KR\XN
MO017G;$N/4,NO5 N"NV)G+W\63Q=^EJ7GDGJTB&02@6%=5NN#I<R4F2F'K,'
M -2H0@;+JV*K8K^90XNW1TD][V(>_ !:]4WSRD_4/N]JK9D^& F&1":%-8<5
M[(/AV;;W^$1[B['V^BM]OS!>+^RI.L'2$LE>1(W/.MJ2"/)7T_]E].?^5SZ=
M9?E,D>5SN7]LB6H^BPKE/$3?_>$9<ZF0A9G0Q89XS-[[I@_F_S>8$]V?X@+?
M[N%_JQZ_F$Z<!$CQ/N<2^[T#)HOFQT.U47X;U5[M 7EK7-87[_GG/1>@ TNN
MZC9(Y.B_A#A+!>0L.?L4\"GUUC@DCS\5M5///<?/G.&WQX/@$CZ(PD8'D<NS
MF70QH+G#]XM <1")T8]6@F0L"9(Y> DBI^_[=R^=MJ ,/J,$R5@2)),4X^2.
M4H)D+ F2V$&4-CJ(;)K-YX/:PY*2((%68_G8K<:V9$QU&0J0\,5 HZGQ*,'T
M[[(J/JADR*UE'I2X_FNWK-7NA!A6X]-(GDI^4]%_ZO:::(P?+MM@SI@WO##L
MKJ!?X:69U[E,EJ\AP*N?T01<ZXY_]!^:ZD-)>FZ_6@)\G0OY$G3JAVKWK7$R
M;F&5X8Y2:H?:??$/8C,#F&,S^=+Z0GL51R<D#?*?T9Q;2QK4%^/.W;!:XR:C
M3R,-0FVX^$P0M:O]L*1!J T7_R"B J>$2H-2#!,NAMV6O)X_ +OM024<:#+O
MT]/B5?AA7/Z>;B7&MX;A-J,K.UEKR=SL\W5!&UX([5EYM50VS_X01?%:AIG[
M$#R")RKZSF%)X+7LL67[SVYFC_(9-IOE#M8.2SXW<Z!VF)?/W]XUB;^ZT;0+
MY;@9?2V;:RFC;Q8E.@I3:RFC9S;:?XDM%K,[L;"./C)6MT:$-DE%:J3X]UR>
MW=QT9I-:O;_-$%G=-[]TC5QJ0E*Y\AFMKWBWGKUZ5=[O7VNYAY(EIV-=T2'*
M[E C+<Y9>:39<28_0LVV!$YD,T,VR^;SA8.UX[C/:,?%DQA/'^_O[:?KZI^?
M+Y]/8H1:>PGPQV81IH.S_S8_D5Q4D-/@$REP;":S&Y,P>8-AQR;A.@Q^GY6J
M2K6L2WUQ)]&WD'+5YMK6X9+*RJ45,ZN*6/>N)_9L6:Y#/*]U+5_*\+=7,QL1
M/?I-1JXK/B"5$6IDQA:+QYF3"34M8Y_#9B8VQ^8R,>KR LNRHU;H[5'R?,H"
MOG4DSR,_KRJU9X%?B'^)Y DU5F-SW&8ANH,S46.?PV8EP3S+\3'LTAB29T?]
M((NALE >1J^O@S^#[<4&_78@?Y[#V&P:]..O:%A?=9KT6>L*8_PU1M1F?45:
M2Q[S.[$$%P\W^DVY<M=XN[2KEB.=UW*!%[[M0[.V/)Q[G$F6P%YXY[[RF]F$
MQ0*;@2ZT3442)HOXYM"N>7 [519>FVC!]^7<\.H'5Q+%OX('?7:'AU8W"^L<
MC!7AV=6&Y:)\CLV4^!VQH&D74,R] "PN!P1&.=M;U*;*A9P?9FN93&P BQ@0
M3S9RWP[@PO(^0'NTH3*9((9.N*5K*OIQ0(:@$OROZ/AAZSZJM]!O?OT<+=[?
MKM^/&@ _WUMHY9N'Z]R/7YTG&2KIX')3]F$P[M,XP8L=/FI(74TUM#?2P@[R
MD$#D7I8[%PPICF;*G0>&:@*60531D9YQ]J<MX=$CZ-:_=K4)8EN^F/[G7Z8^
MAO$E=+PP<L;)QS#@AOG-JFP,%#)9&VCC'%Z1HJ]@9A,1X^+J]O<,^CW1^A[Z
MZY^9K-.W3'0DCW6T?0O-65)' IY/:'_%8(2^-INZ)@R:#S8'R9RG')L%4"L"
M*P.:',!JD&Z'P>4$'P=^,41/1ZJ?X/+W)72E*AX\/H0!=U7$'?A8N1Q+CQ9C
M86DZF9 CCRF.EH$AL&35];C4JL=ESQFD\108CD+R<+!>],"Q/,4@6UT,72RI
M(CDC8X1Q</KHEY.)(J.CT:6IKID#!A0\<14VB X3K9"N+.6 ^**3RJVI9?84
M:?>T ,"!PZ.KI[ X& E@H:+9B&YDZCH.S;CHBXY5-X?RF.-[[ <"3K.F2@'D
MP2+[2;(G5.)YLF@MSS/9Q!E#NX._8BP@P1X?;TZ 5S$(^*KIV:G $_A$$N$S
MBCB+>5:)N!(6<62R"X,GNYC2K9 -DF[V)[U2C67HL&'@04S-*8?\ F8315W"
M4]LAN8IX#F2:!&..0$2,-?@4C(^?"'0,/!9?,GDAP4JWL;\M&'O/^AP?=XC"
ME"TQR5PHD4*-DP'V@+N.*%R1R;-!:MG/ 3Q!01;=R./D$P1M<" AOK3&U#M$
M$"R'+,\!V85DCXI. >9Y!Z^5XL>C&W+)8W@K@.B; @P#\9&C$U05ADJ9PG6E
M("5R60)AFK*$*?S*)2&)W!S0#>N24]:N%,0K9*-/+J9<<K%$\ 5]TDVR7XF!
MSWS2;@N2CD(=VM?SB03%9Y1\3N,N&RKYD$N5<4H^:WZK9=OQ(/ULDP\(6I=&
MB&B ->BWSA@Z%Q-DH?#\K$O/F%U2#M'(>OX&E.M[*7T,E:-TX!$V^!!GS?H*
M]A&!HV0RT8[2HP2S!RWCBG"PN6 J#=@4^-CP8CQWU2'"L'0U99=CT.$*J\<G
MF-:00"DJ@?(LE:!DX;Y%KQ1AA:4BB#S<(SPEF8AGIPQ-$1F*5='4*UH3,?*
MSLZ7(X<[O.Y<NK<H/ZI:_E8==HNC748K#F5\1>DTOB+1\169T_B*T_B*R#&P
MT_B*T_B*9.+116\\N@GJMT)4:!GISZD1$GIV%:0N^59O,2_6Q$FN?#UYSR<5
M93[/A&0@$J>_5.:<\<2;^6QO4;A_+M:,8;5SE__RO=6NM<KU*E/[V0(J[6 N
M;':O:VVF\M!N([)$=D:GUK61@#]OT#EI"BWX!JQ4I:$$@] J,)RY(DSD*<SA
MEL06LD\%&4 6,#42,K0M_##P]8R#C#=]=&\A_Y KK_PT,VGUCQJ%O8Q=_1"4
M<\O,SW!F!!D;V.24'&/=T6=)M(7:Y-@BGQJ>(8+65%C1_,-0@YFLR.#[]Q,Y
MO9_.B_="I/.]Q<_%VTQH%7.O+5O4>X#57<#I:PO.HT5+C]SPM35$[0M'R=9
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MN?"#,(>YUH>>Z?(/+&< /];EF7"%;T9*>R?*<@9K1/^C6Z<KG$W0@]&OL3P
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MKC0>7TRS.>"=A-=RGJJKS(V@FBZ@)X.MTS).7\&@N;A $L^&Y!@]:M>?X.$
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M"%KQ^T@>C,A.GJ%;#SV'O%I SR,KU(;X[U@Z%[X9S 0I(/A@2A=$F32W(<4
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M7&8'\U(Z\_#C]4"O+A_CZM"!P5CM#%]:>G7H8T$AV10.R3+ED&"M6\F!3(*
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MJB$L-8:S*93'#*SK9[V%-\9L,L$E-CAL@=P\7%\CZ6\R\E39%*D)PJUT %U
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MOX?&%VDZHP'/IH$%5/K"=SIFKPXUK\"_UVYY\ &PF1,3_R[\D)+'2VT3.2G
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M_&+WN#M8/NW6/<@"L,N6B9,./6-#EB^O2L!,!G\.J^NO/W7#<*UR2_>T(P[
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M,#(T,#DS,"YX<V102P$"% ,4    "  (,T-: WFJ!3 :  " 00$ %0
M        @ %B&P  96YV8BTR,#(T,#DS,%]C86PN>&UL4$L! A0#%     @
M"#-#6GE<Q)!Q20  F<D$ !4              ( !Q34  &5N=F(M,C R-# Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    (  @S0UHT"B\B\:(  .>C"0 5
M      "  6E_  !E;G9B+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4    "  (
M,T-:XGZ0U$QL  !&;P< %0              @ &-(@$ 96YV8BTR,#(T,#DS
M,%]P<F4N>&UL4$L! A0#%     @ "#-#6F1+NY6STP0 5M M  T
M     ( !#(\! &9O<FTT,C1B-"YH=&U02P4&      8 !@"& 0  ZF(&

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>form424b4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ENVB="http://enveric.com/20240930"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="envb-20240930.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SeriesCRedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SubscriptionReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:SubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_MezzanineEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:MezzanineEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-272025-01-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-01-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:KanubaddiSeparationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:MrKanubaddiEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="AsOf2023-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="AsOf2024-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2024-05-16</instant>
        </period>
    </context>
    <context id="AsOf2023-11-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <instant>2023-11-12</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:PrefundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_country_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_country_AU">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockAwardsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:CommonStockInAbeyanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvstmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:WarrantsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsVestedAndUnIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_RestrictedStockUnitsUnvestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:RestrictedStockUnitsUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:InvestmentOptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ENVB:OptionsToPurchaseSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_ComputerEquipmentAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:ComputerEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-03</startDate>
            <endDate>2023-11-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-03_custom_RegistrationRightsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegistrationRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-03</instant>
        </period>
    </context>
    <context id="From2022-02-132022-02-15_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-13</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-15_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="From2022-02-132022-02-15_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-13</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_UnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="From2022-05-022022-05-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-02</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-02-102022-02-11_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-11_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-02-11_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="AsOf2022-02-14_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-22</instant>
        </period>
    </context>
    <context id="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDOfferingAndPIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:RegisteredDirectSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PIPESecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:PlacementAgentPreferredInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-28_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PreModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PreModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PostModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:PostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-12-282023-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-14</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ENVB:CanaccordGenuityLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_DistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-08_custom_FebruaryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="From2024-03-082024-03-08_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="From2024-05-032024-05-03_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <context id="From2024-05-032024-05-03_custom_PurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-03</startDate>
            <endDate>2024-05-03</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_PurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_PurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_PurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_PurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:BoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ENVB:BoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:TwoThousandTwentyLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-28</startDate>
            <endDate>2023-12-28</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-28_custom_RothAndInducementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:RothAndInducementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-28</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:AkosSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ENVB:AkosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InitialMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoPostModificationWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ENVB:MeasurementInputMarketRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:DerivativeLiabilityMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:WainwrightInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:RDInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:InitialMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:PIPEInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:JanuaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyOneWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ENVB:FebruaryTwentyTwentyTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:SubsequentMeasurementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ENVB:HCWainwrightAndCoLLCInvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:OneTimeMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-25</startDate>
            <endDate>2017-12-26</endDate>
        </period>
    </context>
    <context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ENVB:AdditionalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-25</startDate>
            <endDate>2017-12-26</endDate>
        </period>
    </context>
    <context id="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:VogalNathanPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-25</startDate>
            <endDate>2017-12-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:OtherConsultingAndVendorAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_AvanceClinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ENVB:AvanceClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_OtherConsultingAndVendorAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:OtherConsultingAndVendorAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-05-312023-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-27_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-27</instant>
        </period>
    </context>
    <context id="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:DistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-11-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreeentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ENVB:PurchaseAgreeentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="From2024-10-092024-10-09_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-09</startDate>
            <endDate>2024-10-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-09_us-gaap_SubsequentEventMember_custom_IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ENVB:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-09</instant>
        </period>
    </context>
    <context id="From2024-11-072024-11-07_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_InvestmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ENVB:InvestmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-09-30" id="Fact000004">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType contextRef="From2024-01-01to2024-09-30" id="Fact000005">424B4</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-09-30" id="Fact000006">0000890821</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0035"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0068"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0074"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0075"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0177"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:InducementExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0253"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0262"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0271"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0398"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0400"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0413"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0415"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0428"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2021-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0430"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0580"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0586"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      id="xdx2ixbrl0595"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:InducementExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:NoncashIncomeTaxExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0718"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfEmbeddedDerivative
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0721"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockSubscriptionReceivable
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:OfferingCostsAccruedNotPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:WarrantsIssuedForOfferingCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0731"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0734"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember"
      id="xdx2ixbrl0864"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_CommonStockInAbeyanceMember"
      id="xdx2ixbrl0868"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PrepaidFranchiseTaxReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0913"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillImpairmentLossGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0933"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillCurrencyTranslationImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillForeignCurrencyTranslationGainLossGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0941"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0955"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccruedRestructuringCosts
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1021"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1024"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1153"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1155"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1288"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1350"
      unitRef="Shares"
      xsi:nil="true"/>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1352"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2021-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1354"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1366"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1378"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl1386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember"
      id="xdx2ixbrl1524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl1527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember"
      id="xdx2ixbrl1533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember"
      id="xdx2ixbrl1536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1556"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1558"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_WainwrightInvestmentOptionsMember"
      id="xdx2ixbrl1597"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_RDInvestmentOptionsMember"
      id="xdx2ixbrl1599"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PIPEInvestmentOptionsMember"
      id="xdx2ixbrl1601"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1685"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1687"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="xdx2ixbrl1689"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputExpectedDividendRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      id="xdx2ixbrl1721"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1786"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1793"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1796"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1799"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1801"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1802"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl1807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1833"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1834"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1870"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl1959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1960"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl1965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1966"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl1984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1985"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl1990"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1991"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl2017"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl2018"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl2045"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl2105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl2106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl2125"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl2135"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl2136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2137"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl2140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl2141"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2142"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2198"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2208"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2214"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2221"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2222"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2223"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2234"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2235"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2236"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2245"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2246"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2247"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2309"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2316"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2317"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2318"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl2319"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2329"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2330"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2331"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2340"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2341"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2342"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl2343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2382"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2389"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2390"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2391"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2402"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2403"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2404"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl2405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_custom_SubscriptionReceivableMember"
      id="xdx2ixbrl2431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2455"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2460"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2462"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2463"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2468"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2470"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember"
      id="xdx2ixbrl2483"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl2484"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2507"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2512"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2514"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2515"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2520"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2522"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30"
      id="xdx2ixbrl2542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2556"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2563"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2570"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2575"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-06-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2582"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2591"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2594"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2595"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2598"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2599"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl2600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl2616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl2622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl2623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl2625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2629"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2636"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_custom_MezzanineEquityMember"
      id="xdx2ixbrl2641"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-09-30_custom_RedeemableNoncontrollingInterestMember"
      id="xdx2ixbrl2648"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2682"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2722"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2752"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:DeferredOfferingCostsChargedToOfferingCosts
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2761"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2764"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2766"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl2769"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl2890"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:AccruedRestructuringCosts
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl2962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl2965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl3064"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl3066"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl3068"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-09-30"
      id="xdx2ixbrl3070"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl3086"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl3096"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl3169"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2024-09-30_us-gaap_WarrantMember"
      id="xdx2ixbrl3185"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested
      contextRef="AsOf2024-09-30_us-gaap_WarrantMember"
      id="xdx2ixbrl3193"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      id="xdx2ixbrl3203"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember"
      id="xdx2ixbrl3211"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested
      contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember"
      id="xdx2ixbrl3218"
      unitRef="USD"
      xsi:nil="true"/>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl3242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl3256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000020"
      unitRef="USD">2287977</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000021"
      unitRef="USD">17723884</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000023"
      unitRef="USD">1293554</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000024"
      unitRef="USD">708053</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000026"
      unitRef="USD">3581531</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000027"
      unitRef="USD">18431937</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000032"
      unitRef="USD">507377</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000033"
      unitRef="USD">677485</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000036"
      unitRef="USD">63817</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000038"
      unitRef="USD">210932</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000039"
      unitRef="USD">379686</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000041"
      unitRef="USD">718309</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000042"
      unitRef="USD">1120988</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000044"
      unitRef="USD">4299840</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000045"
      unitRef="USD">19552925</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000053"
      unitRef="USD">1218783</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">463275</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">1075643</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">1705655</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">63820</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">23608</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">851008</us-gaap:OtherLiabilitiesCurrent>
    <ENVB:WarrantLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">25470</ENVB:WarrantLiabilitiesCurrent>
    <ENVB:WarrantLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000066"
      unitRef="USD">185215</ENVB:WarrantLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">727000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">2343504</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">3995973</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000083"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000085"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000087"
      unitRef="Shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000089"
      unitRef="Shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000091"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000093"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000095"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000097"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">885028</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">885028</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000111"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000113"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000115"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000117"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000119"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000121"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000123"
      unitRef="Shares">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000125"
      unitRef="Shares">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000127"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000129"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000131"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000133"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000138"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000140"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000142"
      unitRef="Shares">182625</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">182625</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">138554</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">138554</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">1827</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000136"
      unitRef="USD">1386</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000150"
      unitRef="USD">100841416</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">94415058</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000153"
      unitRef="USD">1817640</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000156"
      unitRef="USD">-96499518</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000157"
      unitRef="USD">-79207786</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000159"
      unitRef="USD">-569749</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000160"
      unitRef="USD">-536734</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">1956336</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">4299840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">19552925</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">8852021</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">11605761</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">7252437</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">8027773</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">7453662</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">343982</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">327910</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000183"
      unitRef="USD">16448440</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000184"
      unitRef="USD">27415106</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000186"
      unitRef="USD">-16448440</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000187"
      unitRef="USD">-27415106</us-gaap:OperatingIncomeLoss>
    <ENVB:InducementExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">1848235</ENVB:InducementExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">-94396</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">-4315236</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">208752</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000199"
      unitRef="USD">3472726</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">727000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-325000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000204"
      unitRef="USD">3708</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000205"
      unitRef="USD">-5249</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000207"
      unitRef="USD">-814379</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000208"
      unitRef="USD">7457713</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000210"
      unitRef="USD">-17262819</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000211"
      unitRef="USD">-19957393</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000213"
      unitRef="USD">28913</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000214"
      unitRef="USD">-1486060</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000217"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">19041</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">33014</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">147988</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000223"
      unitRef="USD">295976</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-17458761</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-18800323</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-33015</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">-505932</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">-17491776</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000235"
      unitRef="USD">-19306255</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000237"
      unitRef="USDPShares">-121.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000239"
      unitRef="USDPShares">-121.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000241"
      unitRef="USDPShares">-195.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000243"
      unitRef="USDPShares">-195.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000245"
      unitRef="Shares">143938</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000247"
      unitRef="Shares">143938</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000249"
      unitRef="Shares">96401</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000251"
      unitRef="Shares">96401</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000264"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000254"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000255"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000266"
      unitRef="Shares">138554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">1386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000257"
      unitRef="USD">94415058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000259"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000260"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000269"
      unitRef="USD">-19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000270"
      unitRef="USD">-19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000272"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000280"
      unitRef="USD">-147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000282"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000286"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000298"
      unitRef="Shares">-1000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000289"
      unitRef="USD">-1052057</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-01-012023-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000290"
      unitRef="USD">-1052057</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">2150160</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">2150160</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000320"
      unitRef="Shares">6910</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000313"
      unitRef="USD">69</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-69</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000332"
      unitRef="Shares">9294</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">93</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">255014</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000330"
      unitRef="USD">255107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ENVB:NetOfferingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">239302</ENVB:NetOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">1967424</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">-280500</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">1686924</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000350"
      unitRef="USD">683997</ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions>
    <ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">683997</ENVB:AdjustmentsToAdditionalPaidInInducedConversionOfWarrantsAndPreferredInvestmentOptions>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">27867</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">279</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">1536861</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2023-01-012023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-1537140</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000375"
      unitRef="USD">-33015</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000376"
      unitRef="USD">-33015</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000386"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">182625</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">1827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">100841416</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact000393"
      unitRef="USD">-1817640</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">-96499518</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">-569749</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000396"
      unitRef="USD">1956336</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">43462</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000407"
      unitRef="USD">434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000408"
      unitRef="USD">83072741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000409"
      unitRef="USD">-60736453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">-30802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000411"
      unitRef="USD">22305920</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000432"
      unitRef="Shares">43462</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000422"
      unitRef="USD">434</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">83072741</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-60736453</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000425"
      unitRef="USD">-30802</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">22305920</us-gaap:StockholdersEquity>
    <ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000443"
      unitRef="Shares">26667</ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">267</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">5802197</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">5802464</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000449"
      unitRef="USD">2620671</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000452"
      unitRef="USD">2620671</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000463"
      unitRef="Shares">60</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000457"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ENVB:RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">402000</ENVB:RedeemableNoncontrollingInterestIssuanceOfEmbeddedDerivative>
    <ENVB:RedeemableNoncontrollingInterestIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">41962</ENVB:RedeemableNoncontrollingInterestIssuanceCosts>
    <ENVB:RedeemableNoncontrollingInterestShares
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000478"
      unitRef="Shares">1000</ENVB:RedeemableNoncontrollingInterestShares>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">556038</ENVB:RedeemableNoncontrollingInterestValue>
    <ENVB:RedeemableNoncontrollingInterestValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000467"
      unitRef="USD">556038</ENVB:RedeemableNoncontrollingInterestValue>
    <ENVB:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000489"
      unitRef="Shares">52685</ENVB:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="0"
      id="Fact000480"
      unitRef="USD">527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000482"
      unitRef="USD">527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000484"
      unitRef="USD">-527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000487"
      unitRef="USD">-527</ENVB:IssuanceOfRedeemableNoncontrollingSeriesPreferredStock>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000493"
      unitRef="USD">-33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000495"
      unitRef="USD">33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000501"
      unitRef="USD">-295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000502"
      unitRef="USD">-295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000518"
      unitRef="Shares">82</ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000512"
      unitRef="USD">1</ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards>
    <ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000513"
      unitRef="USD">-1</ENVB:StockIssuedDuringPeriodValueConversionOfRestrictedStockAwards>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">66667</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCostsShares>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000523"
      unitRef="USD">667</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000524"
      unitRef="USD">3248457</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts>
    <ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">3249124</ENVB:RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000540"
      unitRef="Shares">1616</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000534"
      unitRef="USD">16</ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit>
    <ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">-16</ENVB:IssuanceOfRoundedSharesAsResultOfReverseStockSplit>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact000551"
      unitRef="Shares">-52685</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">-527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">-527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000546"
      unitRef="USD">527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">527</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000559"
      unitRef="USD">-505932</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">-505932</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000567"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000582"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000572"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000573"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000584"
      unitRef="Shares">138554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000574"
      unitRef="USD">1386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000575"
      unitRef="USD">94415058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000577"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000578"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact000597"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact000587"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact000588"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000599"
      unitRef="Shares">138554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000589"
      unitRef="USD">1386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000590"
      unitRef="USD">94415058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000604"
      unitRef="USD">-17291732</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000605"
      unitRef="USD">-18471333</us-gaap:NetIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000610"
      unitRef="USD">-94396</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000611"
      unitRef="USD">-4315236</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000613"
      unitRef="USD">208752</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000614"
      unitRef="USD">3472726</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000616"
      unitRef="USD">727000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000617"
      unitRef="USD">-325000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000619"
      unitRef="USD">2150160</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000620"
      unitRef="USD">2620671</us-gaap:ShareBasedCompensation>
    <ENVB:InducementExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000622"
      unitRef="USD">1848235</ENVB:InducementExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000626"
      unitRef="USD">7453662</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <ENVB:NoncashIncomeTaxExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000629"
      unitRef="USD">-1504302</ENVB:NoncashIncomeTaxExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000631"
      unitRef="USD">64048</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000632"
      unitRef="USD">107291</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000634"
      unitRef="USD">168754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000635"
      unitRef="USD">168750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000637"
      unitRef="USD">175228</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">159160</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000640"
      unitRef="USD">4206</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000646"
      unitRef="USD">6857</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000647"
      unitRef="USD">374058</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000649"
      unitRef="USD">-103848</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000650"
      unitRef="USD">263686</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000652"
      unitRef="USD">64045</ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation>
    <ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000653"
      unitRef="USD">107288</ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000655"
      unitRef="USD">-14094411</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">-17146723</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000661"
      unitRef="USD">5180</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">584165</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000664"
      unitRef="USD">16847</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000667"
      unitRef="USD">11667</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000668"
      unitRef="USD">-584165</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000674"
      unitRef="USD">17222099</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000685"
      unitRef="USD">291084</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">1052057</us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock>
    <us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000692"
      unitRef="USD">958038</us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">-1343141</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000695"
      unitRef="USD">18180137</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000697"
      unitRef="USD">-10022</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">-81364</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000700"
      unitRef="USD">-15435907</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000701"
      unitRef="USD">367885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000703"
      unitRef="USD">17723884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">17355999</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000706"
      unitRef="USD">2287977</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000707"
      unitRef="USD">17723884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000713"
      unitRef="USD">5249</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000715"
      unitRef="USD">9507</us-gaap:IncomeTaxesPaidNet>
    <ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000719"
      unitRef="USD">3595420</ENVB:WarrantsIssuedInConjunctionWithCommonStockIssuance>
    <ENVB:IssuanceOfEmbeddedDerivative
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000722"
      unitRef="USD">402000</ENVB:IssuanceOfEmbeddedDerivative>
    <ENVB:StockSubscriptionReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000724"
      unitRef="USD">1817640</ENVB:StockSubscriptionReceivable>
    <ENVB:OfferingCostsAccruedNotPaid
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000727"
      unitRef="USD">182724</ENVB:OfferingCostsAccruedNotPaid>
    <ENVB:WarrantsIssuedForOfferingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">77991</ENVB:WarrantsIssuedForOfferingCosts>
    <ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000733"
      unitRef="USD">255107</ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts>
    <ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">683997</ENVB:InducedConversionOfWarrantsAndPreferredInvestmentOptions>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000739"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000740"
      unitRef="USD">33014</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000743"
      unitRef="USD">4323734</ENVB:InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance>
    <ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000746"
      unitRef="USD">251357</ENVB:ModificationOfWarrantsAsPartOfShareCapitalRaise>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000749"
      unitRef="USD">295976</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:NatureOfOperations contextRef="From2023-01-012023-12-31" id="Fact000751">&lt;p id="xdx_808_eus-gaap--NatureOfOperations_zcYw7bouB0pi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_827_zeGb70wjgan"&gt;BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nature
of Operations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Enveric
Biosciences, Inc. (&#x201c;Enveric&#x201d; or the &#x201c;Company&#x201d;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#x201c;Jay Pharma&#x201d;), 1306432 B.C. Ltd. (&#x201c;HoldCo&#x201d;),
MagicMed Industries, Inc. (&#x201c;MagicMed&#x201d;), Enveric Canada Inc., and Enveric Therapeutics, Pty. Ltd. (&#x201c;Enveric Therapeutics&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leveraging
its unique discovery and development platform, the  Psybrary&#x2122;, has created a robust intellectual property portfolio
of new chemical entities for specific mental health indications. Enveric&#x2019;s lead program, the EVM201 Series, comprises next
generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#x2013;
EB-373 &#x2013; for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected
to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of
neuroplasticity without also inducing hallucinations in the patient.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the Company&#x2019;s amalgamation with MagicMed completed in September 2021 (the &#x201c;Amalgamation&#x201d;), the Company has continued
to pursue the development of MagicMed&#x2019;s proprietary Psychedelic Derivatives library, the Psybrary&#x2122; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges, including cancer-related distress.
The Company synthesizes novel versions of classic psychedelics, such as psilocybin, DMT, mescaline and MDMA, using a mixture of chemistry
and synthetic biology, resulting in the expansion of the Psybrary&#x2122;, which includes 15 patent families with over a million
potential variations and hundreds of synthesized molecules. Within the Psybrary&#x2122; the Company has three different types of
molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities).
The Company is working to add novel molecular compounds and derivatives (&#x201c;Psychedelic Derivatives&#x201d;) on a regular basis
through its work at the Company&#x2019;s labs in Calgary, Alberta, Canada, where the Company has a team of PhD scientists with
expertise in synthetic biology and chemistry. To date the Company has created over 500 molecules that are housed
in the Psybrary&#x2122;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;The
Company screens newly synthesized molecules in the Psybrary&#x2122; through PsyAI&#x2122;, a proprietary artificial intelligence (&#x201c;AI&#x201d;)
tool. Leveraging AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company
believes it streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological
effects to help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable
can then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New
compounds of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal),
and ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#x2122; and the AI tool to categorize and characterize
the Psybrary&#x2122; substituents to focus on bringing more psychedelics-inspired molecules from discovery to the clinical phase.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Australian
Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 21, 2023, the Company established Enveric Therapeutics, an Australia-based subsidiary, to support the Company&#x2019;s plans to
advance its lead program, the EVM201 Series, comprised of the next generation synthetic prodrugs of the active metabolite, psilocin (&#x201c;EVM201
Series&#x201d;), towards the clinic. Enveric Therapeutics will oversee the Company&#x2019;s preclinical, clinical, and regulatory activities
in Australia, including ongoing interactions with the local Human Research Ethics Committees (HREC) and the Therapeutic Goods Administration
(TGA), Australia&#x2019;s regulatory authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company effected a &lt;span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zlYF6ZHetqpj" title="Reverse stock split"&gt;1-for-15&lt;/span&gt;
reverse stock split (&#x201c;Reverse Stock Split&#x201d;) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025,
pursuant to which every 15 shares of the Company&#x2019;s issued and outstanding common stock were reclassified as one share of
common stock. The Reverse Stock Split had no impact on the par value of the Company&#x2019;s common stock or the authorized number of
shares of common stock. Unless otherwise indicated, all share and per share information in these consolidated financial statements
are adjusted to reflect the Reverse Stock Split, prior to the rounding of any fractional shares. Any fractional share resulting from
the Reverse Stock Split shall be rounded up to the next whole number of shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern, Liquidity and Other Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred a loss since inception resulting in an accumulated deficit of $&lt;span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zeXL2JVUG7I7" title="Accumulated deficit"&gt;96,499,518&lt;/span&gt; as of December 31, 2023 and further losses
are anticipated in the development of its business. Further, the Company has operating cash outflows of $&lt;span id="xdx_908_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20230101__20231231_zC9IEOtZAr8a" title="Net cash used in operating activities"&gt;14,094,411&lt;/span&gt; for the year ended
December 31, 2023. For the year ended December 31, 2023, the Company had a loss from operations of $&lt;span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_di_c20230101__20231231_zptySDPGyAxb" title="Loss from operations"&gt;16,448,440&lt;/span&gt;. Since inception, being
a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its
operations. The Company&#x2019;s operations have been funded principally through the issuance of equity. These factors raise substantial
doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the Company&#x2019;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At December 31, 2023, the Company had
cash of $&lt;span id="xdx_908_eus-gaap--Cash_iI_c20231231_zg6W1PD6T4He" title="Cash"&gt;2,287,977&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and
working capital of $&lt;span id="xdx_909_ecustom--WorkingCapital_iI_c20231231_zwCKXLM8F7e1" title="Working capital"&gt;1,238,027&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Company&#x2019;s current cash on hand is not sufficient enough to satisfy its operating cash needs for the 12 months from the filing
of this Annual Report on Form 10-K. These conditions raise substantial doubt regarding the Company&#x2019;s ability to continue as a going
concern for a period of one year after the date the financial statements are issued. Management&#x2019;s plan to alleviate the conditions
that raise substantial doubt include raising additional working capital through public or private equity or debt financings or other
sources, which has included the Equity Distribution Agreement with Canaccord for proceeds of up to $&lt;span id="xdx_90E_eus-gaap--ProceedsFromShortTermDebt_pn5n6_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_z0bSeaRLLC14" title="Additional working capital"&gt;2.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million (see Note 7), the Purchase Agreement
with Lincoln Park (see Note 7), subject to registration, the Inducement Letters and resulting sales of common stock under the Existing
Warrants for cash proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdbYkH7ofgh3" title="Warrants for cash proceeds"&gt;1.8
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million received in January 2024 (see Note 7),
and the exercise of warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRrqgNwYrtA8" title="Exercise of warrants to purchase"&gt;130,267&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock for cash proceeds
of approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20240201__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxBoa9iJSd54" title="Cash proceeds of warrants"&gt;2.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million in February 2024 (see Note 12), and may
include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may not be available
to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company may be required
to undertake cost-cutting measures including delaying or discontinuing certain operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of these factors, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as
a going concern for a period of one year after the date of the financial statements are issued. The Company&#x2019;s consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reduction
in Force/Restructuring&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#x201c;RIF&#x201d;) of approximately 35% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The Company recognized severance charges of approximately $&lt;span id="xdx_909_eus-gaap--SeveranceCosts1_c20230501__20230531_z8D58hHBUYA" title="Severance costs"&gt;453,059&lt;/span&gt; through
December 31, 2023. The plan included a focus on progressing the Company&#x2019;s existing non-cannabinoid pipeline while reducing the
rate of spend and managing cash flow. In June 2023, the Company completed the reduction in force, with such severance expenses recorded
in general and administrative accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 16, 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#x2019;s President and Chief Operating
Officer (the &#x201c;Kanubaddi Separation Agreement&#x201d;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi&#x2019;s
outstanding restricted stock units (&#x201c;RSUs&#x201d;) will retain their vesting conditions. Mr. Kanubaddi&#x2019;s 2023 salary and benefits
of $&lt;span id="xdx_907_eus-gaap--SalariesAndWages_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_z2eyKHjPXPnh" title="Salaries and benefit"&gt;550,974&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
inclusive of the 2023 performance bonus in the amount of $&lt;span id="xdx_90D_eus-gaap--AccruedBonusesCurrent_iI_c20230616__us-gaap--TypeOfArrangementAxis__custom--KanubaddiSeparationAgreementMember_zrCCgVRmsV6k" title="Performance bonus"&gt;129,760
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;were accrued and the salary and benefits, excluding
the 2023 performance bonus will be paid out in twelve equal monthly installments beginning in July 2023. As of December 31, 2023, the
performance metrics for the 2023 performance bonus were not achieved and the accrued amount of amount of $&lt;span id="xdx_901_eus-gaap--RestructuringReserve_iI_c20231231_zsfpflMKZxWj" title="Reversed amount"&gt;129,760
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;was reversed. Upon termination, any unvested
time-based RSUs became fully vested. The Company accelerated expense recognized related to these shares that vested was $&lt;span id="xdx_90A_ecustom--ExpenseRelatedToAccelerationOfVesting_c20230615__20230616__us-gaap--TypeOfArrangementAxis__custom--MrKanubaddiEmploymentAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4HDlczxCn45" title="Expense related to acceleration of vesting"&gt;231,273&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
All of the &lt;span id="xdx_908_ecustom--MarketPerformanceBasedShares_iI_c20230616__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7CQB1lpNWGf" title="Market performance based shares"&gt;752&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; market performance-based RSUs previously
granted that were subject to the original terms and conditions of Mr. Kanubaddi&#x2019;s employment agreement were forfeited during the
year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_ztulwBwkUNX1" style="display: none"&gt;SCHEDULE
OF RESTRUCTURING COSTS PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;br/&gt;
Restructuring Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;January 1, 2023 Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Restructuring costs incurred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--RestructuringCostsIncurred_c20230101__20231231_zEYhLjXcC6Lc" style="width: 16%; text-align: right" title="Restructuring costs incurred"&gt;1,004,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restructuring costs paid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs"&gt;(572,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restructuring costs reversed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs reversed"&gt;(129,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;December 31, 2023 ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"&gt;301,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zbWxkJfj9qfh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
Risks&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Notice&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that as
of September 30, 2023, the Company did not meet the minimum of $&lt;span id="xdx_90A_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_zRjXM8zUUidi" title="Minimum of stockholders equity required for continued listing pursuant to exchange"&gt;2,500,000&lt;/span&gt; in stockholders&#x2019; equity required for continued listing
pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting the Company an extension
to regain compliance with the minimum stockholders&#x2019; equity requirement by May 20, 2024. If the Company fails to evidence compliance
upon filing its periodic report for June 30, 2024 with the SEC and Nasdaq, the Company may be subject to delisting. The Company plans
to regain and evidence compliance with the Stockholders&#x2019; Equity Requirement by the required deadlines, but it is not assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-01-272025-01-27" id="Fact000753">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">-96499518</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000757"
      unitRef="USD">-14094411</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000759"
      unitRef="USD">-16448440</us-gaap:OperatingIncomeLoss>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">2287977</us-gaap:Cash>
    <ENVB:WorkingCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000763"
      unitRef="USD">1238027</ENVB:WorkingCapital>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2023-01-012023-12-31_custom_EquityDistributionAgreementMember"
      decimals="-5"
      id="Fact000765"
      unitRef="USD">2400000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember"
      decimals="-5"
      id="Fact000767"
      unitRef="USD">1800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000769"
      unitRef="Shares">130267</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-02-012024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact000771"
      unitRef="USD">2700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SeveranceCosts1
      contextRef="From2023-05-012023-05-31"
      decimals="0"
      id="Fact000773"
      unitRef="USD">453059</us-gaap:SeveranceCosts1>
    <us-gaap:SalariesAndWages
      contextRef="From2023-06-152023-06-16_custom_KanubaddiSeparationAgreementMember"
      decimals="0"
      id="Fact000775"
      unitRef="USD">550974</us-gaap:SalariesAndWages>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-06-16_custom_KanubaddiSeparationAgreementMember"
      decimals="0"
      id="Fact000777"
      unitRef="USD">129760</us-gaap:AccruedBonusesCurrent>
    <us-gaap:RestructuringReserve
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000779"
      unitRef="USD">129760</us-gaap:RestructuringReserve>
    <ENVB:ExpenseRelatedToAccelerationOfVesting
      contextRef="From2023-06-152023-06-16_custom_MrKanubaddiEmploymentAgreementMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact000781"
      unitRef="USD">231273</ENVB:ExpenseRelatedToAccelerationOfVesting>
    <ENVB:MarketPerformanceBasedShares
      contextRef="AsOf2023-06-16_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000783"
      unitRef="Shares">752</ENVB:MarketPerformanceBasedShares>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="From2023-01-012023-12-31" id="Fact000785">&lt;p id="xdx_896_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_z5glKSFld41e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_ztulwBwkUNX1" style="display: none"&gt;SCHEDULE
OF RESTRUCTURING COSTS PAYABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;br/&gt;
Restructuring Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;January 1, 2023 Beginning balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20230101__20231231_zAlZ6w4mtdef" style="text-align: right" title="Restructuring cost payable, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Restructuring costs incurred&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--RestructuringCostsIncurred_c20230101__20231231_zEYhLjXcC6Lc" style="width: 16%; text-align: right" title="Restructuring costs incurred"&gt;1,004,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restructuring costs paid&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RestructuringCosts_c20230101__20231231_zH5WzRsnJSdh" style="text-align: right" title="Restructuring costs"&gt;(572,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restructuring costs reversed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OtherRestructuringCosts_c20230101__20231231_zY0iQ8QQEIX6" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs reversed"&gt;(129,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;December 31, 2023 ending balance&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20230101__20231231_z5ABeYZz2MK4" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"&gt;301,645&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <ENVB:RestructuringCostsIncurred
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000789"
      unitRef="USD">1004033</ENVB:RestructuringCostsIncurred>
    <us-gaap:RestructuringCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000791"
      unitRef="USD">-572628</us-gaap:RestructuringCosts>
    <us-gaap:OtherRestructuringCosts
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000793"
      unitRef="USD">-129760</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000795"
      unitRef="USD">301645</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange
      contextRef="AsOf2023-11-21"
      decimals="0"
      id="Fact000797"
      unitRef="USD">2500000</ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-012023-12-31" id="Fact000799">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_z1Usp4Epnijl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_827_z29VOpGCLrQb"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zbIKrsz2JJMb"&gt;Basis
of Presentation and Principal of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zMMySFR20SIc"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods
reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of
changes in such estimates in future periods could be significant. Significant areas requiring management&#x2019;s estimates and
assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred
investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting
research and development efforts. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zFKLsC1vhXHf"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#x2019;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNjHpvv4Gia"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z0Oa78Uy6iHe"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States and Australia and $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount"&gt;100,000&lt;/span&gt; in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at United States financial institutions, less than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt;
at Australian financial institutions, and greater than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; at Canadian financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztBjC43QkT38"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#x2019; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPkCB4Owiyud"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the Psybrary&#x2122; and Patent Applications, In Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) and license
agreements. Psybrary&#x2122; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IPR&amp;amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#x2019;s
expected future cash flows; a sustained, significant decline in the Company&#x2019;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#x2019;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zdX7mG65WS1b"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#x2019;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z622SrpvFB74"&gt;Property
&amp;amp; Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#x2019;s long-lived assets. The estimated
useful lives are typically &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives"&gt;5&lt;/span&gt; years for office furniture and equipment and are depreciated on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--DeferredOfferingCostsPolicyTextBlock_zC3UVlYm5iHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zmmelDy6vXh3"&gt;Deferred
Offering Costs&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of ASC Topic 340, &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt; (&#x201c;ASC 340&#x201d;) and SAB 5A &lt;i&gt;-
Expenses of Offering&lt;/i&gt;. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs"&gt;567,603&lt;/span&gt; in deferred offering costs in connection with the Equity Distribution Agreement (the &#x201c;Distribution
Agreement&#x201d;), with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;) and the Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;)
with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--WarrantLiabilityPolicyTextBlock_zLXVKuvvt2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zH6VWLIKl02j"&gt;Warrant
Liability and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#x201c;Distinguishing
Liabilities from Equity&#x201d; (&#x201c;ASC 480&#x201d;) and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;).
The Company accounts for warrants and investment options for shares of the Company&#x2019;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_z7oMqGQu7b2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zHBF6D1y83y9"&gt;Modification
and Inducement of Warrants and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#x201c;Debt with Conversion and Other
Options&#x201d; (&#x201c;ASC 470-20-40&#x201d;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zBwpH1gx3ZNb"&gt;Derivative
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zsORoSsW5NTg"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#x2019;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#x2019;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#x201c;major&#x201d; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zVtfgEZ2LSf1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#x2019;s reasonable estimates and involve inherent uncertainties and the application
of management&#x2019;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#x2019;s common stock on the date of award grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#x2019;s
board of directors (the &#x201c;Board of Directors&#x201d;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#x2019;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSU&#x2019;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#x2019;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#x2019;s that vest
immediately are charged to expense on the date awarded, value of RSU&#x2019;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#x2019;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#x2019;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#x2019;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#x2019;s
engagement with the Company must either be terminated prior to such conversion of RSU&#x2019;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#x201c;specified
employee&#x201d; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#x2019;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSA&#x2019;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#x2019;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#x2019;s that vest immediately are charged
to expense on the date awarded, value of RSA&#x2019;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zX4N0aihbZJi"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022 the Company issued &lt;span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zzehumrBJq1i" title="Stock and warrants issued"&gt;51,167&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; pre-funded common stock warrants, which were
exercised on various dates during the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26,
2022 based on the terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $&lt;span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_z3Ex19wQ4NN7" title="Warrant exercise price"&gt;0.0015&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;these shares are considered outstanding common shares
and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is
virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3HM0uaIm6yl" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;186,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;43,698&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right"&gt;9,366&lt;/p&gt;
&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock in abeyance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;250,993&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztG9Z6EAI5m2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zKPLQOyArmx4"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zuz1Rz8vQhr9"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#x2019;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a right-of-use asset, which represents the Company&#x2019;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#x2019;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zkZiVDimAdil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_za6xEu8hPKl1"&gt;Redeemable
Non-controlling Interest&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#x201c;RNCI&#x201d;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zww0mCbaLZc1"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines its reporting units in accordance with FASB ASC 280, &#x201c;Segment Reporting&#x201d; (&#x201c;ASC 280&#x201d;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwwObdI2aaB5"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt; (Subtopic 470-20) and &lt;i&gt;Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/i&gt; (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#x2019;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000801">&lt;p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z6VcoZZsSz29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zbIKrsz2JJMb"&gt;Basis
of Presentation and Principal of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements have been prepared in accordance and in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) and the applicable rules
and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding consolidated financial information. All intercompany
transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-012023-12-31" id="Fact000803">&lt;p id="xdx_846_eus-gaap--UseOfEstimates_zLE80GiwQAK1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zMMySFR20SIc"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods
reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of
changes in such estimates in future periods could be significant. Significant areas requiring management&#x2019;s estimates and
assumptions include determining the fair value of transactions involving common stock, the valuation of warrants and preferred
investment options, and the valuation of stock-based compensation and accruals associated with third party providers supporting
research and development efforts. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000805">&lt;p id="xdx_84B_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z5nptn10VcWl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zFKLsC1vhXHf"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
inception through December 31, 2023, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#x2019;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended December
31, 2023 and 2022, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000807">&lt;p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6AeRnFPvu0k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zNjHpvv4Gia"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The
Company did not have any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-012023-12-31" id="Fact000809">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIej6k2jp2B1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z0Oa78Uy6iHe"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zB4bQGBLtGA6" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States and Australia and $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zGy542i4yAyf" title="Cash insured amount"&gt;100,000&lt;/span&gt; in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of December 31, 2023, the Company had greater than $&lt;span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--US_zQv2tJGpW28l" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at United States financial institutions, less than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--AU_zPZgCdbAQVk7" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt;
at Australian financial institutions, and greater than $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20231231__srt--StatementGeographicalAxis__country--CA_zkz71lJ5798l" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; at Canadian financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_US"
      decimals="0"
      id="Fact000811"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_CA"
      decimals="0"
      id="Fact000813"
      unitRef="USD">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_US"
      decimals="0"
      id="Fact000815"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_AU"
      decimals="0"
      id="Fact000817"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31_country_CA"
      decimals="0"
      id="Fact000819"
      unitRef="USD">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000821">&lt;p id="xdx_84C_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zuPlfgRbEyZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztBjC43QkT38"&gt;Comprehensive
Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Comprehensive
loss consists of two components, net loss and other comprehensive income (loss). Other comprehensive loss refers to revenue, expenses,
gains, and losses that under GAAP are recorded as an element of shareholders&#x2019; equity but are excluded from net loss. Other comprehensive
loss consists of foreign currency translation adjustments from those subsidiaries not using the U.S. dollar as their functional currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-012023-12-31" id="Fact000823">&lt;p id="xdx_844_eus-gaap--IntangibleAssetsFiniteLivedPolicy_ziQD2CBAghZ9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zPkCB4Owiyud"&gt;Intangible
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of the Psybrary&#x2122; and Patent Applications, In Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) and license
agreements. Psybrary&#x2122; and Patent Applications intangible assets are valued using the relief from royalty method. The cost of license
agreements is amortized over the economic life of the license. The Company assesses the carrying value of its intangible assets for impairment
each year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IPR&amp;amp;D
intangible assets are acquired in conjunction with the acquisition of a business and are assigned a fair value, using the multi-period
excess earnings method, related to incomplete research projects which, at the time of acquisition, have not reached technological feasibility.
The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion
or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then-useful
life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to
be generated, and begin amortization. The Company tests its intangible assets for impairment at least annually and whenever events or
circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator
of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company&#x2019;s
expected future cash flows; a sustained, significant decline in the Company&#x2019;s stock price and market capitalization; a significant
adverse change in legal factors or in the business climate of the Company&#x2019;s segments; unanticipated competition; and slower growth
rates. If the fair value determined is less than the carrying amount, an impairment loss is recognized in operating results.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2023-01-012023-12-31" id="Fact000825">&lt;p id="xdx_842_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_z32t25Ny06rb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zdX7mG65WS1b"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company tests goodwill for potential impairment at least annually, or more frequently if an event or other circumstance indicates that
the Company may not be able to recover the carrying amount of the net assets of the reporting unit. The Company has determined that the
reporting unit is the entire company, due to the integration of all of the Company&#x2019;s activities. In evaluating goodwill for impairment,
the Company may assess qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50%) that
the fair value of a reporting unit is less than its carrying amount. If the Company bypasses the qualitative assessment, or if the Company
concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then the Company performs
a quantitative impairment test by comparing the fair value of a reporting unit with its carrying amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000827">&lt;p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zNmGyuL93vpj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z622SrpvFB74"&gt;Property
&amp;amp; Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost. Major property additions, replacements, and betterments are capitalized, while maintenance and repairs
that do not extend the useful lives of an asset or add new functionality are expensed as incurred. Depreciation and amortization are
recorded using the straight-line method over the respective estimated useful lives of the Company&#x2019;s long-lived assets. The estimated
useful lives are typically &lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zNDXlWGeWzm" title="Estimated useful lives"&gt;3&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zuaBlK6Ilio2" title="Estimated useful lives"&gt;5&lt;/span&gt; years for office furniture and equipment and are depreciated on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_OfficeEquipmentMember"
      id="Fact000829">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_OfficeEquipmentMember"
      id="Fact000831">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <ENVB:DeferredOfferingCostsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000833">&lt;p id="xdx_841_ecustom--DeferredOfferingCostsPolicyTextBlock_zC3UVlYm5iHf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zmmelDy6vXh3"&gt;Deferred
Offering Costs&lt;/span&gt; &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocates offering costs to the different components of the capital raise on a pro rata basis. Any offering costs allocated to
common stock are charged directly to additional paid-in capital. Any offering costs allocated to warrant liabilities are charged to general
and administrative expenses on the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company complies with the requirements of ASC Topic 340, &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt; (&#x201c;ASC 340&#x201d;) and SAB 5A &lt;i&gt;-
Expenses of Offering&lt;/i&gt;. Offering costs, which consist mainly of legal, accounting and consulting fees directly attributable to the
issuance of an equity contract to be classified in equity are recorded as a reduction in equity. For the year ended December 31, 2023,
the Company incurred $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231_zOw3Bao897qf" title="Deferred offering costs"&gt;567,603&lt;/span&gt; in deferred offering costs in connection with the Equity Distribution Agreement (the &#x201c;Distribution
Agreement&#x201d;), with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;) and the Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;)
with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;). These deferred offering costs will be proportionately offset against
the total proceeds from the issuance of common stock available under the agreements and the Company will expense any remaining balance
of deferred offering costs if the agreements are terminated. For the year ended December 31, 2023, there were no issuances of common
stock under the agreements resulting in the deferral of offering costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000835"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <ENVB:WarrantLiabilityPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000837">&lt;p id="xdx_845_ecustom--WarrantLiabilityPolicyTextBlock_zLXVKuvvt2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zH6VWLIKl02j"&gt;Warrant
Liability and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates all of its financial instruments, including issued stock purchase warrants and investment options, to determine if
such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 &#x201c;Distinguishing
Liabilities from Equity&#x201d; (&#x201c;ASC 480&#x201d;) and FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d; (&#x201c;ASC 815&#x201d;).
The Company accounts for warrants and investment options for shares of the Company&#x2019;s common stock that are not indexed to its own
stock as derivative liabilities at fair value on the consolidated balance sheets. The Company accounts for common stock warrants and
investment options with put options as liabilities under ASC 480. Such warrants and investment options are subject to remeasurement at
each consolidated balance sheet date and any change in fair value is recognized as a component of other expense on the consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration
of such common stock warrants and investment options. At that time, the portion of the warrant liability and investment options related
to such common stock warrants will be reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:WarrantLiabilityPolicyTextBlock>
    <ENVB:ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000839">&lt;p id="xdx_845_ecustom--ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock_z7oMqGQu7b2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zHBF6D1y83y9"&gt;Modification
and Inducement of Warrants and Investment Options&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
change in any of the terms or conditions of warrants is accounted for as a modification. For a warrant modification accounted for under
ASC 815, the effect of a modification shall be measured as the difference between the fair value of the modified warrant over the fair
value of the original warrant immediately before its terms are modified, measured based on the fair value of the shares and other pertinent
factors at the modification date. The accounting for incremental fair value of warrants is based on the specific facts and circumstances
related to the modification. When a modification is directly attributable to equity offerings, the incremental change in fair value of
the warrants are accounted for as equity issuance costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the inducement to exercise warrants in accordance with ASC Subtopic 470-20-40 &#x201c;Debt with Conversion and Other
Options&#x201d; (&#x201c;ASC 470-20-40&#x201d;). ASC 470-20-40 requires the recognition through earnings of an inducement charge equal to
the fair value of the consideration delivered in excess of the consideration issuable under the original conversion terms. Therefore,
the Company recognized a loss on the warrant inducement for the incremental change of the warrants related to the reduced exercise price
and the issuance of new warrants as these components induced the holders to exercise the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:ModificationAndInducementOfWarrantsAndInvestmentOptionsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000841">&lt;p id="xdx_849_eus-gaap--DerivativesPolicyTextBlock_ze8NOutWO18c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zBwpH1gx3ZNb"&gt;Derivative
Liability&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC 815. For derivative financial instruments that are accounted for as assets or liabilities, the derivative
instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the
fair value reported in the consolidated statements of operations. The classification of derivative instruments, including whether such
instruments should be recorded as assets or liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities
are classified in the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion
of the instrument could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000843">&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zL6shVmPF5Cf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zsORoSsW5NTg"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes
is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income.
Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company&#x2019;s assets
and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that
some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws
that might be challenged upon an audit and cause changes to previous estimates of tax liabilities. In management&#x2019;s opinion, adequate
provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances
or reversals of reserves may be necessary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tax
benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The
amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
A liability for &#x201c;unrecognized tax benefits&#x201d; is recorded for any tax benefits claimed in the Company&#x2019;s tax returns that
do not meet these recognition and measurement standards. As of December 31, 2023 and 2022, no liability for unrecognized tax benefits
was required to be recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s policy for recording interest and penalties associated with tax audits is to record such items as a component of operating
expenses. There were no amounts accrued for penalties and interest for the years ended December 31, 2023 and 2022. The Company does not
expect its uncertain tax positions to change during the next twelve months. Management is currently unaware of any issues under review
that could result in significant payments, accruals or material deviations from its position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has identified its United States, Canadian and Australian federal tax returns, and its state and provincial tax returns in Florida,
Massachusetts, New Jersey, Pennsylvania, and Ontario, CA as its &#x201c;major&#x201d; tax jurisdictions. The Company is in the process
of filing its United States federal and state and Australian federal corporate tax returns for the year ended December 31, 2023. The
Company is in the process of filing its Canadian corporate tax returns for the years ended December 31, 2023 and 2022. Net operating
losses for these periods will not be available to reduce future taxable income until the returns are filed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-012023-12-31" id="Fact000845">&lt;p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zEsxkwpAfIyl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zVtfgEZ2LSf1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows ASC 718, Compensation - Stock Compensation, which addresses the accounting for stock-based payment transactions, requiring
such transactions to be accounted for using the fair value method. Awards of shares for property or services are recorded at the more
readily measurable of the estimated fair value of the stock award and the estimated fair value of the service. The Company uses the Black-Scholes
option-pricing model to determine the grant date fair value of certain stock-based awards under ASC 718. The assumptions used in calculating
the fair value of stock-based awards represent management&#x2019;s reasonable estimates and involve inherent uncertainties and the application
of management&#x2019;s judgment. Fair value of restricted stock units or restricted stock awards is determined by the closing price per
share of the Company&#x2019;s common stock on the date of award grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value is amortized as a charge to earnings on a straight-line basis, for awards or portions of awards that do not require
specified milestones or performance criteria as a vesting condition and also depending on the terms and conditions of the award, and
the nature of the relationship of the recipient of the award to the Company. The Company records the grant date fair value in line with
the period over which it was earned. For employees and consultants, this is typically considered to be the vesting period of the award.
The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair value of awards that require specified milestones or recipient performance are charged to expense when such milestones
or performance criteria are probable to be met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted
stock units, restricted stock awards, and stock options are granted at the discretion of the Compensation Committee of the Company&#x2019;s
board of directors (the &#x201c;Board of Directors&#x201d;). These awards are restricted as to the transfer of ownership and generally
vest over the requisite service periods, typically over a 12 to 48-month period. A significant portion of these awards may include vesting
terms that include, without limitation, defined volume weighted average price levels being achieved by the Company&#x2019;s common stock,
specific performance milestones, employment, or engagement by the Company, with no assurances of achievement of any such vesting conditions,
if applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSU&#x2019;s is equal to the product of the number of units awarded, multiplied by the closing price per share of the Company&#x2019;s
common stock on the date of the award. The terms and conditions of each RSU is defined in the RSU agreement and includes vesting terms
that consist of any or all of the following: immediate vesting, vesting over a defined period of time, vesting based on achievement of
a defined volume weighted average price levels at specified times, vesting based on achievement of specific performance milestones within
a specific time frame, change of control, termination of the employee without cause by the Company, resignation of the employee with
good cause. The value assigned to each RSU is charged to expense based on the vesting terms, as follows: value of RSU&#x2019;s that vest
immediately are charged to expense on the date awarded, value of RSU&#x2019;s that vest based upon time, or achievement of stock price
levels over a period of time are charged to expense on a straight line basis over the time frame specified in the RSU and the value of
RSU&#x2019;s that vest based upon achievement of specific performance milestones are charged to expense during the period that such milestone
is achieved. Vested RSU&#x2019;s may be converted to shares of common stock of an equivalent number upon either the termination of the
recipient&#x2019;s employment with the Company, or in the event of a change in control. If the recipient is not an employee, such person&#x2019;s
engagement with the Company must either be terminated prior to such conversion of RSU&#x2019;s to shares of common stock, or in the event
of a change in control. Furthermore, as required by Section 409A of the Internal Revenue Code, if the recipient is a &#x201c;specified
employee&#x201d; (generally, certain officers and highly compensated employees of publicly traded companies), such recipient may only
convert vested RSU&#x2019;s into shares of common stock no earlier than the first day of the seventh month following such recipients termination
of employment with the Company, or the event of change in control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
value of RSA&#x2019;s is equal to the product of the number of restricted shares awarded, multiplied by the closing price per share of
the Company&#x2019;s common stock on the date of the award. The terms and conditions of each RSA is defined in the RSA agreement and includes
vesting terms that consist of any or all of the following: immediate vesting, vesting over a defined period of time, or vesting based
on achievement of a defined volume weighted average price levels at specified times. Upon vesting, the recipient may receive restricted
stock which includes a legend prohibiting sale of the shares during a restriction period that is defined in the RSA agreement. Termination
of employment by or engagement with the Company is not required for the recipient to receive restricted shares of common stock. The value
assigned to each RSA is charged to expense based on the vesting terms, as follows: value of RSA&#x2019;s that vest immediately are charged
to expense on the date awarded, value of RSA&#x2019;s that vest based upon time, or achievement of stock price levels over a period of
time are charged to expense on a straight-line basis over the time frame specified in the RSU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000847">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2bNPdQ0lNxe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zX4N0aihbZJi"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the years ended December 31, 2023 and 2022 excludes
potentially dilutive securities. The computations of net loss per share for each period presented is the same for both basic and fully
diluted. In accordance with ASC 260 &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;), penny warrants were included in the calculation
of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022 the Company issued &lt;span id="xdx_908_eus-gaap--StockIssued1_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_zzehumrBJq1i" title="Stock and warrants issued"&gt;51,167&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; pre-funded common stock warrants, which were
exercised on various dates during the year ended December 31, 2022. The pre-funded common stock warrants became exercisable on July 26,
2022 based on the terms and conditions of the agreements. As the pre-funded common stock warrants are exercisable for $&lt;span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20220101__20221231__us-gaap--AwardTypeAxis__custom--PrefundedCommonStockWarrantsMember_z3Ex19wQ4NN7" title="Warrant exercise price"&gt;0.0015&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;these shares are considered outstanding common shares
and are included in the computation of basic and diluted Earnings Per Share as the exercise of the pre-funded common stock warrants is
virtually assured. The Company included these pre-funded common stock warrants in basic and diluted earnings per share when all conditions
were met on July 26, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3HM0uaIm6yl" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;186,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;43,698&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right"&gt;9,366&lt;/p&gt;
&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock in abeyance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;250,993&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zJID65LmxDb8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockIssued1
      contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember"
      decimals="0"
      id="Fact000849"
      unitRef="USD">51167</us-gaap:StockIssued1>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2022-01-012022-12-31_custom_PrefundedCommonStockWarrantsMember"
      decimals="INF"
      id="Fact000851"
      unitRef="USDPShares">0.0015</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact000853">&lt;p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zdH68EAHLN8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share the years ended
December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_z3HM0uaIm6yl" style="display: none"&gt;SCHEDULE
OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230101__20231231_zcGFJ4eRGa5l" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20220101__20221231_ztjoaXZupq2k" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zlTjAp8X5T8k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;186,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;p style="margin: 0"&gt;43,698&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zau44OFOVg55" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zyIalDA2NqFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 8pt/106% Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: right"&gt;9,366&lt;/p&gt;
&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockAwardsVestedAndUnIssuedMember_zAUei9AmSesh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock awards - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0864"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockInAbeyanceMember_z6kye26yE1F6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Common stock in abeyance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,934&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvstmentOptionsToPurchaseSharesOfCommonStockMember_zKVmKqtM5UNe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zI2t6aaMkVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ztQyJBkBcHI4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;250,993&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;126,740&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000855"
      unitRef="Shares">186614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Shares">43698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Shares">1390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact000859"
      unitRef="Shares">4167</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact000861"
      unitRef="Shares">9366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Shares">4271</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_RestrictedStockAwardsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact000865"
      unitRef="Shares">48</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_CommonStockInAbeyanceMember"
      decimals="INF"
      id="Fact000867"
      unitRef="Shares">46934</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Shares">4667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_InvstmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Shares">71334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000873"
      unitRef="Shares">2022</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Shares">3222</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000876"
      unitRef="Shares">250993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000877"
      unitRef="Shares">126740</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-012023-12-31" id="Fact000879">&lt;p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zqetmarc655b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_ztG9Z6EAI5m2"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value
Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), approximates the carrying amounts in the balance sheets, excluding the derivative,
warrants, and preferred investment option liabilities, primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000881">&lt;p id="xdx_847_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWzfZ1GdSou9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zKPLQOyArmx4"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes
the inputs to valuation methodologies used to measure fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 - Valuations based on quoted prices for identical assets and liabilities in active markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 - Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 - Valuations based on unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by
other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain financial instruments, including cash and accounts payable, the carrying amounts approximate their fair values as of December
31, 2023 and 2022 because of their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-012023-12-31" id="Fact000883">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ziSLQKNyYoCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zuz1Rz8vQhr9"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000885">&lt;p id="xdx_849_eus-gaap--LesseeLeasesPolicyTextBlock_zQ7ioewi5Gc7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease assets are included within right-of-use operating lease asset and operating lease liabilities are included in current portion of
right-of-use operating lease obligation and non-current portion of right-of-use operating lease obligation on the consolidated balance
sheets as of December 31, 2023 and 2022. The Company has elected not to present short-term leases as these leases have a lease term of
12 months or less at lease inception and do not contain purchase options or renewal terms that the Company is reasonably certain to exercise.
Lease payments for short-term leases are recognized on a straight-line basis over the term of the lease. All other lease assets and lease
liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of the
Company&#x2019;s leases do not provide an implicit rate of return, the Company used an incremental borrowing rate based on the information
available at adoption date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain
a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset
and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company
has elected to account for non-lease components associated with its leases and lease components as a single lease component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes a right-of-use asset, which represents the Company&#x2019;s right to use the underlying asset for the lease term, and
a lease liability, which represents the present value of the Company&#x2019;s obligation to make payments arising over the lease term.
The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing
rate&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of
ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset
that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset,
(iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v)
the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of
the lease term. All other leases are recorded as operating leases. Finance lease payments are bifurcated into (i) a portion that is recorded
as interest expense and (ii) a portion that reduces the finance liability associated with the lease. The Company did not have any finance
leases as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <ENVB:RedeemableNoncontrollingInterestPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000887">&lt;p id="xdx_84B_ecustom--RedeemableNoncontrollingInterestPolicyTextBlock_zkZiVDimAdil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_za6xEu8hPKl1"&gt;Redeemable
Non-controlling Interest&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the issuance of Akos Series A Preferred Stock, the Akos Purchase Agreement (as defined below in Note 8) and certificate
of designation contain a put right guaranteed by the Company as defined in Note 8. Applicable accounting guidance requires an equity
instrument that is redeemable for cash or other assets to be classified outside of permanent equity if it is redeemable (a) at a fixed
or determinable price on a fixed or determinable date, (b) at the option of the holder, or (c) upon the occurrence of an event that is
not solely within the control of the issuer. As a result of this feature, the Company recorded the non-controlling interests as Redeemable
Non-Controlling Interests (&#x201c;RNCI&#x201d;) and classified them in mezzanine equity within its consolidated balance sheet initially
at its acquisition-date estimated redemption value or fair value. In addition, the Company has elected to recognize changes in the redemption
value immediately as they occur and adjust the carrying amount of the instrument by accreting the embedded derivative at each reporting
period over 12 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right (as defined below) requiring Akos to force redemption of all of the Akos Series A Preferred Stock. See Note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:RedeemableNoncontrollingInterestPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000889">&lt;p id="xdx_84B_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zQ4s5yz0SOx3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zww0mCbaLZc1"&gt;Segment
Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines its reporting units in accordance with FASB ASC 280, &#x201c;Segment Reporting&#x201d; (&#x201c;ASC 280&#x201d;). The
Company evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating
segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment
that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more
reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines
if the segments are economically similar and, if so, the operating segments are aggregated. The Company has multiple operations related
to psychedelics and cannabinoids. Both of these operations exist under one reporting unit: Enveric. The Company has one operating segment
and reporting unit. The Company is organized and operated as one business. Management reviews its business as a single operating segment,
using financial and other information rendered meaningful only by the fact that such information is presented and reviewed in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-012023-12-31" id="Fact000891">&lt;p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z6VQKIWjEQ2h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zwwObdI2aaB5"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued ASU 2020-06, &lt;i&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt; (Subtopic 470-20) and &lt;i&gt;Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/i&gt; (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;) to simplify certain financial
instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features
from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2023, and should be applied on a full or modified retrospective basis. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company early adopted ASU 2020-06
effective January 1, 2023, and has determined that the adoption of this guidance had no impact on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently evaluating ASU 2023-07 to determine its impact on the Company&#x2019;s
disclosures, however, as the Company currently has one reportable segment, the Company does not expect ASU 2023-07 to have a material
impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its consolidated financial statements
and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2023-01-012023-12-31" id="Fact000893">&lt;p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zaAAsItDs3Mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3.&lt;span&gt; &lt;span id="xdx_82D_z7UD1gS7KARl"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zTydFvT6Kuv4" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;268,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid value-added taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;567,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Franchise tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,293,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;708,053&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zesRhFyyZGE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact000895">&lt;p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_z3Gs4LNqtEXh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, the prepaid expenses and other current assets of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zTydFvT6Kuv4" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_z62twSxO8pL7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_z3hHr38UO7Tf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zIwSnFeaEsv8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;268,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_znbflNJJ4xcj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid value-added taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,782&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_z3HJkewuOo16" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;174,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zRR1RvRhJGo5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,179&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_zv88yG4YKVt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;567,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0910"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zujCa29AAHXe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Franchise tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0913"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zaRKpTVrRgM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zieXSbV2rhJ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,293,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;708,053&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <ENVB:PrepaidResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000897"
      unitRef="USD">46320</ENVB:PrepaidResearchAndDevelopment>
    <ENVB:PrepaidResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000898"
      unitRef="USD">268686</ENVB:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">243429</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000901"
      unitRef="USD">159782</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000903"
      unitRef="USD">149559</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000904"
      unitRef="USD">174406</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000906"
      unitRef="USD">62036</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000907"
      unitRef="USD">105179</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000909"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <ENVB:PrepaidFranchiseTaxReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000912"
      unitRef="USD">79258</ENVB:PrepaidFranchiseTaxReceivable>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000915"
      unitRef="USD">145349</ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">1293554</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000919"
      unitRef="USD">708053</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact000921">&lt;p id="xdx_804_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_z9SCaXsACTk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_828_zBJmKX4zYxVf" style="display: none"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company performs an annual impairment test at the reporting unit level as of December 31 of each fiscal year. As of December 31, 2022,
the Company&#x2019;s goodwill and intangible assets were fully impaired, and thus no annual impairment test was necessary as of December
31, 2023. The following table provides the Company&#x2019;s goodwill, indefinite and definite lives intangible assets as of December 31,
2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s goodwill consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zywzBm3sR0Xd" style="display: none"&gt;SCHEDULE
OF GOODWILL&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Impairment Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Currency Translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance"&gt;9,834,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance"&gt;(8,225,862&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_z6Ico1CR2F3k" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance"&gt;(21,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance"&gt;1,587,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zCD5RPP49Kt" style="text-align: right" title="Goodwill Gross, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0933"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_z62rnT8rmnTk" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zSbfiyEI09me" style="text-align: right" title="Currency Translation, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zg1fcBdDAJz1" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zUb2cKPLhd02" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_z8TE2v2Adkth" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Ending balance"&gt;9,834,855&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance"&gt;(9,711,922&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Ending balance"&gt;(122,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zxEPfyg8txe4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s indefinite lived intangible assets consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zWEh1BmzLMM6" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Indefinite lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;6,375,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses"&gt;(5,967,602&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1pt solid; text-align: right" title="Loss on currency translation"&gt;(407,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; width: 80%"&gt;Definite lived intangible assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 16%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets"&gt;548,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1pt solid; text-align: right"&gt;(168,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right"&gt;379,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization"&gt;(168,754&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zXWcVfQneWi8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
identified definite lived intangible assets, amortization expense amounted to $&lt;span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zk2p8bhGkqR9" title="Intangible assets, amortization expense"&gt;168,754&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zyBCbH7OAWC" title="Intangible assets, amortization expense"&gt;168,750&lt;/span&gt; during the years ended December 31,
2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company amortizes definite lived intangible assets on a&#x202f;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zzVXkKpEcQPl" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;168,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;42,182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finite lived assets amortization
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zPK37hZCJdad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2023-01-012023-12-31" id="Fact000923">&lt;p id="xdx_891_eus-gaap--ScheduleOfGoodwillTextBlock_zNA8zJSGKUU" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s goodwill consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zywzBm3sR0Xd" style="display: none"&gt;SCHEDULE
OF GOODWILL&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Accumulated Impairment Losses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Currency Translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--GoodwillGross_iS_c20220101__20221231_zrL5hyJCBTck" style="width: 11%; text-align: right" title="Goodwill Gross, Beginning balance"&gt;9,834,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNS_di_c20220101__20221231_zoA3HbV75zY9" style="width: 11%; text-align: right" title="Accumulated Impairment Losses, Beginning balance"&gt;(8,225,862&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--GoodwillCurrencyTranslation_iS_c20220101__20221231_z6Ico1CR2F3k" style="width: 11%; text-align: right" title="Currency Translation, Beginning balance"&gt;(21,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--Goodwill_iS_c20220101__20221231_zcXRwm58qzs1" style="width: 11%; text-align: right" title="Goodwill, Beginning balance"&gt;1,587,634&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--GoodwillImpairmentLossGross_iN_di_c20220101__20221231_zCD5RPP49Kt" style="text-align: right" title="Goodwill Gross, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0933"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--GoodwillAccumulatedImpairmentLoss_iN_di_c20220101__20221231_z62rnT8rmnTk" style="text-align: right" title="Accumulated Impairment Losses, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--GoodwillCurrencyTranslationImpairmentLoss_iN_di_c20220101__20221231_zSbfiyEI09me" style="text-align: right" title="Currency Translation, Impairment losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GoodwillImpairmentLoss_iN_di_c20220101__20221231_zsSlcGVeDune" style="text-align: right" title="Goodwill, Impairment losses"&gt;(1,486,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--GoodwillForeignCurrencyTranslationGainLossGross_c20220101__20221231_zg1fcBdDAJz1" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0941"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--GoodwillAccumulatedImpairmentLossForeignCurrencyTranslationGainLoss_c20220101__20221231_zUb2cKPLhd02" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Loss on currency translation"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--GoodwillCurrencyTranslationLoss_c20220101__20221231_z8TE2v2Adkth" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--GoodwillForeignCurrencyTranslationGainLoss_c20220101__20221231_zMG8RIR4uUE4" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Loss on currency translation"&gt;(101,574&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GoodwillGross_iE_c20220101__20221231_zs3uh3Cgc7W3" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill Gross, Ending balance"&gt;9,834,855&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GoodwillImpairedAccumulatedImpairmentLoss_iNE_di_c20220101__20221231_zIXJIohBvg8a" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Impairment Losses, Ending balance"&gt;(9,711,922&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--GoodwillCurrencyTranslation_iE_c20220101__20221231_zW9O3fTzJnD2" style="border-bottom: Black 1pt solid; text-align: right" title="Currency Translation, Ending balance"&gt;(122,933&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Goodwill_iE_c20220101__20221231_zvobPkbyOarl" style="border-bottom: Black 1pt solid; text-align: right" title="Goodwill, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillGross
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000925"
      unitRef="USD">9834855</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000927"
      unitRef="USD">8225862</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <ENVB:GoodwillCurrencyTranslation
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000929"
      unitRef="USD">-21359</ENVB:GoodwillCurrencyTranslation>
    <us-gaap:Goodwill
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000931"
      unitRef="USD">1587634</us-gaap:Goodwill>
    <ENVB:GoodwillAccumulatedImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000935"
      unitRef="USD">1486060</ENVB:GoodwillAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000939"
      unitRef="USD">1486060</us-gaap:GoodwillImpairmentLoss>
    <ENVB:GoodwillCurrencyTranslationLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000945"
      unitRef="USD">-101574</ENVB:GoodwillCurrencyTranslationLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000947"
      unitRef="USD">-101574</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000949"
      unitRef="USD">9834855</us-gaap:GoodwillGross>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000951"
      unitRef="USD">9711922</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <ENVB:GoodwillCurrencyTranslation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000953"
      unitRef="USD">-122933</ENVB:GoodwillCurrencyTranslation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact000957">&lt;p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zUeFBNUXA8mb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the Company&#x2019;s indefinite lived intangible assets consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zWEh1BmzLMM6" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Indefinite lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iS_d0_c20220101__20221231_zYcj6o314Pg" style="width: 16%; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;6,375,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Impairment losses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetImpairmentCharges_iN_di_c20220101__20221231_z8wLJAfYqT8g" style="text-align: right" title="Impairment losses"&gt;(5,967,602&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Loss on currency translation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_c20220101__20221231_z1veDDOEjT78" style="border-bottom: Black 1pt solid; text-align: right" title="Loss on currency translation"&gt;(407,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iE_c20220101__20221231_z7LKtTyUhh1h" style="border-bottom: Black 1pt solid; text-align: right" title="Balance, Indefinite lived intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0965"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2023 and 2022, the definite lived intangible assets consisted of: &#160; &#160; &#160; &#160;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; width: 80%"&gt;Definite lived intangible assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 16%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20220101__20221231_ziSpokWclQNl" style="text-align: right" title="Balance, Definite lived intangible assets"&gt;548,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20220101__20221231_zSxeeR1NJHi1" style="border-bottom: Black 1pt solid; text-align: right"&gt;(168,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20230101__20231231_zoS9i0Nplzqe" style="text-align: right"&gt;379,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20231231_zNNExnK3q2ec" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization"&gt;(168,754&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20230101__20231231_zIT0j5Uxijbd" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000959"
      unitRef="USD">6375492</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000961"
      unitRef="USD">5967602</us-gaap:AssetImpairmentCharges>
    <us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000963"
      unitRef="USD">-407890</us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000967"
      unitRef="USD">548436</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000968"
      unitRef="USD">168750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000969"
      unitRef="USD">379686</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000971"
      unitRef="USD">168754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000973"
      unitRef="USD">210932</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000975"
      unitRef="USD">168754</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000977"
      unitRef="USD">168750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact000979">&lt;p id="xdx_898_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zqb59wU0hIE9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company amortizes definite lived intangible assets on a&#x202f;straight-line basis over their estimated useful lives. Amortization expense
of identified intangible assets based on the carrying amount as of December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zzVXkKpEcQPl" style="display: none"&gt;SCHEDULE
OF FINITE LIVED INTANGIBLE ASSETS AMORTIZATION EXPENSE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zkDZQgKYy2ck"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzC0U_zTyAhx8Iihm4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;168,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzC0U_zWOFDxfsxxFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;42,182&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzC0U_zC9XwcaOuro6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Finite lived assets amortization
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;210,932&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000981"
      unitRef="USD">168750</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000983"
      unitRef="USD">42182</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000985"
      unitRef="USD">210932</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact000987">&lt;p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXXYZu4HU6c9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_825_zaytaYVEUUm6"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#x201c;EBCI&#x201d;), with all amounts translated into U.S. dollars:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zxF5quYUvBz1" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;831,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(357,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(178,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net of accumulated depreciation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;507,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;677,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z2MshGQnoZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20230101__20231231_zaY42joe7YG7" title="Depreciation"&gt;175,228&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--Depreciation_c20220101__20221231_z0vGnuRplH4c" title="Depreciation"&gt;159,160&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-012023-12-31" id="Fact000989">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVVGahhpzvNa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following assets which are located in Calgary, Canada and placed in service by Enveric Biosciences Canada,
Inc. (&#x201c;EBCI&#x201d;), with all amounts translated into U.S. dollars:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zxF5quYUvBz1" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zzCZHNQZFxvd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zvLPGndd0db5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zp4aNQNMWWri" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;831,123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_z9JhYXtwNtFl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zPgLn2Oc6tvg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(357,711&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(178,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zXt2mt3bMunh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net of accumulated depreciation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;507,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;677,485&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="Fact000991"
      unitRef="USD">836709</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">831123</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact000994"
      unitRef="USD">28379</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact000995"
      unitRef="USD">25137</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000997"
      unitRef="USD">357711</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000998"
      unitRef="USD">178775</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001000"
      unitRef="USD">507377</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001001"
      unitRef="USD">677485</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001003"
      unitRef="USD">175228</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001005"
      unitRef="USD">159160</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact001007">&lt;p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zBePLueQV7ve" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_828_zbdmk1JonaWe"&gt;ACCRUED LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z2CYiR69qip9" style="display: none"&gt;SCHEDULE
OF ACCRUED LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Product development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;195,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued salaries, wages, and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,175,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;584,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued restructuring costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued franchise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Patent costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;251,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,705,655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zfLwpnfUgaDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001009">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEC0nxuwQfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and December 31, 2022, the accrued liabilities of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_z2CYiR69qip9" style="display: none"&gt;SCHEDULE
OF ACCRUED LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zIdUdedJs0bc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_ztfCG22lB8m6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_zzTIaLc6TzX6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Product development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;195,104&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zxArVFIfjro7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued salaries, wages, and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,175,963&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zmvujpsSA58g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;584,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,255&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zGJabHMfEVH5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued restructuring costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1021"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_z6PA2plzHgPe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued franchise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1024"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zTXa5jxvaF64" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Patent costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;251,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zHLlMDwwvI65" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,705,655&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ENVB:AccruedProductDevelopmentCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001011"
      unitRef="USD">139981</ENVB:AccruedProductDevelopmentCost>
    <ENVB:AccruedProductDevelopmentCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001012"
      unitRef="USD">195104</ENVB:AccruedProductDevelopmentCost>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001014"
      unitRef="USD">8889</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001015"
      unitRef="USD">1175963</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001017"
      unitRef="USD">584810</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">83255</us-gaap:AccruedProfessionalFeesCurrent>
    <ENVB:AccruedRestructuringCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001020"
      unitRef="USD">301645</ENVB:AccruedRestructuringCosts>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001023"
      unitRef="USD">22318</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001026"
      unitRef="USD">18000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001027"
      unitRef="USD">251333</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001029"
      unitRef="USD">1075643</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001030"
      unitRef="USD">1705655</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact001032">&lt;p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zDwGAQBPdjdj" style="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_821_zPkNv6EA0ckj"&gt;SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Authorized
Capital&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--CommonStockVotingRights_c20230101__20231231_zyP7HBT2y9O4" title="Common stock voting rights"&gt;The
holders of the Company&#x2019;s common stock are entitled to one vote per share&lt;/span&gt;. Holders of common stock are entitled to receive ratably
such dividends, if any, as may be declared by the Board of Directors out of legally available funds. Upon the liquidation, dissolution,
or winding up of the Company, holders of common stock are entitled to share ratably in all assets of the Company that are legally available
for distribution. As of December 31, 2023, &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_z3kEFDBFbKC" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of common stock and &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zBU2P1eYPMuf" title="Preferred stock, shares authorized"&gt;20,000,000&lt;/span&gt; shares of Preferred Stock were authorized
under the Company&#x2019;s articles of incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2023, the Company entered into the Distribution Agreement, with Canaccord, pursuant to which the Company may offer and sell
from time to time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zzPld5phABZh" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share
having an aggregate offering price of up to $&lt;span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zV61LRnnxsQj" title="Common stock, offering price"&gt;10.0&lt;/span&gt; million. Due to the offering limitations applicable to the Company and in accordance
with the terms of the Distribution Agreement, the Company may offer common stock having an aggregate gross sales price of up to $&lt;span id="xdx_900_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zFsQ1hTkiWgf" title="Aggregate gross sales price"&gt;2,392,514&lt;/span&gt;
pursuant to the prospectus supplement dated September 1, 2023 (the &#x201c;Prospectus Supplement&#x201d;). Subject to the terms and conditions
of the Distribution Agreement, Canaccord may sell the common stock by any method permitted by law deemed to be an &#x201c;at-the-market
offering&#x201d;. The Company will pay Canaccord a commission equal to &lt;span id="xdx_909_ecustom--CommissionPercentage_pid_dp_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zXJHXmkSZzdf" title="Commission percentage"&gt;3.0&lt;/span&gt;% of the gross sales price of the common stock sold through
Canaccord under the Distribution Agreement and has also agreed to reimburse Canaccord for certain expenses. The Company may also sell
common stock to Canaccord as principal for Canaccord&#x2019;s own account at a price agreed upon at the time of sale. Any sale of common stock to Canaccord as principal would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Inducement Letters (as defined below within this Note 7) prohibits the Company from entering into any variable rate transaction as defined
in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2) transactions whereby the
Company may issue securities at a future determined price, such as through an at-the-market offering or an equity line of credit. The
variable rate transaction restriction expires after six-month from the closing date of December 28, 2023 for the Inducement Letters for
an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions. Subsequent to December 31, 2023, the limitation on the at-the-market offering was waived. See Note 12.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Lincoln
Park Equity Line&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2023, the Company entered into a Purchase Agreement and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;),
with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $&lt;span id="xdx_904_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zOOeNanEtQna" title="Purchase committment"&gt;10.0&lt;/span&gt; million of the Company&#x2019;s common stock,
par value $&lt;span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zHrjprwA7De7" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share subject to certain limitations and satisfaction of the conditions set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $&lt;span id="xdx_90A_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zs6V54OtPzKd" title="Purchase committment"&gt;10.0&lt;/span&gt; million of the Company&#x2019;s common stock (the &#x201c;Purchase Shares&#x201d;).
However, such sales of common stock by the Company, if any, will be subject to important limitations set forth in the Purchase Agreement,
including limitations on number of shares that may be sold. Sales may occur from time to time, at the Company&#x2019;s sole discretion,
over the 24-month period commencing on the date that the conditions to Lincoln Park&#x2019;s purchase obligation set forth in the Purchase
Agreement are satisfied, including that a registration statement on Form S-1 covering the resale of the shares of our common stock that
have been and may be issued to Lincoln Park under the Purchase Agreement, which the Company has filed with the SEC pursuant to the Registration
Rights Agreement, is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
the purchase price per share to be paid by Lincoln Park for the shares of common stock that we may elect to sell to Lincoln Park under
the Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock at the time we elect to sell shares to
Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the number of shares of Common Stock that
we will sell to Lincoln Park under the Purchase Agreement, the purchase price per share that Lincoln Park will pay for shares purchased
from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Lincoln Park under
the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company has issued no shares of common stock through the Equity Line or the Distribution Agreement.
The Company had capitalized deferred offering costs of $&lt;span id="xdx_900_eus-gaap--DeferredOfferingCosts_iI_c20231231_zzLsnq1k5kij" title="Deferred offering costs"&gt;567,603
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;related to establishing the Distribution Agreement
with Canaccord and the Purchase Agreement with Lincoln Park and no reductions to additional paid in capital. Of this amount, $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zr7r0FupoKy4" title="Number of shares issued"&gt;255,107
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;represents the fair value of &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zu4IDflEHz83" title="Fair value of shares"&gt;9,294&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock issued to Lincoln
Park as consideration for its commitment under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock Activity&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023 a total of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zACfXzyGDWkb" title="Issuance of common shares in exchange for RSU conversions, shares"&gt;6,910&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock were issued pursuant
to the conversion of restricted stock units. During the year ended December 31, 2022, a total of &lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRxGHF4fDd91" title="Stock issued during period conversion of restricted stock award"&gt;82&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; and &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSeZCmLWDOGi"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock were issued pursuant
to the conversion of restricted stock awards and restricted stock units, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2022, the Company completed a public offering of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ziLd9Ejzode" title="Public offering"&gt;26,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock and warrants to purchase
up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvMzmDEx4K17" title="Warrants to purchase"&gt;26,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock for gross proceeds
of approximately $&lt;span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220213__20220215__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z0hwt17EQEm2" title="Proceeds from common stock"&gt;10.0&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, before deducting underwriting discounts
and commissions and other offering expenses. A.G.P./Alliance Global Partners acted as sole book-running manager for the offering. In
addition, Enveric granted the underwriter a 45-day option to purchase up to an additional &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zcNqcSOye8fd" title="Additional shares of common stock purchase"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock and/or warrants to
purchase up to an additional &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zCXdezGPOPNl" title="Additional warrants purchase"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock at the public offering
price, which the underwriter has partially exercised for warrants to purchase up to &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zF8kINnpLKRa" title="Exercised of warrants"&gt;4,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock. At closing, Enveric
received net proceeds from the offering of approximately $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zewrKhoDQgqb" title="Net proceeds from offering"&gt;9.1&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million, after deducting underwriting discounts
and commissions and estimated offering expenses with $&lt;span id="xdx_90B_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z5M5uVBLR4rc" title="Offering expenses"&gt;5.8&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million allocated to equity, $&lt;span id="xdx_907_ecustom--WarrantLiability_iI_pn5n6_c20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_z4AGZErBfTh6" title="Warrant liability"&gt;3.6&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million to warrant liability and the remaining
$&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20220213__20220215__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zjsSpSAPZmB1" title="Warrant expenses"&gt;0.3&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million recorded as an expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2022, the Company entered into a securities purchase agreement (the &#x201c;Registered Direct Securities Purchase Agreement&#x201d;)
with an institutional investor for the purchase and sale of &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zO4AWf4MoaB9" title="Sale of stock"&gt;7,766&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of the Company&#x2019;s common stock,
pre-funded warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zBOqd5rgJ8h7" title="Purchase of common stock"&gt;17,234&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock (the &#x201c;RD Pre-Funded
Warrants&#x201d;), and unregistered preferred investment options (the &#x201c;RD Preferred Investment Options&#x201d;) to purchase up to
&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z8ztx6I6PEH" title="Issued shares"&gt;25,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock (the &#x201c;RD Offering&#x201d;).
The gross proceeds from the RD Offering were approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zeqlBU6CU5x8" title="Proceeds from issuance of warrants"&gt;3,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Subject to certain ownership limitations, the RD Pre-Funded Warrants became immediately exercisable at an exercise price equal to $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zOtc0w6DyGY7" title="Share price"&gt;0.0015&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; per share of common stock. On August 3, 2022,
all of the issued RD Pre-Funded Warrants were exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concurrently
with the RD Offering, the Company entered into a securities purchase agreement (the &#x201c;PIPE Securities Purchase Agreement&#x201d;)
with institutional investors for the purchase and sale of &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_z0hXcaMlX7A4" title="Sale of stock"&gt;7,734&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock, pre-funded warrants
to purchase up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zEjVcBB2ZAOl" title="Purchase of common stock"&gt;33,933&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock (the &#x201c;PIPE Pre-Funded
Warrants&#x201d;), and preferred investment options (the &#x201c;PIPE Preferred Investment Options&#x201d;) to purchase up to &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zGhgi9jt7qq4" title="Issued shares"&gt;41,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of the common stock in a private placement
(the &#x201c;PIPE Offering&#x201d;). The gross proceeds from the PIPE Offering were approximately $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220721__20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_ztr23wWg2MJ3" title="Proceeds from issuance of warrants"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Subject to certain ownership limitations, the PIPE Pre-Funded Warrants became immediately exercisable at an exercise price equal to $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220722__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_z7Bx9J4w0Ahc" title="Share price"&gt;0.0015&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; per share of common stock. All of the issued
PIPE Pre-Funded Warrants were exercised on various dates prior to August 18, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
RD Offering and PIPE Offering closed on July 26, 2022, with aggregate gross proceeds of approximately $&lt;span id="xdx_907_eus-gaap--ProceedsFromOtherEquity_pn6n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zFQmF58p6Dzl" title="Proceeds from RD offerings"&gt;8&lt;/span&gt; million. The aggregate net proceeds
from the offerings, after deducting the placement agent fees and other estimated offering expenses, were approximately $&lt;span id="xdx_90B_ecustom--PaymentsOfStockIssuanceCost_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z5dRaFT5l3X6" title="Offerings costs"&gt;7.1&lt;/span&gt; million,
with $&lt;span id="xdx_90F_ecustom--PaymentsOfAllocatedEquity_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zZXV846aCuJc" title="Payments of allocated equity"&gt;3.2&lt;/span&gt; million allocated to equity, $&lt;span id="xdx_904_ecustom--PaymentsOfInvestmentOptionLiability_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zNzhNf9F6Ud4" title="Payments of investment option liability"&gt;4.3&lt;/span&gt; million to investment option liability, and the remaining $&lt;span id="xdx_90E_ecustom--PaymentsOfStockIssuanceCostsRecordedExpense_pn5n6_c20220725__20220726__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_z4z8FpJlJbme" title="Payments of stock issuance costs recorded expense"&gt;0.4&lt;/span&gt; million recorded as an expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Amendment
to 2020 Long-Term Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 3, 2022, our board of directors (&#x201c;Board&#x201d;) adopted the First Amendment (the &#x201c;Plan Amendment&#x201d;) to the Enveric
Biosciences, Inc. 2020 Long-Term Incentive Plan (the &#x201c;Incentive Plan&#x201d;) to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220502__20220503_zFYY00235oD8" title="Incentive plan description"&gt;(i)
increase the aggregate number of shares available for the grant of awards by 9,739 shares to a total of 13,334 shares,
and (ii) add an &#x201c;evergreen&#x201d; provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive
Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of common
stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company&#x2019;s common stock
authorized for issuance under the Incentive Plan will equal the greater of (x) 13,334 shares, and (y) 15% of the total number
of shares of the Company&#x2019;s common stock outstanding as of such issuance date (the &#x201c;Evergreen Provision&#x201d;). The Plan
Amendment was approved by the Company&#x2019;s shareholders at a special meeting of the Company&#x2019;s shareholders held on July 14,
2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 2, 2023, the shareholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#x201c;Amended Incentive Plan&#x201d;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zKM0879PVxa5" title="Authorized shares reserved"&gt;23,334&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;subject to adjustment, and (ii) removed the Evergreen
Provision implemented in the Plan Amendment. As of December 31, 2023, the total number of shares available for grant under the Incentive
Plan was &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zfjoMgdI7OF" title="Shares available of grant"&gt;7,164&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity under the Company&#x2019;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zu3hZq6igFI4" style="display: none"&gt;SCHEDULE OF STOCK OPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;1,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;1,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;1,552.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding"&gt;34,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;46.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;38.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;
                                                                          &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;2,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;2,107.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;3,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;555.75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;672.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1155"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(1,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;46.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;38.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at end"&gt;2,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end"&gt;857.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end"&gt;1,158.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end"&gt;1,712&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end"&gt;966.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable"&gt;1,330.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zXYm0PO3CNlg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zR9P2uQxAng7" style="display: none"&gt;SCHEDULE OF STOCK OPTION ASSUMPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_z0OXoTSTaL7h" title="Stock price"&gt;46.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price"&gt;46.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility"&gt;112.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zSkXtPvxBb04" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
above assumptions are determined by the Company as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock
    price &#x2013; Based on closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
    average risk-free interest rate &#x2014; Based on the daily yield curve rates for U.S. Treasury obligations with maturities, which
    correspond to the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
    yield &#x2014; The Company has not paid any dividends on common stock since its inception and does not anticipate paying dividends
    on its common stock in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    volatility &#x2014; Based on the historical volatility of comparable companies in a similar industry.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
    term &#x2014; The Company has had no stock options exercised since inception. The expected option term represents the period that
    stock-based awards are expected to be outstanding based on the simplified method provided in Staff Accounting Bulletin (&#x201c;SAB&#x201d;)
    No. 107, Share-Based Payment, which averages an award&#x2019;s weighted-average vesting period and expected term for &#x201c;plain
    vanilla&#x201d; share options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock based compensation expense, recorded within general and administrative expense, related to stock options for the
years ended December 31, 2023 and 2022 was $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zt08RojEH0Xh" title="General and administrative expense"&gt;156,075&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXVmi6fVuBdb" title="General and administrative expense"&gt;180,042&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za7OVdVnQO29" title="Unamortized stock option expense"&gt;84,774&lt;/span&gt; in unamortized stock option expense, which will be recognized over a weighted average period
of &lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zN1HXhFc7nl6"&gt;1.00&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recorded $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoynQV9JMUSl" title="Stock-based compensation expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWmTrUjkTZp7" title="Stock-based compensation expense"&gt;24,363&lt;/span&gt;, respectively, in stock-based compensation expense within
general and administrative expense, related to restricted stock awards. There were no RSA grants during the years ended December 31,
2023 and 2022. As of December 31, 2022, there were no unvested RSA shares. As of December 31, 2023, there were no unamortized stock-based
compensation costs related to restricted share awards. During the year ended December 31, 2023 the Company settled the &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1bnkYOkliK7" title="Common stock , shares issued restricted stock awards"&gt;48&lt;/span&gt; vested and
unissued shares (as of December 31, 2022) for cash of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLFTi9qtv6r6" title="Unissued shares for cash"&gt;14,250&lt;/span&gt;. There are &lt;span id="xdx_904_ecustom--NumberOfVestedAndUnissuedShares_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfYgm2OkyJOl" title="Number of vested and unissued shares"&gt;no&lt;/span&gt; restricted stock awards as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
of Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activity in restricted stock units was as follows for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zOnUfbNkVcx6" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average&lt;br/&gt;
 fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Non-vested at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning"&gt;4,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;1,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted"&gt;2,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted"&gt;502.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited"&gt;(1,785&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;1,194.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Vested"&gt;(576&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;1,958.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-vested at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning"&gt;4,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;1,388.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted"&gt;12,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted"&gt;40.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited"&gt;(2,896&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;385.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested"&gt;(4,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;297.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending"&gt;9,366&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending"&gt;434.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zBLyP5ujOgX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recorded $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zP10g2JH0QCe" title="Stock based compensation, expenses"&gt;1,994,085&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z1WqVEZEw91j" title="Stock based compensation, expenses"&gt;2,416,266&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the consolidated statement of operations and comprehensive loss. As of December 31, 2023, the
Company had unamortized stock-based compensation costs related to restricted stock units of $&lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqhi2IvwBlqe" title="Stock-based compensation, unamortized"&gt;2,021,021&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;which will be recognized over a weighted average
period of &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2g7eZ22vSdd" title="Weighted average period"&gt;1.9&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years and unamortized stock-based costs related
to restricted stock units which will be recognized upon achievement of specified milestones. As of December 31, 2023, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkUMlznJm2Kf" title="Common stock vested restricted stock units"&gt;1,390&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; restricted stock units are vested without
shares of common stock being issued, with all of these shares due as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s recognition of stock-based compensation for restricted stock units for the following periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zwVhDWsRp68h" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,085,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,389,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;908,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,026,907&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation expense for RSUs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zs23cTYn7Nd8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants
and Preferred Investment Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none"&gt;SCHEDULE
OF WARRANTS OUTSTANDING&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning"&gt;13,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;1,965&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;801,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFVujb1NhHh3" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;81,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued"&gt;154.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(51,167&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchanged for common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBqLrW0x4Do" style="border-bottom: Black 1pt solid; text-align: right" title="Exchanged for common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning"&gt;43,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;875.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;5,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI6yD0x3nmf" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;154,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued"&gt;20.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(8,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;20.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, Forfeited"&gt;(3,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPOuapURS518" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;1,672.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end"&gt;186,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end"&gt;176.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable"&gt;186,614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;176.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A4_zPsrElVeMZDe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 11, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with A.G.P./Alliance
Global Partners (the &#x201c;Underwriter&#x201d;). Pursuant to the Underwriting Agreement, the Company agreed to sell, in a firm commitment
offering, &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk3cRDFyl4Qk" title="Sale of stock"&gt;26,667&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
and accompanying warrants to purchase up to an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zd3bmfwqk333" title="Warrant exercises, shares"&gt;26,667&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its common stock (&#x201c;February
2022 Warrants&#x201d;), as well as up to &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220210__20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTzehTdxsXYj" title="Additional shares of common stock"&gt;4,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;additional shares of common stock and/or
warrants to purchase an aggregate of up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_z16mZQonqCC3" title="Warrant exercises, shares"&gt;4,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its common stock that may be purchased
by the Underwriter pursuant to a 45-day option granted to the Underwriter by the Company (the &#x201c;Offering&#x201d;). Each share of
common stock was sold together with a common warrant to purchase one share of common stock, at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIUneReLK98l" title="Warrant, exercise price"&gt;412.50&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. Such common warrants were immediately
exercisable and will expire five years from the date of issuance. There is not expected to be any trading market for the common warrants
issued in the Offering. The combined public offering price of each share of common stock and accompanying common warrant sold in the
Offering was $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20220211__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6xkgupOvnki" title="Sale of stock, price per share"&gt;375.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 14, 2022, the Underwriter exercised
its option to purchase an additional &lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights_iI_c20220214__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJKKouHOOFm9" title="Purchase of additional warrants"&gt;4,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Registered Direct (&#x201c;RD&#x201d;) Offering and the Private Investment in Public Entity (&#x201c;PIPE&#x201d;) Offering
entered into on July 22, 2022, the Company entered into Warrant Amendment (the &#x201c;Warrant Amendments&#x201d;) with the investors in
both offerings to amend certain existing warrants to purchase up to an aggregate of &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zAjZ7cTA5rXl" title="Purchase of common stock"&gt;8,134&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock that were previously
issued to the investors, with an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zvxqzNAYpZI" title="Exercise price"&gt;412.50&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share and expiration date of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220714__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zb4ECxOC8eU1" title="Warrant expiration"&gt;February
15, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. Pursuant to the Warrant Amendments,
the previously issued warrants were amended, effective upon the closing of the offerings, so that the amended warrants have a reduced
exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220722__us-gaap--TypeOfArrangementAxis__custom--WarrantAmendmentAgreementsMember_zBMhaY1KHxhg" title="Exercise price"&gt;116.70&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share and expire five and one-half years
following the closing of the offerings. In connection with this transaction, the Company determined the fair value of the February 2022
Warrants immediately prior to the Warrant Amendment and the fair value of the amended warrants immediately after the Warrant Amendment.
For the year ended December 31, 2022, the incremental change in fair value was deemed to be $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RDOfferingAndPIPEInvestmentOptionsMember_zAcOFLnqEyCl" title="Offerings costs"&gt;251,357&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which was included as equity issuance costs related to the RD and PIPE financing transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrants assumed pursuant to the acquisition of MagicMed contain certain down round features, which were not triggered by the February
2022 and July 2022 public offerings, that would require adjustment to the exercise price upon certain events when the offering price
is less than the stated exercise price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zXmcUZK6ggX1" style="display: none"&gt;SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Investment options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1350"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zGMM0alY6k46" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued"&gt;71,334&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued"&gt;118.95&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;118.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, Exercised"&gt;(66,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zYmM8O9U70xg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised"&gt;20.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1378"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zgN7qwVdAb5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zN7RQXnULVth" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Registered Direct Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase
up to &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_zSsrXPUEdiaa" title="Issued shares"&gt;25,000&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. Subject to certain
ownership limitations, the RD Preferred Investment Options became immediately exercisable at an exercise price equal to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--RegisteredDirectSecuritiesPurchaseAgreementMember_z1uqcDaW7qh" title="Exercise price"&gt;116.70&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share of common stock. The RD Preferred
Investment Options are exercisable for five and one-half years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the PIPE Securities Purchase Agreement the Company issued unregistered preferred investment options to purchase up to
&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zRwQ2nOsp9Nf" title="Issued shares"&gt;41,667&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the common stock. Subject to certain
ownership limitations, PIPE Preferred Investment Options became immediately exercisable at an exercise price equal to $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PIPESecuritiesPurchaseAgreementMember_zkaJQixeHNN1" title="Exercise price"&gt;116.70&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share of common stock. The PIPE Preferred
Investment Options are exercisable for five and one-half years from the date of issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 26, 2022, in connection with the RD Offering and PIPE Offering, the Company issued preferred investment options (the &#x201c;Placement
Agent Preferred Investment Options&#x201d;) to an entity to purchase up to &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220725__20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_zd3qnd5iCLyd" title="Purchase of common stock"&gt;4,667&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the common stock for acting as
a placement agent. The Placement Agent Preferred Investment Options have substantially the same terms as the RD Preferred Investment
Options and the PIPE Preferred Investments Options, except the Placement Agent Preferred Investment Options have an exercise price of
$&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220726__us-gaap--StatementEquityComponentsAxis__custom--PlacementAgentPreferredInvestmentOptionsMember_z5L1L63tFikl" title="Exercise price"&gt;150.00&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share. The Placement Agent Preferred
Investment Options are exercisable for five years from the date of the commencement of the RD Offering and PIPE Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#x201c;Inducement Letters&#x201d;) with certain
holders (the &#x201c;Holders&#x201d;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment options to purchase
shares of the Company&#x2019;s common stock (the &#x201c;Existing Warrants and Investment Options&#x201d;) pursuant to which the Holders
agreed to exercise for cash their Existing Warrants and Investment Options to purchase &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zaKTUOZ2VM1f"&gt;74,800
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock,
in the aggregate, at a reduced exercised price of $&lt;span id="xdx_90B_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zmvD3OtwCWOc"&gt;20.55
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (from an original exercise price
of $&lt;span id="xdx_903_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_z331mhMbpsH9"&gt;116.70
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share), in exchange for the Company&#x2019;s
agreement to issue new warrants (the &#x201c;Inducement Warrants&#x201d;) to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zBLXrJDQsa73"&gt;149,600
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
(the &#x201c;Inducement Warrant Shares&#x201d;), and the Holders to make a cash payment of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zczxnQc98rf6"&gt;1.88
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per Inducement Warrant share for total proceeds
of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zcyzU36Ekmw8"&gt;280,500&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In January 2024, the Company received aggregate gross proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4oN8knfD0g8"&gt;1,817,640
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the exercise of the Existing Warrants and
Investment Options by the Holders and the sale of the Inducement Warrants. Because the Existing Warrants and Investment Options by the
Holders and the sale of the Inducement Warrants that exercised on December 28, 2023 and unsettled until January 2024, the proceeds are
included in the consolidated balance sheet as a subscription receivable as of December 31, 2023. As of December 31, 2023, &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU9SOH6jFOVg"&gt;27,867
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Existing Warrants and Investment
Options exercised were considered issued as the Company had the enforceable right to the obtain the cash proceeds, which were in-transit,
and the Holders were no longer able to rescind the exercise election. Due to the beneficial ownership limitation provisions, &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zxGL0O0hxkrd"&gt;46,934
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Existing Warrants and Investment
Options exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder
that the shares may be issued in compliance with such limitation. &lt;span id="xdx_904_ecustom--ClassOfWarrantOrRightReasonForIssuing_c20230101__20231231_zcAzUmhlaRN9"&gt;The
Company engaged Roth Capital Partners, LLC (&#x201c;Roth&#x201d;) to act as its financial advisor in connection with the transactions summarized
above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth was also issued
warrants to purchase up to 4,488 shares of common stock. The Roth Warrants have the same terms as the Inducement Warrants. The
grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to additional paid in
capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that were charged to additional
paid in capital as issuance costs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also agreed to file a registration statement on Form S-3 covering the resale of the Inducement Warrant Shares issued or issuable
upon the exercise of the Inducement Warrants (the &#x201c;Resale Registration Statement&#x201d;) by January 8, 2024 (filed January 11,
2024). In the Inducement Letters, the Company agreed not to issue any shares of common stock or common stock equivalents or to file any
other registration statement with the SEC (in each case, subject to certain exceptions) for a period ending on February 26, 2024. The
Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement Letters) until December
28, 2024. See the &lt;i&gt;Equity Distribution Agreement&lt;/i&gt; section of this Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with this transaction, the Company determined the fair value of the Existing Warrants and Investment Options immediately prior
to the Inducement Letters and the fair value of the amended warrants and investment options immediately after the Inducement Letters.
The pre-modification measurement of fair value of the Existing Warrants and Investment Options were determined utilizing a Black-Scholes
model considering all relevant assumptions current at the date of modification (i.e. for the Existing Warrants share price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zCbGm8EEY1V3"&gt;23.40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise price of $&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z4tKTV7UOUG6"&gt;116.70&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;term of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zooxgXjsrNd2"&gt;3.6
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years, volatility of &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zofY1yo9JWoe"&gt;94&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
risk-free rate of &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zcquYR7c56k4"&gt;3.96&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
and expected dividend rate of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zokkfbNVJfv7"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
resulting in a fair value per share of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zLgHJhiJMRBd"&gt;8.10
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and for the Investment Options share price
of $&lt;span id="xdx_903_ecustom--InvestmentOptionSharePrice_iI_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zwBfp0BZQ80c"&gt;23.40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;exercise price of $&lt;span id="xdx_900_ecustom--InvestmentOptionExercisePrice_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zKcskuubDUpd"&gt;116.70&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;term of &lt;span id="xdx_903_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zU0nvYB2zE2k"&gt;4.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years, volatility of &lt;span id="xdx_905_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zH70FMRqgzUb"&gt;95&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
risk-free rate of &lt;span id="xdx_90F_ecustom--InvestmentOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zTPQDN37G1rc"&gt;3.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
and expected dividend rate of &lt;span id="xdx_90A_ecustom--InvestmentOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_z8myANWwAgc6"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%,
resulting in a fair value per share of $&lt;span id="xdx_90F_ecustom--SharePriceOption_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember_zp1NydJ78A0g"&gt;9.30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;).
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The total fair value of the &lt;span id="xdx_90A_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zzX9YHTJMqi1"&gt;8,134
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Existing Warrants and &lt;span id="xdx_909_eus-gaap--SharesOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zQDt29TH03gd"&gt;66,667
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Investment Options was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zq7HEdNl3oQb"&gt;65,349
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PreModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zUn4gcd9lAw1"&gt;618,648&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. The post-modification fair value was determined using the intrinsic value of $&lt;span id="xdx_909_ecustom--InvestmentIntrinsicValue_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zu7RNJpEOLU9"&gt;2.85
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;due to the inducement and totaled $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--ExistingWarrantsMember_zNlOcIN0WNE1"&gt;23,180
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember__us-gaap--AwardTypeAxis__custom--InvestmentOptionsMember_zC7xL300AYW4"&gt;190,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the Existing Warrants and Investment Options,
respectively. The change in fair value from the date of the modification prior to modification and the fair value on the date of the
modification after the modification, but prior to exercise was $&lt;span id="xdx_907_ecustom--InvestmentInducementGain_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--PostModificationWarrantsMember_zwUDTSOh5Wb"&gt;470,817&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
which was reflected as an inducement gain, within other expenses on the Company&#x2019;s consolidated statement of operations and comprehensive
loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant date fair value of these Inducement Warrants was estimated to be $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20231228__20231228_z2x1EoMCFBJl"&gt;2,599,552&lt;/span&gt; on December 28, 2023 and the proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231228__20231228_zJIFuTKtruIl"&gt;280,500&lt;/span&gt;,
which were received on January 2, 2024, for the issuance of the Inducement Warrants is reflected as inducement expense, within other
expenses on the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zKA67bcbOmMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zy2L3wh6IEsj" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Roth and Inducement Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 28, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z3AuGTsHI5pl" title="Stock price"&gt;23.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z0UvQEgSl08f" title="Exercise price"&gt;20.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility"&gt;92.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate"&gt;3.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants"&gt;154,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zGfIo4VzY1I" style="text-align: right" title="Value (per share)"&gt;17.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zXHJwPy7aNrd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Series
C Preferred Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 3, 2022, the Board of Directors (the &#x201c;Board&#x201d;) declared a dividend of one one-thousandth of a share of the Company&#x2019;s
Series C Preferred Stock (&#x201c;Series C Preferred Stock&#x201d;) for each outstanding share of the Company&#x2019;s common stock held of record as of 5:00 p.m. Eastern Time on May 13, 2022 (the &#x201c;Record Date&#x201d;). This dividend
was based on the number of outstanding shares of common stock prior to the Reverse Stock Split. The outstanding shares of Series C Preferred
Stock were entitled to vote together with the outstanding shares of the Company&#x2019;s common stock, as a single class, exclusively
with respect to a proposal giving the Board the authority, as it determines appropriate, to implement a reverse stock split within twelve
months following the approval of such proposal by the Company&#x2019;s stockholders (the &#x201c;Reverse Stock Split Proposal&#x201d;),
as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split Proposal (the
&#x201c;Adjournment Proposal&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company held a special meeting of stockholders on July 14, 2022 (the &#x201c;Special Meeting&#x201d;) for the purpose of voting on, among
other proposals, a Reverse Stock Split Proposal and an Adjournment Proposal. All shares of Series C Preferred Stock that were not present
in person or by proxy at the Special Meeting were automatically redeemed by the Company immediately prior to the opening of the polls
at Special Meeting (the &#x201c;Initial Redemption&#x201d;). All shares that were not redeemed pursuant to the Initial Redemption were
redeemed automatically upon the approval by the Company&#x2019;s stockholders of the Reverse Stock Split Proposal at the Special Meeting
(the &#x201c;Subsequent Redemption&#x201d; and, together with the Initial Redemption, the &#x201c;Redemption&#x201d;). &lt;span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220713__20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5dqYDZjASmi" title="Preferred stock voting rights"&gt;Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were&lt;/span&gt; &lt;span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20220714__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdUuJvhOW6s9" title="Redeemable preferred stock, shares outstanding"&gt;52,684.548&lt;/span&gt; shares of Series C Preferred Stock issued and outstanding. As of December 31,
2022, both the Initial Redemption and the Subsequent Redemption had occurred. As a result, no shares of Series C Preferred Stock remain
outstanding. As of December 31, 2023 and 2022, there are &lt;span id="xdx_90E_eus-gaap--PreferredStockCapitalSharesReservedForFutureIssuance_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zjdiSzO1vp5b" title="Preferred Stock authorized for future issuances"&gt;100,000&lt;/span&gt; shares of Series C Preferred Stock authorized for future issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="From2023-01-012023-12-31" id="Fact001034">The
holders of the Company&#x2019;s common stock are entitled to one vote per share</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001036"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="-5"
      id="Fact001042"
      unitRef="USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact001044"
      unitRef="USD">2392514</ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation>
    <ENVB:CommissionPercentage
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact001046"
      unitRef="Pure">0.030</ENVB:CommissionPercentage>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="-5"
      id="Fact001048"
      unitRef="USD">10000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="INF"
      id="Fact001050"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="-5"
      id="Fact001052"
      unitRef="USD">10000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001054"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001056"
      unitRef="USD">255107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001058"
      unitRef="Shares">9294</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001060"
      unitRef="Shares">6910</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Shares">82</ENVB:StockIssuedDuringPeriodSharesConversionOfRestrictedStockAwards>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">60</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-132022-02-15_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001065"
      unitRef="Shares">26667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-15_us-gaap_IPOMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Shares">26667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-02-132022-02-15_us-gaap_IPOMember"
      decimals="-5"
      id="Fact001069"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="INF"
      id="Fact001071"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-15_custom_UnderwritersMember"
      decimals="INF"
      id="Fact001073"
      unitRef="Shares">4000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ENVB:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="INF"
      id="Fact001075"
      unitRef="Shares">4000</ENVB:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001077"
      unitRef="USD">9100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001079"
      unitRef="USD">5800000</us-gaap:DeferredOfferingCosts>
    <ENVB:WarrantLiability
      contextRef="AsOf2022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001081"
      unitRef="USD">3600000</ENVB:WarrantLiability>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-02-132022-02-15_custom_UnderwritersMember"
      decimals="-5"
      id="Fact001083"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001085"
      unitRef="Shares">7766</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001087"
      unitRef="Shares">17234</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001089"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-07-212022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001091"
      unitRef="USD">3000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-22_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001093"
      unitRef="USDPShares">0.0015</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Shares">7734</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001097"
      unitRef="Shares">33933</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Shares">41667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-07-212022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001101"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-22_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001103"
      unitRef="USDPShares">0.0015</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-6"
      id="Fact001105"
      unitRef="USD">8000000</us-gaap:ProceedsFromOtherEquity>
    <ENVB:PaymentsOfStockIssuanceCost
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001107"
      unitRef="USD">7100000</ENVB:PaymentsOfStockIssuanceCost>
    <ENVB:PaymentsOfAllocatedEquity
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001109"
      unitRef="USD">3200000</ENVB:PaymentsOfAllocatedEquity>
    <ENVB:PaymentsOfInvestmentOptionLiability
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001111"
      unitRef="USD">4300000</ENVB:PaymentsOfInvestmentOptionLiability>
    <ENVB:PaymentsOfStockIssuanceCostsRecordedExpense
      contextRef="From2022-07-252022-07-26_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="-5"
      id="Fact001113"
      unitRef="USD">400000</ENVB:PaymentsOfStockIssuanceCostsRecordedExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-05-022022-05-03" id="Fact001115">(i)
increase the aggregate number of shares available for the grant of awards by 9,739 shares to a total of 13,334 shares,
and (ii) add an &#x201c;evergreen&#x201d; provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive
Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of common
stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company&#x2019;s common stock
authorized for issuance under the Incentive Plan will equal the greater of (x) 13,334 shares, and (y) 15% of the total number
of shares of the Company&#x2019;s common stock outstanding as of such issuance date (the &#x201c;Evergreen Provision&#x201d;). The Plan
Amendment was approved by the Company&#x2019;s shareholders at a special meeting of the Company&#x2019;s shareholders held on July 14,
2022.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001117"
      unitRef="Shares">23334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001119"
      unitRef="Shares">7164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001121">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z8YtSqYx16Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity under the Company&#x2019;s incentive plan for the years ended December 31, 2023 and 2022 is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zu3hZq6igFI4" style="display: none"&gt;SCHEDULE OF STOCK OPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zlfachWgXyo4" style="width: 9%; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;1,589&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zBHipcjjafJb" style="width: 9%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;1,185&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231_z3KUiEblBS32" style="width: 9%; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;1,552.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zc6QHY3pugra" title="Weighted Average Remaining Contractual Term (years)"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20221231_zWsvXq7xXltk" style="width: 9%; text-align: right" title="Aggregate Intrinsic Value, Outstanding"&gt;34,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zUwzel36BOnk" style="text-align: right" title="Number of Shares, Granted"&gt;1,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_z5kJ7HfnP6pf" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;46.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znh44xkmKi5a" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;38.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&lt;/span&gt;&lt;/p&gt;
                                                                          &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231_zMwQE9ty7cd5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zODjjvTnFKVd" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;2,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20220101__20221231_znQpNtug7kVc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;2,107.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z8a4TyNt1Z85" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at beginning"&gt;3,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zg98NijbXZh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning"&gt;555.75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231_zIZUyOqQArtj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at beginning"&gt;672.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_z5ShG7pIcpf5" title="Weighted Average Remaining Contractual Term (years)"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zfbN7fLAAKpi" style="text-align: right" title="Number of Shares, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zvXECFVHHTLj" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1155"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20230101__20231231_z4H5Vu8Biz83" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(1,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zV15MinWPaA" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;46.05&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20230101__20231231_zMCYL5FZJYyj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;38.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z0vJtB0G1Poe" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Outstanding at end"&gt;2,022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zTWGbA0Nvv66" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at end"&gt;857.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zUfoA887Azb9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding at end"&gt;1,158.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_za3lss46TUsl" title="Weighted average remaining contractual term, outstanding balance"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20230101__20231231_zN4jPjsgp21g" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end"&gt;1,712&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_ziRZaH57gja8" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end"&gt;966.75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231_zx8Su3tDvHy7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable"&gt;1,330.80&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_z4vf0GnUomE9" title="Weighted average remaining contractual term, exercisable"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001123"
      unitRef="Shares">1589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001125"
      unitRef="USDPShares">1185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001127"
      unitRef="USDPShares">1552.50</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31" id="Fact001129">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact001131"
      unitRef="USD">34333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001133"
      unitRef="Shares">1700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001135"
      unitRef="USDPShares">46.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001137"
      unitRef="USDPShares">38.70</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001139"
      unitRef="Shares">67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001141"
      unitRef="USDPShares">2625</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001143"
      unitRef="USDPShares">2107.50</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001145"
      unitRef="Shares">3222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001147"
      unitRef="USDPShares">555.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001149"
      unitRef="USDPShares">672.30</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31" id="Fact001151">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001157"
      unitRef="Shares">1200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001159"
      unitRef="USDPShares">46.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001161"
      unitRef="USDPShares">38.70</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001163"
      unitRef="Shares">2022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001165"
      unitRef="USDPShares">857.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001167"
      unitRef="USDPShares">1158.30</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact001169">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001171"
      unitRef="Shares">1712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001173"
      unitRef="USDPShares">966.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001175"
      unitRef="USDPShares">1330.80</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-012023-12-31" id="Fact001177">P2Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001179">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEutDXJS5oV9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options
granted during the years ended December 31, 2022 were valued using the Black Scholes model with the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zR9P2uQxAng7" style="display: none"&gt;SCHEDULE OF STOCK OPTION ASSUMPTION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zj6iPtU5AHta" title="Term (years)"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20221231_z0OXoTSTaL7h" title="Stock price"&gt;46.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231_zX3WUGe0AYX2" title="Exercise price"&gt;46.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20221231_z5lvwkDplOW2" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20220101__20221231_zXidb2KriXN1" title="Expected volatility"&gt;112.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231_za8yif42LrIb" title="Risk free interest rate"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31" id="Fact001181">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001183"
      unitRef="USDPShares">46.05</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001185"
      unitRef="USDPShares">46.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001187"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001189"
      unitRef="Pure">1.120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001191"
      unitRef="Pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001193"
      unitRef="USD">156075</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001195"
      unitRef="USD">180042</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact001197"
      unitRef="USD">84774</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2023-01-012023-12-31_us-gaap_StockOptionMember"
      id="Fact001198">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001200"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001202"
      unitRef="USD">24363</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001204"
      unitRef="Shares">48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember"
      decimals="0"
      id="Fact001206"
      unitRef="USD">14250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid>
    <ENVB:NumberOfVestedAndUnissuedShares
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001208"
      unitRef="Shares">0</ENVB:NumberOfVestedAndUnissuedShares>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001210">&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zeKrkjRh7dje" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activity in restricted stock units was as follows for the year ended December 31, 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zOnUfbNkVcx6" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average&lt;br/&gt;
 fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Non-vested at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEDhw9y1hxZb" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning"&gt;4,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaILPTwaljuj" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;1,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zirQtPdDJsZi" style="text-align: right" title="Number of shares, Granted"&gt;2,497&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUYL7MfjSel" style="text-align: right" title="Weighted average fair value, Granted"&gt;502.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxzxsA9U3MM5" style="text-align: right" title="Number of shares, Forfeited"&gt;(1,785&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zoUqJoFo0SPa" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;1,194.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCGHiACcoei3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Vested"&gt;(576&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmbvrrJRPdT2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;1,958.25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Non-vested at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3a70kwxF3V2" style="text-align: right" title="Number of shares, Non-vested beginning"&gt;4,271&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLrYNbURiDu7" style="text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;1,388.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znLFWlg2TGh1" style="text-align: right" title="Number of shares, Granted"&gt;12,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfBGTV22anXd" style="text-align: right" title="Weighted average fair value, Granted"&gt;40.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2mJgukWkvO9" style="text-align: right" title="Number of shares, Forfeited"&gt;(2,896&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxHfzIDptRA4" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;385.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNyxeKRhEEJ3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested"&gt;(4,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrqPsZk6qtR7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;297.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIJwWAqEmkx2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending"&gt;9,366&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJYYLsJCm9Q8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending"&gt;434.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001212"
      unitRef="Shares">4135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001214"
      unitRef="USDPShares">1890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001216"
      unitRef="Shares">2497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001218"
      unitRef="USDPShares">502.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001220"
      unitRef="Shares">1785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001222"
      unitRef="USDPShares">1194.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001224"
      unitRef="Shares">576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001226"
      unitRef="USDPShares">1958.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001228"
      unitRef="Shares">4271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001230"
      unitRef="USDPShares">1388.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001232"
      unitRef="Shares">12167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001234"
      unitRef="USDPShares">40.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001236"
      unitRef="Shares">2896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001238"
      unitRef="USDPShares">385.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001240"
      unitRef="Shares">4176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001242"
      unitRef="USDPShares">297.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001244"
      unitRef="Shares">9366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001246"
      unitRef="USDPShares">434.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001248"
      unitRef="USD">1994085</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001250"
      unitRef="USD">2416266</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001252"
      unitRef="USD">2021021</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact001254">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001256"
      unitRef="Shares">1390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001258">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z3ex9jdX7Hgd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s recognition of stock-based compensation for restricted stock units for the following periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zwVhDWsRp68h" style="display: none"&gt;SCHEDULE OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zPQew5K1VjCh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zCbffNV9umPf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zSOwB6VgYaZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,085,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,389,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zfdu3M9qPMBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;908,294&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,026,907&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zcduJChWGdHc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_zgOmbiRFAoQe" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation expense for RSUs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,994,085&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,416,266&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001260"
      unitRef="USD">1085791</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001261"
      unitRef="USD">1389359</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001263"
      unitRef="USD">908294</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact001264"
      unitRef="USD">1026907</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001266"
      unitRef="USD">1994085</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001267"
      unitRef="USD">2416266</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001269"
      unitRef="USD">1994085</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001270"
      unitRef="USD">2416266</us-gaap:AllocatedShareBasedCompensationExpense>
    <ENVB:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001272">&lt;p id="xdx_899_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zCwAZnLGDADf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about shares issuable under warrants outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_z8ZFdYdYVEvf" style="display: none"&gt;SCHEDULE
OF WARRANTS OUTSTANDING&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTfdpCfJmiBi" style="width: 11%; text-align: right" title="Warrant shares outstanding at beginning"&gt;13,031&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3fi1daRxsLi" style="width: 11%; text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;1,965&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z54Yv7nvu7W9" title="Weighted average remaining life, Outstanding"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKnQZX3WT3" style="width: 11%; text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;801,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFVujb1NhHh3" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;81,834&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq4CkgY3nmbb" style="text-align: right" title="Weighted average exercise price, Issued"&gt;154.65&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoCiirvRQcd1" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(51,167&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchanged for common stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExchanged_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBqLrW0x4Do" style="border-bottom: Black 1pt solid; text-align: right" title="Exchanged for common stock"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziP88dUalGL3" style="text-align: right" title="Warrant shares outstanding at beginning"&gt;43,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgN4PA0LOL52" style="text-align: right" title="Weighted average exercise Price, Outstanding at beginning"&gt;875.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNat7GYdCief" title="Weighted average remaining life, Outstanding"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zif7UujrkK8h" style="text-align: right" title="Intrinsic Value, Outstanding beginning"&gt;5,514&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmI6yD0x3nmf" style="text-align: right" title="Warrant shares outstanding, Issued"&gt;154,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzzaBhPs6fcj" style="text-align: right" title="Weighted average exercise price, Issued"&gt;20.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFg4HAtR0Uo3" style="text-align: right" title="Warrant shares outstanding, Exercised"&gt;(8,134&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjBdEmkvsgQ3" style="text-align: right" title="Weighted average exercise price, Exercised"&gt;20.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWsO7MCiRq3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, Forfeited"&gt;(3,038&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPOuapURS518" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited"&gt;1,672.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zG0zfcvh1EB" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end"&gt;186,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVykSWQShf2c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise Price, Outstanding at end"&gt;176.85&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo234JlDnvN9" title="Weighted average remaining life, Outstanding"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TQKNs9s47l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, Exercisable"&gt;186,614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxF5xDyqxuv9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable"&gt;176.85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziBL756oG0Sj" title="Weighted average remaining life, Exercisable"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znZZJLvwpd7" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic Value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</ENVB:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001274"
      unitRef="Shares">13031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001276"
      unitRef="USDPShares">1965</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember"
      id="Fact001278">P3Y4M24D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001280"
      unitRef="USD">801024</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001282"
      unitRef="Shares">81834</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001284"
      unitRef="USDPShares">154.65</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001286"
      unitRef="Shares">51167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001290"
      unitRef="Shares">43698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001292"
      unitRef="USDPShares">875.40</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      id="Fact001294">P3Y7M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001296"
      unitRef="USD">5514</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001298"
      unitRef="Shares">154088</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001300"
      unitRef="USDPShares">20.55</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001302"
      unitRef="Shares">8134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001304"
      unitRef="USDPShares">20.55</ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001306"
      unitRef="Shares">3038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001308"
      unitRef="USDPShares">1672.50</ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001310"
      unitRef="Shares">186614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001312"
      unitRef="USDPShares">176.85</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001314">P4Y7M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001316"
      unitRef="Shares">186614</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001318"
      unitRef="USDPShares">176.85</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact001320">P4Y7M6D</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001324"
      unitRef="Shares">26667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-02-11_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001326"
      unitRef="Shares">26667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-02-102022-02-11_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001328"
      unitRef="Shares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2022-02-11_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001330"
      unitRef="Shares">4000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-11_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001332"
      unitRef="USDPShares">412.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-02-11_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001334"
      unitRef="USDPShares">375.00</us-gaap:SaleOfStockPricePerShare>
    <ENVB:ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-02-14_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001336"
      unitRef="Shares">4000</ENVB:ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember"
      decimals="INF"
      id="Fact001338"
      unitRef="Shares">8134</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember"
      decimals="INF"
      id="Fact001340"
      unitRef="USDPShares">412.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2022-07-14_custom_WarrantAmendmentAgreementsMember"
      id="Fact001342">2027-02-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-22_custom_WarrantAmendmentAgreementsMember"
      decimals="INF"
      id="Fact001344"
      unitRef="USDPShares">116.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_RDOfferingAndPIPEInvestmentOptionsMember"
      decimals="0"
      id="Fact001346"
      unitRef="USD">251357</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-012023-12-31" id="Fact001348">&lt;p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z00XmdXvzoN8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about investment options outstanding at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zXmcUZK6ggX1" style="display: none"&gt;SCHEDULE
OF WARRANTS  AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Investment options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zEwvcLEoJfDe" style="text-align: right" title="Investment options Outstanding, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1350"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zGMM0alY6k46" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1352"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zlJw8znfo0I4" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 40%; padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zDF48VFSv1A7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Investment options outstanding, Issued"&gt;71,334&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVx10hGW7qx2" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Weighted average exercise price, Issued"&gt;118.95&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zqwHo3jONiyh" style="text-align: right" title="Investment options outstanding, beginning"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zVu0eC11XHn7" style="text-align: right" title="Weighted average exercise price, Outstanding beginning"&gt;118.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7cYhlQli82i" title="Weighted average remaining life, Outstanding"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zW78kJ5dKbha" style="text-align: right" title="Intrinsic value, Outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1366"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLWd0NriqTJ9" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, Exercised"&gt;(66,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zYmM8O9U70xg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Exercised"&gt;20.55&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z1lexvtMAU48" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z64Vkjb4vBD2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zo3u42JYc9hg" title="Weighted average remaining life, Outstanding"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zLfLYOEFU04b" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, Outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1378"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zSZT9LEs53K1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, Exercisable"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zaDEqPn9Z6kf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding end"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zyrHBnlcTyT6" title="Weighted average remaining life, Exercisable"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zgN7qwVdAb5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1386"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued
      contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">71334</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssued>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001358"
      unitRef="USDPShares">118.95</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001360"
      unitRef="Shares">71334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2022-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001362"
      unitRef="USDPShares">118.95</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_custom_InvestmentOptionsMember"
      id="Fact001364">P5Y1M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001368"
      unitRef="Shares">-66667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001370"
      unitRef="USDPShares">20.55</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePriceExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001372"
      unitRef="Shares">4667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001374"
      unitRef="USDPShares">150.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      id="Fact001376">P4Y1M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001380"
      unitRef="Shares">4667</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001382"
      unitRef="USDPShares">150.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      id="Fact001384">P4Y1M6D</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001388"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_RegisteredDirectSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001390"
      unitRef="USDPShares">116.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001392"
      unitRef="Shares">41667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PIPESecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001394"
      unitRef="USDPShares">116.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-252022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember"
      decimals="INF"
      id="Fact001396"
      unitRef="Shares">4667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-26_custom_PlacementAgentPreferredInvestmentOptionsMember"
      decimals="INF"
      id="Fact001398"
      unitRef="USDPShares">150.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001399"
      unitRef="Shares">74800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001400"
      unitRef="USDPShares">20.55</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001401"
      unitRef="USDPShares">116.70</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001402"
      unitRef="Shares">149600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001403"
      unitRef="USDPShares">1.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember"
      decimals="0"
      id="Fact001404"
      unitRef="USD">280500</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-01-31_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001405"
      unitRef="USD">1817640</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001406"
      unitRef="Shares">27867</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact001407"
      unitRef="Shares">46934</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <ENVB:ClassOfWarrantOrRightReasonForIssuing contextRef="From2023-01-012023-12-31" id="Fact001408">The
Company engaged Roth Capital Partners, LLC (&#x201c;Roth&#x201d;) to act as its financial advisor in connection with the transactions summarized
above and will pay Roth approximately $144,000 for its services, in addition to reimbursement for certain expenses. Roth was also issued
warrants to purchase up to 4,488 shares of common stock. The Roth Warrants have the same terms as the Inducement Warrants. The
grant date fair value of these Roth Warrants was estimated to be $77,991 on December 28, 2023 and were charged to additional paid in
capital as issuance costs. The Company also incurred legal fees of $17,254 related to the transactions above that were charged to additional
paid in capital as issuance costs.</ENVB:ClassOfWarrantOrRightReasonForIssuing>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001409"
      unitRef="USDPShares">23.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001410"
      unitRef="Pure">116.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      id="Fact001411">P3Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001412"
      unitRef="Pure">94</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Pure">3.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001414"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001415"
      unitRef="USDPShares">8.10</us-gaap:SharePrice>
    <ENVB:InvestmentOptionSharePrice
      contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001416"
      unitRef="Shares">23.40</ENVB:InvestmentOptionSharePrice>
    <ENVB:InvestmentOptionExercisePrice
      contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001417"
      unitRef="USDPShares">116.70</ENVB:InvestmentOptionExercisePrice>
    <ENVB:InvestmentOptionTerm
      contextRef="From2023-01-012023-12-31_custom_PreModificationWarrantsMember"
      id="Fact001418">P4Y1M6D</ENVB:InvestmentOptionTerm>
    <ENVB:InvestmentOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputOptionVolatilityMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Pure">95</ENVB:InvestmentOutstandingMeasurementInput>
    <ENVB:InvestmentOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001420"
      unitRef="Pure">3.90</ENVB:InvestmentOutstandingMeasurementInput>
    <ENVB:InvestmentOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001421"
      unitRef="Pure">0</ENVB:InvestmentOutstandingMeasurementInput>
    <ENVB:SharePriceOption
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember"
      decimals="INF"
      id="Fact001422"
      unitRef="USDPShares">9.30</ENVB:SharePriceOption>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Shares">8134</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001424"
      unitRef="Shares">66667</us-gaap:SharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001425"
      unitRef="USD">65349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PreModificationWarrantsMember_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001426"
      unitRef="USD">618648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <ENVB:InvestmentIntrinsicValue
      contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember"
      decimals="INF"
      id="Fact001427"
      unitRef="USDPShares">2.85</ENVB:InvestmentIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_ExistingWarrantsMember"
      decimals="INF"
      id="Fact001428"
      unitRef="USD">23180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_PostModificationWarrantsMember_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact001429"
      unitRef="USD">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <ENVB:InvestmentInducementGain
      contextRef="From2023-01-012023-12-31_custom_PostModificationWarrantsMember"
      decimals="INF"
      id="Fact001430"
      unitRef="USDPShares">470817</ENVB:InvestmentInducementGain>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-12-282023-12-28"
      decimals="0"
      id="Fact001431"
      unitRef="USD">2599552</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-12-282023-12-28"
      decimals="0"
      id="Fact001432"
      unitRef="USD">280500</us-gaap:ProceedsFromIssuanceOfWarrants>
    <ENVB:ScheduleOfValuationOfWarrantsTextBlock contextRef="From2023-01-012023-12-31" id="Fact001434">&lt;p id="xdx_899_ecustom--ScheduleOfValuationOfWarrantsTextBlock_zKA67bcbOmMf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its equity classified Inducement Warrants at the date of issuance on December 28, 2023.
The Company used a Black Scholes valuation model in order to determine their value. The key inputs into the Black Scholes valuation model
for the valuation of the warrants are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zy2L3wh6IEsj" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODEL FOR VALUATION OF WARRANTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Roth and Inducement Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 28, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z52K9qwfKrY6" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z3AuGTsHI5pl" title="Stock price"&gt;23.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z0UvQEgSl08f" title="Exercise price"&gt;20.55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zdaTE0h352rg" title="Dividend yield"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zZ8qJnxEV6V3" title="Expected volatility"&gt;92.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_z72dh5NNsTw" title="Risk free interest rate"&gt;3.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zMzy9I7TxUTl" style="text-align: right" title="Warrants, number of warrants"&gt;154,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--RothAndInducementWarrantsMember_zGfIo4VzY1I" style="text-align: right" title="Value (per share)"&gt;17.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENVB:ScheduleOfValuationOfWarrantsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      id="Fact001436">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001438"
      unitRef="USDPShares">23.40</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001440"
      unitRef="USDPShares">20.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001444"
      unitRef="Pure">0.920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-12-282023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001446"
      unitRef="Pure">0.0380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Shares">154088</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-28_custom_RothAndInducementWarrantsMember"
      decimals="INF"
      id="Fact001450"
      unitRef="USDPShares">17.40</us-gaap:SharePrice>
    <us-gaap:PreferredStockVotingRights
      contextRef="From2022-07-132022-07-14_us-gaap_SeriesCPreferredStockMember"
      id="Fact001452">Each share of Series
C Preferred Stock was entitled to receive $0.10 in cash for each 10 whole shares of Series C Preferred Stock immediately prior to the
Redemption. As of June 30, 2022, there were</us-gaap:PreferredStockVotingRights>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2022-07-14_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Shares">52684.548</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2023-12-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001456"
      unitRef="Shares">100000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <ENVB:RedeemableNonControllingInterestTextBlock contextRef="From2023-01-012023-12-31" id="Fact001458">&lt;p id="xdx_80E_ecustom--RedeemableNonControllingInterestTextBlock_zcwkISFrpcJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_820_zpC01KA801s3"&gt;REDEEMABLE NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Spin-Off
and Related Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Spin-Off, on May 5, 2022, Akos and the Company entered into into a Securities Purchase Agreement (the &#x201c;Akos
Purchase Agreement&#x201d;) with an accredited investor (the &#x201c;Akos Investor&#x201d;), pursuant to which Akos agreed to sell up to
an aggregate of &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zcoQUJHN90ug" title="Sale of stock"&gt;5,000&lt;/span&gt; shares of Akos Series A Preferred Stock, at price of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zWiC0QAHltf9" title="Sale of stock price per share"&gt;1,000&lt;/span&gt; per share, and warrants (the &#x201c;Akos Warrants&#x201d;)
to purchase shares of Akos&#x2019; common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_ziqdyNm1proh" title="Common stock par value"&gt;0.01&lt;/span&gt; per share (the &#x201c;Akos Common Stock&#x201d;), for an aggregate purchase
price of up to $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zewKu8BntBy9" title="Sale of stock, value"&gt;5,000,000&lt;/span&gt; (the &#x201c;Akos Private Placement&#x201d;). The Akos Purchase Agreement was guaranteed by the Company. Pursuant
to the Akos Purchase Agreement, Akos issued &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zG8bfr259E7" title="Sale of stock"&gt;1,000&lt;/span&gt; shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7nhFd17DNtk" title="Sale of stock, value"&gt;1,000,000&lt;/span&gt;
on May 5, 2022. The additional $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pdp0_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zxgML5QugCI7" title="Sale of stock, value"&gt;4,000,000&lt;/span&gt; was to be received on or immediately prior to the Spin-Off. The issuance of the Akos Series
A Preferred Stock results in RNCI (see Note 2). Palladium Capital Advisors, LLC (&#x201c;Palladium&#x201d;) acted as placement agent for
the Akos Private Placement. &lt;span id="xdx_901_ecustom--SpinoffAndRelatedPrivatePlacementDescription_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zux8vYKBzXke" title="Spin-off and related private placement, description"&gt;Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.&lt;/span&gt; Palladium was also entitled to warrants to purchase Akos Common Stock in an amount
up to &lt;span id="xdx_907_ecustom--WarrantsToPurchaseCommonStockPercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_z4zdKBKSkhG2" title="Warrants to purchase common stock, percentage"&gt;8&lt;/span&gt;% of the number of shares of Akos Common Stock underlying the shares issuable upon conversion of the Akos Series A Preferred Stock.
As of December 31, 2023, no accruals are required to be recorded for the fees or warrants since the Akos Series A Preferred Stock has
been redeemed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Terms
of Akos Series A Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the Certificate of the Designations, Preferences, and Rights of Series A Convertible Preferred Stock of Akos (the &#x201c;Akos Series
A Preferred Certificate of Designations&#x201d;), on or immediately prior to the completion of the spin-off of Akos into an independent,
separately traded public company listed on the Nasdaq Stock Market, the outstanding Akos Series A Preferred Stock automatically converted
into a number of shares of Akos Common Stock equal to &lt;span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zgm4sLjh8SB5" title="Percentage of stock issued and outstanding"&gt;25&lt;/span&gt;% of the then issued and outstanding Akos Common Stock, subject to the Beneficial
Ownership Limitation (as defined in the Akos Purchase Agreement). Cumulative dividends on each share of Akos Series A Preferred Stock
accrue at the rate of &lt;span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AkosMember_zqfJDBLNLuU3" title="Dividend rate"&gt;5&lt;/span&gt;% annually.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Akos Series A Preferred Certificate of Designations provided that upon the earlier of (i) the one-year anniversary of May 5, 2022, and
only in the event that the Spin-Off has not occurred; or (ii) such time that Akos and the Company have abandoned the Spin-Off or the
Company is no longer pursuing the Spin-Off in good faith, the holders of the Akos Series A Preferred Stock shall have the right (the
&#x201c;Put Right&#x201d;), but not the obligation, to cause Akos to purchase all or a portion of the Akos Series A Preferred Stock for
a purchase price equal to $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20220505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_znidGcp5SmHb" title="Sale of stock, price per share"&gt;1,000&lt;/span&gt; per share, subject to certain adjustments as set forth in the Akos Series A Preferred Certificate of
Designations (the &#x201c;Stated Value&#x201d;), plus all the accrued but unpaid dividends per share. In addition, after the one-year anniversary
of May 5, 2022, and only in the event that the Spin-Off has not occurred and Akos is not in material default of any of the transaction
documents, Akos may, at its option, at any time and from time to time, redeem the outstanding shares of Akos Series A Preferred Stock,
in whole or in part, for a purchase price equal to the aggregate Stated Value of the shares of Akos Series A Preferred Stock being redeemed
and the accrued and unpaid dividends on such shares. Pursuant to the Akos Purchase Agreement, the Company has guaranteed the payment
of the purchase price for the shares purchased under the Put Right.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Akos Series A Preferred Certificate of Designations contains limitations that prevent the holder thereof from acquiring shares of Akos
Common Stock upon conversion of the Akos Series A Preferred Stock that would result in the number of shares of Akos Common Stock beneficially
owned by such holder and its affiliates exceeding 9.99% of the total number of shares of Akos Common Stock outstanding immediately after
giving effect to the conversion (the &#x201c;Beneficial Ownership Limitation&#x201d;), except that upon notice from the holder to Akos,
the holder may increase or decrease the limit of the amount of ownership of outstanding shares of Akos Common Stock after converting
the holder&#x2019;s shares of Akos Series A Preferred Stock, provided that any change in the Beneficial Ownership Limitation shall not
be effective until 61 days following notice to Akos.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Redemption
of Akos Series A Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, pursuant to the Akos Series A Preferred Certificate of Designations, the holders of the Akos Series A Preferred Stock exercised
the Put Right requiring Akos to force redemption of all of the Akos Series A Preferred Stock for $&lt;span id="xdx_900_eus-gaap--DividendsPayableAmountPerShare_iI_pid_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ztQh1TbMgLA2" title="Dividends, per share"&gt;1,000&lt;/span&gt;&#x202f;per share, plus accrued
but unpaid dividends of approximately $&lt;span id="xdx_90A_ecustom--UnpaidDividends_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zGXioCLHfE1e" title="Unpaid dividends"&gt;52,000&lt;/span&gt;&#x202f;for a total of approximately $&lt;span id="xdx_901_eus-gaap--DividendsPreferredStock_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdtM4nK5oH7j" title="Dividends"&gt;1,052,000&lt;/span&gt;. The Company had 20 days following the receipt
of the Put Exercise Notice to make the payment and made payment on May 19, 2023. Upon redemption in May 2023, the Company revalued the
derivative liability and the Company recognized a change in fair value of the derivative liability on the Company&#x2019;s consolidated
statement of operations during the second quarter of 2023 of $&lt;span id="xdx_90D_ecustom--FairValueOfDerivativeLiability_c20230101__20230630_zkgTWFy1WwJj" title="Change in fair value of derivative liability"&gt;714,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, Akos, and the Akos Investor have terminated the Akos Purchase Agreement in connection with the planned Spin-Off and certain
registration rights agreement in connection with the Akos Private Placement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Accounting
for Akos Series A Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since
the shares of Akos Series A Preferred Stock were redeemable at the option of the holder and the redemption is not solely in the control
of the Company, the shares of Akos Series A Preferred Stock were accounted for as a redeemable non-controlling interest and classified
within mezzanine equity in the Company&#x2019;s consolidated balance sheets. The redeemable non-controlling interest was initially measured
at fair value. Dividends on the shares of Akos Series A Preferred Stock were recognized as preferred dividends attributable to redeemable
non-controlling interest in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the reconciliation of changes in redeemable non-controlling interest:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zjoodKpMYtk6" style="display: none"&gt;SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance"&gt;885,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Preferred dividends attributable to redeemable non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock"&gt;19,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value"&gt;147,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Redemption of Akos Series A Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock"&gt;(1,052,057&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1502"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_z5hvmzlTgjq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, the Akos Series A Preferred Stock was redeemed for a total of &lt;span id="xdx_900_ecustom--RedeemableNoncontrollingInterest_c20230501__20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMwz0KsNsOXa" title="Redeemable noncontrolling interest"&gt;1,052,057&lt;/span&gt;, and the balance of the redeemable non-controlling
interest is $&lt;span id="xdx_902_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iI_dxL_c20231231_zAeOWuDFnGDk" title="Redeemable non-controlling interest::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1506"&gt;0&lt;/span&gt;&lt;/span&gt; as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:RedeemableNonControllingInterestTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001460"
      unitRef="Shares">5000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001462"
      unitRef="USDPShares">1000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001464"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_srt_MaximumMember"
      decimals="0"
      id="Fact001466"
      unitRef="USD">5000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001468"
      unitRef="Shares">1000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001470"
      unitRef="USD">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact001472"
      unitRef="USD">4000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ENVB:SpinoffAndRelatedPrivatePlacementDescription
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      id="Fact001474">Pursuant to the Akos Purchase Agreement, Akos had agreed to pay Palladium a fee equal to 9% of the aggregate
gross proceeds raised from the sale of the shares of the Akos Series A Preferred Stock and a non-accountable expense allowance of 1%
of the aggregate gross proceeds raised the sale of the Akos Series A Preferred Stock in the Akos Private Placement. The fee due in connection
with the Akos Private Placement to be paid to Palladium in the form of convertible preferred stock and warrants was on similar terms
to the securities issued in the Akos Private Placement.</ENVB:SpinoffAndRelatedPrivatePlacementDescription>
    <ENVB:WarrantsToPurchaseCommonStockPercentage
      contextRef="From2022-05-042022-05-05_custom_AkosSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001476"
      unitRef="Pure">0.08</ENVB:WarrantsToPurchaseCommonStockPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember"
      decimals="INF"
      id="Fact001478"
      unitRef="Pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2022-05-042022-05-05_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesAPreferredStockMember_custom_AkosMember"
      decimals="INF"
      id="Fact001480"
      unitRef="Pure">0.05</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-05_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact001482"
      unitRef="USDPShares">1000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001484"
      unitRef="USDPShares">1000</us-gaap:DividendsPayableAmountPerShare>
    <ENVB:UnpaidDividends
      contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001486"
      unitRef="USD">52000</ENVB:UnpaidDividends>
    <us-gaap:DividendsPreferredStock
      contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001488"
      unitRef="USD">1052000</us-gaap:DividendsPreferredStock>
    <ENVB:FairValueOfDerivativeLiability
      contextRef="From2023-01-012023-06-30"
      decimals="0"
      id="Fact001490"
      unitRef="USD">714000</ENVB:FairValueOfDerivativeLiability>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001492">&lt;p id="xdx_897_eus-gaap--TemporaryEquityTableTextBlock_zpIqAAdWohPh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below presents the reconciliation of changes in redeemable non-controlling interest:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zjoodKpMYtk6" style="display: none"&gt;SCHEDULE OF RECONCILIATION CHANGE IN REDEEMABLE NONCONTROLLING INTEREST&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Balance at December 31, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iS_c20230101__20231231_z2KtOijK4HZ5" style="width: 16%; text-align: right" title="Beginning balance"&gt;885,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Preferred dividends attributable to redeemable non-controlling interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c20230101__20231231_zjwjD9FtrCoi" style="text-align: right" title="Issuance of redeemable noncontrolling Series C preferred stock"&gt;19,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accretion of embedded derivative and transaction costs associated with Akos Series A Preferred Stock to redemption value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20230101__20231231_zVgFPFbJN1yh" style="text-align: right" title="Accretion of embedded derivative to redemption value"&gt;147,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Redemption of Akos Series A Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PaymentsForRepurchaseOfRedeemablePreferredStock_iN_di_c20230101__20231231_z61deouwmhW3" style="border-bottom: Black 1pt solid; text-align: right" title="Redemption of Akos Series A Preferred Stock"&gt;(1,052,057&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RedeemableNoncontrollingInterestEquityCarryingAmount_iE_c20230101__20231231_z2cCqG7L0c62" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1502"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001494"
      unitRef="USD">885028</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001496"
      unitRef="USD">19041</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001498"
      unitRef="USD">147988</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001500"
      unitRef="USD">1052057</us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock>
    <ENVB:RedeemableNoncontrollingInterest
      contextRef="From2023-05-012023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001504"
      unitRef="USD">1052057</ENVB:RedeemableNoncontrollingInterest>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-012023-12-31" id="Fact001508">&lt;p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zzc4DQdOVCk6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_82E_zsrUTbzuipf3"&gt;FAIR VALUE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none"&gt;SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeMO13hylIPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Warrant liabilities - January 2021 Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTOpwQ8OG55f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant liabilities - February 2021 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwTQbM3dQLe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities - February 2022 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;185,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9i5VrFNGzB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zMdkWlrsIj62" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Derivative liability - May 2022&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEFcbOFbmgyj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1527"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zSWqu8SwspQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Wainwright investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;44,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zWIcJvLDtsLe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;RD investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1533"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;302,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z1YCCLCqkbX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;PIPE investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1536"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziutXKvlcfW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of investment option liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;851,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zlaHAKR4Y6A2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
warrant liabilities, derivative liability, and investment options are all classified as Level 3, for which there is no current market
for these securities such as the determination of fair value requires significant judgment or estimation. Changes in fair value measurement
categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded
within other income (expense) on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Initial
measurement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zyGP5uMpiwf9" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Post-Modification Warrants (See Note 7)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 15, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zVPjfhQ1hMA5" title="Warrants term"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_z7auqGCNbdGa" title="Warrants term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price"&gt;236.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price"&gt;94.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price"&gt;412.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price"&gt;116.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1556"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1558"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zIpLsb0r9873" title="Warrants, measurement input"&gt;74.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zEbPX8XFb5Ej" title="Warrants, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zsu2orPGxhM7" title="Warrants, measurement input"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zYZ9cMkF2kc9" title="Warrants, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants"&gt;30,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants"&gt;8,134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)"&gt;120.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)"&gt;61.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;May 2022 Derivative Liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;May 5, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zaAv4G5sSCic" style="width: 23%; text-align: right" title="Principal"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Market rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zfdU1bv2Iu1d" style="text-align: right" title="Market rate"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Wainwright Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;RD Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;PIPE Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z65GnhDKxrH1"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price"&gt;94.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zjD6zOtXxyef" style="text-align: right" title="Investment, exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;116.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;116.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1599"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;54.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zqJvQKCnT5l7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Subsequent
measurement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zXzjxOoiQ9Qg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zf0YvucZm167" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Warrant Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance"&gt;653,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of February 2022 warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity"&gt;3,595,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value due to modification of February 2022 warrants as part of July 2022 raise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification"&gt;251,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(4,315,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance"&gt;185,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value"&gt;(94,396&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRprDXlaTIXd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of warrants"&gt;(65,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1639"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%; text-align: left; padding-bottom: 1.5pt"&gt;Issuance of May 2022 convertible preferred stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity"&gt;402,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;325,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance"&gt;727,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(727,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Investment Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1651"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%"&gt;Issuance of July 2022 investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity"&gt;4,323,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(3,472,726&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance"&gt;851,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value"&gt;(208,752&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVIt6yDO5kC9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of investment options"&gt;(618,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of investment option liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zTDiFxmrLd74" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zGwJ3NUryGMb" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;January 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 2022 Warrants Unmodified&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zFeN4U2oQbMg" title="Investment option term"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z9qSoxj865ti" title="Investment option term"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zHqUQQehlCYb" title="Investment option term"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za7OVDZZzYCl" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,712.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,675.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;412.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1685"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1687"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input"&gt;89.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input"&gt;88.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input"&gt;87.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;H.C. Wainwright &amp;amp; Co., LLC Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2h5WTjUaE" title="Investment option term"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price"&gt;19.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zYJQsZKqOizg" style="text-align: right" title="Investment, exercise price"&gt;150.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input"&gt;94.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)"&gt;5.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zrbMv2JczZWj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the date of the redemption of the of Akos Series A Preferred Stock in May 2023, the derivative liability fair value was $&lt;span id="xdx_905_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20230531__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBe0f08cNDD6" title="Derivative liability fair value"&gt;0&lt;/span&gt; due to the
probability of a spin-off occurring was zero. See Note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-012023-12-31" id="Fact001510">&lt;p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z7nYIEKnfDSb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table provides the financial liabilities measured on a recurring basis and reported at fair value on the balance sheet as of
December 31, 2023 and 2022, and indicates the fair value of the valuation inputs the Company utilized to determine such fair value of
warrant liabilities, derivative liability, and investment options:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B1_zv5Cq3TrTwbh" style="display: none"&gt;SCHEDULE
OF FAIR VALUE HIERARCHY OF VALUATION INPUTS ON RECURRING BASIS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zwa6pMcie7mj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_ztyBGagJWl2d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zeMO13hylIPg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Warrant liabilities - January 2021 Warrants&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;81&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zTOpwQ8OG55f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant liabilities - February 2021 Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--ClassOfWarrantOrRightAxis__custom--WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zwTQbM3dQLe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities - February 2022 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;25,462&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;185,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9i5VrFNGzB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zBIbM8e99NVb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_z7y8UeEVWOR7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zMdkWlrsIj62" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Derivative liability - May 2022&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1524"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zEFcbOFbmgyj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1527"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;727,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20231231_z7T84h3p4yAc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231_zY86vTWnoNeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zSWqu8SwspQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Wainwright investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;44,904&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zWIcJvLDtsLe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;RD investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1533"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;302,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z1YCCLCqkbX4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;PIPE investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1536"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesRelatedToInvestmentContractsFairValueDisclosure_iI_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ziutXKvlcfW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Fair value of investment option liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;851,008&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001512"
      unitRef="USD">4</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesJanuaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001513"
      unitRef="USD">81</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001515"
      unitRef="USD">4</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyOneWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001516"
      unitRef="USD">79</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001518"
      unitRef="USD">25462</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_custom_WarrantLiabilitiesFebruaryTwentyTwentyTwoWarrantsMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001519"
      unitRef="USD">185055</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001521"
      unitRef="USD">25470</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001522"
      unitRef="USD">185215</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember"
      decimals="0"
      id="Fact001525"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001528"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember"
      decimals="0"
      id="Fact001530"
      unitRef="USD">23608</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WainwrightInvestmentOptionsMember"
      decimals="0"
      id="Fact001531"
      unitRef="USD">44904</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_RDInvestmentOptionsMember"
      decimals="0"
      id="Fact001534"
      unitRef="USD">302289</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_PIPEInvestmentOptionsMember"
      decimals="0"
      id="Fact001537"
      unitRef="USD">503815</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">23608</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact001540"
      unitRef="USD">851008</us-gaap:LiabilitiesRelatedToInvestmentContractsFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_InitialMeasurementMember"
      id="Fact001542">&lt;p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--InitialMeasurementMember_z1QM2DVjkmSk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its warrant liabilities at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BA_zyGP5uMpiwf9" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;February 2022 Post-Modification Warrants (See Note 7)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 15, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zVPjfhQ1hMA5" title="Warrants term"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_z7auqGCNbdGa" title="Warrants term"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zg4vc6tNjoU6" style="text-align: right" title="Warrants, stock price"&gt;236.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zUD00iEXtF7c" style="text-align: right" title="Warrants, stock price"&gt;94.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zMKqRGglU068" style="text-align: right" title="Warrants, exercise price"&gt;412.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKSgY0wy0iyh" style="text-align: right" title="Warrants, exercise price"&gt;116.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVyprhikOUP2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1556"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zFsXu3HGkuPe" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1558"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zIpLsb0r9873" title="Warrants, measurement input"&gt;74.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zEbPX8XFb5Ej" title="Warrants, measurement input"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zsu2orPGxhM7" title="Warrants, measurement input"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zYZ9cMkF2kc9" title="Warrants, measurement input"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z4cDZMXOyqyk" style="text-align: right" title="Warrants, number of warrants"&gt;30,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zw9U56dyLJU3" style="text-align: right" title="Warrants, number of warrants"&gt;8,134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220215__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zSrYFRvG1GD9" style="text-align: right" title="Value (per share)"&gt;120.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoPostModificationWarrantsMember_zc94NSTnQNmh" style="text-align: right" title="Value (per share)"&gt;61.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its derivative liability at the respective date of issuance. The Company used a Weighted
Expected Return valuation model in order to determine their value. The key inputs into the Weighted Expected Return valuation model for
the initial valuations of the warrant liabilities are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;May 2022 Derivative Liability&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;May 5, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Principal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConvertiblePreferredStockPrincipalValue_iI_pid_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember_zaAv4G5sSCic" style="width: 23%; text-align: right" title="Principal"&gt;1,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zMajfNXiCdV7" style="text-align: right" title="Dividend rate"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Market rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20220505__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--DerivativeLiabilityMayTwoThousandTwentyTwoMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketRateMember_zfdU1bv2Iu1d" style="text-align: right" title="Market rate"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established the initial fair value of its investment options at the respective dates of issuance. The Company used a Black Scholes
valuation model in order to determine their value. The key inputs into the Black Scholes valuation model for the initial valuations of
the investment options are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Wainwright Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;RD Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;PIPE Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;July 26, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z65GnhDKxrH1"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zdhDz6mJGNJ"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20220725__20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zfSptC7W7KEg"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zPlSJf5eL0A6" style="text-align: right" title="Investment, stock price"&gt;94.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zqYpSozvjjQ8" style="text-align: right" title="Investment, stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zDLPZtQBQ3f2" style="text-align: right" title="Investment, stock price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;94.95&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zjD6zOtXxyef" style="text-align: right" title="Investment, exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;150.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zidSfPnMN3kc" style="text-align: right" title="Investment, exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;116.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--StockOptionExercisePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z4ui6DjkSRej" style="text-align: right" title="Investment, exercise price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;116.70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zQ8wA9rqzTjb" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zO3qrym8KSpa" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1599"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvzToWtaoU02" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1601"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_ziabNgPIphZ3"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zofjONCNkiQb"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zvIEEezFwTO9"&gt;80.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_z0rmtJQWmDCi"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zKeYY8MkDdMi"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_z9Fo5tlv9cUh"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zYbQQoJTqgg2" style="text-align: right" title="Number of investment options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zwzPQkiN0jy2" style="text-align: right" title="Number of investment options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InvestmentOwnedBalanceShares_iI_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFk1flldufk" style="text-align: right" title="Number of investment options"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--WainwrightInvestmentOptionsMember_zwdNPoSCez9h" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;54.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--RDInvestmentOptionsMember_zCIxDRegUmw8" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharePrice_iI_pid_c20220726__srt--StatementScenarioAxis__custom--InitialMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--PIPEInvestmentOptionsMember_zFdwm4V6zmKk" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;61.05&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      id="Fact001544">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember"
      id="Fact001546">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001548"
      unitRef="USDPShares">236.25</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001550"
      unitRef="USDPShares">94.95</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001552"
      unitRef="USDPShares">412.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001554"
      unitRef="USDPShares">116.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001560"
      unitRef="Pure">74.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001562"
      unitRef="Pure">80.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001564"
      unitRef="Pure">1.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001566"
      unitRef="Pure">2.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001568"
      unitRef="Shares">30667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember"
      decimals="INF"
      id="Fact001570"
      unitRef="Shares">8134</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2022-02-15_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001572"
      unitRef="USDPShares">120.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_FebruaryTwentyTwentyTwoPostModificationWarrantsMember"
      decimals="INF"
      id="Fact001574"
      unitRef="USDPShares">61.05</us-gaap:SharePrice>
    <ENVB:ConvertiblePreferredStockPrincipalValue
      contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember"
      decimals="INF"
      id="Fact001576"
      unitRef="USD">1000000</ENVB:ConvertiblePreferredStockPrincipalValue>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001578"
      unitRef="Pure">5.0</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="AsOf2022-05-05_custom_InitialMeasurementMember_custom_DerivativeLiabilityMayTwoThousandTwentyTwoMember_custom_MeasurementInputMarketRateMember"
      decimals="INF"
      id="Fact001580"
      unitRef="Pure">4.4</us-gaap:AlternativeInvestmentMeasurementInput>
    <ENVB:InvestmentOptionTerm
      contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember"
      id="Fact001581">P5Y</ENVB:InvestmentOptionTerm>
    <ENVB:InvestmentOptionTerm
      contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember"
      id="Fact001582">P5Y6M</ENVB:InvestmentOptionTerm>
    <ENVB:InvestmentOptionTerm
      contextRef="From2022-07-252022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember"
      id="Fact001583">P5Y6M</ENVB:InvestmentOptionTerm>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001585"
      unitRef="USDPShares">94.95</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001587"
      unitRef="USDPShares">94.95</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001589"
      unitRef="USDPShares">94.95</us-gaap:SaleOfStockPricePerShare>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001591"
      unitRef="USDPShares">150.00</ENVB:StockOptionExercisePrice>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001593"
      unitRef="USDPShares">116.70</ENVB:StockOptionExercisePrice>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001595"
      unitRef="USDPShares">116.70</ENVB:StockOptionExercisePrice>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001602"
      unitRef="Pure">80.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001603"
      unitRef="Pure">80.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001604"
      unitRef="Pure">80.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001605"
      unitRef="Pure">2.9</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001606"
      unitRef="Pure">2.9</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001607"
      unitRef="Pure">2.9</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001609"
      unitRef="Shares">4667</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001611"
      unitRef="Shares">25000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001613"
      unitRef="Shares">41667</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_WainwrightInvestmentOptionsMember"
      decimals="INF"
      id="Fact001615"
      unitRef="USDPShares">54.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_RDInvestmentOptionsMember"
      decimals="INF"
      id="Fact001617"
      unitRef="USDPShares">61.05</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2022-07-26_custom_InitialMeasurementMember_custom_PIPEInvestmentOptionsMember"
      decimals="INF"
      id="Fact001619"
      unitRef="USDPShares">61.05</us-gaap:SharePrice>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember"
      id="Fact001621">&lt;p id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zXzjxOoiQ9Qg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the changes in fair value of the warrant liabilities, derivative liability, and investment options that are
classified as Level 3:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zf0YvucZm167" style="display: none"&gt;SCHEDULE
OF FAIR VALUE OF WARRANT LIABILITIES AND DERIVATIVE LIABILITY AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Warrant Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 73%"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfWR0eRZvVP5" style="width: 23%; text-align: right" title="Total beginning balance"&gt;653,674&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of February 2022 warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zXGaIgmvYyJi" style="text-align: right" title="Issuance of equity"&gt;3,595,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value due to modification of February 2022 warrants as part of July 2022 raise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFIntmBPaxCj" style="text-align: right" title="Change in fair value, modification"&gt;251,357&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE0CYMPIHUj4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(4,315,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfghil2mtthe" style="text-align: right" title="Total beginning balance"&gt;185,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkAmp56BB0z3" style="text-align: right" title="Change in fair value"&gt;(94,396&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zRprDXlaTIXd" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of warrants"&gt;(65,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zme9nFXE8ezh" style="border-bottom: Black 2.5pt double; text-align: right" title="Total beginning balance"&gt;25,470&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Derivative Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFGDcN74hZH" style="padding-bottom: 1.5pt; text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1639"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%; text-align: left; padding-bottom: 1.5pt"&gt;Issuance of May 2022 convertible preferred stock&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zPpeS4e84xo4" style="padding-bottom: 1.5pt; width: 23%; text-align: right" title="Issuance of equity"&gt;402,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSM8F2xaqSZb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;325,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaWdjbixGpx4" style="text-align: right" title="Total beginning balance"&gt;727,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value arising from redemption of Akos Series A Preferred Stock - See Note 8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEhyNzluaeM9" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(727,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--DerivativeMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqz7o8NCcsD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1649"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Investment Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value as of December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkafZlF2mmd8" style="text-align: right" title="Total beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1651"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 73%"&gt;Issuance of July 2022 investment options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zJCC3dQ45BP1" style="width: 23%; text-align: right" title="Issuance of equity"&gt;4,323,734&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20220101__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAP0ZMaOKtx2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(3,472,726&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value as of December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsspxHsvJgQ5" style="text-align: right" title="Total beginning balance"&gt;851,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z2wRFtIor8lj" style="text-align: right" title="Change in fair value"&gt;(208,752&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercise of investment options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions_iN_pp0p0_di_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zVIt6yDO5kC9" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise of investment options"&gt;(618,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value of investment option liability as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwfYpkEyGifd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total ending balance"&gt;23,608&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001623"
      unitRef="USD">653674</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001625"
      unitRef="USD">3595420</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001627"
      unitRef="USD">251357</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001629"
      unitRef="USD">4315236</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001631"
      unitRef="USD">185215</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001633"
      unitRef="USD">94396</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001635"
      unitRef="USD">65349</ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001637"
      unitRef="USD">25470</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001641"
      unitRef="USD">402000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2022-01-012022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001643"
      unitRef="USD">-325000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001645"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_DerivativeMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001647"
      unitRef="USD">727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001653"
      unitRef="USD">4323734</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2022-01-012022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001655"
      unitRef="USD">3472726</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001657"
      unitRef="USD">851008</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001659"
      unitRef="USD">208752</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions
      contextRef="From2023-01-012023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001661"
      unitRef="USD">618648</ENVB:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodExerciseOfInvestmentOptions>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_OptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001663"
      unitRef="USD">23608</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember"
      id="Fact001665">&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hsrt--StatementScenarioAxis__custom--SubsequentMeasurementMember_zVmNi2ZEtwR3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the warrant liabilities as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zGwJ3NUryGMb" style="display: none"&gt;SCHEDULE
OF BLACK SCHOLES VALUATION MODELS OF WARRANT LIABILITIES AND INVESTMENT OPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;January 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 2021 Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February 2022 Warrants Unmodified&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zFeN4U2oQbMg" title="Investment option term"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z9qSoxj865ti" title="Investment option term"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zHqUQQehlCYb" title="Investment option term"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_za7OVDZZzYCl" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z43IGWEMy7mi" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsAndRightsOutstandingStockPrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPFDp0gpvu1f" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;19.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zzQ4UuJKdZN" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,712.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zh3valY73Qz2" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,675.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zI70P4KFepEe" style="text-align: right" title="Warrant measurement input"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;412.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zXom3SuDcJeh" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1685"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zmrl5hHMBCm2" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1687"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zrAdZu39f75a" style="text-align: right" title="Warrants, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1689"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zGbl4bmvxqsh" style="text-align: right" title="Warrants, measurement input"&gt;89.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUtVZGZgnQkc" style="text-align: right" title="Warrants, measurement input"&gt;88.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zUdeTyuL8oac" style="text-align: right" title="Warrants, measurement input"&gt;87.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVAXZdk6d31h" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zXrUSp9jZPD9" style="text-align: right" title="Warrants, measurement input"&gt;4.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zMV40M3mGbVf" style="text-align: right" title="Warrants, measurement input"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Number of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zn6PP51bQ6m" style="text-align: right" title="Warrants, number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,429&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_z5JR5WBgvpN8" style="text-align: right" title="Warrants, number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_z7TkfR5O3yy9" style="text-align: right" title="Warrants, number of warrants"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;22,534&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwentyTwentyOneWarrantsMember_zOg7y7IDF7R5" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyOneWarrantsMember_zAR75z9wv3J9" style="text-align: right" title="Value (per share)"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryTwentyTwentyTwoWarrantsMember_zeqE92vGMb9d" style="text-align: right" title="Value (per share)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
key inputs into the Black Scholes valuation model for the Level 3 valuations of the investment options as of December 31, 2023 are below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;H.C. Wainwright &amp;amp; Co., LLC Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--InvestmentOptionTerm_dtY_c20230101__20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2h5WTjUaE" title="Investment option term"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zUboA7OQUpLa" style="text-align: right" title="Investment, stock price"&gt;19.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--StockOptionExercisePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zYJQsZKqOizg" style="text-align: right" title="Investment, exercise price"&gt;150.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zN9N15RArLo6" style="text-align: right" title="Investment, measurement input"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zA3LphOX94wg" title="Investment, measurement input"&gt;94.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput_iI_pid_uPure_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zOhw3RzTphsk" title="Investment, measurement input"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Number of investment options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zl2nEB216o2a" style="text-align: right" title="Number of investment options"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Value (per share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20231231__srt--StatementScenarioAxis__custom--SubsequentMeasurementMember__us-gaap--StatementClassOfStockAxis__custom--HCWainwrightAndCoLLCInvestmentOptionsMember_zucFVItplnkl" style="text-align: right" title="Value (per share)"&gt;5.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember"
      id="Fact001667">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember"
      id="Fact001669">P2Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      id="Fact001671">P3Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001673"
      unitRef="USDPShares">19.50</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001675"
      unitRef="USDPShares">19.50</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <ENVB:WarrantsAndRightsOutstandingStockPrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001677"
      unitRef="USDPShares">19.50</ENVB:WarrantsAndRightsOutstandingStockPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001679"
      unitRef="USDPShares">3712.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001681"
      unitRef="USDPShares">3675.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      decimals="INF"
      id="Fact001683"
      unitRef="USDPShares">412.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001691"
      unitRef="Pure">89.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001693"
      unitRef="Pure">88.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputOptionVolatilityMember"
      decimals="INF"
      id="Fact001695"
      unitRef="Pure">87.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001697"
      unitRef="Pure">4.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001699"
      unitRef="Pure">4.20</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001701"
      unitRef="Pure">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001703"
      unitRef="Shares">2429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001705"
      unitRef="Shares">2286</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001707"
      unitRef="Shares">22534</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_JanuaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001709"
      unitRef="USDPShares">0.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyOneWarrantsMember"
      decimals="INF"
      id="Fact001711"
      unitRef="USDPShares">0.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_FebruaryTwentyTwentyTwoWarrantsMember"
      decimals="INF"
      id="Fact001713"
      unitRef="USDPShares">1.20</us-gaap:SharePrice>
    <ENVB:InvestmentOptionTerm
      contextRef="From2023-01-012023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      id="Fact001715">P3Y7M6D</ENVB:InvestmentOptionTerm>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001717"
      unitRef="USDPShares">19.50</us-gaap:SaleOfStockPricePerShare>
    <ENVB:StockOptionExercisePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputSharePriceMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001719"
      unitRef="USDPShares">150.00</ENVB:StockOptionExercisePrice>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputOptionVolatilityMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001723"
      unitRef="Pure">94.0</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001725"
      unitRef="Pure">4.00</us-gaap:RetainedInvestmentDeconsolidatedSubsidiaryMeasurementInput>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001727"
      unitRef="Shares">4667</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SubsequentMeasurementMember_custom_HCWainwrightAndCoLLCInvestmentOptionsMember"
      decimals="INF"
      id="Fact001729"
      unitRef="USDPShares">5.10</us-gaap:SharePrice>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2023-05-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001731"
      unitRef="USD">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact001733">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJzHQhc2S99e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_824_zLAtIowfPq7c"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#x2019;s
financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Australian
Subsidiary Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-373, the Company&#x2019;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-373 in coordination with the Company&#x2019;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-373. EB-373, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#x2019;s
Therapeutic Goods Administration (TGA) and is currently in preclinical development targeting the treatment of anxiety disorder. The total
cost of the Avance Clinical contract is approximately &lt;span id="xdx_902_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zP5GfH9I9BH2" title="Contract cost"&gt;3,000,000&lt;/span&gt; AUD, which translates to approximately $&lt;span id="xdx_905_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zh1rCXdtro0i" title="Contract cost"&gt;2,000,000&lt;/span&gt; USD as of December
31, 2023. As of December 31, 2023, the Company has paid approximately $&lt;span id="xdx_904_eus-gaap--ConstructionContractCostProgressPaymentOffset_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zBWqr4Io24Ge" title="Payment of contract cost"&gt;1,036,940&lt;/span&gt; of the Avance Clinical contract costs and has accrued
$&lt;span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z3EcyGn4t8s5" title="Accrued liabilities"&gt;523,284&lt;/span&gt; recorded as accrued liabilities and $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zYKiKTtPTDXc" title="Accounts payable"&gt;239,320&lt;/span&gt; as accounts payable on the accompanying consolidated balance sheet. For the year
ended December 31, 2023, the Company has expensed $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_ztSbfQPHmw17" title="Research and development expenses"&gt;1,751,444&lt;/span&gt; in research and development expenses within the accompanying consolidated
statement of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Development
and Clinical Supply Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 22, 2021, the Company entered into a Development and Clinical Supply Agreement (the &#x201c;PureForm Agreement&#x201d;) with PureForm
Global, Inc. (&#x201c;PureForm&#x201d;), pursuant to which PureForm will be the exclusive provider of synthetic cannabidiol (&#x201c;API&#x201d;)
for the Company&#x2019;s development plans for cancer treatment and supportive care. Under the terms of the PureForm Agreement, PureForm
has granted the Company the exclusive right to purchase API and related product for cancer treatment and supportive care during the term
of the Agreement (contingent upon an initial minimum order of 1 kilogram during the first thirty (30) days from the effective date) and
has agreed to manufacture, package and test the API and related product in accordance with specifications established by the parties.
All inventions that are developed jointly by the parties in the course of performing activities under the PureForm Agreement will be
owned jointly by the parties in accordance with applicable law; however, if the Company funds additional research and development efforts
by PureForm, the parties may enter into a further agreement whereby PureForm would assign any resulting inventions or technical information
to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
initial term of the PureForm Agreement is three (3) years commencing on the effective date of the PureForm Agreement, subject to extension
by mutual agreement of the parties. The Company has met the minimum purchase requirement of 1 kilogram during the first thirty days of
the PureForm Agreement&#x2019;s effectiveness. The Company did not pursue an extension of the PureForm Agreement beyond the initial term
and the agreement terminated in 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#x201c;Vogel-Nathan Purchase
Agreement&#x201d;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The Vogel-Nathan Purchase Agreement includes a commitment to pay a one-time milestone
totaling $&lt;span id="xdx_908_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--OneTimeMilestoneMember_zrCCC2obgoyi" title="Long-term purchase commitment, amount"&gt;200,000&lt;/span&gt; upon the issuance of a utility patent in the United States or by the European Patent Office, as defined in the agreement.
The Company has accrued such amount as of December 31, 2021, as a result of the milestone criteria being achieved. Payment was made during
January 2022. In addition, a milestone payment totaling $&lt;span id="xdx_900_eus-gaap--LongTermPurchaseCommitmentAmount_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember__srt--StatementScenarioAxis__custom--AdditionalMilestoneMember_zhdAQxZczHo1" title="Long-term purchase commitment, amount"&gt;300,000&lt;/span&gt; is due upon initiation of a Phase II(b) study. Research activities related
to the relevant patents are still in preclinical stage, and accordingly, this milestone has not been achieved. The Vogel-Nathan Purchase
Agreement contains a commitment for payment of royalties equaling &lt;span id="xdx_90B_ecustom--RoyaltiesPercentage_pid_dp_uPure_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zDQEojQYFYF1" title="Royalties percentage"&gt;2&lt;/span&gt;% of the first $&lt;span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20171225__20171226__us-gaap--TypeOfArrangementAxis__custom--VogalNathanPurchaseAgreementMember_zoZY67IeTyk6" title="Payments for royalties"&gt;20&lt;/span&gt; million in net sales derived from the commercialization
of products utilizing the relevant patent. As these products are still in the preclinical phase of development, no royalties have been
earned.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Consulting and Vendor Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between 1 and 18 months. These agreements, in aggregate, commit the Company to approximately $&lt;span id="xdx_906_eus-gaap--Cash_iI_pn5n6_c20231231__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_zXfWx4ycr8Rc" title="Future cash"&gt;1.3&lt;/span&gt; million in future
cash payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Right-of-use
lease&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 1, 2021, MagicMed entered into a lease agreement (the &#x201c;LSIH Lease&#x201d;) with the University of Calgary for the use and
occupation of lab and office space at the University of Calgary&#x2019;s Life Science Innovation Hub building located in Calgary, Alberta,
Canada (the &#x201c;LSIH Facility&#x201d;). The lease expired in July 2023, and was extended on a month-to-month basis through December
31, 2023. Accordingly, no operating lease liability or right-of-use asset is recorded as of December 31, 2023. The Company terminated
this lease effective in March 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rent
expense is recorded on the straight-line basis. Rent expense under the LSIH Lease for the years ended December 31, 2023 and 2022 was
$&lt;span id="xdx_902_eus-gaap--PaymentsForRent_c20230101__20231231_zBINyAlGGitl" title="Rent expenses"&gt;114,241&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--PaymentsForRent_c20220101__20221231_zTe2yrPNRkw2" title="Rent expenses"&gt;120,667&lt;/span&gt;, respectively. Rent expense is recorded in research and development costs on the consolidated statements of operations
and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zWHvKLl07Vnb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zQfu0TOu6lia" style="display: none"&gt;SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zFSM6H6fbVub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001735"
      unitRef="AUD">3000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001737"
      unitRef="USD">2000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:ConstructionContractCostProgressPaymentOffset
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001739"
      unitRef="USD">1036940</us-gaap:ConstructionContractCostProgressPaymentOffset>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001741"
      unitRef="USD">523284</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001743"
      unitRef="USD">239320</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">1751444</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_OneTimeMilestoneMember"
      decimals="0"
      id="Fact001747"
      unitRef="USD">200000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember_custom_AdditionalMilestoneMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">300000</us-gaap:LongTermPurchaseCommitmentAmount>
    <ENVB:RoyaltiesPercentage
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember"
      decimals="INF"
      id="Fact001751"
      unitRef="Pure">0.02</ENVB:RoyaltiesPercentage>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2017-12-252017-12-26_custom_VogalNathanPurchaseAgreementMember"
      decimals="-6"
      id="Fact001753"
      unitRef="USD">20000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31_custom_OtherConsultingAndVendorAgreementsMember"
      decimals="-5"
      id="Fact001755"
      unitRef="USD">1300000</us-gaap:Cash>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001757"
      unitRef="USD">114241</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001759"
      unitRef="USD">120667</us-gaap:PaymentsForRent>
    <ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001761">&lt;p id="xdx_89B_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_zWHvKLl07Vnb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted-average remaining lease term and the weighted-average discount rate of the lease was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_zQfu0TOu6lia" style="display: none"&gt;SCHEDULE OF WEIGHTED
AVERAGE REMAINING LEASE TERM&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Remaining lease term (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231_zuiWJW2cO47k" title="Operating leases remaining lease term"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20221231_zk4ki5oTON06" title="Operating lease discount rate"&gt;12.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENVB:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2022-12-31" id="Fact001763">P0Y7M6D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001765"
      unitRef="Pure">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-012023-12-31" id="Fact001767">&lt;p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zYdOWhZhqi8i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_82E_zmpByKrEU5va"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s U.S. and foreign loss before income taxes are set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zeA4xpukjyji" style="display: none"&gt;SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,205,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(7,251,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,057,703&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,706,165&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,262,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(19,957,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zhNKqIFZq044" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recorded income tax expense of $&lt;span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_c20230101__20231231_z3Bd8okIz0A9" title="Income tax expenses and benefits"&gt;28,913&lt;/span&gt; and an income tax benefit of $&lt;span id="xdx_900_eus-gaap--IncomeTaxExpenseBenefit_iN_di_c20220101__20221231_zTxFvfZupNSk" title="Income tax expenses and benefits"&gt;1,486,060&lt;/span&gt;,
respectively. The income tax benefit (expense) is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4LFMffO1bGa" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE BENEFITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Current:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1793"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Total
    current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1799"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1801"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total income tax (expense) benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zEMeV37Jgcl8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets and deferred tax liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zVn0082ZSHDi" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,889,863&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,927,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,185,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,348,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_zeLuldfIHLJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development capitalized expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;614,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_z3vKEWbpo3wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,837,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,977,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1834"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zv3ekvcOLIcc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially utilizable net operating loss tax carryforwards:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zt3NjQUFsfF" style="display: none"&gt;SCHEDULE
OF OPERATING LOSS CARRY FORWARDS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;24,268,692&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;18,349,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,220,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,892,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net operating loss tax carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_z7S3r24z5eD4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act of 2017 (the &#x201c;Act&#x201d;) limits the net operating loss deduction to 80% of taxable income for losses
arising in tax years beginning after December 31, 2017. As of December 31, 2023, the Company had federal net operating loss
carryforwards and state net operating loss carryforwards of $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zMyXJ1gm3FJ8"&gt;24,268,692&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zH57liFWfGbk" title="Net operating loss carryforwards"&gt;11,220,065&lt;/span&gt;,
respectively, both of which can be carried forward indefinitely and Canadian net operating loss carryforwards of $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zr2nJ9Kzy0j6" title="Net operating loss carryforwards"&gt;17,672,420&lt;/span&gt;,
which will begin to expire in 2040.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s effective tax rate varied from the statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none"&gt;SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Federal income tax at the statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax rate (net of federal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign tax rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zBQrMCzaAaZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23.3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zsa35ks9ndR2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all
of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of
future taxable income during the periods in which those temporary differences become deductible. The valuation allowance increased by
$&lt;span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20230101__20231231_znu1AgEoYdYj" title="Valuation allowance"&gt;1,859,862&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20220101__20221231_zQeSg7kdYWS3" title="Valuation allowance"&gt;4,429,869&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and state returns. The Company&#x2019;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state and Canadian perspective the years that remain open to examination are consistent with each jurisdiction&#x2019;s
statute of limitations. As of December 31, 2023, the Company has not filed tax returns for the fiscal year 2023 and Canadian corporate
tax returns for fiscal year 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Section
382&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
utilization of the Company&#x2019;s net operating losses may be subject to a substantial limitation in the event of any significant future
changes in its ownership structure under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result
in the expiration of the net operating loss carryforwards before their utilization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Section
174&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Beginning
in 2022, the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) eliminated the option to deduct research and development expenditures
in the current year and requires taxpayers to amortize US expenses over five years and foreign expense over fifteen years pursuant to
IRC Section 174. During the years ended December 31, 2023 and 2022, the Company has estimated and capitalized gross $&lt;span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_z0NaECqIR2Wg" title="Research and development expense gross"&gt;463,696&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20220101__20221231_zOGeQR7Krns5" title="Research and development expense gross"&gt;2,684,319&lt;/span&gt;,
respectively, of research and development expenditures that will be amortized primarily over five years. This did not have a material
impact on the Company&#x2019;s tax liability for the years ended December 31, 2023 and 2022. The Company will continue to evaluate the
impact of these tax law changes on the current and future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
Reduction Act&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 16, 2022, President Joe Biden signed the Inflation Reduction Act of 2022 (the &#x201c;Act&#x201d;) into law. The Act includes a
new 15% corporate minimum tax and a 1% excise tax on the value of corporate stock repurchases, net of new share issuances, after December
31, 2022. These provisions did not have a material impact on the Company&#x2019;s consolidated financial position as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001769">&lt;p id="xdx_89E_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zYpFlmqCGSD2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s U.S. and foreign loss before income taxes are set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zeA4xpukjyji" style="display: none"&gt;SCHEDULE OF EARNING (LOSS) BEFORE INCOME
TAX&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zxZNk46ZRzng" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231_zijVKXfD02T1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_maILFCOzlef_z9MaFVvNgvr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(10,205,116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(7,251,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_maILFCOzlef_zE8rf8karcM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7,057,703&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,706,165&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_mtILFCOzlef_z2B2dgbOYfy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(17,262,819&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(19,957,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001771"
      unitRef="USD">-10205116</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001772"
      unitRef="USD">-7251228</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001774"
      unitRef="USD">-7057703</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001775"
      unitRef="USD">-12706165</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001777"
      unitRef="USD">-17262819</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001778"
      unitRef="USD">-19957393</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001780"
      unitRef="USD">28913</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001782"
      unitRef="USD">-1486060</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001784">&lt;p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zBdQk1cD3aIf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4LFMffO1bGa" style="display: none"&gt;SCHEDULE
OF INCOME TAX EXPENSE BENEFITS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zXpnWXEk0Qnd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220101__20221231_zktAaySoCScj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Current:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentFederalTaxExpenseBenefit_iN_di_maCITEBzYcv_zswZcV5nkVg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1787"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_iN_di_maCITEBzYcv_zAEkzY61kyi6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CurrentForeignTaxExpenseBenefit_iN_di_maCITEBzYcv_zBO2f4fpNnae" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1793"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--CurrentIncomeTaxExpenseBenefit_iNT_di_mtCITEBzYcv_maITEBzKnh_zBI0YA4EbLMh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; Total
    current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zO46stlDOwwa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1799"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_z7PzV6xiY5vd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1801"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_iN_di_maDFITEzdpW_zXxtOtSLhIsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1804"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredIncomeTaxExpenseBenefit_iNT_di_mtDFITEzdpW_maITEBzKnh_zXY6vb4G9k2j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1807"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iNT_di_mtITEBzKnh_z5f9VHGVH2Ya" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total income tax (expense) benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,913&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,486,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001789"
      unitRef="USD">28913</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001795"
      unitRef="USD">28913</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001805"
      unitRef="USD">-1486060</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001808"
      unitRef="USD">-1486060</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001810"
      unitRef="USD">28913</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001811"
      unitRef="USD">-1486060</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001813">&lt;p id="xdx_89B_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zFSERvZE8hD1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s deferred tax assets and deferred tax liabilities consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zVn0082ZSHDi" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zXa1FmWtibt5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zwvxf2F8NBJ1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzNdz_maDTANzxkL_zMNkEZsyD8Wf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;10,889,863&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;8,927,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzxkL_zg5Rc6Cqe1F8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,185,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,348,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ResearchAndDevelopmentCapitalizedExpenses_iI_maDTANzxkL_zeLuldfIHLJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development capitalized expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;614,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsAndIntangibleAmortization_iI_maDTANzxkL_z3vKEWbpo3wi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOther_iI_maDTANzxkL_zLfR2vCU52Pd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzXjO_msDTANzxkL_zMfzrABlkFk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowances&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,837,755&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,977,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzxkL_zeNN2eU460z" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1833"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1834"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001815"
      unitRef="USD">10889863</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001816"
      unitRef="USD">8927330</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001818"
      unitRef="USD">1185399</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001819"
      unitRef="USD">1348928</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ENVB:ResearchAndDevelopmentCapitalizedExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001821"
      unitRef="USD">611245</ENVB:ResearchAndDevelopmentCapitalizedExpenses>
    <ENVB:ResearchAndDevelopmentCapitalizedExpenses
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001822"
      unitRef="USD">614041</ENVB:ResearchAndDevelopmentCapitalizedExpenses>
    <ENVB:DeferredTaxAssetsAndIntangibleAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001824"
      unitRef="USD">80518</ENVB:DeferredTaxAssetsAndIntangibleAmortization>
    <ENVB:DeferredTaxAssetsAndIntangibleAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001825"
      unitRef="USD">54141</ENVB:DeferredTaxAssetsAndIntangibleAmortization>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001827"
      unitRef="USD">70730</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001828"
      unitRef="USD">33453</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001830"
      unitRef="USD">12837755</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001831"
      unitRef="USD">10977893</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2023-01-012023-12-31" id="Fact001836">&lt;p id="xdx_897_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zs9bhRynYJsl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially utilizable net operating loss tax carryforwards:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zt3NjQUFsfF" style="display: none"&gt;SCHEDULE
OF OPERATING LOSS CARRY FORWARDS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231_zulmzGTSNdN8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20221231_zZqWm1R4dBi8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zQU8ncu82Cef" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Federal&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;24,268,692&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;18,349,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zI0OIVbJPSr6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;State&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;11,220,065&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,892,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zzjfJ55ZT1Uj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Foreign&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLossCarryforwards_iI_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zSAitNKZZYjl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net operating loss tax carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,672,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,377,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001838"
      unitRef="USD">24268692</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">18349753</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001841"
      unitRef="USD">11220065</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001842"
      unitRef="USD">16892754</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001844"
      unitRef="USD">17672420</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001845"
      unitRef="USD">16377435</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001847"
      unitRef="USD">17672420</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2022-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001848"
      unitRef="USD">16377435</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_DomesticCountryMember"
      decimals="0"
      id="Fact001849"
      unitRef="USD">24268692</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact001851"
      unitRef="USD">11220065</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_ForeignCountryMember"
      decimals="0"
      id="Fact001853"
      unitRef="USD">17672420</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-012023-12-31" id="Fact001855">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zzVMVNGeNJec" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s effective tax rate varied from the statutory rate as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_z6qq60Xq2gJ2" style="display: none"&gt;SCHEDULE
OF EFFECTIVE STATUTORY INCOME TAX RATE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zcnUsjwkXjAj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_z6WLN5u7FCy" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_maALCzr1A_zmTBblmRYrR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Federal income tax at the statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(21.0&lt;/td&gt;&lt;td style="width: 3%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maALCzr1A_zYGRPLUj28i3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax rate (net of federal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_uPure_maALCzr1A_z9kt9Ydnzk1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Foreign tax rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation_pid_dp_uPure_maALCzr1A_zTghWy4U2b78" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-deductible expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueup_pid_dp_uPure_maALCzr1A_zBQrMCzaAaZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1870"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maALCzr1A_ztmgY4wYYHoh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;23.3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtALCzr1A_zWrMtwwBJC36" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(7.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001857"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001858"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001860"
      unitRef="Pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001861"
      unitRef="Pure">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001863"
      unitRef="Pure">-0.030</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001864"
      unitRef="Pure">-0.031</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001866"
      unitRef="Pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001867"
      unitRef="Pure">-0.040</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciation>
    <ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001869"
      unitRef="Pure">0.132</ENVB:EffectiveIncomeTaxRateReconciliationDeferredTrueup>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001872"
      unitRef="Pure">0.108</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001873"
      unitRef="Pure">0.233</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact001875"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001876"
      unitRef="Pure">-0.074</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001878"
      unitRef="USD">1859862</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001880"
      unitRef="USD">4429869</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001882"
      unitRef="USD">463696</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001884"
      unitRef="USD">2684319</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-012023-12-31" id="Fact001886">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_z18CjkrOmpN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12. &lt;span id="xdx_820_zNqnVHMzgyjl"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company completed a &lt;span id="xdx_906_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zdVV237Bi36e" title="Reverse stock split"&gt;1-for-15&lt;/span&gt;
reverse stock split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. The Reverse Stock Split reduced the number
of shares of the Company&#x2019;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse
Stock Split. The number of shares of the Company&#x2019;s authorized common stock was not affected by the Reverse Stock Split and the
par value of the Company&#x2019;s common stock remained unchanged at $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHPoJR1PQ9U6" title="Share price"&gt;0.01&lt;/span&gt;
per share. No fractional shares were issued in connection with the Reverse Stock Split. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
February 29, 2024, the Company issued all &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXqaJYv860yd" title="Number of common stock issued"&gt;46,934&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; shares of common stock of the &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zR2185JE00Nd" title="Existing Warrants"&gt;46,934&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Existing Warrants and Investment
Options exercised that were held in abeyance due to the beneficial ownership limitation provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 29, 2024, one investor exercised the Inducement Warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0AhH5MmtvB3" title="Warrants to purchase shares of common stock"&gt;130,267&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for cash proceeds
of approximately $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMS2xAAK6T0e" title="Cash proceeds"&gt;2.7&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zSeFskr2Lz9b"&gt;15,246&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock,
par value $&lt;span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zaEtnlXUmCYi"&gt;0.01&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share to the Holders of the Inducement Warrants.
The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction limitation solely with respect
to the entry into and/or issuance of shares of common stock in an at the market offering contained in the Inducement Letters.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to December 31, 2023, the Company sold an aggregate of &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zJmX0hu9ExH5" title="Number of shares sold"&gt;111,200&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for aggregate gross
proceeds of $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_z8Ub17d6Doq3" title="Gross proceeds from sale of shares"&gt;2,392,502&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and net proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240102__20240321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zM52artKaMga" title="Net Proceeds from sale of shares"&gt;2,320,707&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;under the Distribution Agreement with Canaccord.&#x201d;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-01-272025-01-27" id="Fact001888">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact001890"
      unitRef="USDPShares">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001892"
      unitRef="Shares">46934</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001894"
      unitRef="Shares">46934</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001896"
      unitRef="Shares">130267</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-292024-02-29_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="-5"
      id="Fact001898"
      unitRef="USD">2700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001899"
      unitRef="Shares">15246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-08_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact001900"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember"
      decimals="INF"
      id="Fact001902"
      unitRef="Shares">111200</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember"
      decimals="0"
      id="Fact001904"
      unitRef="USD">2392502</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-022024-03-21_us-gaap_SubsequentEventMember_custom_DistributionAgreementMember"
      decimals="0"
      id="Fact001906"
      unitRef="USD">2320707</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:Cash
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001914"
      unitRef="USD">3111683</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001915"
      unitRef="USD">2287977</us-gaap:Cash>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001917"
      unitRef="USD">1226576</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001918"
      unitRef="USD">1293554</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001920"
      unitRef="USD">4338259</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001921"
      unitRef="USD">3581531</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001926"
      unitRef="USD">367689</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001927"
      unitRef="USD">507377</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001929"
      unitRef="USD">84368</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001930"
      unitRef="USD">210932</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001932"
      unitRef="USD">452057</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001933"
      unitRef="USD">718309</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001935"
      unitRef="USD">4790316</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001936"
      unitRef="USD">4299840</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001944"
      unitRef="USD">576324</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001945"
      unitRef="USD">1218783</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001947"
      unitRef="USD">253150</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001948"
      unitRef="USD">1075643</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001950"
      unitRef="USD">4944</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001951"
      unitRef="USD">23608</us-gaap:OtherLiabilitiesCurrent>
    <ENVB:WarrantLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001953"
      unitRef="USD">4748</ENVB:WarrantLiabilitiesCurrent>
    <ENVB:WarrantLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001954"
      unitRef="USD">25470</ENVB:WarrantLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact001956"
      unitRef="USD">839166</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001957"
      unitRef="USD">2343504</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001968"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001970"
      unitRef="USDPShares">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001972"
      unitRef="Shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001974"
      unitRef="Shares">100000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001976"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2024-09-30_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001978"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001980"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2023-12-31_custom_SeriesCRedeemablePreferredStockMember"
      decimals="INF"
      id="Fact001982"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001993"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001995"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact001997"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001999"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002001"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002003"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002005"
      unitRef="Shares">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002007"
      unitRef="Shares">3600000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002009"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002011"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002013"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact002015"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact002023"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002025"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact002027"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002029"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact002031"
      unitRef="Shares">599669</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact002033"
      unitRef="Shares">599669</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002035"
      unitRef="Shares">182625</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002037"
      unitRef="Shares">182625</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002020"
      unitRef="USD">5998</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002021"
      unitRef="USD">1827</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002039"
      unitRef="USD">5998</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002040"
      unitRef="USD">1827</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002042"
      unitRef="USD">107400009</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002043"
      unitRef="USD">100841416</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002046"
      unitRef="USD">1817640</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002048"
      unitRef="USD">-102919859</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002049"
      unitRef="USD">-96499518</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002051"
      unitRef="USD">-534998</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002052"
      unitRef="USD">-569749</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002054"
      unitRef="USD">3951150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002055"
      unitRef="USD">1956336</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002057"
      unitRef="USD">4790316</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002058"
      unitRef="USD">4299840</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002065"
      unitRef="USD">1235661</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002066"
      unitRef="USD">2080644</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002067"
      unitRef="USD">4467065</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002068"
      unitRef="USD">8273344</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002070"
      unitRef="USD">762717</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002071"
      unitRef="USD">1281455</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002072"
      unitRef="USD">1736373</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002073"
      unitRef="USD">5531436</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002075"
      unitRef="USD">84814</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002076"
      unitRef="USD">86296</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002077"
      unitRef="USD">255002</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002078"
      unitRef="USD">259300</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002080"
      unitRef="USD">2083192</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002081"
      unitRef="USD">3448395</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002082"
      unitRef="USD">6458440</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002083"
      unitRef="USD">14064080</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002085"
      unitRef="USD">-2083192</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002086"
      unitRef="USD">-3448395</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002087"
      unitRef="USD">-6458440</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002088"
      unitRef="USD">-14064080</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002095"
      unitRef="USD">122</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002096"
      unitRef="USD">-67822</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002097"
      unitRef="USD">-20722</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002098"
      unitRef="USD">115342</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002100"
      unitRef="USD">-501</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002101"
      unitRef="USD">562715</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002102"
      unitRef="USD">18664</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002103"
      unitRef="USD">-399921</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002108"
      unitRef="USD">727000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002110"
      unitRef="USD">-217</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002111"
      unitRef="USD">2237</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002112"
      unitRef="USD">444</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002113"
      unitRef="USD">3142</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002115"
      unitRef="USD">-840</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002116"
      unitRef="USD">632774</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002117"
      unitRef="USD">39830</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002118"
      unitRef="USD">214879</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002120"
      unitRef="USD">-2084032</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002121"
      unitRef="USD">-2815621</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002122"
      unitRef="USD">-6418610</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002123"
      unitRef="USD">-13849201</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002126"
      unitRef="USD">6595</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002127"
      unitRef="USD">1731</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002128"
      unitRef="USD">6595</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002130"
      unitRef="USD">-2084032</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002131"
      unitRef="USD">-2822216</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002132"
      unitRef="USD">-6420341</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002133"
      unitRef="USD">-13855796</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002138"
      unitRef="USD">19041</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002143"
      unitRef="USD">147988</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002145"
      unitRef="USD">-2084032</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002146"
      unitRef="USD">-2822216</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002147"
      unitRef="USD">-6420341</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002148"
      unitRef="USD">-14022825</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002155"
      unitRef="USD">31497</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002156"
      unitRef="USD">10433</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002157"
      unitRef="USD">34751</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002158"
      unitRef="USD">1115</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002160"
      unitRef="USD">-2052535</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002161"
      unitRef="USD">-2811783</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002162"
      unitRef="USD">-6385590</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002163"
      unitRef="USD">-14021710</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact002165"
      unitRef="USDPShares">-3.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact002167"
      unitRef="USDPShares">-3.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact002169"
      unitRef="USDPShares">-19.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact002171"
      unitRef="USDPShares">-19.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact002173"
      unitRef="USDPShares">-14.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact002175"
      unitRef="USDPShares">-14.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact002177"
      unitRef="USDPShares">-99.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact002179"
      unitRef="USDPShares">-99.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact002181"
      unitRef="Shares">580197</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact002183"
      unitRef="Shares">580197</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact002185"
      unitRef="Shares">144311</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact002187"
      unitRef="Shares">144311</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact002189"
      unitRef="Shares">451411</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact002191"
      unitRef="Shares">451411</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact002193"
      unitRef="Shares">141144</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact002195"
      unitRef="Shares">141144</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002206"
      unitRef="Shares">182625</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002199"
      unitRef="USD">1827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002200"
      unitRef="USD">100841416</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact002201"
      unitRef="USD">-1817640</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002202"
      unitRef="USD">-96499518</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002203"
      unitRef="USD">-569749</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002204"
      unitRef="USD">1956336</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002211"
      unitRef="USD">351488</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002215"
      unitRef="USD">351488</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ENVB:CommonStockEquityDistributionCosts
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002226"
      unitRef="USD">583713</ENVB:CommonStockEquityDistributionCosts>
    <ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002228"
      unitRef="Shares">111200</ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002219"
      unitRef="USD">1112</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002220"
      unitRef="USD">1807677</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002224"
      unitRef="USD">1808789</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002239"
      unitRef="Shares">15246</ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002232"
      unitRef="USD">152</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002233"
      unitRef="USD">322301</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002237"
      unitRef="USD">322453</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002250"
      unitRef="USD">130267</ENVB:StockIssuedDuringPeriodSharesExerciseOfInducementWarrantsForCommonStock>
    <ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002243"
      unitRef="USD">1303</ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock>
    <ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002244"
      unitRef="USD">2675677</ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock>
    <ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002248"
      unitRef="USD">2676980</ENVB:StockIssuedDuringPeriodValueExerciseOfInducementWarrantsForCommonStock>
    <ENVB:NetOfferingCosts
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002261"
      unitRef="USD">12821</ENVB:NetOfferingCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002255"
      unitRef="USD">-12821</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact002256"
      unitRef="USD">280500</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002259"
      unitRef="USD">267679</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002272"
      unitRef="Shares">46934</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002265"
      unitRef="USD">469</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002266"
      unitRef="USD">-469</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31_custom_SubscriptionReceivableMember"
      decimals="0"
      id="Fact002267"
      unitRef="USD">1537140</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002270"
      unitRef="USD">1537140</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002280"
      unitRef="USD">17906</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002281"
      unitRef="USD">17906</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002288"
      unitRef="USD">-2456915</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-03-31"
      decimals="0"
      id="Fact002290"
      unitRef="USD">-2456915</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002301"
      unitRef="Shares">486272</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002294"
      unitRef="USD">4863</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002295"
      unitRef="USD">105985269</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002297"
      unitRef="USD">-98956433</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002298"
      unitRef="USD">-551843</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="Fact002299"
      unitRef="USD">6481856</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002306"
      unitRef="USD">369614</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002310"
      unitRef="USD">369614</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ENVB:CommonStockEquityDistributionCosts
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002321"
      unitRef="USD">82850</ENVB:CommonStockEquityDistributionCosts>
    <ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002323"
      unitRef="Shares">8334</ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002314"
      unitRef="USD">83</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002315"
      unitRef="USD">-83</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002334"
      unitRef="Shares">30534</ENVB:StockIssuedDuringPeriodSharesIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002327"
      unitRef="USD">306</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002328"
      unitRef="USD">448534</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002332"
      unitRef="USD">448840</ENVB:StockIssuedDuringPeriodValueIssuedDirectOfferingNetOfOfferingCost>
    <ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002345"
      unitRef="Shares">105</ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002338"
      unitRef="USD">1</ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-04-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002339"
      unitRef="USD">-1</ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-04-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002353"
      unitRef="USD">-14652</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002354"
      unitRef="USD">-14652</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002361"
      unitRef="USD">-1879394</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012024-06-30"
      decimals="0"
      id="Fact002363"
      unitRef="USD">-1879394</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002374"
      unitRef="Shares">525245</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002367"
      unitRef="USD">5253</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002368"
      unitRef="USD">106803333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002370"
      unitRef="USD">-100835827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002371"
      unitRef="USD">-566495</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact002372"
      unitRef="USD">5406264</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002379"
      unitRef="USD">369614</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002383"
      unitRef="USD">369614</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ENVB:CommonStockEquityDistributionCosts
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002394"
      unitRef="USD">290029</ENVB:CommonStockEquityDistributionCosts>
    <ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002396"
      unitRef="Shares">72699</ENVB:StockIssuedDuringPeriodSharesCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002387"
      unitRef="USD">727</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002388"
      unitRef="USD">227080</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002392"
      unitRef="USD">227807</ENVB:StockIssuedDuringPeriodValueCommonStockSoldUnderEquityDistribution>
    <ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002407"
      unitRef="Shares">1725</ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002400"
      unitRef="USD">18</ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002401"
      unitRef="USD">-18</ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002415"
      unitRef="USD">31497</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002416"
      unitRef="USD">31497</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002423"
      unitRef="USD">-2084032</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002425"
      unitRef="USD">-2084032</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002436"
      unitRef="Shares">599669</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002429"
      unitRef="USD">5998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002430"
      unitRef="USD">107400009</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002432"
      unitRef="USD">-102919859</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002433"
      unitRef="USD">-534998</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002434"
      unitRef="USD">3951150</us-gaap:StockholdersEquity>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact002446"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002438"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002439"
      unitRef="USD">885028</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002448"
      unitRef="Shares">138554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002440"
      unitRef="USD">1386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002441"
      unitRef="USD">94415058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002442"
      unitRef="USD">-79207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002443"
      unitRef="USD">-536734</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002444"
      unitRef="USD">14671924</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002453"
      unitRef="USD">532835</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact002456"
      unitRef="USD">532835</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002458"
      unitRef="USD">-12329</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002459"
      unitRef="USD">-12329</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002461"
      unitRef="USD">12329</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact002464"
      unitRef="USD">12329</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002466"
      unitRef="USD">-110991</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002467"
      unitRef="USD">-110991</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002469"
      unitRef="USD">110991</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact002472"
      unitRef="USD">110991</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002479"
      unitRef="USD">1968</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact002480"
      unitRef="USD">1968</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002486"
      unitRef="USD">-4677527</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact002488"
      unitRef="USD">-4677527</us-gaap:NetIncomeLoss>
    <ENVB:TemporaryEquityShares
      contextRef="AsOf2023-03-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact002498"
      unitRef="Shares">1000</ENVB:TemporaryEquityShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002490"
      unitRef="USD">1008348</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002491"
      unitRef="USD">1008348</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002500"
      unitRef="Shares">138554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002492"
      unitRef="USD">1386</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002493"
      unitRef="USD">94824573</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002494"
      unitRef="USD">-83885313</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002495"
      unitRef="USD">-534766</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="Fact002496"
      unitRef="USD">10405880</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002505"
      unitRef="USD">879738</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact002508"
      unitRef="USD">879738</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002510"
      unitRef="USD">-6712</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002511"
      unitRef="USD">-6712</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002513"
      unitRef="USD">6712</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact002516"
      unitRef="USD">6712</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002518"
      unitRef="USD">-36997</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002519"
      unitRef="USD">-36997</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002521"
      unitRef="USD">36997</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact002524"
      unitRef="USD">36997</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      decimals="INF"
      id="Fact002534"
      unitRef="Shares">-1000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_custom_RedeemableNoncontrollingInterestMember"
      decimals="0"
      id="Fact002526"
      unitRef="USD">-1052057</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2023-04-012023-06-30_custom_MezzanineEquityMember"
      decimals="0"
      id="Fact002527"
      unitRef="USD">-1052057</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002544"
      unitRef="Shares">4235</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002538"
      unitRef="USD">42</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002539"
      unitRef="USD">-42</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002551"
      unitRef="USD">-11286</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact002552"
      unitRef="USD">-11286</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002558"
      unitRef="USD">-6356053</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact002560"
      unitRef="USD">-6356053</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002572"
      unitRef="Shares">142789</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002564"
      unitRef="USD">1428</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002565"
      unitRef="USD">95660560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002566"
      unitRef="USD">-90241366</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002567"
      unitRef="USD">-546052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact002568"
      unitRef="USD">4874570</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002584"
      unitRef="Shares">142789</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002576"
      unitRef="USD">1428</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002577"
      unitRef="USD">95660560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002578"
      unitRef="USD">-90241366</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002579"
      unitRef="USD">-546052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact002580"
      unitRef="USD">4874570</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002589"
      unitRef="USD">372859</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002592"
      unitRef="USD">372859</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002602"
      unitRef="Shares">2676</ENVB:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002596"
      unitRef="USD">27</ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002597"
      unitRef="USD">-27</ENVB:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForVestedRestrictedStockUnits>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002609"
      unitRef="USD">10433</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002610"
      unitRef="USD">10433</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002617"
      unitRef="USD">10433</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002618"
      unitRef="USD">10433</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002624"
      unitRef="USD">-2822216</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002626"
      unitRef="USD">-2822216</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002638"
      unitRef="Shares">145465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002630"
      unitRef="USD">1455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002631"
      unitRef="USD">96033392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002632"
      unitRef="USD">-93063582</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002633"
      unitRef="USD">-535619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002634"
      unitRef="USD">2435646</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002650"
      unitRef="Shares">145465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact002642"
      unitRef="USD">1455</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact002643"
      unitRef="USD">96033392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact002644"
      unitRef="USD">-93063582</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact002645"
      unitRef="USD">-535619</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002646"
      unitRef="USD">2435646</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002655"
      unitRef="USD">-6420341</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002656"
      unitRef="USD">-13855796</us-gaap:NetIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002661"
      unitRef="USD">-20722</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002662"
      unitRef="USD">115342</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnInvestments
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002664"
      unitRef="USD">18664</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002665"
      unitRef="USD">-399921</us-gaap:GainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002668"
      unitRef="USD">727000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002670"
      unitRef="USD">1090716</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002671"
      unitRef="USD">1785432</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002674"
      unitRef="USD">64246</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002676"
      unitRef="USD">126564</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002677"
      unitRef="USD">126566</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002679"
      unitRef="USD">128438</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002680"
      unitRef="USD">132734</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002683"
      unitRef="USD">4219</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002688"
      unitRef="USD">3674</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002689"
      unitRef="USD">746033</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002691"
      unitRef="USD">-1296907</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002692"
      unitRef="USD">429688</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002695"
      unitRef="USD">64244</ENVB:IncreaseDecreaseInRightofuseOperatingLeaseAssetAndObligation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002697"
      unitRef="USD">-6414590</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002698"
      unitRef="USD">-12343363</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002704"
      unitRef="USD">5195</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002707"
      unitRef="USD">16900</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002710"
      unitRef="USD">11705</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002715"
      unitRef="USD">1804819</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002718"
      unitRef="USD">2676980</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002721"
      unitRef="USD">2290186</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ENVB:ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002724"
      unitRef="USD">599862</ENVB:ProceedsFromCommonStockSoldUnderPurchaseAgreementNetOfOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002727"
      unitRef="USD">161461</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002728"
      unitRef="USD">105000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002731"
      unitRef="USD">1052057</us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002733"
      unitRef="USD">7210386</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002734"
      unitRef="USD">-1157057</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002736"
      unitRef="USD">27910</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002737"
      unitRef="USD">31399</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002739"
      unitRef="USD">823706</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002740"
      unitRef="USD">-13457316</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002742"
      unitRef="USD">2287977</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002743"
      unitRef="USD">17723884</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002745"
      unitRef="USD">3111683</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002746"
      unitRef="USD">4266568</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002754"
      unitRef="USD">24001</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002755"
      unitRef="USD">6595</us-gaap:IncomeTaxesPaidNet>
    <ENVB:OfferingCostsAccruedNotPaid
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002757"
      unitRef="USD">35455</ENVB:OfferingCostsAccruedNotPaid>
    <ENVB:OfferingCostsAccruedNotPaid
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002758"
      unitRef="USD">20800</ENVB:OfferingCostsAccruedNotPaid>
    <ENVB:DeferredOfferingCostsChargedToOfferingCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002760"
      unitRef="USD">495544</ENVB:DeferredOfferingCostsChargedToOfferingCosts>
    <ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002763"
      unitRef="USD">771293</ENVB:IssuanceOfCommonSharesForDeferredOfferingCosts>
    <ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002767"
      unitRef="USD">19041</ENVB:PreferredDividendsAttributableToRedeemableNoncontrollingInterest>
    <ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002770"
      unitRef="USD">147988</ENVB:AccretionOfEmbeddedDerivativeToRedemptionValue>
    <us-gaap:NatureOfOperations contextRef="From2024-01-01to2024-09-30" id="Fact002772">&lt;p id="xdx_808_eus-gaap--NatureOfOperations_zh3tk2MuAILb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82F_z9UeT7gQdFnh"&gt;BUSINESS AND LIQUIDITY AND OTHER UNCERTAINTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nature
of Operations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Enveric
Biosciences, Inc. (&#x201c;Enveric&#x201d; or the &#x201c;Company&#x201d;) is a biotechnology company developing novel neuroplastogenic small-molecule
therapeutics for the treatment of depression, anxiety, and addiction disorders. The head office of the Company is located in Naples,
Florida. The Company has the following wholly-owned subsidiaries: Jay Pharma Inc. (&#x201c;Jay Pharma&#x201d;), 1306432 B.C. Ltd., MagicMed
Industries, Inc. (&#x201c;MagicMed&#x201d;), Enveric Biosciences Canada Inc., Akos Biosciences, Inc. (&#x201c;Akos&#x201d;), and Enveric
Therapeutics, Pty. Ltd. (&#x201c;Enveric Therapeutics&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leveraging
its unique discovery and development platform, The Psybrary&#x2122;, Enveric has created a robust intellectual property portfolio of new
chemical entities for specific mental health indications. Enveric&#x2019;s lead program, the EVM201 Series, comprises next generation
synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series &#x2013; EB-002
(formerly EB-373) &#x2013; for the treatment of psychiatric disorders. Enveric is also advancing its product EB-003, a non-hallucinogenic
neuroplastogen from the EVM301 Series, which is expected to offer a first-in-class, new approach to the treatment of difficult-to-address
mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has continued to pursue the development of MagicMed&#x2019;s proprietary library, the Psybrary&#x2122; which the Company believes
will help to identify and develop the right drug candidates needed to address mental health challenges. The Company synthesizes novel
analogues of serotonin, using a mixture of chemistry and synthetic biology, resulting in the expansion of the Psybrary&#x2122;, which
includes 15 patent families with over a million potential variations and hundreds of synthesized molecules. The Company has created over
1,200 novel molecular compounds and derivatives that are housed in the Psybrary&#x2122;. The Company&#x2019;s current focus is to develop
its lead molecules, EB-002 and EB-003, and to out license other molecules from the Psybrary&#x2122;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company screens newly
synthesized molecules in the Psybrary&#x2122; through PsyAI&#x2122;, a proprietary artificial intelligence (&#x201c;AI&#x201d;) tool. Leveraging
AI systems is expected to reduce the time and cost of pre-clinical, clinical, and commercial development. The Company believes it streamlines
pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities, and pharmacological effects to
help determine ideal drug candidates, tailored to each indication. Each of these molecules that the Company believes are patentable can
then be further screened to see how changes to its makeup alter its effects in order to synthesize additional new molecules. New compounds
of sufficient purity are undergoing pharmacological screening, including non-clinical (receptors/cell lines), preclinical (animal), and
ultimately clinical (human) evaluations. The Company intends to utilize the Psybrary&#x2122; and the AI tool to categorize and characterize
the Psybrary&#x2122; substituents to focus on bringing more non-hallucinogenic neuroplastogen molecules from discovery to the clinical
phase.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company effected a &lt;span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zRUwE7LEfoM5" title="Reverse stock split"&gt;1-for-15&lt;/span&gt;
reverse stock split (&#x201c;Reverse Stock Split&#x201d;) on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025,
pursuant to which every 15 shares of the Company&#x2019;s issued and outstanding common stock were reclassified as one share of
common stock. The Reverse Stock Split had no impact on the par value of the Company&#x2019;s common stock or the authorized number of
shares of common stock. Unless otherwise indicated, all share and per share information in these unaudited condensed consolidated
financial statements are adjusted to reflect the Reverse Stock Split, prior to any rounding of fractional shares. Any fractional
share resulting from the Reverse Stock Split shall be rounded up to the next whole number of shares.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Going
Concern, Liquidity and Other Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has incurred a loss since inception resulting in an accumulated deficit of $&lt;span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_di_c20240930_z9jGJolLfKMf" title="Accumulated deficit"&gt;102,919,859&lt;/span&gt; as of September 30, 2024, and further
losses are anticipated in the development of its business. For the nine months ended September 30, 2024, the Company has operating cash
outflows of $&lt;span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_di_c20240101__20240930_z9GsNF9z32yb" title="Net cash used in operating activities"&gt;6,414,590&lt;/span&gt; and had a loss from operations of $&lt;span id="xdx_90D_eus-gaap--OperatingIncomeLoss_di_c20240101__20240930_znnSIVYeYnSk" title="Loss from operations"&gt;6,458,440&lt;/span&gt;. Being a research and development company, since inception, the Company
has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company&#x2019;s operations have
been funded principally through the issuance of equity. These factors raise substantial doubt about the Company&#x2019;s ability to continue
as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
assessing the Company&#x2019;s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate
sufficient cash flow in the future to support its operating and capital expenditure commitments. At September 30, 2024, the Company had
cash of $&lt;span id="xdx_904_eus-gaap--Cash_iI_c20240930_zbypoEditXxg" title="Cash"&gt;3,111,683&lt;/span&gt; and working capital of $&lt;span id="xdx_908_ecustom--WorkingCapital_iI_c20240930_zT7OOFz3QUDh" title="Working capital"&gt;3,499,093&lt;/span&gt;. The Company&#x2019;s current cash on hand is not sufficient to satisfy its operating
cash needs for the 12 months from the filing of this Quarterly Report on Form 10-Q. These conditions raise substantial doubt regarding
the Company&#x2019;s ability to continue as a going concern for a period of one year after the date the financial statements are issued.
Management&#x2019;s plan to alleviate the conditions that raise substantial doubt include raising additional working capital through public
or private equity or debt financings or other sources, the Purchase Agreement with Lincoln Park (see Note 7), subject to registration,
and may include additional collaborations with third parties as well as disciplined cash spending. Adequate additional financing may
not be available to us on acceptable terms, or at all. Should the Company be unable to raise sufficient additional capital, the Company
may be required to undertake further cost-cutting measures including delaying or discontinuing certain operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of these factors, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as
a going concern for a period of one year after the date of the unaudited condensed consolidated financial statements are issued. The
Company&#x2019;s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome
of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Inflation
Risks&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers the current inflationary trend existing in the North American economic environment reasonably likely to have a material
unfavorable impact on results of continuing operations. Higher rates of price inflation, as compared to recent prior levels of price
inflation, have caused a general increase in the cost of labor and materials. In addition, there is an increased risk of the Company
experiencing labor shortages due to a potential inability to attract and retain human resources due to increased labor costs resulting
from the current inflationary environment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Nasdaq
Notice&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 21, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;)
stating that as of September 30, 2023, the Company did not meet the minimum of $&lt;span id="xdx_90C_ecustom--MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange_iI_c20231121_z28sk83ryZt2" title="Minimum of stockholders equity required for continued listing pursuant to exchange"&gt;2,500,000&lt;/span&gt; in stockholders&#x2019; equity required for
continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). On February 6, 2024, the Company received a letter from Nasdaq, granting
the Company an extension to regain compliance with the minimum stockholders&#x2019; equity requirement by May 20, 2024. On May 21, 2024,
the Company received a letter from Nasdaq notifying the Company that it regained compliance with the minimum stockholders&#x2019; equity
requirement for continued listing on the Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 16, 2024, the Company received a letter from Nasdaq&#x2019;s Listing Qualifications Department stating that because the closing bid
price for the Company&#x2019;s common stock listed on Nasdaq was below $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240516_zLQ7bNdCX64f" title="Shares issued price"&gt;1.00&lt;/span&gt; for 30 consecutive business days, the Company no longer meets
the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the &#x201c;Minimum Bid Price Requirement&#x201d;).
The Company received an initial period of 180 calendar days from May 16, 2024, or until November 12, 2024, to regain compliance with
the Minimum Bid Price Requirement and was unable to regain compliance during that time. The Company has applied for a second 180-day
compliance period. As of the date hereof, the Company has not heard whether it will be granted the second compliance period. The Company
anticipates conducting a reverse split during the first or second quarter of 2025 in order to regain compliance with the Minimum Bid
Price Requirement if the bid price of the Company&#x2019;s common stock fails to close at or above $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231112_zbsvJ8owuw56" title="Shares issued price"&gt;1.00&lt;/span&gt; per share for a minimum of 10
consecutive business days prior the end of the second compliance period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-01-272025-01-27" id="Fact002774">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002776"
      unitRef="USD">-102919859</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002778"
      unitRef="USD">-6414590</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002780"
      unitRef="USD">-6458440</us-gaap:OperatingIncomeLoss>
    <us-gaap:Cash
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002782"
      unitRef="USD">3111683</us-gaap:Cash>
    <ENVB:WorkingCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002784"
      unitRef="USD">3499093</ENVB:WorkingCapital>
    <ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange
      contextRef="AsOf2023-11-21"
      decimals="0"
      id="Fact002786"
      unitRef="USD">2500000</ENVB:MinimumOfStockholdersEquityRequiredForContinuedListingPursuantToExchange>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-05-16"
      decimals="INF"
      id="Fact002788"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-11-12"
      decimals="INF"
      id="Fact002790"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002792">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zaoG89jTuAme" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_82E_z9xYFaUkmv21"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zo1UCk4KVdqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z6QO8pI0anKh"&gt;Basis
of Presentation and Principal of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and Article 8 of Regulation S-X. Accordingly,
they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Management&#x2019;s opinion
is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results
for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year
ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated
financial statements for the year ended December 31, 2023, and related notes thereto included in the Company&#x2019;s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 26, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s significant accounting policies and recent accounting standards are summarized in Note 2 of the Company&#x2019;s consolidated
financial statements for the year ended December 31, 2023. There were no significant changes to these accounting policies during the
three and nine months ended September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zgACgUEtt6Ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zlothHQNIky6"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during
the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements
of changes in such estimates in future periods could be significant. Significant areas requiring management&#x2019;s estimates and assumptions
include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options,
and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development
efforts. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTxTblgKKu1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zClPDxHjeuxe"&gt;Reclassification&lt;/span&gt;
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
reclassifications have been made to the prior period&#x2019;s unaudited condensed consolidated financial statements in order to conform
to the current year presentation. In the prior year, the Company included certain investor related expenses within research and development
on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses
in the current year. This reclassification had no effect on the Company&#x2019;s previously reported results of operations, changes in
equity, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z8ih6xEpJN52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z2bBJpwttRF8"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
inception through September 30, 2024, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#x2019;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended September
30, 2024 and 2023, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the unaudited condensed consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zz9zwYQJZi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zufsvTMwOUZc"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zNxf3Y69sUla" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States and Australia and $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zTIEMpIcZPXf" title="Cash insured amount"&gt;100,000&lt;/span&gt; in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of September 30, 2024, the Company had greater than $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zHuCBoZHjDqi" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at United States financial institutions, greater than
$&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--AU_zZeRB6GLgRU2" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at Australian financial institutions, and less than $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zRH1JuJVWiol" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; at Canadian financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zouRUznD8kTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zzq57QAfXM98"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zr47DZI2OVxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zUgDD5X8Yzl3"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and state returns. The Company&#x2019;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state, and Canadian perspective, the years that remain open to examination are consistent with each jurisdiction&#x2019;s
statute of limitations. The Company receives no tax benefit from operating losses due to a full valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_zVUb3yNkNg7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zb8BN8cj268a"&gt;Research
and Development Tax Incentive Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program,
such that a percentage of the Company&#x2019;s qualifying research and development expenditures are reimbursed by the Australian government,
and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive
is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and
the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the
Company based on available information at the time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zqZrJl4CcVT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z1Lg34EJJ6o5"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the three and nine months ended September 30, 2024
and 2023 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same for both
basic and fully diluted. In accordance with ASC 260 &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;), penny warrants were included
in the calculation of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_z5CVvXWyeztg"&gt;SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three and nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three and nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock"&gt;56,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock"&gt;40,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" style="text-align: right" title="Restricted stock units - vested and unissued"&gt;1,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" style="text-align: right" title="Restricted stock units - vested and unissued"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" style="text-align: right" title="Restricted stock units - unvested"&gt;23,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" style="text-align: right" title="Restricted stock units - unvested"&gt;9,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" style="text-align: right" title="Investment options to purchase shares of common stock"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" style="text-align: right" title="Investment options to purchase shares of common stock"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock"&gt;1,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock"&gt;2,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities"&gt;87,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities"&gt;125,392&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zEtlBi6f4E33" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrJYXhzwvHwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zoAJUH5QYSWi"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently assessing the potential impacts of ASU 2023-07, however as the Company
currently has one reportable segment, does not expect this guidance will not have a material impact on its unaudited condensed consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its unaudited condensed consolidated
financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, Disaggregation of Income Statement Expenses&lt;/i&gt;, that requires public companies to disclose, in interim and reporting periods,
additional information about certain expenses in the financial statements. The ASU is effective for annual periods beginning after December
15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective
basis or retrospective basis. The Company is currently assessing the potential impacts of ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_850_zAVno6KnfT8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002794">&lt;p id="xdx_84D_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zo1UCk4KVdqf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z6QO8pI0anKh"&gt;Basis
of Presentation and Principal of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and Article 8 of Regulation S-X. Accordingly,
they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. Management&#x2019;s opinion
is that all adjustments (consisting of normal accruals) considered necessary for a fair presentation have been included. Operating results
for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year
ending December 31, 2024. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated
financial statements for the year ended December 31, 2023, and related notes thereto included in the Company&#x2019;s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 26, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s significant accounting policies and recent accounting standards are summarized in Note 2 of the Company&#x2019;s consolidated
financial statements for the year ended December 31, 2023. There were no significant changes to these accounting policies during the
three and nine months ended September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-09-30" id="Fact002796">&lt;p id="xdx_842_eus-gaap--UseOfEstimates_zgACgUEtt6Ie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zlothHQNIky6"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during
the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements
of changes in such estimates in future periods could be significant. Significant areas requiring management&#x2019;s estimates and assumptions
include determining the fair value of transactions involving common stock, the valuation of warrants and preferred investment options,
and the valuation of stock-based compensation and accruals associated with third party providers supporting research and development
efforts. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2024-01-01to2024-09-30" id="Fact002798">&lt;p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTxTblgKKu1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zClPDxHjeuxe"&gt;Reclassification&lt;/span&gt;
&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Certain
reclassifications have been made to the prior period&#x2019;s unaudited condensed consolidated financial statements in order to conform
to the current year presentation. In the prior year, the Company included certain investor related expenses within research and development
on the unaudited condensed consolidated statements of operations. These expenses were reclassified to general and administrative expenses
in the current year. This reclassification had no effect on the Company&#x2019;s previously reported results of operations, changes in
equity, or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002800">&lt;p id="xdx_84E_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z8ih6xEpJN52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z2bBJpwttRF8"&gt;Foreign
Currency Translation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
inception through September 30, 2024, the reporting currency of the Company was the United States dollar while the functional currency
of certain of the Company&#x2019;s subsidiaries was the Canadian dollar and Australian dollar. For the reporting periods ended September
30, 2024 and 2023, the Company engaged in a number of transactions denominated in Canadian dollars and Australian dollars. As a result,
the Company is subject to exposure from changes in the exchange rates of the Canadian dollar and Australian dollar against the United
States dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company translates the assets and liabilities of its Canadian subsidiaries and Australian subsidiary into the United States dollar at
the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during
each monthly period. Unrealized translation gains and losses are recorded as foreign currency translation gain (loss), which is included
in the unaudited condensed consolidated statements of shareholders&#x2019; equity as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not entered into any financial derivative instruments that expose it to material market risk, including any instruments designed
to hedge the impact of foreign currency exposures. The Company may, however, hedge such exposure to foreign currency exchange fluctuations
in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Adjustments
that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other comprehensive
loss in the unaudited condensed consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-09-30" id="Fact002802">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zz9zwYQJZi8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zufsvTMwOUZc"&gt;Concentration
of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution,
which at times, may exceed the federal depository insurance coverage of $&lt;span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zNxf3Y69sUla" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; in the United States and Australia and $&lt;span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zTIEMpIcZPXf" title="Cash insured amount"&gt;100,000&lt;/span&gt; in Canada.
The Company has not experienced losses on these accounts, and management believes the Company is not exposed to significant risks on
such accounts. As of September 30, 2024, the Company had greater than $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--US_zHuCBoZHjDqi" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at United States financial institutions, greater than
$&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--AU_zZeRB6GLgRU2" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; at Australian financial institutions, and less than $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20240930__srt--StatementGeographicalAxis__country--CA_zRH1JuJVWiol" title="Cash FDIC insured amount"&gt;100,000&lt;/span&gt; at Canadian financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30_country_US"
      decimals="0"
      id="Fact002804"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30_country_CA"
      decimals="0"
      id="Fact002806"
      unitRef="USD">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30_country_US"
      decimals="0"
      id="Fact002808"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30_country_AU"
      decimals="0"
      id="Fact002810"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30_country_CA"
      decimals="0"
      id="Fact002812"
      unitRef="USD">100000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-09-30" id="Fact002814">&lt;p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zouRUznD8kTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zzq57QAfXM98"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to operations as incurred. Research and development expenses include, among other things, internal
and external costs associated with preclinical development, pre-commercialization manufacturing expenses, and clinical trials. The Company
accrues for costs incurred as the services are being provided by monitoring the status of the trial or services provided and the invoices
received from its external service providers. In the case of clinical trials, a portion of the estimated cost normally relates to the
projected cost to treat a patient in the trials, and this cost is recognized based on the number of patients enrolled in the trial. As
actual costs become known, the Company adjusts its accruals accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002816">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zr47DZI2OVxd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zUgDD5X8Yzl3"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company files U.S. federal and state returns. The Company&#x2019;s foreign subsidiary also files a local tax return in their local jurisdiction.
From a U.S. federal, state, and Canadian perspective, the years that remain open to examination are consistent with each jurisdiction&#x2019;s
statute of limitations. The Company receives no tax benefit from operating losses due to a full valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <ENVB:ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002818">&lt;p id="xdx_84A_ecustom--ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock_zVUb3yNkNg7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zb8BN8cj268a"&gt;Research
and Development Tax Incentive Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, through its wholly-owned subsidiary in Australia, participates in the Australian research and development tax incentive program,
such that a percentage of the Company&#x2019;s qualifying research and development expenditures are reimbursed by the Australian government,
and such incentives are reflected as a reduction of research and development expense. The Australian research and development tax incentive
is recognized when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and
the amount of the consideration can be reliably measured. At each period end, management estimates the reimbursement available to the
Company based on available information at the time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:ResearchAndDevelopmentTaxIncentiveReceivablePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002820">&lt;p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zqZrJl4CcVT5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z1Lg34EJJ6o5"&gt;Net
Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.
Diluted loss per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding
during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options and warrants
(using the treasury stock method). The computation of basic net loss per share for the three and nine months ended September 30, 2024
and 2023 excludes potentially dilutive securities. The computations of net loss per share for each period presented is the same for both
basic and fully diluted. In accordance with ASC 260 &#x201c;Earnings per Share&#x201d; (&#x201c;ASC 260&#x201d;), penny warrants were included
in the calculation of weighted average shares outstanding for the purposes of calculating basic and diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_z5CVvXWyeztg"&gt;SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three and nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three and nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock"&gt;56,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock"&gt;40,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" style="text-align: right" title="Restricted stock units - vested and unissued"&gt;1,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" style="text-align: right" title="Restricted stock units - vested and unissued"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" style="text-align: right" title="Restricted stock units - unvested"&gt;23,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" style="text-align: right" title="Restricted stock units - unvested"&gt;9,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" style="text-align: right" title="Investment options to purchase shares of common stock"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" style="text-align: right" title="Investment options to purchase shares of common stock"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock"&gt;1,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock"&gt;2,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities"&gt;87,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities"&gt;125,392&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zEtlBi6f4E33" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002822">&lt;p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z2e55kdxDApg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Potentially
dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share for the three and
nine months ended September 30, 2024 and 2023 because the effect of their inclusion would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span style="display: none"&gt;&lt;span id="xdx_8B7_z5CVvXWyeztg"&gt;SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240701__20240930_zuJ07zAUkWs9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three and nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20230930_z7A8aRpi4FX8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three and nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zmokY0MzskBf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Warrants to purchase shares of common stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zOxUDNAvhEk6" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock"&gt;56,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseSharesOfCommonStockMember_zi0MbLjSRalc" style="width: 16%; text-align: right" title="Warrants to purchase shares of common stock"&gt;40,660&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zO91bkTAoELa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - vested and unissued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zQbUOnU9egRk" style="text-align: right" title="Restricted stock units - vested and unissued"&gt;1,369&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsVestedAndUnIssuedMember_zIzmSLfDE1ph" style="text-align: right" title="Restricted stock units - vested and unissued"&gt;1,390&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zWWzkaQsFZt" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted stock units - unvested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zgH7ofBaRuA" style="text-align: right" title="Restricted stock units - unvested"&gt;23,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsUnvestedMember_zvwoe2GJooBl" style="text-align: right" title="Restricted stock units - unvested"&gt;9,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zyiuJJSupEIb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment options to purchase shares of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_z4GklwMkE5U9" style="text-align: right" title="Investment options to purchase shares of common stock"&gt;4,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--InvestmentOptionsToPurchaseSharesOfCommonStockMember_zWxwwRWHDqXj" style="text-align: right" title="Investment options to purchase shares of common stock"&gt;71,334&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zM4eDlDArebd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options to purchase shares of common stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zkIo6932KGuf" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock"&gt;1,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsToPurchaseSharesOfCommonStockMember_zV2yDlEga2zd" style="border-bottom: Black 1pt solid; text-align: right" title="Options to purchase shares of common stock"&gt;2,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zflzlUhkkcqc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930_zUJrJACLNvFc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities"&gt;87,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930_z2bi5fGQ19dd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total potentially dilutive securities"&gt;125,392&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002824"
      unitRef="Shares">56308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002827"
      unitRef="Shares">56308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002825"
      unitRef="Shares">40660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_WarrantsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002829"
      unitRef="Shares">40660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact002831"
      unitRef="Shares">1369</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact002834"
      unitRef="Shares">1369</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact002832"
      unitRef="Shares">1390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_RestrictedStockUnitsVestedAndUnIssuedMember"
      decimals="INF"
      id="Fact002836"
      unitRef="Shares">1390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact002838"
      unitRef="Shares">23441</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact002841"
      unitRef="Shares">23441</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact002839"
      unitRef="Shares">9884</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_RestrictedStockUnitsUnvestedMember"
      decimals="INF"
      id="Fact002843"
      unitRef="Shares">9884</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002845"
      unitRef="Shares">4667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002848"
      unitRef="Shares">4667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002846"
      unitRef="Shares">71334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_InvestmentOptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002850"
      unitRef="Shares">71334</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002852"
      unitRef="Shares">1538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002855"
      unitRef="Shares">1538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002853"
      unitRef="Shares">2124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_OptionsToPurchaseSharesOfCommonStockMember"
      decimals="INF"
      id="Fact002857"
      unitRef="Shares">2124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact002859"
      unitRef="Shares">87323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact002862"
      unitRef="Shares">87323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact002860"
      unitRef="Shares">125392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30"
      decimals="INF"
      id="Fact002864"
      unitRef="Shares">125392</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002866">&lt;p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrJYXhzwvHwd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zoAJUH5QYSWi"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2023, the FASB issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;. ASU
2023-07 updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses.
ASU 2023-07 is effective for all entities for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The amendments should be applied retrospectively to all prior periods
presented in the financial statements. The Company is currently assessing the potential impacts of ASU 2023-07, however as the Company
currently has one reportable segment, does not expect this guidance will not have a material impact on its unaudited condensed consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the FASB issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which amends the
disclosure to address investor requests for more transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid information and includes certain other amendments to improve the effectiveness
of income tax disclosures. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024, and early
adoption and retrospective application are permitted. Early adoption is permitted. The Company is currently assessing potential impacts
of ASU 2023-09 and does not expect the adoption of this guidance will have a material impact on its unaudited condensed consolidated
financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation
Disclosures, Disaggregation of Income Statement Expenses&lt;/i&gt;, that requires public companies to disclose, in interim and reporting periods,
additional information about certain expenses in the financial statements. The ASU is effective for annual periods beginning after December
15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective
basis or retrospective basis. The Company is currently assessing the potential impacts of ASU 2024-03.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002868">&lt;p id="xdx_80C_eus-gaap--OtherCurrentAssetsTextBlock_zy8Edp5AHpw6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_824_z7Mg8EsfDSL6"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ziQiCk2t3pPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024 and December 31, 2023, the prepaid expenses and other current assets of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zXzvuaP85kP6" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240930_zcoz1KJCoQJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zapJqSbDhavi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zKrZ6miixm9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;106,138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_zFzvo0W6luq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid value-added taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_zu4goeZGb4h8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zvVKHWyHRBF2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_ziA53GvK8xw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs (see Note 7)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;508,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;567,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zlnv5bhFfkHf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Franchise tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zpwpikb515y3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zodaOt1NZx24" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,226,576&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,293,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zD37GGK6TrR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002870">&lt;p id="xdx_893_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_ziQiCk2t3pPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024 and December 31, 2023, the prepaid expenses and other current assets of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B2_zXzvuaP85kP6" style="display: none"&gt;SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240930_zcoz1KJCoQJ3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zapJqSbDhavi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--PrepaidResearchAndDevelopment_iI_maPEAOAzAne_zKrZ6miixm9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Prepaid research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;106,138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;46,320&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PrepaidTaxes_iI_maPEAOAzAne_zFzvo0W6luq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid value-added taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzAne_zu4goeZGb4h8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249,048&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzAne_zvVKHWyHRBF2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;62,036&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredOfferingCosts_iI_maPEAOAzAne_ziA53GvK8xw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs (see Note 7)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;508,599&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;567,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--PrepaidFranchiseTaxReceivable_iI_maPEAOAzAne_zlnv5bhFfkHf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Franchise tax receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,258&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_maPEAOAzAne_zpwpikb515y3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;R&amp;amp;D tax incentive receivable&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2890"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;145,349&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzAne_zodaOt1NZx24" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,226,576&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,293,554&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <ENVB:PrepaidResearchAndDevelopment
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002872"
      unitRef="USD">106138</ENVB:PrepaidResearchAndDevelopment>
    <ENVB:PrepaidResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002873"
      unitRef="USD">46320</ENVB:PrepaidResearchAndDevelopment>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002875"
      unitRef="USD">245972</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002876"
      unitRef="USD">243429</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002878"
      unitRef="USD">249048</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002879"
      unitRef="USD">149559</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002881"
      unitRef="USD">99061</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002882"
      unitRef="USD">62036</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002884"
      unitRef="USD">508599</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002885"
      unitRef="USD">567603</us-gaap:DeferredOfferingCosts>
    <ENVB:PrepaidFranchiseTaxReceivable
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002887"
      unitRef="USD">17758</ENVB:PrepaidFranchiseTaxReceivable>
    <ENVB:PrepaidFranchiseTaxReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002888"
      unitRef="USD">79258</ENVB:PrepaidFranchiseTaxReceivable>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002891"
      unitRef="USD">145349</ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002893"
      unitRef="USD">1226576</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002894"
      unitRef="USD">1293554</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002896">&lt;p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zAfpxE6QXUl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_827_z685ftKZZ6Og"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zEFiR25itP9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024, the Company&#x2019;s intangible assets consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zdH7GSYv7JN4" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Definite lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20240101__20240930_zXzhU8vRzC1f" style="width: 16%; text-align: right" title="Balance, Definite lived intangible assets"&gt;210,932&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20240101__20240930_zV1sP78Womkd" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization"&gt;(126,564&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20240101__20240930_z44UqjI2pVDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets"&gt;84,368&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zCfuHWIedht1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
identified definite lived intangible assets, there was &lt;span id="xdx_90B_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20240701__20240930_znKeMJJlBwz9" title="Identified definite lived assets, impairment loss"&gt;&lt;span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20240101__20240930_zF4knmIMfKF9" title="Identified definite lived assets, impairment loss"&gt;&lt;span id="xdx_90C_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230701__20230930_zpkuTOMQ2knb" title="Identified definite lived assets, impairment loss"&gt;&lt;span id="xdx_90A_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_do_c20230101__20230930_zUDOg1BlZA8" title="Identified definite lived assets, impairment loss"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment expense during the three and nine months ended September 30, 2024
and 2023. For identified definite lived intangible assets, amortization expense amounted to $&lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20240701__20240930_zFV3U9HSup67" title="Intangible assets, amortization expense"&gt;42,188&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20230930_zT56FTwyHc1c" title="Intangible assets, amortization expense"&gt;42,191&lt;/span&gt; during the three months
ended September 30, 2024 and 2023, respectively and $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20240101__20240930_zYo4XRsyJZDf" title="Intangible assets, amortization expense"&gt;126,564&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930_zoQh7EViEtUe" title="Intangible assets, amortization expense"&gt;126,566&lt;/span&gt; during each of the nine months ended September 30, 2024 and
2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002898">&lt;p id="xdx_897_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zEFiR25itP9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024, the Company&#x2019;s intangible assets consisted of:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zdH7GSYv7JN4" style="display: none"&gt;SCHEDULE OF INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Definite lived intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_d0_c20240101__20240930_zXzhU8vRzC1f" style="width: 16%; text-align: right" title="Balance, Definite lived intangible assets"&gt;210,932&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20240101__20240930_zV1sP78Womkd" style="border-bottom: Black 1pt solid; text-align: right" title="Amortization"&gt;(126,564&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;Balance at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_d0_c20240101__20240930_z44UqjI2pVDl" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, Definite lived intangible assets"&gt;84,368&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002900"
      unitRef="USD">210932</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002902"
      unitRef="USD">126564</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002904"
      unitRef="USD">84368</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002906"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002908"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002910"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002912"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002914"
      unitRef="USD">42188</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002916"
      unitRef="USD">42191</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002918"
      unitRef="USD">126564</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002920"
      unitRef="USD">126566</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002922">&lt;p id="xdx_80E_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmzzL4dR4bRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_822_znSH8hz3Mwm"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoCW0JWr2PTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following assets which are located in Calgary, Canada, with all amounts converted into U.S. dollars:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zyyD3AxBoyy6" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240930_zvOcwkWkXuS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zzAklmbnG9Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zZqbY38VQNO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;819,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zqQ9lVXpV0nh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zkzBYSlzRqa2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, gross &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8mcxSLzQ0W8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(479,899&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(357,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zAksAuwNXz57" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net of accumulated depreciation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;367,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;507,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z7AXiGSFvfN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_908_eus-gaap--Depreciation_c20240701__20240930_zaPojReubAp3" title="Depreciation"&gt;42,626&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Depreciation_c20230701__20230930_zZJVuhP4S3s3" title="Depreciation"&gt;44,105&lt;/span&gt; for the three months ended September 30, 2024 and 2023, respectively and $&lt;span id="xdx_90D_eus-gaap--Depreciation_c20240101__20240930_zBFwsYVXwDVd" title="Depreciation"&gt;128,438&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20230101__20230930_z42pMJ8m9Rf1" title="Depreciation"&gt;132,734&lt;/span&gt; for the
nine months ended September 30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002924">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zoCW0JWr2PTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment consists of the following assets which are located in Calgary, Canada, with all amounts converted into U.S. dollars:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zyyD3AxBoyy6" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT NET OF ACCUMULATED DEPRECIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240930_zvOcwkWkXuS1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20231231_zzAklmbnG9Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zZqbY38VQNO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;819,784&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;836,709&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zqQ9lVXpV0nh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndLeaseholdImprovementsMember_zkzBYSlzRqa2" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, gross &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,804&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,379&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_z8mcxSLzQ0W8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(479,899&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(357,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iI_zAksAuwNXz57" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net of accumulated depreciation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;367,689&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;507,377&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-09-30_custom_LabEquipmentMember"
      decimals="0"
      id="Fact002926"
      unitRef="USD">819784</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LabEquipmentMember"
      decimals="0"
      id="Fact002927"
      unitRef="USD">836709</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-09-30_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact002929"
      unitRef="USD">27804</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact002930"
      unitRef="USD">28379</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-09-30_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact002932"
      unitRef="USD">27804</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_ComputerEquipmentAndLeaseholdImprovementsMember"
      decimals="0"
      id="Fact002933"
      unitRef="USD">28379</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002935"
      unitRef="USD">479899</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002936"
      unitRef="USD">357711</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002938"
      unitRef="USD">367689</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002939"
      unitRef="USD">507377</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact002941"
      unitRef="USD">42626</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002943"
      unitRef="USD">44105</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact002945"
      unitRef="USD">128438</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002947"
      unitRef="USD">132734</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002949">&lt;p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFRpZpKPqIVh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_826_zgQfWA4c3m38"&gt;ACCRUED LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zd1I1uSsF2ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024 and December 31, 2023, the accrued liabilities of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8B6_zNKkwJIlhEh2" style="display: none"&gt;SCHEDULE OF ACCRUED LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240930_zvKzlW1DszQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zcTfVPR5LFYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_z77zAkrTjG7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Product development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;112,346&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zhKdxIdipW0j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued salaries, wages, and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,736&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zMeGRmc97SLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;584,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zddf4tXqrQLj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued restructuring costs (see Note 9)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2962"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_zwDevUv4HwWb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued franchise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2965"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zZWtGIQEPn21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Patent costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zqUxNkAHG3Th" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;253,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zBQUxbyVXfxa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002951">&lt;p id="xdx_89F_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zd1I1uSsF2ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024 and December 31, 2023, the accrued liabilities of the Company consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8B6_zNKkwJIlhEh2" style="display: none"&gt;SCHEDULE OF ACCRUED LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240930_zvKzlW1DszQb" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231_zcTfVPR5LFYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedProductDevelopmentCost_iI_maALCANzEsH_z77zAkrTjG7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Product development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;112,346&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;139,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedSalariesCurrent_iI_maALCANzEsH_zhKdxIdipW0j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued salaries, wages, and bonuses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,736&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedProfessionalFeesCurrent_iI_maALCANzEsH_zMeGRmc97SLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114,068&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;584,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccruedRestructuringCosts_iI_maALCANzEsH_zddf4tXqrQLj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued restructuring costs (see Note 9)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2962"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_maALCANzEsH_zwDevUv4HwWb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued franchise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2965"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,318&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccruedRoyaltiesCurrent_iI_maALCANzEsH_zZWtGIQEPn21" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Patent costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;18,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCANzEsH_zqUxNkAHG3Th" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;253,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,643&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ENVB:AccruedProductDevelopmentCost
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002953"
      unitRef="USD">112346</ENVB:AccruedProductDevelopmentCost>
    <ENVB:AccruedProductDevelopmentCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002954"
      unitRef="USD">139981</ENVB:AccruedProductDevelopmentCost>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002956"
      unitRef="USD">8736</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002957"
      unitRef="USD">8889</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002959"
      unitRef="USD">114068</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002960"
      unitRef="USD">584810</us-gaap:AccruedProfessionalFeesCurrent>
    <ENVB:AccruedRestructuringCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002963"
      unitRef="USD">301645</ENVB:AccruedRestructuringCosts>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002966"
      unitRef="USD">22318</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002968"
      unitRef="USD">18000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002969"
      unitRef="USD">18000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact002971"
      unitRef="USD">253150</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact002972"
      unitRef="USD">1075643</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact002974">&lt;p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zBW9WsdE8dR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_82D_zDM5roETPi27"&gt;SHARE CAPITAL AND OTHER EQUITY INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2023, the Company entered into the Equity Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;), with Canaccord
Genuity LLC (&#x201c;Canaccord&#x201d;), pursuant to which the Company may offer and sell from time to time, through Canaccord as sales
agent and/or principal, shares of common stock of the Company, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zQJjjEt5ONJ2" title="Common stock, par value"&gt;0.01&lt;/span&gt; per share having an aggregate offering price of up to
$&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zjMw7eP4KcRk" title="Common stock, offering price"&gt;10.0&lt;/span&gt; million. Due to the offering limitations applicable to the Company and in accordance with the terms of the Distribution Agreement,
the Company may offer Common Stock having an aggregate gross sales price of up to $&lt;span id="xdx_90E_ecustom--SaleOfStockConsiderationExpectedMaximumPriceOnLimitation_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zCKCnopvvOy7" title="Aggregate gross sales price"&gt;2,392,514&lt;/span&gt; pursuant to the prospectus supplement dated
September 1, 2023 (the &#x201c;Prospectus Supplement&#x201d;). Subject to the terms and conditions of the Distribution Agreement, Canaccord
may sell the Common Stock by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d;. The Company will pay Canaccord
a commission equal to &lt;span id="xdx_90C_ecustom--CommissionPercentage_pid_dp_uPure_c20230901__20230901__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zRmow85qe7q2" title="Commission percentage"&gt;3.0&lt;/span&gt;% of the gross sales price of the Common Stock sold through Canaccord under the Distribution Agreement and has
also agreed to reimburse Canaccord for certain expenses. The Company may also sell Common Stock to Canaccord as principal for Canaccord&#x2019;s
own account at a price agreed upon at the time of sale. Any sale of Common Stock to Canaccord as principal would be pursuant to the terms
of a separate terms agreement between the Company and Canaccord.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2024, the Company issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zw6AOQYVAHNh"&gt;111,200
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock for gross proceeds
of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zbcrmnpiUsFd"&gt;2,392,502
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;under the Distribution Agreement, and charged
offering costs of $&lt;span id="xdx_90B_eus-gaap--PaymentsOfStockIssuanceCosts_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_z9buGjtR9bj3"&gt;583,713
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to additional paid in capital on the unaudited
condensed consolidated balance sheet. As of September 30, 2024 and December 31, 2023, there were deferred offering costs related to the
Distribution Agreement of $&lt;span id="xdx_907_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_z6KdFHopkwa"&gt;0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember__dei--LegalEntityAxis__custom--CanaccordGenuityLLCMember_zdCiYoM7MaUk"&gt;171,944&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. As of September 30, 2024, there is $&lt;span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_z34GOkjig08l"&gt;0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;available under the Distribution Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#x201c;Inducement Letters&#x201d;) with certain
holders (the &#x201c;Holders&#x201d;) of the February 2022 Post-Modification Warrants and RD and PIPE preferred investment options to purchase
shares of the Company&#x2019;s common stock (the &#x201c;Existing Warrants and Investment Options&#x201d;) pursuant to which the Holders
agreed to exercise for cash their Existing Warrants and Investment Options to purchase &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zgg3qk8xjax3" title="Issued shares"&gt;74,800&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock,
in the aggregate, at a reduced exercised price of $&lt;span id="xdx_906_eus-gaap--WarrantExercisePriceDecrease_pid_c20231228__20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MinimumMember_zYly7amKklKg" title="Share price"&gt;20.55&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (from an original exercise price
of $&lt;span id="xdx_90E_eus-gaap--WarrantExercisePriceIncrease_pid_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember__srt--RangeAxis__srt--MaximumMember_zL7iumNRkoZj" title="Share price"&gt;116.70&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share), in exchange for the Company&#x2019;s
agreement to issue new warrants (the &#x201c;Inducement Warrants&#x201d;) to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zrltgSwz1F1k" title="Issued shares"&gt;149,600&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
(the &#x201c;Inducement Warrant Shares&#x201d;), and the Holders to make a cash payment of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231228__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z687gHz4pNT8" title="Cash payment"&gt;1.88&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per Inducement Warrant share for total proceeds
of $280,500&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
In January 2024, the Company received aggregate gross proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_c20240101__20240131_zHapCoYD7L6c" title="Gross proceeds"&gt;1,817,640&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;from the exercise of the Existing Warrants and
Investment Options by the Holders and the sale of the Inducement Warrants. Because the Existing Warrants and Investment Options by the
Holders and the sale of the Inducement Warrants that exercised on December 28, 2023 and unsettled until January 2024, the proceeds are
included in the condensed consolidated balance sheet as a subscription receivable as of December 31, 2023. As of December 31, 2023, &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCBXDGsjb9y9" title="Shares other"&gt;27,867&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Existing Warrants and Investment
Options exercised were considered issued as the Company had the enforceable right to the obtain the cash proceeds, which were in-transit,
and the Holders were no longer able to rescind the exercise election. Due to the beneficial ownership limitation provisions, &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zVEWo3btbQQa" title="Issued shares"&gt;46,934&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Existing Warrants and Investment
Options exercised were initially unissued and held in abeyance for the benefit of the Holder until notice is received from the Holder
that the shares may be issued in compliance with such limitation. During the nine months ended September 30, 2024, the Company issued
all &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_z5TF2UUMp6xj" title="Issued shares"&gt;46,934&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock of the &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zg916ElDyDuj" title="Issued shares"&gt;46,934&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Existing Warrants and Investment
Options exercised that were held in abeyance due to the beneficial ownership limitation provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 28, 2023, the Company entered into warrant exercise inducement offer letters (the &#x201c;Inducement Letters&#x201d;) with certain
holders of warrants and preferred investment options. The Inducement Letters prohibit the Company from entering into any variable rate
transaction as defined in the Inducement Letters, including the issuance of (1) any variable priced debt or equity securities or (2)
transactions whereby the Company may issue securities at a future determined price, such as through an at-the-market offering or an equity
line of credit. The variable rate transaction restriction would have expired after six-months from the closing date of December 28, 2023
for the Inducement Letters for an issuance through an at-the-market offering, and one-year for the remaining variable rate transactions,
however the restriction was waived for the at-the-market offering on March 8, 2024 and the equity line on May 3, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 8, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering
of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20240308__us-gaap--ClassOfWarrantOrRightAxis__custom--FebruaryWarrantsMember_zjYNro7XO5I9" title="Issued shares"&gt;15,246&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock
to the Holders of the Inducement Warrants. The issuance was made in exchange for the permanent and irrevocable waiver of the variable
rate transaction limitation solely with respect to the entry into and/or issuance of shares of common stock in an at the market offering
contained in the Inducement Letters. The fair value of the shares issued for consideration of waiving the variable rate transaction limitation
was $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240308__20240308__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zi4HdS5ztZV4" title="Shares issued value"&gt;322,453&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and was charged to additional paid in capital,
as it is direct and incremental to the Distribution Agreement, on the unaudited condensed consolidated balance sheet as an offering cost
related to the Distribution Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Lincoln
Park Equity Line&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 3, 2023, the Company entered into a Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) and a registration rights agreement
(the &#x201c;Registration Rights Agreement&#x201d;), with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant to which
Lincoln Park has committed to purchase up to $&lt;span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zp8ZcmoueLP7" title="Repurchase of common stock"&gt;10.0&lt;/span&gt; million of the Company&#x2019;s common stock subject to certain limitations and satisfaction
of the conditions set forth in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln
Park, and Lincoln Park is obligated to purchase up to $&lt;span id="xdx_902_eus-gaap--PaymentsForRepurchaseOfCommonStock_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zUYzst4x5SUf" title="Purchase committment"&gt;10.0&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million of the Company&#x2019;s Common Stock (the
&#x201c;Purchase Shares&#x201d;). However, such sales of Common Stock by the Company, if any, will be subject to important limitations
set forth in the Purchase Agreement, including limitations on number of shares that may be sold. Sales may occur from time to time, at
the Company&#x2019;s sole discretion, over the 24-month period commencing on the date that the conditions to Lincoln Park&#x2019;s purchase
obligation set forth in the Purchase Agreement are satisfied, including that a registration statement on Form S-1 covering the resale
of the shares of the Company&#x2019;s Common Stock that have been and may be issued to Lincoln Park under the Purchase Agreement, which
the Company has filed with the SEC pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus
relating thereto is filed with the SEC. As required under the Purchase Agreement, the Company registered a resale of &lt;span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zshD4nkGDZ" title="Shares resale"&gt;76,032&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of our common stock, plus the &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodCommitmentShares_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zUdTF7KnqAw7" title="Shares commitment"&gt;9,294&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;commitment shares, by Lincoln Park on a registration
statement on Form S-1 dated November 8, 2023, which was declared effective by the SEC on December 5, 2023. As of July 30, 2024, there
were no remaining shares available to be issued in connection with this registration statement. On September 4, 2024, the Company filed
an amended Form S-1, which was declared effective by the SEC on September 11, 2024. The amended Form S-1 registered an additional &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zPkT5CXxYAD4" title="Shares Issues"&gt;326,667&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock that are available
to be issued to Lincoln Park in connection with this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Because
the purchase price per share to be paid by Lincoln Park for the shares of Common Stock that the Company may elect to sell to Lincoln
Park under the Purchase Agreement, if any, will fluctuate based on the market prices of the Company&#x2019;s Common Stock at the time
the Company elects to sell shares to Lincoln Park pursuant to the Purchase Agreement, if any, it is not possible for us to predict the
number of shares of Common Stock that the Company will sell to Lincoln Park under the Purchase Agreement, the purchase price per share
that Lincoln Park will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that the Company
will receive from those purchases by Lincoln Park under the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 3, 2024, the Company entered into a series of common stock purchase agreements for the issuance in a registered direct offering of
an aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_z9RGlP2zcVE4" title="Shares issued"&gt;30,534&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock,
to certain institutional investors. The issuance was made in exchange for the permanent and irrevocable waiver of the variable rate transaction
limitation with respect to any existing or future agreement by the Company to effect any issuance of shares and issue such shares thereunder,
as contained in those certain Inducement Offer Letters, dated December 28, 2023, between the Company and those certain institutional
investors. The Company will not receive any net proceeds in connection with the offering. The fair value of the shares issued for consideration
of waiving the variable rate transaction limitation was $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zauMQSNDqcY1" title="Issued stock value"&gt;448,840&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and was recorded as deferred offering costs,
as direct and incremental to the Purchase Agreement, within prepaid expenses and other current assets on the unaudited condensed consolidated
balance sheet related to the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock purchase agreements contain customary representations and warranties and certain indemnification obligations of the Company.
The common stock purchase agreements also restrict the Company from issuing, entering into any agreement to issue, or announcing the
issuance of the Company&#x2019;s common stock from the date of the common stock purchase agreements until the earlier of 30 days after
entering into the agreements or at such time as one million (&lt;span id="xdx_900_ecustom--NumberOfCommonStockSharesTraded_pid_c20240503__20240503__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zJkk6Fppt4he" title="Number of shares traded in market"&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of the Company&#x2019;s common stock have
traded in the open market. The closing of the issuance of the Shares pursuant to the common stock purchase agreements closed on May 3,
2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and nine months ended September 30, 2024, the Company had issued &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zAOUCLVuKtYj" title="Issued shares"&gt;72,699&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_z0t8SV8NVqSi" title="Issued shares"&gt;81,033&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock, respectively, through
the Purchase Agreement for gross cash proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zXpw4CYe2v51" title="Proceeds from common stock"&gt;517,836&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zhpbJl87Coyd" title="Proceeds from common stock"&gt;600,686&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. During the three and nine months ended September 30, 2024, the Company charged offering costs of $&lt;span id="xdx_90E_ecustom--CommonStockEquityDistributionCosts_c20240701__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zIVdRvqS6kge" title="Deferred offering costs"&gt;290,029&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90B_ecustom--CommonStockEquityDistributionCosts_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zOsq11v9Qzn3" title="Deferred offering costs"&gt;372,879&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, to additional paid in capital on the unaudited condensed consolidated balance sheet. As of September 30, 2024 and December
31, 2023, the Company has capitalized deferred offering costs of $&lt;span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zBNHG6DEuaXa" title="Offering costs"&gt;508,599&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zxaEsNtxbjE4" title="Offering costs"&gt;395,660&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively. As of September 30, 2024, there were &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember_zpPIvOsSmdR7" title="Issued shares"&gt;321,667&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares available to be issued in connection
with the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Amendment
to 2020 Long-Term Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 2, 2023, the stockholders approved the amendments to the 2020 Long-Term Incentive Plan, which was approved by the Board on August
8, 2023 (the &#x201c;Amended Incentive Plan&#x201d;). The Amended Incentive Plan (i) increased the number of authorized shares reserved
for issuance under the Amended Incentive Plan to a maximum of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231102__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember_zzGuhpjBd435" title="Authorized shares reserved"&gt;23,334&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;subject to equitable adjustment, and (ii) removed
the Evergreen Provision implemented in the Plan Amendment. During the first quarter of 2024, the Board approved an equitable adjustment
to increase the number of shares available under the Plan by &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardMember_zaJLbhjnWrX5" title="Shares available for grant"&gt;8,986&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares. As of September 30, 2024, the total
number of shares available for grant under the Incentive Plan was &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandTwentyLongTermIncentivePlanMember__srt--TitleOfIndividualAxis__custom--BoardMember_z8UIRa1rkCo1" title="Shares available for grant"&gt;418&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z67kgDeUvC4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity under the Company&#x2019;s incentive plan for the nine months ended September 30, 2024 is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z3alfNBYzdpj" style="display: none"&gt;SCHEDULE OF STOCK OPTION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; padding-bottom: 1pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zZW4nPRH5Mh3" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of shares, outstanding at beginning"&gt;2,022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zAPsEeKm3Wsi" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, outstanding at beginning"&gt;857.55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930_zdSYfF4AjHx6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, outstanding at beginning"&gt;1,158.30&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zmJUkZMdSS5" title="Weighted average remaining contractual term, outstanding balance"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_z6DDR6QXTCol" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930_zGyDNncyr5zd" style="text-align: right" title="Number of shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3066"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zdXm97VM8Oqj" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3068"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zVr3xDBu5KQ7" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zCk41xdSAlQc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zAtJuWhyGd0c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;590.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zOdybsNqZRfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;810.30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_ztGb06PyFRPh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, outstanding at end"&gt;1,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zOJratgg199g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end"&gt;941.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zPgNtNP9oxsh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, outstanding at end"&gt;1,267.65&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwyipFQlqdic" title="Weighted average remaining contractual term, outstanding balance"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_zCRR4NZamkL9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, outstanding at end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3086"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_z6UC9WKyhkK9" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end"&gt;1,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zvPkT2It5xdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end"&gt;979.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zy4Bot6yFpwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable"&gt;1,319.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zdxHrNr9o8Xk" title="Weighted average remaining contractual term, exercisable"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zRjNsH3idAti" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zsC91P5ApZF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock based compensation expense, recorded within general and administrative expense in the unaudited condensed consolidated
statement of operations and comprehensive loss, related to stock options for the three months ended September 30, 2024 and 2023 was $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSCA63e3bYTb" title="Stock based compensation expense"&gt;414&lt;/span&gt;
and $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zqjzV3BM2Dj4" title="Stock based compensation expense"&gt;44,606&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s stock-based compensation expense, recorded within general and administrative expense, related to stock options for the
nine months ended September 30, 2024 and 2023 was $(&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zYCgz05w29af" title="Stock based compensation expense"&gt;5,854&lt;/span&gt;) and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVrs83ruFYhb" title="Stock based compensation expense"&gt;147,067&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2024, the Company had $&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZGM38My6z95" title="Unamortized stock option expense"&gt;2,346&lt;/span&gt; in unamortized stock option expense, which will be recognized over a weighted average period
of &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLCZ7PjsyzI2" title="Weighted average period"&gt;1.40&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Issuance
of Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zoide0sTJXC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activity in restricted stock units was as follows for the nine months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zQpY2rCnrVg8" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Non-vested at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSDvnYRjVNsa" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning"&gt;9,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1F1H1syKVd" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;434.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkidLJxfe9Q7" style="text-align: right" title="Number of shares, Granted"&gt;16,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3neHKhmj2c" style="text-align: right" title="Weighted average fair value, Granted"&gt;12.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3Vg6jd5reqj" style="text-align: right" title="Number of shares, Forfeited"&gt;(650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAmEm1RiI2tg" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;43.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTolNPfIHg9j" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested"&gt;(2,042&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zph55MgT0j7d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;333.30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVQeX1FIO7Xc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending"&gt;23,441&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTVyBNeKeyEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending"&gt;152.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z8HprySXCdfa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three months ended September 30, 2024 and 2023, the Company recorded $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zA03ksBXys6h"&gt;369,200
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zupmoATWHKqa"&gt;328,253&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss. For the
nine months ended September 30, 2024 and 2023, the Company recorded $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zsUIxLYL4Eja"&gt;1,096,570
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGzAAvu3Pd9"&gt;1,638,365&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;,
respectively, in stock-based compensation expense related to restricted stock units, which is a component of both general and administrative
and research and development expenses in the condensed consolidated statement of operations and comprehensive loss. As of September 30,
2024, the Company had unamortized stock-based compensation costs related to restricted stock units of $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zhRCjZ6b2pc7"&gt;1,109,526
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;which will be recognized over a weighted average
period of &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4M3FziNZl4k"&gt;1.57
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;years. As of September 30, 2024, &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUV73LUkgLz9"&gt;1,369
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units are vested without
shares of common stock being issued, with all of these shares due as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zTOfSM9LLUo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s recognition of stock-based compensation for restricted stock units for the following periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B0_zUqL5Ly2R5Wg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240701__20240930_zmodFPmdDlIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230701__20230930_zs4PFiYdjkd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_zmf0cVH1oD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20230930_zZEsJ47Nk5Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended September&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended September&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKUvRCyrlXe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;162,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;101,607&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;476,513&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;946,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy5GdtVHSVb2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;207,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;226,646&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,057&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;691,514&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zH3A95M0sis8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;369,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;328,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,570&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,638,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_zIQQsMnjkR3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation
    expense for RSUs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;369,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;328,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,570&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,638,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_z7vtTMy7sp51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants
and Preferred Investment Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zRDuE51nVwug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about shares issuable under warrants outstanding at September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_z71NbaE89wo7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE OF WARRANTS OUTSTANDING&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk17tpUEWLX" style="width: 12%; text-align: right" title="Warrant shares outstanding at beginning"&gt;186,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq56AKA0bj4h" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding at beginning"&gt;176.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUDMMylc2Y6" title="Weighted average remaining life, outstanding"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztviImRtgzRi" style="width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3169"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLbx3ZUsJf3b" style="text-align: right" title="Warrant shares outstanding,expired"&gt;(39&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfKAFC3BlLMa" style="text-align: right" title="Weighted average exercise price, expired"&gt;2,400.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQCb5deT9I3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, exercised"&gt;(130,267&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAy3hDRC9Wj5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;20.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziYaK0NDJNMe" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end"&gt;56,308&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA2daHh19Sa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end"&gt;536.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrcQaXQIW2If" title="Weighted average remaining life, outstanding"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z80MZv9WG0j2" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEU0VfgR2f3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, exercisable"&gt;56,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKD79Pj5ptJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;536.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Gvlbmlniod" title="Weighted average remaining life, exercisable"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wRhNTAjbr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3193"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zG86r2zijGTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRHQg5nAtHC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about investment options outstanding at September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zpBIF7iGXfLf" style="display: none"&gt;SCHEDULE OF   INVESTMENT OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Investment options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; padding-bottom: 1pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7C4CTJ0as81" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment options outstanding, beginning"&gt;4,667&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zwpju5CZtKp8" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted average exercise price, issued"&gt;150.00&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_ziyuoHOnTHS7" title="Weighted average remaining life, outstanding"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zpqBJPNNsSzc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3203"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zrCGOj1W0Is1" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zZ4hyedUtGYe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, issued"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zU4T0rv80XJl" title="Weighted average remaining life, outstanding"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zAZK6Fg6sJZ3" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3211"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zRhtKwHprZp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, exercisable"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z3GskQ71Ikse"&gt;150.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zmmJiJ55bMeg" title="Weighted average remaining life, exercisable"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zcGeBdKJuGgj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3218"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zZrTU04wDWBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact002976"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="-5"
      id="Fact002978"
      unitRef="USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact002980"
      unitRef="USD">2392514</ENVB:SaleOfStockConsiderationExpectedMaximumPriceOnLimitation>
    <ENVB:CommissionPercentage
      contextRef="From2023-09-012023-09-01_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact002982"
      unitRef="Pure">0.030</ENVB:CommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="INF"
      id="Fact002983"
      unitRef="Shares">111200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact002984"
      unitRef="USD">2392502</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-01-012024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact002985"
      unitRef="USD">583713</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-09-30_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact002986"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31_custom_DistributionAgreementMember_custom_CanaccordGenuityLLCMember"
      decimals="0"
      id="Fact002987"
      unitRef="USD">171944</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-09-30_custom_DistributionAgreementMember"
      decimals="0"
      id="Fact002988"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact002990"
      unitRef="Shares">74800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="From2023-12-282023-12-28_custom_FebruaryWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002992"
      unitRef="USDPShares">20.55</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2023-01-012023-12-31_custom_FebruaryWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002994"
      unitRef="USDPShares">116.70</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact002996"
      unitRef="Shares">149600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-28_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact002998"
      unitRef="USDPShares">1.88</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-01-012024-01-31"
      decimals="0"
      id="Fact003000"
      unitRef="USD">1817640</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact003002"
      unitRef="Shares">27867</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2023-12-31_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact003004"
      unitRef="Shares">46934</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-09-30_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact003006"
      unitRef="Shares">46934</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-09-30_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact003008"
      unitRef="Shares">46934</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2024-03-08_custom_FebruaryWarrantsMember"
      decimals="INF"
      id="Fact003010"
      unitRef="Shares">15246</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-03-082024-03-08_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact003012"
      unitRef="USD">322453</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="-5"
      id="Fact003014"
      unitRef="USD">10000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="-5"
      id="Fact003016"
      unitRef="USD">10000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="INF"
      id="Fact003018"
      unitRef="Shares">76032</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <ENVB:StockIssuedDuringPeriodCommitmentShares
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="INF"
      id="Fact003020"
      unitRef="Shares">9294</ENVB:StockIssuedDuringPeriodCommitmentShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-11-032023-11-03_custom_RegistrationRightsAgreementMember"
      decimals="INF"
      id="Fact003022"
      unitRef="Shares">326667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-05-032024-05-03_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact003024"
      unitRef="Shares">30534</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-05-032024-05-03_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact003026"
      unitRef="USD">448840</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ENVB:NumberOfCommonStockSharesTraded
      contextRef="From2024-05-032024-05-03_custom_PurchaseAgreementsMember"
      decimals="INF"
      id="Fact003028"
      unitRef="Shares">1000000</ENVB:NumberOfCommonStockSharesTraded>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-07-012024-09-30_custom_PurchaseAgreementsMember"
      decimals="INF"
      id="Fact003030"
      unitRef="Shares">72699</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementsMember"
      decimals="INF"
      id="Fact003032"
      unitRef="Shares">81033</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-07-012024-09-30_custom_PurchaseAgreementsMember"
      decimals="0"
      id="Fact003034"
      unitRef="USD">517836</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementsMember"
      decimals="0"
      id="Fact003036"
      unitRef="USD">600686</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ENVB:CommonStockEquityDistributionCosts
      contextRef="From2024-07-012024-09-30_custom_PurchaseAgreementsMember"
      decimals="0"
      id="Fact003038"
      unitRef="USD">290029</ENVB:CommonStockEquityDistributionCosts>
    <ENVB:CommonStockEquityDistributionCosts
      contextRef="From2024-01-012024-09-30_custom_PurchaseAgreementsMember"
      decimals="0"
      id="Fact003040"
      unitRef="USD">372879</ENVB:CommonStockEquityDistributionCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2024-09-30_custom_PurchaseAgreementsMember"
      decimals="0"
      id="Fact003042"
      unitRef="USD">508599</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31_custom_PurchaseAgreementsMember"
      decimals="0"
      id="Fact003044"
      unitRef="USD">395660</us-gaap:DeferredOfferingCosts>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_custom_PurchaseAgreementsMember"
      decimals="INF"
      id="Fact003046"
      unitRef="Shares">321667</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-11-02_custom_TwoThousandTwentyLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact003048"
      unitRef="Shares">23334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember"
      decimals="INF"
      id="Fact003050"
      unitRef="Shares">8986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-09-30_custom_TwoThousandTwentyLongTermIncentivePlanMember_custom_BoardMember"
      decimals="INF"
      id="Fact003052"
      unitRef="Shares">418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003054">&lt;p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z67kgDeUvC4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the stock option activity under the Company&#x2019;s incentive plan for the nine months ended September 30, 2024 is presented
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z3alfNBYzdpj" style="display: none"&gt;SCHEDULE OF STOCK OPTION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; padding-bottom: 1pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zZW4nPRH5Mh3" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Number of shares, outstanding at beginning"&gt;2,022&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930_zAPsEeKm3Wsi" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average exercise price, outstanding at beginning"&gt;857.55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930_zdSYfF4AjHx6" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Weighted average grant date fair value, outstanding at beginning"&gt;1,158.30&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 10%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zmJUkZMdSS5" title="Weighted average remaining contractual term, outstanding balance"&gt;3.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20240101__20240930_z6DDR6QXTCol" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20240930_zGyDNncyr5zd" style="text-align: right" title="Number of shares, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3066"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zdXm97VM8Oqj" style="text-align: right" title="Weighted average exercise price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3068"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zVr3xDBu5KQ7" style="text-align: right" title="Weighted average grant date fair value, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3070"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20240930_zCk41xdSAlQc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, forfeited"&gt;(484&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930_zAtJuWhyGd0c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, forfeited"&gt;590.25&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20240930_zOdybsNqZRfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, forfeited"&gt;810.30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_ztGb06PyFRPh" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, outstanding at end"&gt;1,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zOJratgg199g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end"&gt;941.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zPgNtNP9oxsh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value, outstanding at end"&gt;1,267.65&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zwyipFQlqdic" title="Weighted average remaining contractual term, outstanding balance"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20240101__20240930_zCRR4NZamkL9" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate intrinsic value, outstanding at end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3086"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20240930_z6UC9WKyhkK9" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable shares at end"&gt;1,477&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930_zvPkT2It5xdh" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable weighted average price at end"&gt;979.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930_zy4Bot6yFpwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, exercisable"&gt;1,319.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zdxHrNr9o8Xk" title="Weighted average remaining contractual term, exercisable"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20240101__20240930_zRjNsH3idAti" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact003056"
      unitRef="Shares">2022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact003058"
      unitRef="USDPShares">857.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact003060"
      unitRef="USDPShares">1158.30</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-012023-12-31" id="Fact003062">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact003072"
      unitRef="Shares">484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact003074"
      unitRef="USDPShares">590.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-09-30"
      decimals="INF"
      id="Fact003076"
      unitRef="USDPShares">810.30</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact003078"
      unitRef="Shares">1538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact003080"
      unitRef="USDPShares">941.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact003082"
      unitRef="USDPShares">1267.65</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-01-01to2024-09-30" id="Fact003084">P2Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact003088"
      unitRef="Shares">1477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact003090"
      unitRef="USDPShares">979.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact003092"
      unitRef="USDPShares">1319.70</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-01-01to2024-09-30" id="Fact003094">P2Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact003098"
      unitRef="USD">414</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact003100"
      unitRef="USD">44606</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact003102"
      unitRef="USD">5854</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact003104"
      unitRef="USD">147067</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      id="Fact003106"
      unitRef="USD">2346</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-09-30_us-gaap_EmployeeStockOptionMember"
      id="Fact003108">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003110">&lt;p id="xdx_89E_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zoide0sTJXC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s activity in restricted stock units was as follows for the nine months ended September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zQpY2rCnrVg8" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS AND AWARDS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%"&gt;Non-vested at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSDvnYRjVNsa" style="width: 16%; text-align: right" title="Number of shares, Non-vested beginning"&gt;9,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1F1H1syKVd" style="width: 16%; text-align: right" title="Weighted average fair value, Non-vested beginning"&gt;434.55&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkidLJxfe9Q7" style="text-align: right" title="Number of shares, Granted"&gt;16,767&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3neHKhmj2c" style="text-align: right" title="Weighted average fair value, Granted"&gt;12.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3Vg6jd5reqj" style="text-align: right" title="Number of shares, Forfeited"&gt;(650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAmEm1RiI2tg" style="text-align: right" title="Weighted average fair value, Forfeited"&gt;43.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTolNPfIHg9j" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, vested"&gt;(2,042&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zph55MgT0j7d" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average fair value, Vested"&gt;333.30&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Non-vested at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVQeX1FIO7Xc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, non-vested ending"&gt;23,441&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTVyBNeKeyEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average fair value, Non-vested ending"&gt;152.55&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003112"
      unitRef="Shares">9366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003114"
      unitRef="USDPShares">434.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003116"
      unitRef="Shares">16767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003118"
      unitRef="USDPShares">12.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003120"
      unitRef="Shares">650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003122"
      unitRef="USDPShares">43.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003124"
      unitRef="Shares">2042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003126"
      unitRef="USDPShares">333.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003128"
      unitRef="Shares">23441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact003130"
      unitRef="USDPShares">152.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003131"
      unitRef="USD">369200</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003132"
      unitRef="USD">328253</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003133"
      unitRef="USD">1096570</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003134"
      unitRef="USD">1638365</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact003135"
      unitRef="USD">1109526</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="Fact003136">P1Y6M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact003137"
      unitRef="Shares">1369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003139">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zTOfSM9LLUo6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s recognition of stock-based compensation for restricted stock units for the following periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B0_zUqL5Ly2R5Wg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF STOCK-BASED COMPENSATION FOR RESTRICTED STOCK UNITS&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240701__20240930_zmodFPmdDlIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230701__20230930_zs4PFiYdjkd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_zmf0cVH1oD9a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20230930_zZEsJ47Nk5Sd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended September&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended September&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Stock-based compensation expense for RSUs:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zKUvRCyrlXe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;162,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;101,607&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;476,513&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;946,851&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zy5GdtVHSVb2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;207,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;226,646&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;620,057&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;691,514&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_zH3A95M0sis8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;369,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;328,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,570&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,638,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_zIQQsMnjkR3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Stock-based compensation
    expense for RSUs&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;369,200&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;328,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,096,570&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,638,365&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact003141"
      unitRef="USD">162042</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact003142"
      unitRef="USD">101607</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact003143"
      unitRef="USD">476513</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact003144"
      unitRef="USD">946851</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact003146"
      unitRef="USD">207158</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact003147"
      unitRef="USD">226646</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact003148"
      unitRef="USD">620057</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact003149"
      unitRef="USD">691514</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact003151"
      unitRef="USD">369200</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact003152"
      unitRef="USD">328253</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact003153"
      unitRef="USD">1096570</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact003154"
      unitRef="USD">1638365</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact003156"
      unitRef="USD">369200</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact003157"
      unitRef="USD">328253</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact003158"
      unitRef="USD">1096570</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact003159"
      unitRef="USD">1638365</us-gaap:AllocatedShareBasedCompensationExpense>
    <ENVB:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003161">&lt;p id="xdx_893_ecustom--ScheduleOfWarrantsOutstandingTableTextBlock_zRDuE51nVwug" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about shares issuable under warrants outstanding at September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_z71NbaE89wo7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE OF WARRANTS OUTSTANDING&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrant shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk17tpUEWLX" style="width: 12%; text-align: right" title="Warrant shares outstanding at beginning"&gt;186,614&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zq56AKA0bj4h" style="width: 12%; text-align: right" title="Weighted average exercise price, outstanding at beginning"&gt;176.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUDMMylc2Y6" title="Weighted average remaining life, outstanding"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztviImRtgzRi" style="width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3169"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLbx3ZUsJf3b" style="text-align: right" title="Warrant shares outstanding,expired"&gt;(39&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfKAFC3BlLMa" style="text-align: right" title="Weighted average exercise price, expired"&gt;2,400.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQCb5deT9I3g" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding, exercised"&gt;(130,267&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAy3hDRC9Wj5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;20.55&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziYaK0NDJNMe" style="border-bottom: Black 1pt solid; text-align: right" title="Warrant shares outstanding at end"&gt;56,308&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhA2daHh19Sa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, outstanding at end"&gt;536.70&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrcQaXQIW2If" title="Weighted average remaining life, outstanding"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z80MZv9WG0j2" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEU0VfgR2f3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant shares outstanding, exercisable"&gt;56,308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKD79Pj5ptJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;536.70&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4Gvlbmlniod" title="Weighted average remaining life, exercisable"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5wRhNTAjbr5" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3193"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ENVB:ScheduleOfWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003163"
      unitRef="Shares">186614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003165"
      unitRef="USDPShares">176.85</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      id="Fact003167">P4Y7M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003171"
      unitRef="Shares">39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003173"
      unitRef="USDPShares">2400.00</ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003175"
      unitRef="Shares">130267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003177"
      unitRef="USDPShares">20.55</ENVB:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003179"
      unitRef="Shares">56308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003181"
      unitRef="USDPShares">536.70</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      id="Fact003183">P3Y</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003187"
      unitRef="Shares">56308</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact003189"
      unitRef="USDPShares">536.70</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      id="Fact003191">P3Y</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003195">&lt;p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zRHQg5nAtHC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes information about investment options outstanding at September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zpBIF7iGXfLf" style="display: none"&gt;SCHEDULE OF   INVESTMENT OPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Investment options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted average remaining life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; padding-bottom: 1pt"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z7C4CTJ0as81" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment options outstanding, beginning"&gt;4,667&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zwpju5CZtKp8" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Weighted average exercise price, issued"&gt;150.00&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_ziyuoHOnTHS7" title="Weighted average remaining life, outstanding"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iS_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zpqBJPNNsSzc" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Intrinsic value, outstanding beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3203"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zrCGOj1W0Is1" style="border-bottom: Black 1pt solid; text-align: right" title="Investment options outstanding, end"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zZ4hyedUtGYe" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, issued"&gt;150.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zU4T0rv80XJl" title="Weighted average remaining life, outstanding"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsAggregateIntrinsicValueNonvested_iE_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zAZK6Fg6sJZ3" style="border-bottom: Black 1pt solid; text-align: right" title="Intrinsic value, outstanding end"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3211"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zRhtKwHprZp3" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment options outstanding, exercisable"&gt;4,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_z3GskQ71Ikse"&gt;150.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption_dtY_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zmmJiJ55bMeg" title="Weighted average remaining life, exercisable"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsExercisableAggregateIntrinsicValueNonvested_iI_c20240930__us-gaap--StatementEquityComponentsAxis__custom--InvestmentOptionsMember_zcGeBdKJuGgj" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3218"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact003197"
      unitRef="Shares">4667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice
      contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact003199"
      unitRef="USDPShares">150.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExerciseIssuedPrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_custom_InvestmentOptionsMember"
      id="Fact003201">P4Y1M6D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact003205"
      unitRef="Shares">4667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact003207"
      unitRef="USDPShares">150.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsMember"
      id="Fact003209">P2Y10M24D</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber
      contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact003213"
      unitRef="Shares">4667</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber>
    <ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_custom_InvestmentOptionsMember"
      decimals="INF"
      id="Fact003214"
      unitRef="USDPShares">150.00</ENVB:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice>
    <ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption
      contextRef="From2024-01-012024-09-30_custom_InvestmentOptionsMember"
      id="Fact003216">P2Y10M24D</ENVB:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1NonOption>
    <ENVB:LicensingAgreementsDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003220">&lt;p id="xdx_806_ecustom--LicensingAgreementsDisclosureTextBlock_zG52ebE7ez33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_824_zObb3gdTRkdk"&gt;LICENSING AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.35pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 10, 2024, Akos entered into an Exclusive License Agreement (the &#x201c;License Agreement&#x201d;) with Aries Science and Technology,
LLC, an Ohio limited liability company (&#x201c;Aries&#x201d;), pursuant to which Akos granted Aries a license of Akos&#x2019;s patented
radiation dermatitis topical product. The license allows Akos to use the patented formulation to develop pharmaceutical or non-pharmaceutical
products for treating radiation dermatitis suitable for administration to humans or animals. The license is exclusive (subject to certain
exceptions contained in the License Agreement), worldwide, royalty-bearing, and includes the right to sublicense. Akos is entitled to
potential license payments, milestone payments and royalties based on net revenues of the Licensed Product on a licensed product-by-licensed
product and country-by-country basis pursuant to the terms of the Agreement. Aries has the option during the license term, to purchase
the rights to each licensed product (on a licensed product-by-licensed product basis) in the form of an exclusive (as to the applicable
licensed product), fully paid, transferable right and license to the licensed product.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not earned any revenue related to this agreement as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ENVB:LicensingAgreementsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003222">&lt;p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zLh9T8RDzKTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_82D_zwhFZNaJSV1b"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is periodically involved in legal proceedings, legal actions and claims arising in the normal course of business. Management
believes that the outcome of such legal proceedings, legal actions and claims will not have a significant adverse effect on the Company&#x2019;s
financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Australian
Subsidiary Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 23, 2023, the Company issued a press release announcing the selection of Australian CRO, Avance Clinical, in preparation for Phase
1 Study of EB-002, the Company&#x2019;s lead candidate targeting the treatment of anxiety disorders. Under the agreement, Avance Clinical
will manage the Phase 1 clinical trial of EB-002 in coordination with the Company&#x2019;s newly established Australian subsidiary, Enveric
Therapeutics Pty, Ltd. The Phase 1 clinical trial is designed as a multi-cohort, dose-ascending study to measure the safety and tolerability
of EB-002. EB-002, a next-generation proprietary psilocin prodrug, has been recognized as a New Chemical Entity (NCE) by Australia&#x2019;s
Therapeutic Goods Administration and is currently in preclinical development targeting the treatment of anxiety disorder. The total cost
of the Avance Clinical contract is approximately &lt;span id="xdx_906_eus-gaap--CapitalizedContractCostNet_iI_uAUD_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zQ2Bv8HIf6i3" title="Contract cost"&gt;3,400,000&lt;/span&gt; AUD, which translates to approximately $&lt;span id="xdx_904_eus-gaap--CapitalizedContractCostNet_iI_uUSD_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zzF4cy903UQk" title="Contract cost"&gt;2,329,000&lt;/span&gt; USD as of September 30,
2024. As of September 30, 2024, the Company has paid 100% of the Avance Clinical contract costs and has $&lt;span id="xdx_90B_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z8i7qjxAl014" title="Prepaid assets"&gt;0&lt;/span&gt; recorded as prepaid
assets within prepaid and other current assets, accrued $&lt;span id="xdx_905_eus-gaap--AccruedLiabilitiesCurrent_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_z8l8kIySOmok" title="Accrued liabilities"&gt;0&lt;/span&gt; recorded as accrued liabilities and $&lt;span id="xdx_908_eus-gaap--AccountsPayableCurrent_iI_c20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zMpSYaITZFrd" title="Accounts payable"&gt;0&lt;/span&gt; as accounts payable on the accompanying
condensed consolidated balance sheet. For the three and nine months ended September 30, 2024 and 2023, the Company has expensed $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_iN_c20240701__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zZShdU2atqH5" title="Research and development expenses"&gt;264,385&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20240101__20240930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zg1MdD5bmXg7" title="Research and development expenses"&gt;508,774&lt;/span&gt;, and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20230701__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zqSzKt85YCNe" title="Research and development expenses"&gt;157,117&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--AvanceClinicalMember_zkCFSJlnZzDl" title="Research and development expenses"&gt;401,284&lt;/span&gt;, respectively, in research and development expenses within the accompanying unaudited condensed
consolidated statement of operations. As of September 30, 2024, all payments have been made and the project is substantially completed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to Australian tax law, the Company is allowed an R&amp;amp;D tax credit that reduces a company&#x2019;s tax bill in Australia for expenses
incurred in R&amp;amp;D subject to certain requirements. The Company&#x2019;s Australian subsidiary submits R&amp;amp;D tax credit requests annually
for research and development expenses incurred. At September 30, 2024 and December 31, 2023, the Company had a research and development
tax credit receivable of $&lt;span id="xdx_902_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_dxL_c20240930_zRTgxwIWfh43" title="Research and development expense tax credit receivable::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3242"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_90B_ecustom--PrepaidResearchAndDevelopmentTaxIncentiveReceivable_iI_c20231231_zWQavAebeKKl" title="Research and development expense tax credit receivable"&gt;145,349&lt;/span&gt;, respectively, for R&amp;amp;D expenses incurred in Australia, included in prepaid and other current
assets within the accompanying unaudited condensed consolidated statement of operations. The Company received the amount due in relation
to the research and development tax credit during the three months ended September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Purchase
agreement with Prof. Zvi Vogel and Dr. Ilana Nathan &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 26, 2017, Jay Pharma entered into a purchase agreement with Prof. Zvi Vogel and Dr. Ilana Nathan (the &#x201c;Vogel-Nathan Purchase
Agreement&#x201d;), pursuant to which Jay Pharma was assigned ownership rights to certain patents, which were filed and unissued as of
the date of the Vogel-Nathan Purchase Agreement. The patent portfolio acquired and developed under the Vogel-Nathan Purchase Agreement
was sold to undisclosed buyers for an amount not material to these financials in the first quarter of 2024. No additional financial or
other obligations exist regarding the Vogel-Nathan Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Other
Consulting and Vendor Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a number of agreements and work orders for future consulting, clinical trial support, and testing services,
with terms ranging between one and 12 months. These agreements, in aggregate, commit the Company to approximately $&lt;span id="xdx_905_eus-gaap--Cash_iI_pn5n6_c20240930__us-gaap--TypeOfArrangementAxis__custom--OtherConsultingAndVendorAgreementsMember_z4d5IeWyKFrl" title="Future cash"&gt;0.1&lt;/span&gt; million in future
cash payments, inclusive of amounts in accounts payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reduction
in Force/Restructuring&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2023, the Company entered into a cost reduction plan, including a reduction in force (&#x201c;RIF&#x201d;) of approximately &lt;span id="xdx_90C_ecustom--ReductionInForceRestructuringPercentage_pid_dp_uPure_c20230531__20230531_zS8hAWRmTaBd" title="Reduction in force restructuring percentage"&gt;35&lt;/span&gt;% of
its full-time employees to streamline its operations and conserve cash resources. Additionally, contracts with seven consultants that
were focused on the Akos cannabinoid spin-out were terminated. The plan included a focus on progressing the Company&#x2019;s existing
non-cannabinoid pipeline while reducing the rate of spend and managing cash flow. In June 2023, the Company completed the reduction in
force, with such severance expenses recorded in general and administrative accounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Company entered into a separation agreement with Avani Kanubaddi, the Company&#x2019;s President and Chief Operating Officer
(the &#x201c;Kanubaddi Separation Agreement&#x201d;). In accordance with the Kanubaddi Separation Agreement, Mr. Kanubaddi received salary
and benefits that is paid out in twelve monthly installments beginning in July 2023, was eligible for his 2023 performance bonus, which
was not achieved, and any outstanding restricted stock units retained their vesting conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;ENVERIC
BIOSCIENCES, INC. AND SUBSIDIARIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zpFIobmcUyYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Reduction in Force/Restructuring activity and ending balance at September 30, 2024 for the remaining severance
payments included in accrued expenses in the consolidated balance sheet:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B6_zdmdhPytwCO" style="display: none"&gt;SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-right: 0.5in; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    Restructuring Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January 1, 2024 beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20240101__20240930_z2Ef8GLQ4vih" style="width: 14%; text-align: right" title="Restructuring cost payable, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;301,645&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restructuring costs paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RestructuringCosts_c20240101__20240930_zqX3YtRiw8z1" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs paid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(301,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 30, 2024 ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20240101__20240930_zwQfLsOPTXb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3256"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zC3lkyGUS4zf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003224"
      unitRef="AUD">3400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="AsOf2024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003226"
      unitRef="USD">2329000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003228"
      unitRef="USD">0</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003230"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003232"
      unitRef="USD">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003234"
      unitRef="USD">264385</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003236"
      unitRef="USD">508774</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003238"
      unitRef="USD">157117</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_custom_AvanceClinicalMember"
      decimals="0"
      id="Fact003240"
      unitRef="USD">401284</us-gaap:ResearchAndDevelopmentExpense>
    <ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003244"
      unitRef="USD">145349</ENVB:PrepaidResearchAndDevelopmentTaxIncentiveReceivable>
    <us-gaap:Cash
      contextRef="AsOf2024-09-30_custom_OtherConsultingAndVendorAgreementsMember"
      decimals="-5"
      id="Fact003246"
      unitRef="USD">100000</us-gaap:Cash>
    <ENVB:ReductionInForceRestructuringPercentage
      contextRef="From2023-05-312023-05-31"
      decimals="INF"
      id="Fact003248"
      unitRef="Pure">0.35</ENVB:ReductionInForceRestructuringPercentage>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003250">&lt;p id="xdx_89B_eus-gaap--ScheduleOfRestructuringAndRelatedCostsTextBlock_zpFIobmcUyYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Reduction in Force/Restructuring activity and ending balance at September 30, 2024 for the remaining severance
payments included in accrued expenses in the consolidated balance sheet:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B6_zdmdhPytwCO" style="display: none"&gt;SCHEDULE OF REDUCTION IN FORCE/RESTRUCTURING ACTIVITY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%; margin-right: 0.5in; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    Restructuring Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January 1, 2024 beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iS_c20240101__20240930_z2Ef8GLQ4vih" style="width: 14%; text-align: right" title="Restructuring cost payable, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;301,645&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restructuring costs paid&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RestructuringCosts_c20240101__20240930_zqX3YtRiw8z1" style="border-bottom: Black 1pt solid; text-align: right" title="Restructuring costs paid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(301,645&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September 30, 2024 ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RestructuringAndRelatedCostCostIncurredToDate1_iE_c20240101__20240930_zwQfLsOPTXb1" style="border-bottom: Black 2.5pt double; text-align: right" title="Restructuring cost payable, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3256"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003252"
      unitRef="USD">301645</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCosts
      contextRef="From2024-01-01to2024-09-30"
      decimals="0"
      id="Fact003254"
      unitRef="USD">-301645</us-gaap:RestructuringCosts>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-09-30" id="Fact003258">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zxCQVvJ8Awt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_82B_zgbEecB5evBj"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to September 30, 2024, the Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241001__20241114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember_zMKqillto5Fi" title="Stock issued during period shares new issues"&gt;63,334&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock through the Purchase
Agreement with Lincoln Park for gross cash proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20241001__20241114__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zi8yIXYXJKA5" title="Gross proceeds"&gt;405,820&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
As of November 12, 2024, there are &lt;span id="xdx_90F_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20241112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreeentMember_ztVrZ7zIer6d" title="Remaining shares"&gt;258,334&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;remaining registered shares available to
be issued in connection with this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 9, 2024, the Company granted &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20241009__20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgektihs4axg" title="Restricted stock units, shares"&gt;25,776&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock units to its officers and
certain employees, which fully vest on October 9, 2028 and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20241009__20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxlNgw6lAww5" title="Restricted stock awards"&gt;14,586&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;restricted stock awards to its non-employee
directors, which fully vest on December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
October 9, 2024, the Board approved an equitable adjustment to increase the number of shares available under the Incentive Plan by &lt;span id="xdx_90D_eus-gaap--StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_iI_c20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zAlFvAJFFIXi" title="Shares available for grant"&gt;64,402&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares, which increased the total number
of authorized shares under the Incentive Plan to &lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20241009__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--IncentivePlanMember_zS5camNtv1pl" title="Authorized shares"&gt;96,721&lt;/span&gt;
&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 7, 2024, the Company entered into an Out-Licensing Agreement (the &#x201c;Agreement&#x201d;) with MycoMedica Life Sciences, PBC,
a Delaware public benefit corporation (&#x201c;MycoMedica&#x201d;), pursuant to which the Company will out-license EB-002 and its EVM201
series to MycoMedica for further development and sales of the product in treatment of neuropsychiatric disorders. MycoMedica will receive
an exclusive, global license to the formulations, drugs, method of use, and medical devices developed by Enveric to utilize the compound.
As part of the Agreement, the Company will receive modest upfront payments, and if certain conditions are met, will receive development
and sales milestone payments of up to $&lt;span id="xdx_908_ecustom--ProceedsFromAchievingDevelopmentAndSalesMilestones_pn6n6_c20241107__20241107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCjnaEc28OGl"&gt;62
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million and tiered single-digit royalties based
on future sales. MycoMedica has the option during the license term to buyout its milestone and royalty payment obligations at a predetermined
amount depending upon the stage of product development and commercialization at the time of the buyout. Further, MycoMedica has the right
to purchase the licensed patents at a nominal amount upon a change of control of the Company, although doing so does not relieve MycoMedica
of any of its payment obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;T&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;he
Company completed a &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250127__20250127_zQBsqKof122"&gt;1-for-15&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reverse
Stock Split on January 27, 2025, which began trading on a split-adjusted basis on January 29, 2025. The Reverse Stock Split reduced the number of
shares of the Company&#x2019;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse
Stock Split. The number of shares of the Company&#x2019;s authorized common stock was not affected by the Reverse Stock Split and the
par value of the Company&#x2019;s common stock remained unchanged at $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20250127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV3e3b5rhSca"&gt;0.01 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. No fractional shares were issued in connection with the Reverse Stock Split.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-10-012024-11-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember"
      decimals="INF"
      id="Fact003260"
      unitRef="Shares">63334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-10-012024-11-14_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember"
      decimals="0"
      id="Fact003262"
      unitRef="USD">405820</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="AsOf2024-11-12_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_custom_PurchaseAgreeentMember"
      decimals="INF"
      id="Fact003264"
      unitRef="Shares">258334</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-10-092024-10-09_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact003266"
      unitRef="Shares">25776</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2024-10-092024-10-09_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact003268"
      unitRef="Shares">14586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="AsOf2024-10-09_us-gaap_SubsequentEventMember_custom_IncentivePlanMember"
      decimals="INF"
      id="Fact003270"
      unitRef="Shares">64402</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-10-09_us-gaap_SubsequentEventMember_custom_IncentivePlanMember"
      decimals="INF"
      id="Fact003272"
      unitRef="Shares">96721</us-gaap:CommonStockSharesAuthorized>
    <ENVB:ProceedsFromAchievingDevelopmentAndSalesMilestones
      contextRef="From2024-11-072024-11-07_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="Fact003273"
      unitRef="USD">62000000</ENVB:ProceedsFromAchievingDevelopmentAndSalesMilestones>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-01-272025-01-27" id="Fact003274">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-01-27_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact003275"
      unitRef="USDPShares">0.01</us-gaap:SaleOfStockPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
